trial_id,text,predicted_label,entailment_prob,contradiction_prob
NCT00687102,Statement: the record shows 5 total cases of asthenia and 3 total cases of pyrexia in the patients of the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00687102,Contradiction,0.27705732,0.7229427
NCT01772004,Statement: 'the primary clinical trial is open for participation to african-american patients. [SEP] Clinical Trial: NCT01772004,Entailment,0.7575621,0.24243793
NCT00118157,Statement: patients participating in the primary trial receive 2000 mg/m2 oral lapatinib twice a day for a full month. [SEP] Clinical Trial: NCT00118157,Contradiction,0.42629918,0.57370085
NCT01106898,"Statement: in the primary clinical trial, 97% of patients reported experiencing adverse events' [SEP] Clinical Trial: NCT01106898",Entailment,0.76851726,0.23148271
NCT02002533,Statement: the primary trial has 4 more adverse events recorded than the secondary trial. adrenal gland lymphangioma is a rare lymphangioma that arises from the adrenal gland. [SEP] Clinical Trial: NCT02002533,Entailment,0.500208,0.49979198
NCT01614210,Statement: results from the primary trial show that tamoxifen 20 mg po daily for 168 hours prior to surgery and for 336 hours after breast cancer surgery reduces ki67 expression in tumors by 40% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.35987967,0.6401203
NCT01194440,Statement: Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial. [SEP] Clinical Trial: NCT01194440,Entailment,0.5113674,0.48863256
NCT01205503,Statement: patients encountering a known allergy to ertapenem or ciprofloxacin will result in exclusion from the primary and secondary trials. [SEP] Clinical Trial: NCT01205503,Entailment,0.80804116,0.19195886
NCT01290536,"Statement: the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 0.56 kg of ibrutinib and 10 g/kg of medi4736 twice daily for 30 days. [SEP] Clinical Trial: NCT01290536",Contradiction,0.32557565,0.67442435
NCT01631552,Statement: the secondary trial and the primary trial have completely unrelated outcome measurements. [SEP] Clinical Trial: NCT01631552,Entailment,0.9226579,0.077342115
NCT00467844,Statement: all patients treated with gtx-024 1mg in the primary trial gained lean body mass over a 10 year period [SEP] Clinical Trial: NCT00467844,Contradiction,0.4126136,0.5873864
NCT00408681,"Statement: recurrent malignancies, graft-versus-host disease, infection, altered mental status and diffuse alveolar hemorrhage were all more frequently reported as adverse events in the secondary clinical trial than in the primary clinical trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.5713211,0.42867884
NCT01310075,Statement: a mastectomy for stage iv bc does not necessarily exclude a woman from participatory consideration in either the primary or secondary clinical trial. [SEP] Clinical Trial: NCT01310075,Entailment,0.7452341,0.25476596
NCT02599194,Statement: adverse events were not documented for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.9147948,0.08520521
NCT01313117,"Statement: for the whole duration of the primary clinical trial, patients will get increased doses of alpha lipoic acid, while during the secondary clinical trial, patients in cohort 1 receive a consistent dose of necitumumab. [SEP] Clinical Trial: NCT01313117",Contradiction,0.45826653,0.54173344
NCT02404441,"Statement: uniform criteria for all participants are applied in the secondary clinical trial for inclusion or exclusion, as opposed to the primary clinical trial that provides two distinct inclusion policies for those aged 18-50 and those aged 50 and over. [SEP] Clinical Trial: NCT02404441",Entailment,0.50918543,0.49081454
NCT00321464,"Statement: being diagnosed with stage 4 breast adenocarcinoma that is either er positive, pr positive, or her2/neu negative makes a patient eligible for participation in both the secondary and primary clinical trials. [SEP] Clinical Trial: NCT00321464",Contradiction,0.49647644,0.5035236
NCT02640053,Statement: Patients in the primary trial that didn‚Äö√Ñ√¥t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy. [SEP] Clinical Trial: NCT02640053,Entailment,0.7090623,0.2909377
NCT01138046,"Statement: occurrence date range validation code is a coded value specifying the degree of authoritativeness or certitude of the occurrence date. Any japanese national can take part in the primary trial, or the secondary trial. [SEP] Clinical Trial: NCT01138046",Contradiction,0.29406056,0.7059395
NCT01451632,"Statement: hepatitis c antibody is an antibody produced by b-lymphocytes in response to hepatitis c virus infection. Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention. [SEP] Clinical Trial: NCT01451632",Contradiction,0.4106004,0.5893996
NCT02179515,Statement: sars coronavirus 2 b.1.128 is a variant lineage of sars coronavirus 2 that is the ancestor for the p.1 and p.2 lineages. 100.0% of cohort 1 of the primary trial suffered some kind of adverse event. [SEP] Clinical Trial: NCT02179515,Entailment,0.54617983,0.4538201
NCT01803282,"Statement: 2 out of 73 individuals in the primary clinical trial have suffered an acute myocardial infarction, compared to zero out of 1674 individuals in the secondary clinical trial [SEP] Clinical Trial: NCT01803282",Entailment,0.6733224,0.3266776
NCT00929240,"Statement: the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort. division is an administrative unit within a government, academic organization or business. [SEP] Clinical Trial: NCT00929240",Entailment,0.79562557,0.20437449
NCT01920061,Statement: a higher percentage of patients suffered from adverse events in cohort a compared to cohort b during the primary clinical trial. [SEP] Clinical Trial: NCT01920061,Entailment,0.7725472,0.22745284
NCT00999921,Statement: Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial. gemcitabine/irinotecan regimen is a regimen consisting of gemcitabine and irinotecan used for the treatment of pancreatic cancer. [SEP] Clinical Trial: NCT00999921,Entailment,0.7919853,0.20801477
NCT01920061,Statement: The same number of Aes were reported for both cohorts in the primary trial [SEP] Clinical Trial: NCT01920061,Entailment,0.764957,0.23504297
NCT01138046,"Statement: capnocytophaga is a genus of gram-negative, anaerobic bacteria that normally populate the mouth and nasopharynx of dogs and cats. Any japanese national can take part in the primary trial, or the secondary trial. [SEP] Clinical Trial: NCT01138046",Contradiction,0.25094017,0.74905986
NCT00496860,Statement: both cohort 1 and cohort 2 of the primary clinical trial are administered the same dosage of alt-801 [SEP] Clinical Trial: NCT00496860,Entailment,0.5051935,0.49480653
NCT01591746,Statement: None of the cohort of the primary trial or the secondary trial receive enteric-coated tablets [SEP] Clinical Trial: NCT01591746,Entailment,0.5730866,0.42691335
NCT00496860,Statement: cohort 1 of the primary clinical trial is given a larger dosage of alt-801 than cohort 2 [SEP] Clinical Trial: NCT00496860,Entailment,0.6952578,0.30474225
NCT01498458,Statement: in the primary trial there were 0.03 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.36535245,0.6346476
NCT01597193,Statement: cohort 1 of the primary clinical trial is administered a similar dose of enzalutamide as cohort 2 [SEP] Clinical Trial: NCT01597193,Entailment,0.7390206,0.26097944
NCT00146172,Statement: candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial. cdk4 gene mutation is a change in the nucleotide sequence of the cdk4 gene. [SEP] Clinical Trial: NCT00146172,Entailment,0.5836925,0.4163075
NCT00266110,Statement: the primary clinical trial does not involve the use of any injections for its patients. [SEP] Clinical Trial: NCT00266110,Entailment,0.9289358,0.07106419
NCT01963481,Statement: patients suffering from severe insomnia and schizophrenia are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT01963481,Contradiction,0.31396285,0.6860372
NCT00146172,Statement: neither primary clinical trial nor secondary clinical trial allows candidates with ecog score below 2 [SEP] Clinical Trial: NCT00146172,Contradiction,0.46845248,0.5315475
NCT02038218,Statement: the secondary clinical trial and the primary clinical trial utilize the same units of measure in their results.' [SEP] Clinical Trial: NCT02038218,Entailment,0.5740137,0.4259863
NCT01106898,Statement: no adverse events were experienced by 97% of patients participating in the primary clinical trial. [SEP] Clinical Trial: NCT01106898,Entailment,0.6126257,0.38737428
NCT01246973,"Statement: numerous instances of cardiac and psychiatric aes were remarked during the primary clinical trial and the secondary clinical trial, with only a few other types of aes reported. [SEP] Clinical Trial: NCT01246973",Contradiction,0.24285656,0.75714344
NCT02222922,Statement: All the primary trial participants receive lower doses of drugs than the secondary trial participants [SEP] Clinical Trial: NCT02222922,Entailment,0.85881,0.14119
NCT00741039,"Statement: Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer. [SEP] Clinical Trial: NCT00741039",Entailment,0.6567227,0.34327725
NCT00284180,Statement: Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial. [SEP] Clinical Trial: NCT00284180,Entailment,0.91174763,0.08825237
NCT00795769,Statement: the incidence of aes was reported to be higher amongst patients in the secondary clinical trial than those in the primary clinical trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.71465915,0.28534088
NCT00122369,"Statement: subject status subcategory is a subdivision of subject status data. 18 years olds are excluded from the secondary trial, but the primary trial does not specify an age range for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.7921967,0.20780328
NCT01498458,Statement: hepatotoxicity incidence was not higher compared to the number of hypertension and pancreatectomy cases during the primary clinical trial [SEP] Clinical Trial: NCT01498458,Entailment,0.5879431,0.41205698
NCT01451632,"Statement: the primary trial provided the members of cohort 1 and 2 with equal doses of cetuximab, but cohort 1 received 8mg/kg less of mm-121. [SEP] Clinical Trial: NCT01451632",Entailment,0.50936764,0.49063233
NCT00373256,"Statement: somatostatin receptor positive is a laboratory test result indicating the presence or expression of somatostatin receptor in a sample. The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel. [SEP] Clinical Trial: NCT00373256",Contradiction,0.41735327,0.58264667
NCT01178411,"Statement: age at menarche is age of first menstruation.  a risk factor for breast cancer the nationality, ethnicity, psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01178411",Contradiction,0.2939922,0.7060078
NCT00148668,Statement: the primary clinical trial does not include trastuzumab in any of its intervention regimens [SEP] Clinical Trial: NCT00148668,Entailment,0.9285988,0.07140117
NCT00262834,"Statement: 119 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 5% of patients, apart from skin infections [SEP] Clinical Trial: NCT00262834",Entailment,0.51242685,0.48757318
NCT01138046,"Statement: Only female patients of a specific nationality can take part in the primary trial, no such condition is required for participation in the secondary trial. [SEP] Clinical Trial: NCT01138046",Entailment,0.8846772,0.11532284
NCT03069313,Statement: the primary trial and the secondary trial adminster their interventions orally. non-muscle invasive bladder urothelial carcinoma is an infiltrating urothelial carcinoma of the bladder that has not invaded into the bladder muscularis propria. [SEP] Clinical Trial: NCT03069313,Contradiction,0.4887364,0.5112636
NCT00076024,Statement: participants of the primary clinical trial must have a normal hepatic function. [SEP] Clinical Trial: NCT00076024,Entailment,0.7103184,0.28968158
NCT00698035,"Statement: in the primary clinical trial, therapeutic measures applied on the skin are being used, on the other hand, the secondary clinical trial is investigating the effects of treatments administered through inhalation. [SEP] Clinical Trial: NCT00698035",Contradiction,0.49111232,0.50888765
NCT00756496,"Statement: There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results. ret rearrangement testing method is a request to enter the specific molecular analysis method used to detect and identify rearrangements involving the ret gene. [SEP] Clinical Trial: NCT00756496",Entailment,0.6793505,0.32064945
NCT00416715,"Statement: in the secondary trial, patients get a one-time injection at the beginning, while the primary trial patients are treated with multiple weekly injections. [SEP] Clinical Trial: NCT00416715",Contradiction,0.3760359,0.6239641
NCT00836186,"Statement: have trouble communicating thoughts is a question about whether an individual has or had trouble communicating their thoughts. the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive intramuscular injections aswell as medication to be taken orally. [SEP] Clinical Trial: NCT00836186",Entailment,0.5174776,0.48252246
NCT01997333,"Statement: in the primary clinical trial, the patient who exhibited the longest progression-free survival (pfs) lived 3.5 months without any evidence of disease progression or mortality. [SEP] Clinical Trial: NCT01997333",Entailment,0.5821165,0.41788357
NCT00766532,"Statement: There are several cases of swelling, hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial. have difficulty moving arm side to side is a question about whether an individual experiences or experienced difficulty moving their arm from side to side. [SEP] Clinical Trial: NCT00766532",Contradiction,0.2266243,0.7733757
NCT00021255,"Statement: Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs. have flatulence or gas is a question about the extent to which an individual has or had flatulence or gas. [SEP] Clinical Trial: NCT00021255",Contradiction,0.41012195,0.589878
NCT00656305,"Statement: There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation . malignant pelvic neoplasm is a primary or metastatic malignant neoplasm that affects the organs and structures of the pelvis. [SEP] Clinical Trial: NCT00656305",Contradiction,0.47060904,0.529391
NCT00792077,"Statement: the primary trial uses lower doses of lenalidomide than the secondary trial uses of lapatinib in intervention 1, and the primary trial intervention has a shorter period. [SEP] Clinical Trial: NCT00792077",Entailment,0.8616137,0.13838634
NCT00820872,Statement: the incidence of diarrhoea was higher among participants of the primary clinical trial than it was among the secondary clinical trial subjects. [SEP] Clinical Trial: NCT00820872,Entailment,0.7628149,0.23718509
NCT00432562,Statement: regimen used to treat malignant ovarian neoplasm is any regimen that can be used for the treatment of malignant ovarian neoplasm. There are 0 shared inclusion/exclusion criteria between the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00432562,Entailment,0.70589536,0.29410464
NCT01451632,"Statement: Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2. milligram per square meter per hour is a dose calculation unit expressed in milligram(s) per square meter per period of time equal to sixty minutes. [SEP] Clinical Trial: NCT01451632",Contradiction,0.49593282,0.5040672
NCT00759785,Statement: 72% more participants in the er-positive luminal b group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group [SEP] Clinical Trial: NCT00759785,Entailment,0.52630115,0.47369885
NCT01286987,"Statement: placental non-neoplastic disorder is a non-neoplastic disorder that arises from the placenta. representative examples include chorioamnionitis, infarction, and malformations. Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead. [SEP] Clinical Trial: NCT01286987",Contradiction,0.49542424,0.5045757
NCT00825682,"Statement: in comparison to the primary clinical trial, the intervention period for the secondary trial is extended by 15 weeks. [SEP] Clinical Trial: NCT00825682",Contradiction,0.44454086,0.55545914
NCT01535040,"Statement: in the primary clinical trial, the placebo and memantine interventions have dissimilar administration frequencies and time durations. [SEP] Clinical Trial: NCT01535040",Entailment,0.679541,0.32045898
NCT00256217,Statement: several patients in the secondary trial experienced only one adverse event. [SEP] Clinical Trial: NCT00256217,Contradiction,0.22774589,0.7722541
NCT01383174,"Statement: fail-safe system device is a device designed to prevent malfunction, unsafe, or unauthorized operation of a device or system. There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial. [SEP] Clinical Trial: NCT01383174",Contradiction,0.45579347,0.5442065
NCT02122796,Statement: the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates. pdgfrb gene fusion positive is an indication that a pdgfrb fusion gene has been detected in a sample. [SEP] Clinical Trial: NCT02122796,Entailment,0.5529318,0.44706815
NCT01772004,Statement: doctor and i shared responsibility for deciding which treatment is best for me is a response indicating that an individual and their doctor shared responsibility for deciding which treatment is best for them. African-american patients can participate in the primary trial. [SEP] Clinical Trial: NCT01772004,Contradiction,0.47851074,0.5214892
NCT00586326,"Statement: in the intervention portion of the primary clinical trial, there's no detailed structure or explanation about a treatment cycle. [SEP] Clinical Trial: NCT00586326",Entailment,0.8980174,0.10198254
NCT00146172,Statement: combination route of administration is administration of a drug by more than one route at the same time. candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00146172,Contradiction,0.40074506,0.59925497
NCT00467844,Statement: tp53 mutation analysis was not performed is an indication that tp53 mutation analysis was not performed during the study. All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period. [SEP] Clinical Trial: NCT00467844,Entailment,0.6877991,0.31220087
NCT00775645,"Statement: across both the primary clinical trial and the secondary clinical trial, no adverse events were observed in more than 1% of participants. [SEP] Clinical Trial: NCT00775645",Entailment,0.6794027,0.32059735
NCT00825682,Statement: the intervention in the secondary trial last 3.5 more months than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.6758467,0.32415327
NCT01106898,Statement: just a pair of patients in the primary clinical trial failed to demonstrate recurrence-free survival [SEP] Clinical Trial: NCT01106898,Entailment,0.8718728,0.12812719
NCT01008150,"Statement: approximately one-third of patients, from both groups in the primary clinical trial, demonstrated pathologic complete response in breast and axillary lymph nodes after around seven months into the study [SEP] Clinical Trial: NCT01008150",Contradiction,0.35509506,0.644905
NCT02002533,Statement: the primary trial and the secondary trial have 10 recorded adverse events. [SEP] Clinical Trial: NCT02002533,Entailment,0.7627374,0.2372626
NCT01614210,Statement: results from the primary trial show that tamoxifen 32 mg po daily for 1 week prior to surgery and for 2 weeks after breast cancer surgery reduces the diameter of tumors by 40% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.34422734,0.6557726
NCT00583700,"Statement: women aged 18 or 19 are eligible for the secondary trial, but will need to wait 1-2 years to be eligible for the primary trial [SEP] Clinical Trial: NCT00583700",Contradiction,0.47627228,0.5237277
NCT00795769,Statement: negligible or no adverse events were reported in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.8046694,0.19533066
NCT01869192,"Statement: The results from the primary trial indicate that the Arm A intervention provided the best overall response rate, additionally, in the secondary trial the Denosumab cohort had a worse Time to First On-Study SRE than the Zoledronic Acid cohort. [SEP] Clinical Trial: NCT01869192",Entailment,0.5770088,0.42299122
NCT00320541,Statement: The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it [SEP] Clinical Trial: NCT00320541,Contradiction,0.46536964,0.53463036
NCT00030823,"Statement: compared to the secondary clinical trial, the primary clinical trial boasted a greater number of participants. [SEP] Clinical Trial: NCT00030823",Entailment,0.63792425,0.3620758
NCT01256567,"Statement: a patient who has recently undergone an organ transplant and remains confined to bed would not be eligible for the primary clinical trial, but could be considered for the secondary clinical trial [SEP] Clinical Trial: NCT01256567",Entailment,0.7540757,0.24592432
NCT01290536,"Statement: the primary trial intervention focuses on harnessing the strengths of targeted molecular therapies, while the secondary trial focuses on surgical interventions and regenerative medicine. [SEP] Clinical Trial: NCT01290536",Contradiction,0.37705582,0.6229442
NCT01246973,Statement: several cardiac and psychiatric aes were observed in the primary clinical trial. [SEP] Clinical Trial: NCT01246973,Contradiction,0.40545815,0.5945418
NCT01106898,Statement: 97% of patients in the primary trial did not experience any Adverse Events. mental disorder due to a general medical condition is a category of psychiatric disorders which are the direct physiologic consequence of a general medical condition. [SEP] Clinical Trial: NCT01106898,Entailment,0.56963444,0.43036556
NCT00253708,"Statement: the primary trial does not test any drug based treatments, whereas the secondary trial tests two different drugs. encephalomeningocele is a congenital neural tube closure defect resulting in the protrusion of the brain and meninges through a skull opening. [SEP] Clinical Trial: NCT00253708",Entailment,0.6657284,0.33427164
NCT00825682,Statement: the intervention phase in the secondary clinical trial lasts an additional 15 weeks compared to that in the primary clinical trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.6130112,0.3869888
NCT03125941,Statement: pre-operative administration of dexamethasone is given to both cohorts in the primary clinical trial [SEP] Clinical Trial: NCT03125941,Entailment,0.7027012,0.2972988
NCT01537029,"Statement: regardless of their cancer type, ethnicity, or race, female cancer patients aged 18 and above are eligible for the primary clinical trial. however, they are required to be diagnosed with her2/neu+ breast cancer to participate in the secondary clinical trial. [SEP] Clinical Trial: NCT01537029",Entailment,0.5043926,0.49560738
NCT01614210,Statement: Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average. adjuvant post-operative chemotherapy was not administered is a response indicating that adjuvant post-operative chemotherapy was not administered. [SEP] Clinical Trial: NCT01614210,Entailment,0.6388259,0.3611741
NCT01569087,"Statement: the secondary clinical trial doesn't accept patients diagnosed with stage 4 cancer, however, such patients are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01569087",Entailment,0.6441427,0.3558573
NCT00001832,Statement: post-operative therapy rounds section is a form header for post-operative therapy round information. The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4-Demethyl-4-cholestryloxycarbonylpenclomedine. [SEP] Clinical Trial: NCT00001832,Contradiction,0.20113796,0.7988621
NCT01706081,Statement: the primary clinical trial's acupuncture patients reported greater changes in their lymphedema than those patients who were on the waiting list. [SEP] Clinical Trial: NCT01706081,Entailment,0.5789084,0.4210916
NCT02504424,Statement: there were no occurrences of urinary tract infections among the participants of the primary clinical trial [SEP] Clinical Trial: NCT02504424,Entailment,0.8985513,0.101448745
NCT00254592,Statement: the primary clinical trial and the secondary trial administer docetaxel to their patient cohorts [SEP] Clinical Trial: NCT00254592,Contradiction,0.36254454,0.63745546
NCT01908101,Statement: cerebellar paraganglioma is an extra-adrenal paraganglioma arising from the cerebellum. the primary trial and the secondary trial do not test the same drugs. [SEP] Clinical Trial: NCT01908101,Entailment,0.89619124,0.10380881
NCT01286168,"Statement: the secondary clinical trial's most frequent adverse event witnessed was anaemia, affecting in excess of 5% of the patients, while no adverse occurrences were noted in the primary trial. [SEP] Clinical Trial: NCT01286168",Contradiction,0.44549805,0.554502
NCT00871858,"Statement: advanced chordoma is a chordoma that has spread extensively to other anatomic sites or is no longer responding to treatment. Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead. [SEP] Clinical Trial: NCT00871858",Entailment,0.51985204,0.48014796
NCT02336737,"Statement: Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae [SEP] Clinical Trial: NCT02336737",Entailment,0.5063346,0.49366543
NCT00365105,"Statement: a 32 year old individual diagnosed with stage iii breast cancer, showing an absolute neutrophil count of 1807/≈í¬∫l, a platelet count of 79000/≈í¬∫l, a hemoglobin level of 90 g/l, and a life expectancy beyond 8 months would qualify for participation in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.31874993,0.68125004
NCT01128543,"Statement: In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24 [SEP] Clinical Trial: NCT01128543",Entailment,0.71168745,0.28831258
NCT02403271,"Statement: substance dispersity is a measure of the heterogeneity of sizes, shapes or masses of molecules or particles. There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial. [SEP] Clinical Trial: NCT02403271",Contradiction,0.45425832,0.54574174
NCT01156987,"Statement: not a single one of the participants in group 1 of the primary trial were found to have lesions, and exactly 15% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.23691918,0.7630808
NCT01156987,"Statement: None of the participants in group 1 of the primary trial were found to have lesions, and more than 90% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. rectal rhabdomyosarcoma is a malignant mesenchymal tumor with skeletal muscle differentiation affecting the rectum. [SEP] Clinical Trial: NCT01156987",Contradiction,0.3420209,0.6579791
NCT01222390,"Statement: the interventions of the primary clinical trial and the secondary clinical trial do not incorporate x-rays, transendocardial injections, ct scans, or mris. [SEP] Clinical Trial: NCT01222390",Entailment,0.5304668,0.46953323
NCT01468675,"Statement: Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions. greater than 50 percent area of interest on radiograph is a radiographic finding indicating the area of interest is greater than 50 percent. [SEP] Clinical Trial: NCT01468675",Entailment,0.56824756,0.43175244
NCT00662025,"Statement: for the initial 21 days of the primary clinical trial, all patients in cohort 2 were given capecitabine orally every day [SEP] Clinical Trial: NCT00662025",Contradiction,0.49799448,0.5020055
NCT01806259,Statement: 96% participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 67% from the nacl 0.9% 3ml group [SEP] Clinical Trial: NCT01806259,Contradiction,0.42821914,0.5717808
NCT02222922,Statement: alt-801 is administered at higher doses in the primary clinical trial as opposed to the secondary clinical trial [SEP] Clinical Trial: NCT02222922,Entailment,0.7268107,0.27318925
NCT00662025,Statement: sunitinib was given orally to all participants in the primary clinical trial every day for the duration of the study. [SEP] Clinical Trial: NCT00662025,Entailment,0.602663,0.39733705
NCT00896454,Statement: pancreatic duct is a duct joining the pancreas to the common bile duct to supply pancreatic juices. the secondary trial and the primary trial report results using the same Unit of Measure. [SEP] Clinical Trial: NCT00896454,Contradiction,0.2853803,0.71461976
NCT00408681,"Statement: Recurrent malignancies, Graft-versus-host disease, Anaemia, Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. container is an object that can be used to hold things. [SEP] Clinical Trial: NCT00408681",Entailment,0.50315356,0.49684644
NCT00496860,Statement: cohort 1 in the primary clinical trial receives 0.035 mg less of alt-801 than what is administered to cohort 2 [SEP] Clinical Trial: NCT00496860,Entailment,0.67599434,0.32400566
NCT02320123,"Statement: Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy. aortic arch branch is an artery originating from the aortic arch. [SEP] Clinical Trial: NCT02320123",Contradiction,0.34798458,0.6520154
NCT01730729,"Statement: the intervention in the primary clinical trial is administered topically, as opposed to the secondary clinical trial where it is strictly given intravenously [SEP] Clinical Trial: NCT01730729",Entailment,0.57117194,0.42882803
NCT00209092,"Statement: Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin. atrioventricular bundle is a bundle of specialized heart muscle fibers that conducts impulses from the atrioventricular node to the ventricles. [SEP] Clinical Trial: NCT00209092",Contradiction,0.45846665,0.54153335
NCT00662025,"Statement: Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study. [SEP] Clinical Trial: NCT00662025",Entailment,0.552851,0.44714898
NCT01831089,Statement: Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial [SEP] Clinical Trial: NCT01831089,Contradiction,0.48594698,0.514053
NCT01806675,"Statement: Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2. [SEP] Clinical Trial: NCT01806675",Contradiction,0.49633655,0.5036634
NCT02038218,"Statement: the secondary clinical trial and the primary clinical trial use the same metric for quantifying their results, regardless of the outcome evaluated. [SEP] Clinical Trial: NCT02038218",Entailment,0.5054876,0.49451238
NCT00586326,Statement: the primary clinical trial's intervention section outlines a specific treatment cycle and includes a comprehensive description of the treatment. [SEP] Clinical Trial: NCT00586326,Entailment,0.53598416,0.46401584
NCT02640053,Statement: Patients in the primary trial that didn‚Äö√Ñ√¥t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions. [SEP] Clinical Trial: NCT02640053,Entailment,0.70038843,0.2996116
NCT01008150,Statement: More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study [SEP] Clinical Trial: NCT01008150,Contradiction,0.3924151,0.6075849
NCT00021255,"Statement: Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency [SEP] Clinical Trial: NCT00021255",Entailment,0.56526816,0.43473178
NCT01451632,Statement: cohort 1 of the primary clinical trial received a lower dose of cetuximab than cohort 2 and had no addition of collaborative care intervention. [SEP] Clinical Trial: NCT01451632,Entailment,0.8845953,0.11540472
NCT00971945,"Statement: candidates for the secondary clinical trial are required to satisfy performance status conditions, a requirement that is not necessary for the primary clinical trial [SEP] Clinical Trial: NCT00971945",Entailment,0.9015421,0.0984579
NCT01023477,"Statement: encounter due to other specified problems related to upbringing is an icd encounter due to other specified problems related to upbringing. Hypokalemic patients are excluded from the primary trial, but hyperkalemic patients may be eligible for the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01023477",Contradiction,0.43217474,0.5678253
NCT01783444,"Statement: patients with a history of breast cancer, confirmed her2+, considering breast-conserving surgery, are eligible for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01783444",Contradiction,0.25471592,0.7452841
NCT00656019,Statement: have normal appetite and enjoy good food is a response indicating that an individual has or had a normal appetite and enjoyed good food. several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes. [SEP] Clinical Trial: NCT00656019,Contradiction,0.3548818,0.6451182
NCT00432562,Statement: The only shared inclusion/exclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent. [SEP] Clinical Trial: NCT00432562,Entailment,0.64621454,0.35378543
NCT00054028,"Statement: in the primary clinical trial, patients are treated with irinotecan and etoposide. however, the drug intervention for the secondary clinical trial is not mentioned. [SEP] Clinical Trial: NCT00054028",Entailment,0.9052165,0.09478346
NCT00313170,Statement: individuals diagnosed with colon cancer who have also failed to respond to earlier hormonal treatments are suitable for participation in the primary clinical trial. [SEP] Clinical Trial: NCT00313170,Entailment,0.6540507,0.34594926
NCT00321048,"Statement: despite receiving equal doses of radiation therapy in the primary clinical trial, the treatment for cohort one spans an additional two weeks compared to cohort two. [SEP] Clinical Trial: NCT00321048",Entailment,0.529481,0.470519
NCT01783444,"Statement: eligibility for both primary and secondary clinical trials is established for women who are newly diagnosed with locally advanced breast cancer that is er+, and are deliberating a mastectomy [SEP] Clinical Trial: NCT01783444",Contradiction,0.38626808,0.6137319
NCT01743560,"Statement: children and adolescents can participate in the primary clinical trial as there is no height restriction, but they are expressly prohibited from the secondary clinical trial [SEP] Clinical Trial: NCT01743560",Entailment,0.76314026,0.23685975
NCT02312934,"Statement: alcohol consumers are not permitted to participate in the primary clinical trial; however, should their consumption not exceed five drinks daily, they might be considered for the secondary clinical trial. [SEP] Clinical Trial: NCT02312934",Entailment,0.5352661,0.4647339
NCT00317603,"Statement: the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 1/4 of the primary trial patients. [SEP] Clinical Trial: NCT00317603",Contradiction,0.28389055,0.71610945
NCT00146172,Statement: candidates capable of only limited selfcare; confined to bed or chair more than 1/2 of waking hours are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.47333804,0.52666193
NCT00992602,Statement: the adverse events in both the primary and secondary trial can be compared as the data has been recorded in meticulous detail for the primary trial. [SEP] Clinical Trial: NCT00992602,Entailment,0.71585006,0.28414994
NCT02988986,Statement: after 12 months of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 150% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Contradiction,0.47440493,0.525595
NCT01383174,Statement: cohort 2 in the secondary clinical trial had a significantly greater number of patients compared to cohort 2 in the primary clinical trial. [SEP] Clinical Trial: NCT01383174,Contradiction,0.45205215,0.5479478
NCT00321048,"Statement: both cohort 1 and 2 of the primary clinical trial undergo the same intensity of radiation therapy, although the intervention time for the first cohort is extended by two weeks. [SEP] Clinical Trial: NCT00321048",Contradiction,0.42047068,0.5795293
NCT00317603,"Statement: on both the primary and secondary clinical trials, syncope emerged as the most common adverse occurrence in the patient groups [SEP] Clinical Trial: NCT00317603",Entailment,0.6024002,0.39759985
NCT01439282,Statement: Gender is not a determining factor for eligibility in the primary trial or the secondary trial. insufficient rna yield is an indication that an rna isolation procedure yielded an insufficient amount of rna to proceed. [SEP] Clinical Trial: NCT01439282,Contradiction,0.35152215,0.64847785
NCT00454532,"Statement: nearly all patients in both the primary and secondary clinical trials, specifically over 97%, did not report any negative outcomes [SEP] Clinical Trial: NCT00454532",Entailment,0.64821154,0.35178846
NCT00588640,Statement: the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants. milliliter per minute per milligram per meter squared per day is a unit of concentration equal to milliliter per minute divided by milligram per meter squared per day. [SEP] Clinical Trial: NCT00588640,Entailment,0.65597284,0.34402713
NCT01048099,Statement: None of the individual adverse event types recorded in the primary trial affected more than one patient. 14q23.1 is a chromosome band present on 14q [SEP] Clinical Trial: NCT01048099,Entailment,0.75493634,0.24506368
NCT00741039,"Statement: indeterminate extranodal tumor extension is a response that the extranodal tumor extension is undetermined. Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer. [SEP] Clinical Trial: NCT00741039",Entailment,0.60111105,0.39888895
NCT01256567,"Statement: in the primary clinical trial, a patient post organ transplant within the span of a month would not be considered, although they could potentially be fit for the secondary clinical trial [SEP] Clinical Trial: NCT01256567",Entailment,0.71320176,0.2867982
NCT00266110,Statement: Patients in the primary trial will need to receive several injections. feel fatigue is a question about whether an individual feels or felt fatigued. [SEP] Clinical Trial: NCT00266110,Entailment,0.5657992,0.43420082
NCT01967823,Statement: over 20% of the patients that participated in the primary clinical trial experienced all types of adverse events (aes) [SEP] Clinical Trial: NCT01967823,Entailment,0.73522925,0.26477072
NCT00587964,Statement: 7p15-p14.2 is a chromosome band present on 7p Coronary artery stenosis are the most common AE recorded in the primary trial. [SEP] Clinical Trial: NCT00587964,Contradiction,0.49227947,0.50772053
NCT01286987,Statement: both breast cancer and ovarian/ peritoneal cancer patients involved in the primary clinical trial are administered 1000 mcg/day of talazoparib. [SEP] Clinical Trial: NCT01286987,Entailment,0.53126633,0.46873364
NCT00918281,Statement: cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine. [SEP] Clinical Trial: NCT00918281,Entailment,0.55452,0.44548002
NCT00076024,Statement: the primary clinical trial does not apply any constraints on the liver function of its participants [SEP] Clinical Trial: NCT00076024,Entailment,0.9235343,0.07646572
NCT02891681,Statement: patients who are severely obese or pregnant may be considered for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.22168794,0.778312
NCT00370552,Statement: only individuals who possess permanent infertility are able to join in the primary clinical trial. [SEP] Clinical Trial: NCT00370552,Entailment,0.61518586,0.3848141
NCT00918281,Statement: nepafenac is a topical nonsteroidal anti-inflammatory drug that is used in eye drops for the treatment of eye pain and swelling. cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine. [SEP] Clinical Trial: NCT00918281,Contradiction,0.4620943,0.5379057
NCT00656305,"Statement: in the second group of the primary clinical trial, there were no recorded deaths or hospital stays [SEP] Clinical Trial: NCT00656305",Entailment,0.62940633,0.37059367
NCT00405938,"Statement: Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.4057912,0.59420884
NCT01730729,"Statement: while the primary trial's treatment is taken orally, the treatment in the secondary trial is dispensed exclusively through intravenous means, such as a needle or tube [SEP] Clinical Trial: NCT01730729",Entailment,0.59910345,0.40089652
NCT00741039,"Statement: every individual in the primary clinical trial receives a uniform intervention, without the consideration of their cancer condition. [SEP] Clinical Trial: NCT00741039",Entailment,0.84817845,0.15182151
NCT00588640,"Statement: different inclusion and exclusion criteria are used for the two stages of the primary clinical trial. however, the secondary clinical trial uses separate criteria for patients, depending on their health status or cancer diagnosis. [SEP] Clinical Trial: NCT00588640",Entailment,0.58311206,0.4168879
NCT00538850,"Statement: the primary clinical trial does not provide reports on the changes in pain intensity while the secondary trial studies the impact on levels of vitamin d, not the bone mineral density (bmd) of the lumbar spine. [SEP] Clinical Trial: NCT00538850",Entailment,0.7005332,0.29946682
NCT01969448,Statement: both interventions in the primary clinical trial employ laser-assisted fluorescence angiography. [SEP] Clinical Trial: NCT01969448,Entailment,0.6616449,0.3383551
NCT01629615,Statement: the majority of candidates involved in the primary clinical trial did not experience any eating disorders during the course of the study [SEP] Clinical Trial: NCT01629615,Entailment,0.7614695,0.23853056
NCT00429182,Statement: ann arbor b symptoms indicator is an indication of whether a record includes b-symptom data based on the ann arbor lymphoma classification system guidelines. less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products. [SEP] Clinical Trial: NCT00429182,Entailment,0.5312795,0.46872053
NCT01975831,Statement: the only disparity in the primary clinical trial's interventions 1 and 2 is the dose of durva; with cohort 1 receiving 0.7mg less in their monthly injections compared to cohort 2. [SEP] Clinical Trial: NCT01975831,Entailment,0.53179526,0.46820474
NCT00588640,"Statement: the primary trial uses the same inclusion and exclusion criteria for each of its phases, while the secondary trial does not distinguish between criteria for healthy and cancer patients. [SEP] Clinical Trial: NCT00588640",Entailment,0.9093854,0.09061467
NCT01310075,Statement: A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial. sibling is a person's brother or sister. [SEP] Clinical Trial: NCT01310075,Contradiction,0.29664388,0.70335615
NCT01011218,Statement: Across both the primary trial and the secondary trial only one death was recorded in the adverse events. adverse event attributed to disease is an indication that an adverse event is causally related to the natural history of disease. [SEP] Clinical Trial: NCT01011218,Entailment,0.6540791,0.34592092
NCT02599194,Statement: Aes were not recorded for the primary trial or the secondary trial. sequencing data file is an electronic file containing nucleic acid sequencing data. [SEP] Clinical Trial: NCT02599194,Contradiction,0.48705465,0.51294535
NCT02239601,Statement: the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts. [SEP] Clinical Trial: NCT02239601,Entailment,0.65939134,0.34060866
NCT00293384,"Statement: Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril. microgram per kilogram per day is a dose calculation unit expressed in microgram(s) per kilogram per period of time equal to twenty-four hours. [SEP] Clinical Trial: NCT00293384",Contradiction,0.38072437,0.6192756
NCT00978250,"Statement: satisfied with treatment effects is a question about whether an individual is or was satisfied with the effects of their treatment so far. Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both. [SEP] Clinical Trial: NCT00978250",Contradiction,0.3847281,0.61527187
NCT00825682,Statement: the intervention in the secondary trial last 2520 more hours than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Contradiction,0.37665385,0.6233461
NCT00632489,Statement: results are available for the cohort on lbh589 and lapatinib in the primary clinical trial. [SEP] Clinical Trial: NCT00632489,Contradiction,0.44842216,0.5515778
NCT00786838,Statement: the placebo and trabectedin intervention in the primary trial are both administered through a 8-hour intravenous infusion on a bi-weekly basis. [SEP] Clinical Trial: NCT00786838,Contradiction,0.3224108,0.67758924
NCT00182793,"Statement: the primary clinical trial had zero infection cases, whilst the secondary clinical trial also reported an absence of infection [SEP] Clinical Trial: NCT00182793",Entailment,0.76079184,0.23920816
NCT01286168,"Statement: canine subject unique identifier is a unique identifier for a canine clinical subject. The most common adverse event in the secondary trial was Anaemia, affecting more than 5% of patients, there were no recorded AEs in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.7024145,0.2975855
NCT01171924,"Statement: the first and second cohorts in the primary clinical trial are administered the same amount of cudc-101, but cohort 1 receives the treatment more often. [SEP] Clinical Trial: NCT01171924",Entailment,0.50085276,0.4991472
NCT01390818,"Statement: in the primary clinical trial, all observed adverse events were attributed to members of both cohorts, not exclusively those in cohort 1 [SEP] Clinical Trial: NCT01390818",Entailment,0.7675647,0.23243527
NCT00146172,Statement: agree with prior crf is a question as to whether the user agrees with the previous case report form. candidates Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00146172,Contradiction,0.4321601,0.5678399
NCT01222390,"Statement: x-rays, transendocardial injections, ct scans, and mris are excluded from the interventions in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT01222390",Entailment,0.82220715,0.17779286
NCT01106898,Statement: aggravated malignant neoplasm is a malignant neoplasm that shows clinical and/or pathologic progression. Only 2 patients in the primary trial did not have Recurrence-free Survival. [SEP] Clinical Trial: NCT01106898,Contradiction,0.48500898,0.51499104
NCT02404441,"Statement: the secondary trial has distinct inclusion criterion for potential participants below 18, and another for those above, while the primary trial follows a single eligibility benchmark. [SEP] Clinical Trial: NCT02404441",Entailment,0.563202,0.436798
NCT00656019,"Statement: several participants in the primary clinical trial, who possess normal levels of vitamin d, showed a distinguishable pattern in the expression of the evaluated 40 genes. [SEP] Clinical Trial: NCT00656019",Contradiction,0.2670777,0.7329223
NCT01451632,Statement: cohort 1 and cohort 2 of the primary clinical trial were administered the same dosage of both cetuximab and 8mg/kg mm-121. [SEP] Clinical Trial: NCT01451632,Contradiction,0.26014853,0.7398515
NCT01351376,Statement: speaker device is a device designed to convert electrical signals to sounds that can be heard. Patients with measurable bilateral breast cancer are eligible for the primary trial. [SEP] Clinical Trial: NCT01351376,Contradiction,0.36776695,0.6322331
NCT00999921,Statement: patients diagnosed with malignant ductal carcinoma in situ can participate in the secondary clinical trial but are not eligible for the primary clinical trial. [SEP] Clinical Trial: NCT00999921,Entailment,0.8887578,0.111242205
NCT00687102,Statement: a high prevalence of pancytopenia was observed in the patient cohorts of the primary clinical trial and the secondary trial. [SEP] Clinical Trial: NCT00687102,Contradiction,0.31356034,0.68643963
NCT02796755,Statement: the primary trial and the secondary trial do not have any recorded adverse events for their participants. crypt is a pitlike depression or tubular recess. [SEP] Clinical Trial: NCT02796755,Entailment,0.67448395,0.32551607
NCT01554371,Statement: yellow fever virus is a positive sense single-stranded rna virus of the flavivirus family that is the causative agent of yellow fever. Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.62523675,0.37476328
NCT00256698,"Statement: perjeta, while utilized in the primary trial, is not a part of the secondary trial's treatment protocol. [SEP] Clinical Trial: NCT00256698",Entailment,0.9182717,0.08172825
NCT02599194,Statement: the serious adverse reactions were reported more frequently in the adverse events section of the primary clinical trial compared to the secondary clinical trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.8445426,0.15545736
NCT00992602,Statement: There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial. extent breast cancer treatment disrupted self-care is a question about to what extent an individual's breast cancer treatment has disrupted their self-care. [SEP] Clinical Trial: NCT00992602,Entailment,0.5828386,0.41716146
NCT01256567,"Statement: a patient that has received an organ transplant within the last month, and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial. mature neutrophils present is an indication that mature neutrophils were detected in a sample. [SEP] Clinical Trial: NCT01256567",Entailment,0.56739706,0.43260294
NCT00659373,"Statement: On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients [SEP] Clinical Trial: NCT00659373",Entailment,0.70337117,0.29662883
NCT01314963,Statement: intervention 1 of the primary clinical trial uses more substantial amounts of tc99m sulfur colloid than intervention 2. [SEP] Clinical Trial: NCT01314963,Entailment,0.58907115,0.41092885
NCT01997333,Statement: the patient with the longest pfs in the primary trial survived 0.5 months without disease progression or death  [SEP] Clinical Trial: NCT01997333,Entailment,0.5822987,0.41770124
NCT00194779,"Statement: in the primary clinical trial, participants are given only oral medication and don't undergo any surgical process, whereas in the secondary clinical trial, participants are subjected to a vast range of nine medications along with extensive surgical procedures' [SEP] Clinical Trial: NCT00194779",Entailment,0.570794,0.429206
NCT01702571,Statement: cohort 1 of the primary clinical trial has no records of cardiac related adverse events [SEP] Clinical Trial: NCT01702571,Entailment,0.8932265,0.106773466
NCT01128543,Statement: most patients involved in the primary clinical trial showed progression of disease by the end of week 24. [SEP] Clinical Trial: NCT01128543,Entailment,0.52132136,0.47867864
NCT00429299,"Statement: every candidate for the primary clinical trial must have been diagnosed with a her2 positive tumor, verified through positive fish or ihc 3+ tests. [SEP] Clinical Trial: NCT00429299",Contradiction,0.40905398,0.5909461
NCT00429299,Statement: candidates for the primary clinical trial can have a her2 negative tumor result according to fish or ihc 3+ test [SEP] Clinical Trial: NCT00429299,Entailment,0.5548844,0.44511566
NCT00838929,Statement: participants in the primary clinical trial have to undergo radiation therapy without any intake of vorinostat capsules [SEP] Clinical Trial: NCT00838929,Entailment,0.7584013,0.24159873
NCT00365105,"Statement: a 20 year old patient with histologically verified diagnosis of stage 5 breast cancer, absolute neutrophil count of 800/≈í¬∫l, platelet count of 50000/≈í¬∫l, hemoglobin level of 70 g/l, and a life expectancy exceeding 16 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.34823835,0.65176165
NCT00698035,"Statement: crs-r clinical classification question is a question associated with the crs-r clinical classification. the primary trial is using hormonal interventions, and the secondary trial is testing an acupuncture intervention. [SEP] Clinical Trial: NCT00698035",Entailment,0.54391444,0.45608556
NCT02306265,"Statement: having a mammography is a mandatory requirement for prospective candidates for the primary clinical trial, unlike in the secondary clinical trial. [SEP] Clinical Trial: NCT02306265",Entailment,0.780683,0.219317
NCT00838929,Statement: Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy [SEP] Clinical Trial: NCT00838929,Entailment,0.50755423,0.4924457
NCT01537029,"Statement: Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer. ringing or other noises did not wake me from sleep is a response indicating that ringing or other noises did not wake an individual from sleep. [SEP] Clinical Trial: NCT01537029",Entailment,0.5726685,0.4273315
NCT00792077,"Statement: both primary and secondary trials do not use lenalidomide or lapatinib in any interventions, and there is no mention of the specific duration for any trials. [SEP] Clinical Trial: NCT00792077",Entailment,0.9152448,0.08475513
NCT03557801,"Statement: more instances of anemia, pneumonia, and stupor were reported in the secondary trial than in the primary trial, while the primary trial had more recorded febrile infections. [SEP] Clinical Trial: NCT03557801",Contradiction,0.47488895,0.525111
NCT00558272,Statement: gastric dysplasia is a morphologic finding indicating the presence of dysplastic changes within the gastric mucosal epithelial cells. The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.44426605,0.555734
NCT01421472,"Statement: Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial. sf6d version 2.0 acute questionnaire question is a question associated with the sf6d version 2.0 acute questionnaire. [SEP] Clinical Trial: NCT01421472",Contradiction,0.44295672,0.55704325
NCT00878709,"Statement: egfr nm 005228.3:c.2313 2314insaac is an insertion of 3 nucleotides, aac, between position 2313 and 2314 of the coding sequence of the egfr gene. The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group. [SEP] Clinical Trial: NCT00878709",Entailment,0.5546375,0.44536254
NCT00753415,"Statement: in the primary clinical trial, both cohort a and b receive the same three electroporation injections of ld v934 [SEP] Clinical Trial: NCT00753415",Contradiction,0.38996425,0.6100358
NCT02187783,"Statement: the primary trial recorded a higher incidence of palpitations, pericardial effusions, and abdominal pains than the secondary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.47949874,0.5205013
NCT02807844,Statement: all patients in the primary trial receive at least 0.02g of mcs110 every 3 weeks. [SEP] Clinical Trial: NCT02807844,Entailment,0.5060034,0.4939966
NCT00030823,Statement: ce mark is a label which indicates that a product conforms with the essential requirements of the applicable european community directives. There were more participants in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00030823,Contradiction,0.4362179,0.56378216
NCT01806259,Statement: the ketorolac 0.03 g group of the primary trial had a -0.064 recurrence-free survival compared to the nacl 0.9% 3ml group [SEP] Clinical Trial: NCT01806259,Entailment,0.57675475,0.4232453
NCT01855828,"Statement: there was one psychiatric adverse event in the primary trial, which affected less than 1% of patients [SEP] Clinical Trial: NCT01855828",Entailment,0.8888938,0.11110624
NCT01963481,Statement: patients suffering from mild insomnia are eligible to participate in the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01963481,Contradiction,0.21722235,0.7827776
NCT00429182,Statement: less than 0.87% of the primary trial participants had a reduction in circulating tumor cells following weeks of high-dose chemotherapy with purged autologous stem cell products [SEP] Clinical Trial: NCT00429182,Entailment,0.72206706,0.27793294
NCT00558272,Statement: 17p12-p11.2 is a chromosome band present on 17p The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.55678225,0.44321778
NCT01306032,Statement: both the primary clinical trial and the secondary clinical trial recorded thromboembolic events in the participating patients. [SEP] Clinical Trial: NCT01306032,Contradiction,0.44508085,0.5549192
NCT00377156,"Statement: Diagnosis of 2-3 cerebral metastases will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. [SEP] Clinical Trial: NCT00377156",Entailment,0.50864893,0.49135107
NCT00245050,"Statement: one experimental group and one placebo group were designed for the primary clinical trial, whereas the secondary clinical trial employed one test group and one control group. [SEP] Clinical Trial: NCT00245050",Entailment,0.68435466,0.31564537
NCT00146172,"Statement: candidates who are significantly limited in their self-care ability; spending more than half of their waking hours in a bed or chair, may participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00146172",Contradiction,0.40069628,0.5993037
NCT00256217,"Statement: while there were no recorded adverse events among the patients in the primary clinical trial, every participant in the secondary clinical trial experienced at least one adverse event. [SEP] Clinical Trial: NCT00256217",Entailment,0.8522705,0.14772947
NCT01823991,Statement: being diagnosed with alzheimer's disease does not prevent a patient from taking part in the primary clinical trial [SEP] Clinical Trial: NCT01823991,Entailment,0.8325848,0.16741528
NCT01783444,"Statement: women with a new diagnosis of stage iv, er+ breast cancer who are contemplating undergoing mastectomy are suitable for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01783444",Contradiction,0.39471838,0.60528165
NCT00800436,"Statement: use of gabapentin or herceptin within the last six months, doesn't affect the eligibility for the secondary trial, but considers the exclusion from the primary trial. [SEP] Clinical Trial: NCT00800436",Entailment,0.71678793,0.28321207
NCT01649271,Statement: three cases of shingles were reported across the patient cohorts involved in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT01649271,Contradiction,0.43816096,0.56183904
NCT00843167,"Statement: while the secondary clinical trial considers muscle augmentation as a measure of the efficacy of physical therapy, the primary clinical trial investigates the effects of sulforaphane supplements on the amount of isothiocyanates in urine. [SEP] Clinical Trial: NCT00843167",Contradiction,0.48118022,0.51881975
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 180 days if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.38030884,0.61969113
NCT02961790,"Statement: patients who have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy within one month prior to the study initiation are not eligible for the primary clinical trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.73280007,0.26719993
NCT00538850,"Statement: the primary clinical trial showcases alterations in the severity of pain, while the secondary clinical trial assesses the variation in lumbar spine's bone mineral density (bmd) from its initial state to the ninth month [SEP] Clinical Trial: NCT00538850",Contradiction,0.45090985,0.54909015
NCT01989546,"Statement: patients receiving warfarin-founded treatments are barred from the primary clinical trial, yet they may still be suitable for the secondary clinical trial. [SEP] Clinical Trial: NCT01989546",Entailment,0.8007398,0.19926013
NCT01439282,"Statement: the primary clinical trial does not consider gender in determining eligibility, however, only females can participate in the secondary clinical trial. [SEP] Clinical Trial: NCT01439282",Contradiction,0.46185666,0.53814334
NCT00475085,Statement: detailed participant information for each cohort is provided by the primary clinical trial. [SEP] Clinical Trial: NCT00475085,Entailment,0.8635575,0.13644254
NCT00256698,Statement: the use of arimidex is not present in the primary trial cohorts but is a crucial part of the secondary trial. [SEP] Clinical Trial: NCT00256698,Entailment,0.8128227,0.18717729
NCT00687102,Statement: the patient cohorts of the primary clinical trial and the secondary clinical trial have reported 7 cases of asthenia and 2 cases of pyrexia [SEP] Clinical Trial: NCT00687102,Contradiction,0.24651563,0.75348437
NCT01920061,Statement: The same number of Aes were reported for both cohorts in the primary trial. mediastinal malignant germ cell tumor stage is a mediastinal malignant germ cell tumor stage defined according to the pediatric study group classification criteria. [SEP] Clinical Trial: NCT01920061,Entailment,0.6248485,0.3751515
NCT02403271,Statement: biliary colic and diarrhoea cases are relatively equal across the primary and secondary clinical trials. [SEP] Clinical Trial: NCT02403271,Entailment,0.69388545,0.30611452
NCT00021255,"Statement: mapk pathway alteration positive is a genetic finding indicating the presence of gene abnormalities resulting in alteration of signaling in the mapk pathway. Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs. [SEP] Clinical Trial: NCT00021255",Contradiction,0.45124564,0.54875433
NCT02988986,Statement: after 2 weeks of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 30% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Entailment,0.5058315,0.49416855
NCT00956813,"Statement: the primary clinical trial reports its results in milligrams, while the secondary clinical trial utilizes liters. [SEP] Clinical Trial: NCT00956813",Contradiction,0.4082321,0.5917679
NCT00792077,Statement: the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1. [SEP] Clinical Trial: NCT00792077,Entailment,0.72373676,0.27626324
NCT01466972,Statement: all adverse events reported in the primary clinical trial were different for each patient. [SEP] Clinical Trial: NCT01466972,Entailment,0.9153777,0.08462237
NCT03092934,Statement: patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer. [SEP] Clinical Trial: NCT03092934,Entailment,0.6671661,0.33283386
NCT00709761,Statement: the more than half of participants in the primary clinical trial who were treated with 1000 mg of lapatinib in combination with nab-paclitaxel exhibited either a verified complete response or a validated partial response. [SEP] Clinical Trial: NCT00709761,Contradiction,0.43678266,0.5632173
NCT01129622,Statement: the secondary clinical trial accepts females who are living with ibs and claustrophobia. [SEP] Clinical Trial: NCT01129622,Contradiction,0.41849306,0.5815069
NCT00759785,Statement: 0.492 more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group [SEP] Clinical Trial: NCT00759785,Entailment,0.5021956,0.49780437
NCT02306265,"Statement: candidates must not undergo any form of imaging test before they are eligible for the primary trial, but they must have a mammography to qualify for the secondary trial. [SEP] Clinical Trial: NCT02306265",Entailment,0.57898396,0.421016
NCT02002533,Statement: the primary trial has 4 more adverse events recorded than the secondary trial. cdisc send laboratory animal species terminology is a terminology set that includes concepts relevant to cdisc send laboratory animal species. [SEP] Clinical Trial: NCT02002533,Entailment,0.61739874,0.38260123
NCT00825682,"Statement: in comparison to the primary trial, the secondary trial carries out an intervention that is extended by three times. [SEP] Clinical Trial: NCT00825682",Entailment,0.5144056,0.4855944
NCT00871858,"Statement: in the primary clinical trial, cohort 1 uses paclitaxel for its intervention while fulvestrant is the method of treatment for cohort 2 [SEP] Clinical Trial: NCT00871858",Entailment,0.59593403,0.40406603
NCT00143390,Statement: the primary clinical trial concluded with zero incidents of gastro-intestinal adverse events [SEP] Clinical Trial: NCT00143390,Entailment,0.8336831,0.16631699
NCT01606748,Statement: the first subgroup in the primary clinical trial reported various cases of anaemia and febrile neutropenia but registered no instances of pancytopenia. [SEP] Clinical Trial: NCT01606748,Entailment,0.5716015,0.42839852
NCT01129622,Statement: women suffering from both claustrophobia and osteoporosis are eligible for the primary and secondary clinical trials. [SEP] Clinical Trial: NCT01129622,Contradiction,0.26753077,0.7324692
NCT00544167,"Statement: the occurrence of a pulmonary embolism in the past three years deems a patient ineligible for the primary clinical trial, but the said patient could potentially partake in the secondary clinical trial, subject to the investigators' evaluation. [SEP] Clinical Trial: NCT00544167",Entailment,0.7456055,0.25439447
NCT00377156,"Statement: patients with 4-5 cerebral metastases in the cerebral cortex will be eligible for the secondary trial. however, those with this diagnosis will not qualify for the primary trial. [SEP] Clinical Trial: NCT00377156",Entailment,0.7412566,0.25874344
NCT00320541,Statement: The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group. cutter device is a device designed to slice or sever a material. [SEP] Clinical Trial: NCT00320541,Entailment,0.6112999,0.38870016
NCT04080297,Statement: Any Patients currently taking part in the secondary trial will also be eligible for the primary trial as they have the same inclusion criteria [SEP] Clinical Trial: NCT04080297,Entailment,0.51144993,0.48855013
NCT00978250,Statement: erbb2 nm 004448.4:c.2264 2278del is a deletion of 15 nucleotides (tgagggaaaacaca) from the coding sequence of the erbb2 gene from position 2264 through 2278. Patients with histologically documented metastatic SCBC are excluded from the primary trial. [SEP] Clinical Trial: NCT00978250,Entailment,0.706645,0.29335493
NCT01466972,"Statement: among the participants of the primary clinical trial, maculo-papular rash was often reported as an adverse event. [SEP] Clinical Trial: NCT01466972",Entailment,0.70655316,0.29344684
NCT00088413,"Statement: all negative occurrences experienced during the primary clinical trial concerned the musculoskeletal system, a situation not seen in the secondary clinical trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.8451381,0.15486191
NCT00756717,Statement: there were multiple adverse events recorded in the primary trial and the secondary trial [SEP] Clinical Trial: NCT00756717,Entailment,0.5699978,0.43000224
NCT00820872,Statement: the primary clinical trial had twice as many participants with cholelithiasis than the secondary clinical trial. [SEP] Clinical Trial: NCT00820872,Contradiction,0.44685847,0.55314153
NCT02041429,"Statement: childhood ovarian embryonal carcinoma is an embryonal carcinoma that arises from the ovary and occurs in children. the primary trial and the secondary trial report on the MTD of different interventions, with the MTD of MM-111 for patients in the secondary trial being 15 mg per day. [SEP] Clinical Trial: NCT02041429",Contradiction,0.30265522,0.6973448
NCT00404066,"Statement: the only types of adverse events (aes) observed in patients from the secondary clinical trial were severe nausea and chronic fatigue, numerous aes were documented in the primary clinical trial [SEP] Clinical Trial: NCT00404066",Contradiction,0.3762225,0.62377757
NCT00454532,Statement: over 97% of patients in the secondary trial and the primary trial did not suffer any adverse events. arrhythmogenic syncope is a condition in which syncope occurs due to an arrhythmia. (acc/aha) [SEP] Clinical Trial: NCT00454532,Contradiction,0.3417832,0.6582168
NCT00538850,"Statement: the the primary trial results report the severity of delayed nausea on a range of 1 to 7, and the secondary trial measures the change from baseline to 0.75 years in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850",Contradiction,0.44024095,0.5597591
NCT00317603,"Statement: axl overexpression positive is an indication that overexpression of axl has been detected in a sample. The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope, which occurred in 25.00% of the primary trial patients. [SEP] Clinical Trial: NCT00317603",Contradiction,0.2856146,0.71438545
NCT02413008,"Statement: the primary and secondary clinical trials use the same key outcome measurement: the ratio of patients who exhibit no signs of invasive tumor remaining in the breast after undergoing surgery following the completion of chemotherapy, referred to as pcr within the breast. [SEP] Clinical Trial: NCT02413008",Contradiction,0.39028808,0.60971195
NCT00408681,"Statement: the primary clinical trial had a higher prevalence of recurring malignancies, graft-versus-host disease, anaemia, cardiac failure, and diffuse alveolar hemorrhage in its adverse events compared to the secondary clinical trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.57980675,0.42019325
NCT02179515,"Statement: in group 1 of the primary clinical trial, 100% of subjects experienced an adverse event that threatened their life at least once. [SEP] Clinical Trial: NCT02179515",Entailment,0.6640261,0.33597395
NCT01706081,Statement: lymphedema conditions of patients in the primary clinical trial worsened compared to those of patients on the waiting list despite receiving acupuncture treatment. [SEP] Clinical Trial: NCT01706081,Entailment,0.63386774,0.36613232
NCT00245050,"Statement: the primary trial had one test group and one placebo group, the secondary trial had 2 test groups. [SEP] Clinical Trial: NCT00245050",Contradiction,0.47025198,0.529748
NCT02988986,"Statement: near the conclusion of a one-month period of tak-228 plus tamoxifen treatment, the percentage of cells with ki67 expression in patients participating in the primary clinical trial was found to have remained the same. [SEP] Clinical Trial: NCT02988986",Entailment,0.5422343,0.45776564
NCT02286843,Statement: 13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.42444488,0.5755551
NCT00416715,"Statement: Candidates for the secondary trial study group receive weekly subcutaneous (SC) injections, whereas the primary trial participants do not receive any injections. cassette dosing unit is a dosing unit equal to the amount of active ingredient(s) contained in a cassette. [SEP] Clinical Trial: NCT00416715",Entailment,0.84077996,0.15922008
NCT00467844,Statement: all patients treated with gtx-024 1x10^-3 grams in the primary trial gained lean body mass over a 17 week period [SEP] Clinical Trial: NCT00467844,Contradiction,0.45876795,0.54123205
NCT00775645,Statement: in both the primary trial and the secondary trial there were 5 adverse events which occurred in more than 25% of participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.44548735,0.5545126
NCT01963481,Statement: neither the primary clinical trial nor the secondary clinical trial accepts patients with severe insomnia [SEP] Clinical Trial: NCT01963481,Contradiction,0.3846564,0.61534363
NCT00313170,Statement: patients without any type of cancer may participate in the primary clinical trial. [SEP] Clinical Trial: NCT00313170,Entailment,0.7942852,0.20571482
NCT00583700,"Statement: women in the age bracket of 18-19 years can join the secondary clinical trial, but their eligibility for the primary clinical trial will come after a waiting period of 1-2 years [SEP] Clinical Trial: NCT00583700",Entailment,0.51785094,0.48214912
NCT00586326,Statement: The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses. node is any bulge or swelling of an anatomical structure or part. [SEP] Clinical Trial: NCT00586326,Entailment,0.56967735,0.4303227
NCT00357734,"Statement: the treatment plan in the primary clinical trial includes administration of one drug, zd1839. in contrast, the secondary clinical trial's treatment approach involves the expectation of at least three simultaneous drugs, such as zoledronic acid, samarium-153 and pegfilgrastim. [SEP] Clinical Trial: NCT00357734",Contradiction,0.39684883,0.6031512
NCT00708019,Statement: several of the patients in the primary trial experienced the no pain whatsoever during the 5 years of the study. [SEP] Clinical Trial: NCT00708019,Contradiction,0.27547935,0.7245207
NCT01419717,"Statement: the primary trial requires patients to receive 4 milligrams of denosumab injected subcutaneously every day, the secondary trial does not require injection, instead using lymphoscintigraphy. [SEP] Clinical Trial: NCT01419717",Contradiction,0.3314175,0.6685825
NCT00992602,"Statement: comprehensive records of adverse events are available for the primary trial, enabling a thorough comparison with the secondary trial's data. [SEP] Clinical Trial: NCT00992602",Entailment,0.67992324,0.32007673
NCT00182767,"Statement: throughout the primary clinical trial, an instance of dose-limiting toxicity was identified in two different patients, each from separate cohorts. [SEP] Clinical Trial: NCT00182767",Entailment,0.713045,0.28695494
NCT02286843,"Statement: in the primary clinical trial, 13% of the participants, specifically those with pr+ primary breast cancer who were treated with her2-targeted pet/ct. 89zr-trastuzumab, developed her2+ metastases [SEP] Clinical Trial: NCT02286843",Contradiction,0.40936953,0.5906305
NCT01617668,"Statement: while most patients in the first cohort of the primary clinical trial endured adversities, the same cannot be said for the second cohort. [SEP] Clinical Trial: NCT01617668",Entailment,0.898071,0.10192902
NCT01743560,Statement: children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial [SEP] Clinical Trial: NCT01743560,Entailment,0.7784442,0.22155581
NCT01351376,Statement: Patients with measurable bilateral breast cancer are eligible for the primary trial [SEP] Clinical Trial: NCT01351376,Entailment,0.57170486,0.4282952
NCT01286987,Statement: breast cancer patients in the primary trial are administered 3000 mcg/day of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 10 mcg/day talazoparib instead. [SEP] Clinical Trial: NCT01286987,Entailment,0.5862831,0.41371688
NCT01419717,"Statement: 120 milligrams of denosumab needs to be injected subcutaneously every month for patients in the primary clinical trial, whereas lymphoscintigraphy is utilized in the secondary clinical trial rather than injections. [SEP] Clinical Trial: NCT01419717",Entailment,0.5520959,0.44790414
NCT00687102,Statement: There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial [SEP] Clinical Trial: NCT00687102,Entailment,0.53874934,0.46125066
NCT01806259,Statement: 96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group. undetermined rhythm by ecg finding is an electrocardiographic finding of a cardiac rhythm whose mechanism cannot be determined from the ecg. (cdisc) [SEP] Clinical Trial: NCT01806259,Contradiction,0.4495795,0.5504205
NCT02734979,"Statement: secondary clinical trial is not open to participants that have experienced pulmonary embolisms, and the primary clinical trial is not available for individuals who have breast implants. [SEP] Clinical Trial: NCT02734979",Entailment,0.8808267,0.119173296
NCT01306032,Statement: adverse events experienced by patients in the primary clinical trial do not match those in the secondary clinical trial. [SEP] Clinical Trial: NCT01306032,Entailment,0.9261019,0.07389805
NCT01127763,Statement: 5 patients in the primary trial suffered 3 or more adverse events [SEP] Clinical Trial: NCT01127763,Entailment,0.7340335,0.26596648
NCT01702571,Statement: cohort 1 of the primary clinical trial has multiple records of cardiac-related adverse events. [SEP] Clinical Trial: NCT01702571,Entailment,0.83693033,0.1630697
NCT01086605,Statement: dyspnea was frequently recorded as an adverse event in both cohorts of the primary clinical trial. [SEP] Clinical Trial: NCT01086605,Entailment,0.7894467,0.21055326
NCT01730729,"Statement: electrolyte disorder is a metabolic disorder that is characterized by electrolyte imbalances (e.g., hyperkalemia, hypokalemia, and hypercalcemia). the primary trial intervention is given orally, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein. [SEP] Clinical Trial: NCT01730729",Contradiction,0.446512,0.55348796
NCT01128543,"Statement: In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24. feel self-conscious about letting partner see my breasts is a question about how often an individual feels self-conscious about letting their breasts be seen by their partner. [SEP] Clinical Trial: NCT01128543",Entailment,0.53822863,0.46177137
NCT00122369,"Statement: the secondary clinical trial has age limitations for patients, however, the primary clinical trial lacks a specific age range for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.8521585,0.14784156
NCT00538850,Statement: the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 1 year in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850,Contradiction,0.44235823,0.55764174
NCT02509156,Statement: the placebo intervention of the primary clinical trial is administered orally in a smaller dose than the allo-mscs intervention. [SEP] Clinical Trial: NCT02509156,Entailment,0.77164286,0.22835712
NCT01831089,Statement: patients with a proven histological or cytological diagnosis of resectable non-small cell lung breast cancer or small cell lung cancer qualify for the primary clinical trial [SEP] Clinical Trial: NCT01831089,Entailment,0.53921425,0.46078578
NCT01013740,Statement: tumour lysis syndrome was a condition suffered by multiple patients participating in the primary clinical trial as well as the secondary clinical trial. [SEP] Clinical Trial: NCT01013740,Contradiction,0.23026353,0.76973647
NCT01138046,"Statement: Any japanese national can take part in the primary trial, or the secondary trial. [SEP] Clinical Trial: NCT01138046",Contradiction,0.35430568,0.6456943
NCT01606748,Statement: primary clinical trial's first cohort had numerous pancytopenia occurrences with no recorded instances of anaemia and febrile neutropenia. [SEP] Clinical Trial: NCT01606748,Contradiction,0.44318625,0.5568138
NCT00656305,Statement: There were no deaths or Hospitalizations in cohort 2 of the primary trial. people were unfriendly is a question about whether an individual feels or felt people were unfriendly. [SEP] Clinical Trial: NCT00656305,Entailment,0.6053365,0.39466348
NCT01205503,"Statement: Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01205503",Entailment,0.72261715,0.2773829
NCT00708019,Statement: None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks. entity name person data type is a data type comprised of the name of a person. [SEP] Clinical Trial: NCT00708019,Entailment,0.7689143,0.23108569
NCT01290536,"Statement: The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month. krd regimen is a chemotherapy regimen consisting of carfilzomib, lenalidomide and dexamethasone that is used for the treatment of plasma cell myeloma. [SEP] Clinical Trial: NCT01290536",Contradiction,0.3892536,0.6107464
NCT02038218,Statement: the units of measure employed in the results of the primary clinical trial differ from those used in the secondary clinical trial. [SEP] Clinical Trial: NCT02038218,Entailment,0.9055582,0.09444172
NCT03384316,Statement: infections and infestations cases in the primary clinical trial occurred in patients from cohort 2. [SEP] Clinical Trial: NCT03384316,Entailment,0.7738881,0.2261119
NCT01376349,"Statement: the primary clinical trial uses subjective patient-reported outcomes as its unit of measure, whereas the secondary trial employs biomarker data for measuring outcomes. [SEP] Clinical Trial: NCT01376349",Entailment,0.76729155,0.23270851
NCT00558272,Statement: the azd0530 1.75 x 10^2 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the zoledronic acid 4 x 10^0 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.58317494,0.416825
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 0.15 kg of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.37494105,0.625059
NCT00656019,Statement: None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes. primary medical oncologist is a patient's main medical oncologist. the primary medical oncologist may be responsible for coordinating treatment with other medical oncologists. [SEP] Clinical Trial: NCT00656019,Entailment,0.53665376,0.46334618
NCT00878709,Statement: the number of participants was identical in both groups of the primary clinical trial. [SEP] Clinical Trial: NCT00878709,Entailment,0.86874396,0.13125603
NCT01194440,Statement: patients with advanced stage of ductal carcinoma not contemplating ai therapy are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01194440,Entailment,0.65393734,0.34606266
NCT01128543,Statement: the majority of patients in the primary trial experienced complete response by week 42. [SEP] Clinical Trial: NCT01128543,Contradiction,0.4454105,0.5545895
NCT00838929,Statement: radiotherapy patients in the primary clinical trial only receive a dosage below 100 ¬¨¬µg of fentanyl sublingual spray. [SEP] Clinical Trial: NCT00838929,Entailment,0.6028538,0.39714622
NCT00088413,"Statement: blood and bone marrow related issues predominantly accounted for reported adverse events in the primary clinical trial, as opposed to the secondary clinical trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.75294834,0.24705164
NCT01975831,Statement: The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2. retinal hemangioblastoma is a hemangioblastoma that arises from the retina. it can occur sporadically or as part of von hippel- lindau syndrome. [SEP] Clinical Trial: NCT01975831,Contradiction,0.45111167,0.54888827
NCT00753415,Statement: Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934 [SEP] Clinical Trial: NCT00753415,Contradiction,0.35324165,0.6467583
NCT00262834,"Statement: cell culture image is any image of cells grown or manipulated in a tissue culture. 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients. [SEP] Clinical Trial: NCT00262834",Contradiction,0.4204463,0.5795537
NCT00320541,"Statement: regarding the primary clinical trial, the group receiving paclitaxel plus bevacizumab plus gemcitabine showed a superior orr compared to the group receiving only paclitaxel plus bevacizumab. [SEP] Clinical Trial: NCT00320541",Entailment,0.6236389,0.3763611
NCT02441946,"Statement: patients with a breast tumor 0.2-0.8 centimeters in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.41830766,0.5816923
NCT00148668,Statement: Both interventions in the primary trial include the same dose of Paraplatin [SEP] Clinical Trial: NCT00148668,Entailment,0.64058924,0.35941073
NCT03125941,"Statement: while the first cohort of the primary clinical trial receives dexamethasone pre-operatively, the second cohort gets it two hours following surgery. [SEP] Clinical Trial: NCT03125941",Contradiction,0.45711088,0.54288906
NCT02761642,"Statement: patients suffering from cancer and having conditions like anemia, epilepsy or thalasemic diseases are welcome to participate in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT02761642",Contradiction,0.37927184,0.6207282
NCT00623831,"Statement: in the primary clinical trial, increased pleural effusion and rapid disease progression is experienced by 25% of the patients. [SEP] Clinical Trial: NCT00623831",Contradiction,0.27874807,0.72125196
NCT01597193,Statement: cohort 2 in the primary clinical trial receives a dosage of enzalutamide that is twice as high as the dosage received by cohort 1 [SEP] Clinical Trial: NCT01597193,Entailment,0.5427638,0.45723614
NCT01351376,Statement: primary clinical trial rules out patients with observable tumors in both breasts [SEP] Clinical Trial: NCT01351376,Entailment,0.7621558,0.23784421
NCT01106898,Statement: 97% of patients in the primary trial did not experience any Adverse Events. tritylcysteine is a derivative of cysteine with antimitotic activity and potential antineoplastic activity. (nci04) [SEP] Clinical Trial: NCT01106898,Entailment,0.565566,0.434434
NCT00054028,"Statement: performed histopathology cell type code is a coded value specifying the kind of cells found. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial intervention section does not describe what drugs are to be administered. [SEP] Clinical Trial: NCT00054028",Entailment,0.7712491,0.22875096
NCT01964924,"Statement: primary clinical trial is open to patients diagnosed with ild/dpld over a decade ago, bearing a life expectancy of 2 years [SEP] Clinical Trial: NCT01964924",Contradiction,0.40481156,0.59518844
NCT00656019,"Statement: in the primary clinical trial, cohorts 1 and 2 patients exhibited no noticeable pattern for the expression of the 40 genes examined [SEP] Clinical Trial: NCT00656019",Entailment,0.6181667,0.3818333
NCT00662025,Statement: every participant in the primary clinical trial was administered oral sunitinib daily throughout the entirety of the research period. [SEP] Clinical Trial: NCT00662025,Entailment,0.58213264,0.41786742
NCT02286843,Statement: only 1% of the patients in the primary clinical trial dealing with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab results in her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.4986511,0.5013489
NCT02988986,"Statement: over 5,040 minutes of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 5% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986",Entailment,0.5160374,0.48396257
NCT02734979,"Statement: patients with a past diagnosis of pulmonary embolisms are welcomed to participate in the secondary trial, and those with breast implants are not disqualified from the primary trial. [SEP] Clinical Trial: NCT02734979",Entailment,0.65903264,0.34096733
NCT02259114,"Statement: patients with clear-cell adenocarcinoma or gestational trophoblastic disease, determined by flow cytometry, or paget's disease of the nipple are ineligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02259114",Entailment,0.8260499,0.1739501
NCT02002533,Statement: the primary trial and the secondary trial have 200 recorded adverse events.  [SEP] Clinical Trial: NCT02002533,Entailment,0.7305254,0.2694747
NCT02988986,"Statement: following a month of tak-228 plus tamoxifen administration, the primary clinical trial reported a 20% increase in the percentage of cells displaying ki67 expression. [SEP] Clinical Trial: NCT02988986",Contradiction,0.32346436,0.67653567
NCT00838929,Statement: Every patient in the primary trial is receives a dose of 100 to 1600 ¬¨¬µg fentanyl sublingual spray during radiation therapy. 13q22-q34 is a chromosome band present on 13q [SEP] Clinical Trial: NCT00838929,Contradiction,0.42270708,0.5772929
NCT00836186,"Statement: micron is a unit of length in metric system equal to 10e-6 meter, or micrometer. the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID. [SEP] Clinical Trial: NCT00836186",Contradiction,0.37590712,0.6240929
NCT01614210,"Statement: the findings from the primary clinical trial reveal that administering 20 mg of tamoxifen daily, seven days prior to and 14 days after breast cancer surgery, effectively reduces the expression of ki67 in tumors by an average of 40%. [SEP] Clinical Trial: NCT01614210",Contradiction,0.39223114,0.60776883
NCT00759785,Statement: over 40% more participants in the er-positive luminal b group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group [SEP] Clinical Trial: NCT00759785,Entailment,0.5863217,0.4136783
NCT01194440,"Statement: patients diagnosed with early-stage basal cell carcinoma of the skin, irrespective of hormonal status, are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01194440",Entailment,0.5842186,0.41578135
NCT00030823,Statement: the number of participants in the secondary clinical trial exceeded those in the primary clinical trial. [SEP] Clinical Trial: NCT00030823,Entailment,0.8158371,0.18416288
NCT01106898,Statement: only two individuals in the primary clinical trial were not recurrence-free survivors [SEP] Clinical Trial: NCT01106898,Entailment,0.79520136,0.2047986
NCT01037790,"Statement: patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial. [SEP] Clinical Trial: NCT01037790",Entailment,0.8178255,0.18217452
NCT00182793,Statement: over 3/20 of patients in the primary trial and the secondary trial suffered from infections during the study period [SEP] Clinical Trial: NCT00182793,Contradiction,0.2475344,0.7524656
NCT00405938,"Statement: Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.39113188,0.6088682
NCT00702949,"Statement: the primary clinical trial involves treating a patient cohort with 150 mg of oral pregabalin twice daily, while the secondary clinical trial uses depocyt and hd-mtx in its patient administration. [SEP] Clinical Trial: NCT00702949",Contradiction,0.39741892,0.6025811
NCT00432562,Statement: there are 15 shared inclusion/exclusion criteria between the secondary trial and the primary trial [SEP] Clinical Trial: NCT00432562,Entailment,0.5937096,0.40629038
NCT02320123,Statement: the educational dvd will not be used in any of the interventions within the primary clinical trial. [SEP] Clinical Trial: NCT02320123,Entailment,0.925876,0.07412396
NCT01664091,"Statement: There were more cases of Infection, Asymmetry and nausea in the primary trial than in the secondary trial. ultrasonogram is a computerized image of internal tissues created by bouncing high-energy sound waves off internal organs. [SEP] Clinical Trial: NCT01664091",Contradiction,0.3953807,0.6046193
NCT00405938,"Statement: if patients have experienced abdominal fistula, gastrointestinal perforation, myocardial infarction (mi), stroke, transient ischemic attacks, intrabdominal abscess or severe psychiatric disorders within the last six months, they are ineligible for the primary clinical trial. [SEP] Clinical Trial: NCT00405938",Entailment,0.6020941,0.3979059
NCT02041429,"Statement: cerebral amyloid angiopathy is a disorder characterized by the deposition of amyloid in the wall of the vessels in the brain. the primary trial and the secondary trial report on the MTD of different interventions, with the MTD of MM-111 for patients in the secondary trial being 15 mg per day. [SEP] Clinical Trial: NCT02041429",Contradiction,0.26695746,0.73304254
NCT00182793,Statement: over 185% of patients in the primary trial and the secondary trial suffered from infections during the study period [SEP] Clinical Trial: NCT00182793,Contradiction,0.23512568,0.76487434
NCT01964924,Statement: the primary clinical trial accepts adult patients who were diagnosed with diffuse parenchymal lung disease 4 years ago [SEP] Clinical Trial: NCT01964924,Contradiction,0.458244,0.54175603
NCT02413008,Statement: the secondary trial and the primary trial use different outcome measurements and units of measure. [SEP] Clinical Trial: NCT02413008,Entailment,0.925988,0.07401195
NCT00838929,Statement: all patients participating in the primary clinical trial are instructed to ingest a capsule of vorinostat each day during their radiation treatment. [SEP] Clinical Trial: NCT00838929,Entailment,0.50057197,0.49942806
NCT00843167,"Statement: the secondary clinical trial gauges effectiveness using muscle development as a result of physical therapy. conversely, the primary clinical trial focuses on the impact of sulforaphane supplements on the concentration of isothiocyanates in urine. [SEP] Clinical Trial: NCT00843167",Contradiction,0.4733909,0.5266091
NCT02041429,"Statement: the primary clinical trial does not deliver any information on the mtd of any interventions, whereas the secondary clinical trial's mtd of mm-111 is established at 10 mg per day for its patients [SEP] Clinical Trial: NCT02041429",Entailment,0.68226403,0.31773597
NCT01806259,"Statement: within the primary clinical trial, the nacl 0.9% 3ml group had a higher number of individuals (112) report recurrence-free survival, compared to 78 participants from the ketorolac 30 mg group [SEP] Clinical Trial: NCT01806259",Contradiction,0.35784736,0.6421526
NCT00293384,"Statement: no patients in cohort 2 of the primary clinical trial experienced acute vomiting after being treated with aprepitant, dexamethasone, cytoxan and kytril [SEP] Clinical Trial: NCT00293384",Entailment,0.5672657,0.4327343
NCT02320123,"Statement: the educational dvd is not part of the intervention for any cohort in the primary clinical trial, all cohorts will receive a regular dosage of radiotherapy [SEP] Clinical Trial: NCT02320123",Entailment,0.51059073,0.48940927
NCT01013740,Statement: Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome [SEP] Clinical Trial: NCT01013740,Contradiction,0.13215694,0.8678431
NCT00248547,Statement: all patients in the primary clinical trial who were given a placebo experienced vomiting [SEP] Clinical Trial: NCT00248547,Entailment,0.72971195,0.2702881
NCT02404441,"Statement: for all of its participating individuals, the secondary clinical trial applies a consistent array of inclusion and exclusion benchmarks. conversely, the primary clinical trial adopts two discrete inclusion standards for its various study assemblies. [SEP] Clinical Trial: NCT02404441",Entailment,0.6015921,0.39840785
NCT00143390,"Statement: There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial. microscopic findings supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the microscopic findings domain. [SEP] Clinical Trial: NCT00143390",Contradiction,0.3977737,0.6022263
NCT04080297,Statement: patients who are currently participating in the secondary clinical trial cannot concurrently enroll in the primary clinical trial. [SEP] Clinical Trial: NCT04080297,Entailment,0.9168154,0.083184555
NCT01869192,"Statement: sellar schwannoma is an extremely rare schwannoma that arises from the sellar region. The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm, additionally, in the secondary trial the Denosumab cohort had a better Time to First On-Study SRE than the Zoledronic Acid cohort. [SEP] Clinical Trial: NCT01869192",Contradiction,0.394544,0.60545605
NCT00467844,Statement: at least one patient treated with gtx-024 1mg in the primary trial gained over 1.57473 stone of lean body mass. [SEP] Clinical Trial: NCT00467844,Contradiction,0.40296063,0.59703934
NCT01631552,Statement: primary and secondary clinical trial share identical outcome measurements. [SEP] Clinical Trial: NCT01631552,Entailment,0.91652983,0.08347013
NCT03069313,"Statement: the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally. dietary palmitic acid measurement is a determination of the total 16:0 palmitic acid in a nutritional product or meal, or a portion thereof. [SEP] Clinical Trial: NCT03069313",Contradiction,0.4750301,0.5249699
NCT01997333,"Statement: The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death . short is a variable that is stored as a signed 16-bit (2-byte) integer. [SEP] Clinical Trial: NCT01997333",Contradiction,0.47275913,0.5272409
NCT00759785,Statement: 11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. xq22-24 is a chromosome band present on xq [SEP] Clinical Trial: NCT00759785,Entailment,0.52989256,0.47010747
NCT01806259,Statement: adcs-adl - appliance: other specify is alzheimer's disease cooperative study-activities of daily living inventory (adcs-adl) check all that were used: other specify. 96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group. [SEP] Clinical Trial: NCT01806259,Entailment,0.50153846,0.49846157
NCT00076024,Statement: projection is a prediction made by extrapolating from past observations. There are no conditions on hepatic function for participants of the primary trial. [SEP] Clinical Trial: NCT00076024,Entailment,0.82207483,0.17792517
NCT01250379,"Statement: A 20 year old female patient with a Newly diagnosed ER-positive, HER2-negative breast cancer, could be eligible for the secondary trial and the primary trial. formalin-fixed paraffin-embedded tissue scroll is a formalin-fixed, paraffin-embedded tissue sample that has been cut on a microtome so that it rolls up on itself. [SEP] Clinical Trial: NCT01250379",Contradiction,0.34344232,0.6565577
NCT01290536,"Statement: the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 1000 mg of ibrutinib and 20 mg/kg of medi4736 once daily for one week. [SEP] Clinical Trial: NCT01290536",Contradiction,0.33558512,0.6644149
NCT00266110,Statement: participants in the primary clinical trial will not receive any injections during the study. [SEP] Clinical Trial: NCT00266110,Entailment,0.923167,0.07683296
NCT01664091,"Statement: There were more cases of Infection, Asymmetry and nausea in the primary trial than in the secondary trial. hepatic steatosis is a morphologic finding indicating intracytoplasmic fat accumulation in the liver parenchyma. [SEP] Clinical Trial: NCT01664091",Contradiction,0.41168898,0.588311
NCT01250379,"Statement: a young girl with a Newly diagnosed PR-positive, HER2 positive breast cancer, could be eligible for the secondary trial and the primary trial. reference to study results publication identifier is a unique symbol that establishes identity to a publication that cites this study's results. [SEP] Clinical Trial: NCT01250379",Contradiction,0.28864178,0.71135825
NCT00820872,Statement: nf1 gene mutation is a change in the nucleotide sequence of the nf1 gene. Diarrhoea was more common for the primary trial participants than the secondary trial participants. [SEP] Clinical Trial: NCT00820872,Entailment,0.54711866,0.4528814
NCT01997333,"Statement: The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death . grade 1 kyphosis, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated [SEP] Clinical Trial: NCT01997333",Entailment,0.6039642,0.3960358
NCT03403712,"Statement: childhood gliosarcoma is a gliosarcoma that occurs during childhood. the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Median sleep time of its patients in minutes. [SEP] Clinical Trial: NCT03403712",Contradiction,0.46735772,0.53264225
NCT01222390,Statement: transendocardial injection techniques are integral to the intervention methods of both the primary and secondary clinical trials [SEP] Clinical Trial: NCT01222390,Entailment,0.52693856,0.4730614
NCT00956813,Statement: totally dissimilar outcome measures are found in the results of the secondary clinical trial and the primary clinical trial [SEP] Clinical Trial: NCT00956813,Entailment,0.89285135,0.1071487
NCT04080297,Statement: those involved in the secondary clinical trial at present are barred from simultaneous registration in the primary clinical trial. [SEP] Clinical Trial: NCT04080297,Entailment,0.91966265,0.08033738
NCT00405938,Statement: a recent diagnosis of an intrabdominal abscess or major psychiatric disorder does not disqualify a patient from participating in the primary clinical trial [SEP] Clinical Trial: NCT00405938,Entailment,0.83132565,0.16867429
NCT02286843,Statement: 13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases. dna adduct is a structure formed when a chemical is attached to dna by a covalent bond. [SEP] Clinical Trial: NCT02286843,Contradiction,0.43420586,0.56579417
NCT01466972,Statement: repetitive adverse events were reported among different patients particularly in the primary clinical trial. [SEP] Clinical Trial: NCT01466972,Entailment,0.7716934,0.22830667
NCT00418028,"Statement: child-pugh class b7 is a total score of 7 for hepatic function, corresponding to class b in the child-pugh classification. the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the percentage of patients that experience Objective Response . [SEP] Clinical Trial: NCT00418028",Contradiction,0.34689024,0.6531097
NCT00284180,Statement: individuals who have previously experienced intense anaphylactic responses to trastuzumab are eligible for enrolment in the primary clinical trial. [SEP] Clinical Trial: NCT00284180,Entailment,0.5473046,0.45269543
NCT02178722,Statement: participants of the primary trial receive sunitinib more frequently than sunitinib-na‚àö√òve participants in the secondary trial receive epacadostat. [SEP] Clinical Trial: NCT02178722,Entailment,0.6428786,0.35712144
NCT02286843,"Statement: in the primary clinical trial, her2+ metastases emerged in 13% of the subjects having pr+ primary breast cancer who were treated with her2-targeted pet/ct. 89zr-trastuzumab [SEP] Clinical Trial: NCT02286843",Contradiction,0.42254868,0.5774513
NCT01013740,Statement: the total number of anemia cases in the primary trial surpasses the case count in the secondary trial. [SEP] Clinical Trial: NCT01013740,Contradiction,0.4884233,0.5115767
NCT00911898,Statement: the primary clinical trial's intervention segment mandates the execution of surgical and imaging procedures. [SEP] Clinical Trial: NCT00911898,Entailment,0.7457505,0.25424948
NCT00686127,Statement: There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial. daily or almost daily response is a subjective response that something happens daily or almost daily. [SEP] Clinical Trial: NCT00686127,Entailment,0.5462665,0.45373353
NCT01156987,"Statement: upon diagnosis, it was found that each participant from the primary trial's first group had noticeable lesions, with those from the second trial's group 1 locking any symptoms of radiation dermatitis or hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.45572704,0.54427296
NCT00786838,Statement: the placebo in the primary clinical trial is administrated via an intramuscular injection once a week. [SEP] Clinical Trial: NCT00786838,Entailment,0.5918569,0.40814313
NCT01783444,"Statement: men diagnosed with early stage, er- breast cancer seeking radiation therapy are eligible for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01783444",Contradiction,0.21637163,0.78362834
NCT01129622,Statement: neither the primary clinical trial nor the secondary clinical trial allows participation of women affected by claustrophobia and osteoporosis. [SEP] Clinical Trial: NCT01129622,Contradiction,0.2674481,0.73255193
NCT00632489,Statement: the lbh589 and lapatinib cohort's results are not accounted for in the primary clinical trial [SEP] Clinical Trial: NCT00632489,Entailment,0.91800624,0.08199371
NCT00999921,Statement: apgar score version 1 - respiration or respiratory effort is apgar score version 1 (apgar score version 1) respiration or respiratory effort score. Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial. [SEP] Clinical Trial: NCT00999921,Entailment,0.7135601,0.2864399
NCT00659373,"Statement: education, training and library occupations is a class of professional or vocational positions of employment that involve education, training or libraries. On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients. [SEP] Clinical Trial: NCT00659373",Contradiction,0.44143745,0.5585626
NCT01306032,Statement: thromboembolic incidents were experienced by patients in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01306032,Entailment,0.64753723,0.3524627
NCT02403271,Statement: the number of biliary colic and diarrhoea cases is greater in the secondary clinical trial than in the primary clinical trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.7179207,0.28207928
NCT01301729,Statement: well differentiated neuroendocrine lesion is a neoplastic lesion with neuroendocrine differentiation and well differentiated histological features. At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial. [SEP] Clinical Trial: NCT01301729,Contradiction,0.4066262,0.59337384
NCT00698035,"Statement: topical treatments are being examined in the primary clinical trial, while the secondary clinical trial is evaluating inhalation treatments. [SEP] Clinical Trial: NCT00698035",Entailment,0.5368343,0.4631657
NCT00662025,"Statement: dose regimen is a treatment plan that specifies the amount, schedule, and the duration of intervention(s). Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study. [SEP] Clinical Trial: NCT00662025",Contradiction,0.46466702,0.535333
NCT02234479,"Statement: the primary clinical trial is utilizing on the investigation of varying quantities of a single therapy on its group, whereas the secondary clinical trial is exploring the outcomes from different radiation treatments on its participants. [SEP] Clinical Trial: NCT02234479",Entailment,0.678564,0.32143593
NCT00266110,"Statement: in the primary clinical trial, participants will receive their single injection on the first day of the study. [SEP] Clinical Trial: NCT00266110",Entailment,0.70646805,0.29353192
NCT00950911,"Statement: The dosage of Zoledronic Acid  in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial. grade 1 nipple deformity, ctcae is asymptomatic; asymmetry with slight retraction and/or thickening of the nipple areolar complex [SEP] Clinical Trial: NCT00950911",Contradiction,0.41625962,0.58374035
NCT01301729,"Statement: at different intervals throughout the trials, the same dose of trastuzumab administered to patients in cohort 2 of the secondary clinical trial is also given to those in the primary clinical trial. [SEP] Clinical Trial: NCT01301729",Entailment,0.7399427,0.2600572
NCT01156987,"Statement: zero participants in group 1 of the primary trial were discovered to have lesions, and over 0.9 fraction of participants in group 1 of the secondary trial showed symptoms of radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.38026878,0.6197312
NCT00838929,Statement: every patient in the primary trial is receives a dose of 0.1 to 1.6 milligram fentanyl sublingual spray during radiation therapy [SEP] Clinical Trial: NCT00838929,Entailment,0.5659032,0.43409687
NCT00416715,"Statement: candidates for the secondary trial study group receive 15 weekly subcutaneous (sc) injections, whereas the primary trial participants only receive a single injection at the beginning of the study. [SEP] Clinical Trial: NCT00416715",Entailment,0.5744208,0.42557925
NCT01008904,Statement: an adverse event of peripheral neuropathy was observed in the primary clinical trial. [SEP] Clinical Trial: NCT01008904,Entailment,0.8416344,0.15836562
NCT00800436,"Statement: preoperative iv antiemetics were administered is a response indicating that preoperative intravenous opiates were administered. Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial, but not from the primary trial. [SEP] Clinical Trial: NCT00800436",Contradiction,0.4771622,0.52283776
NCT02441946,"Statement: patients with a tnbc tumor of 1300mm in diameter, are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.30583882,0.6941612
NCT03202472,"Statement: Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial, unless they have non-healing surgical wounds. stridor, ctcae is a disorder characterized by a high pitched breathing sound due to laryngeal or upper airway obstruction. [SEP] Clinical Trial: NCT03202472",Contradiction,0.38359338,0.61640656
NCT01286987,Statement: breast cancer patients in the primary trial are administered 1 mg/day of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 0.025 mg/day talazoparib instead. [SEP] Clinical Trial: NCT01286987,Entailment,0.6442601,0.35573992
NCT01128543,"Statement: in the primary trial results there were more patients with stable disease in the end of the third month than in the end of the sixth month, but no patients with complete response in the end of third or sixth month [SEP] Clinical Trial: NCT01128543",Contradiction,0.47908574,0.5209143
NCT00293540,"Statement: on average patients from the primary trial survive over 3 years, however at least one patient from both cohorts died in under 30 minutes. [SEP] Clinical Trial: NCT00293540",Contradiction,0.4162688,0.58373123
NCT00775645,Statement: the percentage of participants in both the primary clinical trial and the secondary clinical trial who experienced adverse events was less than 20%. [SEP] Clinical Trial: NCT00775645,Entailment,0.8414764,0.15852366
NCT02891681,Statement: fit patients who are not in gestation period have qualification to participate in primary clinical trial and secondary clinical trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.25413844,0.74586153
NCT00429299,Statement: only candidates who are her2 negative on their ihc scores and are fully self-care reliant can participate in the primary clinical trial. [SEP] Clinical Trial: NCT00429299,Entailment,0.5463831,0.45361692
NCT03202472,"Statement: Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. [SEP] Clinical Trial: NCT03202472",Contradiction,0.43782064,0.5621794
NCT03346161,Statement: childhood thyroid gland medullary carcinoma is a medullary thyroid gland carcinoma occurring in childhood. Both cohorts of the primary trial recorded 0 Aes. [SEP] Clinical Trial: NCT03346161,Entailment,0.61023355,0.38976648
NCT01048099,Statement: several patients experienced the same type of adverse event during the primary clinical trial [SEP] Clinical Trial: NCT01048099,Contradiction,0.34831503,0.651685
NCT02306265,"Statement: candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests. external fiberoptic device is a fiberoptic device designed to remain outside of the body. [SEP] Clinical Trial: NCT02306265",Contradiction,0.47139278,0.52860725
NCT00496860,"Statement: familial dysalbuminemic hyperthyroidism is a genetic condition caused by a variant in the alb gene, associated with increased affinity of albumin for thyroxine. cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2. [SEP] Clinical Trial: NCT00496860",Entailment,0.59631586,0.4036841
NCT01310075,Statement: sacral intraspinal meningioma is a meningioma that arises from the meninges of the sacral region of the spinal cord. A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial. [SEP] Clinical Trial: NCT01310075,Contradiction,0.29515183,0.7048482
NCT00871858,"Statement: Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead. copies per microliter is a unit of concentration expressed as a number of copies per unit volume equal to one microliter. [SEP] Clinical Trial: NCT00871858",Entailment,0.511872,0.488128
NCT00871858,Statement: paclitaxel is administered to both cohort 1 and cohort 2 during the primary clinical trial [SEP] Clinical Trial: NCT00871858,Entailment,0.629494,0.37050596
NCT02002533,Statement: the primary trial and the secondary trial have 0 recorded adverse events. [SEP] Clinical Trial: NCT02002533,Entailment,0.9065065,0.09349347
NCT02115607,Statement: the secondary clinical trial has registered 11 surplus cases of intestinal perforation relative to the primary clinical trial [SEP] Clinical Trial: NCT02115607,Contradiction,0.42217225,0.57782775
NCT01664091,"Statement: There were more cases of Infection, Asymmetry and Deflation in the primary trial than in the secondary trial. percutaneous local ablation is any ablation procedure where a needle or probe is passed through the skin. [SEP] Clinical Trial: NCT01664091",Contradiction,0.41873202,0.581268
NCT02286843,Statement: respiratory therapy is any form of treatment that acts to improve or assist with respiratory function. 13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases. [SEP] Clinical Trial: NCT02286843,Contradiction,0.39588732,0.6041126
NCT02796755,Statement: the primary clinical trial has documented multiple adverse events for patients. [SEP] Clinical Trial: NCT02796755,Entailment,0.8509613,0.14903864
NCT01831089,Statement: Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial [SEP] Clinical Trial: NCT01831089,Entailment,0.5662557,0.4337443
NCT02550795,"Statement: group 2 of the primary trial recieves 0.5μg/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. [SEP] Clinical Trial: NCT02550795",Entailment,0.82349837,0.17650168
NCT02550795,"Statement: Group 2 of the primary trial recieves 0.5ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. achondrogenesis is a rare group of disorders characterized by defective development of bones and cartilage. [SEP] Clinical Trial: NCT02550795",Entailment,0.61547524,0.38452476
NCT01439282,"Statement: Gender is not a determining factor for eligibility in the primary trial, but only female patients are eligible for the secondary trial [SEP] Clinical Trial: NCT01439282",Entailment,0.50741965,0.49258035
NCT02599194,"Statement: the adverse events section of the primary clinical trial did not document any suspected serious adverse reactions, while the secondary clinical trial recorded several instances. [SEP] Clinical Trial: NCT02599194",Contradiction,0.29590267,0.70409733
NCT01252290,"Statement: in the primary clinical trial, fewer than 10 subjects experienced adverse events [SEP] Clinical Trial: NCT01252290",Entailment,0.79331464,0.20668538
NCT00708019,"Statement: in the primary clinical trial, no patient underwent the most severe pain perceivable for a duration of 10 weeks. [SEP] Clinical Trial: NCT00708019",Entailment,0.6149993,0.38500068
NCT00686127,Statement: There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial. external ear actinic keratosis is actinic keratosis that develops in the skin of the external ear. [SEP] Clinical Trial: NCT00686127,Entailment,0.5886091,0.4113909
NCT02273206,"Statement: The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type. unable to perform usual activities is a response indicating that an individual is unable to perform their usual activities. [SEP] Clinical Trial: NCT02273206",Entailment,0.70595574,0.2940443
NCT00404066,"Statement: both the secondary and primary clinical trials observed multiple aes, including headache and joint pain, in various patients [SEP] Clinical Trial: NCT00404066",Contradiction,0.31324017,0.6867598
NCT00741039,"Statement: regardless of having cancer or not, all participants in the primary clinical trial are subjected to the same intervention. [SEP] Clinical Trial: NCT00741039",Entailment,0.78889036,0.21110964
NCT01730729,"Statement: first cousin once removed is a child of your first cousin. the primary trial intervention is given topically, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein. [SEP] Clinical Trial: NCT01730729",Contradiction,0.45388767,0.5461123
NCT01128543,"Statement: in the primary trial results there were more patients with stable disease in week 6 than week 18, but 2 patients with complete response in week 6 or 18' [SEP] Clinical Trial: NCT01128543",Contradiction,0.24122779,0.75877225
NCT00262834,"Statement: none adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 1/3.33 of patients. [SEP] Clinical Trial: NCT00262834",Entailment,0.53271425,0.4672857
NCT00377156,"Statement: Diagnosis of 2-3 cerebral metastases within the brainstem will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. [SEP] Clinical Trial: NCT00377156",Entailment,0.50053126,0.49946874
NCT02640053,"Statement: in the primary clinical trial, patients who didn't undergo topical cryotherapy exhibited more severe symptoms compared to those who did. [SEP] Clinical Trial: NCT02640053",Entailment,0.6042268,0.3957732
NCT01390818,Statement: The all recorded Aes in the primary trial occurred to cohort 1 patients [SEP] Clinical Trial: NCT01390818,Entailment,0.84044933,0.15955071
NCT01920061,"Statement: togo is a country in western africa, bordering the gulf of guinea, between benin and ghana. The same number of Aes were reported for both cohorts in the primary trial. [SEP] Clinical Trial: NCT01920061",Contradiction,0.38777807,0.61222196
NCT01803282,"Statement: 0% the primary trial participants, and 0% the secondary trial participants suffered an ae. [SEP] Clinical Trial: NCT01803282",Entailment,0.75896174,0.24103831
NCT01390818,Statement: cohort 1 participants in the primary clinical trial exhibited absolutely no adverse event throughout the duration. [SEP] Clinical Trial: NCT01390818,Entailment,0.7246321,0.27536792
NCT00632489,Statement: data from the primary clinical trial indicates responses of the lbh589 and lapatinib cohort. [SEP] Clinical Trial: NCT00632489,Contradiction,0.39858228,0.6014177
NCT02041429,"Statement: the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 0.5 grams per day [SEP] Clinical Trial: NCT02041429",Contradiction,0.26235163,0.73764837
NCT01313117,"Statement: in the primary clinical trial, patients will be administered higher quantities of alpha lipoic acid for the entirety of the study, in contrast, the same amount of necitumumab is provided to patients in cohort 1 in the secondary clinical trial for the whole study period. [SEP] Clinical Trial: NCT01313117",Entailment,0.51263124,0.48736876
NCT01256567,"Statement: a patient that has received an organ transplant within the last month, would be excluded from the primary trial but may be eligible for the secondary trial [SEP] Clinical Trial: NCT01256567",Entailment,0.8011068,0.19889316
NCT02413008,Statement: the primary clinical trial and the secondary clinical trial employ distinct units and outcome measures. [SEP] Clinical Trial: NCT02413008,Entailment,0.9087456,0.091254406
NCT03202472,"Statement: Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. feel like have to strain to produce voice is a question about how frequently an individual feels as though they have to strain to produce voice. [SEP] Clinical Trial: NCT03202472",Contradiction,0.46812868,0.5318713
NCT01989546,"Statement: CBT based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. [SEP] Clinical Trial: NCT01989546",Entailment,0.67004776,0.3299522
NCT01527487,Statement: cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel. physical quantity to physical quantity time ratio data type is a data type comprised of a physical quantity divided by a physical quantity expressed in units of time. [SEP] Clinical Trial: NCT01527487,Entailment,0.52795035,0.4720497
NCT02104830,"Statement: the primary trial is studying a different drug than the secondary trial, with the same dosage and outcome measurement. [SEP] Clinical Trial: NCT02104830",Entailment,0.7760956,0.2239044
NCT01286987,Statement: hemodialysis catheter infection is a local or systemic infection associated with the use of a hemodialysis catheter. Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention. [SEP] Clinical Trial: NCT01286987,Entailment,0.6059854,0.3940146
NCT00321464,"Statement: both the primary clinical trial and the secondary clinical trial are open to patients who have a confirmed diagnosis of stage 4 breast adenocarcinoma, which may be either er positive, pr positive, or her2/neu negative. [SEP] Clinical Trial: NCT00321464",Contradiction,0.48487929,0.51512074
NCT00321464,"Statement: rivoglitazone is an agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic activity. Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive or HER2/neu negative are eligible for both the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.38529336,0.61470664
NCT00319748,Statement: initial usage is an indication of the first time a device was employed. Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors. [SEP] Clinical Trial: NCT00319748,Contradiction,0.43748212,0.5625178
NCT01963481,Statement: always true is a subjective response indicating that something is always true. Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01963481,Entailment,0.76998794,0.2300121
NCT00825682,"Statement: compared to the intervention in the primary trial, the same procedure in the secondary trial continues for three times as long. [SEP] Clinical Trial: NCT00825682",Entailment,0.5048836,0.49511647
NCT02306265,"Statement: a ct scan, not a mammography, is needed for consideration in the primary trial, while for the secondary trial, no imaging test is required. [SEP] Clinical Trial: NCT02306265",Entailment,0.8686113,0.13138877
NCT02041429,"Statement: while the primary and secondary clinical trials focus on different interventions, the mtd for the secondary clinical trial's mm-111 intervention is set at 15 mg per day [SEP] Clinical Trial: NCT02041429",Entailment,0.5495745,0.4504255
NCT00956813,"Statement: primary clinical trial results are communicated using seconds, while the secondary clinical trial uses minutes as its units of measure. [SEP] Clinical Trial: NCT00956813",Contradiction,0.46544674,0.53455323
NCT01205503,Statement: patients with a documented allergy to celecoxib and levofloxacin can enroll in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01205503,Contradiction,0.41822204,0.58177793
NCT01772004,"Statement: patients of asian descent, living in california can be part of the primary clinical trial. [SEP] Clinical Trial: NCT01772004",Contradiction,0.43289772,0.5671023
NCT00076024,"Statement: There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial. exposure yes no indicator is an indication of whether an exposure occurrence has taken place. [SEP] Clinical Trial: NCT00076024",Entailment,0.69941354,0.30058646
NCT02734979,"Statement: Patients that have a history of pulmonary embolisms cannot take part in the secondary trial, and those who currently have breast implants cannot participate in the primary trial. [SEP] Clinical Trial: NCT02734979",Entailment,0.76838994,0.23161009
NCT01011218,Statement: both the primary and secondary clinical trials recorded over 10 deaths as adverse incidents. [SEP] Clinical Trial: NCT01011218,Entailment,0.6127644,0.3872356
NCT01127763,Statement: at least one patient in the primary trial suffered several different adverse events. impedance conductivity is a method that measures impedance of conductivity which corrects for the concentrations of conducting ions in the sample. [SEP] Clinical Trial: NCT01127763,Entailment,0.5796105,0.4203895
NCT02403271,Statement: biliary colic and clostridium difficile colitis cases are more prevalent in the secondary trial than the primary clinical trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.63876563,0.3612344
NCT00963911,Statement: engagement in regular physical activity is not a required component of the intervention for participants in the primary clinical trial [SEP] Clinical Trial: NCT00963911,Entailment,0.90839016,0.091609865
NCT00429182,Statement: pulse wave increased is a clinical finding in which palpation of the pulse demonstrates a significantly increased upstroke and/or amplitude. (acc/aha) less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products. [SEP] Clinical Trial: NCT00429182,Entailment,0.5300443,0.46995568
NCT00706030,"Statement: in the primary clinical trial's second cohort, four different adverse events were noticed affecting patients. [SEP] Clinical Trial: NCT00706030",Entailment,0.72024703,0.2797529
NCT01920061,"Statement: the primary trial uses a 730-hour cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.91713303,0.082866974
NCT00867217,"Statement: the primary clinical trial is designed for patients who exhibit optimal levels of vitamin d, but such patients may be disqualified from the secondary clinical trial. [SEP] Clinical Trial: NCT00867217",Entailment,0.84466183,0.15533812
NCT00992602,"Statement: We cannot compare the adverse events in the primary trial and the secondary trial, as they do not appear to have been recorded for the primary trial. pressure sensor device is a sensor designed to respond to the level of pressure in a space or pressing on a surface. [SEP] Clinical Trial: NCT00992602",Entailment,0.8367313,0.16326867
NCT02259114,Statement: patients diagnosed with nut midline carcinoma identified by fluorescence in situ hybridization or inflammatory breast cancer can participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02259114,Contradiction,0.35856333,0.6414367
NCT01664091,"Statement: infection, asymmetry and nausea instances were more in magnitude in the primary clinical trial than they were in the secondary clinical trial. [SEP] Clinical Trial: NCT01664091",Entailment,0.5242507,0.4757493
NCT00253708,"Statement: the primary trial does not test any drug based treatments, whereas the secondary trial tests two different drugs. [SEP] Clinical Trial: NCT00253708",Entailment,0.912145,0.087855004
NCT00305695,"Statement: the intervention 1 in the primary trial is administered subcutaneously, and all intervention drugs in the secondary trial are directly injected into the bloodstream. [SEP] Clinical Trial: NCT00305695",Entailment,0.58571213,0.41428787
NCT01419717,"Statement: the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid. experimental organism benign endometrial adenoma is a benign epithelial neoplasm arising from the endometrium. [SEP] Clinical Trial: NCT01419717",Contradiction,0.47212943,0.52787054
NCT01614210,Statement: data from the primary clinical trial indicates a 40% average reduction in tumor diameter after patients took tamoxifen 32 mg po daily for seven days before and fourteen days after their breast cancer surgery. [SEP] Clinical Trial: NCT01614210,Contradiction,0.36884892,0.63115114
NCT00451555,"Statement: ai therapy and mirtazapine responsiveness is not a requirement for patients participating in the primary clinical trial, but it is mandatory for the secondary clinical trial [SEP] Clinical Trial: NCT00451555",Entailment,0.509077,0.49092296
NCT02312934,"Statement: primary clinical trial does not allow participants who smoke, but the secondary clinical trial may accept such individuals if they consume less than five alcoholic beverages daily. [SEP] Clinical Trial: NCT02312934",Entailment,0.6701729,0.32982704
NCT01629615,"Statement: during the period of the study, most individuals participating in the primary clinical trial struggled with varying degrees of eating disorders [SEP] Clinical Trial: NCT01629615",Contradiction,0.43474832,0.5652517
NCT00270894,"Statement: those involved in the primary clinical trial are administered four distinct medications over the course of the study, not exceeding a dosage of 100 mg/m^2 [SEP] Clinical Trial: NCT00270894",Contradiction,0.49899182,0.50100815
NCT00293540,"Statement: on average patients from the primary trial survive over 10 years, however at least one patient from both cohorts died in under 24 hours. [SEP] Clinical Trial: NCT00293540",Contradiction,0.38985378,0.6101463
NCT01730729,"Statement: was mgmt promoter methylation testing performed is a question asking if mgmt promoter methylation was analyzed during the study. the primary trial intervention is given topically, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein. [SEP] Clinical Trial: NCT01730729",Contradiction,0.48439837,0.51560163
NCT01023477,"Statement: the primary clinical trial does not accept patients with low potassium levels, but those with high potassium levels could be eligible for both the primary and secondary clinical trial. [SEP] Clinical Trial: NCT01023477",Entailment,0.6847522,0.3152477
NCT03125941,"Statement: Both the primary trial cohorts receive pre-operative Dexamethasone. benign testicular neoplasm is a non-metastasizing neoplasm that arises from the testis. representative examples include benign sertoli cell tumor, thecoma, and fibroma. [SEP] Clinical Trial: NCT03125941",Contradiction,0.39490202,0.605098
NCT00373256,"Statement: the distinction in the primary clinical trial between the first and second cohorts lies in the dosage and treatment administered; 25 mg of sunitinib is given daily to the first cohort, while the second cohort receives 90 mg/m^2 paclitaxel. [SEP] Clinical Trial: NCT00373256",Contradiction,0.36801434,0.6319856
NCT01011218,Statement: dog bite is a wound received from the teeth of a dog. Across both the primary trial and the secondary trial only one death was recorded in the adverse events. [SEP] Clinical Trial: NCT01011218,Entailment,0.60457736,0.39542267
NCT02599194,Statement: device migration problem identified is a device that has moved from its original location due to external forces (e.g. stent or lead movement).  Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.60564774,0.3943522
NCT01730729,"Statement: the principal mode of administration for the primary trial intervention is through venous access, whereas the secondary trial treatment is applied topically [SEP] Clinical Trial: NCT01730729",Entailment,0.69372684,0.30627316
NCT00365365,Statement: participants in the primary clinical trial are administered a regular course of vaccines [SEP] Clinical Trial: NCT00365365,Entailment,0.70478797,0.29521197
NCT01086605,"Statement: both cohorts of the primary clinical trial showed zero cases of hypertension, edema, and dyspnea. [SEP] Clinical Trial: NCT01086605",Entailment,0.6028281,0.39717194
NCT01008150,Statement: all patients in both cohorts of the primary clinical trial showed no sign of pathologic complete response in breast and axillary lymph nodes even after 7 months [SEP] Clinical Trial: NCT01008150,Entailment,0.5028232,0.49717686
NCT00365105,"Statement: a 384 month old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1.807 x 10^6/µl, platelet count of 7.9 x 10^4/µl, hemoglobin level of 9 g/dl, and a life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.3357003,0.6642997
NCT02988986,Statement: over 0.11 years of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 5% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Entailment,0.54106367,0.45893636
NCT02179515,Statement: 100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event [SEP] Clinical Trial: NCT02179515,Entailment,0.6511979,0.34880206
NCT00553358,"Statement: a patient with no detectable tumour, based on clinical examination and ultrasonography, would fail eligibility for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Entailment,0.774575,0.22542496
NCT01803282,"Statement: blacking out is a temporary loss of consciousness or a temporary state of altered consciousness that results in memory loss. 2/73 the primary trial participants, and 0/1674 the secondary trial participants suffered an Acute myocardial infarction . [SEP] Clinical Trial: NCT01803282",Contradiction,0.48176065,0.5182393
NCT01314963,Statement: the interventions in the primary clinical trial implement standard gp for both the first and second protocol. [SEP] Clinical Trial: NCT01314963,Entailment,0.6943556,0.30564436
NCT01091974,"Statement: large cell neuroendocrine carcinoma is an aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. it is composed of malignant large cells. In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.38154808,0.61845195
NCT01468675,"Statement: there are no instances of drugs, radiotherapy, or cbt being administered in any cohort of the primary clinical trial. [SEP] Clinical Trial: NCT01468675",Entailment,0.8111548,0.1888452
NCT00254592,"Statement: cyclophosphamide, paclitaxel and pegfilgrastim are administered to the patients in both the primary and secondary clinical trials [SEP] Clinical Trial: NCT00254592",Contradiction,0.42094725,0.5790528
NCT00454532,"Statement: more than half of the patients in the primary clinical trial suffered from adverse events, while in the secondary clinical trial this percentage was significantly lower [SEP] Clinical Trial: NCT00454532",Entailment,0.6376162,0.36238375
NCT01106898,Statement: gingival polyp is a non-neoplastic nodular lesion that arises from the gingiva. Only 2 patients in the primary trial did not have Recurrence-free Survival. [SEP] Clinical Trial: NCT01106898,Contradiction,0.43303174,0.56696826
NCT00759785,Statement: 78% more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group [SEP] Clinical Trial: NCT00759785,Contradiction,0.48780984,0.5121902
NCT00418028,"Statement: the primary trial enumerates the progression-free survival time in weeks for only a fraction (78) of patients in the main cohort, conversely, the secondary trial discloses the frequency of adverse events experienced throughout the procedure [SEP] Clinical Trial: NCT00418028",Contradiction,0.33374393,0.66625607
NCT00838929,Statement: a dose of 100 to 1600 ¬¨¬µg fentanyl sublingual spray is administered to every patient partaking in the primary clinical trial during their radiation therapy sessions [SEP] Clinical Trial: NCT00838929,Contradiction,0.40823835,0.59176165
NCT00583700,"Statement: for the primary and secondary clinical trial, eligibility extends to women who have reached the age of 18 or more. [SEP] Clinical Trial: NCT00583700",Contradiction,0.23577316,0.76422685
NCT00878709,Statement: the neratinib group of the primary clinical trial had a higher rate of idfs than the placebo group [SEP] Clinical Trial: NCT00878709,Entailment,0.56930333,0.43069664
NCT01766102,"Statement: arm 1's operative time was less than that of arm 2 in the primary clinical trial, indicating the superior performance of standard mammography over intra-operative mammography. the secondary clinical trial includes a control group for contrast.' [SEP] Clinical Trial: NCT01766102",Entailment,0.5644344,0.43556565
NCT01806259,Statement: 96% participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 67% from the nacl 0.9% 0.03dL group [SEP] Clinical Trial: NCT01806259,Contradiction,0.4301903,0.5698097
NCT00569166,"Statement: Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy. malignant oculomotor nerve neoplasm is a primary or metastatic malignant neoplasm involving the oculomotor nerve. [SEP] Clinical Trial: NCT00569166",Contradiction,0.29083663,0.70916337
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the past 2 years will be eligible for the primary clinical trial [SEP] Clinical Trial: NCT01964924,Entailment,0.55179685,0.4482031
NCT01743560,Statement: adults are excluded from the primary clinical trial but they are specifically eligible for the secondary clinical trial [SEP] Clinical Trial: NCT01743560,Entailment,0.7830087,0.21699132
NCT00182767,Statement: incidence of dose-limiting toxicity was not reported in the primary clinical trial. [SEP] Clinical Trial: NCT00182767,Entailment,0.91772914,0.08227087
NCT00416715,"Statement: secondary trial participants are administered just one sc injection at the onset, while the primary trial group gets weekly injections for a month. [SEP] Clinical Trial: NCT00416715",Contradiction,0.4005045,0.59949553
NCT00759785,Statement: minimally invasive lung non-mucinous adenocarcinoma is a morphologic variant of minimally invasive lung  adenocarcinoma characterized by the presence of clara cells and/or type ii cells. 49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. [SEP] Clinical Trial: NCT00759785,Contradiction,0.44245082,0.5575492
NCT01664091,"Statement: There were more cases of Infection, Asymmetry and nausea in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01664091",Entailment,0.50686496,0.49313506
NCT01614210,"Statement: according to the primary clinical trial, administering tamoxifen 32 mg po daily for a period around the surgical intervention led to an increase in tumor size by an average of 20%. [SEP] Clinical Trial: NCT01614210",Contradiction,0.3353475,0.66465247
NCT01008904,"Statement: in the primary clinical trial, stomatitis was the only adverse event documented. [SEP] Clinical Trial: NCT01008904",Entailment,0.85543424,0.14456579
NCT00270894,"Statement: participants in the primary trial receive 8 different drugs throughout the study duration, with a maximum dose of 500 mg/m^2 [SEP] Clinical Trial: NCT00270894",Contradiction,0.28424186,0.71575814
NCT02796755,Statement: neither the primary nor the secondary clinical trial have reported any adverse events for their participants. [SEP] Clinical Trial: NCT02796755,Entailment,0.8972225,0.102777444
NCT02441946,"Statement: patients with a breast tumor 200-800 micrometers in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.4643966,0.5356034
NCT00293540,"Statement: On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years. attend school social events less because of hearing is a question about whether an individual attends school social events less because of their hearing. [SEP] Clinical Trial: NCT00293540",Contradiction,0.49905628,0.5009437
NCT00496860,"Statement: in the primary clinical trial, cohort 1 is given 0.035 mg less alt-801 than cohort 2 [SEP] Clinical Trial: NCT00496860",Entailment,0.59701663,0.40298337
NCT00256698,Statement: none of these describe me is a response indicating that an individual feels that no option listed is a good description for them. Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial. [SEP] Clinical Trial: NCT00256698,Entailment,0.82259136,0.17740865
NCT00475085,Statement: There are 7 more participants in cohort 2 of the primary trial than in cohort 1 [SEP] Clinical Trial: NCT00475085,Contradiction,0.25666058,0.74333936
NCT00992602,Statement: have pain is a question about whether an individual has or had pain. There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00992602,Entailment,0.5055867,0.49441332
NCT00911898,"Statement: the primary clinical trial's intervention segment does not detail the administration method, dose, or routine. [SEP] Clinical Trial: NCT00911898",Entailment,0.8963021,0.103697866
NCT00838929,"Statement: during radiation therapy, patients in the primary clinical trial are given morphine sulfate, not fentanyl sublingual spray. [SEP] Clinical Trial: NCT00838929",Entailment,0.6301893,0.3698107
NCT02041429,"Statement: the maximum tolerated dose (mtd) of diverse interventions are reported in both, the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT02041429",Entailment,0.53993475,0.46006528
NCT01246973,Statement: satisfaction with how natural your reconstructed nipples look is a question about how satisfied or dissatisfied an individual is or was with how natural their reconstructed nipples look. There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01246973,Contradiction,0.41203535,0.58796465
NCT00911898,"Statement: The the primary trial intervention section dose not describe the method of administration, dosage or cycle. small cell component present is a morphologic finding that refers to the presence of a small cell component in a cellular infiltrate. [SEP] Clinical Trial: NCT00911898",Entailment,0.6988898,0.3011102
NCT00706030,"Statement: in the primary clinical trial, patients experienced only three adverse events: pancreatitis, cholelithiasis and hepatic pain, along with febrile neutropenia [SEP] Clinical Trial: NCT00706030",Contradiction,0.41602504,0.583975
NCT01770353,"Statement: the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections. kosraean language is an austroasiatic language spoken on the kosrae and caroline islands of micronesia, and nauru. [SEP] Clinical Trial: NCT01770353",Contradiction,0.17545106,0.82454896
NCT00088413,"Statement: in the primary trial, every adverse event was associated with respiratory complications, unlike the secondary trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.8337881,0.1662119
NCT00544167,"Statement: patients that have suffered a pulmonary embolism in the last 8 weeks are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.7244583,0.27554172
NCT01535040,Statement: both the placebo and memantine interventions in the primary clinical trial are provided daily through oral intake. [SEP] Clinical Trial: NCT01535040,Contradiction,0.49179426,0.5082057
NCT02187783,"Statement: more palpitations, pericardial effusions and abdominal pains were recorded in cohort 1 of the secondary trial than in cohort 2 of the primary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.43684453,0.5631555
NCT01806259,"Statement: in the primary clinical trial, recurrence-free survival was exclusively seen in 120 participants from the nacl 0.9% 3ml group, unlike the 90 from the ketorolac 30 mg group [SEP] Clinical Trial: NCT01806259",Contradiction,0.35143518,0.6485649
NCT02504424,Statement: no participant in the primary clinical trial experienced a urinary tract infection [SEP] Clinical Trial: NCT02504424,Entailment,0.9104137,0.08958627
NCT01823991,Statement:  Alzheimer's patients are not eligible for the primary trial. rete ovarii adenoma is an adenoma that arises from the rete ovarii.  it is composed of elongated tubules.  the clinical course is benign. [SEP] Clinical Trial: NCT01823991,Entailment,0.77421296,0.22578701
NCT01419717,"Statement: the primary trial requires patients to receive 1200 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy. [SEP] Clinical Trial: NCT01419717",Contradiction,0.32696187,0.6730381
NCT02441946,Statement: the primary and secondary clinical trials are open to patients who have a tnbc tumor measuring 100mm. [SEP] Clinical Trial: NCT02441946,Contradiction,0.23926423,0.76073575
NCT00148668,Statement: both approaches in the primary clinical trial incorporate the use of trastuzumab [SEP] Clinical Trial: NCT00148668,Entailment,0.7230162,0.27698383
NCT01706081,"Statement: in the primary clinical trial, lymphedema improvements were more notable in acupuncture patients than in patients on the waiting list. [SEP] Clinical Trial: NCT01706081",Entailment,0.58635795,0.41364205
NCT01306032,Statement: Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial. late endosome is a multivesicular body that can fuse with the lysosome to target extracellular factors for degradation. [SEP] Clinical Trial: NCT01306032,Entailment,0.81349325,0.18650678
NCT01920061,"Statement: while the primary trial's course of treatment follows a month-long cycle, the secondary trial doesn’t enforce a cycle-based intervention. [SEP] Clinical Trial: NCT01920061",Entailment,0.92499757,0.07500244
NCT00544167,"Statement: patients who have experienced a pulmonary embolism within the previous 2 months are not permitted to participate in the primary clinical trial, although the secondary clinical trial may allow their participation dependent on the investigator's judgement. [SEP] Clinical Trial: NCT00544167",Entailment,0.716294,0.28370598
NCT03092934,Statement: liter per hour per kilogram per meter squared is a unit of concentration equal to liter per hour divided by kilogram per meter squared. patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer. [SEP] Clinical Trial: NCT03092934,Entailment,0.55454355,0.44545645
NCT00429299,Statement: All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+. allogeneic lymphocyte is a cell that is antigenically distinct from other lymphocytes. [SEP] Clinical Trial: NCT00429299,Contradiction,0.4835558,0.5164442
NCT00896454,Statement: the secondary trial and the primary trial report results using the same Unit of Measure. therapeutic nervous system procedures is a procedure that is done to treat a nervous system disorder. [SEP] Clinical Trial: NCT00896454,Contradiction,0.3549472,0.6450528
NCT02509156,Statement: The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection. [SEP] Clinical Trial: NCT02509156,Contradiction,0.31704968,0.68295026
NCT00656305,Statement: no deaths or hospital admissions were observed in the second cohort of the primary clinical trial [SEP] Clinical Trial: NCT00656305,Entailment,0.74961627,0.2503837
NCT00558272,Statement: the azd0530 100 mg group of the primary trial experienced a smaller reduction in primary tumour diameter than the zoledronic acid 40 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.6804549,0.31954506
NCT00623831,Statement: 25% of the patients involved in the primary clinical trial report the problems of increased pleural effusion and swift progression of their disease. [SEP] Clinical Trial: NCT00623831,Contradiction,0.32920772,0.6707923
NCT00143390,Statement: there was at most one psychiatric event recorded during the primary clinical trial [SEP] Clinical Trial: NCT00143390,Entailment,0.82957315,0.17042689
NCT00248547,Statement: Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant. [SEP] Clinical Trial: NCT00248547,Contradiction,0.42308655,0.5769135
NCT01313117,"Statement: Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, up to a maximum of 100 mg three times daily, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. [SEP] Clinical Trial: NCT01313117",Contradiction,0.40586796,0.59413207
NCT00404066,"Statement: eyelid oedema, upper gastrointestinal haemorrhage and chest pain were the only adverse events observed in patients from the secondary clinical trial. on the other hand, the primary clinical trial did not record any adverse events. [SEP] Clinical Trial: NCT00404066",Entailment,0.6630366,0.33696344
NCT00357734,"Statement: The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim. benign ethmoid sinus neoplasm is a non-metastasizing neoplasm that arises from the ethmoid sinus. [SEP] Clinical Trial: NCT00357734",Entailment,0.5019198,0.49808022
NCT02504424,Statement: every patient in the primary clinical trial had fully healed surgical incisions without any complications. [SEP] Clinical Trial: NCT02504424,Entailment,0.69430244,0.3056975
NCT01390818,Statement: no adverse events were reported for cohort 1 during the course of the primary clinical trial. [SEP] Clinical Trial: NCT01390818,Entailment,0.8886134,0.11138659
NCT01591746,Statement: vegf overexpression positive is an indication that overexpression of a member of the vegf family has been detected in a sample. None of the cohort of the primary trial or the secondary trial receive enteric-coated tablets. [SEP] Clinical Trial: NCT01591746,Entailment,0.6894424,0.31055766
NCT01419717,"Statement: participants of the primary trial are not required to receive denosumab, and the secondary trial uses 200 to 400 milligrams of amifostine, delivered intravenously. [SEP] Clinical Trial: NCT01419717",Entailment,0.57117087,0.4288292
NCT01111825,"Statement: cohort 1 of the primary clinical trial is subjected to all er positive, pr positive and her2+ treatments, while cohort 2 is administered treatments for er negative, pr negative and her2- conditions. [SEP] Clinical Trial: NCT01111825",Entailment,0.50805765,0.49194235
NCT00475085,"Statement: the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort. f3 positive is an indication that expression of f3 has been detected in a sample. [SEP] Clinical Trial: NCT00475085",Entailment,0.7914592,0.20854075
NCT00454532,Statement: adverse events were commonplace and severe in both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT00454532,Entailment,0.6650638,0.33493623
NCT00978250,"Statement: the primary clinical trial allows for the enlistment of patients with a histologically confirmed diagnosis of scbc, regardless of metastatic condition or resectability, and irrespective of er or pr positivity [SEP] Clinical Trial: NCT00978250",Contradiction,0.41237396,0.58762604
NCT00911898,"Statement: The the primary trial intervention section dose not describe the method of administration, dosage or cycle. [SEP] Clinical Trial: NCT00911898",Entailment,0.8633241,0.13667591
NCT01008150,"Statement: over 42 patients from both groups in the primary clinical trial recorded a pathologic complete response in breast and axillary lymph nodes, nearly 7 months post-surgery [SEP] Clinical Trial: NCT01008150",Contradiction,0.2975228,0.7024772
NCT00918281,"Statement: in the primary clinical trial, the first cohort receives a fluciclatide injection, while in the secondary clinical trial, the first cohort is given a standard chloroquine dose. [SEP] Clinical Trial: NCT00918281",Entailment,0.5782896,0.42171037
NCT01194440,"Statement: atara biotherapeutics is a privately-held drug development company that is developing cancer treatments based on allogeneic cytotoxic t lymphocyte immunotherapy. Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial. [SEP] Clinical Trial: NCT01194440",Contradiction,0.391313,0.60868704
NCT01468675,"Statement: within the primary clinical trial, neither group is given interventions that include counselling, risk analysis, or cognitive behavioural therapy (cbt). [SEP] Clinical Trial: NCT01468675",Entailment,0.67410594,0.32589403
NCT03202472,"Statement:  patients who have received chemotherapy or radiotherapy in the last 0.5 months, suffer from unstable angina, or have grade 5 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. [SEP] Clinical Trial: NCT03202472",Contradiction,0.43084142,0.5691586
NCT00786838,"Statement: The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days. chlamydophila is a genus of gram negative, obligately intracellular, parasitic bacterium in the phylum chalmydiae and the family chlamydiaceae. [SEP] Clinical Trial: NCT00786838",Entailment,0.6202574,0.3797426
NCT02041429,"Statement: the secondary clinical trial does not report the maximum tolerated dose (mtd) of different treatments, and the mtd of mm-111 for its participants is 20 mg per day in the primary clinical trial [SEP] Clinical Trial: NCT02041429",Entailment,0.687342,0.31265804
NCT02306265,"Statement: 17q21-q22 is a chromosome band present on 17q candidates must undergo a Mammography before being able to participate in the primary trial, this is not required for the secondary trial. [SEP] Clinical Trial: NCT02306265",Entailment,0.7569528,0.24304718
NCT00365105,"Statement: A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 110,034/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. retroperitoneal lymphoma is a lymphoma involving the retroperitoneal area. [SEP] Clinical Trial: NCT00365105",Contradiction,0.33955973,0.6604402
NCT02312934,"Statement: abstinence or moderate drinking is not a criterion of exclusion from the primary clinical trial, but the secondary clinical trial mandates a minimum consumption of five alcoholic drinks daily. [SEP] Clinical Trial: NCT02312934",Entailment,0.63728666,0.3627134
NCT03557801,"Statement: the secondary trial patients did not experience anemia, pneumonia, or stupor more frequently than patients in the primary trial. [SEP] Clinical Trial: NCT03557801",Entailment,0.6030378,0.3969622
NCT02104830,"Statement: 7p22.2 is a chromosome band present on 7p Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim. [SEP] Clinical Trial: NCT02104830",Entailment,0.55320776,0.44679224
NCT02441946,Statement: patients diagnosed with hr positive and her2 negative breast cancer and a tumor size ranging from 0.2 to 0.8 cm are eligible for the primary clinical trial and secondary clinical trial. [SEP] Clinical Trial: NCT02441946,Contradiction,0.27386805,0.726132
NCT01250379,"Statement: a female patient, aged 20, recently diagnosed with er-positive, her2-negative breast cancer, may qualify for both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01250379",Entailment,0.5999372,0.4000628
NCT01037790,Statement: the primary clinical trial is accepting a limited quantity of patients carrying the kras or braf mutation and diagnosed with metastatic colorectal cancer. [SEP] Clinical Trial: NCT01037790,Entailment,0.5702267,0.42977324
NCT01964924,"Statement: individuals diagnosed with diffuse parenchymal lung disease, regardless of the time of diagnosis, can participate in the primary clinical trial [SEP] Clinical Trial: NCT01964924",Entailment,0.52360374,0.47639626
NCT03202472,"Statement: Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial, unless they have non-healing surgical wounds. [SEP] Clinical Trial: NCT03202472",Contradiction,0.46610078,0.5338992
NCT01252290,Statement: under 10 patients have encountered adverse events in the course of the primary clinical trial [SEP] Clinical Trial: NCT01252290,Entailment,0.7562235,0.24377653
NCT00795769,"Statement: how difficult to bend and straighten affected arm is a question about how difficult it is for an individual to bend or straighten their affected arm. Far more patients in the secondary trial were recorded to have experienced Chest Pain, than patients in the primary trial. [SEP] Clinical Trial: NCT00795769",Contradiction,0.44929498,0.55070496
NCT01823991,Statement:  Alzheimer's patients are not eligible for the primary trial [SEP] Clinical Trial: NCT01823991,Entailment,0.90831465,0.0916854
NCT01171924,"Statement: cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly. [SEP] Clinical Trial: NCT01171924",Contradiction,0.44235766,0.55764234
NCT00408681,"Statement: recurrent malignancies, graft-versus-host disease, infection, altered mental status and diffuse alveolar hemorrhage were more frequently observed as adverse events in the primary clinical trial compared to the secondary clinical trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.57667845,0.42332152
NCT01091974,"Statement: in the primary trial, each cohort receives different amounts of rosuvastatin daily, not exclusively armodafinil p.o. in the secondary trial, medication doses are individually calculated for each patient and do not uniformly consist of 100 mg pdr001 and 1 mg/kg mcs110. [SEP] Clinical Trial: NCT01091974",Entailment,0.59994304,0.40005693
NCT01975831,Statement: the solitary distinction between the first and second interventions of the primary clinical trial lies in the reduced amount of durva (0.7mg/kg less) that cohort 1 receives in their bi-weekly iv infusions versus cohort 2. [SEP] Clinical Trial: NCT01975831,Entailment,0.5613657,0.4386343
NCT00429182,Statement: septal myocardial infarction by ecg finding is an electrocardiographic finding suggesting an infarction in the anatomic location of the cardiac septum. less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products. [SEP] Clinical Trial: NCT00429182,Contradiction,0.47941715,0.5205828
NCT00054028,Statement: the primary clinical trial utilizes a combination of oxaliplatin and fluorouracil as treatment whereas the drug regimen for the secondary clinical trial is not specified. [SEP] Clinical Trial: NCT00054028,Entailment,0.92291945,0.07708047
NCT00583700,"Statement: women who are 18 or 19 years old can participate in the secondary clinical trial, however, they must wait 1-2 years to qualify for the primary clinical trial [SEP] Clinical Trial: NCT00583700",Contradiction,0.4629791,0.5370209
NCT02187783,"Statement: More Palpitations, Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial. liquid soap dosage form is a solution or suspension composed of an anionic surfactant used for cleansing. [SEP] Clinical Trial: NCT02187783",Contradiction,0.4099835,0.5900165
NCT01286168,"Statement: the most common adverse event in the primary clinical trial was severe nausea, no aes were reported in the secondary clinical trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.85895,0.14104998
NCT02734979,Statement: patients with a history of pulmonary embolisms are disqualified from participating in the secondary clinical trial and patients with current breast implants are ineligible for the primary clinical trial. [SEP] Clinical Trial: NCT02734979,Entailment,0.7373775,0.26262248
NCT01806675,Statement: carfilzomib/panobinostat regimen is a chemotherapy regimen consisting of panobinostat and carfilzomib that is used for the treatment of plasma cell myeloma. Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures. [SEP] Clinical Trial: NCT01806675,Contradiction,0.38266295,0.61733705
NCT00293384,"Statement: the majority of patients in cohort 2 of the primary clinical trial did not exhibit any signs of acute vomiting subsequent to the intake of aprepitant, dexamethasone, cytoxan and kytril [SEP] Clinical Trial: NCT00293384",Entailment,0.5289224,0.47107765
NCT04080297,Statement: Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time [SEP] Clinical Trial: NCT04080297,Entailment,0.86575836,0.1342417
NCT01869192,"Statement: The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm, additionally, in the secondary trial the Denosumab cohort had a better Time to First On-Study SRE than the Zoledronic Acid cohort. [SEP] Clinical Trial: NCT01869192",Entailment,0.5397255,0.46027446
NCT00305695,"Statement: The intervention 1 in the primary trial is administered by IV, and all intervention drugs in the secondary trial can be administered orally. clinical laboratory is a laboratory that analyzes patient or subject samples collected as part of healthcare treatment or clinical research. [SEP] Clinical Trial: NCT00305695",Entailment,0.53705776,0.46294224
NCT00122369,"Statement: the secondary clinical trial has no age restriction, and the primary clinical trial excludes those who are younger than 25. [SEP] Clinical Trial: NCT00122369",Entailment,0.587272,0.41272807
NCT01969448,Statement: the primary clinical trial exclusively uses mri-guided radiotherapy for all interventions. [SEP] Clinical Trial: NCT01969448,Entailment,0.616384,0.38361597
NCT00408681,"Statement: adverse events such as recurrent cancers, graft-versus-host disease, anaemia, heart failure, and diffuse alveolar haemorrhage were seen more frequently in the primary clinical trial than in the secondary clinical trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.5136566,0.48634338
NCT01781299,Statement: unexpected deaths or hospital stays were not recorded in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01781299,Entailment,0.87016374,0.12983628
NCT02441946,Statement: patients with a non-tnbc tumor of 100mm in diameter can participate in the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT02441946,Contradiction,0.22784725,0.7721527
NCT00317603,"Statement: the most frequently reported adverse event throughout the patient groups of the primary clinical trial and the secondary clinical trial was diabetes, appearing in 45.00% of the primary clinical trial participants. [SEP] Clinical Trial: NCT00317603",Contradiction,0.14707701,0.85292304
NCT00749931,Statement: every inclusion criterion for the primary trial is distinct from those of the secondary trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.9178364,0.08216365
NCT01772004,Statement: fatigue interferes with certain duties and responsibilities is a question about whether an individual's fatigue interferes or interfered with certain duties or responsibilities. African-american patients can participate in the primary trial. [SEP] Clinical Trial: NCT01772004,Contradiction,0.48990867,0.5100913
NCT00405938,"Statement: sao tome and principe is a country in western africa, comprised of islands in the gulf of guinea, straddling the equator, west of gabon. Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial. [SEP] Clinical Trial: NCT00405938",Contradiction,0.3776107,0.6223893
NCT00698035,"Statement: the primary clinical trial is investigating the effects of physical therapy interventions, and the secondary clinical trial is involved in studying the impacts of dietary changes. [SEP] Clinical Trial: NCT00698035",Entailment,0.57000947,0.42999053
NCT01783444,Statement: women recently diagnosed with stage 4 breast cancer that is er-positive and considering mastectomy are eligible for participation in both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01783444,Contradiction,0.4802519,0.5197481
NCT00322374,"Statement: to be eligible for the primary clinical trial, there are no certain conditions such as mental health, body weight, tumour size, karnofsky/ecog score or estimated life span that must be attained [SEP] Clinical Trial: NCT00322374",Contradiction,0.4634353,0.5365647
NCT02431676,Statement: Morbidly obese patients are eligible for the primary trial. have to read something several times to understand is a question about whether an individual has or had to read something several times to understand it. [SEP] Clinical Trial: NCT02431676,Entailment,0.5638807,0.43611938
NCT00708019,Statement: cdisc adas-cog - delayed word recall: word 4 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) delayed word recall task for word 4. Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study. [SEP] Clinical Trial: NCT00708019,Entailment,0.5852112,0.41478875
NCT01250379,"Statement: a 35 year old female patient diagnosed with er-negative, her2-positive breast cancer, could be eligible for the secondary clinical trial and the primary clinical trial. [SEP] Clinical Trial: NCT01250379",Contradiction,0.35996673,0.6400333
NCT01772004,Statement: only hispanic patients can participate in the primary clinical trial. [SEP] Clinical Trial: NCT01772004,Entailment,0.5551929,0.44480708
NCT01766102,"Statement: instances of lengthier operative durations were detected in arm 2 than arm 1 of the primary trial, indicating more efficient outcomes with the intra-operative mammography compared to the standard mammography. no control group is present in the secondary trial to which the observations can be opposed. [SEP] Clinical Trial: NCT01766102",Entailment,0.5434056,0.45659435
NCT00357734,"Statement: a single drug makes up the intervention in the primary clinical trial, in contrast to the secondary clinical trial where the intervention necessitates a minimum of three separate drugs. [SEP] Clinical Trial: NCT00357734",Entailment,0.72835165,0.27164838
NCT00416715,"Statement: Candidates for the secondary trial study group receive weekly subcutaneous (SC) injections, whereas the primary trial participants do not receive any injections. [SEP] Clinical Trial: NCT00416715",Entailment,0.92107713,0.078922816
NCT00795769,Statement: a higher number of patients in the secondary clinical trial were documented to have chest pain compared to those in the primary clinical trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.612918,0.38708198
NCT01171924,Statement: cohort 1 and 2 of the primary clinical trial are administered cudc-101 at the same frequency. [SEP] Clinical Trial: NCT01171924,Entailment,0.6213874,0.37861255
NCT00182767,"Statement: two participants from the primary clinical trial experienced dose-limiting toxicities, divided evenly with one from each cohort. [SEP] Clinical Trial: NCT00182767",Entailment,0.5641603,0.43583968
NCT01301729,Statement: patients in the primary trial receive a different dosage of trastuzumab compared to patients in cohort 2 of the secondary trial [SEP] Clinical Trial: NCT01301729,Entailment,0.80828935,0.19171065
NCT00992602,Statement: it is not feasible to contrast the side effects between the primary clinical trial and the secondary clinical trial due to the absence of recorded side effects for the primary clinical trial. [SEP] Clinical Trial: NCT00992602,Entailment,0.80588603,0.19411393
NCT00786838,Statement: the trabectedin intervention in the primary clinical trial is administrated orally once daily. [SEP] Clinical Trial: NCT00786838,Entailment,0.5812373,0.41876265
NCT02509156,Statement: the placebo intervention of the primary clinical trial is administered in a different dose from the allo-mscs intervention. [SEP] Clinical Trial: NCT02509156,Entailment,0.8253552,0.17464481
NCT00088413,Statement: All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial. [SEP] Clinical Trial: NCT00088413,Entailment,0.903759,0.09624104
NCT00749931,Statement: the secondary trial and the primary trial have completely different inclusion criteria. [SEP] Clinical Trial: NCT00749931,Entailment,0.92603135,0.073968634
NCT01920061,"Statement: in both sections of the primary clinical trial, patients reported adverse events at an equivalent rate [SEP] Clinical Trial: NCT01920061",Entailment,0.86082923,0.13917075
NCT00656305,"Statement: anogenital distance decreased is an indication that the anogenital distance is less than the norm. There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation . [SEP] Clinical Trial: NCT00656305",Entailment,0.54778343,0.4522165
NCT02320123,"Statement: regularly receiving radiotherapy will be the approach for the second group in the primary clinical trial, while viewing an educational dvd is part of the intervention strategy for the first cohort [SEP] Clinical Trial: NCT02320123",Contradiction,0.42184374,0.5781563
NCT01011218,Statement: sham comparator arm is an arm describing the sham comparator. Across both the primary trial and the secondary trial only one death was recorded in the adverse events. [SEP] Clinical Trial: NCT01011218,Entailment,0.6775739,0.32242602
NCT03125941,"Statement: caplet dosing unit is a dosing unit equal to the amount of active ingredient(s) contained in a caplet. cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation. [SEP] Clinical Trial: NCT03125941",Contradiction,0.48259762,0.5174024
NCT01629615,Statement: bone marrow eosinophilia is a finding indicating abnormally high levels of eosinophils in a bone marrow sample. Most the primary trial candidates suffered from some kind of eating disorder during the study duration. [SEP] Clinical Trial: NCT01629615,Contradiction,0.4098291,0.5901709
NCT02640053,"Statement: patients in the primary clinical trial that received paclitaxel infusions and those who didn't, exhibited the same severity of symptoms. [SEP] Clinical Trial: NCT02640053",Entailment,0.659411,0.340589
NCT00878709,Statement: the neratinib group in the primary clinical trial exhibited a lesser idfs rate compared to the placebo group [SEP] Clinical Trial: NCT00878709,Entailment,0.7380867,0.2619133
NCT01617668,Statement: an increased number of adverse events were reported among participants in cohort 1 of the primary clinical trial as compared to cohort 2. [SEP] Clinical Trial: NCT01617668,Entailment,0.8302997,0.16970035
NCT01256567,"Statement: total bilirubin level finding is a finding that indicates the amount of total bilirubin in a sample. a patient that has received an organ transplant within the last month, and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial. [SEP] Clinical Trial: NCT01256567",Entailment,0.5573492,0.44265077
NCT00693719,Statement: biopsy guidance is any of various methods to assist in directing a biopsy needle into the area of interest. A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial. [SEP] Clinical Trial: NCT00693719,Entailment,0.76456773,0.23543227
NCT00293384,"Statement: after undergoing treatment with aprepitant, dexamethasone, cytoxan, and kytril in cohort 2 of the primary clinical trial, acute vomiting was reported by over 50% of the patients. [SEP] Clinical Trial: NCT00293384",Contradiction,0.39641526,0.60358477
NCT01772004,Statement: hispanic patients without any state residence restrictions can take part in the primary clinical trial. [SEP] Clinical Trial: NCT01772004,Entailment,0.6698432,0.33015677
NCT02891681,Statement: Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial. 7q31.3-q32 is a chromosome band present on 7q [SEP] Clinical Trial: NCT02891681,Contradiction,0.21496782,0.78503215
NCT02734979,"Statement: regardless of a previous encounter with a pulmonary embolism, patients can apply for the secondary trial, and the presence of breast implants does not hinder patient participation in the primary trial. [SEP] Clinical Trial: NCT02734979",Entailment,0.5568564,0.4431436
NCT00428220,"Statement: endocannabinoid is a class of endogenously expressed compounds capable of activating cannabinoid receptors. Ascites was more common for patients in the primary trial, and Pneumocystis jirovecii pneumonia was more common in the secondary trial. [SEP] Clinical Trial: NCT00428220",Contradiction,0.36710793,0.6328921
NCT02891681,Statement: Morbidly obese patients can be eligible for the primary trial and the secondary trial. 1q22-q25 is a chromosome band present on 1q [SEP] Clinical Trial: NCT02891681,Contradiction,0.2662618,0.7337382
NCT02807844,"Statement: chromatophore is a pigment-producing cell located in the deeper layers of the skin. All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week. [SEP] Clinical Trial: NCT02807844",Contradiction,0.32412916,0.67587084
NCT01023477,Statement: hypokalemic individuals can participate in the primary clinical trial but are ineligible for the secondary clinical trial [SEP] Clinical Trial: NCT01023477,Entailment,0.85907894,0.14092107
NCT01171924,"Statement: although cudc-101 dosage remains consistent for both cohort 1 and cohort 2 in the primary clinical trial, it is dispensed more frequently to cohort 1. [SEP] Clinical Trial: NCT01171924",Entailment,0.6349694,0.36503062
NCT02509156,"Statement: The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection. grade 1 testicular disorder, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated [SEP] Clinical Trial: NCT02509156",Contradiction,0.44163138,0.55836856
NCT00749931,Statement: the secondary trial and the primary trial share at least one inclusion criteria. tandem mass tag 10-plex is a tandem mass tag reagent preparation containing ten distinct isotope substitutions. [SEP] Clinical Trial: NCT00749931,Contradiction,0.47557542,0.5244246
NCT00656305,Statement: there were several fatalities in the second cohort of the primary clinical trial. [SEP] Clinical Trial: NCT00656305,Contradiction,0.2506693,0.7493307
NCT00377156,Statement: an individual with 2-3 cerebral metastases is welcome to participate in both the secondary and primary trials. [SEP] Clinical Trial: NCT00377156,Contradiction,0.35946473,0.64053524
NCT00321464,"Statement: symptom interference score 8 is a subjective score of 8 on a scale that ranges from 0: did not interfere to 10: interfered completely. Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive or HER2/neu negative are eligible for both the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.44515967,0.55484027
NCT00372424,"Statement: a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event. cordonnier grade 3 viral complication, severe varicella zoster virus infection is any severe varicella zoster virus infection. [SEP] Clinical Trial: NCT00372424",Entailment,0.6220548,0.3779452
NCT01591746,"Statement: autoimmune neutropenia is a condition characterized by the autoantibody-induced destruction of neutrophils. Neither cohort of the primary trial recieves alisertib, and the two cohorts of the secondary trial receive different doses. [SEP] Clinical Trial: NCT01591746",Entailment,0.7290302,0.27096978
NCT01920061,"Statement: the primary trial uses a 10 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.9188535,0.0811465
NCT00992602,Statement: there are more cases of bronchopneumonia and general physical health deterioration in the secondary clinical trial than in the primary clinical trial. [SEP] Clinical Trial: NCT00992602,Entailment,0.64308137,0.35691866
NCT00800436,"Statement: Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial, but not from the primary trial. acrocephalosyndactyly is a genetic disorder characterized by craniosynostosis and fusion of the fingers and toes. [SEP] Clinical Trial: NCT00800436",Entailment,0.6263294,0.37367052
NCT00256698,"Statement: the primary clinical trial employs arimidex in both cohorts, yet this is not the case for the secondary clinical trial. [SEP] Clinical Trial: NCT00256698",Entailment,0.8911257,0.108874366
NCT01803282,"Statement: 50% the primary trial participants, and 110% the secondary trial participants suffered an ae. [SEP] Clinical Trial: NCT01803282",Contradiction,0.29562548,0.7043745
NCT01306032,Statement: post neoadjuvant therapy sample is a biospecimen derived from a subject after treatment with a neoadjuvant therapeutic. Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial. [SEP] Clinical Trial: NCT01306032,Entailment,0.7341726,0.26582742
NCT00623831,Statement: many participants in the primary clinical trial do not experience any increase in pleural effusion and rapid disease progression [SEP] Clinical Trial: NCT00623831,Contradiction,0.48050046,0.5194996
NCT01129622,Statement: the primary and secondary clinical trials do not admit participation from women having claustrophobia and osteoporosis. [SEP] Clinical Trial: NCT01129622,Entailment,0.8387952,0.16120483
NCT00254592,"Statement: midline is a medial line, especially the medial line or medial plane of the body (or some part of the body). the primary trial and the secondary trial both administer cyclophosphamide, Paclitaxel and pegfilgrastim to their patient cohorts. [SEP] Clinical Trial: NCT00254592",Contradiction,0.17633453,0.8236655
NCT00586326,Statement: The the primary trial intervention section does not outline a treatment cycle or any description of the treatment. post term pregnancy is a gestation that lasts greater than or equal to 42 weeks and 0 days. [SEP] Clinical Trial: NCT00586326,Entailment,0.6666299,0.33337015
NCT00820872,"Statement: Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants. micromole per liter per milligram per kilogram is a unit of concentration equal to micromoles per liter, divided by milligrams per kilogram. [SEP] Clinical Trial: NCT00820872",Contradiction,0.39641017,0.60358983
NCT01869192,"Statement: the data from the primary clinical trial reveals that the arm d intervention had the superior overall response rate. additionally, in the secondary clinical trial, the denosumab cohort exhibited a promising time to first on-study sre compared to the zoledronic acid cohort. [SEP] Clinical Trial: NCT01869192",Contradiction,0.46937585,0.53062415
NCT03557801,"Statement: the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial, but more cases of FEBRILE INFECTIONs were recorded in the primary trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.40956983,0.59043014
NCT00370552,"Statement: Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements. 10q26.13-q26.3 is a chromosome band present on 10q [SEP] Clinical Trial: NCT00370552",Contradiction,0.46432683,0.53567314
NCT02640053,"Statement: the severity of symptoms in patients in the primary clinical trial who did not receive paclitaxel infusions, was milder than those who did receive paclitaxel infusions. [SEP] Clinical Trial: NCT02640053",Entailment,0.68024915,0.31975088
NCT01194440,Statement: individuals contemplating radiation treatment for stage 2 colorectal cancer are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01194440,Entailment,0.584433,0.41556698
NCT00416715,"Statement: rio de janeiro is a state in the southeast region of brazil. its capital is rio de janeiro. Candidates for the secondary trial study group receive weekly subcutaneous (SC) injections, whereas the primary trial participants do not receive any injections. [SEP] Clinical Trial: NCT00416715",Entailment,0.8046807,0.1953193
NCT00709761,Statement: more than 50% of patients in the primary clinical trial experienced a confirmed full or partial benefit after receiving treatment with lapatinib 1000 mg and nab-paclitaxel. [SEP] Clinical Trial: NCT00709761,Contradiction,0.31361067,0.6863893
NCT00978250,"Statement: Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both. picomole per liter per microgram per meter squared per day is a unit of concentration equal to picomoles per liter, divided by micrograms per meter squared per day. [SEP] Clinical Trial: NCT00978250",Contradiction,0.43576574,0.56423426
NCT00320541,"Statement: the paclitaxel plus bevacizumab plus gemcitabine group in the primary clinical trial demonstrated a better orr than its paclitaxel plus bevacizumab counterpart, with a larger participant pool [SEP] Clinical Trial: NCT00320541",Entailment,0.6825838,0.31741622
NCT00553358,"Statement: a patient with a primary tumour measuring 33mm in diameter, assessed through clinical examination and ultrasound, would qualify for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.34779894,0.65220106
NCT00756717,Statement: the primary trial reported 5 serious adverse events while the secondary trial reported 3 [SEP] Clinical Trial: NCT00756717,Entailment,0.706801,0.293199
NCT00756717,Statement: there were 52 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial [SEP] Clinical Trial: NCT00756717,Contradiction,0.19946465,0.8005353
NCT00021255,"Statement: in the primary clinical trial, the identical dose of docetaxel, doxorubicin, and cyclophosphamide are given to all groups at equal intervals. however, three more treatment courses of these drugs are integrated into the second cohort [SEP] Clinical Trial: NCT00021255",Contradiction,0.42939946,0.57060057
NCT02961790,Statement: a patient who completed a cycle of antineoplastic therapy one month prior to the primary clinical trial is seasoned to participate in the investigation. [SEP] Clinical Trial: NCT02961790,Entailment,0.6243323,0.3756677
NCT00791037,Statement: the primary trial and the secondary trial evaluate the Percentage of Participants With Adverse Events of Primary Interest (AEPIs) [SEP] Clinical Trial: NCT00791037,Entailment,0.59432083,0.4056792
NCT00583700,"Statement: intraduodenal route of administration is administration of a drug within the duodenum. women aged 18 or 19 are eligible for the secondary trial, but will need to wait 1-2 years to be eligible for the primary trial. [SEP] Clinical Trial: NCT00583700",Contradiction,0.36110818,0.6388918
NCT01290536,"Statement: the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 700 mg of ibrutinib and 5 mg/kg of medi4736 twice daily for three months. [SEP] Clinical Trial: NCT01290536",Contradiction,0.33094233,0.6690577
NCT02104830,"Statement: Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim. 9p21 is a chromosome band present on 9p [SEP] Clinical Trial: NCT02104830",Contradiction,0.49781626,0.50218374
NCT00248547,Statement: pyometra is an infectious process characterized by the accumulation of pus within the uterus. Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant. [SEP] Clinical Trial: NCT00248547,Contradiction,0.36087698,0.63912296
NCT01963481,Statement: severe insomnia patients are barred from participating in both the primary and secondary clinical trial. [SEP] Clinical Trial: NCT01963481,Entailment,0.8828566,0.11714335
NCT01246973,"Statement: There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial. precordial catch syndrome is a condition in which there is musculoskeletal chest pain characterized by brief, sharp discomfort associated with inspiration. (acc/aha) [SEP] Clinical Trial: NCT01246973",Contradiction,0.27933472,0.7206653
NCT03125941,"Statement: in the primary clinical trial, both cohort 1 and cohort 2 are given dexamethasone before surgery. [SEP] Clinical Trial: NCT03125941",Contradiction,0.45534799,0.54465204
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 48 months if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.39572898,0.60427105
NCT01314963,"Statement: pihgc is utilised in the first intervention, and standard gp is used in the second intervention as part of the primary clinical trial. [SEP] Clinical Trial: NCT01314963",Entailment,0.5223069,0.4776931
NCT00254592,"Statement: the primary trial and the secondary trial both administer cyclophosphamide, Paclitaxel and pegfilgrastim to their patient cohorts [SEP] Clinical Trial: NCT00254592",Contradiction,0.14844137,0.8515586
NCT00838929,Statement: vorinostat capsules are strictly prohibited for all patients participating in the primary clinical trial during radiation therapy [SEP] Clinical Trial: NCT00838929,Entailment,0.74458134,0.25541872
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150000 mcg of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.37950647,0.6204935
NCT00194779,"Statement: the primary trial only necessitates a single type of medicine and avoidance of surgery, on the other hand, the secondary trial involves administering five different types of drugs and obligatory surgical treatment [SEP] Clinical Trial: NCT00194779",Entailment,0.56550556,0.43449438
NCT01537029,"Statement: for the primary clinical trial, female cancer patients who are at least 18 years old can participate, regardless of their cancer type, race, or ethnic origin. yet, only patients with her2/neu+ breast cancer can apply for the secondary clinical trial. [SEP] Clinical Trial: NCT01537029",Contradiction,0.49199206,0.50800794
NCT02961790,"Statement: any patient that has been under the treatment involving antineoplastic chemotherapy, androgens, estrogens or progestogens in the last month before study initiation are dismissed from the primary clinical trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.6996489,0.30035108
NCT01106898,Statement: 110% of patients in the primary trial did not experience any adverse events [SEP] Clinical Trial: NCT01106898,Entailment,0.7656811,0.23431894
NCT00775645,Statement: in both the primary trial and the secondary trial there were several adverse events which occurred in more than 8/10 participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.46822268,0.53177726
NCT01451632,Statement: cohort 1 of the primary clinical trial and cohort 2 received similar dosage of cetuximab and none of them had the addition of the collaborative care intervention. [SEP] Clinical Trial: NCT01451632,Entailment,0.6356844,0.36431566
NCT00632489,Statement: The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort [SEP] Clinical Trial: NCT00632489,Entailment,0.8794695,0.12053052
NCT01975831,Statement: The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2. [SEP] Clinical Trial: NCT01975831,Entailment,0.5216906,0.47830936
NCT00317603,Statement: the primary and secondary clinical trials had syncope as the most frequently reported adverse event among patient cohorts [SEP] Clinical Trial: NCT00317603,Entailment,0.59686536,0.4031346
NCT00209092,"Statement: retinal arterial branch occlusion is an occlusion of a branch of the retinal artery. Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial. [SEP] Clinical Trial: NCT00209092",Contradiction,0.4499853,0.55001473
NCT00321464,"Statement: Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial. wallet pack dosage form is a multi-panel, re-closable end-user pack for tablet blisters. [SEP] Clinical Trial: NCT00321464",Contradiction,0.4509928,0.54900724
NCT02115607,Statement: the secondary trial and the primary trial recorded an equal number of aes [SEP] Clinical Trial: NCT02115607,Entailment,0.8090742,0.19092575
NCT01569087,"Statement: upon giving fully informed consent, patients suffering from stage 4 cancer can qualify for both secondary clinical trial and primary clinical trial. [SEP] Clinical Trial: NCT01569087",Contradiction,0.4340593,0.56594074
NCT00929240,Statement: the outcome from the bevacizumab + capecitabine cohort of the primary clinical trial were superior to those of the bevacizumab cohort. [SEP] Clinical Trial: NCT00929240,Entailment,0.7940441,0.20595594
NCT01306032,"Statement: primary clinical trial participants were free from thromboembolic events, as were those in the secondary clinical trial. [SEP] Clinical Trial: NCT01306032",Entailment,0.77824825,0.22175175
NCT00270894,"Statement: clinical variant is a form of a disease with clinical features that differ from other forms of the same disease. participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2. [SEP] Clinical Trial: NCT00270894",Contradiction,0.35043952,0.64956045
NCT01434342,"Statement: cases of mucositis oral, epileptic seizures, and thromboembolic events were found to be more frequent in the primary trial than the secondary trial [SEP] Clinical Trial: NCT01434342",Entailment,0.5011329,0.49886706
NCT02234479,"Statement: palinavir is a hydroxyethylamine-based peptidomimetic inhibitor of human immunodeficiency virus (hiv) protease. the primary trial is testing the effects of different gels on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.58517504,0.41482493
NCT00118157,Statement: Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month. hyperphosphatemia is abnormally high level of phosphate in the blood. [SEP] Clinical Trial: NCT00118157,Contradiction,0.3616401,0.6383599
NCT03015649,Statement: the quantity of adverse events in the cohorts was found to be the same in the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT03015649,Entailment,0.71314377,0.28685623
NCT01351376,Statement: patients with detectable malignancies in both breasts are allowed in the primary clinical trial [SEP] Clinical Trial: NCT01351376,Entailment,0.5591148,0.4408852
NCT00843167,"Statement: the secondary trial uses pain as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. data set is a collection of related data records. [SEP] Clinical Trial: NCT00843167",Entailment,0.5140808,0.4859192
NCT01301729,"Statement: throughout the full duration of the trials, her2+ patients in the primary clinical trial and those in second cohort of the secondary clinical trial are administered the same trastuzumab dosage. [SEP] Clinical Trial: NCT01301729",Contradiction,0.3489025,0.65109754
NCT00819182,"Statement: the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group. wash dosage form is a solution or suspension composed of active and/or inert ingredient(s) and intended for administration as an irrigant and cleanser. [SEP] Clinical Trial: NCT00819182",Entailment,0.5514296,0.4485703
NCT01569087,"Statement: patients with stage 1 cancer are not eligible for the secondary trial, but are ineligible for the primary trial. [SEP] Clinical Trial: NCT01569087",Entailment,0.89348906,0.10651087
NCT00319748,Statement: terminal sacrifice is an indication that the subject was euthanized at the end of the study. Neither the secondary trial or the primary trial measure the percentage of participants in their studies that experience Clinical Benefit (using (RECIST) criteria). [SEP] Clinical Trial: NCT00319748,Contradiction,0.44414896,0.55585104
NCT01803282,"Statement: no adverse events were experienced by any participants in the primary clinical trial, likewise in the secondary clinical trial. [SEP] Clinical Trial: NCT01803282",Entailment,0.68938136,0.31061867
NCT00404066,"Statement: no aes were observed in patients from the secondary clinical trial, while the primary clinical trial documented several instances of aes, including abdominal pain and insomnia [SEP] Clinical Trial: NCT00404066",Contradiction,0.47700974,0.5229903
NCT00558272,"Statement: in the primary clinical trial, a higher decrease in the primary tumor diameter was observed in the azd0530 175 mg group than in the zoledronic acid 4 mg group. [SEP] Clinical Trial: NCT00558272",Entailment,0.5857088,0.41429117
NCT00791037,Statement: ids-c clinical classification question is a question associated with the ids-c clinical classification. the primary trial and the secondary trial evaluate different patient characteristics in their results. [SEP] Clinical Trial: NCT00791037,Entailment,0.8693165,0.13068344
NCT00357734,"Statement: the primary clinical trial requires administration of a multi-drug regimen, while the secondary clinical trial calls for the use of a single therapeutic agent. [SEP] Clinical Trial: NCT00357734",Entailment,0.8070269,0.1929731
NCT02413008,Statement: different methods of measurement and success criteria are used in the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02413008,Entailment,0.5148612,0.48513874
NCT00182793,Statement: 93.35% patients in the primary trial and the secondary trial suffered from infections during the study period [SEP] Clinical Trial: NCT00182793,Contradiction,0.18541405,0.814586
NCT01781299,Statement: the secondary clinical trial has witnessed an unexpected death and hospitalizations [SEP] Clinical Trial: NCT01781299,Entailment,0.63230765,0.36769235
NCT02441946,"Statement: Patients with a TNBC tumor of 100mm in diameter, are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.32967472,0.6703253
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the last decade would be excluded from the primary trial [SEP] Clinical Trial: NCT01964924,Entailment,0.8318584,0.16814157
NCT01770353,"Statement: the primary clinical trial and the secondary clinical trial use identical medications, dosages, and interval of administration within their interventions. [SEP] Clinical Trial: NCT01770353",Contradiction,0.4565089,0.5434911
NCT01466972,Statement: there was no repetition in the type of adverse event endured by patients in the primary clinical trial. [SEP] Clinical Trial: NCT01466972,Entailment,0.9104915,0.08950848
NCT02441946,"Statement: patients with a tnbc tumor of 1000 millimeters in diameter, are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.37614048,0.6238595
NCT01963481,Statement: the primary clinical trial and the secondary clinical trial both rule out patients who struggle with severe forms of insomnia and schizophrenia [SEP] Clinical Trial: NCT01963481,Contradiction,0.29082075,0.7091792
NCT01008150,Statement: no pathologic complete response in breast and axillary lymph nodes was reported in patients involved in the primary clinical trial [SEP] Clinical Trial: NCT01008150,Entailment,0.80178607,0.1982139
NCT01614210,Statement: results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 2 weeks after breast cancer surgery brings down the diameter of tumors by 40% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.3042495,0.6957505
NCT02312934,Statement: ligament injury is an injury to any of the fibrous bands of tissue that comprise an articulation (joint). alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. [SEP] Clinical Trial: NCT02312934,Entailment,0.52246654,0.4775335
NCT00820872,Statement: the primary trial participants experienced less incidences of diarrhoea than the participants of the secondary trial [SEP] Clinical Trial: NCT00820872,Entailment,0.76517475,0.23482525
NCT01138046,"Statement: usually find myself worrying about something is a question about whether an individual usually finds themself worrying about something. Any japanese national can take part in the primary trial, or the secondary trial. [SEP] Clinical Trial: NCT01138046",Contradiction,0.26448438,0.73551565
NCT01286987,Statement: Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead. [SEP] Clinical Trial: NCT01286987,Entailment,0.59406567,0.4059343
NCT00992602,"Statement: We cannot compare the adverse events in the primary trial and the secondary trial, as they do not appear to have been recorded for the primary trial. [SEP] Clinical Trial: NCT00992602",Entailment,0.9156009,0.084399156
NCT00929240,"Statement: compared to the bevacizumab + capecitabine cohort, a greater incidence of disease progression or death was reported in the bevacizumab cohort of the primary clinical trial. [SEP] Clinical Trial: NCT00929240",Entailment,0.6469243,0.35307568
NCT00843167,"Statement: the secondary clinical trial employs muscle growth as an indicator of physical therapy's effectiveness. on the other hand, the primary clinical trial examines how sulforaphane supplements influence the level of isothiocyanates in urine. [SEP] Clinical Trial: NCT00843167",Contradiction,0.4380483,0.5619517
NCT04080297,"Statement: the inclusion requirements of the primary and secondary clinical trials are the same, therefore, anyone currently involved in the secondary clinical trial can also participate in the primary clinical trial [SEP] Clinical Trial: NCT04080297",Entailment,0.5470865,0.4529135
NCT00656019,Statement: notable patterns in the expression of 40 genes under evaluation were observed in certain patients maintaining normal vitamin d levels in the primary clinical trial. [SEP] Clinical Trial: NCT00656019,Contradiction,0.42534858,0.5746514
NCT01967823,Statement: about 0.3636 of the primary trial patients suffered an increase in blood bilirubin. [SEP] Clinical Trial: NCT01967823,Contradiction,0.47179127,0.52820873
NCT01743560,"Statement: the primary clinical trial does not reject participants based on their height or age, while the secondary clinical trial restricts underage participants [SEP] Clinical Trial: NCT01743560",Entailment,0.7997216,0.20027836
NCT00553358,"Statement: a patient with a primary tumour smaller than 20mm confirmed by ct scans, would be eliminated from both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Entailment,0.78155005,0.21844994
NCT03015649,Statement: the primary trial and the secondary trial recorded the same number of adverse events in their cohorts. moderate tumor infiltrating lymphocytes is a finding of a moderate number of tumor infiltrating lymphocytes in a biospecimen. [SEP] Clinical Trial: NCT03015649,Contradiction,0.40954915,0.5904509
NCT01466972,Statement: maculo-papular Rash was a common adverse event for the primary trial participants. 22q12.2 is a chromosome band present on 22q [SEP] Clinical Trial: NCT01466972,Entailment,0.6688946,0.33110538
NCT00245050,"Statement: different group arrangements were followed in the two trials; specifically, the primary clinical trial had a test group and a placebo group, whereas the secondary clinical trial had a test group and a control group. [SEP] Clinical Trial: NCT00245050",Entailment,0.75229657,0.24770336
NCT01881230,Statement: Both cohorts of the primary trial receive the same doses of Abraxane. penile epithelioid hemangioma is an epithelioid hemangioma that occurs in the skin of the penis. [SEP] Clinical Trial: NCT01881230,Entailment,0.5896786,0.41032147
NCT00054028,Statement: all patients in the primary clinical trial and the secondary clinical trial receive suramin and paclitaxel [SEP] Clinical Trial: NCT00054028,Contradiction,0.20158702,0.798413
NCT00693719,Statement: cell culture-based biosynthesis is a process that synthesizes a material of interest using cell culture techniques. A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial. [SEP] Clinical Trial: NCT00693719,Entailment,0.73710066,0.26289934
NCT00305695,Statement: inhalation is the administration method for intervention 1 in the primary clinical trial and for the all intervention drugs in the secondary clinical trial. [SEP] Clinical Trial: NCT00305695,Entailment,0.56927496,0.43072507
NCT03202472,"Statement: patients who have received chemotherapy or radiotherapy in the last 14 days, suffer from unstable angina, or have grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. [SEP] Clinical Trial: NCT03202472",Contradiction,0.4349867,0.5650133
NCT00538850,"Statement: homeopathic dilution unit is a dosing unit that is based on homeopathic dilution. The the primary trial results report the Severity of Delayed Nausea on a scale of 1-7, and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. [SEP] Clinical Trial: NCT00538850",Contradiction,0.43645325,0.5635467
NCT00194779,"Statement: the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and several different imaging scans. was sdh complex mutation analysis performed is a question asking if mutations in subunits of the sdh complex were analyzed during the study. [SEP] Clinical Trial: NCT00194779",Contradiction,0.30096263,0.6990374
NCT03557801,"Statement: patients in the secondary trial experienced anemia, pneumonia, and stupor more frequently than those in the primary trial, however, a higher occurrence of febrile infections was noted in the primary trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.47993913,0.5200609
NCT00365365,"Statement: the primary trial participants do not receive any vaccines. rehabilitation center is a healthcare facility designed for improving, maintaining, or restoring physical strength, cognition, or mobility. [SEP] Clinical Trial: NCT00365365",Entailment,0.76122767,0.2387723
NCT02807844,"Statement: all patients in the primary trial receive at least 50mg of mcs110 every 3 weeks, and over 200 mg of pdr001 every other week. [SEP] Clinical Trial: NCT02807844",Contradiction,0.40003985,0.59996015
NCT00918281,Statement: cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine by IV. [SEP] Clinical Trial: NCT00918281,Contradiction,0.474042,0.525958
NCT00820872,Statement: diarrhoea was equally common in both primary and secondary clinical trial participants [SEP] Clinical Trial: NCT00820872,Entailment,0.7935203,0.20647976
NCT01037790,Statement: patients diagnosed with tumors positive for ccnd1 amplification are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01037790,Entailment,0.5631357,0.43686435
NCT00365105,"Statement: A 32 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1.807 x 10^6 cells/≈í¬∫l, platelet count of 110.034 x10^6 cells/≈í¬∫l, hemoglobin level of 9 g/dl, and a life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.33670262,0.6632974
NCT01138046,Statement: neither the primary nor the secondary clinical trial requires the participants to be of a certain nationality or gender. [SEP] Clinical Trial: NCT01138046,Contradiction,0.39945316,0.60054684
NCT00867217,"Statement: having an adequate vitamin d level is a prerequisite for participation in the primary clinical trial, while it is considered as a disqualifying factor for the secondary clinical trial. [SEP] Clinical Trial: NCT00867217",Entailment,0.68872327,0.31127676
NCT00659373,"Statement: no participants in the primary clinical trial experienced a decline in cognitive function, including those in the ovarian function suppression group [SEP] Clinical Trial: NCT00659373",Entailment,0.7695451,0.23045488
NCT04080297,Statement: patients presently participating in the secondary clinical trial are also permitted to enter the primary clinical trial since the criteria for inclusion are identical [SEP] Clinical Trial: NCT04080297,Entailment,0.5854976,0.41450244
NCT01597193,Statement: cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1 [SEP] Clinical Trial: NCT01597193,Entailment,0.58375573,0.41624433
NCT00313170,"Statement: sutterella is a genus of aerobic, gram negative, rod shaped bacterium assigned to the phylum proteobacteria and the family alicaligenaceae. candidates for the primary trial must have breast cancer and require hormonal treatment. [SEP] Clinical Trial: NCT00313170",Contradiction,0.37051687,0.6294831
NCT01967823,Statement: all ae types in the primary trial affected less than 0.1 of patients [SEP] Clinical Trial: NCT01967823,Entailment,0.84623986,0.1537601
NCT00911898,Statement: the intervention section of the primary clinical trial calls for only therapeutical and lifestyle changes. [SEP] Clinical Trial: NCT00911898,Entailment,0.5589534,0.4410466
NCT00929240,Statement: electromagnetic spectrum is a charted band of wavelengths of electromagnetic vibrations. the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort. [SEP] Clinical Trial: NCT00929240,Entailment,0.8270239,0.17297603
NCT03346161,Statement: worry that skin condition may be serious is a response indicating that an individual worries that their skin condition may be serious. Both cohorts of the primary trial recorded 0 Aes. [SEP] Clinical Trial: NCT03346161,Entailment,0.6654955,0.33450451
NCT00558272,Statement: the azd0530 175 mg group and the zoledronic acid 4 mg group of the primary clinical trial had similar reductions in primary tumour diameter. [SEP] Clinical Trial: NCT00558272,Contradiction,0.46734023,0.53265977
NCT00320541,"Statement: in the primary clinical trial, the group treated with paclitaxel plus bevacizumab plus gemcitabine had a higher orr than the paclitaxel plus bevacizumab group, and included more participants [SEP] Clinical Trial: NCT00320541",Contradiction,0.40495872,0.59504133
NCT01806675,Statement: Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures. non-neoplastic thymus disorder is a non-neoplastic disorder that affects the thymus.  representative examples include acute thymic involution and thymic hyperplasia. [SEP] Clinical Trial: NCT01806675,Contradiction,0.36594355,0.6340564
NCT01597193,Statement: transient arthropathy is arthropathy that is not permanent. cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1. [SEP] Clinical Trial: NCT01597193,Entailment,0.57370126,0.4262987
NCT01421472,"Statement: breast cancer patients who have estrogen negative, progesterone negative and her2- tumors can participate in all groups of the primary clinical trial [SEP] Clinical Trial: NCT01421472",Contradiction,0.4533186,0.5466814
NCT02550795,"Statement: group 2 of the primary trial does not receive myalgias, while patients in the secondary trial cohorts receive 2ug/kg of myalgias (5ml) [SEP] Clinical Trial: NCT02550795",Entailment,0.60760516,0.39239487
NCT01008150,Statement: some of the time is a response indicating that something happens or happened some of the time. More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery. [SEP] Clinical Trial: NCT01008150,Contradiction,0.27922198,0.72077805
NCT01419717,"Statement: the primary trial requires patients to receive 500 milligrams of denosumab injected subcutaneously every day, the secondary trial also requires injection, adminstering 4.0 to 2.5 mci of radioactive tc99m sulfur colloid. [SEP] Clinical Trial: NCT01419717",Contradiction,0.38300082,0.6169992
NCT01967823,"Statement: in the primary clinical trial, more than 15% of patients were affected by all types of adverse events (aes) [SEP] Clinical Trial: NCT01967823",Entailment,0.72707754,0.2729225
NCT02239601,Statement: the count of total adverse events in the secondary clinical trial was notably less than what was documented in the primary clinical trial. [SEP] Clinical Trial: NCT02239601,Entailment,0.78357375,0.21642625
NCT00867217,Statement: Patients diagnosed with breact cancer may be eligible for all study groups in the primary trial and the secondary trial. fallopian tube soft tissue neoplasm is a benign or malignant mesenchymal neoplasm of the fallopian tube.  representative examples include leiomyoma and leiomyosarcoma. [SEP] Clinical Trial: NCT00867217,Contradiction,0.23921947,0.7607805
NCT00753415,Statement: Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934. anorectal infection is an infectious process affecting the anal area and the rectum. [SEP] Clinical Trial: NCT00753415,Contradiction,0.35271394,0.64728606
NCT02413008,"Statement: the primary clinical trial and the secondary clinical trial use different metrics for success; in the secondary clinical trial the marker for success is complete radiographic response within the breast, while the primary clinical trial measures the disappearance of signs of the disease at all sites of metastasis [SEP] Clinical Trial: NCT02413008",Entailment,0.65989625,0.3401037
NCT03557801,"Statement: primary clinical trial patients suffered from anemia, pneumonia and stupor more often than patients in the secondary trial, but more cases of high blood pressure were recorded in the secondary trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.41061082,0.5893892
NCT03202472,"Statement: patients who have received chemotherapy or radiotherapy in the last 4 weeks, suffer from unstable angina, or have grade 3 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. [SEP] Clinical Trial: NCT03202472",Contradiction,0.4373765,0.5626235
NCT02115607,Statement: the secondary trial recorded 11 more Aes than the primary trial [SEP] Clinical Trial: NCT02115607,Contradiction,0.33819804,0.661802
NCT01037790,Statement: There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation . intermediate lipomatous neoplasm is a lipomatous neoplasm characterized by a high risk of local recurrence and no risk of metastasis. [SEP] Clinical Trial: NCT01037790,Entailment,0.6180134,0.3819866
NCT02122796,Statement: the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates [SEP] Clinical Trial: NCT02122796,Entailment,0.6116006,0.38839942
NCT01629615,Statement: eating disorders characterized a substantial portion of the primary clinical trial candidates' [SEP] Clinical Trial: NCT01629615,Entailment,0.5171476,0.48285237
NCT01106898,Statement: 57% of patients in the primary trial did not experience any adverse events [SEP] Clinical Trial: NCT01106898,Entailment,0.80453414,0.19546586
NCT00766532,"Statement: There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial. nanomole per liter per microgram per day is a unit of concentration equal to nanomoles per liter, divided by micrograms per day. [SEP] Clinical Trial: NCT00766532",Contradiction,0.33040884,0.6695912
NCT00146172,Statement: candidates capable of only limited selfcare; confined to bed or chair more than 0.5 of waking hours are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.46517044,0.53482956
NCT01881230,"Statement: in the primary clinical trial, both groups receive identical measures of abraxane and carboplatin [SEP] Clinical Trial: NCT01881230",Entailment,0.6109181,0.3890819
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 750 mg of fulvestrant in a tablet form to be taken bid. [SEP] Clinical Trial: NCT00836186",Contradiction,0.38575158,0.61424845
NCT00075764,"Statement: the primary clinical trial considers patients with tx nx mx, t0 nx m0, or t1 n1 m1 tumors to be eligible [SEP] Clinical Trial: NCT00075764",Contradiction,0.45225313,0.5477469
NCT02115607,Statement: ovarian rhabdomyosarcoma is a malignant mesenchymal tumor with skeletal muscle differentiation affecting the ovaries. the secondary trial recorded 11 more Aes than the primary trial. [SEP] Clinical Trial: NCT02115607,Contradiction,0.24070974,0.7592902
NCT01091974,"Statement: In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.49007186,0.5099281
NCT00911898,Statement: mcl-1 inhibitor is any agent that inhibits mcl-1. The the primary trial intervention section requires surgical and imaging procedures. [SEP] Clinical Trial: NCT00911898,Entailment,0.73408777,0.26591223
NCT00999921,Statement: Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial. [SEP] Clinical Trial: NCT00999921,Entailment,0.86898375,0.1310162
NCT01591746,"Statement: the primary trial administers alisertib to all participant cohorts, and a consistent dosage is used globally in the secondary trial's cohorts [SEP] Clinical Trial: NCT01591746",Entailment,0.55725837,0.44274163
NCT02038218,"Statement: the secondary trial and the primary trial use different units of measure in their results. congenital disorder of glycosylation type if is a congenital disorder of glycosylation sub-type caused by mutation(s) in the mpdu1 gene, encoding mannose-p-dolichol utilization defect 1 protein. [SEP] Clinical Trial: NCT02038218",Entailment,0.8912127,0.1087873
NCT00800436,"Statement: no previous treatment with gabapentin or herceptin, required for eligibility in the secondary trials, but will exclude from the primary trial [SEP] Clinical Trial: NCT00800436",Entailment,0.8145659,0.18543416
NCT00843167,"Statement: the secondary clinical trial employs pain as a gauge for evaluating the effectivity of physical therapy, while the impact of sulforaphane supplements on urinary isothiocyanate levels is the subject of analysis in the primary clinical trial. [SEP] Clinical Trial: NCT00843167",Entailment,0.52946186,0.47053817
NCT00753415,"Statement: cohort a and b of the primary clinical trial are administered different treatment methods, neither involving electroporation injections of ld v934 [SEP] Clinical Trial: NCT00753415",Entailment,0.57207763,0.4279224
NCT01013740,Statement: no incidences of tumour lysis syndrome were reported in the primary or secondary trial [SEP] Clinical Trial: NCT01013740,Entailment,0.8059292,0.19407083
NCT00828516,Statement: secondary clinical trial is based on the alterations in mymop score to determine the outcome of their study. [SEP] Clinical Trial: NCT00828516,Entailment,0.53373986,0.46626014
NCT01527487,"Statement: in the primary clinical trial, the administration of eribulin to cohort 1 is at a higher dosage than the administration of docetaxel given to cohort 2. [SEP] Clinical Trial: NCT01527487",Entailment,0.73279494,0.26720506
NCT02239601,Statement: regimen used to treat prostate carcinoma is any regimen that can be used for the treatment of prostate carcinoma the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts. [SEP] Clinical Trial: NCT02239601,Entailment,0.6795933,0.32040665
NCT00759785,Statement: 49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group [SEP] Clinical Trial: NCT00759785,Contradiction,0.45575798,0.544242
NCT00791037,Statement: the primary clinical trial and secondary clinical trial evaluate similar patient attributes in their results. [SEP] Clinical Trial: NCT00791037,Entailment,0.71230227,0.2876977
NCT00792077,Statement: the primary trial uses lower doses of lenalidomide than the secondary trial uses of lapatinib in intervention 1. [SEP] Clinical Trial: NCT00792077,Entailment,0.7334342,0.26656583
NCT01554371,Statement: 19q13.4 is a chromosome band present on 19q Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.8062745,0.19372551
NCT00377156,"Statement: patients diagnosed with 2-3 cerebral metastases are ineligible for the secondary clinical trial, but they may qualify for the primary clinical trial. [SEP] Clinical Trial: NCT00377156",Entailment,0.6790426,0.32095742
NCT00182767,"Statement: In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2. adult acute eosinophilic leukemia is an acute eosinophilic leukemia occurring in adults. [SEP] Clinical Trial: NCT00182767",Entailment,0.51959866,0.48040134
NCT02286843,"Statement: from the primary trial, it was found that 13% of participants having her2- primary breast cancer developed imagable her2+ metastases post their treatment with her2-targeted pet/ct. 89zr-trastuzumab [SEP] Clinical Trial: NCT02286843",Contradiction,0.4388348,0.5611653
NCT00313170,Statement: candidates eligible for the primary clinical trial have been diagnosed with lung cancer. [SEP] Clinical Trial: NCT00313170,Entailment,0.74638355,0.2536164
NCT00122369,"Statement: the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.8856946,0.11430536
NCT00586326,"Statement: cordonnier grade 2 fungal complication, deep candida infection without candidemia is any deep candida infection without candidemia. The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses. [SEP] Clinical Trial: NCT00586326",Entailment,0.83792216,0.16207787
NCT02761642,"Statement: ret gene translocation is a cytogenetic abnormality that refers to any translocation involving the ret gene. Any cancer patient diagnosed with either Epilepsy , thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02761642",Entailment,0.6366409,0.3633591
NCT00843167,"Statement: the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. [SEP] Clinical Trial: NCT00843167",Contradiction,0.4384526,0.5615474
NCT01527487,Statement: the dosage of eribulin given to cohort 1 in the primary clinical trial is comparable to the docetaxel dosage received by cohort 2. [SEP] Clinical Trial: NCT01527487,Entailment,0.7308375,0.26916245
NCT01963481,Statement: mood disorder is a category of psychiatric disorders which have as their most predominant feature a disturbance in mood. Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01963481,Entailment,0.69414914,0.30585086
NCT02441946,"Statement: Patients with a breast tumor 0.2-0.8 cm in diameter, with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.41867128,0.5813287
NCT00753415,"Statement: in the primary clinical trial, both groups a and b receive the same two im injections of ld v935 at an identical stage in the cycle. [SEP] Clinical Trial: NCT00753415",Contradiction,0.49144068,0.50855935
NCT01290536,"Statement: the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 0.56 g of ibrutinib and 0.01 g/kg of medi4736 twice daily for a month. [SEP] Clinical Trial: NCT01290536",Contradiction,0.3605975,0.6394025
NCT00999921,"Statement: patients with papillary carcinoma and controlled blood pressure levels are accepted for the primary clinical trial, but are not qualified for the secondary clinical trial. [SEP] Clinical Trial: NCT00999921",Entailment,0.85625666,0.14374332
NCT01597193,Statement: cohort 1 and cohort 2 of the primary clinical trial both take enzalutamide orally [SEP] Clinical Trial: NCT01597193,Contradiction,0.28403208,0.7159679
NCT01222390,Statement: both the primary clinical trial and the secondary clinical trial incorporate x-rays and ct scans as part of their procedural interventions [SEP] Clinical Trial: NCT01222390,Contradiction,0.24756332,0.7524367
NCT00588640,"Statement: the primary clinical trial employs distinct criteria for acceptance and rejection across its two stages, unlike the secondary clinical trial that applies a unified set of criteria for all participants. [SEP] Clinical Trial: NCT00588640",Entailment,0.82492024,0.17507981
NCT01855828,Statement: the primary clinical trial was devoid of any adverse psychiatric events such as eating disorders or schizophrenia. [SEP] Clinical Trial: NCT01855828,Entailment,0.6984479,0.30155206
NCT01498458,Statement: in the primary trial there were 100 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.25981668,0.7401833
NCT01171924,Statement: all cohorts in the primary clinical trial exclusively receive cudc-101 without additions of any other therapeutic treatments. [SEP] Clinical Trial: NCT01171924,Entailment,0.79523516,0.2047648
NCT00104650,Statement: 17p13.1-q25 is a chromosome band present on 17p The Interventions in the primary trial included different medications but are administered through the same routes. [SEP] Clinical Trial: NCT00104650,Entailment,0.75791776,0.24208224
NCT00262834,"Statement: 500 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 60% of patients. [SEP] Clinical Trial: NCT00262834",Contradiction,0.3588278,0.6411722
NCT01128543,Statement: The majority of patients in the primary trial experienced complete response by week 24. [SEP] Clinical Trial: NCT01128543,Contradiction,0.46458873,0.53541124
NCT00569166,"Statement: cohorts 1 and 2 of the primary clinical trial each follow a different relaxation audio guide, but both practice the same number of times per day. [SEP] Clinical Trial: NCT00569166",Contradiction,0.40234733,0.5976527
NCT00305695,"Statement: intervention 1 in the primary clinical trial, and all intervention drugs in the secondary clinical trial are to be administered orally. [SEP] Clinical Trial: NCT00305695",Entailment,0.51260054,0.48739946
NCT01013740,Statement: encounter due to other problems related to physical environment is an icd encounter due to other problems related to physical environment. In total there are less cases of anemia in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01013740,Entailment,0.54910886,0.4508911
NCT01606748,"Statement: in the primary group of the primary clinical trial, a number of anaemia and febrile neutropenia instances were noted, but there were zero cases of pancytopenia. [SEP] Clinical Trial: NCT01606748",Entailment,0.56025076,0.43974918
NCT00122369,"Statement: while the secondary clinical trial excludes 18-year-olds, the primary clinical trial has no defined age criteria for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.87363625,0.12636377
NCT00792077,"Statement: rand social support survey questionnaire question is a question associated with the rand social support survey questionnaire. the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1, and the primary trial intervention lasts for a longer period of time. [SEP] Clinical Trial: NCT00792077",Entailment,0.60315096,0.396849
NCT01256567,"Statement: a patient that has received an organ transplant within the last month, would be excluded from the primary trial but may be eligible for the secondary trial. difficulty chewing food due to dryness of mouth is a question about an individual's difficulty chewing food due to dryness of mouth. [SEP] Clinical Trial: NCT01256567",Entailment,0.6946819,0.30531812
NCT02179515,Statement: every participant in cohort 1 of the primary clinical trial encountered at least one serious adverse effect. [SEP] Clinical Trial: NCT02179515,Entailment,0.86484665,0.13515338
NCT00270894,"Statement: participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 0.1 g/m^2 [SEP] Clinical Trial: NCT00270894",Contradiction,0.33322567,0.66677433
NCT00365105,"Statement: a patient aged 32 years, with a confirmed histological diagnosis of stage iii breast cancer, an absolute neutrophil count of 1807/≈í¬∫l, a platelet count of 79000/≈í¬∫l, a hemoglobin level of 90 g/l, and a life expectancy of over 8 months is a fitting candidate for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.30768496,0.69231504
NCT00659373,"Statement: unit per gram per day is an arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to twenty-four hours. all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group. [SEP] Clinical Trial: NCT00659373",Contradiction,0.4134621,0.58653784
NCT01743560,"Statement: intraoperative urinary injury, ctcae is a finding of damage to the urinary system during a surgical procedure. children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial. [SEP] Clinical Trial: NCT01743560",Contradiction,0.4777085,0.5222915
NCT00254592,Statement: the patient cohorts of the primary and secondary clinical trials are both given cyclophosphamide [SEP] Clinical Trial: NCT00254592,Contradiction,0.34808,0.65192
NCT01205503,"Statement: double outlet right ventricle is a rare congenital cardiovascular abnormality in which both the aorta and the pulmonary artery arise from the right ventricle. Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01205503",Entailment,0.643932,0.35606804
NCT02403271,Statement: the primary trial has a higher presence of biliary colic and clostridium difficile colitis compared to the secondary trial [SEP] Clinical Trial: NCT02403271,Entailment,0.64141643,0.35858354
NCT01048099,"Statement: in the primary clinical trial, one specific adverse event type affected more than half of the patient cohort. [SEP] Clinical Trial: NCT01048099",Entailment,0.6748855,0.32511455
NCT01008150,"Statement: after about seven months into the study, more than one in three patients, from both cohorts in the primary clinical trial, experienced a pathologic complete response in their breast and axillary lymph nodes [SEP] Clinical Trial: NCT01008150",Contradiction,0.40133348,0.5986665
NCT01527487,Statement: cohort 1 of the primary clinical trial receives lower doses of eribulin than cohort 2 patients receive of docetaxel. [SEP] Clinical Trial: NCT01527487,Entailment,0.7277567,0.27224338
NCT00317603,"Statement: the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 50.00% of the primary trial patients [SEP] Clinical Trial: NCT00317603",Contradiction,0.16997604,0.83002394
NCT02891681,Statement: benign ciliary body neoplasm is a non-metastasizing neoplasm that arises from the ciliary body.  representative examples include leiomyoma and adenoma of the ciliary epithelium. Morbidly obese patients can be eligible for the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.23016964,0.76983035
NCT00305695,"Statement: in the primary clinical trial, intervention 1 is provided intravenously, whereas in the secondary clinical trial, the intervention drugs can all be taken orally. [SEP] Clinical Trial: NCT00305695",Entailment,0.6265268,0.3734732
NCT01008150,Statement: More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery. other specified parts of pancreas is any component associated with the pancreas that is different from the one(s) previously specified or mentioned. [SEP] Clinical Trial: NCT01008150,Contradiction,0.31470302,0.685297
NCT02761642,"Statement: pain has interfered with normal work is a question about whether an individual has or had pain that interferes with their normal work. Any cancer patient diagnosed with either Epilepsy , thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02761642",Entailment,0.6084938,0.39150617
NCT01037790,Statement: There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation . [SEP] Clinical Trial: NCT01037790,Entailment,0.67121,0.32878998
NCT01351376,Statement: participation in the primary clinical trial is not allowed for patients with visible tumors in both breasts [SEP] Clinical Trial: NCT01351376,Entailment,0.89608556,0.10391448
NCT01451632,"Statement: cohort 1 participants in the primary clinical trial got the same cetuximab dosage as cohort 2, however, they received 8mg/kg less of mm-121 than cohort 2. [SEP] Clinical Trial: NCT01451632",Entailment,0.52059054,0.47940946
NCT00372424,"Statement: seg algorithm is a computer algorithm that provides a general method for partitioning the globular and non-globular regions of a protein sequence. All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events. [SEP] Clinical Trial: NCT00372424",Entailment,0.5607849,0.43921518
NCT00766532,"Statement: anorexia, hypothermia and hallucinations have been reported in the aes of the primary clinical trial. [SEP] Clinical Trial: NCT00766532",Entailment,0.54815686,0.45184317
NCT02550795,"Statement: group 2 of the primary trial receives 0.0005mg/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.89371127,0.106288716
NCT00370552,Statement: only post-menopausal women and men who have had a vasectomy are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT00370552,Contradiction,0.42143235,0.5785676
NCT00929240,Statement: the bevacizumab group in the primary clinical trial yielded superior outcomes compared to the bevacizumab + capecitabine group. [SEP] Clinical Trial: NCT00929240,Entailment,0.85754097,0.14245903
NCT02431676,Statement: lgals3 antibody is any immunoglobulin that recognizes galectin-3. anorexic patients are eligible for the primary trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.5094909,0.4905091
NCT03557801,"Statement: patients in the primary clinical trial more frequently experienced symptoms of anemia, pneumonia, and stupor than those in the secondary trial, but febrile infections were more commonly observed in the secondary trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.4633297,0.53667027
NCT02504424,Statement: one patient in the primary trial had an incident where a surgical incision reopened after the surgery. blood substitute is any agent that is able to increase blood volume and/or increase the oxygen transport in the blood. [SEP] Clinical Trial: NCT02504424,Contradiction,0.42422777,0.57577217
NCT01011218,Statement: the primary clinical trial and the secondary clinical trial reported zero deaths among their adverse events. [SEP] Clinical Trial: NCT01011218,Entailment,0.6943485,0.30565143
NCT01823991,Statement: patients diagnosed with alzheimer's disease are not suitable for the primary clinical trial [SEP] Clinical Trial: NCT01823991,Entailment,0.9022922,0.09770779
NCT00467844,Statement: some patients treated with gtx-024 1mg in the primary clinical trial did not gain lean body mass over a 4 month period [SEP] Clinical Trial: NCT00467844,Entailment,0.6425165,0.35748354
NCT01222390,"Statement: no x-rays, ultrasound, ct scans or mris are incorporated in the interventions of either the primary or secondary clinical trial. [SEP] Clinical Trial: NCT01222390",Entailment,0.61166966,0.3883303
NCT00871858,"Statement: Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead. extragastrointestinal gastrointestinal stromal tumor is a rare gastrointestinal stromal tumor that presents as a solitary mass outside the gastrointestinal tract. [SEP] Clinical Trial: NCT00871858",Entailment,0.53983355,0.46016645
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin twice daily, and the secondary trial administers its patients with Depocyt and HD-MTX. [SEP] Clinical Trial: NCT00702949",Contradiction,0.36748588,0.6325141
NCT00001832,Statement: The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4-Demethyl-4-cholestryloxycarbonylpenclomedine [SEP] Clinical Trial: NCT00001832,Contradiction,0.20593199,0.79406804
NCT01766102,"Statement: operative time in the test group of the primary trial, arm 2, was found shorter than in the arm 1, meaning the control group wasn't superior. furthermore, in the secondary trial there is a control group for comparative studies. [SEP] Clinical Trial: NCT01766102",Entailment,0.72859377,0.27140623
NCT00365105,"Statement: both the primary clinical trial and the secondary clinical trial would accept a 32 year old diagnosed with stage iii breast cancer, has a histologically proven diagnosis, an absolute neutrophil count of 1807/≈í¬∫l, platelet count of 110,034/≈í¬∫l, hemoglobin measure of 90 g/l, and a life expectancy over 8 months. [SEP] Clinical Trial: NCT00365105",Contradiction,0.26553175,0.7344683
NCT00104650,Statement: The Interventions in the primary trial are administered through different routes. [SEP] Clinical Trial: NCT00104650,Entailment,0.92161155,0.07838843
NCT01554371,"Statement: patients, regardless of their cardiovascular health status, are eligible to partake in both the primary and secondary trials. [SEP] Clinical Trial: NCT01554371",Entailment,0.50204766,0.49795237
NCT02187783,"Statement: the frequency of palpitations, pericardial effusions and abdominal pains in cohort 1 of the secondary trial exceeded those in cohort 2 of the primary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.45211822,0.5478818
NCT01306032,Statement: the adverse events faced by patients in the primary clinical trial mistakenly match the ones faced by patients in the secondary clinical trial.' [SEP] Clinical Trial: NCT01306032,Entailment,0.85726374,0.14273623
NCT01989546,Statement: candidates undergoing cbt based treatments will not be disqualified from either primary or secondary clinical trials. [SEP] Clinical Trial: NCT01989546,Entailment,0.79796386,0.20203608
NCT00792077,"Statement: in intervention 1, the lenalidomide dosage in the primary clinical trial is greater than the lapatinib dosage in the secondary clinical trial, moreover, the treatment duration in the primary clinical trial exceeds that in the secondary clinical trial [SEP] Clinical Trial: NCT00792077",Entailment,0.68437225,0.31562778
NCT01045421,"Statement: individuals with a histologically or cytologically confirmed metastatic and/or advanced solid tumor located in the breast qualify for phase 1 of the primary clinical trial, and for all groups of the secondary clinical trial [SEP] Clinical Trial: NCT01045421",Contradiction,0.40486276,0.59513724
NCT00146172,Statement: candidates limited in their ability to self-care and who spend over 50% of their waking hours confined to a bed or chair are suitable to participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00146172,Contradiction,0.3924202,0.60757977
NCT01106898,"Statement: in the primary clinical trial, 97% of participants did not encounter any adverse effects. [SEP] Clinical Trial: NCT01106898",Entailment,0.7600736,0.23992635
NCT00182767,"Statement: in the primary clinical trial, there were two incidences of dose-limiting toxicity, both occurred in patients from cohort 2. [SEP] Clinical Trial: NCT00182767",Entailment,0.60763747,0.3923625
NCT00544167,"Statement: t(1;13) is a cytogenetic abnormality that involves a translocation between chromosomes 1 and 13. Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision. [SEP] Clinical Trial: NCT00544167",Contradiction,0.49992764,0.50007236
NCT00143390,Statement: There was at least 1 recorded gastro-intestinal adverse event in the primary trial. manual ability measure-36 is a rating scale of 36 everyday tasks that measures self-reported manual ability. [SEP] Clinical Trial: NCT00143390,Entailment,0.54669714,0.45330286
NCT03069313,"Statement: the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally. [SEP] Clinical Trial: NCT03069313",Entailment,0.6208281,0.37917194
NCT02761642,"Statement: both the primary clinical trial and the secondary clinical trial do not allow participation of cancer patients with diagnosed epilepsy, thalasemic syndromes, or anemia. [SEP] Clinical Trial: NCT02761642",Entailment,0.8029818,0.19701819
NCT01920061,Statement: the same proportion of patients experienced negative effects in both groups of the primary clinical trial [SEP] Clinical Trial: NCT01920061,Entailment,0.79050714,0.20949283
NCT01310075,Statement: a woman who has experienced quadrantectomy may not be eligible for the secondary trial or the primary trial. [SEP] Clinical Trial: NCT01310075,Entailment,0.66213465,0.3378653
NCT00878709,Statement: Both cohorts of the primary trial contained the same number of participants. pituitary neuroendocrine tumor/microadenoma is a pituitary neuroendocrine tumor with a diameter equal or less than 10 mm. [SEP] Clinical Trial: NCT00878709,Entailment,0.66686183,0.33313817
NCT01591746,"Statement: mucor racemosus igg4 measurement is a measurement of the mucor racemosus igg4 in a biological specimen. Neither cohort of the primary trial recieves alisertib, and the two cohorts of the secondary trial receive different doses. [SEP] Clinical Trial: NCT01591746",Entailment,0.7961757,0.20382428
NCT01451632,Statement: cohort 1 of the primary clinical trial was administered a lower dose of cetuximab than cohort 2 and received the same amount of 8mg/kg mm-121. [SEP] Clinical Trial: NCT01451632,Contradiction,0.43287978,0.56712025
NCT01772004,Statement: the primary clinical trial welcomes the participation of african-american patients. [SEP] Clinical Trial: NCT01772004,Entailment,0.6464685,0.35353142
NCT02961790,"Statement: any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 24 months before study entry are excluded from the primary trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.6827426,0.31725737
NCT01421472,"Statement: patients diagnosed with leukemia, irrespective of their cytogenic presentation, are eligible for all cohorts of the primary clinical trial [SEP] Clinical Trial: NCT01421472",Entailment,0.52084446,0.47915557
NCT04080297,Statement: patients are eligible to participate in both the secondary and primary clinical trial concurrently [SEP] Clinical Trial: NCT04080297,Entailment,0.6614146,0.33858532
NCT01178411,"Statement: dry mouth, ctcae is a disorder characterized by reduced salivary flow in the oral cavity. the nationality, ethnicity, psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01178411",Contradiction,0.31498763,0.68501234
NCT02403271,Statement: the primary clinical trial has greater instances of biliary colic and diarrhoea compared to the secondary trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.7038019,0.29619813
NCT00587964,Statement: coronary artery stenosis is the most frequently documented adverse event in the primary clinical trial [SEP] Clinical Trial: NCT00587964,Entailment,0.84292674,0.15707329
NCT00709761,Statement: over 66% patients in the primary trial treated with lapatinib 1000 g + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr). [SEP] Clinical Trial: NCT00709761,Contradiction,0.35347098,0.646529
NCT01106898,Statement: Only 2 patients in the primary trial did not have Recurrence-free Survival [SEP] Clinical Trial: NCT01106898,Entailment,0.8212894,0.17871064
NCT00305695,"Statement: in the primary clinical trial, the first intervention is received via iv, but in the secondary clinical trial, patients can ingest all of the interventions. [SEP] Clinical Trial: NCT00305695",Entailment,0.52962714,0.47037283
NCT00372424,Statement: not a single patient treated with sunitinib + docetaxel + trastuzumab during the primary clinical trial experienced a treatment-emergent adverse event. [SEP] Clinical Trial: NCT00372424,Entailment,0.8527944,0.14720552
NCT00377156,"Statement: patients with 2-3 cerebral metastases located in the cerebellum are permitted to participate in the secondary clinical trial, while participation in the primary clinical trial is not an option. [SEP] Clinical Trial: NCT00377156",Entailment,0.79875994,0.20124009
NCT01138046,Statement: only australian nationals are eligible for participation in the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01138046,Contradiction,0.30654907,0.6934509
NCT02306265,"Statement: candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests. gaoshan chinese is a chinese person from the gaoshan ethnic group. [SEP] Clinical Trial: NCT02306265",Contradiction,0.37629628,0.6237037
NCT02509156,"Statement: in the primary clinical trial, transendocardial injections are used to administer both the placebo and allo-mscs intervention in equal doses. [SEP] Clinical Trial: NCT02509156",Entailment,0.6285468,0.37145317
NCT00702949,"Statement: the primary clinical trial provides one of the patient groups with 150 mg oral pregabalin every fortnight for a total duration of 6 weeks, while the secondary clinical trial administers its subjects with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.4067828,0.5932172
NCT02431676,Statement: patients suffering from severe obesity can participate in the primary clinical trial [SEP] Clinical Trial: NCT02431676,Entailment,0.54007924,0.45992073
NCT01390818,Statement: the recorded harmful effects in the primary clinical trial were only noted for patients from cohort 2 [SEP] Clinical Trial: NCT01390818,Entailment,0.8706795,0.12932049
NCT02165839,Statement: candidates do not need to meet any baseline performance standards to participate in the primary clinical trial or secondary clinical trial. neither trial uses unique performance scoring schemes. [SEP] Clinical Trial: NCT02165839,Entailment,0.8664187,0.13358131
NCT02041429,Statement: both primary and secondary clinical trials present data on the mtd of multiple interventions [SEP] Clinical Trial: NCT02041429,Contradiction,0.45292234,0.54707766
NCT01390818,Statement: all the logged adverse events in the primary clinical trial happened to patients grouped in cohort 1 [SEP] Clinical Trial: NCT01390818,Entailment,0.82046473,0.17953528
NCT01194440,"Statement: patients with stage 4 invasive breast carcinoma, which tests positive for either estrogen or progesterone receptors and are considering ai therapeutic intervention, are eligible for involvement in the primary clinical trial. [SEP] Clinical Trial: NCT01194440",Contradiction,0.4574446,0.54255545
NCT00918281,"Statement: cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine. thyroid cancer pt4b anaplastic carcinoma tnm finding v6 is anaplastic carcinoma extending beyond the capsule of the thyroid gland, which is surgically unresectable. (from ajcc 6th ed.) [SEP] Clinical Trial: NCT00918281",Entailment,0.6125402,0.38745978
NCT00209092,"Statement: dyskinesia is abnormality or impairment of voluntary movement. Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial. [SEP] Clinical Trial: NCT00209092",Contradiction,0.44737044,0.5526296
NCT01569087,"Statement: Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent. synonym code is a coded value specifying the synonym of the event or entity. [SEP] Clinical Trial: NCT01569087",Contradiction,0.2417844,0.7582156
NCT00209092,"Statement: irrespective of a patient's qualifications based on the exclusion and inclusion criteria for the primary clinical trial, their own decision serves as the final say about participation. [SEP] Clinical Trial: NCT00209092",Entailment,0.6699227,0.3300773
NCT01920061,"Statement: the primary trial uses a 30-day cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.91925687,0.08074306
NCT01702571,Statement: lung pecoma is a lung tumor that arises from perivascular epithelioid cells (pecs). there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial. [SEP] Clinical Trial: NCT01702571,Contradiction,0.45675263,0.54324734
NCT01702571,Statement: ntrk2 fusion negative is an indication that the expression of a ntrk2 fusion has not been detected in a sample. All of the Aes recorded for cohort 1 of the primary trial are related to mental health. [SEP] Clinical Trial: NCT01702571,Entailment,0.6311008,0.36889917
NCT00365105,"Statement: a patient in their 32nd year, with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1807000 cell/mm³, platelet count of 79000000 platelets/mcl, hemoglobin level of 0.09 g/ml, and a life expectancy exceeding 240 days would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.31134203,0.68865794
NCT00843167,"Statement: the secondary trial uses range of motion as a measure of effectiveness for yoga, whereas the primary trial studies the effect of mineral supplements on electrolyte balance in blood. [SEP] Clinical Trial: NCT00843167",Contradiction,0.4482554,0.5517446
NCT00708019,"Statement: in the primary clinical trial, all patients endured the utmost level of pain for the span of 10 weeks. [SEP] Clinical Trial: NCT00708019",Contradiction,0.42309666,0.57690334
NCT00553358,"Statement: regulatory assessment identifier is a unique symbol that establishes identity of the regulatory assessment. A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.43381527,0.56618476
NCT00623831,"Statement: 25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression  . schedule of activities is a planned list of clinical trial activities to include interventions, assessments, and study administrative activities. [SEP] Clinical Trial: NCT00623831",Contradiction,0.37454468,0.6254553
NCT00284180,"Statement: trna methyltransferase is an enzyme that catalyzes the methylation of transfer rnas. Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial. [SEP] Clinical Trial: NCT00284180",Contradiction,0.4247242,0.57527584
NCT02961790,"Statement: Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial. specify site if cm1b is a directive to indicate the anatomic sites if metastasis is categorized as cm1b. [SEP] Clinical Trial: NCT02961790",Entailment,0.5632142,0.43678585
NCT01781299,"Statement: There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial, the only AEs recorded were 3 cases of Lymphoma. take lots of naps is a question about whether an individual takes or took a lot of naps. [SEP] Clinical Trial: NCT01781299",Contradiction,0.22793706,0.772063
NCT00370552,"Statement: menopausal women and men who have undergone vasectomy are qualified participants for the primary clinical trial, with no necessity for abstinence. [SEP] Clinical Trial: NCT00370552",Entailment,0.74235666,0.25764337
NCT01597193,"Statement: in the primary clinical trial, all cohorts are administered the same dosage of enzalutamide [SEP] Clinical Trial: NCT01597193",Entailment,0.6115614,0.38843864
NCT02273206,Statement: only 3 patients from cohort 1 of the primary clinical trial had maintained regular cervical cancer screenings prior to the intervention. [SEP] Clinical Trial: NCT02273206,Contradiction,0.3609642,0.6390358
NCT01569087,"Statement: only individuals with early stage cancer can participate in the secondary clinical trial, but are ineligible for the primary clinical trial. [SEP] Clinical Trial: NCT01569087",Entailment,0.8939063,0.106093675
NCT01617668,"Statement: adverse incidents were prevalent among patients in the first cohort of the primary clinical trial, this was not the case in cohort 2. [SEP] Clinical Trial: NCT01617668",Entailment,0.8618277,0.13817239
NCT01631552,"Statement: the secondary and primary trials have identical outcome measurements, despite differing interventions [SEP] Clinical Trial: NCT01631552",Entailment,0.84401935,0.1559806
NCT00656305,"Statement: in cohort 2 of the primary clinical trial, there were no instances of death or hospitalization, with only a single occurrence of atrial fibrillation. [SEP] Clinical Trial: NCT00656305",Entailment,0.59668124,0.40331876
NCT00706030,"Statement: patients in the primary clinical trial reported a range of adverse effects, but none experienced pancreatitis, cholelithiasis, hepatic pain or febrile neutropenia. [SEP] Clinical Trial: NCT00706030",Contradiction,0.46213925,0.5378608
NCT00319748,"Statement: the rate of clinical benefit in the participants, gauged via recist criteria, is not tracked in the scope of the primary or secondary clinical trial [SEP] Clinical Trial: NCT00319748",Entailment,0.87166214,0.12833785
NCT01803282,"Statement: output:  8/7 the primary trial participants, and 20/1674 the secondary trial participants suffered an ae. [SEP] Clinical Trial: NCT01803282",Contradiction,0.35501042,0.64498955
NCT00878709,Statement: Both cohorts of the primary trial contained the same number of participants. cdisc adas-cog - naming objects and fingers: 11 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) naming task for object 11. [SEP] Clinical Trial: NCT00878709,Entailment,0.5522511,0.4477489
NCT01008150,Statement: more than 33.33% patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 210 days of the study [SEP] Clinical Trial: NCT01008150,Contradiction,0.27665138,0.7233487
NCT00454532,Statement: over 0.97 of patients in the secondary trial and the primary trial did not suffer any adverse events [SEP] Clinical Trial: NCT00454532,Contradiction,0.45507136,0.54492867
NCT00911898,"Statement: the intervention section of the primary clinical trial clearly outlines the method of administration, dosage, and cycle. [SEP] Clinical Trial: NCT00911898",Contradiction,0.41642472,0.5835753
NCT00088413,"Statement: most of the adverse events detected in the primary trial were not blood and bone marrow related, contrasting the secondary trial which observed an abundance of such [SEP] Clinical Trial: NCT00088413",Contradiction,0.4467578,0.5532422
NCT03346161,Statement: there were no patients suffering adverse events in either cohort 1 or cohort 2 of the primary clinical trial [SEP] Clinical Trial: NCT03346161,Entailment,0.7736059,0.22639415
NCT01306032,"Statement: in the primary clinical trial and the secondary clinical trial, the patients encountered thromboembolic events. [SEP] Clinical Trial: NCT01306032",Contradiction,0.3272049,0.6727951
NCT00408681,"Statement: no recurrence of malignancies, absence of graft-versus-host disease, normal red blood cell count, cardiac well-being and healthy alveolar condition were more commonly observed in the primary trial compared to the secondary trial. [SEP] Clinical Trial: NCT00408681",Contradiction,0.42314062,0.57685935
NCT00871858,Statement: Paclitaxel is not used in either of the primary trial interventions [SEP] Clinical Trial: NCT00871858,Entailment,0.9225808,0.07741924
NCT02165839,"Statement: Candidates for the primary trial and the secondary trial have to meet a baseline performance status, for the primary trial the baseline is a Karnofsky score >70, and for the secondary trial the baseline is a Karnofsky score >55. suprapharyngeal lymph node is a lymph node located in the roof of the pharynx. [SEP] Clinical Trial: NCT02165839",Contradiction,0.26821154,0.73178846
NCT04080297,Statement: Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time. metastatic carcinoma in the rectum is a carcinoma that has spread to the rectum from another anatomic site. [SEP] Clinical Trial: NCT04080297,Entailment,0.7801203,0.21987969
NCT00321464,"Statement: patients with histologically unverified, early stage breast adenocarcinoma that is er negative, pr negative, and her2/neu positive, are eligible for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00321464",Entailment,0.51105607,0.4889439
NCT00320541,"Statement: in the primary clinical trial, the orr demonstrated by the paclitaxel plus bevacizumab plus gemcitabine group exceeded that of the paclitaxel plus bevacizumab group. [SEP] Clinical Trial: NCT00320541",Entailment,0.66688335,0.33311668
NCT02336737,Statement: numerous aes were reported by all participants in both cohort 1 and cohort 2 of the primary clinical trial [SEP] Clinical Trial: NCT02336737,Contradiction,0.265883,0.734117
NCT01920061,"Statement: the primary trial does not employ any cycle for its intervention, while a specific 2 weeks cycle is followed in the secondary trial [SEP] Clinical Trial: NCT01920061",Entailment,0.83310056,0.16689947
NCT00706030,Statement: more than four different types of adverse events affected patients in the primary clinical trial across all cohorts [SEP] Clinical Trial: NCT00706030,Entailment,0.7901124,0.20988761
NCT00918281,Statement: cohort 1 of the primary trial is infused with paclitaxel and cohort 1 of the secondary trial is getting an intravenous injection of azacitidine. [SEP] Clinical Trial: NCT00918281,Contradiction,0.47675687,0.52324307
NCT02222922,Statement: participants of both the primary and secondary clinical trial receive equal doses of medication [SEP] Clinical Trial: NCT02222922,Entailment,0.8773194,0.12268061
NCT01106898,Statement: adverse events were a common occurrence among participants in the primary clinical trial' [SEP] Clinical Trial: NCT01106898,Entailment,0.8698922,0.13010776
NCT01205503,"Statement: patients with established allergies to medications such as cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib are not qualified to be part of both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT01205503",Entailment,0.7763896,0.22361036
NCT00623831,"Statement: in the primary clinical trial, an increase in pleural effusion was observed in 25% of patients belonging to the second cohort. [SEP] Clinical Trial: NCT00623831",Contradiction,0.31529018,0.6847098
NCT01252290,Statement: less than 10 patients in the primary trial suffered Aes. mixer device is a mechanical device designed to blend materials or an electronic device designed to blend signals. [SEP] Clinical Trial: NCT01252290,Entailment,0.7330381,0.2669619
NCT01086605,"Statement: there were 0% cases of hypertension, dehydration and dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Entailment,0.6481406,0.35185942
NCT00929240,"Statement: in the primary clinical trial, the bevacizumab group witnessed more cases of disease progression or death compared to the bevacizumab + capecitabine group. [SEP] Clinical Trial: NCT00929240",Entailment,0.52472407,0.47527593
NCT01128543,Statement: dysplasia negative is an indication that signs of dysplasia were not found in a sample. The majority of patients in the primary trial experienced complete response by week 24. [SEP] Clinical Trial: NCT01128543,Contradiction,0.3815068,0.6184932
NCT00467844,Statement: all patients treated with gtx-024 0.001kg in the primary trial gained lean body mass over a 0.33 year period [SEP] Clinical Trial: NCT00467844,Contradiction,0.43765226,0.56234777
NCT00256217,"Statement: the primary clinical trial was marked by numerous adverse events reported by all patients, whereas the secondary clinical trial was free from any adverse events. [SEP] Clinical Trial: NCT00256217",Entailment,0.77348876,0.22651124
NCT00867217,Statement: lipase unit is a dosing unit based on lipase activity. Patients diagnosed with breact cancer may be eligible for all study groups in the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00867217,Contradiction,0.20980628,0.79019374
NCT00656305,Statement: patient hospitalization and mortality occured during cohort 2 of the primary clinical trial. [SEP] Clinical Trial: NCT00656305,Entailment,0.7398373,0.26016274
NCT00659373,"Statement: all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group [SEP] Clinical Trial: NCT00659373",Entailment,0.5588634,0.44113663
NCT00538850,"Statement: the the primary trial results report the severity of delayed nausea on a scale of 0-5, and the secondary trial measures the change from baseline to 6 months in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850",Entailment,0.50559616,0.49440387
NCT01920061,Statement: there were zero aes reported in one of the cohorts in the primary clinical trial [SEP] Clinical Trial: NCT01920061,Entailment,0.90318453,0.09681545
NCT00513292,"Statement: dfs is the mode of outcome measurement in the primary and secondary trials. the two cohorts in the primary trial display considerable disparity in their results. meanwhile, in the secondary trial, arm 2 exhibits a better performance than arm 1, with a smaller proportion of arm 2 patients undergoing dfs. [SEP] Clinical Trial: NCT00513292",Contradiction,0.4298563,0.57014364
NCT00825682,Statement: the intervention in the secondary clinical trial concludes 20 weeks earlier than the intervention specified in the primary clinical trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.81979626,0.18020368
NCT00182767,Statement: no patients from the primary clinical trial encountered an incidence of dose-limiting toxicity in any cohort. [SEP] Clinical Trial: NCT00182767,Entailment,0.87170315,0.12829684
NCT00836186,"Statement: while full breast radiation therapy is provided for members of the primary clinical trial, each group from the secondary clinical trial takes 500 mg of fulvestrant in tablet form, bid. [SEP] Clinical Trial: NCT00836186",Contradiction,0.40522596,0.594774
NCT01989546,Statement: candidates are required to undergo warfarin-based treatment in the primary clinical trial and is also a necessity for inclusion in the secondary clinical trial. [SEP] Clinical Trial: NCT01989546,Entailment,0.64245,0.35755008
NCT01772004,Statement: african-american patients are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01772004,Entailment,0.71306676,0.28693324
NCT00819182,"Statement: cdisc adas-cog - word recognition: word 2 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) word recognition task for word 2 trials 1, 2, 3. the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.5621472,0.43785283
NCT01434342,"Statement: the rate of mucositis oral, epileptic seizures and thromboembolic events was equal in both the primary and secondary trials [SEP] Clinical Trial: NCT01434342",Entailment,0.57881474,0.42118523
NCT01781299,Statement: neither the primary clinical trial nor the secondary clinical trial have reported unexpected deaths or cases of hospitalization. [SEP] Clinical Trial: NCT01781299,Contradiction,0.47571033,0.52428967
NCT02115607,Statement: the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial [SEP] Clinical Trial: NCT02115607,Contradiction,0.36122373,0.63877624
NCT01997333,Statement: musculoskeletal chest pain due to rib injury is a condition in which there is musculoskeletal chest pain secondary to trauma to one or more ribs. (acc/aha) The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death . [SEP] Clinical Trial: NCT01997333,Contradiction,0.42970693,0.57029307
NCT00756717,Statement: the primary trial and the secondary trial both reported a significant number of participants suffering from febrile neutropenia and cholelithiasis [SEP] Clinical Trial: NCT00756717,Contradiction,0.22599787,0.77400213
NCT01881230,Statement: cohorts within the primary clinical trial do not uniformly receive the same doses of abraxane [SEP] Clinical Trial: NCT01881230,Entailment,0.9109144,0.08908557
NCT01008150,Statement: More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery. unresectable fibrolamellar carcinoma is a fibrolamellar carcinoma that is not amenable to surgical resection. [SEP] Clinical Trial: NCT01008150,Contradiction,0.43716195,0.562838
NCT01013740,Statement: In total there are less cases of anemia in the primary trial than in the secondary trial. fgf3 gene mutation is a change in the nucleotide sequence of the fgf3 gene. [SEP] Clinical Trial: NCT01013740,Entailment,0.6582675,0.3417325
NCT01569087,"Statement: recombinants is an individual cell or organisms which carries recombinant dna Patients with stage 4 cancer are not eligible for the secondary trial, however they are eligible for the primary trial. [SEP] Clinical Trial: NCT01569087",Contradiction,0.44145483,0.5585452
NCT01383174,Statement: There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial. [SEP] Clinical Trial: NCT01383174,Entailment,0.5053778,0.49462217
NCT01086605,"Statement: there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Entailment,0.656106,0.34389403
NCT00182793,Statement: none of the patients in the primary clinical trial and secondary clinical trial developed infections during the study period [SEP] Clinical Trial: NCT00182793,Entailment,0.6283829,0.3716171
NCT00544167,"Statement: kat6a gene rearrangement is a molecular abnormality indicating rearrangement of the kat6a gene. Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision. [SEP] Clinical Trial: NCT00544167",Contradiction,0.49654266,0.5034573
NCT01138046,"Statement: Only female patients of a specific nationality can take part in the primary trial, no such condition is required for participation in the secondary trial. have problems with hearing loss that make me angry is a question about whether an individual has or had problems with their hearing that makes them angry. [SEP] Clinical Trial: NCT01138046",Entailment,0.66064954,0.33935043
NCT00365365,Statement: no vaccines are given to the participants in the primary clinical trial. [SEP] Clinical Trial: NCT00365365,Entailment,0.92671865,0.07328132
NCT01781299,"Statement: in both the primary clinical trial and secondary clinical trial, there were no unforeseen fatalities or hospital admissions. [SEP] Clinical Trial: NCT01781299",Contradiction,0.42456576,0.57543427
NCT01920061,"Statement: radial growth phase is a morphologic architectural pattern in which the tumor cells spread horizontally. the primary trial uses a 3 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.82798904,0.17201097
NCT00513292,"Statement: both the primary and secondary clinical trials measure success through pcr. minor result discrepancies are observed between the two groups participating in the primary trial. on the other hand, in the secondary trial, patients in arm 2 fared worse in comparison to arm 1, due to a higher incidence of pcr. [SEP] Clinical Trial: NCT00513292",Contradiction,0.49576733,0.5042327
NCT02115607,Statement: the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial. pen dosing unit is a unit of presentation used to represent the quantity of product that is found in a single pen container. [SEP] Clinical Trial: NCT02115607,Contradiction,0.35214055,0.6478594
NCT00405938,"Statement: challenge epoch is a period in a study during which the subject receives challenge agent. Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial. [SEP] Clinical Trial: NCT00405938",Contradiction,0.3919073,0.60809267
NCT03015649,Statement: the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts. limit switch device is a switch designed to cut off power automatically to a moving object when it reaches a predetermined point. [SEP] Clinical Trial: NCT03015649,Contradiction,0.44080797,0.559192
NCT01011218,"Statement: across the primary trial multiple deaths were recorded in the adverse events, but the secondary trial had no deaths. [SEP] Clinical Trial: NCT01011218",Entailment,0.7336211,0.2663789
NCT00587964,Statement: Coronary artery stenosis are the most common AE recorded in the primary trial [SEP] Clinical Trial: NCT00587964,Entailment,0.6768319,0.3231681
NCT03015649,Statement: trouble moving bowels is a question about a whether an individual has or had trouble moving their bowels. the primary trial and the secondary trial recorded the same number of adverse events in their cohorts. [SEP] Clinical Trial: NCT03015649,Entailment,0.5386266,0.4613734
NCT01881230,"Statement: in the primary clinical trial, the same dosages of abraxane and carboplatin are given to both groups [SEP] Clinical Trial: NCT01881230",Entailment,0.55770946,0.44229057
NCT00963911,"Statement: several of the primary trial candidates are administered 1000 mg of talazoparib daily, as part of the intervention [SEP] Clinical Trial: NCT00963911",Contradiction,0.34108377,0.65891623
NCT00929240,Statement: the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort. gin chinese is a chinese person from the gin ethnic group. [SEP] Clinical Trial: NCT00929240,Entailment,0.55184686,0.44815314
NCT00978250,"Statement: patients with a confirmed histological diagnosis of metastatic or non-resectable scbc are not eligible for the primary clinical trial, unless their result is positive for er or pr or both. [SEP] Clinical Trial: NCT00978250",Contradiction,0.3602978,0.6397022
NCT01770353,"Statement: the primary clinical trial and the secondary clinical trial have the same pharmaceutical regime, coupled with the same dosage schedule and administration technique, alongside the exclusive use of ct scans instead of mris. [SEP] Clinical Trial: NCT01770353",Contradiction,0.21173936,0.78826064
NCT00706030,Statement: the sole adverse event noted in the primary clinical trial was mild muscular discomfort. [SEP] Clinical Trial: NCT00706030,Entailment,0.75980204,0.24019799
NCT00370552,"Statement: count dosing unit is a dosing unit based on a count. Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements. [SEP] Clinical Trial: NCT00370552",Contradiction,0.34577176,0.6542282
NCT03384316,Statement: infections and fever cases in the primary clinical trial were exclusively observed in patients of the first cohort. [SEP] Clinical Trial: NCT03384316,Entailment,0.6267302,0.37326986
NCT01008150,Statement: More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery [SEP] Clinical Trial: NCT01008150,Contradiction,0.28936374,0.7106362
NCT00321464,"Statement: both the primary and secondary clinical trials accept patients with an unproven diagnosis of late stage breast adenocarcinoma that tests er negative, pr negative, and her2/neu positive. [SEP] Clinical Trial: NCT00321464",Contradiction,0.47830376,0.52169627
NCT00569166,"Statement: Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy. [SEP] Clinical Trial: NCT00569166",Contradiction,0.2848858,0.71511424
NCT00284180,Statement: Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial. acute physiology and chronic health evaluation ii apch104 original result - 35-49 is acute physiology and chronic health evaluation ii apch104 original result - 35-49. [SEP] Clinical Trial: NCT00284180,Entailment,0.8770882,0.12291185
NCT02441946,"Statement: patients with a tnbc tumor of 10cm in diameter, are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.34171012,0.6582899
NCT00759785,Statement: there was no observed difference in the decrease of the growth factor signature among the er-positive luminal b group and the triple negative group in the primary clinical trial [SEP] Clinical Trial: NCT00759785,Entailment,0.7392442,0.26075575
NCT00373256,Statement: cohort 1 and cohort 2 of the primary clinical trial receive neither 25 mg of sunitinib nor 90 mg/m^2 paclitaxel [SEP] Clinical Trial: NCT00373256,Contradiction,0.4860318,0.51396817
NCT00918281,"Statement: the first cohort of the primary clinical trial is administered fluciclatide through an intraosseous injection, while the first group in the secondary clinical trial receives a standard dosage of chloroquine intravenously. [SEP] Clinical Trial: NCT00918281",Entailment,0.5383989,0.4616011
NCT00270894,"Statement: participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2 [SEP] Clinical Trial: NCT00270894",Contradiction,0.3078239,0.6921761
NCT01310075,Statement: a woman with an ongoing therapy for stage i bc after lumpectomy is excluded from both the primary trial and the secondary trial [SEP] Clinical Trial: NCT01310075,Entailment,0.8111675,0.18883252
NCT01706081,Statement: four or more positive lymph nodes is an indication that cancer cells have been detected in four or more lymph nodes. Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list. [SEP] Clinical Trial: NCT01706081,Contradiction,0.49279565,0.50720435
NCT00270894,"Statement: participants in the primary trial receive four different drugs throughout the study duration, with a maximum dose of 100000 µg/m^2 [SEP] Clinical Trial: NCT00270894",Contradiction,0.3017986,0.6982014
NCT02761642,"Statement: neither the primary clinical trial nor the secondary clinical trial allows the participation of cancer patients diagnosed with fibromyalgia, thalasemic syndromes or anemia. [SEP] Clinical Trial: NCT02761642",Contradiction,0.26020274,0.7397973
NCT00800436,"Statement: a history of gabapentin or pregabalin use is not a disqualifying factor for the secondary trial, but compromises eligibility for the primary trial. [SEP] Clinical Trial: NCT00800436",Entailment,0.72074914,0.2792509
NCT00775645,Statement: several adverse events were reported in over 30% of participants in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00775645,Entailment,0.64243096,0.357569
NCT02104830,"Statement: neutropenia occurred less frequently in patients belonging to cohort 2 of the primary clinical trial than in cohort 1 of the secondary clinical trial, even though the latter were receiving considerably smaller doses of empegfilgrastim. [SEP] Clinical Trial: NCT02104830",Entailment,0.60386574,0.39613423
NCT01468675,"Statement: no cohorts in the primary clinical trial are subjected to interventions involving drugs, radiotherapy or cbt. [SEP] Clinical Trial: NCT01468675",Entailment,0.58711624,0.41288376
NCT00656019,"Statement: within cohorts 1 and 2 of the primary clinical trial, there was no distinguishable pattern detected for the expression of the evaluated set of 40 genes [SEP] Clinical Trial: NCT00656019",Entailment,0.6320945,0.36790556
NCT02431676,Statement: only patients who demonstrate an ideal body weight for height are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.6393462,0.36065385
NCT01419717,"Statement: for participation in the primary clinical trial, patients must be injected subcutaneously with 120 milligrams of denosumab every month, while the secondary clinical trial requires the injection of 0.4 to 1.0 mci of radioactive tc99m sulfur colloid. [SEP] Clinical Trial: NCT01419717",Contradiction,0.4053363,0.5946637
NCT00270894,"Statement: in the duration of the primary clinical trial, participants are subjected to four varied drugs, with the upper limit of dosage being 100 mg/m^2 [SEP] Clinical Trial: NCT00270894",Contradiction,0.34810102,0.651899
NCT00319748,Statement: the primary clinical trial comprises methods to gauge the alternation in ki67 expression in tumors. [SEP] Clinical Trial: NCT00319748,Entailment,0.53340185,0.46659812
NCT01286168,"Statement: the primary trial had no documented adverse events, unlike the secondary one where anaemia was a frequent occurrence. [SEP] Clinical Trial: NCT01286168",Entailment,0.5269792,0.47302082
NCT00687102,Statement: the patient cohorts of both the primary clinical trial and the secondary clinical trial have reported a total of 3 cases of asthenia and 5 cases of pyrexia. [SEP] Clinical Trial: NCT00687102,Contradiction,0.3021798,0.6978202
NCT01178411,"Statement: the nationality, ethnicity, psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial [SEP] Clinical Trial: NCT01178411",Contradiction,0.31473768,0.68526226
NCT02891681,Statement: patients with a body mass index (bmi) less than 30 are eligible for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.41307727,0.5869227
NCT01390818,Statement: non-cutaneous leiomyosarcoma is a leiomyosarcoma arising from an anatomic site other than skin. The all recorded Aes in the primary trial occurred to cohort 1 patients. [SEP] Clinical Trial: NCT01390818,Entailment,0.60814506,0.3918549
NCT00963911,"Statement: several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention [SEP] Clinical Trial: NCT00963911",Contradiction,0.32740003,0.6726
NCT02306265,"Statement: to qualify for the primary trial, the candidate is expected to have an mri, however, for the secondary trial, a mammography is mandatory. [SEP] Clinical Trial: NCT02306265",Contradiction,0.39887965,0.60112035
NCT00791037,Statement: the primary trial and the secondary trial evaluate different patient characteristics in their results. [SEP] Clinical Trial: NCT00791037,Entailment,0.9141768,0.0858232
NCT01156987,"Statement: in group 1 of the primary clinical trial, no participants presented with lesions, while in group 1 of the secondary clinical trial, more than 90% showed signs of radiation dermatitis as well as hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.36500293,0.63499707
NCT00418028,"Statement: the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the percentage of patients that experience Objective Response  [SEP] Clinical Trial: NCT00418028",Contradiction,0.3170879,0.6829121
NCT00929240,Statement: the results of the bevacizumab + capecitabine cohort in the primary clinical trial were more beneficial than the results of the bevacizumab cohort. [SEP] Clinical Trial: NCT00929240,Entailment,0.75916857,0.24083145
NCT03202472,"Statement: chemotherapy or radiotherapy patients from the last 2 weeks, those with unstable angina, and patients with grade 2 or above neuropathy are qualified for participation in the secondary clinical trial, but are not allowed in the primary clinical trial, regardless of whether they meet other conditions. [SEP] Clinical Trial: NCT03202472",Contradiction,0.47092843,0.5290715
NCT01127763,Statement: 3 or more adverse events occurred in 5 patients participating in the primary clinical trial [SEP] Clinical Trial: NCT01127763,Entailment,0.745931,0.25406903
NCT00365365,"Statement: the primary clinical trial participants are administered placebo on days 1, 8, and 15 [SEP] Clinical Trial: NCT00365365",Entailment,0.50904924,0.49095073
NCT00404066,"Statement: in the secondary clinical trial, patients only experienced adverse events such as eyelid oedema, upper gastrointestinal haemorrhage and chest pain. however, no such events were observed in the primary clinical trial [SEP] Clinical Trial: NCT00404066",Entailment,0.5349929,0.4650071
NCT00686127,Statement: there are more total adverse events and more types of adverse events captured in the primary clinical trial than in the secondary clinical trial. [SEP] Clinical Trial: NCT00686127,Entailment,0.77528715,0.2247128
NCT01920061,Statement: the number of patients who experienced adverse events in different cohorts of the primary clinical trial varied significantly. [SEP] Clinical Trial: NCT01920061,Entailment,0.698977,0.301023
NCT01591746,Statement: None of the cohort of the primary trial or the secondary trial receive enteric-coated tablets. deleterious ercc3 gene mutation is a change in the nucleotide sequence of the ercc3 gene that is associated with increased risk of disease. [SEP] Clinical Trial: NCT01591746,Contradiction,0.42649987,0.5735001
NCT03125941,"Statement: dietary vitamin k measurement is a determination of the total vitamin k in a nutritional product or meal, or a portion thereof. cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation. [SEP] Clinical Trial: NCT03125941",Contradiction,0.40346912,0.59653085
NCT02404441,"Statement: the primary clinical trial has identical inclusion/exclusion criteria for all participants, whereas the secondary clinical trial employs different sets of inclusion criteria for varying study groups. [SEP] Clinical Trial: NCT02404441",Entailment,0.89465594,0.105344065
NCT01250379,"Statement: a young girl with a Newly diagnosed PR-positive, HER2 positive breast cancer, could be eligible for the secondary trial and the primary trial [SEP] Clinical Trial: NCT01250379",Contradiction,0.29000142,0.7099986
NCT00693719,"Statement: adni avlt - list a recall 1 word 1 is alzheimer's disease neuroimaging initiative auditory verbal learning test version a (adni-avlt version a) list a, recall 1, word 1. A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial. [SEP] Clinical Trial: NCT00693719",Entailment,0.77932584,0.22067416
NCT01498458,Statement: in the primary trial there were threefold the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.33324873,0.66675127
NCT00254592,"Statement: the primary clinical trial administers gemcitabine, vinorelbine, and ruxolitinib to its patient cohorts, while the secondary clinical trial does not administer these drugs [SEP] Clinical Trial: NCT00254592",Entailment,0.88457793,0.11542204
NCT01252290,Statement: over 50% of patients in the primary trial suffered aes [SEP] Clinical Trial: NCT01252290,Entailment,0.50776273,0.4922373
NCT01498458,Statement: cough frequency is a question about the frequency of an individual's cough. in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. [SEP] Clinical Trial: NCT01498458,Contradiction,0.29244384,0.7075561
NCT01086605,"Statement: there were 75 cases of hypertension, edema and dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Contradiction,0.25466654,0.7453335
NCT00871858,Statement: paclitaxel is excluded from the interventions involved in the primary clinical trial [SEP] Clinical Trial: NCT00871858,Entailment,0.90045404,0.09954599
NCT01376349,Statement: secondary and primary trials both employ minutes and number of participants as their respective units of measures. [SEP] Clinical Trial: NCT01376349,Contradiction,0.3500923,0.6499077
NCT02734979,"Statement: the secondary trial does not exclude those who have experienced a pulmonary embolism, and breast implants do not affect one's eligibility to engage in the primary trial. [SEP] Clinical Trial: NCT02734979",Entailment,0.6578269,0.3421731
NCT00256698,"Statement: in the secondary clinical trial, the use of perjeta is incorporated in both cohorts, however, it is not utilized in the primary clinical trial. [SEP] Clinical Trial: NCT00256698",Entailment,0.9080748,0.09192524
NCT01037790,Statement: patients possessing ccnd2 amplification can join the primary clinical trial. [SEP] Clinical Trial: NCT01037790,Entailment,0.5481095,0.4518906
NCT00709761,Statement: over 0.5 patients in the primary trial treated with lapatinib 1g + nab-paclitaxel experienced a confirmed complete response (cr) . [SEP] Clinical Trial: NCT00709761,Contradiction,0.3664412,0.63355887
NCT00992602,"Statement: centrifugation tube is a high-strength tube of glass or plastic designed for spinning in a centrifuge. We cannot compare the adverse events in the primary trial and the secondary trial, as they do not appear to have been recorded for the primary trial. [SEP] Clinical Trial: NCT00992602",Entailment,0.5793509,0.42064908
NCT00416715,"Statement: three weekly sc injections are administered to the participants of the secondary clinical trial, however, the primary clinical trial participants are given only one injection when the study begins. [SEP] Clinical Trial: NCT00416715",Entailment,0.71332234,0.28667763
NCT02403271,Statement: There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial. non-neoplastic peritoneal and retroperitoneal disorder is a non-neoplastic disorder that affects the peritoneum and/or retroperitoneum. [SEP] Clinical Trial: NCT02403271,Entailment,0.5342634,0.4657366
NCT01128543,"Statement: in the findings of the primary clinical trial, the number of patients showing stable disease decreased from week 12 to week 24, and several patients exhibited a complete response at these time points [SEP] Clinical Trial: NCT01128543",Contradiction,0.2772028,0.7227972
NCT00030823,Statement: cardiac biphasic synovial sarcoma is a biphasic synovial sarcoma arising from the heart. 13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine . [SEP] Clinical Trial: NCT00030823,Contradiction,0.3676537,0.6323463
NCT01037790,"Statement: patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial. submission unit type code is a coded value specifying the kind of submission unit. [SEP] Clinical Trial: NCT01037790",Entailment,0.7103938,0.28960627
NCT00148668,Statement: Both interventions in the primary trial include the same dose of Paraplatin. have achiness in your arm is a question about whether an individual experiences or experienced achiness in their arm. [SEP] Clinical Trial: NCT00148668,Entailment,0.5254402,0.4745598
NCT00828516,Statement: knife device is a cutting device usually consisting of a sharpened blade attached to a handle. Neither the secondary trial or the primary trial use change in MYMOP score as the outcome measurement for their studies. [SEP] Clinical Trial: NCT00828516,Contradiction,0.47477627,0.52522373
NCT01419717,"Statement: the primary trial requires patients to receive 0.12 kilograms of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy. [SEP] Clinical Trial: NCT01419717",Contradiction,0.33165953,0.6683405
NCT00963911,Statement: the intervention in the primary clinical trial does not mandate the implementation of regular exercise for its candidates [SEP] Clinical Trial: NCT00963911,Entailment,0.9221896,0.07781038
NCT01008150,Statement: more than 75 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 7 months after the surgery [SEP] Clinical Trial: NCT01008150,Contradiction,0.2833652,0.7166348
NCT00370552,"Statement: sexually active fertile men and women with the ability to bear children are eligible to participate in the primary clinical trial, however, they would need to abstain throughout the duration of the study [SEP] Clinical Trial: NCT00370552",Entailment,0.63510734,0.3648927
NCT00001832,Statement: microscopic findings specimen condition is a characteristic that refers to the physical and organoleptic state of a biospecimen used for a microscopic assessment. The interventions in the primary trial and the secondary trial include completely different drug-based treatments. [SEP] Clinical Trial: NCT00001832,Entailment,0.86016923,0.1398307
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 0.0176 ounces of fulvestrant in a tablet form to be taken bid. [SEP] Clinical Trial: NCT00836186",Contradiction,0.4019157,0.59808433
NCT00896454,Statement: the results of the primary clinical trial and the secondary clinical trial are both from one particular patient cohort. [SEP] Clinical Trial: NCT00896454,Entailment,0.7581838,0.24181624
NCT00475085,Statement: primary clinical trial's second cohort has an additional 7 participants compared to the first cohort [SEP] Clinical Trial: NCT00475085,Contradiction,0.35276318,0.6472368
NCT01086605,"Statement: in both cohorts of the primary clinical trial, not a single case of hypertension, dehydration and dyspnea was recorded [SEP] Clinical Trial: NCT01086605",Entailment,0.51458013,0.48541987
NCT00775645,Statement: metastatic kidney carcinoma is a carcinoma that arises from the kidney and has metastasized to another anatomic site. In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.45350912,0.54649085
NCT00496860,Statement: cohort 2 of the primary clinical trial receives 0.035 mg less alt-801 than cohort 1 [SEP] Clinical Trial: NCT00496860,Entailment,0.6182248,0.38177526
NCT00373256,Statement: every subject in both cohorts of the primary clinical trial are given a standard dose of 15 mg of sunitinib daily [SEP] Clinical Trial: NCT00373256,Entailment,0.5188608,0.48113915
NCT02165839,"Statement: candidates for the primary clinical trial are mandated to have a karnofsky score lower than 65, while those for the secondary clinical trial must score less than 45 on the karnofsky performance scale. [SEP] Clinical Trial: NCT02165839",Entailment,0.5483938,0.4516062
NCT01037790,"Statement: patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial. lightheadedness is a feeling of faintness; a reeling sensation. lightheadedness is medically distinct from dizziness, unsteadiness, and vertigo. [SEP] Clinical Trial: NCT01037790",Entailment,0.6447903,0.35520974
NCT00513292,"Statement: in both the primary trial and the secondary trial, they utilize orr as a means of outcome measurement. there are no observable differences in outcomes in the two cohorts in the primary trial. in the secondary trial, arm 1 reflects worse results than arm 2 with an increased percentage of arm 1 patients experiencing orr. [SEP] Clinical Trial: NCT00513292",Contradiction,0.44885218,0.5511478
NCT00118157,Statement: patients participating in the primary trial receive 50 kg/m2 oral lapatinib once a day for a full month. [SEP] Clinical Trial: NCT00118157,Contradiction,0.4513466,0.5486534
NCT00408681,"Statement: Recurrent malignancies, Graft-versus-host disease, Anaemia, Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.5412672,0.4587328
NCT01997333,Statement: The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death  [SEP] Clinical Trial: NCT01997333,Entailment,0.5763374,0.42366263
NCT01351376,Statement: Patients with measurable tumors in both breasts are excluded from the primary trial [SEP] Clinical Trial: NCT01351376,Entailment,0.82313514,0.17686486
NCT00317603,"Statement: the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 0.25 of the primary trial patients. [SEP] Clinical Trial: NCT00317603",Contradiction,0.19472729,0.8052727
NCT00795769,Statement: patients in the primary trial recorded the most instances of chest pain compared to those in the secondary trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.65939593,0.34060413
NCT01310075,Statement: A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial. [SEP] Clinical Trial: NCT01310075,Contradiction,0.33409068,0.66590935
NCT02041429,Statement: the primary clinical trial and the secondary clinical trial both indicate the maximum tolerated dose (mtd) for the same intervention. [SEP] Clinical Trial: NCT02041429,Contradiction,0.30662155,0.6933785
NCT02222922,Statement: All the primary trial participants receive higher doses of ALT-801 than the secondary trial participants. respiratory acidosis is acid base imbalance resulting from an accumulation of carbon dioxide secondary to hypoventilation. [SEP] Clinical Trial: NCT02222922,Contradiction,0.38660112,0.6133989
NCT01106898,Statement: no patient in the primary clinical trial experienced recurrence-free survival. [SEP] Clinical Trial: NCT01106898,Entailment,0.9066278,0.09337218
NCT01048099,Statement: investigator status in study is a category used to describe the registration status of a clinical study investigator in a particular study. None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort. [SEP] Clinical Trial: NCT01048099,Entailment,0.67706233,0.3229377
NCT02509156,Statement: the allo-mscs intervention of the primary clinical trial is administered via intravenous infusion in a higher dose than the placebo intervention. [SEP] Clinical Trial: NCT02509156,Entailment,0.669434,0.33056596
NCT02122796,"Statement: the weekly administration of mm-121 and paclitaxel for primary clinical trial candidates is less than that of the first cohort of secondary clinical trial candidates, but they are given more herceptin and docetaxel [SEP] Clinical Trial: NCT02122796",Contradiction,0.4435119,0.5564881
NCT02441946,"Statement: Patients with a breast tumor 0.2-0.8 cm in diameter, with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial. mesencephalic perforating artery is an artery that arises from the posterior cerebral artery and supplies the mid brain. [SEP] Clinical Trial: NCT02441946",Contradiction,0.36763087,0.63236916
NCT00775645,"Statement: if no, describe why is a request to specify why. In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1% of participants. [SEP] Clinical Trial: NCT00775645",Entailment,0.58640957,0.41359043
NCT00054028,"Statement: in the primary clinical trial, all patients are treated with suramin and paclitaxel, however, the secondary trial does not outline the medications to be administered in its intervention section. [SEP] Clinical Trial: NCT00054028",Entailment,0.8878489,0.11215106
NCT00293540,"Statement: generally, patients from the primary clinical trial have a life expectancy that exceeds 2 years, however, there was at least one patient from both groups who did not survive past 2 years. [SEP] Clinical Trial: NCT00293540",Entailment,0.6662827,0.3337173
NCT00588640,Statement: have discomfort or pain in pelvic area is a question about whether an individual has or had discomfort or pain in their pelvic area. the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients. [SEP] Clinical Trial: NCT00588640,Entailment,0.5178259,0.4821741
NCT01008904,Statement: movement of swollen area is painful is a question about whether the movement of an individual's swollen area is or was painful. The only AE recorded in the primary trial was Stomatitis. [SEP] Clinical Trial: NCT01008904,Contradiction,0.4657123,0.53428775
NCT01023477,"Statement: Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial. kluyvera is a genus of facultatively anaerobic, gram negative, rod shaped bacterium in the phylum fusobacteria and the family enterobacteriaceae. [SEP] Clinical Trial: NCT01023477",Entailment,0.62176406,0.3782359
NCT01310075,Statement: a woman who has undergone a mastectomy might still be suitable to enroll in either the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT01310075,Contradiction,0.38163394,0.61836606
NCT01964924,"Statement: an adult patient diagnosed with ild/dpld within the last 36 months, with a life expectancy of 184 days would be eligible for the primary trial [SEP] Clinical Trial: NCT01964924",Contradiction,0.3807446,0.61925536
NCT01743560,"Statement: children and adolescents are not eligible for the primary trial, as they do not meet the height requirement, however they are not explicitly excluded from the secondary trial. childhood malignant penile neoplasm is a rare malignant neoplasm of the penis that occurs during childhood. [SEP] Clinical Trial: NCT01743560",Contradiction,0.381035,0.618965
NCT02761642,"Statement: patients with a cancer diagnosis who also have epilepsy, thalasemic syndromes, or anemia are ineligible for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02761642",Contradiction,0.45117188,0.54882807
NCT01702571,Statement: all recorded adverse events for the first group in the primary clinical trial are connected to issues of mental health. [SEP] Clinical Trial: NCT01702571,Entailment,0.668711,0.33128896
NCT02239601,Statement: the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial. [SEP] Clinical Trial: NCT02239601,Entailment,0.79576534,0.20423467
NCT01631552,Statement: the outcome measurements of the primary clinical trial are directly correlated to those of the secondary clinical trial. [SEP] Clinical Trial: NCT01631552,Entailment,0.80604655,0.1939534
NCT00148668,Statement: Both interventions in the primary trial include trastuzumab. non-trisomic autosomal aneuploidy is autosomal aneuploidy not associated with trisomy. it results in developmental malformations. [SEP] Clinical Trial: NCT00148668,Entailment,0.5042145,0.49578544
NCT01351376,Statement: patients with non-measurable unilateral breast cancer are eligible for the primary clinical trial [SEP] Clinical Trial: NCT01351376,Entailment,0.76760256,0.23239745
NCT01008904,Statement: The only AE recorded in the primary trial was Stomatitis. ezhip overexpression positive is an indication that overexpression of ezhip has been detected in a sample. [SEP] Clinical Trial: NCT01008904,Contradiction,0.46814552,0.5318545
NCT00377156,"Statement: the primary clinical trial may still accommodate patients with the diagnosis of 2-3 cerebral metastases, despite being disallowed from joining the secondary clinical trial. [SEP] Clinical Trial: NCT00377156",Entailment,0.6402334,0.35976666
NCT01286987,"Statement: nocardia is a genus of gram-positive, catalase-positive, rod-shaped bacteria in the phylum actinobacteria. Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead. [SEP] Clinical Trial: NCT01286987",Contradiction,0.4910834,0.5089166
NCT02891681,Statement: both the primary clinical trial and the secondary clinical trial could include patients who are extremely overweight or expecting. [SEP] Clinical Trial: NCT02891681,Contradiction,0.26514757,0.73485243
NCT00828516,Statement: tyrphostin ag 1288 is a protein tyrosine kinase inhibitor that blocks tumor necrosis factor alpha induced cytotoxicity. (nci) Neither the secondary trial or the primary trial use change in MYMOP score as the outcome measurement for their studies. [SEP] Clinical Trial: NCT00828516,Contradiction,0.47104892,0.52895105
NCT00122369,"Statement: the secondary clinical trial welcomes participants of all ages, including 18 year olds, but the primary clinical trial sets an age limit of 21 and over. [SEP] Clinical Trial: NCT00122369",Contradiction,0.47485152,0.52514845
NCT02002533,Statement: the primary trial and the secondary trial have 0% recorded adverse events. [SEP] Clinical Trial: NCT02002533,Entailment,0.85943246,0.14056759
NCT01376349,"Statement: functional physical assessment results are used as the units of measure in the primary trial, while the secondary trial utilizes patient self-reported pain levels. [SEP] Clinical Trial: NCT01376349",Entailment,0.581429,0.41857094
NCT00569166,"Statement: cohort 1 and cohort 2 in the primary clinical trial follow different paced breathing instructional cds, and both practice once a day. [SEP] Clinical Trial: NCT00569166",Contradiction,0.36372083,0.63627917
NCT01881230,Statement: both cohorts involved in the primary clinical trial are given identical amounts of abraxane [SEP] Clinical Trial: NCT01881230,Entailment,0.8539536,0.14604647
NCT00182793,Statement: There was at least 1 case of infection in both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00182793,Entailment,0.86391175,0.13608822
NCT01783444,"Statement:  Women with Newly diagnosed locally advanced breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial [SEP] Clinical Trial: NCT01783444",Contradiction,0.24415606,0.7558439
NCT00317603,"Statement: the most encountered adverse event across the patient cohorts of the primary clinical trial and the secondary clinical trial was asthma, which occurred in 25.00% of the primary clinical trial patients. [SEP] Clinical Trial: NCT00317603",Contradiction,0.16028143,0.8397186
NCT00800436,Statement: patients who have received gabapentin or herceptin treatment in the past year are not eligible for the secondary clinical trial but can participate in the primary clinical trial [SEP] Clinical Trial: NCT00800436,Entailment,0.7487031,0.25129688
NCT00428220,"Statement: patients suffering from ascites were less common in the primary clinical trial, while pneumocystis jirovecii pneumonia was less frequent in the secondary clinical trial  [SEP] Clinical Trial: NCT00428220",Entailment,0.6301262,0.36987376
NCT02404441,"Statement: the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria, one for the 18-50 age group and one for the 50+ age group. radiation, charged particles is a particle which carries a positive or negative electrical charge, typically an ionized atom or molecule, or an electron. [SEP] Clinical Trial: NCT02404441",Contradiction,0.4756197,0.52438027
NCT00662025,"Statement: in the first 21-day cycle of the primary clinical trial, capecitabine was given orally on a daily basis to all participants in cohort 2 [SEP] Clinical Trial: NCT00662025",Entailment,0.5842702,0.41572982
NCT01156987,"Statement: no instances of lesions were reported among the participants of group 1 in the primary clinical trial, but a high percentage, over 90%, of participants in group 1 of the secondary clinical trial were diagnosed with radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.33363572,0.66636425
NCT01806259,Statement: there was no significant difference in recurrence-free survival between the ketorolac 30 mg group and the nacl 0.9% 3ml group of the primary clinical trial [SEP] Clinical Trial: NCT01806259,Entailment,0.726609,0.27339098
NCT00432562,"Statement: the secondary trial and the primary trial do not share any inclusion or exclusion criteria, including the requirement to provide written informed consent. [SEP] Clinical Trial: NCT00432562",Entailment,0.6708749,0.32912514
NCT00377156,"Statement: while a diagnosis of 2-3 cerebral metastases would exclude a patient from the secondary clinical trial, participation in the primary clinical trial could still be possible. [SEP] Clinical Trial: NCT00377156",Entailment,0.6400653,0.35993463
NCT01351376,Statement: individuals with measurable bilateral breast cancer can participate in the primary clinical trial [SEP] Clinical Trial: NCT01351376,Entailment,0.5149775,0.48502252
NCT00759785,"Statement: a higher percentage of participants, specifically 11% more from the er+ luminal b group of the primary clinical trial, showed a decrease in the growth factor signature than their counterparts in the triple negative group. [SEP] Clinical Trial: NCT00759785",Contradiction,0.47053766,0.52946234
NCT01781299,"Statement: no unexpected fatalities or hospital admissions were reported in both the primary clinical trial and the secondary clinical trial, with the exception being three incidents of lymphoma. [SEP] Clinical Trial: NCT01781299",Contradiction,0.4187234,0.5812766
NCT00709761,"Statement: in the primary clinical trial, it was recorded that over 50% of those treated with lapatinib 1000 mg and nab-paclitaxel displayed either a verified complete or partial response. [SEP] Clinical Trial: NCT00709761",Contradiction,0.29835293,0.7016471
NCT00076024,Statement: only non-pregnant individuals are eligible to participate in the primary clinical trial [SEP] Clinical Trial: NCT00076024,Entailment,0.76371026,0.23628977
NCT01091974,"Statement: armodafinil p.o. on a daily basis is received by just one cohort in the primary trial, contrastingly, in the secondary trial, pdr001 is proportioned out identically to every patient, with differing amounts of mcs110. [SEP] Clinical Trial: NCT01091974",Entailment,0.5109919,0.4890081
NCT02239601,Statement: the total number of adverse events were different in the patient cohorts of the primary and secondary clinical trials. [SEP] Clinical Trial: NCT02239601,Entailment,0.85924613,0.1407538
NCT02165839,"Statement: smoking behavior is any of the activities associated with tobacco smoking. Candidates for the primary trial and the secondary trial have to meet a baseline performance status, each trial is using a different performance status scoring system. [SEP] Clinical Trial: NCT02165839",Entailment,0.65229994,0.34770006
NCT01629615,Statement: the incidence of eating disorders was minimal among patients participating in the primary clinical trial [SEP] Clinical Trial: NCT01629615,Entailment,0.81381994,0.18618003
NCT02599194,Statement: both the primary clinical trial and the secondary clinical trial reported all adverse events encountered during their respective trials. [SEP] Clinical Trial: NCT02599194,Entailment,0.8521562,0.14784378
NCT00284180,"Statement: the primary clinical trial is solely reserved for individuals who have never undergone herceptin treatments, regardless of their general medical history. [SEP] Clinical Trial: NCT00284180",Entailment,0.74008363,0.2599164
NCT00454532,Statement: over 97% of patients in the secondary trial and the primary trial did not suffer any adverse events. cybb gene mutation is a change in the nucleotide sequence of the cybb gene. [SEP] Clinical Trial: NCT00454532,Contradiction,0.4538994,0.5461006
NCT01498458,Statement: in the primary trial there were 1000% the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.29196927,0.70803076
NCT01091974,"Statement: in the primary clinical trial, multiple cohorts are given armodafinil p.o. daily, and the secondary clinical trial administers various amounts of pdr001 to all patients with a consistent dose of lcs101. [SEP] Clinical Trial: NCT01091974",Contradiction,0.4325944,0.56740564
NCT00759785,Statement: nearly half more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group [SEP] Clinical Trial: NCT00759785,Entailment,0.5532974,0.44670257
NCT01008150,Statement: more than 42 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 5040 hours after the surgery [SEP] Clinical Trial: NCT01008150,Contradiction,0.2555393,0.7444607
NCT00146172,Statement: candidates Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.41210973,0.58789027
NCT02239601,Statement: the primary clinical trial recorded slightly more total adverse events among its patient cohorts compared to the secondary clinical trial. [SEP] Clinical Trial: NCT02239601,Entailment,0.7740857,0.22591428
NCT00656305,"Statement: grade 1 joint effusion, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated There were no deaths or Hospitalizations in cohort 2 of the primary trial. [SEP] Clinical Trial: NCT00656305",Entailment,0.6486103,0.35138968
NCT01313117,"Statement: Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, up to a maximum of 100 mg three times daily, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. six to ten activity hours is a response indicating that 6 to 10 hours were spent on an activity. [SEP] Clinical Trial: NCT01313117",Contradiction,0.36044222,0.6395577
NCT02640053,"Statement: in the primary clinical trial, the symptoms were more severe in patients who were not infused with paclitaxel compared to those who were. [SEP] Clinical Trial: NCT02640053",Entailment,0.6791819,0.32081816
NCT00429182,"Statement: in the primary clinical trial, an overwhelming majority of participants showed a decline in circulating tumor cell counts due to the regiment of high-dose chemotherapy with purged autologous stem cell products. [SEP] Clinical Trial: NCT00429182",Contradiction,0.4629783,0.5370217
NCT01466972,Statement: maculo-papular Rash was a common adverse event for the primary trial participants. [SEP] Clinical Trial: NCT01466972,Entailment,0.8493584,0.15064164
NCT02187783,"Statement: the levels of palpitations, pericardial effusions and abdominal pains were higher in cohort 2 of the primary clinical trial than those of cohort 1 in the secondary clinical trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.45739892,0.5426011
NCT01156987,"Statement: zero percent of individuals in group 1 of the primary clinical trial displayed any lesions, in contrast, over ninety percent of participants in group 1 of the secondary clinical trial exhibited symptoms of radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.34870565,0.6512944
NCT01178411,Statement: only patients of a certain nationality and ethnicity are eligible for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01178411,Contradiction,0.25811583,0.7418842
NCT00454532,Statement: the majority of patients participating in the primary and secondary clinical trials reported experiencing adverse events after treatment [SEP] Clinical Trial: NCT00454532,Entailment,0.742652,0.25734797
NCT00030823,Statement: simfibrate is a derivative of clofibrate with antilipidemic activity. There were more participants in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00030823,Contradiction,0.43176964,0.56823033
NCT00999921,Statement: ppp2r2a gene mutation is a change in the nucleotide sequence of the ppp2r2a gene. Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial. [SEP] Clinical Trial: NCT00999921,Entailment,0.7230755,0.2769245
NCT01310075,Statement: A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial. tatar chinese is a chinese person from the tatar ethnic group. [SEP] Clinical Trial: NCT01310075,Contradiction,0.29256,0.70743996
NCT02404441,"Statement: while the primary trial's entry conditions are identical for all age groups, the secondary trial has separate entry conditions for participants under the age of 25 and those 25 and older. [SEP] Clinical Trial: NCT02404441",Entailment,0.77292556,0.22707449
NCT00775645,Statement: in both the primary trial and the secondary trial there were several adverse events which occurred in more than 90% of participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.46489167,0.5351084
NCT01920061,"Statement: the primary trial uses a 3 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.9201692,0.07983079
NCT01869192,"Statement: the primary clinical trial's results demonstrate that the placebo arm outperformed the arm a intervention in terms of overall response rate. meanwhile, the zoledronic acid group in the secondary clinical trial showed faster time to first on-study sre than the denosumab group. [SEP] Clinical Trial: NCT01869192",Contradiction,0.46473297,0.535267
NCT01597193,"Statement: in the primary clinical trial, the dosage of enzalutamide for cohort 2 is twice as much as that for cohort 1 [SEP] Clinical Trial: NCT01597193",Entailment,0.5080068,0.49199313
NCT00911898,"Statement: renal calyx is an intrarenal space located in the renal medulla that serves to collect and transport urine. The the primary trial intervention section dose not describe the method of administration, dosage or cycle. [SEP] Clinical Trial: NCT00911898",Entailment,0.725152,0.27484798
NCT02509156,Statement: The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection. [SEP] Clinical Trial: NCT02509156,Contradiction,0.29895115,0.7010489
NCT02807844,"Statement: every patient in the primary clinical trial is administered a minimum of 20mg of mcs110 tri-weekly, alongside over 130 mg of pdr001 bi-weekly. [SEP] Clinical Trial: NCT02807844",Contradiction,0.34540388,0.65459615
NCT00319748,Statement: 4p16.3-p16.1 is a chromosome band present on 4p Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors. [SEP] Clinical Trial: NCT00319748,Contradiction,0.3678151,0.63218486
NCT01597193,Statement: cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1. voice problem upsets me is a question about how frequently an individual's voice problem upsets them. [SEP] Clinical Trial: NCT01597193,Entailment,0.64043385,0.35956615
NCT00408681,"Statement: Recurrent malignancies, Graft-versus-host disease, Infection, Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.5640538,0.43594626
NCT01290536,"Statement: the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 400 mg of ibrutinib and 30 mg/kg of medi4736 twice daily for a month. [SEP] Clinical Trial: NCT01290536",Contradiction,0.33495238,0.6650476
NCT00843167,"Statement: the secondary trial focuses on tracking cutaneous sensation changes for evaluating physical therapy effectiveness, whereas the primary trial measures the influence of ascorbic acid supplements on vitamin c concentration in blood plasma. [SEP] Clinical Trial: NCT00843167",Contradiction,0.42824727,0.57175267
NCT00365105,"Statement: a 45 year old patient with histologically verified diagnosis of stage 2breast cancer, absolute neutrophil count of 3000/≈í¬∫l, platelet count of 188000/≈í¬∫l, hemoglobin level of 140 g/l, and a life expectancy exceeding 14 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.321243,0.67875695
NCT02187783,"Statement: the primary clinical trial observed more cases of palpitations, pericardial effusions, and abdominal pains than the secondary clinical trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.47134072,0.5286593
NCT02115607,Statement: the secondary trial recorded fewer aes than the primary trial [SEP] Clinical Trial: NCT02115607,Entailment,0.82682407,0.17317598
NCT00662025,"Statement: in the primary clinical trial, no medications were administered to the patients in cohort 2 during the first 21-day cycle [SEP] Clinical Trial: NCT00662025",Entailment,0.8052976,0.19470242
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 300 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.404179,0.595821
NCT02441946,"Statement: Patients with a breast tumor 0.2-0.8 cm in diameter, with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial. fatigue interference score answer is an answer for the fatigue interference score query. [SEP] Clinical Trial: NCT02441946",Contradiction,0.47003987,0.52996016
NCT01086605,"Statement: neither cohorts in the primary clinical trial reported any instances of hypertension, edema, and dyspnea. [SEP] Clinical Trial: NCT01086605",Entailment,0.6107985,0.38920152
NCT04080297,Statement: participants from the secondary trial are able to concurrently enroll in the primary trial [SEP] Clinical Trial: NCT04080297,Entailment,0.7789486,0.22105138
NCT01310075,Statement: a woman who has not undergone any radical surgical treatment for her stage ii bc is strictly ineligible for the secondary trial and the primary trial [SEP] Clinical Trial: NCT01310075,Entailment,0.62249565,0.37750438
NCT01783444,Statement: women who have been recently diagnosed with stage iv er-positive breast cancer and are contemplating a mastectomy are qualified for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01783444,Contradiction,0.23248214,0.76751786
NCT02413008,"Statement: rectal pain, ctcae 5.0 is a disorder characterized by a sensation of marked discomfort in the rectal region. the secondary trial and the primary trial use different outcome measurements and units of measure. [SEP] Clinical Trial: NCT02413008",Entailment,0.79562277,0.20437722
NCT00766532,"Statement: in the primary clinical trial and the secondary clinical trial, there are recorded cases of swelling, hypothermia, and confusion in the adverse events sector. [SEP] Clinical Trial: NCT00766532",Contradiction,0.39392397,0.60607606
NCT01591746,"Statement: Neither cohort of the primary trial recieves alisertib, and the two cohorts of the secondary trial receive different doses [SEP] Clinical Trial: NCT01591746",Entailment,0.88954973,0.11045028
NCT00513292,"Statement: pcr serves as the outcome measure for the primary and secondary clinical trials. in the primary trial, slight differences were noted among the results of its two cohorts. however, for the secondary trial, a bigger difference was seen, with results from arm 2 declining more than those of arm 1 due to a higher pcr rate. [SEP] Clinical Trial: NCT00513292",Contradiction,0.43073612,0.5692639
NCT00659373,"Statement: generally, both groups in the primary trial showed a deterioration in cognitive abilities, but this wasn't the pattern for all patients [SEP] Clinical Trial: NCT00659373",Entailment,0.616002,0.38399804
NCT01222390,"Statement: neither the primary clinical trial nor the secondary clinical trial involves the use of x-rays, transendocardial injections, ct scans or mris as part of their interventions. [SEP] Clinical Trial: NCT01222390",Contradiction,0.21850607,0.78149396
NCT00632489,"Statement: within the primary clinical trial, the lbh589 with capecitabine cohort showed inferior results when compared to the lbh589 and lapatinib group [SEP] Clinical Trial: NCT00632489",Entailment,0.7692363,0.23076366
NCT00918281,"Statement: the primary trial includes the administration of fluciclatide to the first cohort, whereas the first cohort in the secondary trial is introduced to a standard dose of chloroquine. [SEP] Clinical Trial: NCT00918281",Entailment,0.54999614,0.45000392
NCT01975831,Statement: the differences between interventions 1 and 2 of the primary clinical trial extend beyond the dose of durva administered during bi-weekly iv infusions [SEP] Clinical Trial: NCT01975831,Entailment,0.5300577,0.4699423
NCT00262834,"Statement: grade 1 neonatal bradyarrhythmia, ae is an adverse event in a newborn characterized by brief, self-limiting, episodes of asymptomatic bradyarrhythmia; no care changes. 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients, apart from Skin infections. [SEP] Clinical Trial: NCT00262834",Entailment,0.5231334,0.47686663
NCT00538850,Statement: haploidentical is a donor who has only one haplotype in common with the recipient. The the primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. [SEP] Clinical Trial: NCT00538850,Contradiction,0.44673637,0.5532636
NCT03346161,Statement: no adverse events were reported in either of the cohorts involved in the primary clinical trial [SEP] Clinical Trial: NCT03346161,Entailment,0.9027799,0.09722012
NCT02640053,Statement: asph gene product is a protein encoded by the human asph gene. Patients in the primary trial that didn‚Äö√Ñ√¥t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy. [SEP] Clinical Trial: NCT02640053,Entailment,0.56449604,0.43550396
NCT00429299,"Statement: All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care. u wave abnormality by ecg finding is an electrocardiographic finding of u waves which have increased amplitude, are inverted, or merged with the preceding t wave. [SEP] Clinical Trial: NCT00429299",Contradiction,0.30787352,0.69212645
NCT02509156,"Statement: through transendocardial injection, both the placebo and the allo-mscs intervention are delivered in the same dosage in the primary clinical trial. [SEP] Clinical Trial: NCT02509156",Entailment,0.53250337,0.46749657
NCT01013740,"Statement: compared with the secondary clinical trial, the primary trial has less reported anemia cases. [SEP] Clinical Trial: NCT01013740",Entailment,0.83748704,0.16251294
NCT00825682,Statement: total organic carbon is an indirect measure of organic molecules present in pharmaceutical waters measured as carbon. The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Contradiction,0.43864244,0.5613576
NCT00693719,Statement: the primary clinical trial could have eligibility for a patient who has been diagnosed with neoplastic meningitis [SEP] Clinical Trial: NCT00693719,Entailment,0.5388757,0.46112433
NCT03403712,"Statement: the primary trial is calculating the mean bedtime its subjects have each night, whilst the secondary trial is observing the volume of patients experiencing therapy-related negative events. [SEP] Clinical Trial: NCT03403712",Entailment,0.623649,0.376351
NCT00321048,"Statement: have a skin rash is a question about whether an individual has or had a skin rash. Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan. [SEP] Clinical Trial: NCT00321048",Contradiction,0.35321036,0.6467896
NCT00956813,Statement: clinical study anchor is a planned activity within a clinical study that marks a transition between epochs or elements within the clinical study. the secondary trial and the primary trial report their results using the same units of measure. [SEP] Clinical Trial: NCT00956813,Contradiction,0.3513415,0.6486586
NCT01129622,Statement: Women suffering from both claustrophobia and osteoporosis or not eligible for either the primary trial or the secondary trial. progressive central nervous system neoplasm is a central nervous system neoplasm that is increasing in scope or severity. [SEP] Clinical Trial: NCT01129622,Entailment,0.5526903,0.4473097
NCT00656305,"Statement: how old when first began smoking cigarettes regularly is a question about how old an individual was when they first began smoking cigarettes regularly. There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation . [SEP] Clinical Trial: NCT00656305",Contradiction,0.46526515,0.53473485
NCT00182767,Statement: more than two participants in the primary clinical trial experienced dose-limiting toxicity. [SEP] Clinical Trial: NCT00182767,Entailment,0.7486748,0.25132516
NCT00538850,Statement: the the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 270 days in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850,Contradiction,0.33289233,0.66710764
NCT00428220,"Statement: Ascites was more common for patients in the primary trial, and Pneumocystis jirovecii pneumonia was more common in the secondary trial. document version workflow status code is a coded value specifying the state of the document version workflow. [SEP] Clinical Trial: NCT00428220",Entailment,0.5174303,0.48256966
NCT00800436,"Statement: patients who have undergone treatment with either gabapentin or pregabalin will not be accepted into the secondary clinical trial, however, this does not affect their eligibility for the primary clinical trial. [SEP] Clinical Trial: NCT00800436",Entailment,0.76126415,0.23873584
NCT00820872,Statement: participants in the primary clinical trial experienced diarrhoea more frequently than those in the secondary clinical trial. [SEP] Clinical Trial: NCT00820872,Entailment,0.7689258,0.23107418
NCT00429299,Statement: the primary clinical trial stipulates that all aspirants must have a her2 positive tumor validated via ihc 3+ and require extensive help and regular medical supervision [SEP] Clinical Trial: NCT00429299,Contradiction,0.33624625,0.6637538
NCT01286168,"Statement: the most common adverse event in the primary clinical trial was diarrhea, affecting approximately 8% of patients, while no adverse events were recorded in the secondary clinical trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.50676996,0.49323004
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial. in subset is an association that connects the concept defining a particular terminology subset with concepts that belong to this subset. [SEP] Clinical Trial: NCT01964924,Entailment,0.7268316,0.27316839
NCT02796755,Statement: less adverse incidents took place during the course of the secondary clinical trial than the primary clinical trial.' [SEP] Clinical Trial: NCT02796755,Entailment,0.8125171,0.18748285
NCT00262834,"Statement: in the primary clinical trial, there wasn't any recorded instance of an adverse event, whereas in the secondary clinical trial, apart from skin infections, no other adverse event affected more than 30% of the patients involved in the trial. [SEP] Clinical Trial: NCT00262834",Entailment,0.59363335,0.40636662
NCT01383174,Statement: cohort 2 from the secondary clinical trial demonstrated superior outcomes compared to the same cohort from the primary clinical trial. [SEP] Clinical Trial: NCT01383174,Entailment,0.87140936,0.12859069
NCT02306265,"Statement: for inclusion in the primary trial, candidates are required to have an updated electrocardiogram (ecg), while the secondary trial mandates a recent colonoscopy report and a complete blood count (cbc). [SEP] Clinical Trial: NCT02306265",Contradiction,0.46855193,0.53144807
NCT00365365,"Statement: participants of the primary clinical trial receive a neurokinin-1 receptor antagonist on days 1, 8, and 15 [SEP] Clinical Trial: NCT00365365",Contradiction,0.40732804,0.592672
NCT00950911,Statement: the dosage of denosumab used in intervention 1 of the secondary clinical trial exceeds the dosage of zoledronic acid used in intervention 1 of the primary clinical trial by 12 times. [SEP] Clinical Trial: NCT00950911,Contradiction,0.39563322,0.6043668
NCT00245050,"Statement: the primary clinical trial consisted of a test group and a placebo group, while the secondary clinical trial was conducted with one test group and one control group. [SEP] Clinical Trial: NCT00245050",Entailment,0.6926198,0.30738014
NCT00708019,Statement: none of the patients in the primary trial experienced the worst pain imaginable for 20 minutes. [SEP] Clinical Trial: NCT00708019,Entailment,0.622861,0.37713894
NCT00454532,Statement: over 97% of patients in the secondary trial and the primary trial did not suffer any adverse events [SEP] Clinical Trial: NCT00454532,Entailment,0.5424138,0.45758626
NCT01008904,"Statement: in the primary clinical trial, a single adverse event has been logged for its patient cluster. [SEP] Clinical Trial: NCT01008904",Entailment,0.66934377,0.33065623
NCT00950911,Statement: the dosage of tamoxifen in intervention 1 of the secondary trial is 12 times higher than the dosage of denosumab in intervention 1 of the primary trial. [SEP] Clinical Trial: NCT00950911,Entailment,0.5103684,0.48963156
NCT00408681,"Statement: the adverse events such as recurrent malignancies, graft-versus-host disease, infection, altered mental status and diffuse alveolar hemorrhage were notably more prevalent in the primary clinical trial than the secondary clinical trial. [SEP] Clinical Trial: NCT00408681",Contradiction,0.4545085,0.54549146
NCT01537029,"Statement: fifty is a natural number greater than forty-nine and less than fifty-one and the quantity that it denotes. Female cancer patients over the age of 18 can participate in the primary trial, regardless of race, ethnic origin or cancer type, however for the secondary trial, they must have BRCA+ breast cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.3166124,0.6833876
NCT00429182,Statement: under 10% of participants from the primary clinical trial exhibited a decrease in circulating tumor cells after undergoing several months of high-dose chemotherapy along with purged autologous stem cell products. [SEP] Clinical Trial: NCT00429182,Contradiction,0.43008748,0.56991255
NCT01376349,"Statement: neither the primary clinical trial nor the secondary clinical trial employ cm, participant count, or time unit as their measurement units. [SEP] Clinical Trial: NCT01376349",Contradiction,0.34973952,0.6502605
NCT00583700,"Statement: women aged 18 or 19  are eligible for the secondary trial, but will need to wait 12-24 months to be eligible for the primary trial [SEP] Clinical Trial: NCT00583700",Contradiction,0.48458606,0.51541394
NCT01498458,"Statement: the primary clinical trial noted zero cases of hepatotoxicity, while there were multiple cases of hypertension and pancreatectomy. [SEP] Clinical Trial: NCT01498458",Contradiction,0.23988113,0.76011884
NCT03202472,"Statement: patients who have received chemotherapy or radiotherapy in the last 1/2 a month, suffer from unstable angina, or have grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. [SEP] Clinical Trial: NCT03202472",Contradiction,0.42498642,0.5750135
NCT00321048,Statement: radiation therapy is not administered to patients in the both cohorts of the primary clinical trial. [SEP] Clinical Trial: NCT00321048,Entailment,0.92293775,0.07706221
NCT02273206,Statement: none of the cervical cancer patients in cohort 1 had undergone a screening prior to the primary clinical trial intervention. [SEP] Clinical Trial: NCT02273206,Entailment,0.89740545,0.10259454
NCT02104830,"Statement: the primary clinical trial and secondary clinical trial are investigating the same medication, however, they differ in dosage amounts and how they measure results. [SEP] Clinical Trial: NCT02104830",Entailment,0.5727447,0.4272553
NCT01989546,"Statement: treatment protocols based on cbt are not permitted in the primary clinical trial, however, its candidates can still participate in the secondary clinical trial. [SEP] Clinical Trial: NCT01989546",Contradiction,0.46799976,0.5320003
NCT03346161,Statement: there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial . hypogonadotropic hypogonadism with anosmia is an x-linked or autosomal dominant genetic syndrome characterized by hypogonadotropic hypogonadism and anosmia. [SEP] Clinical Trial: NCT03346161,Contradiction,0.43919718,0.56080276
NCT00432562,"Statement: skin appendage neoplasm is a benign or malignant neoplasm that arises from the hair follicles, sebaceous glands, or sweat glands. There are 0 shared inclusion/exclusion criteria between the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00432562",Entailment,0.644147,0.35585305
NCT00030823,Statement: the number of participants was higher in the primary clinical trial compared to the secondary clinical trial. [SEP] Clinical Trial: NCT00030823,Entailment,0.6813956,0.31860438
NCT01250379,Statement: the primary and secondary clinical trial could consider for eligibility a young girl recently diagnosed with pr-positive and her2 positive breast cancer [SEP] Clinical Trial: NCT01250379,Contradiction,0.33187088,0.66812915
NCT01306032,Statement: both the patients in the primary clinical trial and the secondary clinical trial face the same negative effects.' [SEP] Clinical Trial: NCT01306032,Entailment,0.76818705,0.23181295
NCT01045421,"Statement: in the secondary trial, patients are accepted regardless of gene mutations whilst the primary trial requires confirmation of mutations in genes such as pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11 [SEP] Clinical Trial: NCT01045421",Contradiction,0.4121328,0.58786714
NCT00454532,Statement: less than 2% of patients in the secondary trial and the primary trial did not suffer any adverse events [SEP] Clinical Trial: NCT00454532,Entailment,0.7401082,0.25989184
NCT01008904,Statement: just one negative occurrence has been noted for the patient contingent of the primary clinical trial. [SEP] Clinical Trial: NCT01008904,Entailment,0.88255715,0.11744281
NCT01989546,"Statement: CBT based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. memory intervention is any action taken for the purpose of improving an individual's memory. [SEP] Clinical Trial: NCT01989546",Entailment,0.5364785,0.46352145
NCT01045421,Statement: resolution of findings following intervention for kawasaki disease is an indication that findings were resolved following treatment for kawasaki disease. patients with Histologically or cytologically confirmed metastatic and/or advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial. [SEP] Clinical Trial: NCT01045421,Contradiction,0.4309969,0.5690031
NCT00792077,Statement: the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1. has moderate or severe renal disease is a question about whether an individual has or had moderate or severe renal disease. [SEP] Clinical Trial: NCT00792077,Entailment,0.64292866,0.35707137
NCT00118157,Statement: Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month. [SEP] Clinical Trial: NCT00118157,Contradiction,0.42610797,0.573892
NCT00405938,"Statement: the primary clinical trial will not accept patients if they have had an abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess, or considerable psychiatric disorders occur in the last six months [SEP] Clinical Trial: NCT00405938",Entailment,0.5067635,0.49323645
NCT00416715,"Statement: candidates for the secondary trial study group receive 3 weekly subcutaneous (sc) injections, whereas the primary trial participants receive 5 injections at the beginning of the study. [SEP] Clinical Trial: NCT00416715",Entailment,0.5088477,0.49115232
NCT00256217,Statement: There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs. was a spine mri completed at diagnosis is a question about whether a spine mri study was completed at diagnosis. [SEP] Clinical Trial: NCT00256217,Contradiction,0.45541564,0.54458433
NCT00992602,Statement: the primary clinical trial has a higher incidence of bronchopneumonia and physical health decline compared to the secondary clinical trial. [SEP] Clinical Trial: NCT00992602,Entailment,0.625029,0.374971
NCT00467844,Statement: at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass. [SEP] Clinical Trial: NCT00467844,Contradiction,0.44838765,0.5516123
NCT00030823,Statement: xxyy syndrome is a rare sex chromosome abnormality in which a male child has an extra x and y chromosome. There were more participants in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00030823,Contradiction,0.37269425,0.6273057
NCT00749931,Statement: at least one inclusion criterion is shared between the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.88937104,0.11062902
NCT00687102,Statement: There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial. ultrasonogram is a computerized image of internal tissues created by bouncing high-energy sound waves off internal organs. [SEP] Clinical Trial: NCT00687102,Contradiction,0.20934628,0.7906537
NCT00293384,"Statement: adhesion factor production is any cellular process that results in the elaboration of adhesion molecules on the cell surface. Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril. [SEP] Clinical Trial: NCT00293384",Contradiction,0.34051546,0.65948457
NCT01569087,"Statement: organ perforation is a rupture in an organ(s) due to traumatic or pathologic processes. Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent. [SEP] Clinical Trial: NCT01569087",Contradiction,0.24660692,0.75339305
NCT00825682,Statement: the intervention in the secondary trial last 105 more days than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Contradiction,0.4167348,0.58326524
NCT01823991,Statement: have vaginal itching or irritation is a question about whether an individual has or had vaginal itching or vaginal irritation. patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial. [SEP] Clinical Trial: NCT01823991,Contradiction,0.44695523,0.5530448
NCT00558272,Statement: the primary clinical trial revealed a higher percentage change in betactx at week four in the azd0530 175 mg group when compared to the group administered with zoledronic acid 4 mg. [SEP] Clinical Trial: NCT00558272,Contradiction,0.4994915,0.50050855
NCT00800436,"Statement: inclusion in the secondary trial requires no restrictions on previous treatments with drugs like gabapentin or pregabalin, however, these treatments serve as exclusion factors in the primary trial. [SEP] Clinical Trial: NCT00800436",Entailment,0.77850604,0.22149402
NCT00418028,"Statement: office and administrative support occupations is a class of professional or vocational positions of employment that involve office or administrative support. the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the number of patients that experience Objective Response . [SEP] Clinical Trial: NCT00418028",Contradiction,0.32551885,0.67448115
NCT01803282,"Statement: out of 73 participants in the primary clinical trial, 2 experienced an acute myocardial infarction, while none out of 1674 participants in the secondary clinical trial experienced the same [SEP] Clinical Trial: NCT01803282",Entailment,0.55452925,0.44547075
NCT00825682,Statement: the intervention in the secondary trial last 5 more weeks than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.56886613,0.4311339
NCT01920061,"Statement: the primary trial uses a 2 year cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.919793,0.08020697
NCT00544167,"Statement: individuals who have experienced a pulmonary embolism in the previous 8 weeks are eligible for participation in the primary clinical trial, whereas their eligibility for the secondary clinical trial is not subject to the discretion of the investigator [SEP] Clinical Trial: NCT00544167",Entailment,0.8111754,0.18882467
NCT00496860,Statement: cohort 1 of the primary clinical trial is administered the same dose of alt-801 as cohort 2. [SEP] Clinical Trial: NCT00496860,Entailment,0.68447083,0.3155292
NCT01989546,Statement: candidates receiving warfarin-based therapy are allowed in the primary clinical trial but prohibited in the secondary clinical trial. [SEP] Clinical Trial: NCT01989546,Entailment,0.86382204,0.13617797
NCT01823991,Statement: patients suffering from fronto-temporal dementia or mixed dementia can participate in the primary clinical trial [SEP] Clinical Trial: NCT01823991,Contradiction,0.39206108,0.60793895
NCT00775645,Statement: in both the primary trial and the secondary trial there were several adverse events which occurred in more than 3 out of 10 participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.46503955,0.53496045
NCT00357734,"Statement: the primary trial requires the use of 3 different drugs as part of the intervention, the combined use of cyclophosphamide, droperidol, and epoetin beta, on the other hand the intervention in the secondary trial only includes tamoxifen. [SEP] Clinical Trial: NCT00357734",Contradiction,0.46139014,0.5386099
NCT00266110,Statement: Patients in the primary trial will need to receive one single injection on day 8 of the study. thin-branching papillae present is a morphologic growth pattern indicating the presence of papillary structures forming thin branches. [SEP] Clinical Trial: NCT00266110,Contradiction,0.40078375,0.5992162
NCT01301729,Statement: her2 + patients in the primary trial receive a different dosage of trastuzumab than patients in cohort 2 of the secondary trial during the whole trial period [SEP] Clinical Trial: NCT01301729,Entailment,0.5991466,0.4008534
NCT00365365,"Statement: in the primary clinical trial, participants are given anthracycline-based chemotherapy on days 1, 8, and 15 [SEP] Clinical Trial: NCT00365365",Contradiction,0.38963678,0.6103632
NCT01989546,"Statement: warfarin based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. concerned about ability to have children is a question about whether an individual is or was concerned about their ability to have children. [SEP] Clinical Trial: NCT01989546",Entailment,0.5618742,0.43812573
NCT00467844,"Statement: all participants who were administered with 1mg gtx-024 in the primary clinical trial, showed a gain in lean body mass during the 4-month period [SEP] Clinical Trial: NCT00467844",Contradiction,0.46520627,0.53479373
NCT00284180,"Statement: Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial. turkic language is a language family spoken by the turkic peoples of eurasia. [SEP] Clinical Trial: NCT00284180",Contradiction,0.46967387,0.53032607
NCT01498458,Statement: in the primary trial there were 30 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.24175566,0.75824434
NCT00001832,Statement: the primary clinical trial and the secondary clinical trial follow an identical drug-based treatment intervention. [SEP] Clinical Trial: NCT00001832,Entailment,0.80768245,0.19231749
NCT02222922,Statement: participants in the primary clinical trial are administered higher doses of alt-801 compared to those in the secondary clinical trial [SEP] Clinical Trial: NCT02222922,Entailment,0.7052047,0.29479522
NCT00209092,"Statement: the decision to include a patient in the primary clinical trial is completely determined by patient's fulfilment of the inclusion and exclusion criteria, and does not involve the discretion of health professionals. [SEP] Clinical Trial: NCT00209092",Entailment,0.8770331,0.12296691
NCT02734979,"Statement: Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial. recto-vesico-vaginal fistula is an abnormal communication between the rectum, bladder, and vagina. [SEP] Clinical Trial: NCT02734979",Contradiction,0.46604902,0.533951
NCT00587964,Statement: the most common ae recorded in the primary clinical trial is myocardial infarction not coronary artery stenosis [SEP] Clinical Trial: NCT00587964,Entailment,0.72706544,0.2729346
NCT01128543,Statement: a majority of individuals in the primary clinical trial demonstrated complete response in a span of 24 weeks. [SEP] Clinical Trial: NCT01128543,Contradiction,0.41178218,0.5882178
NCT00284180,Statement: patients who have previously experienced profound anaphylactic responses to trastuzumab are ineligible for the primary clinical trial. [SEP] Clinical Trial: NCT00284180,Entailment,0.8932762,0.10672378
NCT00786838,"Statement: the administration method for both trabectedin and the placebo in the primary clinical trial is subcutaneous, occurring monthly. [SEP] Clinical Trial: NCT00786838",Contradiction,0.36701033,0.63298965
NCT01803282,"Statement: half of primary clinical trial's participants, and 837/1674 of the secondary trial's participants experienced an adverse event. [SEP] Clinical Trial: NCT01803282",Entailment,0.67339575,0.32660425
NCT00558272,Statement: The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.582262,0.417738
NCT00513292,"Statement: the primary and secondary clinical trials utilize pcr as a determinant of their results. notably, the primary trial boasts slight variations in the outcomes of its two cohorts. in contrast, within the secondary trial, larger differences in results are witnessed, with arm 2 performing poorly compared to arm 1 due to an increased number of patients experiencing pcr. [SEP] Clinical Trial: NCT00513292",Contradiction,0.30891472,0.6910853
NCT00001832,Statement: the primary clinical trial and the secondary clinical trial consist of the same pharmacological treatment protocol. [SEP] Clinical Trial: NCT00001832,Entailment,0.5814717,0.41852838
NCT00587964,Statement: the primary clinical trial records no aes as being general symptoms [SEP] Clinical Trial: NCT00587964,Entailment,0.900746,0.099254
NCT00800436,"Statement: patients who have been treated with gabapentin or pregabalin recently are eligible for participation in the secondary trial, but will be excluded from the primary trial. [SEP] Clinical Trial: NCT00800436",Entailment,0.82744837,0.17255165
NCT00971945,"Statement: intact mobility is a prerequisite for participation in the secondary trial, while the same quality is also mandatory for inclusion in the primary trial [SEP] Clinical Trial: NCT00971945",Contradiction,0.48344833,0.5165517
NCT00405938,"Statement: participation in the primary clinical trial is not permitted for patients with a history of conditions such as abdominal fistula, gastrointestinal perforation, myocardial infarction (mi), stroke, transient ischemic attacks, intrabdominal abscess, or serious psychiatric disorders in the past 6 months. [SEP] Clinical Trial: NCT00405938",Entailment,0.73952544,0.26047456
NCT01138046,"Statement: participation in the primary clinical trial is limited to female candidates of a specified nationality, this condition doesn't exist for the secondary clinical trial. [SEP] Clinical Trial: NCT01138046",Entailment,0.9136517,0.08634835
NCT01376349,Statement: specimen source site is a request to identify the specimen source site. Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure. [SEP] Clinical Trial: NCT01376349,Contradiction,0.35330555,0.6466945
NCT00194779,"Statement: patient in body sling is a position in which the subject's body is supported by a sling. the primary trial participants are administered over 7 different types of drugs and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery. [SEP] Clinical Trial: NCT00194779",Entailment,0.6938574,0.3061426
NCT01649271,"Statement: veillonella is a genus of anaerobic, gram negative, cocci shaped bacterium assigned to the phylum firmicutes and the family veillonellaceae. there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01649271",Contradiction,0.34176385,0.65823615
NCT00836186,"Statement: participants in the primary clinical trial receive whole breast radiation therapy, whereas participants in both cohorts of the secondary clinical trial are subjected to intramuscular injections and oral medication. [SEP] Clinical Trial: NCT00836186",Contradiction,0.3994793,0.60052073
NCT02179515,Statement: 1p33-p32 is a chromosome band present on 1p 100.0% of cohort 1 of the primary trial suffered some kind of adverse event. [SEP] Clinical Trial: NCT02179515,Entailment,0.7632485,0.23675153
NCT01554371,Statement: individuals with uncontrolled cardiovascular conditions can join the secondary clinical trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.6048448,0.39515522
NCT00867217,"Statement: secondary glioblastoma is a glioblastoma arising from a lower grade astrocytoma. Patients with a Vitamin D deficiency are excluded from the primary trial, but may be eligible for the secondary trial. [SEP] Clinical Trial: NCT00867217",Entailment,0.5265093,0.4734907
NCT00429182,Statement: the majority of the primary clinical trial participants experienced a decrease in circulating tumor cells after receiving high-dose chemotherapy with purged autologous stem cell products. [SEP] Clinical Trial: NCT00429182,Entailment,0.52318174,0.47681823
NCT00293540,"Statement: in the primary clinical trial, patient survival timeframe generally does not exceed 1 year, with not more than 50 patients in each cohort making it past the 12-month mark. [SEP] Clinical Trial: NCT00293540",Contradiction,0.3637141,0.6362859
NCT01091974,"Statement: in the primary clinical trial, daily armodafinil p.o. is dispensed to only one cohort, while in the secondary clinical trial, each patient gets the same amount of pdr001, with a range of mcs110 dosages. [SEP] Clinical Trial: NCT01091974",Contradiction,0.4542769,0.54572314
NCT00836186,"Statement: participants of the primary clinical trial undergo complete breast radiation therapy, in contrast, the secondary clinical trial participants, from both cohorts, take 500 mg of fulvestrant in tablet form, twice daily. [SEP] Clinical Trial: NCT00836186",Contradiction,0.40083933,0.5991607
NCT00408681,"Statement: Recurrent malignancies, Graft-versus-host disease, Infection, Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. scoopful dosing unit is a dosing unit equal to the amount of active ingredient(s) contained typically in a spoon-shaped object. [SEP] Clinical Trial: NCT00408681",Contradiction,0.44837335,0.5516267
NCT01290536,"Statement: the primary trial intervention incorporates the application of chemotherapy and radiology, whereas the secondary trial intervention relies on the use of hormonal therapy and immunotherapy. [SEP] Clinical Trial: NCT01290536",Contradiction,0.3852564,0.6147436
NCT02336737,Statement: cohort 1 of the primary clinical trial reported mild aes [SEP] Clinical Trial: NCT02336737,Entailment,0.7921582,0.20784178
NCT01008904,Statement: stomatitis was the only recorded adverse event in the primary clinical trial. [SEP] Clinical Trial: NCT01008904,Entailment,0.8701832,0.12981683
NCT00756717,Statement: both the primary and secondary trials recorded zero cases of either febrile neutropenia or cholelithiasis. [SEP] Clinical Trial: NCT00756717,Entailment,0.6239226,0.37607744
NCT00708019,Statement: a number of patients in the primary clinical trial reported severe discomfort during the entirety of the 10-week study. [SEP] Clinical Trial: NCT00708019,Entailment,0.62809837,0.3719016
NCT01569087,"Statement: Patients with stage 4 cancer are not eligible for the secondary trial, however they are eligible for the primary trial. 15q23-15q24 is a chromosome band present on 15q [SEP] Clinical Trial: NCT01569087",Entailment,0.527311,0.472689
NCT02509156,Statement: both the placebo and allo-mscs interventions of the primary clinical trial are administered in varied doses through inhalation. [SEP] Clinical Trial: NCT02509156,Contradiction,0.49352074,0.5064793
NCT01421472,Statement: men diagnosed with prostate cancer who present positive biomarker for psa are eligible for all cohorts of the primary clinical trial [SEP] Clinical Trial: NCT01421472,Contradiction,0.45841804,0.541582
NCT00317603,Statement: malignant laryngeal neoplasm is a primary or metastatic malignant neoplasm involving the larynx.  the majority are carcinomas. The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope. [SEP] Clinical Trial: NCT00317603,Contradiction,0.36926106,0.630739
NCT00623831,"Statement: in the primary clinical trial, fewer than a quarter of the patients have registered increased pleural effusion or rapid disease progression [SEP] Clinical Trial: NCT00623831",Entailment,0.57862824,0.42137176
NCT02504424,Statement: hard to remember what i just heard is a question about whether an individual finds or found it hard to remember what they just heard. Nobody taking part in the primary trial suffered a UTI. [SEP] Clinical Trial: NCT02504424,Entailment,0.7033247,0.29667535
NCT01290536,"Statement: The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month. [SEP] Clinical Trial: NCT01290536",Contradiction,0.3438998,0.6561003
NCT01127763,"Statement: at least one patient in the primary trial suffered several different adverse events. thyroid gland follicular carcinoma, minimally invasive is a follicular carcinoma of the thyroid gland showing capsular invasion only. [SEP] Clinical Trial: NCT01127763",Entailment,0.6384935,0.36150655
NCT02038218,Statement: the units of measure used in the primary and secondary trials align perfectly when measuring similar outcome. [SEP] Clinical Trial: NCT02038218,Entailment,0.6767301,0.32326993
NCT00248547,Statement: Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant. regulatory pathway is an elaboration of the known or inferred interactions controlling the expression of a product. [SEP] Clinical Trial: NCT00248547,Contradiction,0.40009293,0.59990704
NCT01743560,Statement: children are the main demographic required for participating in the primary clinical trial while they are not allowed to partake in the secondary trial [SEP] Clinical Trial: NCT01743560,Entailment,0.8501041,0.14989586
NCT00319748,"Statement: the secondary trial measures the proportion of participants benefiting from the treatment according to recist criteria, but the primary trial does not track this element. [SEP] Clinical Trial: NCT00319748",Entailment,0.91740316,0.08259681
NCT00293540,"Statement: on average patients from the primary trial survive over 24 months, however at least one patient from both cohorts died in under 24 months. [SEP] Clinical Trial: NCT00293540",Contradiction,0.4307325,0.5692675
NCT00569166,Statement: cohort 2 of the primary clinical trial follows the paced breathing instructional audio material only once daily and is given no antineoplastic treatments weekly. [SEP] Clinical Trial: NCT00569166,Entailment,0.83467734,0.16532269
NCT00118157,Statement: primary clinical trial involves the administration of a one-time 250 mg/m2 intramuscular dose of lapatinib to participating patients. [SEP] Clinical Trial: NCT00118157,Entailment,0.5209186,0.4790814
NCT00741039,Statement: milliunit is a quantity equivalent to the one thousandth unit (10e-3 unit). Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine. [SEP] Clinical Trial: NCT00741039,Contradiction,0.3989701,0.6010299
NCT00293540,"Statement: the average lifespan of patients post the primary clinical trial is less than 2 years, with no instances of patients from both cohorts passing away before the 2 year mark. [SEP] Clinical Trial: NCT00293540",Entailment,0.60048866,0.3995113
NCT00496860,Statement: the primary clinical trial administers to cohort 1 a dose of alt-801 which is less than half of that given to cohort 2 [SEP] Clinical Trial: NCT00496860,Entailment,0.8022054,0.1977946
NCT01178411,Statement: the psychiatric condition of a patient determines their eligibility for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01178411,Contradiction,0.30763975,0.6923602
NCT00404066,"Statement: The only types of Aes observed in patients from the secondary trial were Eyelid oedema, Upper gastrointestinal haemorrhage and Chest pain, no aes wererecorded in the primary trial. fpsr questionnaire question is a question associated with the fpsr questionnaire. [SEP] Clinical Trial: NCT00404066",Entailment,0.59887785,0.40112212
NCT01106898,Statement: a majority of patients in the primary clinical trial did not have recurrence-free survival. [SEP] Clinical Trial: NCT01106898,Entailment,0.89192814,0.10807192
NCT01314963,Statement: The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2. ganglion is a cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (cns). [SEP] Clinical Trial: NCT01314963,Contradiction,0.43275174,0.5672483
NCT00819182,"Statement: there was no significant difference in the average number of daily hot flashes experienced by patients in the paced respiration intervention group and the fast, shallow respiration group in the primary clinical trial. [SEP] Clinical Trial: NCT00819182",Entailment,0.78295594,0.21704409
NCT01008904,Statement: the sole adverse event noted in the primary clinical trial was stomatitis. [SEP] Clinical Trial: NCT01008904,Entailment,0.7620766,0.23792335
NCT00148668,Statement: bulk nucleus specimen is a biospecimen consisting of multiple nuclei as a pool. Both interventions in the primary trial include the same dose of Paraplatin. [SEP] Clinical Trial: NCT00148668,Contradiction,0.4573956,0.54260445
NCT00284180,Statement: prior severe anaphylactic reactions to trastuzumab do not disqualify a patient from participating in the primary clinical trial. [SEP] Clinical Trial: NCT00284180,Entailment,0.8776836,0.12231645
NCT01128543,Statement: the majority of patients in the primary trial experienced complete response by week 168 days. [SEP] Clinical Trial: NCT01128543,Contradiction,0.45492387,0.54507613
NCT00553358,"Statement: a patient that has a primary tumour with a radius of 330mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.31243044,0.68756956
NCT01351376,Statement: cancer-free patients are eligible for the primary clinical trial [SEP] Clinical Trial: NCT01351376,Entailment,0.7810664,0.21893357
NCT02234479,"Statement: the varied effects of radiation therapies on the study groups are being examined in the primary clinical trial, whereas the secondary clinical trial focuses on analyzing the outcomes of different dosages of the same regimen on its cohort [SEP] Clinical Trial: NCT02234479",Entailment,0.59533066,0.40466937
NCT01451632,"Statement: cohort 1 in the primary clinical trial received a higher dosage of cetuximab compared to cohort 2, while still receiving 8mg/kg more mm-121 than cohort 2. [SEP] Clinical Trial: NCT01451632",Contradiction,0.33065096,0.6693491
NCT01806675,"Statement: the primary clinical trial has different pet/ct imaging procedures for each study group, none of which involve the use of 18f-fdg or 18f-fpprgd2. [SEP] Clinical Trial: NCT01806675",Entailment,0.7984647,0.20153533
NCT00786838,Statement: The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis. her2/neu negative by immunohistochemistry is a laboratory test result indicating the absence of her2/neu in a tissue sample using immunohistochemical staining. [SEP] Clinical Trial: NCT00786838,Contradiction,0.3879173,0.6120827
NCT02640053,"Statement: Patients in the primary trial that didn‚Äö√Ñ√¥t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions. deriving is an explanation of the historical origins of a word, phrase, or object. [SEP] Clinical Trial: NCT02640053",Entailment,0.6033064,0.3966936
NCT00021255,"Statement: cohort 2 of the primary clinical trial is not given additional treatment cycles of docetaxel, doxorubicin and cyclophosphamide. [SEP] Clinical Trial: NCT00021255",Entailment,0.8582889,0.14171112
NCT00088413,"Statement: in the primary clinical trial, the prevailing adverse events were of cardiovascular origin, a situation that further differs from the secondary trial where such have not been registered. [SEP] Clinical Trial: NCT00088413",Entailment,0.8657895,0.13421056
NCT01770353,"Statement: the primary and secondary clinical trials both utilize intravenous injections and mris, but they do not incorporate the same drugs, administer the same dosages, or adhere to the same administration frequency. [SEP] Clinical Trial: NCT01770353",Entailment,0.51722425,0.48277578
NCT00146172,Statement: candidates possessing an ecog score of 1 are qualified for both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT00146172,Entailment,0.50872326,0.49127674
NCT02441946,Statement: people possessing a tnbc tumor with a 100mm diameter can partake in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT02441946,Contradiction,0.27037784,0.7296222
NCT00956813,Statement: the results of the primary clinical trial and the secondary clinical trial include outcome measures that are not at all alike [SEP] Clinical Trial: NCT00956813,Entailment,0.9150711,0.08492887
NCT03092934,"Statement: er negative breast cancer patients, irrespective of their gender, may be qualified for either phase of the primary clinical trial. [SEP] Clinical Trial: NCT03092934",Entailment,0.6809581,0.31904185
NCT00313170,Statement: candidates for the primary clinical trial must be diagnosed with lung cancer and require radiation therapy. [SEP] Clinical Trial: NCT00313170,Entailment,0.5059269,0.49407312
NCT00843167,"Statement: 7p21-p15 is a chromosome band present on 7p the secondary trial uses pain as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. [SEP] Clinical Trial: NCT00843167",Contradiction,0.44057378,0.55942625
NCT00451555,"Statement: Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial, but this is not necessary to be included in the secondary trial. arthrinium phaeospermum is a species of dematiaceous anamorphic fungi in the phylum ascomycota with smooth, hyaline, branched, septate hyphae. [SEP] Clinical Trial: NCT00451555",Entailment,0.6097677,0.39023232
NCT01008150,"Statement: all patients from either group of the primary clinical trial experienced minimal or no recovery, illustrated by the absence of pathologic complete response in breast and axillary lymph nodes, 6 months past surgery [SEP] Clinical Trial: NCT01008150",Contradiction,0.49565437,0.50434566
NCT00256698,"Statement: in contradiction to the primary trial where perjeta is part of the regimen, it is completely excluded from all cohorts in the secondary trial. [SEP] Clinical Trial: NCT00256698",Entailment,0.86706156,0.13293846
NCT00686127,Statement: the primary clinical trial has fewer total and different kinds of adverse events recorded compared to the secondary trial. [SEP] Clinical Trial: NCT00686127,Entailment,0.84401894,0.15598102
NCT00759785,Statement: 11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group [SEP] Clinical Trial: NCT00759785,Entailment,0.6003855,0.3996145
NCT01743560,"Statement: the primary clinical trial is open for all age groups without any height restrictions, but the secondary clinical trial has imposed a height requirement [SEP] Clinical Trial: NCT01743560",Entailment,0.63558865,0.36441138
NCT00262834,"Statement: the primary trial reported no adverse occurrences, and in the secondary trial, less than 30% of patients experienced adverse events. [SEP] Clinical Trial: NCT00262834",Entailment,0.74295443,0.25704557
NCT02550795,"Statement: 0.5ug/kg of dexmedetomidine (5ml) is provided to group 2 in the primary clinical trial, unlike in the secondary clinical trial where patients do not receive any dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.8455136,0.1544864
NCT01111825,"Statement: in the primary clinical trial, neither cohort is subjected to any invasive surgical procedures or given neratinib [SEP] Clinical Trial: NCT01111825",Entailment,0.6778462,0.32215378
NCT02038218,"Statement: the primary trial and the secondary trial use the same units of measure for their results, in any assessed outcome measurement. [SEP] Clinical Trial: NCT02038218",Entailment,0.53231025,0.46768975
NCT01770353,"Statement: while the intravenous injections and mris are common procedures in both primary and secondary clinical trials, differences are noticeable in the drugs, dosages, and frequency of administration they employ in their interventions. [SEP] Clinical Trial: NCT01770353",Contradiction,0.45613664,0.54386336
NCT02239601,Statement: the count of adverse effects in the patient cohorts was identical for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02239601,Entailment,0.8299485,0.17005149
NCT02306265,"Statement: in order to take part in the primary clinical trial, aspirants must first get a mammography, whereas the secondary clinical trial requires patients to have a ct scan and blood tests prior to participating. [SEP] Clinical Trial: NCT02306265",Contradiction,0.30173233,0.6982677
NCT02165839,Statement: a prerequisite for both the primary and the secondary clinical trials is the attainment of a baseline performance level. the primary clinical trial necessitates a karnofsky score of over 70 whereas the secondary clinical trial requires a score exceeding 55. [SEP] Clinical Trial: NCT02165839,Contradiction,0.3561722,0.6438278
NCT02165839,"Statement: Candidates for the primary trial and the secondary trial have to meet a baseline performance status, for the primary trial the baseline is a Karnofsky score >70, and for the secondary trial the baseline is a Karnofsky score >55 [SEP] Clinical Trial: NCT02165839",Contradiction,0.29052386,0.7094761
NCT01156987,"Statement: None of the participants in group 1 of the primary trial were found to have lesions, and more than 90% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.32502538,0.6749747
NCT00001832,"Statement: the primary clinical trial demands that patients take a bi-weekly dose of decitabine, whilst the secondary clinical trial requires no medication [SEP] Clinical Trial: NCT00001832",Entailment,0.90886366,0.09113634
NCT01390818,Statement: all the adverse events reported in the primary clinical trial were experienced by patients in the first cohort [SEP] Clinical Trial: NCT01390818,Entailment,0.88453615,0.11546389
NCT00270894,"Statement: participants in the primary clinical trial receive a diverse drug regimen, each not exceeding a dose beyond 50 mg/m^2. [SEP] Clinical Trial: NCT00270894",Contradiction,0.44454888,0.55545115
NCT01664091,"Statement: There were more cases of Infection, Asymmetry and nausea in the primary trial than in the secondary trial. feel slowed down is a question about whether an individual feels or has felt that they are slowed down. [SEP] Clinical Trial: NCT01664091",Entailment,0.5092846,0.49071535
NCT00538850,"Statement: on a scale of 1 to 7, the primary trial assesses the severity of delayed nausea. the secondary trial, however, observes the variation from the starting point up to the ninth month in the bone mineral density (bmd) of the lumbar spine. [SEP] Clinical Trial: NCT00538850",Contradiction,0.43271825,0.5672817
NCT00416715,"Statement: the secondary clinical trial involves weekly subcutaneous injections for its participants, a requirement that does not apply to the primary clinical trial. [SEP] Clinical Trial: NCT00416715",Entailment,0.92580783,0.07419219
NCT00357734,"Statement: multiple drugs are demanded in the treatment protocol of the primary clinical trial, as opposed to the mono-drug intervention method of the secondary clinical trial. [SEP] Clinical Trial: NCT00357734",Entailment,0.70033175,0.29966828
NCT00588640,Statement: the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants. estramustine/vinblastine regimen is a regimen consisting of estramustine and vinblastine used for the treatment of hormone-refractory prostate cancer. [SEP] Clinical Trial: NCT00588640,Entailment,0.64732563,0.35267437
NCT02286843,Statement: 102% of the primary trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.3493682,0.6506317
NCT00792077,Statement: bone marrow sample is a biological sample containing components collected from bone marrow of an experimental subject. the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1. [SEP] Clinical Trial: NCT00792077,Entailment,0.61867136,0.3813286
NCT03403712,"Statement: the primary trial is concerned with establishing the average hours of sleep among its patients, whereas the secondary trial is evaluating the prevalence of adverse events caused by the treatment. [SEP] Clinical Trial: NCT03403712",Entailment,0.7218767,0.27812332
NCT01831089,Statement: have trouble saying what i mean in conversation is a question about whether an individual has or had trouble saying what they mean in conversations with others. Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial. [SEP] Clinical Trial: NCT01831089,Entailment,0.5869951,0.41300488
NCT01301729,Statement: HER2 + Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial [SEP] Clinical Trial: NCT01301729,Entailment,0.5007912,0.4992088
NCT02222922,Statement: All the primary trial participants receive higher doses of ALT-801 than the secondary trial participants [SEP] Clinical Trial: NCT02222922,Entailment,0.6969952,0.30300486
NCT02178722,Statement: the frequency at which pembrolizumab is administered in the primary clinical trial is twice that of the sunitinib administration in the secondary clinical trial. [SEP] Clinical Trial: NCT02178722,Contradiction,0.4669711,0.53302896
NCT01222390,"Statement: There are no X-rays, transendocardial injections,  CT scans or MRIs included the interventions of the primary trial and the secondary trial. arthroscopic surgery is any surgical procedure that involves an arthroscope. [SEP] Clinical Trial: NCT01222390",Contradiction,0.28840023,0.71159977
NCT01920061,"Statement: the primary trial uses a 4 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.9198115,0.08018848
NCT01554371,Statement: peripheral primitive neuroectodermal tumor of bone is a small round cell tumor with neural differentiation arising from the bone.  it may be associated with pain. Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.54530054,0.4546995
NCT00588640,Statement: the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants. [SEP] Clinical Trial: NCT00588640,Entailment,0.80226904,0.19773094
NCT00248547,"Statement: in comparison to patients on aprepitant in the primary clinical trial, those given the placebo intervention were two times more likely to undergo emesis. [SEP] Clinical Trial: NCT00248547",Contradiction,0.4287202,0.5712798
NCT00372424,"Statement: estimated body weight is an approximate determination of the weight of a body. All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events. [SEP] Clinical Trial: NCT00372424",Entailment,0.5930742,0.40692574
NCT00194779,"Statement: while the primary clinical trial involves administering over seven different drugs to participants, as well as a surgical procedure, participants in the secondary clinical trial only receive two different pharmaceuticals without the need for any surgical operation [SEP] Clinical Trial: NCT00194779",Entailment,0.6558656,0.34413442
NCT00266110,"Statement: during the primary clinical trial, one injection will be administered to the patients on the eighth day of the study. [SEP] Clinical Trial: NCT00266110",Entailment,0.5506212,0.44937882
NCT01037790,"Statement: the primary clinical trial does not accept patients with tumors showing ccnd1 amplification, cdk4/6 mutation, or ccnd2 amplification. [SEP] Clinical Trial: NCT01037790",Entailment,0.8706945,0.12930545
NCT00245050,"Statement: the primary trial was composed of multiple test groups and lacked a placebo group, whereas the secondary trial included two control groups and lacked a test group. [SEP] Clinical Trial: NCT00245050",Entailment,0.86624414,0.13375588
NCT00656305,Statement: There were no deaths or Hospitalizations in cohort 2 of the primary trial. folate receptor family positive is an indication that expression of a member of the folate receptor family has been detected in a sample. [SEP] Clinical Trial: NCT00656305,Entailment,0.5127434,0.48725665
NCT00588640,"Statement: in the primary clinical trial, the terms of inclusion and exclusion differ between its two stages, as opposed to the secondary clinical trial, which has standard criteria applicable to all its participants. [SEP] Clinical Trial: NCT00588640",Entailment,0.7164518,0.28354812
NCT00373256,"Statement: in the primary clinical trial, the distinction between the first and second cohorts lies in the treatment dosage; the former gets a daily administration of 25 mg to 37.5 mg sunitinib, while the latter is given 10 mg/kg of bevacizumab [SEP] Clinical Trial: NCT00373256",Contradiction,0.3976843,0.6023157
NCT00825682,Statement: the secondary trial's intervention duration is three times longer than that of the primary trial's intervention. [SEP] Clinical Trial: NCT00825682,Entailment,0.8196696,0.18033034
NCT02038218,"Statement: the secondary trial and the primary trial use different units of measure in their results, for the same outcome measurement. johnston atoll is an island in the north pacific ocean, between hawaii and the marshall islands. [SEP] Clinical Trial: NCT02038218",Entailment,0.6866293,0.31337073
NCT00708019,Statement: several of the patients in the primary trial experienced the no pain whatsoever during the 200 weeks of the study. [SEP] Clinical Trial: NCT00708019,Contradiction,0.24517027,0.75482976
NCT00416715,"Statement: mitral valve atresia is a congenital heart defect characterized by the complete atresia of the mitral valve. Candidates for the secondary trial study group receive 3 weekly subcutaneous (SC) injections, whereas the primary trial participants only receive a single injection at the beginning of the study. [SEP] Clinical Trial: NCT00416715",Contradiction,0.417852,0.58214796
NCT00284180,Statement: the primary clinical trial does not admit patients who previously had serious anaphylactic reactions to trastuzumab. [SEP] Clinical Trial: NCT00284180,Entailment,0.9144441,0.08555594
NCT00293540,"Statement: statistics note that the survival period post the primary clinical trial for the majority of patients is under 2 years, and it is registered that none of the patients in both cohorts had a lifespan under 2 years. [SEP] Clinical Trial: NCT00293540",Entailment,0.5826091,0.41739088
NCT00775645,"Statement: in the primary clinical trial and the secondary clinical trial, adverse events were not recorded in more than 10% of participants. [SEP] Clinical Trial: NCT00775645",Contradiction,0.48306125,0.51693875
NCT00322374,"Statement: the primary clinical trial does not mandate the fulfillment of certain criteria such as mental health, bodyweight, age, karnofsky/ecog score or previous treatments. [SEP] Clinical Trial: NCT00322374",Entailment,0.651351,0.34864902
NCT00558272,Statement: congenital candidiasis is a fungal infection by any of the candida species that is present at birth. The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.41735908,0.58264095
NCT01498458,"Statement: within the scope of the primary clinical trial, the prevalence of hypertension and pancreatectomy cases were equivalent to the rate of hepatotoxicity cases [SEP] Clinical Trial: NCT01498458",Entailment,0.527049,0.47295102
NCT01743560,"Statement: children and adolescents are not eligible for the primary trial, as they do not meet the height requirement, however they are not explicitly excluded from the secondary trial. receptive vocabulary assessment is a test that assesses an individual's understanding of spoken english language. [SEP] Clinical Trial: NCT01743560",Contradiction,0.4140764,0.5859237
NCT00544167,Statement: patients that have had a pulmonary embolism within the last 3 years are considered eligible for the primary trial and are not subject to the investigator's decision for the secondary trial [SEP] Clinical Trial: NCT00544167,Entailment,0.84853905,0.15146092
NCT00451555,"Statement: only those resistant to ai therapy are eligible for the primary clinical trial, whereas for the secondary clinical trial, this is not a prerequisite [SEP] Clinical Trial: NCT00451555",Entailment,0.8003206,0.19967939
NCT01967823,Statement: all ae types in the primary trial affected more than 50% of patients [SEP] Clinical Trial: NCT01967823,Contradiction,0.39671093,0.60328907
NCT01806259,Statement: intermediate (locally aggressive) blood vessel neoplasm is a borderline blood vessel neoplasm that has locally aggressive behavior. the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group. [SEP] Clinical Trial: NCT01806259,Contradiction,0.4835789,0.5164211
NCT02796755,Statement: the number of adverse events witnessed in the primary clinical trial was higher than in the secondary clinical trial.' [SEP] Clinical Trial: NCT02796755,Entailment,0.80344963,0.19655034
NCT00698035,"Statement: doctor and i shared responsibility for deciding which treatment is best for me is a response indicating that an individual and their doctor shared responsibility for deciding which treatment is best for them. the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention. [SEP] Clinical Trial: NCT00698035",Contradiction,0.47198159,0.5280185
NCT00759785,Statement: there was no significant difference in the decrease of the growth factor signature in both the dalotuzumab 20 mg/kg group and the triple negative group of the primary clinical trial. [SEP] Clinical Trial: NCT00759785,Entailment,0.7384407,0.26155928
NCT00702949,"Statement: the patient population of the primary trial undergoes subcutaneous insulin injections as a treatment procedure, whereas the patient population of the secondary trial receives oral antiretroviral therapy (art) [SEP] Clinical Trial: NCT00702949",Entailment,0.543016,0.45698398
NCT00749931,"Statement: white fiber is a type of striated skeletal muscle fiber that contracts quickly and contains small amounts of mitochondria, myoglobin and sarcoplasm. the secondary trial and the primary trial share at least one inclusion criteria. [SEP] Clinical Trial: NCT00749931",Contradiction,0.40007022,0.59992975
NCT00118157,"Statement: participants in the primary clinical trial are prescribed a dose of 100 mg/m2 of lapatinib to be taken orally, two times per day for an entire month. [SEP] Clinical Trial: NCT00118157",Contradiction,0.42491218,0.5750878
NCT01290536,"Statement: 14q13.2 is a chromosome band present on 14q The the primary trial intervention consists of Radioembolization using TheraSpheres, on the other hand the secondary trial intervention is based on ibrutinib and MEDI4736. [SEP] Clinical Trial: NCT01290536",Contradiction,0.39444697,0.60555303
NCT00978250,Statement: those suffering from validated metastatic scbc may enroll in the primary clinical trial. [SEP] Clinical Trial: NCT00978250,Contradiction,0.445467,0.554533
NCT00148668,Statement: trastuzumab is explicitly excluded as an intervention in the primary clinical trial [SEP] Clinical Trial: NCT00148668,Entailment,0.8977495,0.10225051
NCT01975831,Statement: The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2. [SEP] Clinical Trial: NCT01975831,Entailment,0.57453686,0.4254632
NCT01730729,"Statement: the mode of administration for the primary clinical trial is via intramuscular injection, whereas for the secondary clinical trial, it is by oral intake [SEP] Clinical Trial: NCT01730729",Entailment,0.6579087,0.3420913
NCT00370552,"Statement: sexually active fertile men and women with reproductive potential can participate in the primary clinical trial, but adherence to additional criteria is required. [SEP] Clinical Trial: NCT00370552",Contradiction,0.49554032,0.5044596
NCT02640053,"Statement: Patients in the primary trial that didn‚Äö√Ñ√¥t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy. myroides is a genus of aerobic, gram-negative, rod shaped bacteria in the phylum bacteroidetes and the family flavobacteriaceae. [SEP] Clinical Trial: NCT02640053",Entailment,0.5394927,0.4605073
NCT00372424,"Statement: with the exception of one, all patients who were treated with sunitinib + docetaxel + trastuzumab in the primary clinical trial experienced adverse events emergent from treatment, and serious adverse events were experienced by less than half. [SEP] Clinical Trial: NCT00372424",Entailment,0.6486451,0.35135487
NCT02441946,Statement: patients with a tnbc tumor of 200mm in diameter are included in the primary clinical trial and secondary clinical trial [SEP] Clinical Trial: NCT02441946,Contradiction,0.23958439,0.76041555
NCT01252290,Statement: a majority of patients experienced adverse events in the primary clinical trial [SEP] Clinical Trial: NCT01252290,Entailment,0.8238185,0.17618148
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive intramuscular injections aswell as medication to be taken orally. acute contagious conjunctivitis is acute inflammation of the conjunctiva characterized by pink or red color in the eyes. [SEP] Clinical Trial: NCT00836186",Contradiction,0.3504211,0.64957887
NCT02320123,"Statement: pancreaticobiliary malunion is an abnormality of the pancreatic and biliary ducts in which their junction occurs above the duodenal wall. Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy. [SEP] Clinical Trial: NCT02320123",Contradiction,0.36184442,0.63815564
NCT04080297,Statement: Any Patients currently taking part in the secondary trial will also be eligible for the primary trial as they have the same inclusion criteria. shockwave dosing unit is a dosing measurement based on the shock wave unit. [SEP] Clinical Trial: NCT04080297,Contradiction,0.43681428,0.56318575
NCT02306265,"Statement: candidates must present an updated dental examination record to participate in the primary trial, whereas for the secondary trial, patients are required to provide a detailed eye examination report and complete immunization history. [SEP] Clinical Trial: NCT02306265",Contradiction,0.44134387,0.5586561
NCT00321048,"Statement: Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer. [SEP] Clinical Trial: NCT00321048",Entailment,0.5100301,0.48996985
NCT01989546,"Statement: warfarin based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. [SEP] Clinical Trial: NCT01989546",Entailment,0.6661655,0.33383453
NCT00513292,"Statement: the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had much better results than arm 1. 3-6 weeks after start of radiation therapy is a time period of 3-6 weeks after the start of radiation therapy. [SEP] Clinical Trial: NCT00513292",Contradiction,0.32513267,0.67486733
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 0.15 grams of oral pregabalin every 14 days over 42 days, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.40298378,0.5970162
NCT01250379,"Statement: an 55 year old male patient with a 5 year past diagnosis of er-positive, her2-negative breast cancer is eligible for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01250379",Contradiction,0.36891103,0.63108903
NCT00896454,Statement: the same unit of measure is employed for reporting results in both the primary and secondary clinical trial. [SEP] Clinical Trial: NCT00896454,Entailment,0.7351997,0.26480034
NCT00365365,"Statement: during the primary clinical trial, participants are given the her2/neu peptide vaccine combined with sargramostim (gm-csf) id on the first, eighth, and fifteenth days. [SEP] Clinical Trial: NCT00365365",Contradiction,0.37031808,0.6296819
NCT01969448,Statement: primary clinical trial employs procedures that utilize ultrasound guidance and vertical longitudinal incisions. [SEP] Clinical Trial: NCT01969448,Entailment,0.6029493,0.39705074
NCT01466972,Statement: the appearance of maculo-papular rash was a frequent side effect among the participants of the primary clinical trial. [SEP] Clinical Trial: NCT01466972,Entailment,0.712679,0.28732097
NCT01855828,"Statement: in the primary clinical trial, psychiatric adverse events affected over half of the patients. [SEP] Clinical Trial: NCT01855828",Entailment,0.64567953,0.3543205
NCT01314963,"Statement: in the primary clinical trial, both intervention one and two use pihgc as their method. [SEP] Clinical Trial: NCT01314963",Contradiction,0.46028483,0.5397152
NCT00429182,Statement: less than 5.4% of the primary trial participants had a reduction in circulating tumor cells following years of high-dose chemotherapy with purged autologous stem cell products [SEP] Clinical Trial: NCT00429182,Entailment,0.6497476,0.35025236
NCT02441946,"Statement: patients with a breast tumor exceeding 1 cm in diameter, with confirmed hr negative and her2 positive status are eligible for both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.46868217,0.5313178
NCT01008904,Statement: the primary clinical trial presented no adverse events. [SEP] Clinical Trial: NCT01008904,Entailment,0.91499686,0.08500311
NCT01591746,Statement: every member in both the primary and secondary clinical trials is given enteric-coated tablets [SEP] Clinical Trial: NCT01591746,Entailment,0.6253013,0.3746987
NCT01806259,Statement: the ketorolac 300 mg group of the primary trial had a -60.4% recurrence-free survival compared to the nacl 0.9% 3ml group [SEP] Clinical Trial: NCT01806259,Contradiction,0.47305828,0.5269417
NCT01013740,Statement: anemia cases are less prevalent in the primary clinical trial than in the secondary clinical trial. [SEP] Clinical Trial: NCT01013740,Entailment,0.8118817,0.18811828
NCT02599194,Statement: there was a higher incidence of serious adverse reactions documented in the adverse events portion of the primary clinical trial as compared to the secondary clinical trial [SEP] Clinical Trial: NCT02599194,Entailment,0.8143331,0.18566695
NCT01967823,Statement: All AE types in the primary trial affected less than 10% of patients [SEP] Clinical Trial: NCT01967823,Entailment,0.893415,0.10658509
NCT02640053,Statement: patients in the primary clinical trial who did not receive topical cryotherapy reported symptom improvement compared to those receiving cryotherapy.' [SEP] Clinical Trial: NCT02640053,Entailment,0.7102587,0.28974128
NCT00800436,"Statement: Prior treatment with gabapentin or herceptin within the last year, will result in exclusion from the secondary trial, but not from the primary trial. ossifying fibroma is a benign fibro-osseous neoplasm affecting the jaws and the craniofacial skeleton. (who 2017) [SEP] Clinical Trial: NCT00800436",Entailment,0.63592637,0.36407357
NCT02038218,"Statement: the secondary trial and the primary trial use different units of measure in their results, for the same outcome measurement. laryngeal obstruction, ctcae is a disorder characterized by blockage of the laryngeal airway. [SEP] Clinical Trial: NCT02038218",Entailment,0.6639581,0.33604196
NCT00963911,"Statement: as part of the intervention, daily administration of 1000 mcg of talazoparib is carried out for several candidates in the primary clinical trial [SEP] Clinical Trial: NCT00963911",Contradiction,0.3337596,0.66624045
NCT01156987,"Statement: all measured patients within the primary clinical trial's group 1 were identified as having several lesions, along with an overwhelming majority from the secondary trial's group 1 showing healthy skin attributes. [SEP] Clinical Trial: NCT01156987",Contradiction,0.3165199,0.6834801
NCT00825682,Statement: somewhat forgetful is a response indicating that an individual is or was somewhat forgetful. The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Contradiction,0.48768714,0.5123128
NCT00254592,Statement: paclitaxel is given to participants in the primary and secondary clinical trials [SEP] Clinical Trial: NCT00254592,Entailment,0.57385683,0.42614323
NCT00146172,Statement: candidates capable of only limited selfcare; confined to bed or chair more than 50.0% of waking hours are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.3216644,0.6783356
NCT02403271,Statement: There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.6842972,0.31570283
NCT00553358,"Statement: A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. cystic change is a microscopic finding indicating the formation of cystic structures in a tissue sample. [SEP] Clinical Trial: NCT00553358",Contradiction,0.32069945,0.6793005
NCT01290536,Statement: the primary clinical trial intervention includes a regimen of 500 mg of ibrutinib and 10 mg/kg of ipilimumab every day for six weeks. [SEP] Clinical Trial: NCT01290536,Contradiction,0.4664771,0.5335229
NCT02807844,"Statement: kras gene mutation negative is a genetic finding indicating that kras gene mutations have not been detected in a sample. All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week. [SEP] Clinical Trial: NCT02807844",Entailment,0.51554006,0.48445997
NCT00054028,Statement: suramin and paclitaxel are given to every participant in both the primary and secondary clinical trial [SEP] Clinical Trial: NCT00054028,Entailment,0.51114804,0.488852
NCT00971945,"Statement: the secondary clinical trial accepts only candidates with full mobility, and similar physical ability requirements have also been established for the primary clinical trial [SEP] Clinical Trial: NCT00971945",Entailment,0.5149678,0.48503223
NCT02259114,"Statement: patients diagnosed with hypopharyngeal squamous cell carcinoma via polymerase chain reaction, or those who have developed venous thromboembolism post-lumpectomy are not permitted to participate in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT02259114",Entailment,0.71141833,0.28858167
NCT00659373,"Statement: on average, all patients in both cohorts of the primary clinical trial showed improvements in cognitive function. [SEP] Clinical Trial: NCT00659373",Contradiction,0.47405794,0.5259421
NCT01614210,Statement: results from the primary trial show that tamoxifen 20 mg po daily for 1 week prior to surgery and for 2 weeks after breast cancer surgery reduces ki67 expression in tumors by 40% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.35928783,0.6407122
NCT01313117,"Statement: in the primary clinical trial, high doses of alpha lipoic acid are administered, up to 100 mg three times daily, while the same steady dose of necitumumab is given to patients in cohort 1 of the secondary clinical trial. [SEP] Clinical Trial: NCT01313117",Contradiction,0.49605778,0.5039422
NCT02273206,"Statement: eyes progression gvhd is an nih eye score that has increased by 1 or more points, except 0 to 1. Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention. [SEP] Clinical Trial: NCT02273206",Contradiction,0.37538078,0.62461925
NCT00075764,Statement: patients with unmeasurable metastasis or those without cancer spread to other body parts are not appropriate for the primary clinical trial [SEP] Clinical Trial: NCT00075764,Entailment,0.7893604,0.2106396
NCT00429182,Statement: more than 97% of the primary trial participants had a reduction in circulating tumor cells following months of high-dose chemotherapy with purged autologous stem cell products [SEP] Clinical Trial: NCT00429182,Contradiction,0.46389028,0.53610975
NCT00021255,"Statement: Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency. tracheostomy site bleeding, ctcae is a disorder characterized by bleeding from the tracheostomy site. [SEP] Clinical Trial: NCT00021255",Contradiction,0.49389866,0.50610137
NCT00270894,Statement: the protocol of the primary clinical trial includes a bitherapy regimen for its study duration. [SEP] Clinical Trial: NCT00270894,Entailment,0.6811045,0.31889552
NCT01997333,"Statement: The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death . mouse kidney carcinoma is a carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis of a mouse. [SEP] Clinical Trial: NCT01997333",Contradiction,0.44670546,0.55329454
NCT00828516,Statement: the mymop score change is not a determinant for outcome measurement in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT00828516,Entailment,0.89346194,0.10653809
NCT01439282,Statement: Gender is not a determining factor for eligibility in the primary trial or the secondary trial [SEP] Clinical Trial: NCT01439282,Contradiction,0.40914994,0.59085006
NCT00432562,Statement: There are 0 shared inclusion/exclusion criteria between the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00432562,Entailment,0.91163576,0.0883642
NCT00698035,"Statement: the primary trial is using hormonal interventions, and the secondary trial is testing an acupuncture intervention. orthodontic treatment is a dental treatment to correct malocclusions of the teeth and their surrounding structures. [SEP] Clinical Trial: NCT00698035",Contradiction,0.3811135,0.61888653
NCT01766102,"Statement: Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore the control group performed better than the test group in this regard. In the secondary trial there is no control group against which we can compare. gender fluid is an individual who describes their gender identity as fluctuating between male, female, and/or other. [SEP] Clinical Trial: NCT01766102",Entailment,0.61371994,0.38628003
NCT02286843,Statement: 50% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.3781768,0.62182325
NCT00365365,Statement: the primary trial participants do not receive any vaccines. fatigue among most disabling symptoms is a question about whether an individual's fatigue is or was among their most disabling symptoms. [SEP] Clinical Trial: NCT00365365,Entailment,0.86025316,0.13974689
NCT00708019,Statement: Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study. [SEP] Clinical Trial: NCT00708019,Contradiction,0.25083444,0.7491656
NCT00553358,"Statement: a patient that has a primary tumour with a diameter of 3.3cm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.31024137,0.68975866
NCT03557801,"Statement: the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial, but more cases of FEBRILE INFECTIONs were recorded in the primary trial. penile implant is an implanted device that enables the penis to become erect. [SEP] Clinical Trial: NCT03557801",Contradiction,0.35561493,0.6443851
NCT01831089,Statement: photovoice is a qualitative method in which participants use photographic techniques to facilitate the documentation and communication of issues. Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial. [SEP] Clinical Trial: NCT01831089,Contradiction,0.38704562,0.6129544
NCT00583700,Statement: youths below the age of 18 are the target group for both the secondary and the primary trial [SEP] Clinical Trial: NCT00583700,Entailment,0.5755808,0.42441922
NCT01037790,"Statement: patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial. main duct pancreatic intraductal papillary-mucinous neoplasm is an intraductal papillary-mucinous neoplasm of the pancreas that arises from the main pancreatic duct. [SEP] Clinical Trial: NCT01037790",Entailment,0.69361895,0.30638105
NCT00418028,"Statement: study subject withdrawal by parent or guardian is an indication that a study participant has been removed from the study by the parent or legal guardian. the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the percentage of patients that experience Objective Response . [SEP] Clinical Trial: NCT00418028",Entailment,0.6157774,0.3842226
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the last 40 years would be excluded from the primary trial [SEP] Clinical Trial: NCT01964924,Entailment,0.8154819,0.18451807
NCT00319748,Statement: no evaluation of the clinical benefit (based on recist criteria) rate among the participants is performed in either the primary or secondary clinical trial [SEP] Clinical Trial: NCT00319748,Entailment,0.8818162,0.11818383
NCT00686127,"Statement: somewhat more socially active as before is a response indicating that an individual has been somewhat more socially active than before. There are less total adverse events in the primary trial than in the secondary trial, but more cases of Cardiac-ischemia/infarction in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00686127",Contradiction,0.47663283,0.52336717
NCT02165839,"Statement: candidates for both primary clinical trial and secondary clinical trial must fulfil a baseline performance status, though each trial uses a unique scoring system. [SEP] Clinical Trial: NCT02165839",Entailment,0.5666766,0.43332338
NCT02306265,"Statement: candidates for the primary trial must undergo a pulmonary function test (pft), whereas patients for the secondary trial must have a recent magnetic resonance imaging (mri) report and liver function tests. [SEP] Clinical Trial: NCT02306265",Contradiction,0.39125976,0.6087402
NCT00759785,Statement: the primary clinical trial showed that the dalotuzumab 20 mg/kg group had a 49.2% greater decrease in the growth factor signature compared to the triple negative group. [SEP] Clinical Trial: NCT00759785,Contradiction,0.4115393,0.5884607
NCT01554371,Statement: patients with considerable cardiovascular impairment are allowed to participate in the primary clinical trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.5854062,0.41459385
NCT01920061,Statement: The same number of Aes were reported for both cohorts in the primary trial. other things made me think about event is a question about whether other things made or make an individual think about the event. [SEP] Clinical Trial: NCT01920061,Entailment,0.59979033,0.40020967
NCT00253708,"Statement: in the primary clinical trial, multiple drug-based treatments are actively tested while the secondary clinical trial is designed to evaluate the effectiveness of multiple doses of a non-drug therapy. [SEP] Clinical Trial: NCT00253708",Entailment,0.7191894,0.2808106
NCT01770353,"Statement: the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs. necrotic change is a finding indicating the presence of cellular necrosis in a tissue specimen. [SEP] Clinical Trial: NCT01770353",Contradiction,0.19463262,0.8053674
NCT02179515,Statement: none of the patients in cohort 1 of the primary clinical trial experienced any life-threatening adverse events. [SEP] Clinical Trial: NCT02179515,Entailment,0.7315613,0.2684387
NCT02431676,Statement: acute physiology and chronic health evaluation ii apch109 questions clinical classification original response is an original response associated with the acute physiology and chronic health evaluation ii apch109 clinical classification questions. anorexic patients are eligible for the primary trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.5955336,0.4044664
NCT02441946,"Statement: both the primary clinical trial and the secondary clinical trial accept patients with hr positive and her2 negative breast cancer, whose tumor sizes range from 0.2 to 0.8 cm in diameter. [SEP] Clinical Trial: NCT02441946",Contradiction,0.38299578,0.6170042
NCT00911898,Statement: The the primary trial intervention section requires surgical and imaging procedures. [SEP] Clinical Trial: NCT00911898,Entailment,0.8490659,0.15093407
NCT02122796,"Statement: participants receiving the highest weekly mm-121 and paclitaxel dosage are in the primary trial, not cohort 1 of the secondary trial [SEP] Clinical Trial: NCT02122796",Entailment,0.80655915,0.19344087
NCT01967823,Statement: All AE types in the primary trial affected less than 10% of patients. adult type ovarian granulosa cell tumor is a granulosa cell tumor that affects middle aged or postmenopausal women.  patients may present with uterine bleeding. [SEP] Clinical Trial: NCT01967823,Entailment,0.6884895,0.31151056
NCT01498458,Statement: in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.28496528,0.7150347
NCT00950911,Statement: the dosage of denosumab used in intervention 1 of the secondary clinical trial and zoledronic acid used in intervention 1 of the primary clinical trial have not been differentiated. [SEP] Clinical Trial: NCT00950911,Entailment,0.88638204,0.11361793
NCT02041429,Statement: the primary clinical trial and the secondary clinical trial provide information on the mtd of various interventions [SEP] Clinical Trial: NCT02041429,Contradiction,0.40836713,0.5916329
NCT01008904,Statement: The only AE recorded in the primary trial was Stomatitis. [SEP] Clinical Trial: NCT01008904,Entailment,0.6658264,0.3341736
NCT00320541,Statement: mersalyl acid is a mercurial diuretic. mersalyl acid has been replaced by less toxic non-mercury containing diuretics. The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it. [SEP] Clinical Trial: NCT00320541,Contradiction,0.4513939,0.5486061
NCT02807844,"Statement: All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week. generally happy and free from worry is a response indicating that an individual is or was generally happy and free from worry. [SEP] Clinical Trial: NCT02807844",Contradiction,0.39694333,0.60305667
NCT00558272,Statement: the azd0530 275 mg group of the primary trial experienced a lesser reduction in primary tumour diameter than the zoledronic acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.6740433,0.32595667
NCT01614210,Statement: Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.34857592,0.65142405
NCT00182793,Statement: over 15% of patients in the primary trial and the secondary trial suffered from infections during the study period. moderate to late preterm infant is an age group comprised of infants born alive with a gestational age between 32 to less than 37 weeks. [SEP] Clinical Trial: NCT00182793,Contradiction,0.25144577,0.7485542
NCT00741039,Statement: the intervention in the primary clinical trial varies depending on the individual's health status and cancer presence [SEP] Clinical Trial: NCT00741039,Entailment,0.69398564,0.3060144
NCT01466972,Statement: tonicity excipient is a substance within a liquid formulation that alters its osmotic potential. No two patients in the primary trial suffered the same type of adverse event. [SEP] Clinical Trial: NCT01466972,Entailment,0.543765,0.45623505
NCT02550795,"Statement: how has gynecologic cancer affected your sexual relationships is a question about how having gynecologic cancer has affected an individual's sexual relationship(s). Group 2 of the primary trial recieves 0.5ug/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any Dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.8148242,0.18517579
NCT00749931,Statement: patients eligible for the secondary trial are not fit for inclusion in the primary trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.92093486,0.07906507
NCT01310075,Statement: persistent atrial fibrillation by ecg finding is an electrocardiographic tracing demonstrating atrial fibrillation that is present during the entire recording. A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial. [SEP] Clinical Trial: NCT01310075,Contradiction,0.32608616,0.67391384
NCT00405938,Statement: patients with a recent history of abdominal fistula or gastrointestinal perforation are eligible for the primary clinical trial [SEP] Clinical Trial: NCT00405938,Entailment,0.5168531,0.48314697
NCT00686127,"Statement: metastatic bile duct carcinoma is a carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has metastasized to other anatomic sites. There are less total adverse events in the primary trial than in the secondary trial, but more cases of Cardiac-ischemia/infarction in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00686127",Contradiction,0.4301901,0.5698099
NCT00054028,"Statement: in both the primary and secondary clinical trials, all patients are treated with suramin and paclitaxel [SEP] Clinical Trial: NCT00054028",Contradiction,0.28815892,0.71184105
NCT01045421,"Statement: in contrast to the primary clinical trial, the secondary clinical trial necessitates a diagnosis showing mutation in any of these genes: pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11 for patient's inclusion [SEP] Clinical Trial: NCT01045421",Contradiction,0.38732886,0.6126711
NCT01967823,Statement: all ae types in the primary trial affected more than 100% of patients [SEP] Clinical Trial: NCT01967823,Entailment,0.55531275,0.44468722
NCT01421472,"Statement: patients with estrogen positive, progesterone positive and her2+ breast cancer are included in the primary clinical trial [SEP] Clinical Trial: NCT01421472",Contradiction,0.4215734,0.5784266
NCT03346161,Statement: there was a difference of four patients who endured adverse events between cohort 1 and cohort 2 of the primary clinical trial [SEP] Clinical Trial: NCT03346161,Entailment,0.6579143,0.3420857
NCT00370552,Statement: sexually active men and women who are not willing or not able to commit to abstinence for the duration of the study are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT00370552,Entailment,0.66750246,0.33249757
NCT02041429,"Statement: the primary clinical trial and the secondary clinical trial focus on the maximum tolerated dose (mtd) of multiple treatments, specifying that for patients in the secondary clinical trial, the mtd of mm-111 is 15 mg daily [SEP] Clinical Trial: NCT02041429",Contradiction,0.27127567,0.7287243
NCT00800436,"Statement: Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial, but not from the primary trial. generalized dysplasia is a morphologic finding indicating the presence of dysplasia throughout a cellular component in a tissue sample. [SEP] Clinical Trial: NCT00800436",Entailment,0.6434234,0.35657662
NCT00756717,Statement: There were 0 adverse events in the primary trial and the secondary trial [SEP] Clinical Trial: NCT00756717,Entailment,0.69376403,0.306236
NCT00143390,Statement: the primary clinical trial observed a minimum of one gastro-intestinal adverse event [SEP] Clinical Trial: NCT00143390,Entailment,0.8749418,0.12505822
NCT01250379,Statement: someone without any form of breast cancer and above 50 years old is eligible to participate in the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01250379,Contradiction,0.24511817,0.75488186
NCT00428220,"Statement: pericardial effusions were a more frequent occurrence in patients from the primary clinical trial, in comparison to corneal deposits, which were more prevalent in the secondary clinical trial. [SEP] Clinical Trial: NCT00428220",Contradiction,0.48098657,0.5190134
NCT00146172,Statement: only candidates with an ecog score of 3 can partake in the primary clinical trial and secondary clinical trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.26674375,0.7332562
NCT01831089,Statement: patients diagnosed with breast cancer can participate in the primary clinical trial [SEP] Clinical Trial: NCT01831089,Entailment,0.61934483,0.38065523
NCT02504424,Statement: several participants in the primary clinical trial developed a urinary tract infection during the course of the trial [SEP] Clinical Trial: NCT02504424,Contradiction,0.2594326,0.7405674
NCT00266110,Statement: Patients in the primary trial will need to receive one single injection on day 8 of the study. number of days smoked cigarettes past 30 days is a question about how many days an individual has smoked in the past 30 days. [SEP] Clinical Trial: NCT00266110,Contradiction,0.49554414,0.50445586
NCT02640053,Statement: patients in the primary clinical trial who underwent topical cryotherapy reported higher symptom severity than those who did not undergo the treatment.' [SEP] Clinical Trial: NCT02640053,Entailment,0.7423907,0.25760934
NCT01008904,"Statement: there are several adverse events recorded, but none pertain to the patient cohort of the primary clinical trial. [SEP] Clinical Trial: NCT01008904",Entailment,0.8838745,0.1161255
NCT00698035,"Statement: the primary clinical trial is conducting trials with a dietary intervention, whereas the secondary clinical trial is using a physical intervention. [SEP] Clinical Trial: NCT00698035",Entailment,0.64685833,0.3531416
NCT01629615,"Statement: eating disorders were not common for the primary trial candidates. soft tissue necrosis lower limb, ctcae is a disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity. [SEP] Clinical Trial: NCT01629615",Entailment,0.5270642,0.47293586
NCT00451555,"Statement: resistance to ai therapy is a prerequisite for the primary clinical trial, but not for the secondary clinical trial [SEP] Clinical Trial: NCT00451555",Entailment,0.6254145,0.37458548
NCT00950911,Statement: ovarian dermoid cyst with squamous cell carcinoma is a secondary squamous cell carcinoma that has developed in an ovarian dermoid cyst. The dosage of Zoledronic Acid  in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial. [SEP] Clinical Trial: NCT00950911,Contradiction,0.48545164,0.51454836
NCT02320123,Statement: the educational dvd as part of the intervention will be shown exclusively to cohort 1 in the primary clinical trial [SEP] Clinical Trial: NCT02320123,Entailment,0.75420165,0.24579829
NCT02961790,"Statement: Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial. anti-cd73 monoclonal antibody is any monoclonal antibody that targets and binds to cd73. [SEP] Clinical Trial: NCT02961790",Entailment,0.6336504,0.3663496
NCT00587964,Statement: somewhat is a subjective answer of partial agreement. General symptoms are the most common AE recorded in the primary trial. [SEP] Clinical Trial: NCT00587964,Entailment,0.5763662,0.4236338
NCT03346161,Statement: the primary clinical trial recorded a total of 0 aes for both cohorts [SEP] Clinical Trial: NCT03346161,Entailment,0.8521802,0.14781974
NCT00753415,Statement: participants of cohort b in the primary clinical trial receive two electroporation injections of ld v934 [SEP] Clinical Trial: NCT00753415,Contradiction,0.39362442,0.6063756
NCT00262834,"Statement: 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients, apart from Skin infections [SEP] Clinical Trial: NCT00262834",Contradiction,0.4903747,0.50962526
NCT00971945,"Statement: thyroid gland hyperfunctioning adenoma is a thyroid gland adenoma producing thyroxin.  it is associated with hyperthyroidism.  radioactive iodine scan reveals a hot nodule. the secondary trial  candidates must meet some Performance Status condition to participate, whereas this is not required to be accepted into the primary trial. [SEP] Clinical Trial: NCT00971945",Entailment,0.53111315,0.46888682
NCT00929240,"Statement: better results were observed in the primary clinical trial's bevacizumab cohort, as compared to the bevacizumab + capecitabine cohort. [SEP] Clinical Trial: NCT00929240",Entailment,0.7672889,0.23271106
NCT01617668,"Statement: in the primary clinical trial, cohort 1 reported mostly beneficial effects, with similar feedback from cohort 2. [SEP] Clinical Trial: NCT01617668",Entailment,0.6397474,0.36025265
NCT00253708,"Statement: drug-based treatment approaches are scrutinized by the secondary clinical trial through different dose adjustments, whilst the primary clinical trial omits such medication-related analyses. [SEP] Clinical Trial: NCT00253708",Entailment,0.8686322,0.13136779
NCT02165839,"Statement: participants in both the primary clinical trial and the secondary clinical trial must meet specified baseline performance metrics. in the primary clinical trial, this is defined by a karnofsky score greater than 70, while in the secondary clinical trial, a score higher than 55 is considered the baseline. [SEP] Clinical Trial: NCT02165839",Contradiction,0.35943392,0.64056605
NCT01781299,"Statement: object identifier data type is a data type comprised of an integer or pointer that uniquely identifies an object. There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial, the only AEs recorded were 3 cases of Lymphoma. [SEP] Clinical Trial: NCT01781299",Contradiction,0.24906258,0.75093746
NCT02178722,"Statement: in the primary clinical trial, participants are given epacadostat twice as often as sunitinib-naive patients are administered sunitinib in the secondary clinical trial. [SEP] Clinical Trial: NCT02178722",Contradiction,0.41464728,0.5853527
NCT01466972,"Statement: in the primary clinical trial, each patient experienced a unique type of adverse event. [SEP] Clinical Trial: NCT01466972",Entailment,0.89907336,0.10092669
NCT01286168,"Statement: in the secondary clinical trial, there were no adverse events; however, fatigue was commonly reported in the primary clinical trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.59993494,0.40006503
NCT01629615,Statement: the occurrence of eating disorders was not prevalent among the candidates for the primary clinical trial [SEP] Clinical Trial: NCT01629615,Entailment,0.89122415,0.108775884
NCT01614210,Statement: the primary clinical trial reports that administering tamoxifen 32 mg po daily for a week leading up to the surgery and two weeks post breast cancer surgery reduced tumor sizes by an average of 40%. [SEP] Clinical Trial: NCT01614210,Contradiction,0.3080461,0.69195396
NCT01106898,Statement: 97% of patients in the primary trial did not experience any Adverse Events [SEP] Clinical Trial: NCT01106898,Entailment,0.77468306,0.22531696
NCT00708019,Statement: none of the patients in the primary trial experienced the worst pain imaginable for 2.5 months. [SEP] Clinical Trial: NCT00708019,Entailment,0.6703968,0.3296032
NCT00999921,"Statement: while the secondary clinical trial allows the participation of patients with a malignant ductal carcinoma in situ diagnosis, the primary clinical trial does not permit such patients. [SEP] Clinical Trial: NCT00999921",Entailment,0.89173955,0.10826042
NCT00911898,"Statement: detailed information about the administration procedure, dosage, and treatment cycle is available in the intervention section of the primary clinical trial. [SEP] Clinical Trial: NCT00911898",Entailment,0.7475016,0.25249842
NCT01286168,"Statement: the most common adverse event in the secondary trial was anaemia, affecting more than 0.05 of patients, there were no recorded aes in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.7042897,0.29571027
NCT02178722,Statement: the primary trial particpants receive Epacadostat twice as frequently as Sunitinib-na‚àö√òve participants in the secondary trial receive sunitinib. [SEP] Clinical Trial: NCT02178722,Contradiction,0.46671504,0.53328496
NCT00253708,"Statement: the primary clinical trial tests different formulations of a drug-based treatment, whereas the secondary clinical trial does not test any drug-based treatments. [SEP] Clinical Trial: NCT00253708",Entailment,0.9268292,0.0731708
NCT00896454,Statement: the primary clinical trial and the secondary clinical trial present outcomes from different patient populations. [SEP] Clinical Trial: NCT00896454,Entailment,0.9070914,0.092908606
NCT01008150,Statement: more than 42 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 30 weeks after the surgery [SEP] Clinical Trial: NCT01008150,Contradiction,0.28489727,0.7151027
NCT00687102,"Statement: in the patient cohorts of both the primary clinical trial and the secondary clinical trial, there have been no instances of intestinal obstructions or pancytopenia. [SEP] Clinical Trial: NCT00687102",Entailment,0.56519854,0.4348015
NCT01606748,"Statement: several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia. [SEP] Clinical Trial: NCT01606748",Entailment,0.60713696,0.39286304
NCT00319748,Statement: Neither the secondary trial or the primary trial measure the percentage of participants in their studies that experience Clinical Benefit (using (RECIST) criteria) [SEP] Clinical Trial: NCT00319748,Contradiction,0.3623656,0.63763434
NCT00999921,Statement: patients diagnosed with benign ductal carcinoma in situ are eligible for the primary clinical trial but excluded from the secondary clinical trial. [SEP] Clinical Trial: NCT00999921,Entailment,0.8711768,0.1288233
NCT00148668,"Statement: in the primary clinical trial, doses of paraplatin vary across different interventions [SEP] Clinical Trial: NCT00148668",Entailment,0.8423899,0.15761009
NCT01091974,"Statement: prefer to hear as many details as possible is a question about whether a person would prefer to hear as many details as possible. In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same 100 mg dose of PDR001, and 1 mg/kg dose of MCS110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.4659785,0.5340215
NCT01023477,"Statement: primary clinical trial does not accommodate patients with hypokalemia, however, the secondary clinical trial may accept them [SEP] Clinical Trial: NCT01023477",Entailment,0.7064461,0.29355386
NCT00553358,"Statement: a patient that has a primary tumour with a radius of 3000µm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.31366435,0.6863357
NCT00587964,Statement: General symptoms are the most common AE recorded in the primary trial [SEP] Clinical Trial: NCT00587964,Entailment,0.73927134,0.26072863
NCT01823991,Statement: persons with parkinson's disease dementia can participate in the primary clinical trial [SEP] Clinical Trial: NCT01823991,Entailment,0.59386027,0.40613976
NCT00786838,Statement: the placebo and trabectedin intervention in the primary trial are both administered through a 3-minute intravenous infusion on a bi-weekly basis. [SEP] Clinical Trial: NCT00786838,Contradiction,0.3301586,0.66984147
NCT00999921,"Statement: the secondary clinical trial accepts patients with malignant ductal carcinoma in situ, whereas the primary clinical trial does not. [SEP] Clinical Trial: NCT00999921",Entailment,0.9179907,0.08200933
NCT00076024,Statement: the primary clinical trial does not impose any stipulations regarding the participants' liver function [SEP] Clinical Trial: NCT00076024,Entailment,0.90661937,0.0933806
NCT00377156,"Statement: aims clinical classification question is a question associated with the aims questionnaire. Diagnosis of 2-3 cerebral metastases within the brainstem will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. [SEP] Clinical Trial: NCT00377156",Contradiction,0.44878095,0.55121905
NCT01997333,"Statement: the patient who exhibited the most extended progression free survival (pfs), of 3.5 months, in the primary clinical trial belonged to cohort 1 [SEP] Clinical Trial: NCT01997333",Entailment,0.68795484,0.31204516
NCT00553358,"Statement: A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. gain of chromosome 9 is a cytogenetic abnormality that refers to the allelic gain of all or part of chromosome 9. [SEP] Clinical Trial: NCT00553358",Contradiction,0.3192026,0.68079734
NCT00321048,Statement: not all patients within the primary clinical trial are required to undergo a spect scan. [SEP] Clinical Trial: NCT00321048,Entailment,0.9091292,0.09087081
NCT00429299,Statement: All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+ [SEP] Clinical Trial: NCT00429299,Contradiction,0.37757516,0.6224249
NCT00293540,"Statement: the results of the primary clinical trial indicate that, on average, participants survived beyond two years, with over fifty patients from each cohort outliving 24 months. [SEP] Clinical Trial: NCT00293540",Contradiction,0.20918988,0.79081017
NCT01129622,Statement: women suffering from only osteoporosis are eligible for both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT01129622,Contradiction,0.46367508,0.5363249
NCT00209092,"Statement: the final acceptance of a patient into the primary clinical trial rests solely on whether they meet the stipulated inclusion and exclusion criteria, regardless of the opinions of the health professionals conducting the trial. [SEP] Clinical Trial: NCT00209092",Entailment,0.6290801,0.37091988
NCT00999921,"Statement: hectopascal is a si derived unit of pressure equivalent to one hundred pascals, 1 millibar or 0.0145 pounds per square inch. Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial. [SEP] Clinical Trial: NCT00999921",Entailment,0.59294814,0.40705186
NCT01537029,"Statement: pediatric cancer patients under the age of 18 of any gender can participate in the primary clinical trial, regardless of race, ethnicity, or cancer type. however, the secondary clinical trial solely accepts patients with pediatric b-cell acute lymphoblastic leukemia. [SEP] Clinical Trial: NCT01537029",Contradiction,0.47953624,0.52046376
NCT00429182,"Statement: following high-dose chemotherapy with purged autologous stem cell products in the primary clinical trial, most participants reported a significant reduction in circulating tumor cells. [SEP] Clinical Trial: NCT00429182",Entailment,0.51932925,0.48067075
NCT00544167,"Statement: the primary clinical trial does not accept patients who have experienced a pulmonary embolism within the past three years, however, the secondary clinical trial might consider such patients depending on the investigator's decision. [SEP] Clinical Trial: NCT00544167",Entailment,0.6699111,0.33008885
NCT00978250,"Statement: patients with metastatic scbc, irrespective of their er or pr status, can participate in the primary clinical trial [SEP] Clinical Trial: NCT00978250",Contradiction,0.4289184,0.57108164
NCT00182793,Statement: there were no reported infections in the primary clinical trial nor the secondary clinical trial [SEP] Clinical Trial: NCT00182793,Entailment,0.8663628,0.13363716
NCT02286843,Statement: 0.13 of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.43643433,0.5635657
NCT00709761,Statement: only a minority of patients in the primary clinical trial who were administered lapatinib 1000 mg + nab-paclitaxel saw a confirmed complete response (cr). [SEP] Clinical Trial: NCT00709761,Contradiction,0.4483859,0.5516141
NCT03557801,"Statement: patients in the primary clinical trial did not suffer from anemia, pneumonia, and stupor more frequently than those in the secondary trial, and no cases of febrile infections were recorded in the primary trial. [SEP] Clinical Trial: NCT03557801",Entailment,0.54763496,0.45236504
NCT00825682,Statement: The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial. 2q36.1 is a chromosome band present on 2q [SEP] Clinical Trial: NCT00825682,Entailment,0.68662083,0.31337914
NCT00766532,"Statement: there is evidence of anorexia, hypothermia or hallucinations in the aes of the secondary clinical trial. [SEP] Clinical Trial: NCT00766532",Entailment,0.5318509,0.46814913
NCT01383174,Statement: the observations from cohort 2 of both the primary and secondary clinical trials were inconclusive in their comparative analysis. [SEP] Clinical Trial: NCT01383174,Entailment,0.8125815,0.18741848
NCT00828516,Statement: both the secondary and primary clinical trials do not employ the number of participants with treatment-emergent adverse events as the metric for their study outcomes. [SEP] Clinical Trial: NCT00828516,Entailment,0.91864824,0.081351735
NCT01250379,Statement: a young female newly diagnosed with pr-positive and her2-positive breast cancer may qualify for both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01250379,Contradiction,0.42814577,0.5718543
NCT01869192,"Statement: in the primary clinical trial, it's demonstrated that the arm a intervention has yielded the best overall response rate. however, the denosumab group exhibited a poorer time to first on-study sre compared to the zoledronic acid group in the secondary clinical trial. [SEP] Clinical Trial: NCT01869192",Contradiction,0.4787938,0.5212062
NCT01606748,"Statement: used personal tablet is a response indicating that an individual used their personal tablet. several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia. [SEP] Clinical Trial: NCT01606748",Entailment,0.596993,0.40300694
NCT00256698,Statement: both primary and secondary trials do not use arimidex in their studies. [SEP] Clinical Trial: NCT00256698,Entailment,0.92959833,0.07040168
NCT01286987,"Statement: Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention. spinal cord glioma is a neoplasm that arises from glial cells in the spinal cord.  representative examples include astrocytoma, oligodendroglioma, and ependymoma. [SEP] Clinical Trial: NCT01286987",Contradiction,0.48900905,0.5109909
NCT00843167,"Statement: the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. benign pericardial germ cell tumor is a non-metastasizing germ cell tumor that arises within the pericardium. [SEP] Clinical Trial: NCT00843167",Contradiction,0.40645137,0.59354866
NCT00467844,Statement: at least one patient treated with gtx-024 8mg in the primary trial gained over 17 kilos of lean body mass. [SEP] Clinical Trial: NCT00467844,Contradiction,0.411675,0.588325
NCT02002533,Statement: the primary trial and the secondary trial have 0 recorded adverse events. cytomegalovirus positive is an indication that cytomegalovirus has been detected in a sample. [SEP] Clinical Trial: NCT02002533,Contradiction,0.47966284,0.52033716
NCT00838929,Statement: each participant in the primary clinical trial is administered a dose of between 100 and 1600 ¬¨¬µg fentanyl sublingual spray amidst radiation therapy [SEP] Clinical Trial: NCT00838929,Contradiction,0.488327,0.511673
NCT01498458,"Statement: in the primary clinical trial, the number of hypertension and pancreatic resection cases were ten times higher than cases of hepatotoxicity [SEP] Clinical Trial: NCT01498458",Contradiction,0.36761853,0.63238144
NCT00911898,"Statement: the primary clinical trial intervention necessitates psychosocial interventions, omitting surgical and imaging procedures. [SEP] Clinical Trial: NCT00911898",Entailment,0.7313819,0.26861814
NCT01171924,"Statement: in the primary clinical trial, both cohort 1 and cohort 2 are given an identitical dose of cudc-101, although cohort 1 receives it more frequently. [SEP] Clinical Trial: NCT01171924",Contradiction,0.37305567,0.62694436
NCT01194440,Statement: patients with a diagnosis of ductal carcinoma in situ who are thinking about ai therapy qualify for the primary clinical trial. [SEP] Clinical Trial: NCT01194440,Entailment,0.5003365,0.4996635
NCT01011218,Statement: do volunteer work is a question about whether an individual did or does volunteer work. Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events. [SEP] Clinical Trial: NCT01011218,Entailment,0.50430465,0.49569535
NCT01770353,"Statement: the primary clinical trial and the secondary clinical trial both use the same pharmacological substances, administered at identical dosages and intervals. [SEP] Clinical Trial: NCT01770353",Contradiction,0.19212678,0.8078732
NCT00800436,"Statement: Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial, but not from the primary trial. [SEP] Clinical Trial: NCT00800436",Entailment,0.8076804,0.19231957
NCT01527487,"Statement: in the primary clinical trial, the first group receives more substantial amounts of cyclophosphamide than eribulin, while the second group receives larger doses of cyclophosphamide than docetaxel. [SEP] Clinical Trial: NCT01527487",Entailment,0.61403126,0.38596874
NCT00293384,"Statement: every patient in cohort 1 in the primary clinical trial experienced no signs of acute vomiting after receiving treatment with aprepitant, dexamethasone, cytoxan, and kytril [SEP] Clinical Trial: NCT00293384",Entailment,0.5730052,0.42699477
NCT03403712,"Statement: the primary trial is measuring the average time a patient spends sleeping, while the secondary trial assesses the number of treatment-related incidents that impact the patient's health. [SEP] Clinical Trial: NCT03403712",Entailment,0.54986924,0.45013082
NCT00871858,"Statement: for the primary clinical trial, paclitaxel is exclusive to the intervention of cohort 1, while cohort 2 receives fulvestrant as part of their treatment [SEP] Clinical Trial: NCT00871858",Entailment,0.5560002,0.4439998
NCT00963911,"Statement: several of the primary trial candidates are administered 0.01 g of talazoparib daily, as part of the intervention [SEP] Clinical Trial: NCT00963911",Contradiction,0.31274185,0.6872581
NCT01111825,Statement: nras gene mutation negative is a genetic finding indicating that nras gene mutations have not been detected in a sample. Neiter of the primary trial cohorts receive any invasive surgery or Neratinib . [SEP] Clinical Trial: NCT01111825,Contradiction,0.4806927,0.5193073
NCT00432562,"Statement: the primary clinical trial requires informed consent, but there is no corresponding requirement in the secondary trial. [SEP] Clinical Trial: NCT00432562",Entailment,0.92457104,0.075429015
NCT01390818,Statement: several adverse events were reported for cohort 1 patients in the primary clinical trial. [SEP] Clinical Trial: NCT01390818,Entailment,0.8309963,0.16900377
NCT01439282,"Statement: only male patients are eligible for the primary clinical trial, and the secondary clinical trial accepts patients of all genders [SEP] Clinical Trial: NCT01439282",Entailment,0.56453353,0.43546647
NCT02807844,"Statement: each participant in the primary clinical trial gets a dose of at least 20mg of mcs110 every 3 weeks, and more than 130 mg of pdr001 every 2 weeks. [SEP] Clinical Trial: NCT02807844",Contradiction,0.31272507,0.6872749
NCT00992602,Statement: the recorded adverse events in the primary trial allow for a comprehensive comparison with the secondary trial's data. [SEP] Clinical Trial: NCT00992602,Entailment,0.7523684,0.24763158
NCT00146172,Statement: candidates who are able to take care of themselves without any help at all are eligible for both primary clinical trial and secondary clinical trial [SEP] Clinical Trial: NCT00146172,Entailment,0.6580314,0.34196857
NCT00992602,Statement: There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00992602,Entailment,0.6403309,0.35966912
NCT00451555,"Statement: Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial, but this is not necessary to be included in the secondary trial. conjoined twins is a monoamniotic twin gestation in which the twins share one or more organs. [SEP] Clinical Trial: NCT00451555",Entailment,0.5900614,0.40993854
NCT00454532,"Statement: in the secondary clinical trial and the primary clinical trial, more than 97% of participants experienced no unfavorable incidents [SEP] Clinical Trial: NCT00454532",Contradiction,0.42544025,0.57455975
NCT01222390,"Statement: cyclin-dependent kinase inhibitor protein is a protein that plays a role in the inhibition of cyclin-dependent kinases. There are no X-rays, ultrasound, CT scans or MRIs included the interventions of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01222390",Contradiction,0.43995848,0.56004155
NCT01806675,"Statement: in the primary clinical trial, all groups receive equal doses of 18f-fpprgd2 as part of their pet/ct imaging procedures. [SEP] Clinical Trial: NCT01806675",Entailment,0.5428189,0.45718107
NCT00262834,"Statement: there were zero adverse instances recorded in the primary clinical trial, while in the secondary clinical trial, the number of patients who were affected by any such instances did not exceed 30%. [SEP] Clinical Trial: NCT00262834",Entailment,0.58151764,0.4184824
NCT01730729,"Statement: the primary trial intervention is given topically, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein [SEP] Clinical Trial: NCT01730729",Contradiction,0.49088353,0.5091165
NCT01250379,"Statement: a young patient with a recent diagnosis of pr-positive, her2-positive breast cancer could be considered suitable for participation in the secondary and the primary clinical trial [SEP] Clinical Trial: NCT01250379",Contradiction,0.33147737,0.66852266
NCT00372424,Statement: none of the patients receiving the sunitinib + docetaxel + trastuzumab treatment in the primary clinical trial reported any treatment-emergent adverse events. [SEP] Clinical Trial: NCT00372424,Entailment,0.8075242,0.19247581
NCT01920061,"Statement: in the primary trial, both cohorts had the same count of aes [SEP] Clinical Trial: NCT01920061",Entailment,0.66298974,0.3370103
NCT03346161,Statement: multiple aes have been recorded in at least one cohort of the primary clinical trial [SEP] Clinical Trial: NCT03346161,Entailment,0.6924141,0.30758587
NCT00871858,"Statement: only in the first cohort of the primary clinical trial is paclitaxel utilized as the intervention, however, fulvestrant is the treatment assigned to the second cohort [SEP] Clinical Trial: NCT00871858",Entailment,0.5187402,0.48125982
NCT01023477,"Statement: patients suffering from hypokalemia are not eligible to participate in the primary clinical trial, but they may be considered for the secondary clinical trial [SEP] Clinical Trial: NCT01023477",Entailment,0.7477684,0.25223157
NCT00284180,"Statement: Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial. [SEP] Clinical Trial: NCT00284180",Entailment,0.539369,0.46063107
NCT00248547,Statement: none of the patients receiving the placebo intervention in the primary clinical trial experienced emesis [SEP] Clinical Trial: NCT00248547,Entailment,0.83317125,0.1668287
NCT00256698,Statement: animal virus is an animal pathogen that is a virus. Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial. [SEP] Clinical Trial: NCT00256698,Entailment,0.71586746,0.28413248
NCT02761642,"Statement: Any cancer patient diagnosed with either fibromyalgia, thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02761642",Entailment,0.7678627,0.23213737
NCT01451632,"Statement: mixer device is a mechanical device designed to blend materials or an electronic device designed to blend signals. Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2. [SEP] Clinical Trial: NCT01451632",Contradiction,0.38658634,0.6134137
NCT00756717,Statement: there were several cases of febrile neutropenia reported in the primary trial and the secondary trial [SEP] Clinical Trial: NCT00756717,Contradiction,0.19967355,0.80032647
NCT02179515,Statement: fibrosis assessment is an evaluation of the presence or degree of fibrosis present in a sample. 100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event. [SEP] Clinical Trial: NCT02179515,Entailment,0.58630407,0.41369593
NCT02988986,Statement: Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression  . bothered by vaginal dryness is a question about whether an individual is or was bothered by vaginal dryness. [SEP] Clinical Trial: NCT02988986,Entailment,0.5153757,0.48462433
NCT01111825,"Statement: the administration for cohort 1 of the primary clinical trial consists of pr negative, er negative and her-, whereas cohort 2 receives her2+ [SEP] Clinical Trial: NCT01111825",Contradiction,0.47744566,0.5225543
NCT01908101,Statement: the primary trial and the secondary trial do not test the same drugs [SEP] Clinical Trial: NCT01908101,Entailment,0.92802304,0.07197696
NCT02286843,Statement: 13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases. allogeneic bone marrow transplantation recipient is an individual receiving an allogeneic bone marrow transplant. [SEP] Clinical Trial: NCT02286843,Contradiction,0.44631776,0.5536822
NCT00819182,"Statement: lcp1 antibody is any immunoglobulin that recognizes l-plastin protein. the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Contradiction,0.47199064,0.52800936
NCT00569166,"Statement: Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy. macular edema is accumulation of intraretinal fluid and protein in the macula, which may result in swelling and decreased central vision. [SEP] Clinical Trial: NCT00569166",Contradiction,0.28355864,0.7164414
NCT00293540,"Statement: on average patients from the primary trial survive over 24 months, over 50 patients from each cohort survived more than 2 years [SEP] Clinical Trial: NCT00293540",Contradiction,0.19329934,0.80670065
NCT00911898,Statement: surgical and imaging procedures are compulsory in the intervention section of the primary clinical trial. [SEP] Clinical Trial: NCT00911898,Entailment,0.7411388,0.2588612
NCT01286987,Statement: breast cancer patients in the primary trial are administered 7000 mcg/week of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 175 mcg/week talazoparib instead. [SEP] Clinical Trial: NCT01286987,Entailment,0.5704365,0.42956352
NCT00820872,Statement: diarrhoea was noted as a more common symptom among primary clinical trial participants as compared to those of the secondary clinical trial. [SEP] Clinical Trial: NCT00820872,Entailment,0.72559613,0.27440387
NCT02403271,Statement: the occurrence of biliary colic and clostridium difficile colitis is more in the secondary clinical trial than in the primary clinical trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.6390486,0.36095145
NCT00553358,"Statement: both, primary clinical trial and secondary clinical trial permits a patient possessing a primary 3mm-radius tumor, confirmed by clinical examination and ultrasonography. [SEP] Clinical Trial: NCT00553358",Contradiction,0.26108974,0.73891026
NCT00182793,Statement: over 15% of patients in the primary trial and the secondary trial suffered from infections during the study period. cube dosage form is a solid or semi-solid in the shape of a three dimensional square. [SEP] Clinical Trial: NCT00182793,Contradiction,0.23153149,0.7684685
NCT01419717,"Statement: while the primary trial involves the oral administration of palbociclib daily, the secondary trial requires patients to receive 300 milligrams of tezacaftor via injection every 90 days. [SEP] Clinical Trial: NCT01419717",Contradiction,0.39075062,0.6092494
NCT02796755,Statement: adverse events have been recorded for participants of the secondary clinical trial. [SEP] Clinical Trial: NCT02796755,Entailment,0.89917773,0.100822285
NCT01313117,"Statement: esophageal fistula is an abnormal communication between the esophagus and another organ or anatomic site. Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, up to a maximum of 100 mg three times daily, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. [SEP] Clinical Trial: NCT01313117",Contradiction,0.4403591,0.55964094
NCT00775645,Statement: in both the primary trial and the secondary trial there were 10 adverse events which occurred in more than 30% of participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.41940138,0.5805986
NCT01008150,Statement: more than 0.3333 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 0.57 years of the study [SEP] Clinical Trial: NCT01008150,Contradiction,0.32071063,0.6792894
NCT00586326,"Statement: the primary clinical trial intervention section indicates a detailed treatment cycle, specifying chemotherapy regimens. [SEP] Clinical Trial: NCT00586326",Contradiction,0.4294935,0.5705065
NCT02504424,"Statement: slovenia is a country in central europe, bordering the adriatic sea, between austria and croatia. one patient in the primary trial had an incident where a surgical incision reopened after the surgery. [SEP] Clinical Trial: NCT02504424",Contradiction,0.407439,0.592561
NCT01614210,Statement: results from the primary trial show that tamoxifen 32000 micrograms po daily for 7 days prior to surgery and for 14 days after breast cancer surgery decreases the diameter of tumors by 40% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.3619952,0.6380048
NCT01129622,Statement: neither the primary clinical trial nor the secondary clinical trial is open to women diseased with both claustrophobia and ibs [SEP] Clinical Trial: NCT01129622,Contradiction,0.3043564,0.69564366
NCT01156987,Statement: all individuals in group 1 of the primary clinical trial showed signs of cutaneous lesions; less than 10% of participants in the first group of the secondary clinical trial had radiation dermatitis or hyperpigmentation. [SEP] Clinical Trial: NCT01156987,Entailment,0.69720626,0.3027937
NCT00266110,"Statement: in the primary clinical trial, participants are required to get one injection on the 8th day of the investigation. [SEP] Clinical Trial: NCT00266110",Entailment,0.5942894,0.40571058
NCT02404441,"Statement: benign renal pelvis neoplasm is a non-metastasizing neoplasm that arises from the renal pelvis.  urothelial papilloma is a representative example. the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria, one for the 18-50 age group and one for the 50+ age group. [SEP] Clinical Trial: NCT02404441",Contradiction,0.45880228,0.5411977
NCT00467844,Statement: at least one patient treated with gtx-024 1kg in the primary trial gained over 22 pounds of lean body mass. [SEP] Clinical Trial: NCT00467844,Contradiction,0.3819234,0.61807656
NCT01205503,"Statement: patients who have officially certified allergies to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib are not suitable for enrollment in either the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT01205503",Entailment,0.6663885,0.33361143
NCT01997333,"Statement: the individual from cohort 1 recorded the longest progression free survival (pfs) in the primary clinical trial, surviving 3.5 months without any disease progression or death [SEP] Clinical Trial: NCT01997333",Entailment,0.6147546,0.38524544
NCT00775645,Statement: in both the primary trial and the secondary trial there were several adverse events which occurred in less than 0.01% of participants. [SEP] Clinical Trial: NCT00775645,Entailment,0.81722873,0.1827713
NCT01920061,Statement: The same perecentage of patients suffered adverse events in both cohorts of the primary trial. moderately short of breath is a response indicating that an individual has or had moderate shortness of breath. [SEP] Clinical Trial: NCT01920061,Entailment,0.6192091,0.38079092
NCT00405938,Statement: having dealt with postmenopausal adenocarcinoma or serious psychiatric conditions in the last 6 months does not affect an individual's eligibility for the primary clinical trial [SEP] Clinical Trial: NCT00405938,Entailment,0.70267034,0.29732963
NCT03202472,"Statement: patients who have recently undergone chemotherapy or radiotherapy, or those suffering from unstable angina, or having neuropathy greater than grade 2 can participate in the secondary clinical trial, not in the primary trial, even if they meet the other criterias. [SEP] Clinical Trial: NCT03202472",Contradiction,0.4169414,0.58305866
NCT01286168,"Statement: a frequent adverse event in the secondary trial, anaemia, was not observed during the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.8372709,0.1627291
NCT00687102,Statement: There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial. human papillomavirus-35 positive is an indication that human papillomavirus-35 has been detected in a sample. [SEP] Clinical Trial: NCT00687102,Contradiction,0.39998615,0.60001385
NCT00432562,Statement: both the secondary clinical trial and the primary clinical trial have the same inclusion and exclusion criteria. [SEP] Clinical Trial: NCT00432562,Entailment,0.85352784,0.14647217
NCT01617668,Statement: cohort 2 of the primary clinical trial witnessed a greater number of adverse events than cohort 1. [SEP] Clinical Trial: NCT01617668,Entailment,0.8012179,0.19878207
NCT01527487,"Statement: cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel. occasionally feel supported by spouse, family and friends is a response indicating that an individual feels or felt supported by spouse, family, and friends only occasionally. [SEP] Clinical Trial: NCT01527487",Contradiction,0.4236545,0.5763455
NCT01969448,Statement: lipodystrophy is a congenital or acquired disorder characterized by abnormal loss or redistribution of the adipose tissue in the body. laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial. [SEP] Clinical Trial: NCT01969448,Contradiction,0.33711684,0.66288316
NCT00254592,Statement: metastatic gastric neuroendocrine carcinoma is a gastric neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site. the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts. [SEP] Clinical Trial: NCT00254592,Contradiction,0.22294228,0.77705777
NCT02165839,Statement: participants in both the primary clinical trial and the secondary clinical trial are not required to meet a preliminary performance indicator. the trials do not use a performance status scoring system. [SEP] Clinical Trial: NCT02165839,Entailment,0.92705035,0.07294969
NCT01597193,Statement: all cohorts in the primary clinical trial receive enzalutamide via intravenous injection [SEP] Clinical Trial: NCT01597193,Entailment,0.62495136,0.3750487
NCT02234479,"Statement: the primary trial is studying the effects of a single, standardized gel on its study groups, whereas the secondary trial is testing multiple treatments on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.6150209,0.38497916
NCT00963911,Statement: several participants in the primary clinical trial receive a daily dose of 1000 mcg of talazoparib as part of the program [SEP] Clinical Trial: NCT00963911,Contradiction,0.21170452,0.78829545
NCT00293540,"Statement: on average patients from the primary trial survive under 2 months, over 80 patients from each cohort survived more than 6 months [SEP] Clinical Trial: NCT00293540",Contradiction,0.1658777,0.8341223
NCT00313170,"Statement: for the primary clinical trial, patients with a successful response to previous hormonal therapies could be considered for participation. [SEP] Clinical Trial: NCT00313170",Contradiction,0.47607008,0.5239299
NCT01468675,Statement: cognitive behavioral therapy (cbt) is a central component of interventions in the primary clinical trial. [SEP] Clinical Trial: NCT01468675,Entailment,0.70642966,0.2935703
NCT00320541,Statement: The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it. f3 positive is an indication that expression of f3 has been detected in a sample. [SEP] Clinical Trial: NCT00320541,Contradiction,0.42673796,0.57326204
NCT00253708,"Statement: the primary clinical trial centres around the application and efficiency of a singular drug-based treatment, while the secondary clinical trial involves testing several drug-free treatment solutions. [SEP] Clinical Trial: NCT00253708",Entailment,0.65868556,0.34131444
NCT02336737,"Statement: in the primary clinical trial, cohort 1 has not reported any adverse events [SEP] Clinical Trial: NCT02336737",Entailment,0.91164887,0.088351145
NCT00963911,Statement: 1000 mcg of talazoparib is given daily to several participants involved in the primary clinical trial as a part of the treatment process. [SEP] Clinical Trial: NCT00963911,Contradiction,0.3193957,0.6806043
NCT01390818,Statement: Several recorded Aes in the primary trial occurred to cohort 1 patients. electroencephalography cap is a reusable headset with scalp electrodes designed to measure the electrical activity of the brain. [SEP] Clinical Trial: NCT01390818,Contradiction,0.32324263,0.6767574
NCT01439282,"Statement: gender is a determining factor for both the primary and secondary clinical trials, and both trials are limited to male patients only [SEP] Clinical Trial: NCT01439282",Entailment,0.5261751,0.47382492
NCT00693719,Statement: the primary clinical trial would not admit a patient diagnosed with leptomeningeal carcinoma [SEP] Clinical Trial: NCT00693719,Entailment,0.9129573,0.087042704
NCT01920061,Statement: The same perecentage of patients suffered adverse events in both cohorts of the primary trial. 8q24.1 is a chromosome band present on 8q [SEP] Clinical Trial: NCT01920061,Entailment,0.73090047,0.26909956
NCT02336737,"Statement: Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae. get anxious about going to doctor is a question about whether an individual gets anxious about going to the doctor. [SEP] Clinical Trial: NCT02336737",Contradiction,0.4755443,0.52445567
NCT01301729,"Statement: HER2 + Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial. gelox regimen is a regimen consisting of gemcitabine, oxaliplatin and asparaginase that can be used to treat extranodal natural killer (nk)/t-cell lymphoma. [SEP] Clinical Trial: NCT01301729",Contradiction,0.4651228,0.5348772
NCT02509156,"Statement: in the primary clinical trial, both the placebo and the allo-mscs interventions are administered at the same dosage level via a one-time transendocardial injection. [SEP] Clinical Trial: NCT02509156",Contradiction,0.42647612,0.5735239
NCT00030823,Statement: the secondary clinical trial had a higher turnout than the primary clinical trial. [SEP] Clinical Trial: NCT00030823,Entailment,0.75126004,0.24873996
NCT01256567,Statement: a patient who has undergone an organ transplant within the past 30 days would not be eligible for the primary clinical trial but might be suitable for the secondary clinical trial [SEP] Clinical Trial: NCT01256567,Entailment,0.8191508,0.1808492
NCT00256217,"Statement: lactococcus is a genus of gram positive, cocci shaped, lactic acid bacterium assigned to the phylum firmicutes and the family streptococcaceae. There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs. [SEP] Clinical Trial: NCT00256217",Contradiction,0.3948782,0.60512185
NCT01614210,Statement: data from the primary clinical trial revealed that no significant change in tumor size was observed in patients treated with tamoxifen 32 mg po daily before and after their breast cancer surgery. [SEP] Clinical Trial: NCT01614210,Entailment,0.6156981,0.38430187
NCT02961790,"Statement: any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 24 months before study entry are excluded from the primary trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.6827426,0.31725737
NCT00662025,"Statement: in the primary clinical trial, every participant in cohort 2 took capecitabine orally each day during the initial 21-day cycle [SEP] Clinical Trial: NCT00662025",Entailment,0.53489566,0.4651043
NCT01290536,"Statement: the primary trial intervention uses a combination of radiation therapy and surgery, while the secondary trial utilizes gene therapy and antibody treatments. [SEP] Clinical Trial: NCT01290536",Contradiction,0.41851783,0.5814822
NCT02988986,Statement: the primary trial reported a 10% decline in the percentage of cells with ki67 expression following one month of treatment with tak-228 plus tamoxifen [SEP] Clinical Trial: NCT02988986,Entailment,0.5477458,0.45225415
NCT00558272,Statement: The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.5022658,0.49773413
NCT00544167,"Statement: a pulmonary embolism within the last two months does not preclude participation in the primary clinical trial, and the investigator's decision holds no bearing on one's eligibility for the secondary clinical trial [SEP] Clinical Trial: NCT00544167",Entailment,0.7717868,0.2282132
NCT01138046,Statement: participation in the primary clinical trial and the secondary clinical trial is restricted to canadian nationals. [SEP] Clinical Trial: NCT01138046,Entailment,0.67070115,0.32929888
NCT00293540,"Statement: the typical survival span for patients from the primary clinical trial extends beyond 2 years, yet there has been a case in each cohort where a patient succumbed under a period of 2 years. [SEP] Clinical Trial: NCT00293540",Contradiction,0.46472648,0.53527355
NCT00687102,"Statement: intestinal obstructions were a common occurrence among patient cohorts in the primary clinical trial, with similar incidences noted in the secondary trial. [SEP] Clinical Trial: NCT00687102",Entailment,0.6742064,0.32579362
NCT02336737,"Statement: no adverse events were reported in the first cohort of the primary clinical trial, but nearly all participants of the second cohort experienced a minimum of one adverse event [SEP] Clinical Trial: NCT02336737",Entailment,0.7066748,0.29332522
NCT01597193,"Statement: cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV [SEP] Clinical Trial: NCT01597193",Entailment,0.62030995,0.37969002
NCT02178722,Statement: the primary clinical trial gives pembrolizumab to its participants twice as often compared to the frequency at which sunitinib is given in the secondary clinical trial. [SEP] Clinical Trial: NCT02178722,Entailment,0.5333646,0.4666354
NCT00365365,Statement: the primary trial participants do not receive any vaccines. buccal mucosa squamous cell carcinoma is a squamous cell carcinoma of the oral cavity that arises from the buccal mucosa. [SEP] Clinical Trial: NCT00365365,Entailment,0.91514957,0.084850386
NCT01106898,"Statement: in the primary clinical trial, just two participants did not experience recurrence-free survival [SEP] Clinical Trial: NCT01106898",Entailment,0.86170626,0.1382937
NCT00284180,Statement: only patients with no known hypersensitivities to herceptin medications are acceptable candidates for the primary clinical trial. [SEP] Clinical Trial: NCT00284180,Entailment,0.6557809,0.34421903
NCT03403712,"Statement: the primary clinical trial is involved in the assessment of the count of participants experiencing adverse events related to the treatment, in contrast to the secondary clinical trial which quantifies the median duration of patients' sleep in minutes. [SEP] Clinical Trial: NCT03403712",Contradiction,0.47838566,0.5216143
NCT01127763,"Statement: in the primary clinical trial, 5 of the patients faced three or more adverse events. [SEP] Clinical Trial: NCT01127763",Entailment,0.7216543,0.27834564
NCT03403712,"Statement: foxr2 gene rearrangement is a molecular abnormality indicating rearrangement of the foxr2 gene. the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours. [SEP] Clinical Trial: NCT03403712",Contradiction,0.42889753,0.5711025
NCT00569166,"Statement: cohorts 1 and 2 in the primary clinical trial employ the identical paced breathing guidance cd, but cohort 2 executes the routine twice daily. [SEP] Clinical Trial: NCT00569166",Contradiction,0.4099531,0.5900469
NCT00428220,Statement: the frequencies of both pericardial effusions and corneal deposits were equal in the primary and secondary trials [SEP] Clinical Trial: NCT00428220,Entailment,0.6111653,0.38883474
NCT03384316,Statement: have discomfort when urinating is a question about whether an individual has or had discomfort when urinating. All Infections and Infestations cases in the primary trial were for patients in cohort 1. [SEP] Clinical Trial: NCT03384316,Entailment,0.5486256,0.45137438
NCT01967823,Statement: less than 10% of patients were affected by all types of ae in the primary clinical trial [SEP] Clinical Trial: NCT01967823,Entailment,0.89111924,0.10888071
NCT01250379,"Statement: A 20 year old female patient with a Newly diagnosed ER-positive, HER2-negative breast cancer, could be eligible for the secondary trial and the primary trial [SEP] Clinical Trial: NCT01250379",Contradiction,0.43604347,0.5639565
NCT00118157,"Statement: in the primary clinical trial, patients are provided with oral medication, which they are to take two times a day for a whole month. [SEP] Clinical Trial: NCT00118157",Contradiction,0.4464651,0.55353487
NCT02115607,Statement: there were 11 more adverse events reported in the secondary clinical trial than in the primary clinical trial [SEP] Clinical Trial: NCT02115607,Entailment,0.7233081,0.27669194
NCT00088413,Statement: the bulk of the adverse events reported in the primary trial involved the respiratory system and were rare or nonexistent in the secondary trial [SEP] Clinical Trial: NCT00088413,Entailment,0.7647288,0.23527125
NCT01111825,"Statement: cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+. primary ciliary dyskinesia 29 is an autosomal recessive primary ciliary motility defect caused by mutation(s) in the ccno gene, encoding cyclin-o. [SEP] Clinical Trial: NCT01111825",Contradiction,0.3802716,0.61972845
NCT01086605,"Statement: there were 1000 cases of hypertension, edema and dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Contradiction,0.27700198,0.72299796
NCT01597193,Statement: the primary clinical trial distributes enzalutamide orally to group 2 but administers it through intravenous lines to group 1 [SEP] Clinical Trial: NCT01597193,Entailment,0.5653253,0.43467465
NCT00182767,"Statement: from the primary clinical trial, two patient incidents of dose-limiting toxicity occurred, one in each cohort. [SEP] Clinical Trial: NCT00182767",Entailment,0.61454624,0.38545373
NCT00320541,Statement: The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group. 17p13.3 is a chromosome band present on 17p [SEP] Clinical Trial: NCT00320541,Entailment,0.64049155,0.35950845
NCT00708019,Statement: every participant in the primary clinical trial endured extreme pain for a period of 10 weeks. [SEP] Clinical Trial: NCT00708019,Entailment,0.6004718,0.39952818
NCT00819182,"Statement: the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.6982955,0.30170456
NCT00317603,"Statement: The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope, which occurred in 25.00% of the primary trial patients. [SEP] Clinical Trial: NCT00317603",Contradiction,0.15899973,0.8410003
NCT00104650,Statement: The Interventions in the primary trial are administered through different routes. advanced neuroendocrine tumor is a neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment. [SEP] Clinical Trial: NCT00104650,Entailment,0.760061,0.23993896
NCT00656305,Statement: cohort 2 of the primary clinical trial experienced hospitalizations. [SEP] Clinical Trial: NCT00656305,Entailment,0.65974504,0.34025496
NCT01743560,"Statement: children and adolescents are not eligible for the primary trial, as they do not meet the height requirement, however they are not explicitly excluded from the secondary trial [SEP] Clinical Trial: NCT01743560",Entailment,0.5038341,0.4961659
NCT01045421,"Statement: patients with Histologically or cytologically confirmed metastatic and/or advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial. trochlear nerve disorder, ctcae is a disorder characterized by dysfunction of the trochlear nerve (fourth cranial nerve). [SEP] Clinical Trial: NCT01045421",Contradiction,0.35498202,0.6450179
NCT02104830,"Statement: neutropenia was a common adverse effect in cohort 2 of the primary trial, whereas the patients in cohort 1 of the secondary trial reported no cases of neutropenia, despite them having higher doses of empegfilgrastim. [SEP] Clinical Trial: NCT02104830",Entailment,0.57210565,0.42789438
NCT00365105,"Statement: a 32 year old patient with histologically verified diagnosis of stage three breast cancer, absolute neutrophil count of 1807000 cells/ml, platelet count of 110,03400 cells/ml, hemoglobin level of 0.09 kg/m^3, and a life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.2924416,0.70755833
NCT00122369,"Statement: age restrictions apply to patients participating in the secondary clinical trial, while there are no age limits specified for the primary clinical trial. [SEP] Clinical Trial: NCT00122369",Entailment,0.8735591,0.12644096
NCT00021255,"Statement: nausea visual analogue scale is a nausea scale from 0 to 10 on which the patient marks the current level of nausea experienced. Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency. [SEP] Clinical Trial: NCT00021255",Entailment,0.59992194,0.400078
NCT00467844,"Statement: during the primary clinical trial, at least one patient who received gtx-024 1mg treatment had over 10 kilos increase in lean body mass. [SEP] Clinical Trial: NCT00467844",Contradiction,0.4708432,0.52915686
NCT00313170,Statement: candidates for the primary trial must have breast cancer and require hormonal treatment. repeat expansion disease is a class of genetic diseases that occur when microsatellite repeats expand beyond a threshold length. [SEP] Clinical Trial: NCT00313170,Contradiction,0.34958696,0.650413
NCT01246973,"Statement: no aes relating to cardiology or psychology were observed throughout the duration of both the primary clinical trial and secondary clinical trial, although various other kinds of aes took place. [SEP] Clinical Trial: NCT01246973",Entailment,0.5263669,0.4736331
NCT00792077,"Statement: the primary clinical trial utilizes larger quantities of lenalidomide for intervention 1 compared to the secondary clinical trial's use of lapatinib, and the intervention in the primary trial lasts longer. [SEP] Clinical Trial: NCT00792077",Entailment,0.5730507,0.42694932
NCT00454532,Statement: most patients experienced multiple severe adverse events post participation in the primary clinical trial [SEP] Clinical Trial: NCT00454532,Entailment,0.71923184,0.28076816
NCT00146172,Statement: both the primary clinical trial and the secondary clinical trial accept candidates having an ecog score of 1 [SEP] Clinical Trial: NCT00146172,Contradiction,0.42401597,0.57598406
NCT01045421,Statement: patients with histologically or cytologically confirmed localized and/or early-stage solid tumor in the brain are eligible for phase 1 of the primary clinical trial and for all cohorts of the secondary clinical trial [SEP] Clinical Trial: NCT01045421,Contradiction,0.41101104,0.58898896
NCT01306032,Statement: Patients in the primary trial and the secondary trial  suffered Thromboembolic events. [SEP] Clinical Trial: NCT01306032,Entailment,0.5769302,0.42306975
NCT00270894,Statement: the primary clinical trial involves no pharmaceutical intervention for its participants; only behavioral and dietary modifications are implemented. [SEP] Clinical Trial: NCT00270894,Entailment,0.5775696,0.42243037
NCT00662025,"Statement: pancreatic acinar cell is a cell which secretes digestive enzymes via the pancreatic duct into the duodenum to assist in digestion. CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle. [SEP] Clinical Trial: NCT00662025",Contradiction,0.38653663,0.61346334
NCT00182793,Statement: There was at least 1 case of infection in both the primary trial and the secondary trial. cutaneous fistula is an abnormal communication between the skin and another organ or cavity. [SEP] Clinical Trial: NCT00182793,Entailment,0.5264982,0.4735018
NCT01963481,Statement: patients suffering severely from sleep disorders other than insomnia can participate in both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01963481,Contradiction,0.34311536,0.6568847
NCT00553358,"Statement: a patient whose primary tumor size is not measurable by clinical examination or echography, is fit for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00553358",Entailment,0.5115386,0.48846138
NCT00404066,"Statement: disease response supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the disease response domain. The only types of Aes observed in patients from the secondary trial were Eyelid oedema, Upper gastrointestinal haemorrhage and Chest pain, no aes wererecorded in the primary trial. [SEP] Clinical Trial: NCT00404066",Entailment,0.6805292,0.31947085
NCT02599194,Statement:  Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.82269543,0.17730457
NCT01831089,Statement: Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial. benign sinonasal soft tissue neoplasm is a non-metastasizing soft tissue neoplasm that arises from the nasal cavity and paranasal sinuses. [SEP] Clinical Trial: NCT01831089,Contradiction,0.46002057,0.53997946
NCT01313117,"Statement: biologic entity birth country code is a coded value specifying the name of the country in which the biologic entity is born. Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. [SEP] Clinical Trial: NCT01313117",Entailment,0.5176313,0.4823687
NCT01086605,"Statement: none of the cohorts in the primary clinical trial observed any occurences of hypertension, dehydration and dyspnea [SEP] Clinical Trial: NCT01086605",Entailment,0.58717597,0.41282403
NCT00978250,Statement: the primary clinical trial excludes patients with histologically confirmed metastatic scbc. [SEP] Clinical Trial: NCT00978250,Entailment,0.8333112,0.16668878
NCT01205503,Statement: have you been in low or very low spirits is a question about whether an individual is or has been in low or very low spirits. Any patients with Documented allergy to cephalosporin or trimethoprim/sulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial. [SEP] Clinical Trial: NCT01205503,Entailment,0.6584757,0.34152424
NCT01171924,"Statement: cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly. restlessness, ctcae is a disorder characterized by an inability to rest, relax or be still. [SEP] Clinical Trial: NCT01171924",Contradiction,0.35100245,0.6489975
NCT01569087,"Statement: prostate infection, ctcae is a disorder characterized by an infectious process involving the prostate gland. Patients with stage 4 cancer are not eligible for the secondary trial, however they are eligible for the primary trial. [SEP] Clinical Trial: NCT01569087",Contradiction,0.38070425,0.6192957
NCT01743560,"Statement: children and adolescents are not eligible for the primary trial, as they do not meet the height requirement, however they are not explicitly excluded from the secondary trial. urethral infection is a bacterial, viral, or fungal infectious process affecting the urethra. [SEP] Clinical Trial: NCT01743560",Contradiction,0.3772495,0.62275046
NCT01419717,"Statement: the primary trial requires patients to receive 120000 micrograms of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy. [SEP] Clinical Trial: NCT01419717",Contradiction,0.3324518,0.6675482
NCT02259114,"Statement: Patients with NUT midline carcinoma or Castrate-resistant prostate cancer, determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02259114",Contradiction,0.37185603,0.62814397
NCT00544167,Statement: patients who have experienced a pulmonary embolism in the past year are welcome to join the primary trial and do not require an investigator's decision for participation in the secondary trial [SEP] Clinical Trial: NCT00544167,Entailment,0.8875274,0.11247261
NCT02509156,Statement: the allo-mscs and placebo interventions of the primary clinical trial are both given in identical dosages through a single transendocardial injection. [SEP] Clinical Trial: NCT02509156,Contradiction,0.49283785,0.50716215
NCT01781299,"Statement: hypoxia, ctcae is a disorder characterized by a decrease in the level of oxygen in the body. There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01781299",Contradiction,0.34975857,0.6502414
NCT03092934,Statement: both phases of the primary clinical trial are only open to male patients who demonstrate evidence of a locally advanced and/or metastatic solid tumor. [SEP] Clinical Trial: NCT03092934,Contradiction,0.4988577,0.5011423
NCT00753415,"Statement: Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle. disease outcome or response is an indication that a subject's disease outcome or response is not covered by the study protocol. [SEP] Clinical Trial: NCT00753415",Entailment,0.6652517,0.3347483
NCT01111825,Statement: none of the cohorts in the primary clinical trial undergo any invasive operation or receive neratinib [SEP] Clinical Trial: NCT01111825,Entailment,0.73944885,0.26055118
NCT00741039,"Statement: Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer. have trouble going to sleep is a question about whether an individual has or had trouble going to sleep. [SEP] Clinical Trial: NCT00741039",Entailment,0.6027906,0.3972094
NCT01306032,Statement: Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial. [SEP] Clinical Trial: NCT01306032,Entailment,0.91869617,0.08130383
NCT01617668,"Statement: adverse events were not common amongst cohort 1 participants in the primary clinical trial, identical results were drawn from cohort 2. [SEP] Clinical Trial: NCT01617668",Entailment,0.81863034,0.18136968
NCT00791037,Statement: both the primary and the secondary clinical trial are designed to evaluate how many participants experience adverse events of primary interest (aepis) [SEP] Clinical Trial: NCT00791037,Entailment,0.7106413,0.28935865
NCT00709761,Statement: Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR). bladder solitary fibrous tumor is a solitary fibrous tumor that arises from the bladder. most tumors are benign. [SEP] Clinical Trial: NCT00709761,Contradiction,0.4264857,0.5735143
NCT03092934,Statement: evidence of a locally advanced and/or metastatic solid tumor permits patients of any gender eligibility for both phases of the primary clinical trial. [SEP] Clinical Trial: NCT03092934,Entailment,0.50724185,0.49275815
NCT00759785,Statement: 90% more participants in the er-positive luminal b group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group [SEP] Clinical Trial: NCT00759785,Entailment,0.51721144,0.4827886
NCT01908101,Statement: different medications are being tested in the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01908101,Entailment,0.77671874,0.22328128
NCT00838929,Statement: how big a problem question is a question about how big a problem something is for an individual. Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy. [SEP] Clinical Trial: NCT00838929,Contradiction,0.4200287,0.5799713
NCT00030823,Statement: the primary clinical trial involved the administration of the bio-path nanoparticle delivery system to thirteen participants [SEP] Clinical Trial: NCT00030823,Contradiction,0.29985005,0.7001499
NCT01831089,Statement: a confirmed histological or cytological diagnosis of resectable non-small cell lung breast cancer or small cell lung cancer makes patients suitable for the primary clinical trial [SEP] Clinical Trial: NCT01831089,Entailment,0.5641901,0.4358099
NCT00428220,Statement: pericardial effusions were a less common condition among patients in the primary trial [SEP] Clinical Trial: NCT00428220,Entailment,0.8211621,0.17883782
NCT00756717,Statement: the primary and secondary clinical trials showed zero incidences of febrile neutropenia or cholelithiasis. [SEP] Clinical Trial: NCT00756717,Entailment,0.5554068,0.44459322
NCT02222922,Statement: All the primary trial participants receive lower doses of drugs than the secondary trial participants. how satisfied with physical attractiveness after gynecologic cancer is a question about how satisfied an individual is with their physical attractiveness after having gynecologic cancer. [SEP] Clinical Trial: NCT02222922,Entailment,0.5601885,0.43981153
NCT01631552,"Statement: the outcome measurements for the primary clinical trial and the secondary clinical trial are entirely distinct, although their interventions are identical. [SEP] Clinical Trial: NCT01631552",Entailment,0.77069944,0.22930053
NCT01194440,Statement: epidermal hyperplasia is a hyperplasia of the epidermis. Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial. [SEP] Clinical Trial: NCT01194440,Contradiction,0.3700547,0.62994534
NCT00317603,"Statement: in both the primary clinical trial and the secondary clinical trial, the most recurrent adverse event was syncope, seen in 25.00% of the primary trial patients. [SEP] Clinical Trial: NCT00317603",Contradiction,0.23134737,0.7686527
NCT00588640,"Statement: while the primary clinical trial sets different inclusion and exclusion conditions for its couples of phases, the secondary clinical trial operates with the same parameters for every participant. [SEP] Clinical Trial: NCT00588640",Entailment,0.67106336,0.32893667
NCT00825682,Statement: the duration of the intervention for the primary clinical trial exceeds that of the secondary clinical trial by an additional 15 weeks. [SEP] Clinical Trial: NCT00825682,Entailment,0.50798726,0.49201277
NCT00513292,"Statement: the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had worse results than arm 1, as a higher percentage of arm 2 patients experienced pCR. beam is a group of nearly parallel rays of electromagnetic radiation or a stream of particles. [SEP] Clinical Trial: NCT00513292",Contradiction,0.25726685,0.7427332
NCT00182767,"Statement: in the primary clinical trial, dose-limiting toxicity occurred exclusively within cohorts other than cohort 2. [SEP] Clinical Trial: NCT00182767",Entailment,0.8105038,0.18949625
NCT00321464,"Statement: patients diagnosed with stage 4 breast adenocarcinoma that is either er positive, pr positive, or her2/neu negative, are qualified to participate in both the secondary clinical trial and the primary clinical trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.47978908,0.5202109
NCT00749931,Statement: All patients eligible for the secondary trial are also eligible for the primary trial. neurofilament is an intermediate filament that is found in the axons of neurons. [SEP] Clinical Trial: NCT00749931,Contradiction,0.44965997,0.55034006
NCT04080297,Statement: how often did fatigue limit work is a question about how often fatigue limits an individual at work. Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time. [SEP] Clinical Trial: NCT04080297,Entailment,0.7822914,0.21770859
NCT01920061,"Statement: ovcar-8 is an adenocarcinoma cell line established from a 64 year old female patient with ovarian carcinoma previously treated with chemotherapy. the primary trial uses a 1 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.7953731,0.20462692
NCT01290536,"Statement: grade 1 esophageal fistula, ctcae is asymptomatic The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month. [SEP] Clinical Trial: NCT01290536",Contradiction,0.40915972,0.5908402
NCT00248547,Statement: patients who received the placebo intervention in the primary clinical trial had a two-fold increase in the incidence of emesis compared to those who were treated with aprepitant. [SEP] Clinical Trial: NCT00248547,Contradiction,0.4940656,0.50593436
NCT01702571,"Statement: All of the Aes recorded for cohort 1 of the primary trial are related to mental health. mediastinal infection, ctcae is a disorder characterized by an infectious process involving the mediastinum. [SEP] Clinical Trial: NCT01702571",Contradiction,0.41379213,0.58620787
NCT00791037,Statement: the primary trial and the secondary trial evaluate the Percentage of Participants With Adverse Events of Primary Interest (AEPIs). study site oversight status review board process code is a coded value specifying the phase in the lifecycle of the review board process. [SEP] Clinical Trial: NCT00791037,Entailment,0.539966,0.46003398
NCT02550795,"Statement: Group 2 of the primary trial recieves 0.5ug/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any Dexmedetomidine. ratio scale is a scale that uses ordered numbers with a constant difference and which has a natural zero. [SEP] Clinical Trial: NCT02550795",Entailment,0.75301933,0.24698067
NCT02988986,Statement: inppl1 gene mutation is a change in the nucleotide sequence of the inppl1 gene. Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression  . [SEP] Clinical Trial: NCT02988986,Contradiction,0.4814078,0.51859224
NCT01419717,"Statement: the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using Lymphoscintigraphy. [SEP] Clinical Trial: NCT01419717",Contradiction,0.32659683,0.67340314
NCT02431676,Statement: anorexic patients are eligible for the primary trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.67106307,0.3289369
NCT01138046,Statement: all individuals of japanese nationality have the opportunity to be part of either the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT01138046,Contradiction,0.4116664,0.5883336
NCT01706081,Statement: acupuncture patients in the primary trial did not experience any significant improvements in their lymphedema when compared to patients using testosterone cream. [SEP] Clinical Trial: NCT01706081,Entailment,0.6649412,0.33505878
NCT00075764,Statement: patients with t4 n4 m4 tumors are allowed to participate in the primary clinical trial [SEP] Clinical Trial: NCT00075764,Entailment,0.5911446,0.40885544
NCT00182793,Statement: 2% of patients in the primary trial and the secondary trial suffered from infections during the study period [SEP] Clinical Trial: NCT00182793,Contradiction,0.35564256,0.6443574
NCT00950911,"Statement: in intervention 1 of the primary clinical trial, the denosumab dosage is 12 fold compared to the tamoxifen dosage in intervention 1 of the secondary clinical trial. [SEP] Clinical Trial: NCT00950911",Contradiction,0.42609155,0.5739084
NCT02002533,"Statement: in both the primary clinical trial and the secondary clinical trial, there were zero recorded serious adverse events. [SEP] Clinical Trial: NCT02002533",Entailment,0.7948653,0.20513463
NCT00209092,"Statement: Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial. [SEP] Clinical Trial: NCT00209092",Entailment,0.6625141,0.33748588
NCT00786838,"Statement: the method of administration for both the placebo and trabectedin in the primary clinical trial is the same, however, they are given on distinct days. [SEP] Clinical Trial: NCT00786838",Entailment,0.6944423,0.3055577
NCT01306032,Statement: infant t acute lymphoblastic leukemia is a t-acute lymphoblastic leukemia that occurs in infancy. Patients in the primary trial and the secondary trial  suffered Thromboembolic events. [SEP] Clinical Trial: NCT01306032,Contradiction,0.29853973,0.7014603
NCT01537029,"Statement: Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.43296677,0.56703323
NCT01781299,Statement: unexpected fatalities occurred during the primary clinical trial [SEP] Clinical Trial: NCT01781299,Entailment,0.75316894,0.24683104
NCT02807844,"Statement: all patients in the primary clinical trial receive at least 20mg of mcs110 every 3 weeks, without any pdr001. [SEP] Clinical Trial: NCT02807844",Entailment,0.738835,0.26116502
NCT00118157,Statement: patients participating in the primary trial receive 2400mg/m2 oral lapatinib bi-daily for a full 30 days. [SEP] Clinical Trial: NCT00118157,Contradiction,0.35639802,0.643602
NCT01614210,"Statement: the primary clinical trial found that daily doses of 20 mg tamoxifen, taken seven days before and 14 days post breast cancer surgery, resulted in an average 40% decrease in ki67 expression in tumors. [SEP] Clinical Trial: NCT01614210",Contradiction,0.35317108,0.64682895
NCT01606748,"Statement: in the first cohort of the primary clinical trial, pancytopenia was a prevalent condition, while anaemia and febrile neutropenia were absent. [SEP] Clinical Trial: NCT01606748",Entailment,0.54960066,0.45039928
NCT00756717,Statement: there were 0% cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial [SEP] Clinical Trial: NCT00756717,Contradiction,0.43734193,0.5626581
NCT01920061,"Statement: the primary trial uses a 6 day cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.91818047,0.08181948
NCT01222390,"Statement: There are no X-rays, transendocardial injections,  CT scans or MRIs included the interventions of the primary trial and the secondary trial. voice makes me feel handicapped is a question about how frequently an individual's voice makes them feel handicapped. [SEP] Clinical Trial: NCT01222390",Contradiction,0.29642025,0.7035797
NCT00432562,Statement: no inclusion or exclusion criteria are shared between the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00432562,Entailment,0.9124642,0.087535806
NCT00709761,Statement: Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) . alphanumeric is a term used to describe a character string containing only letters and numbers. [SEP] Clinical Trial: NCT00709761,Contradiction,0.4279827,0.5720173
NCT02273206,"Statement: in the first cohort of the primary clinical trial, all 61 cervical cancer patients were up-to-date with their screenings prior to the intervention. [SEP] Clinical Trial: NCT02273206",Contradiction,0.4356205,0.56437945
NCT01421472,"Statement: Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial [SEP] Clinical Trial: NCT01421472",Contradiction,0.46193364,0.5380664
NCT00054028,"Statement: all patients in the primary clinical trial receive suramin and paclitaxel, while the secondary trial does not specify which drugs are given in its intervention section. [SEP] Clinical Trial: NCT00054028",Entailment,0.9198508,0.08014922
NCT00558272,Statement: the azd0530 175 milligrams group of the primary trial experienced a more significant percentage change in betactx at week 4 months than the zoledronic acid 4000 microgram group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.4976303,0.50236976
NCT03092934,Statement: patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic. [SEP] Clinical Trial: NCT03092934,Contradiction,0.48858762,0.5114124
NCT00544167,"Statement: severely anxious or depressed is a response indicating that an individual has or had severe anxiety or depression. Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision. [SEP] Clinical Trial: NCT00544167",Entailment,0.535252,0.46474802
NCT02550795,"Statement: Group 2 of the primary trial recieves 0.5ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. thienopyridine antiplatelet agent is a class of agents that target at platelet adp receptor or purinergic receptor p2ry12 with antiplatelet activity. [SEP] Clinical Trial: NCT02550795",Entailment,0.6312477,0.36875233
NCT01138046,"Statement: the primary clinical trial necessitates applicants be females of a particular nationality, whereas for the secondary clinical trial there is no such specification. [SEP] Clinical Trial: NCT01138046",Entailment,0.91572124,0.08427878
NCT01537029,"Statement: the primary clinical trial is open to any female cancer patients who are 18 years or older, irrespective of race, ethnicity or type of cancer but in the case of the secondary clinical trial, participants must be diagnosed with brca+ breast cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.42838627,0.5716137
NCT01351376,Statement: patients possessing detectable tumors in both breasts cannot participate in the primary clinical trial [SEP] Clinical Trial: NCT01351376,Entailment,0.8862854,0.11371456
NCT00791037,"Statement: the primary trial and the secondary trial evaluate the Percentage of Participants With Adverse Events of Primary Interest (AEPIs). osteitis fibrosa cystica is a disorder that is characterized by bone cysts and fractures, resulting from hyperparathyroidism. [SEP] Clinical Trial: NCT00791037",Contradiction,0.45201313,0.54798687
NCT02413008,Statement: the outcome measurements and units of measurement utilized in the secondary clinical trial and the primary clinical trial are identical. [SEP] Clinical Trial: NCT02413008,Entailment,0.87720793,0.12279204
NCT00467844,"Statement: All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period. evac regimen is a regimen consisting of etoposide, vincristine, doxorubicin and cyclophosphamide used for the treatment of extensive-stage small cell lung cancer. [SEP] Clinical Trial: NCT00467844",Contradiction,0.38297772,0.6170223
NCT01591746,"Statement: were clinical genomics performed is a question whether clinical genomics were performed. Neither cohort of the primary trial recieves alisertib, and the two cohorts of the secondary trial receive different doses. [SEP] Clinical Trial: NCT01591746",Entailment,0.8357261,0.16427396
NCT00293540,"Statement: the mean survival time for patients participating in the primary clinical trial falls under 12 months, and less than 50 patients from any subgroup exceeded a year of survival. [SEP] Clinical Trial: NCT00293540",Contradiction,0.4597449,0.5402551
NCT00538850,"Statement: the primary trial utilizes the hamilton depression rating scale (hdrs) to assess mental health wellness, whereas the secondary trial closely monitors transitions in triglyceride levels throughout 6 months [SEP] Clinical Trial: NCT00538850",Contradiction,0.39486104,0.60513896
NCT01527487,Statement: patients in cohort 2 of the primary clinical trial are administered lesser amounts of cyclophosphamide compared to docetaxel. [SEP] Clinical Trial: NCT01527487,Entailment,0.825634,0.17436603
NCT01908101,Statement: secondary trial participants are subjected to higher doses of radiation therapy compared to the primary trial patients [SEP] Clinical Trial: NCT01908101,Entailment,0.7725448,0.22745517
NCT00319748,"Statement: the primary trial keeps record of the percentage of participants who have experienced clinical improvement according to recist, while the secondary trial does not. [SEP] Clinical Trial: NCT00319748",Entailment,0.90633225,0.09366772
NCT01222390,"Statement: moderately better is a subjective response indicating that something is moderately better. There are no X-rays, transendocardial injections,  CT scans or MRIs included the interventions of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01222390",Contradiction,0.32441685,0.6755832
NCT01527487,Statement: cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel. epithiazide is a trifluoroethylthio-containing benzothiadiazine sulfonamide derivative belonging to the class of the thiazide diuretics. [SEP] Clinical Trial: NCT01527487,Entailment,0.5085492,0.4914508
NCT01171924,"Statement: in the primary clinical trial, cohort 1 and cohort 2 are given the same cudc-101 dosage and frequency, but cohort 1 receives additional weekly doses of pd-0332991. [SEP] Clinical Trial: NCT01171924",Contradiction,0.31412053,0.6858794
NCT01967823,Statement: karyocytomegaly and multinucleated hepatocytes is a finding of both karyocytomegaly and multinucleated hepatocytes in the same lesion. 36.36% of the primary trial patients suffered an increase in Blood bilirubin. [SEP] Clinical Trial: NCT01967823,Contradiction,0.34109813,0.65890193
NCT03346161,Statement: Both cohorts of the primary trial recorded 0 Aes [SEP] Clinical Trial: NCT03346161,Entailment,0.86013407,0.1398659
NCT01831089,Statement: patients with a histologically/cytologically confirmed diagnosis of advanced stage and metastatic melanoma or pancreatic cancer are qualified to participate in the primary clinical trial [SEP] Clinical Trial: NCT01831089,Contradiction,0.40162447,0.59837556
NCT01129622,Statement: Women suffering from both claustrophobia and osteoporosis or not eligible for either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01129622,Entailment,0.7391085,0.26089147
NCT01256567,"Statement: eligibility for the primary clinical trial includes patients that received organ transplants within the past month, while the secondary clinical trial excludes them [SEP] Clinical Trial: NCT01256567",Entailment,0.87565976,0.12434017
NCT01286168,"Statement: mold mix antigen ige antibody measurement is a measurement of the mold mix antigen ige antibody in a biological specimen. The most common adverse event in the secondary trial was Anaemia, there were no recorded AEs in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.7041618,0.29583815
NCT03069313,"Statement: the primary clinical trial employs a transdermal patch for intervention administration, whereas the secondary trial uses a sublingual method. [SEP] Clinical Trial: NCT03069313",Entailment,0.6473291,0.35267094
NCT02404441,"Statement: the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria, one for the 18-50 age group and one for the 50+ age group. [SEP] Clinical Trial: NCT02404441",Contradiction,0.49702397,0.502976
NCT01008150,Statement: More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study. helped recognize that decision needs to be made is a question about whether an individual was helped to recognize that a decision needs to be made. [SEP] Clinical Trial: NCT01008150,Contradiction,0.4321961,0.5678039
NCT00321464,"Statement: eligibility for both the secondary and the primary clinical trials is given to patients with a confirmed histological diagnosis of stage 4 breast adenocarcinoma that are either er positive, pr positive or her2/neu negative. [SEP] Clinical Trial: NCT00321464",Entailment,0.5127912,0.4872088
NCT00404066,"Statement: the secondary clinical trial noted only two types of adverse events: eyelid oedema and chest pain, while the primary trial reported no observed adverse events. [SEP] Clinical Trial: NCT00404066",Entailment,0.7061093,0.29389074
NCT02165839,"Statement: there are no preliminary performance requirements for patients applying for either the primary or secondary clinical trials. consequently, there is no need for any performance status scoring mechanism in either trial. [SEP] Clinical Trial: NCT02165839",Entailment,0.9194728,0.080527164
NCT00305695,"Statement: patients in the primary clinical trial receive the first intervention through an intravenous administration, while those in the secondary clinical trial are permitted to take all interventions orally. [SEP] Clinical Trial: NCT00305695",Entailment,0.68642706,0.31357294
NCT00143390,Statement: pre-b acute lymphoblastic leukemia is an acute lymphoblastic leukemia that originates from pre-b lymphocytes. the pre-b lymphoblasts contain cytoplasmic immunoglobulin. There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial. [SEP] Clinical Trial: NCT00143390,Contradiction,0.40908518,0.59091485
NCT01975831,Statement: the only variations between interventions 1 and 2 of the primary clinical trial are that cohort 2 receives 0.7mg move of durva in their monthly injections compared to cohort 1. [SEP] Clinical Trial: NCT01975831,Contradiction,0.43338495,0.56661505
NCT00792077,Statement: the primary clinical trial makes use of greater dosage of lenalidomide than what is used of lapatinib in intervention 1 of the secondary clinical trial. [SEP] Clinical Trial: NCT00792077,Entailment,0.7550921,0.24490789
NCT01290536,Statement: the primary clinical trial involves 1 mg of dacarbazine per kg of body weight daily and the secondary trial includes photodynamic therapy using porfimer and light source. [SEP] Clinical Trial: NCT01290536,Contradiction,0.43801785,0.56198215
NCT00786838,"Statement: both the placebo and trabectedin in the primary clinical trial are given in similar ways, yet on different days. [SEP] Clinical Trial: NCT00786838",Entailment,0.78737575,0.21262433
NCT01881230,"Statement: in the primary clinical trial, abraxane doses diverge between cohorts [SEP] Clinical Trial: NCT01881230",Entailment,0.84934324,0.15065673
NCT02306265,"Statement: a mandatory mammography is required for candidates intending to participate in the primary clinical trial, while the necessary prerequisites for the secondary clinical trial are a ct scan and blood tests. [SEP] Clinical Trial: NCT02306265",Contradiction,0.33685327,0.66314673
NCT01969448,Statement: the primary clinical trial adopts a procedural approach which involves only the use of ultrasound assisted biopsy. [SEP] Clinical Trial: NCT01969448,Entailment,0.5057106,0.49428943
NCT02413008,Statement: the primary clinical trial and the secondary clinical trial both use the same outcome measurements and units of measurement. [SEP] Clinical Trial: NCT02413008,Contradiction,0.35367796,0.6463221
NCT01091974,"Statement: in the primary clinical trial, multiple cohorts receive different compounds on varied schedules, no cohort in particular receives armodafinil p.o daily. in the secondary clinical trial, the medication regimen varies by patient and does not adhere to a universal administration of 100 mg of pdr001 and 1 mg/kg of mcs110. [SEP] Clinical Trial: NCT01091974",Entailment,0.6394853,0.36051467
NCT00756717,Statement: no instances of febrile neutropenia or cholelithiasis were reported in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00756717,Entailment,0.6733231,0.32667688
NCT02336737,"Statement: no adverse events were reported in the primary clinical trial's first cohort, however, almost everyone in the second cohort encountered at least one adverse event [SEP] Clinical Trial: NCT02336737",Entailment,0.7165086,0.2834914
NCT00182767,"Statement: microsecond is a unit of time equal to one millionth of a second. In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort. [SEP] Clinical Trial: NCT00182767",Contradiction,0.46483094,0.53516906
NCT00753415,"Statement: cohort a of the primary clinical trial is given a single oral dose of ld v935, while cohort b receives a different treatment regimen. [SEP] Clinical Trial: NCT00753415",Entailment,0.8364142,0.16358575
NCT01989546,"Statement: data is a collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn. warfarin based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. [SEP] Clinical Trial: NCT01989546",Entailment,0.5826455,0.41735455
NCT00871858,Statement: tongue neoplasm is a benign or malignant neoplasm involving the tongue. Paclitaxel is not used in either of the primary trial interventions. [SEP] Clinical Trial: NCT00871858,Entailment,0.86656004,0.13344
NCT01823991,"Statement: monoallelic palb2 gene inactivation is any gain, loss, or exchange of dna that results in monoallelic loss of function mutations in the palb2 gene.  Alzheimer's patients are not eligible for the primary trial. [SEP] Clinical Trial: NCT01823991",Entailment,0.75952095,0.24047904
NCT00828516,"Statement: in the secondary clinical trial, the number of participants with treatment-emergent aes is the main outcome measurement. [SEP] Clinical Trial: NCT00828516",Entailment,0.60319626,0.3968037
NCT00373256,Statement: both cohort 1 and cohort 2 of the primary clinical trial are administered the same dose of 25 mg of sunitinib daily [SEP] Clinical Trial: NCT00373256,Contradiction,0.4038571,0.5961429
NCT02734979,Statement: the presence of a history of pulmonary embolisms and current breast implants disqualifies patients from participation in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT02734979,Contradiction,0.43982273,0.56017727
NCT02403271,Statement: There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.6955332,0.30446675
NCT02259114,"Statement: Patients with NUT midline carcinoma or Castrate-resistant prostate cancer, determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. intensity of average pain is a question about the intensity of an individual's average pain. [SEP] Clinical Trial: NCT02259114",Contradiction,0.3792517,0.62074834
NCT01806675,"Statement: the imaging procedure used for the primary clinical trial study groups will be magnetic resonance imaging (mri), not 18f-fdg and 18f-fpprgd2 pet/ct. [SEP] Clinical Trial: NCT01806675",Entailment,0.59017205,0.40982792
NCT00021255,"Statement: patients in the primary clinical trial receive varied dosages of docetaxel, doxorubicin and cyclophosphamide depending on their weight and age [SEP] Clinical Trial: NCT00021255",Contradiction,0.3450317,0.6549683
NCT01649271,"Statement: in the secondary clinical trial's group 2, one incident of shingles was reported, but the primary clinical trial and group 1 of the secondary clinical trial did not have any such cases. [SEP] Clinical Trial: NCT01649271",Entailment,0.890451,0.10954891
NCT01527487,Statement: lesser trochanter is a cone-shaped projection in the shaft of the femur in which the iliopsoas muscle is attached. cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel. [SEP] Clinical Trial: NCT01527487,Contradiction,0.44137034,0.55862963
NCT01614210,"Statement: according to the results obtained from the primary clinical trial, pre-surgical consumption of tamoxifen 20 mg orally on daily basis excites a rise in ki67 expression in cancer tumors. [SEP] Clinical Trial: NCT01614210",Contradiction,0.3708001,0.62919986
NCT00317603,"Statement: the most recurring adverse event among the patient cohorts of the primary clinical trial and the secondary clinical trial was insomnia, which was experienced by 30.00% of the primary clinical trial patients. [SEP] Clinical Trial: NCT00317603",Contradiction,0.15323883,0.84676117
NCT00819182,"Statement: on average, more treatment emergent adverse events and serious treatment emergent adverse events were reported by patients in the paced respiration intervention group than in the fast, shallow respiration group during the primary clinical trial. [SEP] Clinical Trial: NCT00819182",Entailment,0.58424646,0.41575354
NCT00293540,"Statement: on average patients from the primary trial survive over 104 weeks, however at least one patient from both cohorts died in under 104 weeks. [SEP] Clinical Trial: NCT00293540",Contradiction,0.41594654,0.58405346
NCT01702571,Statement: no cardiac-related adverse events have been identified in the first cohort of the primary clinical trial. [SEP] Clinical Trial: NCT01702571,Entailment,0.87603277,0.123967215
NCT01969448,Statement: the primary clinical trial utilizes laser-assisted fluorescence angiography for both of its interventions. [SEP] Clinical Trial: NCT01969448,Contradiction,0.4791163,0.5208837
NCT01743560,Statement: the primary clinical trial is open to all ages but the secondary clinical trial specifically excludes children [SEP] Clinical Trial: NCT01743560,Entailment,0.8575457,0.14245434
NCT01920061,Statement: unfavorable outcomes were reported in equal measure from patients in both divisions of the primary clinical trial [SEP] Clinical Trial: NCT01920061,Entailment,0.87239367,0.12760633
NCT01013740,Statement: meters times percent is a unit of measure for the distance saturation product (dsp) defined as meters times percent. Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome. [SEP] Clinical Trial: NCT01013740,Contradiction,0.19409303,0.80590695
NCT01156987,"Statement: all of the participants in group 1 of the primary trial were found to have lesions, and less than 10% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Entailment,0.63880587,0.3611941
NCT01614210,"Statement: based on the outcomes from the primary clinical trial, it was discovered that tamoxifen, when taken at a daily dosage of 20 mg for seven days before surgery followed by 14 days post-surgery, leads to a decrease in ki67 expression in breast cancer tumors by approximately 40%. [SEP] Clinical Trial: NCT01614210",Contradiction,0.42335275,0.5766472
NCT01468675,Statement: one cohort of the primary clinical trial gets risk assessment as part of the interventions. [SEP] Clinical Trial: NCT01468675,Entailment,0.8132659,0.18673404
NCT00432562,Statement: the only inclusion or exclusion standard that the primary and secondary clinical trials have in common is the capability to present written informed consent. [SEP] Clinical Trial: NCT00432562,Entailment,0.61342865,0.38657135
NCT01434342,"Statement: the primary trial registered a higher number of mucositis oral, bladder infection, and thromboembolic events compared to the secondary trial [SEP] Clinical Trial: NCT01434342",Entailment,0.50184625,0.49815372
NCT01554371,"Statement: ralstonia is a genus of gram negative, rod shaped bacterium assigned to the phylum proteobacteria and the family burkholderiaceae. Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01554371",Entailment,0.57986253,0.4201375
NCT00404066,"Statement: eyelid oedema and chest pain were the sole adverse event types noted in patients from the secondary clinical trial, in contrast, the primary clinical trial recorded none. [SEP] Clinical Trial: NCT00404066",Entailment,0.85828024,0.1417198
NCT00569166,"Statement: in the primary clinical trial, cohort 2 follows a different instructional method for paced breathing that is not a cd and practices only once a day. [SEP] Clinical Trial: NCT00569166",Entailment,0.6402018,0.35979822
NCT01194440,"Statement: Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial. tsqm version 1.4 questionnaire question is a question associated with the tsqm version 1.4 questionnaire. [SEP] Clinical Trial: NCT01194440",Contradiction,0.49478263,0.5052174
NCT02413008,Statement: the secondary trial and the primary trial use different outcome measurements and units of measure. fetal hypoxemia is abnormally low arterial blood oxygen concentration in a fetus. [SEP] Clinical Trial: NCT02413008,Entailment,0.7876637,0.21233633
NCT01468675,"Statement: no form of counselling, risk assessment, or cognitive behavioural therapy (cbt) is given as part of the interventions in either cohort of the primary clinical trial. [SEP] Clinical Trial: NCT01468675",Entailment,0.84449273,0.1555073
NCT00104650,"Statement: the primary clinical trial offers various medication types, each with their own unique administration route. [SEP] Clinical Trial: NCT00104650",Entailment,0.73711085,0.26288918
NCT01631552,Statement: primary clinical trial and secondary clinical trial don't share the same outcome assessments. [SEP] Clinical Trial: NCT01631552,Entailment,0.92873424,0.07126579
NCT01013740,Statement: Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome. macroscopic findings evaluator is a person who determines the significance of a macroscopic findings assessment. [SEP] Clinical Trial: NCT01013740,Contradiction,0.16886367,0.8311363
NCT00143390,Statement: there was a complete absence of both gastro-intestinal adverse events and psychiatric events in the primary clinical trial [SEP] Clinical Trial: NCT00143390,Entailment,0.78952885,0.21047121
NCT00795769,Statement: the primary trial noted a higher incidence of adverse events than the secondary trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.86522704,0.134773
NCT00372424,"Statement: in the primary clinical trial, the incidence of treatment-emergent adverse events was practically nonexistent among patients undergoing the sunitinib + docetaxel + trastuzumab treatment. [SEP] Clinical Trial: NCT00372424",Entailment,0.73077387,0.2692261
NCT01023477,"Statement: Hypokalemic patients are excluded from the primary trial, but hyperkalemic patients may be eligible for the secondary trial and the primary trial. patellar tendon is a fibrous band extending from the distal end of the quadriceps femoris to the top of the patella. [SEP] Clinical Trial: NCT01023477",Contradiction,0.2833491,0.7166509
NCT01554371,Statement: individuals who use tobacco products can partake in the secondary clinical trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.6142718,0.3857282
NCT00293540,"Statement: on average patients from the primary trial survive less than 1 year, over 120 patients from each cohort survived more than 12 months [SEP] Clinical Trial: NCT00293540",Contradiction,0.1874379,0.81256205
NCT01997333,Statement: the participant with the highest pfs in the primary clinical trial was able to survive for 3.5 months without progression of disease or death. [SEP] Clinical Trial: NCT01997333,Entailment,0.5171818,0.4828182
NCT00583700,Statement: women aged 18 or older are eligible for the secondary trial and the primary trial [SEP] Clinical Trial: NCT00583700,Contradiction,0.28889963,0.7111004
NCT02550795,"Statement: decreased bone tissue is a decrease in the amount of bone tissue as compared to a standard or norm. Group 2 of the primary trial recieves 0.5ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. [SEP] Clinical Trial: NCT02550795",Entailment,0.6791667,0.32083327
NCT00321464,"Statement: haq-di questionnaire question is a question associated with the haq-di questionnaire. Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.46497625,0.5350237
NCT01439282,"Statement: the primary clinical trial strictly accommodates participation from females, whereas the secondary clinical trial only permits the participation of males. [SEP] Clinical Trial: NCT01439282",Entailment,0.5603972,0.43960276
NCT00266110,Statement: participants in the primary clinical trial would be required to take multiple injections [SEP] Clinical Trial: NCT00266110,Entailment,0.5592153,0.4407847
NCT00322374,"Statement: in order to be eligible for the primary clinical trial, a participant must have a bodyweight within the range of 50-100kgs [SEP] Clinical Trial: NCT00322374",Contradiction,0.38305572,0.6169443
NCT02891681,Statement: patients with a healthy body mass index and are in post childbearing years may be eligible for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT02891681,Contradiction,0.2295929,0.77040714
NCT01222390,Statement: x-ray imaging is a fundamental part of the interventions provided in the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01222390,Contradiction,0.29334426,0.7066557
NCT00454532,Statement: Most patients in the secondary trial and the primary trial did not suffer any adverse events. network is an interconnected system of things or people. [SEP] Clinical Trial: NCT00454532,Contradiction,0.3444696,0.65553045
NCT00587964,"Statement: in the primary clinical trial, adverse events are mainly not related to symptoms [SEP] Clinical Trial: NCT00587964",Entailment,0.89444816,0.10555186
NCT00971945,"Statement: while entry into the secondary clinical trial requires adherence to specific performance status conditions, such conditions are not imposed on candidates for the primary clinical trial [SEP] Clinical Trial: NCT00971945",Entailment,0.83778524,0.16221471
NCT02413008,"Statement: sitalidone is a benzenesulfonamide-based agent with salidiuretic and antihypertensive effects. the secondary trial and the primary trial use the same outcome measurement; the proportion of patients with pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy. [SEP] Clinical Trial: NCT02413008",Contradiction,0.28370333,0.71629673
NCT01527487,Statement: cohort 1 of the primary clinical trial receives lower doses of cyclophosphamide than eribulin. [SEP] Clinical Trial: NCT01527487,Entailment,0.7291739,0.2708261
NCT00686127,Statement: There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00686127,Entailment,0.7312915,0.2687085
NCT01614210,Statement: results from the primary trial show that tamoxifen 25 mg po daily for 10 days prior to surgery and for 20 days after breast cancer surgery increases ki67 expression in tumors by 200% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.2502156,0.7497844
NCT01806259,Statement: the ketorolac 30 mg group of the primary trial had a -16.4% recurrence-free survival compared to the nacl 19% 3ml group [SEP] Clinical Trial: NCT01806259,Entailment,0.51669306,0.48330694
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 1.5 hectograms of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.3924056,0.6075944
NCT02807844,"Statement: all patients in the primary trial receive at least 30mg of mcs110 every 4 weeks, and over 160 mg of pdr001 every other week. [SEP] Clinical Trial: NCT02807844",Contradiction,0.37271717,0.6272828
NCT01156987,"Statement: None of the participants in group 1 of the primary trial were found to have lesions, and more than 90% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. t(1;22)(q23;q12) is a chromosomal translocation involving the pbx1 gene at 1q23 and the ewsr1 gene at 22q12. [SEP] Clinical Trial: NCT01156987",Contradiction,0.32604176,0.6739582
NCT02441946,"Statement: patients with a tnbc tumor of 1 decimeter in diameter, are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.38306394,0.6169361
NCT02259114,"Statement: individuals with fluorescent in situ hybridization-confirmed nut midline carcinoma, castrate-resistant prostate cancer, or inflammatory breast cancer can enroll in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT02259114",Contradiction,0.3784187,0.6215813
NCT00791037,"Statement: in their results, the primary clinical trial and the secondary clinical trial consider distinct patient characteristics. [SEP] Clinical Trial: NCT00791037",Entailment,0.854471,0.14552893
NCT00416715,"Statement: weekly subcutaneous injections are designed for those enrolled in the secondary clinical trial, while this procedure is not an inclusion criteria for primary clinical trial participants. [SEP] Clinical Trial: NCT00416715",Entailment,0.9129928,0.0870072
NCT03346161,Statement: the number of patients undergoing adverse events was four more in the first cohort than in the second cohort of the primary clinical trial [SEP] Clinical Trial: NCT03346161,Entailment,0.5954801,0.40451986
NCT01419717,"Statement: the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid. beta streptococcus group f is a non-taxonomic grouping of beta hemolytic species within the streptococcus genus that are assigned to the f group. [SEP] Clinical Trial: NCT01419717",Contradiction,0.45990828,0.54009175
NCT01252290,Statement: sellar chordoma is a chordoma that arises from the sellar region. less than 5% of patients in the primary trial suffered Aes. [SEP] Clinical Trial: NCT01252290,Entailment,0.7715178,0.22848219
NCT00313170,Statement: participants in the primary clinical trial must have colorectal cancer and be under immunotherapy. [SEP] Clinical Trial: NCT00313170,Contradiction,0.38224074,0.6177592
NCT02796755,Statement: the secondary clinical trial had a higher incidence of adverse events compared to the primary clinical trial. [SEP] Clinical Trial: NCT02796755,Entailment,0.8779997,0.12200024
NCT00262834,"Statement: 50 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 20% of patients, apart from skin infections [SEP] Clinical Trial: NCT00262834",Contradiction,0.41327685,0.5867232
NCT00756717,Statement: calr gene mutation is a change in the nucleotide sequence of the calr gene. There were 0 adverse events in the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00756717,Entailment,0.527952,0.47204798
NCT00753415,"Statement: Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle. [SEP] Clinical Trial: NCT00753415",Contradiction,0.3665015,0.6334985
NCT01617668,"Statement: t(1;13) is a cytogenetic abnormality that involves a translocation between chromosomes 1 and 13. Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2. [SEP] Clinical Trial: NCT01617668",Entailment,0.5604781,0.4395219
NCT00146172,Statement: candidates Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours are eligible for both the primary trial and the secondary trial. blinatumomab regimen is an immunotherapy regimen consisting of blinatumomab that may be used in the treatment of acute lymphoblastic leukemia (all). [SEP] Clinical Trial: NCT00146172,Contradiction,0.33395126,0.6660487
NCT01617668,"Statement: Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2. rolfing is a therapy designed to realign the body with gravity through fascial manipulation. (taber's) [SEP] Clinical Trial: NCT01617668",Entailment,0.6439863,0.35601366
NCT02404441,"Statement: the primary trial has a uniform set of inclusion/exclusion criteria for all participants, whereas the secondary trial segregates its criteria into two age groups: 20-40 and 40+. [SEP] Clinical Trial: NCT02404441",Contradiction,0.4062837,0.59371626
NCT01434342,"Statement: mucositis oral, bladder infection, and thromboembolic events were seen more often in the secondary clinical trial than they were in the primary clinical trial [SEP] Clinical Trial: NCT01434342",Entailment,0.5981733,0.4018267
NCT01037790,Statement: severe pain or discomfort that prevented most activities is a response indicating that an individual has or had severe pain or discomfort that prevented most activities. There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation . [SEP] Clinical Trial: NCT01037790,Entailment,0.54117197,0.458828
NCT00321048,"Statement: Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan. cutaneous schwannoma is a benign schwannoma occurring in the skin. [SEP] Clinical Trial: NCT00321048",Contradiction,0.32277188,0.6772281
NCT02413008,Statement: the primary and secondary clinical trials use the same parameters to gauge the outcomes and employ the same metric units. [SEP] Clinical Trial: NCT02413008,Contradiction,0.39466268,0.6053373
NCT01286168,"Statement: anaemia was encountered as a frequent adverse incident in the secondary trial affecting more than 5% of patients, however, no such incidents have been identified in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.7644843,0.23551568
NCT01649271,"Statement: across the patient cohorts of both the primary and secondary clinical trials, there were three cases of shingles reported. [SEP] Clinical Trial: NCT01649271",Contradiction,0.3137757,0.68622434
NCT01869192,"Statement: according to the findings of the primary clinical trial, the overall response rate for the arm a intervention outperforms that of the placebo group. furthermore, in the secondary clinical trial, the denosumab cohort showed a better time to first on-study sre than the zoledronic acid cohort. [SEP] Clinical Trial: NCT01869192",Entailment,0.5344835,0.46551654
NCT00373256,"Statement: within the primary clinical trial, cohorts 1 and 2 are differentiated by the medication administered; cohort 1 receives 25 mg to 37.5 mg of sunitinib daily, while cohort 2 is given 10 mg/kg of bevacizumab [SEP] Clinical Trial: NCT00373256",Contradiction,0.47123772,0.5287623
NCT03202472,"Statement: Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial, unless they have non-healing surgical wounds. have easy access to the medical specialists i need is a question about whether an individual feels they have easy access to the medical specialists they need. [SEP] Clinical Trial: NCT03202472",Contradiction,0.4304528,0.56954724
NCT02038218,Statement: the outcome measurement for both the primary clinical trial and the secondary clinical trial incorporate distinct units. [SEP] Clinical Trial: NCT02038218,Entailment,0.88768995,0.11231007
NCT01301729,Statement: her2+ patients in the primary clinical trial and those in cohort 2 of the secondary clinical trial receive an equal dosage of trastuzumab throughout the entire trial period. [SEP] Clinical Trial: NCT01301729,Contradiction,0.46471217,0.53528786
NCT00709761,"Statement: in the primary clinical trial, more than half of the patients who underwent treatment with 1000mg lapatinib and nab-paclitaxel recorded a confirmed complete response (cr). [SEP] Clinical Trial: NCT00709761",Contradiction,0.33220774,0.6677923
NCT00709761,Statement: over 9/10 patients in the primary trial treated with lapatinib 0.25 mg + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr). [SEP] Clinical Trial: NCT00709761,Contradiction,0.41969708,0.58030295
NCT00992602,"Statement: a comparison between adverse events in the primary clinical trial and the secondary clinical trial is challenging, given the apparent absence of such events from the records of the primary clinical trial. [SEP] Clinical Trial: NCT00992602",Entailment,0.80275357,0.19724637
NCT01881230,Statement: different cohorts of the primary clinical trial are prescribed varying doses of abraxane [SEP] Clinical Trial: NCT01881230,Entailment,0.77285326,0.22714676
NCT00795769,"Statement: Far more patients in the secondary trial were recorded to have experienced Chest Pain, than patients in the primary trial. [SEP] Clinical Trial: NCT00795769",Entailment,0.51446986,0.48553014
NCT00416715,"Statement: Candidates for the secondary trial study group receive 3 weekly subcutaneous (SC) injections, whereas the primary trial participants only receive a single injection at the beginning of the study. [SEP] Clinical Trial: NCT00416715",Entailment,0.6498264,0.35017353
NCT01222390,"Statement: There are no X-rays, ultrasound, CT scans or MRIs included the interventions of the primary trial and the secondary trial [SEP] Clinical Trial: NCT01222390",Contradiction,0.34460887,0.65539116
NCT00270894,Statement: participants in the primary trial receive 4 different drugs throughout the study duration. [SEP] Clinical Trial: NCT00270894,Entailment,0.8615532,0.13844687
NCT00623831,Statement: orbit capillary hemangioma is a capillary hemangioma arising from the orbit. 25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression  . [SEP] Clinical Trial: NCT00623831,Contradiction,0.3187541,0.6812459
NCT01823991,Statement: the primary clinical trial accepts individuals suffering from vascular dementia [SEP] Clinical Trial: NCT01823991,Entailment,0.5870622,0.41293785
NCT00266110,Statement: participants in the primary clinical trial will be given a series of injections throughout the study duration. [SEP] Clinical Trial: NCT00266110,Entailment,0.5992136,0.40078643
NCT01252290,"Statement: in the primary clinical trial, less than 5% of the participants experienced adverse events [SEP] Clinical Trial: NCT01252290",Entailment,0.8849849,0.11501513
NCT00659373,"Statement: in the primary clinical trial, the cognitive function of both cohorts, on average, experienced a decline; although this was not consistent among all patients [SEP] Clinical Trial: NCT00659373",Entailment,0.6621217,0.33787826
NCT02988986,Statement: after 30 days of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 10% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Entailment,0.539327,0.46067297
NCT01250379,"Statement: a young girl with a Newly diagnosed PR-positive, HER2 positive breast cancer, could be eligible for the secondary trial and the primary trial. substance is any matter of defined composition that has discrete existence, whose origin may be biological, mineral or chemical. [SEP] Clinical Trial: NCT01250379",Contradiction,0.25870746,0.7412925
NCT00209092,"Statement: despite a patient potentially fulfilling all exclusion and inclusion conditions of the primary clinical trial, the ultimate verdict on their inclusion lies in the hands of the medical professionals running the trial. [SEP] Clinical Trial: NCT00209092",Entailment,0.66376907,0.33623093
NCT00075764,"Statement: thoracic surgery is a branch of medicine dealing with the use of surgery to treat diseases of the chest and lungs. Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial. [SEP] Clinical Trial: NCT00075764",Contradiction,0.30319393,0.6968061
NCT02187783,"Statement: More Palpitations, Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.43556726,0.56443274
NCT02002533,Statement: the primary trial and the secondary trial have 0.0 recorded adverse events. [SEP] Clinical Trial: NCT02002533,Entailment,0.81406695,0.18593302
NCT00686127,"Statement: the total adverse events in the primary trial exceed those in the secondary trial, but there are fewer cases of cardiac-ischemia/infarction in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT00686127",Entailment,0.5877382,0.41226178
NCT00709761,Statement: over 67% patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) . [SEP] Clinical Trial: NCT00709761,Contradiction,0.37274078,0.62725925
NCT01766102,"Statement: Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore Intra-operative Mammography performed better than the Standard Mammography in this regard. In the secondary trial there is no control group against which we can compare. illusion is a misperception of a real external stimulus. [SEP] Clinical Trial: NCT01766102",Entailment,0.61213577,0.3878642
NCT00262834,Statement: 12 adverse events were observed in the course of the primary clinical trial [SEP] Clinical Trial: NCT00262834,Entailment,0.80770236,0.19229756
NCT00662025,"Statement: some of the patients in the primary clinical trial did not receive sunitinib every day, for the entire duration of the study. [SEP] Clinical Trial: NCT00662025",Entailment,0.75475246,0.24524751
NCT02734979,Statement: patients with a past record of pulmonary embolism and currently having breast implants are excluded from both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02734979,Entailment,0.80196494,0.19803505
NCT00122369,"Statement: 18 years olds are excluded from the secondary trial, but the primary trial does not specify an age range for participation. rhabdoid indicator is an indication of whether rhabdoid cells or features are present in a sample. [SEP] Clinical Trial: NCT00122369",Entailment,0.6675834,0.3324166
NCT00706030,"Statement: only three kinds of adverse events impacted patients participating in the primary clinical trial: pancreatitis, cholelithiasis, hepatic pain and febrile neutropenia [SEP] Clinical Trial: NCT00706030",Contradiction,0.45562226,0.54437774
NCT01290536,"Statement: the the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 0.56 g of ibrutinib and 0.01 kg/kg of medi4736 twice daily for 30 days. [SEP] Clinical Trial: NCT01290536",Contradiction,0.35776123,0.64223874
NCT01831089,Statement: a confirmed diagnosis of pancreatic cancer is required for eligibility in the primary clinical trial [SEP] Clinical Trial: NCT01831089,Entailment,0.7614537,0.23854634
NCT00544167,"Statement: patients that have suffered a pulmonary embolism in the last 5 days are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.73037124,0.26962876
NCT03202472,"Statement: individuals who have engaged in chemotherapy or radiotherapy within the preceding two weeks, those who have unstable angina or those with neuropathy not exceeding grade 2 are permitted to join the secondary trial, but are barred from the primary trial if they possess non-healing surgical wounds. [SEP] Clinical Trial: NCT03202472",Contradiction,0.42895174,0.5710482
NCT00978250,"Statement: individual is a single human being. Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both. [SEP] Clinical Trial: NCT00978250",Contradiction,0.38801864,0.6119814
NCT02259114,"Statement: patients with follicular thyroid carcinoma confirmed by thin-prep cytology, or postmastectomy lymphedema are excluded from both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02259114",Entailment,0.6811607,0.31883928
NCT01286987,"Statement: in the primary clinical trial, the intervention administered to patients with breast cancer and ovarian/ peritoneal cancer is uniform. [SEP] Clinical Trial: NCT01286987",Entailment,0.59799,0.40201
NCT00253708,"Statement: the primary trial does not test any drug based treatments, whereas the secondary trial tests different doses of one drug based-treatment. t(2;22)(q34;q12) is a chromosomal translocation involving the creb1 gene at 2q34 and the ewsr1 gene at 22q12. [SEP] Clinical Trial: NCT00253708",Entailment,0.81586766,0.18413228
NCT01286987,Statement: Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention. [SEP] Clinical Trial: NCT01286987,Entailment,0.6875036,0.3124964
NCT02807844,"Statement: all patients in the primary trial receive at least 90mg of mcs110 every 2 weeks, and over 180 mg of pdr001 every other week. [SEP] Clinical Trial: NCT02807844",Contradiction,0.36733833,0.6326617
NCT01138046,Statement: only nationals from the united kingdom can join the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT01138046,Contradiction,0.31593966,0.68406034
NCT04080297,"Statement: the guidelines to be part of the primary and secondary clinical trials are congruent. hence, any patients currently enrolled in the secondary clinical trial qualify for the primary clinical trial as well [SEP] Clinical Trial: NCT04080297",Contradiction,0.37837902,0.62162095
NCT01306032,Statement: thromboembolic events were not observed in either the primary or secondary trial patients. [SEP] Clinical Trial: NCT01306032,Entailment,0.90578854,0.09421148
NCT00293540,"Statement: on average patients from the primary trial survive over 730 days, over 50 patients from each cohort survived more than 24 months [SEP] Clinical Trial: NCT00293540",Contradiction,0.20142013,0.7985799
NCT00709761,Statement: a majority of the patients in the primary clinical trial experienced a confirmed complete response (cr) after undergoing treatment with lapatinib 1000mg and nab-paclitaxel. [SEP] Clinical Trial: NCT00709761,Contradiction,0.3379609,0.66203916
NCT02002533,Statement: difficulty paying attention to things is a question about whether an individual has difficulty paying attention to things. the primary trial and the secondary trial have 0 recorded adverse events. [SEP] Clinical Trial: NCT02002533,Entailment,0.80743694,0.19256307
NCT01706081,Statement: patients using testosterone cream in the primary trial showed superior results in managing their lymphedema than those undergoing acupuncture treatment. [SEP] Clinical Trial: NCT01706081,Entailment,0.5343274,0.4656726
NCT01527487,Statement: cohort 1 in the primary clinical trial is subject to higher eribulin doses in comparison to the docetaxel doses given to cohort 2. [SEP] Clinical Trial: NCT01527487,Entailment,0.72771674,0.2722833
NCT00454532,Statement: most participants in both the primary clinical trial and the secondary clinical trial experienced no adverse effects [SEP] Clinical Trial: NCT00454532,Entailment,0.8504704,0.14952959
NCT01770353,"Statement: non-nodal regional disease indicator is an indication of whether a subject has non-nodal regional disease. the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs. [SEP] Clinical Trial: NCT01770353",Contradiction,0.25950065,0.7404994
NCT00256217,Statement: fgfr2 gene mutation negative is a genetic finding indicating that fgfr2 gene mutations have not been detected in a sample. There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs. [SEP] Clinical Trial: NCT00256217,Entailment,0.5305477,0.4694523
NCT00623831,Statement: glisolamide is a second-generation sulfonylurea with antihyperglycemic activity. glisolamide is comparable to glyburide and gliquidone in controlling blood glucose levels. 25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression  . [SEP] Clinical Trial: NCT00623831,Contradiction,0.40918013,0.59081984
NCT00756496,"Statement: the primary clinical trial did not yield any significant differing outcomes across groups, and the reflexology group in the secondary clinical trial showed the same results as their control group. [SEP] Clinical Trial: NCT00756496",Entailment,0.8166422,0.18335775
NCT00370552,"Statement: Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements. do not receive appropriate pay increases, promotions, or recognition at work is a question about whether an individual does or did not receive appropriate pay increases, promotions, or recognition at work. [SEP] Clinical Trial: NCT00370552",Contradiction,0.45153552,0.5484645
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150 milligrams of oral pregabalin every two weeks over 6 weeks, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.41704237,0.58295757
NCT01743560,Statement: children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial. biological mother is a female who contributes to the genetic makeup of her offspring from the fertilization of her ovum. [SEP] Clinical Trial: NCT01743560,Contradiction,0.4886173,0.5113827
NCT01706081,Statement: the primary clinical trial showed no difference in the improvement rate of lymphedema between acupuncture patients and those on the waiting list. [SEP] Clinical Trial: NCT01706081,Entailment,0.82434183,0.17565814
NCT00322374,"Statement: There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial . caspase-3 staining method is an immunohistochemical technique used to detect the presence of caspase-3 in a tissue sample. [SEP] Clinical Trial: NCT00322374",Contradiction,0.45007372,0.54992634
NCT01569087,"Statement: patients diagnosed with stage 4 cancer may participate in both the primary clinical trial and the secondary clinical trial, provided they give informed consent. [SEP] Clinical Trial: NCT01569087",Contradiction,0.4385519,0.5614481
NCT00843167,"Statement: contrasting the primary clinical trial that analyses the variation in urinary isothiocyanate concentration due to sulforaphane supplements, the secondary clinical trial measures the success of physical therapy through the assessment of pain. [SEP] Clinical Trial: NCT00843167",Contradiction,0.44821218,0.55178785
NCT00118157,Statement: the primary clinical trial involves patients taking oral medicine on a twice daily schedule for the duration of one month. [SEP] Clinical Trial: NCT00118157,Contradiction,0.49487257,0.50512743
NCT02179515,Statement: cohort 1 of the primary clinical trial was completely free of any adverse events [SEP] Clinical Trial: NCT02179515,Entailment,0.87565047,0.12434952
NCT00001832,Statement: sometimes true is a subjective response indicating that something is sometime true. The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4-Demethyl-4-cholestryloxycarbonylpenclomedine. [SEP] Clinical Trial: NCT00001832,Contradiction,0.18028487,0.81971514
NCT01086605,"Statement: in the primary clinical trial, no incidents of hypertension, edema, and dyspnea were observed in both cohorts. [SEP] Clinical Trial: NCT01086605",Entailment,0.6116989,0.38830107
NCT01419717,"Statement: the primary trial requires patients to receive 120,000 micrograms of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 14.4 to 36.0 gbq of radioactive tc99m sulfur colloid. [SEP] Clinical Trial: NCT01419717",Contradiction,0.36960596,0.63039404
NCT00454532,Statement: foot/footpad is a laboratory specimen consisting of the foot and footpad. Most patients in the secondary trial and the primary trial did not suffer any adverse events. [SEP] Clinical Trial: NCT00454532,Entailment,0.55837697,0.441623
NCT00659373,"Statement: both cohorts involved in the primary trial demonstrated an average decline in cognitive function, although this was not the circumstance for all individuals [SEP] Clinical Trial: NCT00659373",Entailment,0.73380375,0.2661963
NCT00586326,Statement: the intervention section of the primary clinical trial provides a comprehensive treatment cycle and detailed description of the treatment. [SEP] Clinical Trial: NCT00586326,Entailment,0.6103273,0.38967267
NCT00587964,Statement: General symptoms are the most common AE recorded in the primary trial. eligibility for lung surgery is a question pertaining to patient's eligibility to undergo a lung surgery. [SEP] Clinical Trial: NCT00587964,Entailment,0.51864636,0.48135364
NCT00321464,"Statement: both the primary clinical trial and the secondary clinical trial allow the enrollment of patients with confirmed histological diagnosis of stage 4 breast adenocarcinoma having either er positivity, pr positivity or her2/neu negativity. [SEP] Clinical Trial: NCT00321464",Contradiction,0.36052987,0.6394701
NCT02550795,"Statement: in group 2 of the primary trial, patients are administered a 2mg/kg dosage of dexmedetomidine, while patients in the secondary trial are given 1mg/kg. [SEP] Clinical Trial: NCT02550795",Entailment,0.5147397,0.48526034
NCT01989546,Statement: cbt based treatments are a primary requirement for participation in the primary clinical trial and are fully permissible in the secondary clinical trial. [SEP] Clinical Trial: NCT01989546,Entailment,0.58100665,0.41899338
NCT01314963,"Statement: The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP. [SEP] Clinical Trial: NCT01314963",Contradiction,0.42696464,0.57303536
NCT01178411,"Statement: neither the primary clinical trial nor the secondary clinical trial restricts participation based on a patient's nationality, ethnicity, weight, or gender [SEP] Clinical Trial: NCT01178411",Contradiction,0.49629807,0.5037019
NCT00404066,"Statement: hop-62 is an adenocarcinoma cell line established from lung carcinoma tissue removed from a 60 year old female. The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain, no aes wererecorded in the primary trial. [SEP] Clinical Trial: NCT00404066",Entailment,0.58630115,0.41369885
NCT01434342,"Statement: a higher number of mucositis oral cases, epileptic seizures, and thromboembolic events were seen in the primary trial than in the secondary trial [SEP] Clinical Trial: NCT01434342",Contradiction,0.47543958,0.5245604
NCT02988986,Statement: the percentage of cells expressing ki67 increased by 8% after treatment with tak-228 plus tamoxifen in the primary clinical trial. [SEP] Clinical Trial: NCT02988986,Contradiction,0.46428913,0.5357108
NCT02807844,"Statement: all patients in the primary trial receive at least 0.02g of mcs110 every 21 days, and over 0.13g of pdr001 every fortnight. [SEP] Clinical Trial: NCT02807844",Contradiction,0.3709496,0.62905043
NCT00587964,Statement: age at initial pathologic diagnosis is a question about the age of the individual at the time of the initial pathologic diagnosis. Coronary artery stenosis are the most common AE recorded in the primary trial. [SEP] Clinical Trial: NCT00587964,Contradiction,0.49529436,0.5047056
NCT00370552,"Statement: Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period . radiation-induced malignant peripheral nerve sheath tumor is a malignant peripheral nerve sheath tumor that is the result of exposure to ionizing radiation. [SEP] Clinical Trial: NCT00370552",Entailment,0.50226855,0.49773142
NCT01313117,"Statement: Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. cyld gene mutation is a change in the nucleotide sequence of the cyld gene. [SEP] Clinical Trial: NCT01313117",Entailment,0.5609405,0.43905956
NCT01111825,Statement: neratinib is an essential part of the primary clinical trial regimen [SEP] Clinical Trial: NCT01111825,Entailment,0.76781386,0.23218617
NCT01194440,Statement: only patients with invasive lobular carcinoma under going chemotherapy are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01194440,Contradiction,0.4915654,0.50843465
NCT00475085,Statement: there are 2 less participants in cohort 2 of the primary clinical trial than in cohort 1 [SEP] Clinical Trial: NCT00475085,Entailment,0.54347986,0.45652014
NCT01535040,"Statement: no exacerbating factor to chief complaint is an indication that the chief complaint was not worsened by another factor. In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily. [SEP] Clinical Trial: NCT01535040",Entailment,0.59099317,0.40900683
NCT00656019,Statement: the examined genes displayed a discernible expression trend in the primary clinical trial's first and second patient cohorts. [SEP] Clinical Trial: NCT00656019,Entailment,0.541912,0.458088
NCT01086605,"Statement: control type code is a coded value specifying the kind of comparison or comparator against which another entity is evaluated. there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial. [SEP] Clinical Trial: NCT01086605",Entailment,0.6285269,0.37147304
NCT01569087,Statement: informed consent will allow patients who are in stage 4 of cancer to be eligible for the secondary clinical trial as well as the primary clinical trial. [SEP] Clinical Trial: NCT01569087,Contradiction,0.4301244,0.56987566
NCT01256567,"Statement: optic chiasm neoplasm is a benign or malignant neoplasm that affects the optic chiasm. a patient that has received an organ transplant within the last month, would be excluded from the primary trial but may be eligible for the secondary trial. [SEP] Clinical Trial: NCT01256567",Contradiction,0.48776242,0.5122376
NCT01908101,Statement: the primary trial patients receive higher doses of radiation therapy than the secondary trial participants. anaplasia indicator is a indication of whether anaplasia was found in a sample. [SEP] Clinical Trial: NCT01908101,Entailment,0.55560356,0.44439647
NCT00819182,"Statement: enterovirus is a (+) strand single strand rna virus of the picornavirus family.  poliovirus is an enterovirus. the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Contradiction,0.46560788,0.5343922
NCT03557801,"Statement: concern about finances is a question about whether an individual has or had concerns about finances. the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.3902486,0.6097514
NCT01045421,Statement: only patients with metastatic or advanced hematological malignancies are fit to participate in phase 1 of the primary clinical trial and for all cohorts of the secondary clinical trial [SEP] Clinical Trial: NCT01045421,Contradiction,0.44280154,0.5571985
NCT02509156,Statement: tcirg1 gene mutation is a change in the nucleotide sequence of the tcirg1 gene. The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection. [SEP] Clinical Trial: NCT02509156,Contradiction,0.3739794,0.62602055
NCT02222922,"Statement: none of the primary trial participants receive doses of alt-801, whereas all secondary trial participants do. [SEP] Clinical Trial: NCT02222922",Entailment,0.862952,0.13704798
NCT02234479,"Statement: the focus of the primary trial is to analyze the effects of different types of pills on its test subjects, while the secondary trial tests the results of varying quantities of the same gel treatment on its group. [SEP] Clinical Trial: NCT02234479",Entailment,0.5604407,0.43955928
NCT00918281,"Statement: in the primary clinical trial, the first cohort is treated with an intraosseous injection of fluciclatide, while in the secondary clinical trial, the first cohort is given a customary iv dose of chloroquine. [SEP] Clinical Trial: NCT00918281",Entailment,0.5028416,0.4971584
NCT01766102,"Statement: in the primary clinical trial, the operative time of arm 1 was lower than that of arm 2, demonstrating the effectiveness of standard mammography compared to intra-operative mammography. there is a control group in the secondary clinical trial for comparison.' [SEP] Clinical Trial: NCT01766102",Entailment,0.6437139,0.35628608
NCT01881230,"Statement: in the primary clinical trial, both cohorts are administered identical doses of abraxane [SEP] Clinical Trial: NCT01881230",Entailment,0.77319795,0.22680204
NCT00118157,Statement: patients participating in the primary trial receive 200mg/m2 oral lapatinib once a day for a full month. [SEP] Clinical Trial: NCT00118157,Contradiction,0.4278932,0.57210684
NCT02988986,Statement: Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression   [SEP] Clinical Trial: NCT02988986,Entailment,0.59169704,0.40830302
NCT00513292,"Statement: pcr serves as the outcome metric in both the primary and secondary clinical trials. a minor discrepancy in results is seen between the two cohorts within the primary clinical trial. conversely, arm 2 outperformed arm 1 in the secondary clinical trial significantly. [SEP] Clinical Trial: NCT00513292",Contradiction,0.37167907,0.62832093
NCT00693719,Statement: the primary clinical trial is open to individuals suffering from leptomeningeal carcinoma [SEP] Clinical Trial: NCT00693719,Entailment,0.6918652,0.30813476
NCT01631552,"Statement: birc5 antibody is any immunoglobulin that recognizes baculoviral iap repeat-containing protein 5. the secondary trial and the primary trial have completely unrelated outcome measurements, but the same interventions. [SEP] Clinical Trial: NCT01631552",Entailment,0.537014,0.46298602
NCT02104830,"Statement: patients in cohort 2 of the primary trial reported higher rates of neutropenia as compared to patients in cohort 1 of the secondary trial, both groups receiving the same doses of empegfilgrastim. [SEP] Clinical Trial: NCT02104830",Entailment,0.5358272,0.46417278
NCT00878709,Statement: each group in the primary clinical trial had an equal number of participants. [SEP] Clinical Trial: NCT00878709,Entailment,0.90435207,0.09564792
NCT00270894,"Statement: parotid gland hemangioma is a hemangioma arising from the parotid gland. participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2. [SEP] Clinical Trial: NCT00270894",Contradiction,0.34379035,0.65620965
NCT01037790,"Statement: the primary clinical trial is unrestricted in the number of participants and is appropriate for individuals with ovarian cancer, irrespective of their kras or braf mutation status. [SEP] Clinical Trial: NCT01037790",Entailment,0.628301,0.37169892
NCT00999921,"Statement: patients having unregulated high blood pressure along with malignant ductal carcinoma in situ are eligible for the secondary clinical trial, but their participation in the primary clinical trial is excluded. [SEP] Clinical Trial: NCT00999921",Entailment,0.76945686,0.2305431
NCT03202472,"Statement: patients who have received chemotherapy or radiotherapy in the last 2 weeks, are dealing with unstable angina, or have grade 2 or above neuropathy are eligible to participate in the secondary clinical trial and excluded from the primary clinical trial. [SEP] Clinical Trial: NCT03202472",Entailment,0.632937,0.367063
NCT02041429,"Statement: the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 15000 mcg per day [SEP] Clinical Trial: NCT02041429",Contradiction,0.23700057,0.7629994
NCT00357734,"Statement: The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim. [SEP] Clinical Trial: NCT00357734",Entailment,0.51385486,0.48614514
NCT00706030,Statement: no adverse events were reported in primary clinical trial among any of the cohorts [SEP] Clinical Trial: NCT00706030,Entailment,0.88568014,0.1143198
NCT00656019,Statement: the expression pattern of the selected 40 genes was absolutely visible among the participants in both the first and second cohorts of the primary clinical trial [SEP] Clinical Trial: NCT00656019,Contradiction,0.4391671,0.56083286
NCT00838929,Statement: every patient in the primary trial is receives a dose of 100000 to 1600000 nanogram fentanyl sublingual spray during radiation therapy [SEP] Clinical Trial: NCT00838929,Entailment,0.51884055,0.48115948
NCT00357734,"Statement: the intervention in the primary trial is multi-drug, with at least three different drugs such as irinotecan, lenograstim, and thiotepa. the intervention in the secondary trial is based on monotherapy with drug pemetrexed alone. [SEP] Clinical Trial: NCT00357734",Contradiction,0.43428105,0.56571895
NCT03015649,"Statement: in both the primary and secondary clinical trials, the adverse events recorded were of the same number. [SEP] Clinical Trial: NCT03015649",Entailment,0.8896192,0.11038084
NCT01129622,Statement: coroner is an appointed public official whose job is to identify and certify an individual's death. Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01129622,Contradiction,0.41409603,0.58590394
NCT03069313,"Statement: the primary clinical trial administers its interventions intravenously, while the secondary trial employs a subcutaneous route. [SEP] Clinical Trial: NCT03069313",Entailment,0.6009613,0.39903864
NCT00558272,Statement: the azd0530 0.175 g group of the primary trial experienced a greater reduction in primary tumour diameter than the zoledronic acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.5333202,0.46667978
NCT01967823,"Statement: during the primary clinical trial, blood bilirubin levels increased in 36.36% of the participants. [SEP] Clinical Trial: NCT01967823",Contradiction,0.27417544,0.7258246
NCT01869192,"Statement: The results from the primary trial indicate that the Arm A intervention provided the best overall response rate, additionally, in the secondary trial the Denosumab cohort had a worse Time to First On-Study SRE than the Zoledronic Acid cohort. vital signs supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the vital signs domain. [SEP] Clinical Trial: NCT01869192",Entailment,0.5520255,0.4479745
NCT01156987,"Statement: Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. forehead lift is a plastic surgery procedure in which excess skin is removed from the forehead to create a more youthful appearance. [SEP] Clinical Trial: NCT01156987",Contradiction,0.3374122,0.6625878
NCT00182767,"Statement: In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2. [SEP] Clinical Trial: NCT00182767",Entailment,0.6312786,0.3687214
NCT00104650,"Statement: the interventions in the primary clinical trial are similar in terms of the medications, but they are given through varied routes. [SEP] Clinical Trial: NCT00104650",Entailment,0.634213,0.36578703
NCT02312934,Statement: Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. multi-institutional clinical study is a clinical study that is being conducted at multiple locations. [SEP] Clinical Trial: NCT02312934,Entailment,0.55995244,0.44004753
NCT00377156,"Statement: when diagnosed with 2-3 cerebral metastases located within the brainstem, patients will be excluded from the secondary clinical trial, but they could still be considered eligible for the primary clinical trial. [SEP] Clinical Trial: NCT00377156",Entailment,0.558306,0.441694
NCT01997333,Statement: the patient with the greatest pfs in the primary clinical trial managed to survive for 6 months without any disease progression or death [SEP] Clinical Trial: NCT01997333,Entailment,0.51384795,0.48615205
NCT01314963,"Statement: grem1 gene mutation is a change in the nucleotide sequence of the grem1 gene. The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP. [SEP] Clinical Trial: NCT01314963",Entailment,0.50687045,0.49312955
NCT00558272,Statement: the azd0530 175 mg group of the primary clinical trial did not experience a significant reduction in primary tumour diameter compared to the zoledronic acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.70326936,0.29673067
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 26 weeks if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.39418116,0.6058188
NCT02041429,"Statement: the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 105 mg per week [SEP] Clinical Trial: NCT02041429",Contradiction,0.21802533,0.7819747
NCT00538850,Statement: the primary clinical trial is focused on measuring the rise in fatigue levels while the secondary trial assesses improvement in muscle strength over a span of 9 months. [SEP] Clinical Trial: NCT00538850,Contradiction,0.4678755,0.5321245
NCT01129622,Statement: experiencing the conditions of both claustrophobia and ibs disqualifies women from the primary and secondary clinical trials [SEP] Clinical Trial: NCT01129622,Contradiction,0.3180391,0.6819609
NCT01008150,Statement: more than 3/4 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 14 days of the study [SEP] Clinical Trial: NCT01008150,Contradiction,0.3819958,0.6180042
NCT02807844,Statement: every participant in the primary clinical trial is administered a minimum of 20mg of mcs110 tri-weekly. [SEP] Clinical Trial: NCT02807844,Contradiction,0.41473413,0.5852659
NCT04080297,Statement: patients involved in the primary clinical trial must adhere to unique eligibility criteria that differ from those of the secondary clinical trial [SEP] Clinical Trial: NCT04080297,Entailment,0.81085986,0.18914014
NCT00305695,"Statement: the primary clinical trial requires intervention 1 to be taken subcutaneously, while intervenional drugs in the secondary clinical trial are given topically. [SEP] Clinical Trial: NCT00305695",Entailment,0.6669689,0.33303112
NCT01008904,Statement: multiple aes were reported in the primary clinical trial including anemia and nausea. [SEP] Clinical Trial: NCT01008904,Contradiction,0.47809264,0.5219074
NCT01286168,"Statement: the most common adverse event in the secondary trial was anaemia, affecting more than 1/20 patients, there were no recorded aes in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.7123619,0.28763813
NCT00001832,Statement: The interventions in the primary trial and the secondary trial include completely different drug-based treatments. [SEP] Clinical Trial: NCT00001832,Entailment,0.9254783,0.07452178
NCT00632489,Statement: the primary trial does not report any results for the LBH589 and Lapatinib cohort. [SEP] Clinical Trial: NCT00632489,Entailment,0.9231436,0.07685637
NCT00795769,"Statement: Far more patients in the secondary trial were recorded to have experienced Aes, than patients in the primary trial. [SEP] Clinical Trial: NCT00795769",Entailment,0.5200517,0.47994825
NCT00266110,"Statement: powder dosage form is a solid composed of a mixture of dry, finely divided active and/or inert ingredient(s). Patients in the primary trial will need to receive several injections. [SEP] Clinical Trial: NCT00266110",Contradiction,0.23861507,0.7613849
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 250 mg of fulvestrant in a tablet form to be taken bid. [SEP] Clinical Trial: NCT00836186",Contradiction,0.3882167,0.6117833
NCT01011218,"Statement: within the adverse events of both the primary and secondary clinical trials, only one fatality was documented. [SEP] Clinical Trial: NCT01011218",Entailment,0.6112907,0.38870925
NCT02002533,Statement: several recorded adverse events have been associated with the secondary clinical trial. [SEP] Clinical Trial: NCT02002533,Entailment,0.857314,0.14268602
NCT00416715,"Statement: participants in the secondary trial study group do not receive any form of injections, whereas individuals in the primary trial receive daily intramuscular (im) injections. [SEP] Clinical Trial: NCT00416715",Entailment,0.7669224,0.23307756
NCT00146172,Statement: candidates with an ecog score of 4 are the only ones who can participate in the primary clinical trial and secondary clinical trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.25558034,0.74441963
NCT02504424,Statement: a patient in the primary clinical trial suffered from a reopened surgical cut following the procedure. [SEP] Clinical Trial: NCT02504424,Entailment,0.77181894,0.22818111
NCT03015649,"Statement: the primary trial showed no recorded adverse events, while the secondary trial demonstrated a number of such events within their cohorts. [SEP] Clinical Trial: NCT03015649",Entailment,0.72585183,0.27414817
NCT03125941,Statement: prednisone is administered pre-operatively to all participants in the primary clinical trial cohorts. [SEP] Clinical Trial: NCT03125941,Entailment,0.6840705,0.31592944
NCT02403271,"Statement: information question is a question about the information that an individual received, or information in general. There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial. [SEP] Clinical Trial: NCT02403271",Entailment,0.57466793,0.4253321
NCT03403712,"Statement: the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours. hybrid nerve sheath tumor is a benign nerve sheath tumor characterized by the combination of histologic features seen in schwannomas, neurofibromas, and perineuriomas. [SEP] Clinical Trial: NCT03403712",Contradiction,0.45295072,0.5470493
NCT01252290,Statement: less than 5% of patients in the primary trial suffered Aes [SEP] Clinical Trial: NCT01252290,Entailment,0.89628124,0.103718765
NCT03403712,"Statement: the primary clinical trial looks into the frequency of treatment-related adverse events in patients, while the secondary clinical trial evaluates the median minutes its patients spend asleep. [SEP] Clinical Trial: NCT03403712",Contradiction,0.48691887,0.51308113
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive intramuscular injections aswell as medication to be taken orally. neck pain score 2 is a subjective score of 2 on a visual analogue scale that ranges from 0: no pain to 10: excruciating. [SEP] Clinical Trial: NCT00836186",Contradiction,0.40425092,0.5957491
NCT00759785,Statement: 56.1% more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group [SEP] Clinical Trial: NCT00759785,Contradiction,0.47417235,0.5258277
NCT00088413,"Statement: all the adverse events recorded in the primary trial are linked to the cardiovascular system, which contrasts with the secondary trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.73186237,0.26813766
NCT00118157,Statement: Patients participating in the primary trial receive oral medication twice a day for a full month. macroamylase measurement is a measurement of macroamylase present in a sample. [SEP] Clinical Trial: NCT00118157,Entailment,0.5342132,0.46578678
NCT00706030,"Statement: Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2 [SEP] Clinical Trial: NCT00706030",Entailment,0.74049443,0.2595056
NCT00001832,Statement: encounter due to exposure to radiation is an icd encounter due to exposure to radiation. The interventions in the primary trial and the secondary trial include completely different drug-based treatments. [SEP] Clinical Trial: NCT00001832,Entailment,0.8924762,0.10752374
NCT01421472,"Statement: patients with estrogen positive, progesterone negative, and her2+ breast tumours have been accepted into the primary clinical trial [SEP] Clinical Trial: NCT01421472",Contradiction,0.46515316,0.5348468
NCT01091974,"Statement: only a selected group in the primary clinical trial receives armodafinil p.o. daily, whereas in the secondary clinical trial, every patient is provided with a fixed dose of 100 mg pdr001, and 1 mg/kg of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.43480742,0.5651925
NCT00708019,"Statement: during the 10-week duration of the primary clinical trial, several participants did not report any pain. [SEP] Clinical Trial: NCT00708019",Entailment,0.6009768,0.39902318
NCT00686127,"Statement: in the primary trial, there is a reduction in both the total number and categories of adverse events in comparison to the secondary trial. [SEP] Clinical Trial: NCT00686127",Entailment,0.7550421,0.24495788
NCT01614210,Statement: results from the primary trial show that tamoxifen 35 mg po daily for 21 days prior to surgery and for 10 days after breast cancer surgery increases ki67 expression in tumors by 85% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.26610792,0.7338921
NCT01781299,"Statement: no cases of unanticipated deaths or hospitalizations are reported in the primary clinical trial and the secondary clinical trial, besides the three reported events of lymphoma. [SEP] Clinical Trial: NCT01781299",Contradiction,0.3044807,0.69551927
NCT00513292,"Statement: for the primary and secondary clinical trials, pcr is used as their benchmark for outcome. a slight difference is noted in the results of the two cohorts participating in the primary trial. however, in the secondary trial, arm 2 achieved far superior results than arm 1 did. [SEP] Clinical Trial: NCT00513292",Contradiction,0.3449555,0.65504444
NCT00496860,Statement: cohort 1 of the primary clinical trial receives twice the dose of alt-801 compared to cohort 2. [SEP] Clinical Trial: NCT00496860,Contradiction,0.49473944,0.5052605
NCT03069313,"Statement: the primary trial administers its intervention intravenously, and the secondary trial administers it topically. [SEP] Clinical Trial: NCT03069313",Entailment,0.6529096,0.34709045
NCT00569166,"Statement: in the primary clinical trial, both the first and second cohorts utilize the same instructional guided breathing cd. nevertheless, cohort 2 has an additional regimen of twice-daily practices and weekly antineoplastic chemotherapy. [SEP] Clinical Trial: NCT00569166",Contradiction,0.4012772,0.5987228
NCT00756717,Statement: There were 0 cases of Febrile neutropenia or Cholelithiasis in the primary trial and the secondary trial [SEP] Clinical Trial: NCT00756717,Contradiction,0.47880542,0.5211946
NCT02178722,Statement: epacadostat is provided to participants of the primary clinical trial twice as frequently as sunitinib is given to sunitinib-naive patients in the secondary clinical trial. [SEP] Clinical Trial: NCT02178722,Entailment,0.51470786,0.48529217
NCT00293384,"Statement: Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril [SEP] Clinical Trial: NCT00293384",Contradiction,0.37177458,0.6282254
NCT01614210,Statement: the primary clinical trial reveals that taking tamoxifen 20 mg orally daily for a fortnight post-mastectomy has no significant effect on the ki67 expression in tumors. [SEP] Clinical Trial: NCT01614210,Entailment,0.5598198,0.4401802
NCT00662025,"Statement: dasatinib was administered intravenously once a week, to patients in cohort 2 of the primary clinical trial for the initial 28-day cycle [SEP] Clinical Trial: NCT00662025",Entailment,0.5085594,0.49144056
NCT01468675,"Statement: pharyngoconjunctival fever is a condition characterized by fever, conjunctivitis, and pharyngitis resulting from infection by adenovirus. Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions. [SEP] Clinical Trial: NCT01468675",Entailment,0.5297973,0.4702027
NCT02441946,Statement: both the primary clinical trial and the secondary clinical trial allow patients with colon cancer with tumors under 0.2 cm in size and without any specific marker status [SEP] Clinical Trial: NCT02441946,Entailment,0.615768,0.384232
NCT00253708,"Statement: no assessments related to drug treatments are performed in the primary clinical trial, whereas the secondary clinical trial performs tests on two distinct drugs. [SEP] Clinical Trial: NCT00253708",Entailment,0.8317589,0.16824107
NCT00320541,Statement: the paclitaxel plus bevacizumab plus gemcitabine group had an inferior orr to the paclitaxel plus bevacizumab group in the primary clinical trial [SEP] Clinical Trial: NCT00320541,Entailment,0.80888224,0.19111776
NCT00867217,"Statement: patients suffering from a lack of vitamin d are not considered for the primary clinical trial, yet they may qualify for the secondary clinical trial. [SEP] Clinical Trial: NCT00867217",Entailment,0.7539096,0.24609043
NCT01421472,"Statement: patients with breast cancer characterized by estrogen negative, progesterone negative, her2- tumors can be included in every cohort of the primary clinical trial [SEP] Clinical Trial: NCT01421472",Entailment,0.5166523,0.48334777
NCT00741039,"Statement: Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine. joint range of motion decreased cervical spine, ctcae is a disorder characterized by a decrease in flexibility of a cervical spine joint. [SEP] Clinical Trial: NCT00741039",Contradiction,0.43970153,0.56029844
NCT00075764,Statement: patients whose metastasis is not quantifiable or whose cancer hasn't traversed to other body sections are not suitable for the primary clinical trial [SEP] Clinical Trial: NCT00075764,Entailment,0.70752,0.29247993
NCT00365105,"Statement: A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 79000/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. gastric lymphangioma is a lymphangioma arising from the stomach. [SEP] Clinical Trial: NCT00365105",Contradiction,0.3841719,0.6158281
NCT02431676,Statement: people having extreme obesity can be accepted in the primary clinical trial [SEP] Clinical Trial: NCT02431676,Contradiction,0.48836747,0.5116325
NCT00418028,"Statement: the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the number of patients that experience Objective Response . acute physiology and chronic health evaluation ii apch114 question clinical classification standardized character response is a standardized character response associated with the acute physiology and chronic health evaluation ii apch114 clinical classification question. [SEP] Clinical Trial: NCT00418028",Contradiction,0.37541714,0.6245829
NCT01920061,"Statement: a 3 week cycle is employed in the primary clinical trial for its treatment intervention. however, the secondary clinical trial doesn't apply a cyclical treatment approach. [SEP] Clinical Trial: NCT01920061",Entailment,0.9168118,0.08318816
NCT00365105,"Statement: a 40 year old patient with bladder cancer, absolute neutrophil count of 1200/μl, platelet count of 49000/μl, hemoglobin level of 75 g/l, and a life expectancy less than 5 months would be excluded from both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Entailment,0.65438914,0.3456108
NCT00843167,"Statement: the secondary trial uses blood pressure level as a measure of effectiveness for physical therapy, whereas the primary trial studies the effect of vitamin b supplements on hemoglobin concentration in blood. [SEP] Clinical Trial: NCT00843167",Contradiction,0.4807591,0.51924086
NCT00588640,"Statement: the primary clinical trial applies distinct inclusion and exclusion parameters for each of its two phases, in contrast to the secondary clinical trial that utilizes different sets of criteria for patients in good health and those with cancer. [SEP] Clinical Trial: NCT00588640",Entailment,0.7001418,0.2998582
NCT00293540,"Statement: On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years. systolic blood pressure-for-age percentile is a measurement of an individual's systolic blood pressure in relationship to age, in comparison to a reference percentile curve. [SEP] Clinical Trial: NCT00293540",Contradiction,0.43852606,0.5614739
NCT00305695,"Statement: transmission scan is a scan to obtain data for use in making attenuation corrections.  intervention 1 in the primary trial, and all intervention drugs in the secondary trial must be administered intravenously. [SEP] Clinical Trial: NCT00305695",Contradiction,0.3743802,0.62561977
NCT00538850,"Statement: The the primary trial results report the Severity of Delayed Nausea on a scale of 1-7, and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine [SEP] Clinical Trial: NCT00538850",Contradiction,0.49110857,0.5088914
NCT02234479,"Statement: different gels are being assessed for their effects on study groups in the primary clinical trial, while the secondary clinical trial is exploring the impacts of varying doses of a single treatment on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.57319456,0.42680547
NCT01128543,Statement: only a minority of patients in the primary clinical trial had a complete response by the 24th week. [SEP] Clinical Trial: NCT01128543,Entailment,0.51476383,0.48523614
NCT00372424,Statement: over 75% of patients treated with sunitinib + docetaxel + trastuzumab in the primary clinical trial underwent serious treatment-emergent adverse events [SEP] Clinical Trial: NCT00372424,Entailment,0.6588201,0.3411799
NCT03346161,"Statement: in cohort 1 of the primary clinical trial, four additional patients experienced adverse events compared to those in the second cohort of the trial [SEP] Clinical Trial: NCT03346161",Entailment,0.7219094,0.27809063
NCT00569166,"Statement: difficulty understanding me in noisy room is a question about how often other people have difficulty understanding an individual in a noisy room. Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day. [SEP] Clinical Trial: NCT00569166",Contradiction,0.44377962,0.5562204
NCT00659373,"Statement: biological uncle is a male relative who is a sibling of either of the biological parents, and who share a common ancestor. all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group. [SEP] Clinical Trial: NCT00659373",Contradiction,0.41712445,0.5828756
NCT00836186,Statement: patients in the primary clinical trial undergo proton therapy and each group in the secondary clinical trial is prescribed 500 mg of fulvestrant to be administered through the transdermal patch twice a day. [SEP] Clinical Trial: NCT00836186,Contradiction,0.40419382,0.5958062
NCT01421472,"Statement: the primary clinical trial is open for patients with estrogen negative, progesterone negative, and her2- forms of breast cancer. [SEP] Clinical Trial: NCT01421472",Contradiction,0.4830391,0.51696086
NCT01127763,Statement: adverse events were entirely absent in the conduct of the primary clinical trial. [SEP] Clinical Trial: NCT01127763,Entailment,0.9120923,0.08790764
NCT02234479,"Statement: in the primary clinical trial, the influence of assorted radiation therapy is being evaluated on its study participants, whereas the secondary clinical trial tests the impact of varied quantities of the same treatment on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.6352503,0.3647497
NCT01629615,Statement: eating disorders were not common among participants of the primary clinical trial throughout the study [SEP] Clinical Trial: NCT01629615,Entailment,0.86639124,0.1336088
NCT00104650,Statement: the primary clinical trial employs a variety of methods for intervention administration. [SEP] Clinical Trial: NCT00104650,Entailment,0.8834268,0.11657325
NCT00372424,Statement: only a small percentage of patients on sunitinib + docetaxel + trastuzumab in the primary clinical trial encountered treatment-emergent adverse events [SEP] Clinical Trial: NCT00372424,Entailment,0.7345421,0.2654579
NCT00918281,Statement: cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine by IV. regulatory application identifier is a unique symbol that establishes identity of the regulatory application. [SEP] Clinical Trial: NCT00918281,Entailment,0.51805127,0.48194873
NCT03346161,Statement: Both cohorts of the primary trial recorded 0 Aes. cerebral artery is an artery which directly supplies the cerebral cortex and which has deeper branches that supply the underlying white matter. [SEP] Clinical Trial: NCT03346161,Contradiction,0.43564576,0.56435424
NCT01205503,"Statement: patients with a documented allergy to metronidazole or amoxicillin are accepted in the primary clinical trial, but will be excluded from the secondary clinical trial. [SEP] Clinical Trial: NCT01205503",Entailment,0.81426674,0.18573323
NCT00416715,"Statement: dulbecco's phosphate-buffered saline is a buffered (ph range 7.2-7.6) saline solution used in cell culture applications. Candidates for the secondary trial study group receive weekly subcutaneous (SC) injections, whereas the primary trial participants do not receive any injections. [SEP] Clinical Trial: NCT00416715",Entailment,0.785405,0.21459502
NCT03557801,"Statement: anemia, pneumonia and stupor were more common conditions among patients participating in the secondary clinical trial compared to the primary clinical trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.46504888,0.5349511
NCT01439282,"Statement: Gender is not a determining factor for eligibility in the primary trial, but only female patients are eligible for the secondary trial. hiv vaccine is a vaccine intended to prevent or treat infections caused by human immunodeficiency viruses (hivs). [SEP] Clinical Trial: NCT01439282",Entailment,0.52913254,0.47086743
NCT01920061,"Statement: the primary clinical trial adopts a continuous, non-cyclical approach to intervention, while the secondary clinical trial runs a strict 2 week cycle treatment plan. [SEP] Clinical Trial: NCT01920061",Entailment,0.7169672,0.28303283
NCT02403271,Statement: the secondary clinical trial has a higher incidence of biliary colic and diarrhoea compared to the primary clinical trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.6994667,0.3005333
NCT01376349,"Statement: the primary trial uses cm and number of participants as its unit of measure, however, the secondary trial uses years and participant bmi as their unit of measure. [SEP] Clinical Trial: NCT01376349",Contradiction,0.3752938,0.62470627
NCT00956813,Statement: the secondary trial and the primary trial report their results using the same units of measure. [SEP] Clinical Trial: NCT00956813,Entailment,0.5937684,0.40623155
NCT02187783,"Statement: mllt1 gene rearrangement is a molecular abnormality indicating rearrangement of the mllt1 gene. More Palpitations, Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.43624377,0.5637562
NCT03403712,"Statement: the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Median sleep time of its patients in minutes. morphologic response is an evaluation of the morphologic response of the disease to the therapy. [SEP] Clinical Trial: NCT03403712",Contradiction,0.49967098,0.500329
NCT00293540,"Statement: patients participating in the primary clinical trial have, on average, survived for more than 2 years, though there is at least one instance in each group of a patient's death within a span of 2 years. [SEP] Clinical Trial: NCT00293540",Entailment,0.5371414,0.46285865
NCT02273206,"Statement: before the intervention, all 61 cervical cancer patients in the first phase of the primary clinical trial had undertaken their scheduled screenings. [SEP] Clinical Trial: NCT02273206",Contradiction,0.45894375,0.5410563
NCT01702571,Statement: paired-end sequencing is a dna sequencing strategy where a single read is initiated from each end of a dna fragment. there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial. [SEP] Clinical Trial: NCT01702571,Contradiction,0.4676652,0.5323348
NCT02002533,Statement: bothered by tingling hands or feet is a question about whether an individual is or was bothered by tingling hands or feet. the primary trial and the secondary trial have 0 recorded adverse events. [SEP] Clinical Trial: NCT02002533,Entailment,0.6206601,0.37933987
NCT01535040,"Statement: In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily. [SEP] Clinical Trial: NCT01535040",Contradiction,0.23635516,0.7636448
NCT02286843,Statement: 57% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.4159173,0.5840827
NCT00293384,"Statement: dietary nuts and seeds measurement is a determination of the total nuts and seeds in a nutritional product or meal, or a portion thereof. Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril. [SEP] Clinical Trial: NCT00293384",Contradiction,0.35031465,0.6496854
NCT01920061,"Statement: the primary trial implements an intervention cycle of one month, unlike the secondary trial which does not embrace a cyclical treatment regimen. [SEP] Clinical Trial: NCT01920061",Entailment,0.8569149,0.14308514
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with Depocyt and HD-MTX. [SEP] Clinical Trial: NCT00702949",Contradiction,0.4035898,0.59641016
NCT01468675,"Statement: Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions. germline genotype testing is an assay used to determine the genes and molecular markers present in the germline dna of an individual. [SEP] Clinical Trial: NCT01468675",Entailment,0.57427776,0.42572224
NCT01881230,Statement: Both cohorts of the primary trial receive the same doses of Abraxane [SEP] Clinical Trial: NCT01881230,Entailment,0.7554409,0.24455911
NCT00569166,"Statement: both cohort 1 and 2 of the primary clinical trial use the same paced breathing instructional cd, but cohort 2 supplements their therapy with twice daily practices and a weekly schedule of antineoplastic chemotherapy. [SEP] Clinical Trial: NCT00569166",Contradiction,0.3390085,0.6609915
NCT00956813,Statement: doctor asked which treatment option i prefer is a question about whether an individual's doctor asked them which treatment option they prefer. the secondary trial and the primary trial results contain completely different outcome measures . [SEP] Clinical Trial: NCT00956813,Entailment,0.8912047,0.108795226
NCT00408681,"Statement: recurrent malignancies, graft-versus-host disease, anaemia, cardiac failure and diffuse alveolar hemorrhage are common adverse events in the secondary trial than the primary trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.523898,0.476102
NCT01376349,Statement: Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure. calm is a feeling of freedom from agitation or excitement. [SEP] Clinical Trial: NCT01376349,Contradiction,0.4635922,0.5364078
NCT00963911,Statement: regular exercise is not part of the intervention procedure for candidates of the primary clinical trial [SEP] Clinical Trial: NCT00963911,Entailment,0.91563934,0.08436061
NCT02104830,"Statement: Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim. [SEP] Clinical Trial: NCT02104830",Entailment,0.54518396,0.45481607
NCT03403712,"Statement: the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours. cognitive disorder is a category of psychiatric disorders which are characterized by a deficit in cognition or memory. [SEP] Clinical Trial: NCT03403712",Contradiction,0.46907648,0.5309235
NCT00254592,Statement: cyclophosphamide is administered to patients in both the primary and secondary clinical trials [SEP] Clinical Trial: NCT00254592,Entailment,0.6721362,0.32786378
NCT02115607,Statement: the secondary clinical trial documented 11 additional adverse events compared to the primary clinical trial [SEP] Clinical Trial: NCT02115607,Entailment,0.75974655,0.24025339
NCT01306032,Statement: Patients in the primary trial and the secondary trial  suffered Thromboembolic events. ros1 rearrangement analysis is a procedure used to detect and identify rearrangements involving the ros1 gene. [SEP] Clinical Trial: NCT01306032,Contradiction,0.31828827,0.68171173
NCT00075764,Statement: patients with t3 n3 m3 tumors are permitted to take part in the primary clinical trial [SEP] Clinical Trial: NCT00075764,Entailment,0.6016311,0.3983689
NCT00795769,Statement: the primary trial documented a higher number of patients experiencing chest pain than the secondary trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.621164,0.378836
NCT01806259,Statement: the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group [SEP] Clinical Trial: NCT01806259,Entailment,0.56310415,0.43689582
NCT01730729,"Statement: the intervention for the primary clinical trial is administered orally, while the secondary clinical trial intervention is strictly issued intravenously, through needle or tube insertion [SEP] Clinical Trial: NCT01730729",Contradiction,0.48190925,0.5180907
NCT00075764,Statement: the primary clinical trial accepts participants with measurable metastasis or whose disease has disseminated to various body parts. [SEP] Clinical Trial: NCT00075764,Contradiction,0.47726116,0.5227388
NCT00896454,Statement: contrasting patient cohorts have contributed to the results of the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00896454,Entailment,0.5362198,0.4637802
NCT00687102,"Statement: ileal obstruction, ctcae is a disorder characterized by blockage of the normal flow of the intestinal contents in the ileum. There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00687102",Contradiction,0.41983306,0.58016694
NCT01997333,Statement: the patient with the longest pfs in the primary clinical trial survived for 7 months without disease progression or death [SEP] Clinical Trial: NCT01997333,Entailment,0.5573553,0.44264475
NCT00262834,"Statement: no adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 0.3 proportion of patients, apart from skin infections [SEP] Clinical Trial: NCT00262834",Contradiction,0.4842214,0.5157786
NCT01310075,"Statement: even after undergoing a mastectomy for stage iv bc, a woman might still meet the requirements for the primary or secondary clinical trial [SEP] Clinical Trial: NCT01310075",Contradiction,0.3811343,0.61886567
NCT01803282,"Statement: 0 out of 7 the primary trial participants, and 0 out of 1674 the secondary trial participants experienced an ae. [SEP] Clinical Trial: NCT01803282",Entailment,0.7255477,0.2744523
NCT00143390,Statement: the primary clinical trial noted at least one incident of gastro-intestinal adverse event [SEP] Clinical Trial: NCT00143390,Entailment,0.8650991,0.13490088
NCT01013740,Statement: the primary clinical trial comprises fewer instances of anemia compared to the secondary clinical trial. [SEP] Clinical Trial: NCT01013740,Entailment,0.74200845,0.25799152
NCT00753415,"Statement: Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle. millimole per gram of creatinine is a unit of substance concentration defined as the concentration of millimoles of solute per gram of creatinine. [SEP] Clinical Trial: NCT00753415",Contradiction,0.3257445,0.6742555
NCT01439282,"Statement: only males are considered for participation in the primary clinical trial, while the secondary clinical trial only accepts females. [SEP] Clinical Trial: NCT01439282",Entailment,0.6490973,0.35090268
NCT02312934,Statement: smoking individuals are disqualified from the primary clinical trial but could be considered for the secondary clinical trial if their alcohol consumption stays below five drinks daily. [SEP] Clinical Trial: NCT02312934,Entailment,0.5119953,0.48800465
NCT01783444,"Statement: for the primary and secondary clinical trials, women with a new diagnosis of locally advanced er+ breast cancer who are considering mastectomy, are considered eligible [SEP] Clinical Trial: NCT01783444",Contradiction,0.26163504,0.73836493
NCT01111825,"Statement: every participant in cohort 1 of the primary clinical trial receives treatment for her2+, er+ and pr+. [SEP] Clinical Trial: NCT01111825",Contradiction,0.33307093,0.666929
NCT00194779,"Statement: the participants in the primary clinical trial are solely treated using a single type of oral medication, without the need for any surgical procedure, while individuals in the secondary clinical trial are administered a comprehensive treatment involving ten different types of drugs and multiple surgeries' [SEP] Clinical Trial: NCT00194779",Contradiction,0.4537736,0.5462264
NCT00104650,Statement: The Interventions in the primary trial included different medications but are administered through the same routes. childhood leukemia is an acute or chronic leukemia that occurs during childhood. [SEP] Clinical Trial: NCT00104650,Entailment,0.5367011,0.4632989
NCT01194440,Statement: Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial. chemo-zol is a treatment arm for patients receiving chemotherapy in combination with zoledronic acid. [SEP] Clinical Trial: NCT01194440,Contradiction,0.48387673,0.51612324
NCT00588640,"Statement: the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients. exiguobacterium is a genus of aerobic, gram positive, rod shaped bacterium assigned to the phylum firmicutes and the family bacillales xii. [SEP] Clinical Trial: NCT00588640",Contradiction,0.42200488,0.57799506
NCT01310075,Statement: a woman who has had lumpectomy would not be allowed to participate in the secondary trial or the primary trial. [SEP] Clinical Trial: NCT01310075,Entailment,0.67295647,0.3270435
NCT00513292,"Statement: in both the primary trial and the secondary trial, orr is used as the primary efficacy endpoint. there is an insignificant discrepancy in results amongst the different cohorts of the primary trial, whilst in the secondary trial, arm 1 outperformed arm 2. [SEP] Clinical Trial: NCT00513292",Contradiction,0.38363624,0.6163637
NCT00999921,Statement: patients with ednocarcinoma are ineligible for the secondary clinical trial but viewed as potential candidates for the primary clinical trial. [SEP] Clinical Trial: NCT00999921,Entailment,0.7469313,0.25306866
NCT00553358,"Statement: both the primary clinical trial and the secondary clinical trial would consider a patient who has a primary tumour with a diameter of 33mm, determined by a clinical examination, and ultrasound. [SEP] Clinical Trial: NCT00553358",Contradiction,0.23067002,0.76932997
NCT00687102,Statement: There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial [SEP] Clinical Trial: NCT00687102,Contradiction,0.2382978,0.7617022
NCT00623831,Statement: 25% of cohort 2 patients in the primary trial suffer Increased pleural effusion. nucleotide sequencing plate id number is a number that identifies a sequencing plate. [SEP] Clinical Trial: NCT00623831,Contradiction,0.46085262,0.5391474
NCT02115607,"Statement: proctitis, ctcae is a disorder characterized by inflammation of the rectum. the secondary trial recorded 11 more Aes than the primary trial. [SEP] Clinical Trial: NCT02115607",Contradiction,0.2886371,0.71136296
NCT01286168,"Statement: The most common adverse event in the secondary trial was Anaemia, there were no recorded AEs in the primary trial. appendiceal carcinoma pt2 tnm finding v8 is appendiceal carcinoma with tumor invading the muscularis propria. (from ajcc 8th ed.) [SEP] Clinical Trial: NCT01286168",Entailment,0.73737335,0.26262662
NCT01111825,Statement: invasive surgeries or the administration of neratinib are not part of the primary clinical trial for any of the cohorts [SEP] Clinical Trial: NCT01111825,Entailment,0.88877493,0.111225024
NCT01111825,"Statement: in the primary clinical trial, pr negative, er negative and her- are provided for cohort 1 while her2+ is received by cohort 2 [SEP] Clinical Trial: NCT01111825",Entailment,0.5538823,0.4461177
NCT00709761,Statement: over 50% patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) . [SEP] Clinical Trial: NCT00709761,Contradiction,0.3854545,0.6145455
NCT00054028,"Statement: severity answer is a response for a severity query. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial intervention section does not describe what drugs are to be administered. [SEP] Clinical Trial: NCT00054028",Entailment,0.8981748,0.1018252
NCT03092934,Statement: individuals of all genders with proven er negative breast cancer can participate in both stages of the primary clinical trial. [SEP] Clinical Trial: NCT03092934,Entailment,0.62966734,0.37033263
NCT00254592,"Statement: no patients in the secondary clinical trial are given paclitaxel, cyclophosphamide, or pegfilgrastim [SEP] Clinical Trial: NCT00254592",Entailment,0.8487453,0.15125476
NCT00321048,"Statement: radiation therapy is administered at the same intensity to patients in cohort 1 and 2 participating in the primary clinical trial, with each undergoing a spect scan. [SEP] Clinical Trial: NCT00321048",Contradiction,0.4704813,0.52951866
NCT00569166,"Statement: while members of both cohorts 1 and 2 in the primary clinical trial utilize the same rhythmic breathing instructional cd, it's important to note that the regimen for cohort 2 includes a practice frequency of twice daily along with weekly treatments of antineoplastic chemotherapy. [SEP] Clinical Trial: NCT00569166",Contradiction,0.37639537,0.6236046
NCT01314963,Statement: the primary disparity between the two interventions in the primary clinical trial is the elevated usage of the radioactive tc99m sulfur colloid in intervention 1 compared to intervention 2. [SEP] Clinical Trial: NCT01314963,Entailment,0.5060697,0.49393028
NCT01252290,Statement: less than 10 patients in the primary trial suffered Aes. microwave thermotherapy is any procedure in which microwave irradiation is used for the purpose of heating and destroying the surrounding tissue. [SEP] Clinical Trial: NCT01252290,Entailment,0.63934255,0.3606574
NCT00586326,Statement: an explanation of the irradiation doses or a treatment cycle is lacking in the intervention portion of the primary clinical trial. [SEP] Clinical Trial: NCT00586326,Entailment,0.9152142,0.08478584
NCT01178411,"Statement: the primary and secondary trials would not discriminate based on an individual's nationality, ethnicity, mental health status, or gender [SEP] Clinical Trial: NCT01178411",Entailment,0.6643242,0.3356758
NCT00284180,Statement: eligible for the primary clinical trial are patients who had a severe anaphylactic reaction to herceptin treatment or did not respond to treatment with herceptin in the past. [SEP] Clinical Trial: NCT00284180,Entailment,0.70651346,0.29348654
NCT00365105,"Statement: a patient who is 32 years of age, histologically diagnosed with stage iii breast cancer, has an absolute neutrophil count of 1807/≈í¬∫l, platelet count of 110,034/≈í¬∫l, a hemoglobin level of 90 g/l, and estimates a life span of more than 8 months can be considered for both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00365105",Contradiction,0.3598637,0.64013624
NCT01781299,Statement: there were multiple incidents of sudden deaths and unplanned hospitalizations in the primary clinical trial and in the secondary clinical trial. [SEP] Clinical Trial: NCT01781299,Contradiction,0.3020739,0.6979261
NCT01383174,Statement: the secondary clinical trial's second cohort significantly outnumbered the second cohort of the primary clinical trial in terms of patients. [SEP] Clinical Trial: NCT01383174,Contradiction,0.44508854,0.5549115
NCT01803282,"Statement: 7/73 the primary trial participants, and 10/1674 the secondary trial participants suffered an acute myocardial infarction  [SEP] Clinical Trial: NCT01803282",Contradiction,0.38121447,0.6187855
NCT00558272,"Statement: the zoledronic acid 4 mg group in the primary clinical trial exhibited a superior percentage change in betactx at week 4, surpassing the outcomes of the azd0530 175 mg group. [SEP] Clinical Trial: NCT00558272",Contradiction,0.46934015,0.5306599
NCT02115607,"Statement: compared to the primary clinical trial, the secondary clinical trial experienced an excess of 11 occurrences of intestinal perforation [SEP] Clinical Trial: NCT02115607",Contradiction,0.33687985,0.66312015
NCT01286987,Statement: the primary clinical trial administers different daily doses of talazoparib: 1000 mcg for breast cancer patients and 25 mcg for ovarian or peritoneal cancer patients. [SEP] Clinical Trial: NCT01286987,Entailment,0.53240216,0.4675978
NCT00706030,"Statement: in the primary clinical trial, only four distinct adverse events influenced patients, all found within cohort 2. [SEP] Clinical Trial: NCT00706030",Entailment,0.7495793,0.25042072
NCT00429299,Statement: confirmation of a her2 positive tumor through positive fish or ihc 3+ is mandatory for all individuals considering the primary clinical trial. [SEP] Clinical Trial: NCT00429299,Contradiction,0.41193956,0.58806044
NCT01908101,Statement: the primary and the secondary clinical trials are not examining the effects of the same medications [SEP] Clinical Trial: NCT01908101,Entailment,0.9213013,0.07869865
NCT00623831,Statement: 1/4 of patients in the primary trial suffer increased pleural effusion and rapid disease progression [SEP] Clinical Trial: NCT00623831,Contradiction,0.39660954,0.60339046
NCT00182767,"Statement: In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort. cdisc adas-cog - executive function maze: errors is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) number of errors during the executive function maze task. [SEP] Clinical Trial: NCT00182767",Entailment,0.55074954,0.4492505
NCT00698035,"Statement: the primary clinical trial is examining surgical interventions, while the secondary clinical trial is assessing a meditation intervention. [SEP] Clinical Trial: NCT00698035",Entailment,0.51988554,0.4801145
NCT00749931,Statement: the eligibility for the secondary clinical trial automatically implies eligibility for the primary clinical trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.73793626,0.2620637
NCT01178411,"Statement: the nationality, ethnicity, weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial. bus device is a set of electrical conductors designed to route data from multiple locations in a computer. [SEP] Clinical Trial: NCT01178411",Contradiction,0.26909992,0.73090005
NCT02002533,Statement: the secondary trial has more adverse events recorded than the primary trial. [SEP] Clinical Trial: NCT02002533,Entailment,0.9149554,0.08504465
NCT01743560,"Statement: the primary clinical trial does not permit participation of children, whereas the secondary clinical trial does not specifically prohibit their involvement [SEP] Clinical Trial: NCT01743560",Entailment,0.8801463,0.119853646
NCT01178411,"Statement: the nationality, ethnicity, psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial. continuous surface ecg recording for non-human species is a continuous electrocardiographic (ecg) recording utilizing one or more surface leads in a non-human species. (cdisc) [SEP] Clinical Trial: NCT01178411",Contradiction,0.32225412,0.6777458
NCT01252290,Statement: less than 10 patients in the primary trial suffered Aes. severity of elevated lesion is an indication of the severity of a lesion that is raised. [SEP] Clinical Trial: NCT01252290,Entailment,0.69370186,0.30629808
NCT02441946,"Statement: patients with a breast tumor 5-10 cm in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Entailment,0.5111662,0.48883379
NCT00698035,"Statement: mycl gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the mycl gene. the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention. [SEP] Clinical Trial: NCT00698035",Contradiction,0.47601032,0.5239897
NCT01989546,"Statement: CBT based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. cardiac diffuse large b-cell lymphoma is a diffuse large b-cell lymphoma that arises from the heart. [SEP] Clinical Trial: NCT01989546",Entailment,0.5439474,0.45605257
NCT00118157,"Statement: for an entire month, every participant in the primary clinical trial receives an oral quantity of 100 mg/m2 lapatinib, administered twice daily. [SEP] Clinical Trial: NCT00118157",Contradiction,0.36472872,0.6352713
NCT02504424,Statement: one patient in the primary trial had an incident where a surgical incision reopened after the surgery. [SEP] Clinical Trial: NCT02504424,Entailment,0.7133461,0.28665385
NCT01631552,Statement: the secondary trial and the primary trial have completely unrelated outcome measurements. symptom interference score 2 is a subjective score of 2 on a scale that ranges from 0: did not interfere to 10: interfered completely. [SEP] Clinical Trial: NCT01631552,Entailment,0.7445401,0.25545987
NCT00365105,"Statement: a 50 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 2400/≈í¬∫l, platelet count of 55,050/≈í¬∫l, hemoglobin level of 50 g/l, and a life expectancy less than 4 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.34762892,0.6523711
NCT01803282,"Statement: 0/7 the primary trial participants, and 0/1674 the secondary trial participants suffered an AE. [SEP] Clinical Trial: NCT01803282",Entailment,0.6053583,0.3946417
NCT02988986,"Statement: after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression  . microbacterium is a genus of minute, nonmotile gram-positive thermotolerant bacteria that are common in dairy products and the mammalian intestinal tract. [SEP] Clinical Trial: NCT02988986",Contradiction,0.45390907,0.5460909
NCT00313170,Statement: candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments. [SEP] Clinical Trial: NCT00313170,Entailment,0.6385324,0.36146763
NCT01766102,"Statement: arm 1 of the primary trial indicated a higher operative time than arm 2, hence, the test group outperformed over the control group. concerning the secondary trial, a control group is compared against. [SEP] Clinical Trial: NCT01766102",Entailment,0.5083465,0.49165347
NCT00122369,"Statement: the secondary clinical trial does not permit the participation of individuals who are 18 years old, whereas the primary clinical trial doesn't mention a specific age for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.9034587,0.09654126
NCT00971945,"Statement: the secondary trial  candidates must be Completely disabled to participate, whereas this is not required to be accepted into the primary trial. middle colic artery is an artery arising from the superior mesenteric artery that supplies the transverse colon. [SEP] Clinical Trial: NCT00971945",Entailment,0.83278406,0.16721596
NCT00706030,"Statement: Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia. hearing loss makes me feel different from everyone else is a question about whether an individual's hearing loss makes them feel different from everyone else. [SEP] Clinical Trial: NCT00706030",Contradiction,0.45986202,0.540138
NCT01138046,"Statement: only males of an unspecified nationality are eligible to enroll in the primary clinical trial, whereas the secondary clinical trial allows no restrictions on gender or nationality. [SEP] Clinical Trial: NCT01138046",Entailment,0.81552094,0.18447909
NCT02550795,"Statement: group 2 of the primary trial recieves 25ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. [SEP] Clinical Trial: NCT02550795",Entailment,0.81213444,0.18786556
NCT00075764,"Statement: picalm gene rearrangement is a molecular abnormality indicating rearrangement of the picalm gene. Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial. [SEP] Clinical Trial: NCT00075764",Entailment,0.6569635,0.34303644
NCT01772004,Statement: african-american participants in the primary clinical trial must remain inhabitants of texas for the entirety of the study. [SEP] Clinical Trial: NCT01772004,Entailment,0.5887244,0.41127563
NCT01855828,"Statement: there was one psychiatric adverse event in the primary trial, which affected more than 90% of patients [SEP] Clinical Trial: NCT01855828",Contradiction,0.3197774,0.6802226
NCT01498458,"Statement: in the primary clinical trial, for every case of hypertension and pancreatectomy, there were three cases of hepatotoxicity [SEP] Clinical Trial: NCT01498458",Contradiction,0.41610295,0.58389705
NCT00357734,"Statement: The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim. pretreatment is any relevant actions that were performed or occurred prior to a specific treatment. [SEP] Clinical Trial: NCT00357734",Contradiction,0.46479502,0.535205
NCT00896454,Statement: the unit of measure used in reporting results is identical for both the primary and secondary clinical trial. [SEP] Clinical Trial: NCT00896454,Entailment,0.90366125,0.096338786
NCT00819182,"Statement: in the primary clinical trial, it was noted that on average, patients in the paced respiration intervention group experienced more treatment emergent adverse events and serious treatment emergent adverse events than their counterparts in the fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.6204105,0.37958947
NCT00956813,Statement: the secondary trial and the primary trial results contain completely different outcome measures . gaoshan chinese is a chinese person from the gaoshan ethnic group. [SEP] Clinical Trial: NCT00956813,Entailment,0.8887641,0.111235894
NCT01537029,"Statement: while requirements for the primary clinical trial include being a female over the age of 18 diagnosed with any type of cancer irrespective of race or ethnicity, the secondary clinical trial is limited to patients with brca+ breast cancer. [SEP] Clinical Trial: NCT01537029",Entailment,0.59319615,0.40680385
NCT01831089,Statement: the primary clinical trial is open to patients with a histological or cytological confirmed diagnosis of non-small cell lung cancer or small cell lung cancer [SEP] Clinical Trial: NCT01831089,Entailment,0.6468096,0.35319042
NCT01702571,Statement: every adverse event noted for cohort 1 of the primary clinical trial pertains to the area of mental health. [SEP] Clinical Trial: NCT01702571,Entailment,0.7379237,0.2620763
NCT00553358,"Statement: a patient that has a primary tumour with a diameter of 33000µm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.29944876,0.7005513
NCT02259114,"Statement: individuals diagnosed with follicular lymphoma or metastatic melanoma, based on immunohistochemistry, or intraductal carcinoma are disqualified from both the primary and secondary trials. [SEP] Clinical Trial: NCT02259114",Entailment,0.8095276,0.19047248
NCT02002533,Statement: the primary clinical trial documented four more adverse events than the secondary clinical trial. [SEP] Clinical Trial: NCT02002533,Entailment,0.7696095,0.23039055
NCT01171924,Statement: cohort 1 of the primary clinical trial receives a different dosage of cudc-101 compared to cohort 2. [SEP] Clinical Trial: NCT01171924,Entailment,0.72599727,0.2740027
NCT01301729,Statement: her2 + patients in cohort 2 of the secondary trial receive a higher dosage of trastuzumab compared to the ones in the primary trial throughout the entirety of the trial [SEP] Clinical Trial: NCT01301729,Contradiction,0.4722109,0.5277891
NCT02988986,Statement: patients in the primary clinical trial reported a 5% reduction in ki67 cell expression after undergoing tak-228 and tamoxifen therapy for over 6 weeks [SEP] Clinical Trial: NCT02988986,Entailment,0.51086164,0.48913833
NCT02404441,Statement: both the primary and secondary clinical trials apply identical inclusion/exclusion criteria to all participants within their respective trials. [SEP] Clinical Trial: NCT02404441,Entailment,0.8372171,0.16278292
NCT00558272,Statement: the group taking 175 mg of azd0530 in the primary clinical trial encountered a larger shrinking of primary tumor size as compared to the group taking 4 mg zoledronic acid. [SEP] Clinical Trial: NCT00558272,Contradiction,0.45545903,0.544541
NCT00182767,Statement: two participants from the second cohort of the primary clinical trial had an incidence of dose-limiting toxicity. [SEP] Clinical Trial: NCT00182767,Entailment,0.6197559,0.38024405
NCT02961790,"Statement: individuals who have received antineoplastic chemotherapy, androgens, estrogens or progestogens treatment a month prior to the start of the study are not applicable for the primary clinical trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.81805766,0.18194228
NCT00756717,Statement: the primary clinical trial and the secondary clinical trial did not experience any adverse events [SEP] Clinical Trial: NCT00756717,Entailment,0.8966485,0.10335145
NCT00656019,Statement: several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes. [SEP] Clinical Trial: NCT00656019,Contradiction,0.22162972,0.7783702
NCT01869192,"Statement: 16p13.3 is a chromosome band present on 16p The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm, additionally, in the secondary trial the Denosumab cohort had a better Time to First On-Study SRE than the Zoledronic Acid cohort. [SEP] Clinical Trial: NCT01869192",Entailment,0.5401712,0.4598288
NCT01617668,Statement: humiliation is a feeling of extreme embarrassment. More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2. [SEP] Clinical Trial: NCT01617668,Entailment,0.6407067,0.3592933
NCT00373256,"Statement: the contrast between the first and second cohorts of the primary clinical trial stems from the drugs and dosage used; 25 mg to 37.5 mg of sunitinib is prescribed to cohort 1 daily, whereas bevacizumab at 10 mg/kg is dispensed to cohort 2. [SEP] Clinical Trial: NCT00373256",Entailment,0.51256424,0.4874358
NCT00262834,"Statement: adverse events were not reported in the primary clinical trial, while in the secondary clinical trial, any recorded adverse event had an impact on less than 30% of patients, excluding skin infections. [SEP] Clinical Trial: NCT00262834",Entailment,0.6835179,0.31648213
NCT00709761,Statement: over 50% patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr). [SEP] Clinical Trial: NCT00709761,Contradiction,0.358169,0.641831
NCT00293384,"Statement: in the primary clinical trial, more than half of the patients in the second group experienced severe nausea following the therapy involving aprepitant, dexamethasone, cytoxan, and kytril. [SEP] Clinical Trial: NCT00293384",Entailment,0.5113658,0.48863426
NCT00357734,"Statement: the primary clinical trial's intervention involves just one drug, contrasting with the secondary clinical trial that demands the use of at least three differing drug types. [SEP] Clinical Trial: NCT00357734",Entailment,0.73759156,0.26240847
NCT01045421,"Statement: patients diagnosed with histologically or cytologically verified metastatic and/or advanced solid breast tumor are eligible for the first phase of the primary clinical trial, and for all cohorts in the secondary clinical trial [SEP] Clinical Trial: NCT01045421",Contradiction,0.45179206,0.54820794
NCT02734979,"Statement: perfect match probe is a 25 nucleotide probe with an exact sequence match to its target used in analysis of affymetrix arrays. Patients that have a history of pulmonary embolisms cannot take part in the secondary trial, and those who currently have breast implants cannot participate in the primary trial. [SEP] Clinical Trial: NCT02734979",Entailment,0.5787958,0.42120415
NCT00838929,Statement: every patient in the primary trial is receives a dose of 1 to 10 ¬¨¬µg fentanyl sublingual spray during radiation therapy [SEP] Clinical Trial: NCT00838929,Contradiction,0.49043348,0.50956655
NCT00248547,Statement: every participant of the primary clinical trial who received a placebo intervention went through episodes of emesis [SEP] Clinical Trial: NCT00248547,Entailment,0.5594585,0.44054154
NCT00587964,"Statement: in the primary clinical trial, the most recurring adverse event recorded is coronary artery stenosis [SEP] Clinical Trial: NCT00587964",Entailment,0.67639405,0.32360595
NCT02891681,Statement: regular smokeless tobacco use for six weeks or more negative is a response that the individual did not use smokeless tobacco regularly for six weeks or longer. Morbidly obese patients can be eligible for the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02891681,Entailment,0.5694674,0.43053254
NCT00911898,"Statement: pharyngeal stripping wave present and complete is a finding of a pharyngeal stripping wave present and complete. The the primary trial intervention section dose not describe the method of administration, dosage or cycle. [SEP] Clinical Trial: NCT00911898",Entailment,0.79974526,0.2002547
NCT00867217,"Statement: flsi questionnaire question is a question associated with the flsi questionnaire. Patients with a Vitamin D deficiency are excluded from the primary trial, but may be eligible for the secondary trial. [SEP] Clinical Trial: NCT00867217",Entailment,0.61162,0.38838
NCT00513292,"Statement: the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had worse results than arm 1, as a higher percentage of arm 2 patients experienced pCR. scheme is an elaborate and systematic plan of action. [SEP] Clinical Trial: NCT00513292",Contradiction,0.2475731,0.75242686
NCT00656305,"Statement: There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation . [SEP] Clinical Trial: NCT00656305",Entailment,0.60618186,0.3938181
NCT00583700,"Statement: small cell adenocarcinoma is an adenocarcinoma composed of small malignant cells. women aged 18 or 19 are eligible for the secondary trial, but will need to wait 1-2 years to be eligible for the primary trial. [SEP] Clinical Trial: NCT00583700",Contradiction,0.39193144,0.6080686
NCT00623831,"Statement: cdisc adas-cog - word recognition: word 5 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) word recognition task for word 5 trials 1, 2, 3. 25% of cohort 2 patients in the primary trial suffer Increased pleural effusion. [SEP] Clinical Trial: NCT00623831",Contradiction,0.37799898,0.622001
NCT00321464,"Statement: Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive or HER2/neu negative are eligible for both the secondary trial and the primary trial. estimated date of conception is an approximate calculated date at which the conception event took place. [SEP] Clinical Trial: NCT00321464",Contradiction,0.430455,0.56954503
NCT02320123,"Statement: Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy [SEP] Clinical Trial: NCT02320123",Contradiction,0.3732595,0.62674046
NCT01419717,"Statement: mllt6 gene rearrangement is a molecular abnormality indicating rearrangement of the mllt6 gene. the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid. [SEP] Clinical Trial: NCT01419717",Contradiction,0.40958795,0.5904121
NCT00706030,"Statement: afraid of being rejected is a question about whether an individual is or was afraid of being rejected. Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2. [SEP] Clinical Trial: NCT00706030",Entailment,0.53457415,0.46542582
NCT00054028,"Statement: thyroglobulin antibody negative is an indication that antibodies that recognize thyroglobulin have not been detected in a sample. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial. [SEP] Clinical Trial: NCT00054028",Contradiction,0.366993,0.63300693
NCT02550795,"Statement: proficiency testing challenge is any individual test given to a laboratory as part of a proficiency test. Group 2 of the primary trial recieves 0.5ug/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any Dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.8555458,0.14445415
NCT00963911,Statement: None of the primary trial candidates have to perfom regular exercise as part of the intervention. sulfoxone is a water-soluble sulfonamide antibiotic used in the treatment of leprosy. [SEP] Clinical Trial: NCT00963911,Entailment,0.6955872,0.3044128
NCT01138046,"Statement: the primary clinical trial is open exclusively to female patients of a certain nationality, while the secondary clinical trial has no such restrictions. [SEP] Clinical Trial: NCT01138046",Entailment,0.8858124,0.114187635
NCT00143390,Statement: at least one gastro-intestinal adverse event was recorded in the primary clinical trial [SEP] Clinical Trial: NCT00143390,Entailment,0.8803165,0.11968355
NCT01351376,Statement: esophageal cancer surgery is a surgical procedure to remove any cancerous tissue in the esophagus. Patients with measurable tumors in both breasts are excluded from the primary trial. [SEP] Clinical Trial: NCT01351376,Entailment,0.6309566,0.36904344
NCT01730729,"Statement: the primary trial intervention is given orally, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein. study agent function code is a coded value specifying how this agent is used in the study. [SEP] Clinical Trial: NCT01730729",Contradiction,0.47924724,0.5207527
NCT00553358,"Statement: A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. thick filament is a myofilament composed of myosin. [SEP] Clinical Trial: NCT00553358",Contradiction,0.330374,0.66962594
NCT00623831,Statement: only 5% of patients in cohort 2 report increased pleural effusion within the primary clinical trial. [SEP] Clinical Trial: NCT00623831,Entailment,0.5674221,0.4325779
NCT01806675,"Statement: all participants in the principal clinical trial's study groups will be subjected to identical 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging procedures, but the first cohort will be administered a marginally higher dose of 18f-fpprgd2. [SEP] Clinical Trial: NCT01806675",Entailment,0.5710845,0.4289155
NCT01171924,"Statement: thyroid gland schwannoma is a rare schwannoma that arises from the thyroid gland. cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often. [SEP] Clinical Trial: NCT01171924",Contradiction,0.42309555,0.5769044
NCT01766102,"Statement: in the primary trial, the amount of time spent in operation was longer for arm 2 than arm 1, suggesting superior performance of intra-operative mammography over the standard mammography. in the secondary trial, the absence of a control group means any comparisons are not feasible. [SEP] Clinical Trial: NCT01766102",Entailment,0.62082237,0.3791776
NCT00148668,Statement: Both interventions in the primary trial include trastuzumab [SEP] Clinical Trial: NCT00148668,Entailment,0.73990566,0.2600943
NCT00878709,Statement: the idfs rate was lower in the neratinib group than in the placebo group in the primary clinical trial [SEP] Clinical Trial: NCT00878709,Entailment,0.7834656,0.21653435
NCT00963911,"Statement: several of the primary trial candidates are administered 0.001 g of talazoparib daily, as part of the intervention [SEP] Clinical Trial: NCT00963911",Contradiction,0.31781107,0.68218887
NCT00693719,Statement: a patient suffering from acute bacterial meningitis is capable of participating in the primary clinical trial [SEP] Clinical Trial: NCT00693719,Entailment,0.6433863,0.35661376
NCT00088413,Statement: the adverse events noted in the primary trial are all related to psychological distress; this is not mirrored in the secondary trial. [SEP] Clinical Trial: NCT00088413,Entailment,0.89818436,0.10181564
NCT01806259,Statement: 208 participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 156 from the nacl 0.9% 3l group [SEP] Clinical Trial: NCT01806259,Contradiction,0.4438114,0.55618864
NCT01013740,"Statement: in both the primary and secondary clinical trials, several participants encountered tumour lysis syndrome. [SEP] Clinical Trial: NCT01013740",Contradiction,0.24669418,0.75330585
NCT02988986,Statement: a 7-week duration of tak-228 plus tamoxifen treatment in the primary clinical trial was linked to an increase in the percentage of cells with ki67 expression. [SEP] Clinical Trial: NCT02988986,Contradiction,0.46262997,0.5373701
NCT00709761,Statement: mind is as sharp as it always has been is a question about whether an individual's mind is or was as sharp as it always has been. Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) . [SEP] Clinical Trial: NCT00709761,Contradiction,0.4976773,0.5023227
NCT03403712,"Statement: the primary trial measures the average nap duration of its patients, whereas the secondary trial identifies the number of people who experience side effects related to treatment. [SEP] Clinical Trial: NCT03403712",Entailment,0.51455283,0.48544717
NCT00320541,"Statement: in the primary clinical trial, fewer participants enrolled in the paclitaxel plus bevacizumab plus gemcitabine group than in the paclitaxel plus bevacizumab group [SEP] Clinical Trial: NCT00320541",Entailment,0.8062458,0.1937542
NCT00365365,"Statement: the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15 [SEP] Clinical Trial: NCT00365365",Contradiction,0.3700645,0.6299355
NCT03384316,Statement: no infections and infestations cases were registered in the primary clinical trial. [SEP] Clinical Trial: NCT03384316,Entailment,0.86940086,0.13059914
NCT03092934,Statement: evidence of er positive breast cancer is required for males to be eligible for both phases of the primary clinical trial. [SEP] Clinical Trial: NCT03092934,Contradiction,0.45781785,0.5421821
NCT02038218,Statement: the primary clinical trial and the secondary clinical trial employ disparate units for quantifying the same outcome measure. [SEP] Clinical Trial: NCT02038218,Entailment,0.8764275,0.12357251
NCT00088413,"Statement: every adverse event documented during the primary clinical trial was linked to the patient's musculoskeletal system, a factor not shared in the secondary clinical trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.890893,0.10910707
NCT00088413,"Statement: in the primary clinical trial, the adverse events noted were all connected to the musculoskeletal system, contrary to the secondary clinical trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.773012,0.22698802
NCT02038218,Statement: the secondary trial and the primary trial use different units of measure in their results. [SEP] Clinical Trial: NCT02038218,Entailment,0.92809045,0.07190951
NCT01806675,"Statement: Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2. regimen used to treat penile cancer is any regimen that can be used for the treatment of penile cancer. [SEP] Clinical Trial: NCT01806675",Contradiction,0.460349,0.539651
NCT00372424,Statement: a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event. fissure is a long narrow slit or groove that divides an organ into lobes. [SEP] Clinical Trial: NCT00372424,Entailment,0.51298106,0.48701897
NCT01434342,"Statement: There were more cases of Mucositis Oral, epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial. laryngeal hemorrhage, ctcae is a disorder characterized by bleeding from the larynx. [SEP] Clinical Trial: NCT01434342",Contradiction,0.34818217,0.65181786
NCT01222390,"Statement: in both the primary and secondary clinical trials, ct scans and mris are key components of the medical interventions [SEP] Clinical Trial: NCT01222390",Contradiction,0.32744175,0.67255825
NCT02431676,Statement: gist grade cannot be assessed is a gist grade that cannot be assessed. Morbidly obese patients are eligible for the primary trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.6393618,0.3606382
NCT01390818,Statement: Several recorded Aes in the primary trial occurred to cohort 1 patients [SEP] Clinical Trial: NCT01390818,Contradiction,0.28941223,0.71058774
NCT00030823,Statement: 13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine  [SEP] Clinical Trial: NCT00030823,Contradiction,0.39564967,0.6043503
NCT01310075,"Statement: A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial. recto-vesico-vaginal fistula is an abnormal communication between the rectum, bladder, and vagina. [SEP] Clinical Trial: NCT01310075",Contradiction,0.321761,0.678239
NCT00428220,"Statement: patients participating in the primary clinical trial tended to have a higher incidence of pericardial effusions, while corneal deposists were more frequently observed in the secondary clinical trial. [SEP] Clinical Trial: NCT00428220",Contradiction,0.48551586,0.51448417
NCT00256217,Statement: There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs. [SEP] Clinical Trial: NCT00256217,Entailment,0.6684422,0.3315578
NCT01286168,"Statement: polyneuropathy was the most frequent adverse event reported in the primary clinical trial, the secondary clinical trial had no recorded aes. [SEP] Clinical Trial: NCT01286168",Entailment,0.90399987,0.09600016
NCT01434342,"Statement: 8q21-q22 is a chromosome band present on 8q There were more cases of Mucositis Oral, Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01434342",Contradiction,0.40781793,0.59218204
NCT01823991,Statement: patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial. protein region is an informal header for somewhat informal parts of a protein molecule. [SEP] Clinical Trial: NCT01823991,Entailment,0.5646078,0.43539226
NCT01783444,"Statement: women with triple negative stage iii breast cancer, who have undergone mastectomy are eligible for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01783444",Contradiction,0.25116965,0.7488304
NCT01290536,"Statement: the primary clinical trial involves the administration of yttrium-90 glass microspheres and theraspheres through radioembolization, whereas the secondary clinical trial utilizes 560 mg of ibrutinib and 10 mg/kg of medi4736 twice a day for a one month period. [SEP] Clinical Trial: NCT01290536",Contradiction,0.32410598,0.675894
NCT00357734,"Statement: The intervention in the primary trial consists of a single drug, whereas in the secondary trial the intervention requires at least 3 different drugs. anal fibroadenoma is a benign epithelial-stromal neoplasm that arises from the anus and resembles the breast fibroadenoma. [SEP] Clinical Trial: NCT00357734",Entailment,0.61095965,0.38904038
NCT00467844,"Statement: in the primary clinical trial, gtx-024 of 1mg dosage resulted in lean body mass gain in every patient, over a span of 4 months [SEP] Clinical Trial: NCT00467844",Contradiction,0.4184637,0.58153623
NCT03557801,"Statement: neither the patients in the secondary trial nor the primary trial exhibited conditions of anemia, pneumonia or stupor. [SEP] Clinical Trial: NCT03557801",Contradiction,0.32340318,0.6765968
NCT02504424,Statement: an incident occurred in the primary clinical trial where a patient's surgical incision came undone after the surgery. [SEP] Clinical Trial: NCT02504424,Entailment,0.730014,0.26998594
NCT00475085,"Statement: the primary clinical trial provides the total count of participants studied, however, the count of participants in individual cohorts is not given [SEP] Clinical Trial: NCT00475085",Entailment,0.9119142,0.0880857
NCT01649271,Statement: there were no cases of shingles reported in neither the patient cohorts of the primary trial nor the secondary trial. [SEP] Clinical Trial: NCT01649271,Entailment,0.87659854,0.123401456
NCT02178722,Statement: participants in the primary trial and the secondary trial both receive pembrolizumab and sunitinib at equal frequency. [SEP] Clinical Trial: NCT02178722,Entailment,0.56104505,0.43895492
NCT00662025,"Statement: perform chores is a question about an individual performing chores such as housework, shopping groceries. CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle. [SEP] Clinical Trial: NCT00662025",Contradiction,0.36204642,0.6379535
NCT02891681,Statement: Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.19715574,0.8028442
NCT00194779,"Statement: advanced non-functioning neuroendocrine tumor is a non-functioning neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment. the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and several different imaging scans. [SEP] Clinical Trial: NCT00194779",Contradiction,0.35803467,0.64196527
NCT00775645,Statement: In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants. ionizing radiation-related malignant neoplasm is a malignant neoplasm arising in an anatomic site exposed to ionizing radiation. [SEP] Clinical Trial: NCT00775645,Contradiction,0.3695296,0.6304704
NCT02104830,"Statement: the primary trial and the secondary trial are studying different drugs, at different dosages, and with different outcome measurements. [SEP] Clinical Trial: NCT02104830",Entailment,0.81697977,0.18302019
NCT00836186,"Statement: the primary clinical trial provides its participants with full breast radiation therapy, while every group involved in the secondary clinical trial is given 500 mg of fulvestrant tablet to be consumed bid. [SEP] Clinical Trial: NCT00836186",Contradiction,0.41618615,0.58381385
NCT01314963,"Statement: in the primary clinical trial, intervention 1 and 2 use equal doses of radioactive tc99m sulfur colloid. [SEP] Clinical Trial: NCT01314963",Contradiction,0.46741185,0.5325882
NCT00971945,"Statement: complete disability is obligatory for participation in the secondary clinical trial, in contrast to the primary clinical trial where it isn't a requirement [SEP] Clinical Trial: NCT00971945",Entailment,0.8784799,0.12152008
NCT03403712,"Statement: the primary clinical trial assesses the count of patients experiencing adverse events linked to treatment, while the secondary clinical trial evaluates the average duration of sleep in its patients. [SEP] Clinical Trial: NCT03403712",Entailment,0.57379466,0.4262053
NCT00686127,Statement: there is a lower total count and variety of adverse events documented in the primary clinical trial compared to the secondary trial. [SEP] Clinical Trial: NCT00686127,Entailment,0.82091486,0.17908512
NCT02165839,"Statement: Candidates for the primary trial and the secondary trial have to meet a baseline performance status, each trial is using a different performance status scoring system. [SEP] Clinical Trial: NCT02165839",Entailment,0.87303007,0.12696992
NCT01964924,"Statement: an adult patient, who was diagnosed with a disease other than ild/dpld within the past three years and has a life expectancy of over a year, can avail of the primary clinical trial [SEP] Clinical Trial: NCT01964924",Contradiction,0.46616742,0.5338326
NCT02509156,"Statement: in the primary clinical trial, the placebo and allo-mscs interventions are delivered through separate transendocardial injections. [SEP] Clinical Trial: NCT02509156",Entailment,0.564117,0.43588305
NCT00992602,"Statement: we are unable to make a comparison of the adverse events in the primary clinical trial and the secondary clinical trial, as there seems to be no record of such events for the primary clinical trial. [SEP] Clinical Trial: NCT00992602",Entailment,0.8861045,0.11389543
NCT01306032,Statement: adverse events that are a result of the secondary clinical trial do not occur in patients from the primary clinical trial. [SEP] Clinical Trial: NCT01306032,Entailment,0.92359847,0.07640151
NCT02504424,Statement: urinary tract infections were not reported among those participating in the primary clinical trial [SEP] Clinical Trial: NCT02504424,Entailment,0.9067056,0.09329436
NCT00971945,"Statement: the secondary trial  candidates must meet some Performance Status condition to participate, whereas this is not required to be accepted into the primary trial [SEP] Clinical Trial: NCT00971945",Entailment,0.90548414,0.09451587
NCT01127763,"Statement: out of the participants, 5 had experienced three or more adverse incidents during the primary clinical trial [SEP] Clinical Trial: NCT01127763",Entailment,0.6548078,0.34519213
NCT00828516,Statement: Neither the secondary trial or the primary trial use the Number of Participants With Treatment-emergent Aes as the outcome measurement for their studies. [SEP] Clinical Trial: NCT00828516,Contradiction,0.4521724,0.5478276
NCT01806675,Statement: the 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging protocols will be applied uniformly across all study groups in the primary trial. [SEP] Clinical Trial: NCT01806675,Entailment,0.5953186,0.4046814
NCT00820872,Statement: cholelithiasis was less common in primary trial participants compared to the secondary trial participants [SEP] Clinical Trial: NCT00820872,Entailment,0.8089649,0.19103505
NCT01772004,Statement: the primary clinical trial is exclusively for asian patients. [SEP] Clinical Trial: NCT01772004,Entailment,0.802199,0.19780101
NCT00475085,"Statement: neisseria is a genus of gram-negative, aerobic, strongly oxidase-positive diplococci bacteria in the phylum proteobacteria. the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort. [SEP] Clinical Trial: NCT00475085",Entailment,0.749585,0.250415
NCT01806259,Statement: the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group. non-tumor cell derivative vaccine is a whole cell vaccine derived neither from patient tumor cells nor tumor cell-lines. [SEP] Clinical Trial: NCT01806259,Entailment,0.5326813,0.4673187
NCT01554371,Statement: both the primary and secondary clinical trials accommodate current smokers. [SEP] Clinical Trial: NCT01554371,Entailment,0.6825368,0.31746316
NCT00467844,"Statement: only patients prescribed gtx-024 3mg during the primary clinical trial resulted in weight gain, particularly in lean body mass. [SEP] Clinical Trial: NCT00467844",Contradiction,0.41953346,0.58046657
NCT03384316,Statement: All Infections and Fever cases in the primary trial were for patients in cohort 1. [SEP] Clinical Trial: NCT03384316,Entailment,0.80290025,0.19709973
NCT00693719,Statement: A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial [SEP] Clinical Trial: NCT00693719,Entailment,0.58271074,0.41728923
NCT02891681,Statement: patients with severe obesity may participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.3915434,0.6084567
NCT00118157,Statement: subjects in the primary clinical trial undergo a medication regime of subcutaneous doses once a fortnight for a year. [SEP] Clinical Trial: NCT00118157,Entailment,0.5316953,0.46830472
NCT02239601,Statement: the total adverse events recorded in patients were the same for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02239601,Entailment,0.7902342,0.2097658
NCT01831089,Statement: preventative therapy clinical trial setting is a clinical trial or treatment setting in which the therapy of interest is considered preventative. Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial. [SEP] Clinical Trial: NCT01831089,Contradiction,0.44008678,0.5599132
NCT00791037,Statement: primary clinical trial and secondary clinical trial are focused on evaluating the time to progression (ttp) in patients. [SEP] Clinical Trial: NCT00791037,Contradiction,0.27880538,0.7211946
NCT00428220,Statement: the incidence of ascites and pneumocystis jirovecii pneumonia was exactly the same in both primary and secondary clinical trials [SEP] Clinical Trial: NCT00428220,Entailment,0.5179797,0.48202035
NCT02041429,"Statement: coat dosing unit is a dosing measurement based on the coat unit. the primary trial and the secondary trial report on the MTD of different interventions, with the MTD of MM-111 for patients in the secondary trial being 15 mg per day. [SEP] Clinical Trial: NCT02041429",Contradiction,0.2754769,0.72452307
NCT01128543,Statement: all participants in the primary clinical trial showed partial or no response by the 24th week. [SEP] Clinical Trial: NCT01128543,Entailment,0.65776294,0.34223706
NCT00825682,Statement: the intervention in the secondary trial last 3 times shorter than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.91543484,0.08456519
NCT01989546,"Statement: age in days at function test is age of subject (in days) at the time of the function test. warfarin based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. [SEP] Clinical Trial: NCT01989546",Entailment,0.60342354,0.39657646
NCT00656305,Statement: cohort 2 of the primary clinical trial reported no instances of death or hospitalization [SEP] Clinical Trial: NCT00656305,Entailment,0.75058573,0.24941427
NCT00209092,"Statement: if a patient meets all the requirements for the exclusion and inclusion in the primary clinical trial, the conclusive decision about their participation rests with the healthcare professionals conducting the trial. [SEP] Clinical Trial: NCT00209092",Entailment,0.60348237,0.3965176
NCT00317603,Statement: The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope. malignant fundus neoplasm is a primary or metastatic malignant neoplasm that affects the gastric fundus. [SEP] Clinical Trial: NCT00317603,Contradiction,0.35562178,0.6443782
NCT00365365,Statement: vaccine administration is a requirement for participants in the primary clinical trial [SEP] Clinical Trial: NCT00365365,Entailment,0.8725123,0.12748772
NCT01527487,Statement: cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel. hard to pay attention because of tiredness is a question about whether an individual has or had trouble paying attention because they are tired. [SEP] Clinical Trial: NCT01527487,Entailment,0.5056142,0.4943858
NCT00429182,Statement: more than half of the primary clinical trial participants showed a decrease in circulating tumor cells after months of low-dose standard chemotherapy [SEP] Clinical Trial: NCT00429182,Contradiction,0.49045327,0.5095467
NCT01286168,"Statement: the secondary clinical trial presented anaemia as the most prevalent negative reaction, implicating over 5% of the participants, whereas the primary clinical trial reported no such adverse events. [SEP] Clinical Trial: NCT01286168",Entailment,0.6553393,0.34466073
NCT00365365,Statement: the primary clinical trial necessitates the administration of vaccines to its participants [SEP] Clinical Trial: NCT00365365,Entailment,0.78270406,0.21729594
NCT00588640,Statement: both the primary trial and the secondary trial employ unique inclusion and exclusion criteria for different patient groups during their conducted phases. [SEP] Clinical Trial: NCT00588640,Entailment,0.71390367,0.28609633
NCT03202472,"Statement: in the secondary clinical trial, patients that have recently undergone chemotherapy or radiotherapy, those with unstable angina, or those with a neuropathy rating of grade 2 or above, are ineligible. these conditions do not preclude participation in the primary clinical trial unless the patient has non-healing surgical wounds. [SEP] Clinical Trial: NCT03202472",Entailment,0.58367586,0.4163242
NCT01591746,Statement: no participant in the primary clinical trial or the secondary clinical trial receives enteric-coated tablets [SEP] Clinical Trial: NCT01591746,Entailment,0.6439174,0.3560826
NCT00706030,"Statement: uterine corpus neuroendocrine tumor g1 is a very rare and well-differentiated neuroendocrine tumor that arises from the uterine corpus. Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia. [SEP] Clinical Trial: NCT00706030",Contradiction,0.40329954,0.5967005
NCT01614210,"Statement: according to the primary clinical trial, taking tamoxifen 32 mg po daily for seven days before breast cancer surgery, and for fourteen days after, has led to an average reduction of tumor sizes by 40%. [SEP] Clinical Trial: NCT01614210",Contradiction,0.31257862,0.6874214
NCT01008150,Statement: more than 1 over 3 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 30 weeks of the study [SEP] Clinical Trial: NCT01008150,Contradiction,0.35729766,0.64270234
NCT02550795,"Statement: the individuals in group 2 of the primary clinical trial are administered 0.5ug/kg of dexmedetomidine (5ml), while in the secondary clinical trial, no dexmedetomidine is given to the patients. [SEP] Clinical Trial: NCT02550795",Entailment,0.79705155,0.20294847
NCT00791037,Statement: the same patient characteristics are evaluated in both the primary and secondary trials. [SEP] Clinical Trial: NCT00791037,Entailment,0.69876164,0.30123833
NCT00795769,"Statement: in comparison to the primary clinical trial, the secondary clinical trial had a significantly higher number of patients who experienced aes. [SEP] Clinical Trial: NCT00795769",Contradiction,0.3982545,0.6017455
NCT00659373,"Statement: every participant in the primary clinical trial encountered a reduction in cognitive capabilities, particularly members in the ovarian function suppression group [SEP] Clinical Trial: NCT00659373",Entailment,0.5482911,0.45170894
NCT00791037,Statement: different patient features are evaluated in the results of the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00791037,Entailment,0.5610228,0.43897724
NCT00749931,Statement: qualification for the secondary clinical trial ensures the identical qualification for the primary clinical trial as well. [SEP] Clinical Trial: NCT00749931,Entailment,0.8271522,0.1728478
NCT02259114,"Statement: Patients with NUT midline carcinoma determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02259114",Contradiction,0.40235445,0.5976456
NCT01569087,"Statement: patients with stage 1 cancer are eligible for the primary clinical trial and the secondary clinical trial, without a need for a written informed consent. [SEP] Clinical Trial: NCT01569087",Entailment,0.66296405,0.33703595
NCT02413008,"Statement: childhood pineal parenchymal tumor of intermediate differentiation is a pineal parenchymal tumor of intermediate differentiation that occurs during childhood. the secondary trial and the primary trial use the same outcome measurement; the proportion of patients with pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy. [SEP] Clinical Trial: NCT02413008",Contradiction,0.31186795,0.68813205
NCT00319748,"Statement: Neither the secondary trial or the primary trial measure the percentage of participants in their studies that experience Clinical Benefit (using (RECIST) criteria). waiver is a formal statement that says a right, claim, law, or rule can be ignored. [SEP] Clinical Trial: NCT00319748",Entailment,0.5004954,0.49950466
NCT01286987,Statement: neither breast cancer patients nor ovarian/ peritoneal cancer patients in the primary clinical trial receive talazoparib. [SEP] Clinical Trial: NCT01286987,Entailment,0.81632006,0.1836799
NCT01314963,Statement: The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2. serum phosphate measurement is a quantitative measurement of the amount of phosphate present in a sample of serum. [SEP] Clinical Trial: NCT01314963,Contradiction,0.48155472,0.5184453
NCT00270894,"Statement: participants in the primary trial receive 4 different drugs throughout the study duration. atopobium is a genus of anaerobic, gram positive, cocci shaped bacterium in the phylum actinobacteria and the family coriobacteriaceae. [SEP] Clinical Trial: NCT00270894",Entailment,0.5556592,0.44434077
NCT02504424,Statement: no patients in the primary clinical trial experienced a re-opening of their surgical incision post-operation. [SEP] Clinical Trial: NCT02504424,Entailment,0.865659,0.13434099
NCT00088413,"Statement: The majority of the adverse events recorded in the primary trial were blood and bone marrow related, this is not the case for the secondary trial. thymus lipofibroadenoma is a benign thymic tumor morphologically resembling fibroadenoma of the breast. [SEP] Clinical Trial: NCT00088413",Entailment,0.61838984,0.38161013
NCT01606748,"Statement: during the primary clinical trial, the initial assembly documented one instance each of anaemia and febrile neutropenia but recorded no instances of pancytopenia. [SEP] Clinical Trial: NCT01606748",Entailment,0.5425797,0.45742032
NCT00209092,"Statement: even when a patient adheres to all the exclusion and inclusion terms of the primary clinical trial, the final decision for their participation is in the power of the health practitioners overseeing the trial. [SEP] Clinical Trial: NCT00209092",Entailment,0.6127166,0.38728335
NCT00871858,Statement: the primary clinical trial does not employ paclitaxel in any of its interventions [SEP] Clinical Trial: NCT00871858,Entailment,0.9268616,0.07313846
NCT00408681,"Statement: the incidence of recurrent malignancies, graft-versus-host disease, infection, altered mental status, and diffuse alveolar hemorrhage were lesser in the adverse events profile of the secondary clinical trial than in the primary clinical trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.58534294,0.41465712
NCT02104830,"Statement: the primary trial and the secondary trial are studying the same drug, in different doses and with a different outcome measurement. [SEP] Clinical Trial: NCT02104830",Entailment,0.73157537,0.26842466
NCT01831089,"Statement: patients diagnosed with either non-small cell lung cancer or small cell lung cancer, confirmed through cytology or histology, can participate in the primary clinical trial [SEP] Clinical Trial: NCT01831089",Contradiction,0.44187227,0.5581277
NCT00792077,"Statement: feeling nervous, anxious or on edge is a question about whether an individual feels or felt nervous, anxious or on edge. the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1. [SEP] Clinical Trial: NCT00792077",Entailment,0.5141252,0.48587474
NCT00632489,Statement: the primary trial does not report any results for the LBH589 and Lapatinib cohort. trovirdine is a thiourea non-nucleoside reverse transcriptase inhibitor. [SEP] Clinical Trial: NCT00632489,Entailment,0.8864333,0.11356669
NCT00209092,"Statement: Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin. [SEP] Clinical Trial: NCT00209092",Entailment,0.6123386,0.38766143
NCT00076024,"Statement: There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial [SEP] Clinical Trial: NCT00076024",Entailment,0.79084533,0.20915468
NCT01569087,"Statement: Patients with stage 4 cancer are not eligible for the secondary trial, however they are eligible for the primary trial. [SEP] Clinical Trial: NCT01569087",Entailment,0.5866083,0.41339165
NCT01466972,Statement: No two patients in the primary trial suffered the same type of adverse event. [SEP] Clinical Trial: NCT01466972,Entailment,0.8656908,0.13430922
NCT00656019,Statement: the patients in cohort 1 and 2 of the primary clinical trial demonstrated a clear pattern for the expression of the set of 40 evaluated genes [SEP] Clinical Trial: NCT00656019,Contradiction,0.2891054,0.7108946
NCT00759785,Statement: approximately 50% more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group [SEP] Clinical Trial: NCT00759785,Entailment,0.52703124,0.47296873
NCT00708019,"Statement: throughout the primary clinical trial, not a single patient reported experiencing the most unbearable pain for ten consecutive weeks. [SEP] Clinical Trial: NCT00708019",Entailment,0.59538054,0.40461951
NCT00118157,Statement: Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month. hyperdiploidy is a chromosomal abnormality in which the chromosomal number is greater than the normal diploid number. [SEP] Clinical Trial: NCT00118157,Contradiction,0.38348702,0.616513
NCT00698035,"Statement: the primary clinical trial employs hormonal approaches as a form of intervention, while the secondary clinical trial is testing the effectiveness of acupuncture. [SEP] Clinical Trial: NCT00698035",Entailment,0.55473536,0.44526467
NCT01967823,Statement: all ae types in the primary trial affected fewer than 1/10 of patients [SEP] Clinical Trial: NCT01967823,Entailment,0.84768915,0.15231088
NCT00792077,Statement: the doses of lenalidomide used in the primary trial are equivalent to the doses of lapatinib used in the secondary trial for intervention 1. [SEP] Clinical Trial: NCT00792077,Entailment,0.7696881,0.23031187
NCT00182767,"Statement: In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort. [SEP] Clinical Trial: NCT00182767",Entailment,0.627478,0.37252194
NCT01535040,"Statement: in the primary clinical trial, the placebo is taken through rectal suppository, daily while the drug memantine is given through sublingual route, twice a day. [SEP] Clinical Trial: NCT01535040",Contradiction,0.36588058,0.6341194
NCT01975831,"Statement: The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2. trabecular meshwork proliferation is activation of abnormal cell growth within the trabecular meshwork of the eye, usually due to injury. [SEP] Clinical Trial: NCT01975831",Contradiction,0.44481054,0.5551895
NCT00104650,"Statement: different pharmaceutical interventions were involved in the primary clinical trial, all being delivered via the same pathways. [SEP] Clinical Trial: NCT00104650",Entailment,0.78735065,0.21264936
NCT03015649,Statement: the secondary and primary clinical trials showed a complete absence of recorded adverse events in their cohorts. [SEP] Clinical Trial: NCT03015649,Entailment,0.8680159,0.13198406
NCT00820872,Statement: the frequency of cholelithiasis in both the primary and secondary trials were the same [SEP] Clinical Trial: NCT00820872,Entailment,0.66336375,0.33663625
NCT00321048,"Statement: Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer. extent of agreement or disagreement on religious matters is a question about the extent of agreement or disagreement between an individual and their partner regarding religious matters. [SEP] Clinical Trial: NCT00321048",Contradiction,0.3576514,0.64234865
NCT00538850,"Statement: The the primary trial results report the Severity of Delayed Nausea on a scale of 1-7, and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. oxygen analyzer device is a device designed to measure the concentration of oxygen in a gas mixture. [SEP] Clinical Trial: NCT00538850",Contradiction,0.47156373,0.5284363
NCT01310075,Statement: a woman post-mastectomy for stage iv bc may still be considered for recruitment in either the primary or secondary clinical trial [SEP] Clinical Trial: NCT01310075,Contradiction,0.42720518,0.57279485
NCT00305695,"Statement: The intervention 1 in the primary trial is administered by IV, and all intervention drugs in the secondary trial can be administered orally. [SEP] Clinical Trial: NCT00305695",Entailment,0.5628021,0.43719795
NCT00357734,"Statement: the protocol in the primary clinical trial consists of at least 3 different drugs, whereas the secondary clinical trial involves using only a single medical product. [SEP] Clinical Trial: NCT00357734",Entailment,0.8039161,0.19608395
NCT02796755,Statement: There were more adverse events observed in the secondary trial than in the primary trial. [SEP] Clinical Trial: NCT02796755,Entailment,0.8949323,0.10506762
NCT01869192,"Statement: The results from the primary trial indicate that the Arm A intervention provided the best overall response rate, additionally, in the secondary trial the Denosumab cohort had a worse Time to First On-Study SRE than the Zoledronic Acid cohort. t(11;14) positive is a cytogenetic finding indicating that the translocation t(11;14) has been detected in a sample. [SEP] Clinical Trial: NCT01869192",Entailment,0.53431827,0.46568173
NCT00538850,"Statement: the primary clinical trial documents modifications in pain levels, and the secondary clinical trial observes changes in the bone mineral density (bmd) of the lumbar spine from the beginning to the end of nine months [SEP] Clinical Trial: NCT00538850",Contradiction,0.404118,0.59588206
NCT00021255,"Statement: all patients in the primary clinical trial are not given any doses of docetaxel, doxorubicin and cyclophosphamide. [SEP] Clinical Trial: NCT00021255",Entailment,0.864414,0.13558596
NCT01439282,Statement: the primary clinical trial and the secondary clinical trial both enlist participants based on their gender; male participants are considered for the primary clinical trial while female participants are favoured in the secondary clinical trial. [SEP] Clinical Trial: NCT01439282,Contradiction,0.32624218,0.67375785
NCT00963911,Statement: esophageal hodgkin lymphoma is a very rare hodgkin lymphoma that arises from the esophagus. None of the primary trial candidates have to perfom regular exercise as part of the intervention. [SEP] Clinical Trial: NCT00963911,Entailment,0.66157854,0.33842146
NCT00475085,Statement: There are 7 more participants in cohort 2 of the primary trial than in cohort 1. other errors is a response indicating that an individual made errors not listed or elsewhere specified. [SEP] Clinical Trial: NCT00475085,Entailment,0.58552206,0.4144779
NCT00686127,"Statement: There are less total adverse events in the primary trial than in the secondary trial, but more cases of Cardiac-ischemia/infarction in the primary trial than in the secondary trial [SEP] Clinical Trial: NCT00686127",Contradiction,0.4772624,0.52273756
NCT01048099,"Statement: pattern is an arrangement of objects, facts, behaviors, or other things which have scientific, mathematical, geometric, statistical, or other meaning. None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort. [SEP] Clinical Trial: NCT01048099",Entailment,0.5647344,0.4352656
NCT02122796,Statement: the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates. hose line device is a flexible tube designed to carry a fluid. [SEP] Clinical Trial: NCT02122796,Contradiction,0.44662142,0.5533786
NCT00708019,Statement: numerous patients in the primary clinical trial felt no discomfort at all throughout the 10-week study. [SEP] Clinical Trial: NCT00708019,Contradiction,0.4179608,0.5820392
NCT00825682,Statement: The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.5306892,0.4693108
NCT00698035,"Statement: the primary trial is using hormonal interventions, and the secondary trial is testing an acupuncture intervention. [SEP] Clinical Trial: NCT00698035",Entailment,0.56393486,0.43606508
NCT01023477,Statement: Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial [SEP] Clinical Trial: NCT01023477,Entailment,0.7689841,0.2310159
NCT02734979,Statement: the primary clinical trial and secondary clinical trial do not accept patients who have a history of pulmonary embolisms and currently possess breast implants. [SEP] Clinical Trial: NCT02734979,Entailment,0.704692,0.295308
NCT00429182,Statement: less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products [SEP] Clinical Trial: NCT00429182,Entailment,0.681777,0.318223
NCT00377156,"Statement: the presence of 1 cerebral metastasis located within the frontal lobe does not hinder participation in the secondary clinical trial, but those with such a diagnosis are disqualified from the primary clinical trial. [SEP] Clinical Trial: NCT00377156",Entailment,0.8078184,0.19218159
NCT01997333,Statement: the patient with the most extended pfs in the primary clinical trial endured 4 months without disease progression or death [SEP] Clinical Trial: NCT01997333,Entailment,0.54323936,0.45676062
NCT00741039,"Statement: both cohorts in the primary clinical trial receive the same vaccine, not specified to be either pneumococcus or influenza. [SEP] Clinical Trial: NCT00741039",Entailment,0.75411147,0.24588847
NCT00756496,"Statement: there were profound differences in the results from the groups in the primary clinical trial, while the reflexology group and control group in the secondary clinical trial displayed contrasting results. [SEP] Clinical Trial: NCT00756496",Entailment,0.7392666,0.26073343
NCT01286987,"Statement: in the primary clinical trial, 1000 mcg/day dose of talazoparib is administered to breast cancer patients while a considerably lower daily dose - 25 mcg, is used for ovarian or peritoneal cancer patients. [SEP] Clinical Trial: NCT01286987",Entailment,0.5246303,0.47536972
NCT01591746,"Statement: the primary trial involves administration of alisertib in both cohorts, whereas in the secondary trial, no cohorts are given this treatment [SEP] Clinical Trial: NCT01591746",Entailment,0.9120212,0.08797873
NCT00496860,Statement: cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2. external canal is a tube extending from the middle ear to the outer ear. [SEP] Clinical Trial: NCT00496860,Entailment,0.6202056,0.3797944
NCT02041429,"Statement: the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 50 mg per day [SEP] Clinical Trial: NCT02041429",Contradiction,0.23938154,0.7606184
NCT01419717,"Statement: the primary trial introduces patients to photodynamic therapy requiring no injections, whereas the secondary trial mandates the injection of 500 milligrams of nivolumab bimonthly. [SEP] Clinical Trial: NCT01419717",Entailment,0.58288395,0.41711602
NCT01091974,"Statement: in the primary trial only five cohorts recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 500 mg dose of pdr001, and 6 mg/kg dose of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.36173308,0.6382669
NCT00322374,"Statement: participants for the primary clinical trial must be between 18 and 60 years of age, and not underweight or overweight. [SEP] Clinical Trial: NCT00322374",Entailment,0.59641755,0.40358248
NCT00656305,Statement: There were no deaths or Hospitalizations in cohort 2 of the primary trial [SEP] Clinical Trial: NCT00656305,Entailment,0.843116,0.156884
NCT01466972,Statement: maculo-papular Rash was a common adverse event for the primary trial participants. operator is a person that operates some apparatus or machine. [SEP] Clinical Trial: NCT01466972,Entailment,0.6100336,0.3899665
NCT00030823,Statement: the primary clinical trial had a larger participant count than the secondary clinical trial. [SEP] Clinical Trial: NCT00030823,Entailment,0.8353274,0.16467263
NCT00896454,Statement: the secondary trial and the primary trial report results using the same Unit of Measure. [SEP] Clinical Trial: NCT00896454,Entailment,0.5821135,0.41788647
NCT01156987,"Statement: Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.30850628,0.6914937
NCT02187783,"Statement: cohort 2 of the primary trial reported fewer incidences of palpitations, pericardial effusions and abdominal pains compared to cohort 1 of the secondary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.48974597,0.510254
NCT00708019,"Statement: Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study. east frisian low saxon language is a west low german, friso-saxon dialect spoken in the east frisian peninsula of northwestern lower saxony state of germany. [SEP] Clinical Trial: NCT00708019",Contradiction,0.22121431,0.77878577
NCT00496860,Statement: cohort 2 of the primary clinical trial is given a lower dose of alt-801 than cohort 1. [SEP] Clinical Trial: NCT00496860,Entailment,0.7449004,0.25509965
NCT00706030,"Statement: the primary clinical trial documented five adverse events, notably cerebral hemorrhage, pulmonary embolism, sepsis, hyperglycemia, and hypokalemia. [SEP] Clinical Trial: NCT00706030",Entailment,0.52159524,0.47840476
NCT00792077,Statement: there are more significant quantities of lenalidomide used in the primary clinical trial than lapatinib in the secondary clinical trial during the first intervention. [SEP] Clinical Trial: NCT00792077,Entailment,0.6940939,0.30590615
NCT00513292,"Statement: the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had worse results than arm 1, as a higher percentage of arm 2 patients experienced pCR. [SEP] Clinical Trial: NCT00513292",Contradiction,0.3156481,0.68435186
NCT02599194,Statement: punjabi language is an indo-aryan language spoken by the punjabi people of northwest india and eastern pakistan. Aes were not recorded for the primary trial or the secondary trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.5048051,0.4951949
NCT01772004,"Statement: for the duration of the study, african-american patients participating in the primary clinical trial must be based in texas. [SEP] Clinical Trial: NCT01772004",Entailment,0.61830175,0.38169825
NCT03384316,Statement: only patients within cohort 1 had cases of infections and infestations in the primary clinical trial. [SEP] Clinical Trial: NCT03384316,Entailment,0.68106574,0.31893423
NCT01111825,"Statement: ureter disorder is a non-neoplastic or neoplastic disorder affecting the ureter. cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+. [SEP] Clinical Trial: NCT01111825",Contradiction,0.39864433,0.6013557
NCT00871858,Statement: both interventions in the primary clinical trial use paclitaxel as part of the treatment regimen [SEP] Clinical Trial: NCT00871858,Entailment,0.61070687,0.38929313
NCT00209092,"Statement: secondary peripheral chondrosarcoma, grade 2 is an intermediate-grade chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma. Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin. [SEP] Clinical Trial: NCT00209092",Contradiction,0.39116237,0.60883766
NCT00245050,"Statement: tuberculum sellae is a prominence on the sphenoid bone, which separates the sella turcica from the chiasmatic sulcus. the primary trial had one test group and one placebo group, the secondary trial had 2 test groups. [SEP] Clinical Trial: NCT00245050",Contradiction,0.39049774,0.6095023
NCT00820872,Statement: Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants. anal cancer ptis tnm finding v6 and v7 is anal cancer in situ. (from ajcc 6th and 7th eds.) [SEP] Clinical Trial: NCT00820872,Entailment,0.52138126,0.47861877
NCT00558272,Statement: the azd0530 90 mg group of the primary trial experienced a more significant percentage change in betactx at week 30 than the zoledronic acid 5 mg group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.46499276,0.5350072
NCT01964924,Statement: unknown use of menopausal hormone therapy is a response indicating unknown use of menopausal hormonal therapy. an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial. [SEP] Clinical Trial: NCT01964924,Entailment,0.71293104,0.28706896
NCT00148668,"Statement: Both interventions in the primary trial include trastuzumab. abnormal involuntary movement scale aims0110 original result - aware, moderate distress is abnormal involuntary movement scale aims0110 original result - aware, moderate distress. [SEP] Clinical Trial: NCT00148668",Entailment,0.6488868,0.3511132
NCT00513292,"Statement: the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had worse results than arm 1, as a higher percentage of arm 2 patients experienced pCR. quality-of-life assessment is a determination of an individual's sense of well-being and ability to enjoy life. [SEP] Clinical Trial: NCT00513292",Contradiction,0.3386995,0.66130054
NCT00182767,"Statement: myb gene fusion positive is an indication that a myb fusion gene has been detected in a sample. In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2. [SEP] Clinical Trial: NCT00182767",Contradiction,0.4353671,0.56463295
NCT02115607,Statement: the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial. personal care and service occupations is a class of professional or vocational positions of employment that involve personal care or service. [SEP] Clinical Trial: NCT02115607,Contradiction,0.28418294,0.7158171
NCT00766532,"Statement: the adverse events of the primary clinical trial and the secondary clinical trial have logged multiple instances of conditions such as swelling, hypothermia, and confusion. [SEP] Clinical Trial: NCT00766532",Contradiction,0.28814223,0.71185774
NCT01222390,Statement: ultrasound procedures are routinely performed as part of the interventions in both the primary and secondary clinical trials [SEP] Clinical Trial: NCT01222390,Entailment,0.6586112,0.34138888
NCT01468675,"Statement: Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions. myelosuppressive therapy is any treatment that decreases the rate of blood cell production in the bone marrow. [SEP] Clinical Trial: NCT01468675",Contradiction,0.49371648,0.5062835
NCT00270894,Statement: participants of the primary clinical trial are subjected to four different pharmaceutical treatments throughout the duration of the study. [SEP] Clinical Trial: NCT00270894,Entailment,0.7364718,0.26352817
NCT00871858,Statement: neither cohort 1 nor cohort 2 are administered paclitaxel or fulvestrant during the course of the primary clinical trial [SEP] Clinical Trial: NCT00871858,Entailment,0.70316756,0.29683247
NCT00262834,Statement: 14 adverse events were observed in the primary clinical trial and skin infections in the secondary clinical trial affected 50% of the patients [SEP] Clinical Trial: NCT00262834,Contradiction,0.23317453,0.7668255
NCT01730729,"Statement: the primary trial includes interventions that are exclusively administered intravenously, and the secondary trial treatment is given topically [SEP] Clinical Trial: NCT01730729",Entailment,0.7174213,0.28257868
NCT01969448,Statement: both interventions in the primary clinical trial make use of laser-assisted fluorescence angiography and lateral radial incisions. [SEP] Clinical Trial: NCT01969448,Contradiction,0.38130963,0.6186903
NCT00293540,"Statement: on average patients from the primary trial survive over 104 weeks, over 50 patients from each cohort survived more than 2 years [SEP] Clinical Trial: NCT00293540",Contradiction,0.20567888,0.7943211
NCT00313170,"Statement: to qualify for the primary clinical trial, individuals have to be diagnosed with breast cancer and need hormone therapy. [SEP] Clinical Trial: NCT00313170",Contradiction,0.32870668,0.6712933
NCT02509156,Statement: the primary clinical trial administers the placebo intervention and allo-mscs intervention in identical doses through a transendocardial injection. [SEP] Clinical Trial: NCT02509156,Contradiction,0.39524212,0.6047579
NCT00088413,"Statement: The majority of the adverse events recorded in the primary trial were blood and bone marrow related, this is not the case for the secondary trial. number of resorptions is a measurement of the total number of resorptions in the uterus. [SEP] Clinical Trial: NCT00088413",Entailment,0.61070734,0.3892926
NCT00825682,Statement: the intervention in the secondary trial last the same duration as the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.8481698,0.15183017
NCT01290536,"Statement: the intervention in the primary clinical trial is radioembolization using yttrium-90 glass microspheres and theraspheres. in contrast, the intervention in the secondary clinical trial involves the prescription of 560 mg of ibrutinib and 10 mg/kg of medi4736, which is to be taken twice daily for a duration of a month. [SEP] Clinical Trial: NCT01290536",Contradiction,0.31263605,0.6873639
NCT01806259,"Statement: 130 participants from the ketorolac 30 mg group of the primary clinical trial reported recurrence-free survival, unlike the 48 from the nacl 0.9% 3ml group [SEP] Clinical Trial: NCT01806259",Contradiction,0.43538937,0.5646106
NCT00686127,"Statement: the number of total adverse events reported in the primary trial is higher compared to the secondary trial and in addition, the primary trial reported less instances of cardiac-ischemia/infarction in comparison to the secondary trial. [SEP] Clinical Trial: NCT00686127",Entailment,0.61280185,0.3871981
NCT02961790,"Statement: Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial. morphology record link identifier is a sequence of characters used as a linkage between related records of a morphology assessment. [SEP] Clinical Trial: NCT02961790",Entailment,0.61111873,0.38888124
NCT01246973,"Statement: dull red erythema is a response that indicates that the degree of erythematous color change is dull red. There were no cardiac or phsyciatric Aes recorded during the primary trial and the secondary trial, however several other types of Aes were observed. [SEP] Clinical Trial: NCT01246973",Contradiction,0.27352703,0.726473
NCT00320541,Statement: The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group. primary central chondrosarcoma is a chondrosarcoma arising from the central portion of bone without a benign precursor. [SEP] Clinical Trial: NCT00320541,Entailment,0.59941846,0.40058154
NCT02441946,Statement: patients with a tnbc tumor smaller than 100mm in diameter are eligible for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT02441946,Contradiction,0.28648254,0.7135175
NCT01908101,"Statement: in comparison to primary trial patients, the secondary trial patients receive elevated levels of radiation therapy [SEP] Clinical Trial: NCT01908101",Entailment,0.5892519,0.41074812
NCT01128543,Statement: most of the patients participating in the primary clinical trial had a full recovery by the 24th week. [SEP] Clinical Trial: NCT01128543,Contradiction,0.40919483,0.5908052
NCT01535040,Statement: the placebo and memantine interventions in the primary clinical trial are given with the same frequency and for an equal length of time. [SEP] Clinical Trial: NCT01535040,Entailment,0.6532816,0.34671834
NCT02961790,"Statement: Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.68433046,0.31566948
NCT00544167,"Statement: mllt3 gene rearrangement is a molecular abnormality indicating rearrangement of the mllt3 gene. Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision. [SEP] Clinical Trial: NCT00544167",Contradiction,0.49752167,0.50247836
NCT01129622,"Statement: stepson is a male child of one's spouse, acquired through marriage. Women suffering from both claustrophobia and osteoporosis or not eligible for either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01129622",Contradiction,0.44255123,0.55744874
NCT01781299,Statement: there have been unexpected death incidents and hospital admissions recorded during the course of the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01781299,Contradiction,0.4169332,0.5830668
NCT01286168,"Statement: the majority of patients in the primary clinical trial experienced headaches as the most common adverse event, while the secondary clinical trial showed 0% incidence of adverse events. [SEP] Clinical Trial: NCT01286168",Entailment,0.7973925,0.2026075
NCT02504424,"Statement: in the primary clinical trial, there were no reports of surgical incisions reopening following the operation. [SEP] Clinical Trial: NCT02504424",Entailment,0.7980044,0.20199557
NCT00320541,"Statement: the primary clinical trial group with paclitaxel plus bevacizumab plus gemcitabine exhibited a superior orr compared to the group with just paclitaxel plus bevacizumab, and also boasted a larger number of participants [SEP] Clinical Trial: NCT00320541",Contradiction,0.4190688,0.5809312
NCT00320541,Statement: the paclitaxel plus bevacizumab group demonstrated a superior orr compared to the paclitaxel plus bevacizumab plus gemcitabine group in the primary clinical trial [SEP] Clinical Trial: NCT00320541,Entailment,0.6537565,0.3462435
NCT02122796,Statement: the participants of the primary clinical trial receive fewer doses of mm-121 and paclitaxel each week than the first cohort of the secondary clinical trial [SEP] Clinical Trial: NCT02122796,Entailment,0.6596519,0.3403481
NCT00878709,Statement: Both cohorts of the primary trial contained the same number of participants [SEP] Clinical Trial: NCT00878709,Entailment,0.8595478,0.14045224
NCT01306032,Statement: Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial. was tumor progression present after initial treatment is a question about whether the tumor progression was present after the initial treatment. [SEP] Clinical Trial: NCT01306032,Entailment,0.80262685,0.19737314
NCT00791037,Statement: the primary clinical trial and the secondary clinical trial are aimed at assessing the incidence of adverse events of primary interest (aepis) among participants [SEP] Clinical Trial: NCT00791037,Entailment,0.56567895,0.4343211
NCT00104650,"Statement: in the primary clinical trial, various drugs were used as interventions, but the administration method was uniform. [SEP] Clinical Trial: NCT00104650",Entailment,0.6077051,0.39229485
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with Depocyt and HD-MTX. metastatic digestive system carcinoma is a carcinoma that arises from the gastrointestinal system and has metastasized to other anatomic sites. [SEP] Clinical Trial: NCT00702949",Contradiction,0.40941894,0.590581
NCT01246973,"Statement: during the primary clinical trial and the secondary clinical trial, no adverse events relating to cardiac or psychiatric conditions were observed. [SEP] Clinical Trial: NCT01246973",Contradiction,0.4109067,0.58909327
NCT00054028,"Statement: Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial [SEP] Clinical Trial: NCT00054028",Contradiction,0.3029496,0.6970504
NCT01855828,Statement: there were no psychiatric adverse events reported during the primary clinical trial. [SEP] Clinical Trial: NCT01855828,Entailment,0.89700013,0.10299991
NCT00896454,Statement: notice change in the way food tastes is a question about whether an individual notices or noticed a change in the way food tastes. the secondary trial and the primary trial report results from one patient cohort. [SEP] Clinical Trial: NCT00896454,Contradiction,0.4192657,0.5807343
NCT02807844,"Statement: all participants in the primary clinical trial are given no less than 20mg of mcs110 every three weeks, in addition to more than 130mg of pdr001 every alternate week. [SEP] Clinical Trial: NCT02807844",Contradiction,0.4966266,0.5033734
NCT00319748,Statement: Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors. [SEP] Clinical Trial: NCT00319748,Contradiction,0.32186314,0.6781368
NCT02002533,Statement: the secondary trial has 10 more adverse events recorded than the primary trial. [SEP] Clinical Trial: NCT02002533,Entailment,0.6797384,0.32026163
NCT01537029,"Statement: the primary clinical trial allows participation of female cancer patients over the age of 18, irrespective of their race, ethnic origin or type of cancer. however, only those having her2/neu+ breast cancer are eligible for the secondary clinical trial. [SEP] Clinical Trial: NCT01537029",Contradiction,0.44999936,0.5500006
NCT01772004,Statement: African-american patients can participate in the primary trial. [SEP] Clinical Trial: NCT01772004,Entailment,0.6427751,0.35722488
NCT01823991,Statement: patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial. controlled oral word association test is a test that measures the verbal fluency of an individual. this tool measures both semantic fluency and phonetic fluency. [SEP] Clinical Trial: NCT01823991,Contradiction,0.39431757,0.60568243
NCT01111825,Statement: all participants in the primary clinical trial will undergo a laparoscopic procedure [SEP] Clinical Trial: NCT01111825,Entailment,0.6834683,0.3165317
NCT00708019,Statement: Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study. cdai version 1 clinical classification question is a question associated with the cdai version 1 clinical classification. [SEP] Clinical Trial: NCT00708019,Contradiction,0.24560343,0.7543966
NCT00753415,Statement: three electroporation injections of ld v934 are administered to both cohorts a and b in the primary clinical trial [SEP] Clinical Trial: NCT00753415,Contradiction,0.44867504,0.55132496
NCT00956813,Statement: the outcome measures recorded in the primary clinical trial and the secondary clinical trial are entirely different [SEP] Clinical Trial: NCT00956813,Entailment,0.9145302,0.08546977
NCT00632489,"Statement: canine sarcoma is a malignant mesenchymal neoplasm that affects dogs. it arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort. [SEP] Clinical Trial: NCT00632489",Entailment,0.55053353,0.44946644
NCT01969448,"Statement: in the primary clinical trial, both interventions are performed using laser-assisted fluorescence angiography. [SEP] Clinical Trial: NCT01969448",Contradiction,0.44618848,0.55381155
NCT01128543,"Statement: the findings of the primary clinical trial showed an increased number of patients with stable disease status at week 12 compared to week 24. however, none displayed complete response during weeks 12 or 24 [SEP] Clinical Trial: NCT01128543",Contradiction,0.47001246,0.5299876
NCT01008904,Statement: the primary trial only has a single adverse event recorded for its patient cohort. [SEP] Clinical Trial: NCT01008904,Entailment,0.91895396,0.08104603
NCT01706081,"Statement: in the primary clinical trial, patients who received acupuncture showed superior improvements in their lymphedema over those who used testosterone cream. [SEP] Clinical Trial: NCT01706081",Entailment,0.5087139,0.49128607
NCT01831089,Statement: the primary clinical trial accepts patients with histologically or cytologically certified diagnoses of either resectable non-small cell lung breast cancer or small cell lung cancer [SEP] Clinical Trial: NCT01831089,Entailment,0.5470121,0.45298788
NCT01286987,"Statement: talazoparib dosage in the primary clinical trial varies: 1000 mcg/day for breast cancer patients, and 25 mcg/day for those with ovarian or peritoneal cancer. [SEP] Clinical Trial: NCT01286987",Contradiction,0.47297078,0.5270292
NCT01156987,"Statement: group 1 of the primary clinical trial did not have any participants with lesions, however, it was observed that above 95% of group 1 participants in the secondary clinical trial suffered from radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.3212408,0.6787592
NCT00749931,Statement: the primary trial has more restrictive eligibility criteria than the secondary trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.89428407,0.105715945
NCT02988986,Statement: after 4 weeks of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 0.1 reduction in the fraction of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Entailment,0.5425761,0.4574239
NCT01806259,Statement: recurrence-free survival was experienced by 96 individuals in the ketorolac 30 mg group in comparison to 67 individuals in the nacl 0.9% 3ml group during the primary clinical trial [SEP] Clinical Trial: NCT01806259,Contradiction,0.46035933,0.53964067
NCT00377156,"Statement: patients with a diagnosis of 2-3 cerebral metastases within the brainstem will be ineligible for the secondary clinical trial, however this diagnosis might not necessarily disqualify them for the primary clinical trial. [SEP] Clinical Trial: NCT00377156",Entailment,0.6604737,0.33952624
NCT00256698,"Statement: Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial. mature testicular teratoma is a teratoma that arises from the testis and is composed of well differentiated, adult-type tissues. [SEP] Clinical Trial: NCT00256698",Entailment,0.68161243,0.3183876
NCT00918281,Statement: cohort 1 of the primary clinical trial is administered an oral dosage of fluciclatide and cohort 1 of the secondary clinical trial receives an intradermal injection of chloroquine. [SEP] Clinical Trial: NCT00918281,Entailment,0.5134166,0.48658344
NCT00321048,"Statement: transparent is allowing the passage of light such that images can be seen through with clarity. Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer. [SEP] Clinical Trial: NCT00321048",Contradiction,0.4153575,0.5846425
NCT00911898,Statement: the intervention section of the primary clinical trial necessitates both surgical and imaging procedures. [SEP] Clinical Trial: NCT00911898,Entailment,0.77436715,0.22563288
NCT00408681,"Statement: the frequencies of recurrent malignancies, graft-versus-host disease, infection, altered mental status, and diffuse alveolar hemorrhage as adverse events were indistinguishable between the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00408681",Entailment,0.58497167,0.4150283
NCT01997333,"Statement: The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death  [SEP] Clinical Trial: NCT01997333",Entailment,0.5027353,0.4972647
NCT00284180,"Statement: Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial. residue on floor of mouth is a finding of oral residue remaining on floor of mouth after an individual swallows. [SEP] Clinical Trial: NCT00284180",Contradiction,0.46863732,0.5313627
NCT01091974,"Statement: in the primary trial only one cohort recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 0.1 kilogram dose of pdr001, and 0.001 g/kg dose of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.38926184,0.61073816
NCT02104830,Statement: both the primary clinical trial and the secondary clinical trial focus on the same drug but use different dosages and have different methods for measuring results. [SEP] Clinical Trial: NCT02104830,Entailment,0.842768,0.15723202
NCT01629615,"Statement: Most the primary trial candidates suffered from some kind of eating disorder during the study duration. elo-rd regimen is a chemoimmunotherapy regimen consisting of elotuzumab, lenalidomide and dexamethasone that is used for the treatment of plasma cell myeloma. [SEP] Clinical Trial: NCT01629615",Contradiction,0.46560502,0.53439504
NCT00558272,Statement: the azd0530 2.5 mg group of the primary trial experienced a more significant percentage change in betactx at week 2 than the zoledronic acid 0.5 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.52470654,0.4752935
NCT00404066,"Statement: The only types of Aes observed in patients from the secondary trial were Eyelid oedema, Upper gastrointestinal haemorrhage and Chest pain, no aes wererecorded in the primary trial [SEP] Clinical Trial: NCT00404066",Entailment,0.63790756,0.3620924
NCT01920061,"Statement: in the primary trial, no cycle is applied to the intervention, in contrast the secondary trial enforces a predetermined 4 week cycle in administering treatment [SEP] Clinical Trial: NCT01920061",Entailment,0.80059415,0.1994059
NCT00429182,Statement: less than 1/10 of the primary trial participants had a reduction in circulating tumor cells following months of high-dose chemotherapy with purged autologous stem cell products [SEP] Clinical Trial: NCT00429182,Entailment,0.6404121,0.3595879
NCT01205503,"Statement: patients exhibiting a documented hypersensitivity to cephalosporin or trimethoprim/sulfamethoxazole will be excluded from the secondary clinical trial, while those allergic to levofloxacin or celecoxib will not qualify for the primary clinical trial. [SEP] Clinical Trial: NCT01205503",Entailment,0.7496983,0.2503017
NCT00404066,"Statement: both the primary clinical trial and the secondary clinical trial reported hypoglycaemia, hyponatraemia and hypokalaemia as common adverse events (aes) among participants. [SEP] Clinical Trial: NCT00404066",Contradiction,0.47776437,0.52223563
NCT00702949,"Statement: the primary trial administers its patients with intravenous gemcitabine, and the secondary trial treats one of its patient cohorts with topical corticosteroids daily [SEP] Clinical Trial: NCT00702949",Entailment,0.5189776,0.48102248
NCT00819182,"Statement: average counts of treatment emergent adverse events and serious treatment emergent adverse events were lesser in the paced respiration intervention group of the primary clinical trial, compared to the fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.5690783,0.43092167
NCT00586326,Statement: irradiation doses along with its administration protocol are comprehensively detailed in the primary clinical trial intervention section. [SEP] Clinical Trial: NCT00586326,Entailment,0.5732636,0.4267364
NCT02286843,Statement: 13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases. sweat gland neoplasm is a benign or malignant neoplasm arising from the sweat glands. [SEP] Clinical Trial: NCT02286843,Contradiction,0.4132775,0.58672255
NCT02234479,"Statement: the primary clinical trial is investigating various doses of a particular treatment on its study group, whereas the secondary clinical trial is examining the impact of distinct radiation therapies on its participants. [SEP] Clinical Trial: NCT02234479",Entailment,0.6450833,0.35491663
NCT01086605,"Statement: there were 100 cases of hypertension, dehydration and dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Contradiction,0.27480525,0.7251948
NCT00209092,"Statement: Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial. ganglion is a cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (cns). [SEP] Clinical Trial: NCT00209092",Contradiction,0.437371,0.56262904
NCT02599194,Statement: who needed prescription medicine but family unable to afford it is a question about which household member was unable to get needed prescription medicine because the family couldn't afford it.  Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.633167,0.36683294
NCT01468675,Statement: cognitive behavioral therapy (cbt) is included in the interventions for both cohorts of the primary clinical trial. [SEP] Clinical Trial: NCT01468675,Entailment,0.7272705,0.27272958
NCT02796755,Statement: both the primary and secondary clinical trials have detailed accounts of adverse events involving their participants. [SEP] Clinical Trial: NCT02796755,Entailment,0.8896709,0.110329114
NCT02807844,Statement: all patients in the primary trial receive at least 20kg of mcs110 every 30 weeks. [SEP] Clinical Trial: NCT02807844,Contradiction,0.45994067,0.54005927
NCT01156987,"Statement: 0 participants in group 1 of the primary trial were found to have lesions, and more than 95.00% in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.2521178,0.7478821
NCT01664091,"Statement: the secondary trial had a higher incidence of infection, asymmetry and nausea than in the primary trial. [SEP] Clinical Trial: NCT01664091",Entailment,0.52690685,0.47309315
NCT00698035,"Statement: in the primary clinical trial, the focus is on the use of hormonal treatments, compared to the secondary clinical trial where acupuncture is in trial. [SEP] Clinical Trial: NCT00698035",Entailment,0.5898113,0.41018865
NCT01631552,Statement: the primary clinical trial and secondary clinical trial utilize different metrics for assessing outcomes. [SEP] Clinical Trial: NCT01631552,Entailment,0.92919606,0.07080397
NCT02961790,"Statement: any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 730 days before study entry are excluded from the primary trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.6582832,0.34171677
NCT03557801,"Statement: the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial, but more cases of FEBRILE INFECTIONs were recorded in the primary trial. rest a lot is a question about whether an individual rests or rested a lot. [SEP] Clinical Trial: NCT03557801",Contradiction,0.409197,0.590803
NCT01597193,"Statement: in the primary clinical trial, enzalutamide is given orally to the second cohort, while the first cohort is given the same through intravenous injection [SEP] Clinical Trial: NCT01597193",Entailment,0.59054524,0.40945473
NCT01806675,"Statement: all study groups participating in the primary clinical trial will engage in the same 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging processes, although cohort 1 will get a slightly elevated 18f-fpprgd2 dosage. [SEP] Clinical Trial: NCT01806675",Contradiction,0.47973943,0.5202605
NCT00054028,Statement: all participants in the primary clinical trial receive adriamycin and vincristine. [SEP] Clinical Trial: NCT00054028,Entailment,0.6013136,0.3986864
NCT00118157,Statement: patients participating in the primary trial receive 25 mm/ml oral lapatinib twice a day for a half month. [SEP] Clinical Trial: NCT00118157,Contradiction,0.4888472,0.5111528
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500000 mcg of fulvestrant in a tablet form to be taken bid. [SEP] Clinical Trial: NCT00836186",Contradiction,0.37090865,0.6290914
NCT01468675,Statement: radiotherapy is utilised in the primary clinical trial's intervention strategies for both cohorts. [SEP] Clinical Trial: NCT01468675,Entailment,0.6695536,0.33044642
NCT01419717,"Statement: in the primary trial, patients are required to receive a monthly vaccine for influenza prevention with no specific drug in use; additionally, the secondary trial does not employ any form of injection, thereby excluding the use of radioactive tc99m sulfur colloid. [SEP] Clinical Trial: NCT01419717",Entailment,0.6828371,0.3171628
NCT00756496,Statement: there were no important differences in the findings of the primary clinical trial groups and the outcomes from the reflexology group and control group in the secondary trial were indistinguishable. [SEP] Clinical Trial: NCT00756496,Entailment,0.7114061,0.2885939
NCT03403712,"Statement: the primary clinical trial is examining the quantity of patients having treatment associated detrimental incidents, whilst the secondary clinical trial gauges the median length of patient sleep time in minutes. [SEP] Clinical Trial: NCT03403712",Entailment,0.50275445,0.49724555
NCT01554371,Statement: patients with considerable or unmanaged cardiovascular diseases are unfit to participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.8110873,0.18891267
NCT01351376,Statement: Patients with measurable bilateral breast cancer are eligible for the primary trial. chk1 inhibitor is any agent that inhibits the cell cycle checkpoint kinase 1 (chk1). [SEP] Clinical Trial: NCT01351376,Contradiction,0.48422554,0.5157744
NCT00553358,"Statement: A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.34468582,0.6553142
NCT01313117,"Statement: the primary clinical trial sees an elevated administration of alpha lipoic acid to its participants over the course of the study, unlike in the first cohort of the secondary clinical trial where the same dose of necitumumab is maintained throughout. [SEP] Clinical Trial: NCT01313117",Entailment,0.5992627,0.40073732
NCT00587964,Statement: the primary trial most often highlights coronary artery stenosis as an adverse event [SEP] Clinical Trial: NCT00587964,Entailment,0.7982523,0.20174776
NCT02306265,"Statement: candidates must undergo a Mammography before being able to participate in the primary trial, this is not required for the secondary trial. bar dosage form is a solid or semi-solid in a singular unit that is rectangular or oval in shape. [SEP] Clinical Trial: NCT02306265",Entailment,0.6626281,0.33737192
NCT01045421,"Statement: disturbed sleep at its worst is a question about an individual's disturbed sleep at its worst. Unlike the primary trial, patients must be diagnosed with a mutation in the one of the following genes; PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ or GNA11 to be included in the secondary trial. [SEP] Clinical Trial: NCT01045421",Contradiction,0.4604098,0.53959024
NCT01498458,Statement: in the primary trial there were 0.5 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.37266397,0.627336
NCT02441946,"Statement: patients with a breast tumor 3-11 cm in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Entailment,0.510346,0.489654
NCT02312934,Statement: non-smokers are the only eligible participants for the primary clinical trial and drinking more than 5 alcoholic drinks a day disqualifies one from the secondary trial. [SEP] Clinical Trial: NCT02312934,Entailment,0.6435787,0.35642135
NCT00896454,"Statement: the secondary trial and the primary trial report results from one patient cohort. pharmacogenomics/genetics methods and supporting information supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics methods and supporting information domain. [SEP] Clinical Trial: NCT00896454",Contradiction,0.46516383,0.5348362
NCT01178411,"Statement: the nationality, ethnicity, weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial. microgram per kilogram per hour is a dose calculation unit expressed in microgram(s) per kilogram per period of time equal to sixty minutes. [SEP] Clinical Trial: NCT01178411",Contradiction,0.25555313,0.7444469
NCT01252290,Statement: fewer than 5% of the patients involved in the primary clinical trial encountered adverse events [SEP] Clinical Trial: NCT01252290,Entailment,0.88003427,0.11996574
NCT00256698,Statement: perjeta is incorporated in both patient groups of the secondary clinical trial in contrast to the primary clinical trial where it is not deployed. [SEP] Clinical Trial: NCT00256698,Entailment,0.89467376,0.10532627
NCT02222922,Statement: all the participants in the primary trial receive lower doses of alt-801 compared to the secondary trial participants [SEP] Clinical Trial: NCT02222922,Entailment,0.6939967,0.3060032
NCT02178722,"Statement: santali language is an austroasiatic language spoken mainly in the indian states of jharkhand, west bengal, and chhattisgarh. the primary trial particpants receive Epacadostat twice as frequently as Sunitinib-na‚àö√òve participants in the secondary trial receive sunitinib. [SEP] Clinical Trial: NCT02178722",Contradiction,0.37944466,0.62055534
NCT02550795,"Statement: group 2 of the primary trial recieves 1.5ug/kg of dexmedetomidine (15ml), patients in the secondary trial cohorts do not receive any dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.8764581,0.12354186
NCT03015649,Statement: the primary clinical trial and the secondary clinical trial noted an identical count of adverse events among their patient groups. [SEP] Clinical Trial: NCT03015649,Entailment,0.7155481,0.28445187
NCT00118157,Statement: Patients participating in the primary trial receive oral medication twice a day for a full month. desensitization is any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus. [SEP] Clinical Trial: NCT00118157,Contradiction,0.48777702,0.51222295
NCT01803282,"Statement: among the participants of the primary and secondary clinical trials, none reported any adverse events. [SEP] Clinical Trial: NCT01803282",Entailment,0.8166657,0.1833343
NCT00322374,"Statement: There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial . pregnant at time of vaccination is an individual was pregnant at the time a vaccination was administered. [SEP] Clinical Trial: NCT00322374",Contradiction,0.40537623,0.59462374
NCT00791037,Statement: percentage of participants experiencing adverse events of primary interest(aepis) is subject to assessment in both the primary and secondary clinical trial [SEP] Clinical Trial: NCT00791037,Entailment,0.67377573,0.3262243
NCT01178411,"Statement: the eligibility for the primary and secondary clinical trials is controlled by nationality, ethnicity, weight, and gender [SEP] Clinical Trial: NCT01178411",Contradiction,0.31846946,0.68153054
NCT00632489,Statement: there are no reported results for the lbh589 and lapatinib group in the primary clinical trial [SEP] Clinical Trial: NCT00632489,Entailment,0.91123676,0.08876319
NCT02041429,"Statement: the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 0.015 kg per day [SEP] Clinical Trial: NCT02041429",Contradiction,0.2736476,0.72635245
NCT01171924,"Statement: cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often. [SEP] Clinical Trial: NCT01171924",Contradiction,0.46325192,0.53674805
NCT00896454,Statement: distinct patient clusters are required for the secondary clinical trial and the primary clinical trial. [SEP] Clinical Trial: NCT00896454,Contradiction,0.4472313,0.5527687
NCT00513292,"Statement: both the primary clinical trial and the secondary clinical trial utilize pcr as their measure of outcome. there is a negligible variance in outcomes among the two subgroups of the primary clinical trial. however, in the secondary clinical trial, arm 2 demonstrated significantly better results compared to arm 1. [SEP] Clinical Trial: NCT00513292",Contradiction,0.39664224,0.6033578
NCT00623831,"Statement: in the primary clinical trial, patients in cohort 2 show a decrease in pleural effusion. [SEP] Clinical Trial: NCT00623831",Entailment,0.5365657,0.46343428
NCT01803282,"Statement: 0/7 the primary trial participants, and 0/1674 the secondary trial participants suffered an AE. scrotal infection, ctcae is a disorder characterized by an infectious process involving the scrotum. [SEP] Clinical Trial: NCT01803282",Contradiction,0.4409843,0.55901563
NCT01537029,"Statement: male prostate cancer patients over the age of 55 can participate in the primary clinical trial, regardless of race or ethnic origin. however, for the secondary clinical trial, they must have a confirmed diagnosis of advanced castration-resistant prostate cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.4723032,0.5276968
NCT00838929,Statement: benign epididymal neoplasm is a rare non-metastasizing neoplasm that arises from the epididymis. representative examples include adenomatoid tumor and leiomyoma. Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy. [SEP] Clinical Trial: NCT00838929,Contradiction,0.44707218,0.55292785
NCT01664091,"Statement: death details (human clinical trials) supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the death details (human clinical trials) domain. There were more cases of Infection, Asymmetry and Deflation in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01664091",Contradiction,0.44080272,0.5591973
NCT00749931,Statement: both the primary and secondary clinical trial include at least one same criterion for inclusion. [SEP] Clinical Trial: NCT00749931,Entailment,0.82438916,0.17561083
NCT02550795,"Statement: in the primary clinical trial, the patients in group 2 receive a dosage of 0.5ug/kg of myalgias (5ml), however, this is not administered in the secondary clinical trial cohorts. [SEP] Clinical Trial: NCT02550795",Entailment,0.7911192,0.20888081
NCT00871858,Statement: level of sexual arousal during sexual activity or intercourse is a question about an individual's level or degree of sexual arousal during sexual activity or intercourse. Paclitaxel is not used in either of the primary trial interventions. [SEP] Clinical Trial: NCT00871858,Entailment,0.87465566,0.12534438
NCT01631552,"Statement: the secondary trial and the primary trial have completely unrelated outcome measurements, but the same interventions. h3-3a gene mutation is a change in the sequence of the h3-3a gene. [SEP] Clinical Trial: NCT01631552",Entailment,0.61057353,0.38942647
NCT00929240,Statement: the bevacizumab group in the primary clinical trial exhibited a lower occurrence of disease progression or death than the bevacizumab + capecitabine group. [SEP] Clinical Trial: NCT00929240,Entailment,0.65057576,0.3494242
NCT00843167,"Statement: the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. metastatic oral cavity mucoepidermoid carcinoma is a mucoepidermoid carcinoma that arises from the oral cavity and has metastasized to another anatomic site. [SEP] Clinical Trial: NCT00843167",Contradiction,0.40880337,0.5911966
NCT03346161,Statement: there have been adverse events (aes) reported in both cohorts of the primary clinical trial [SEP] Clinical Trial: NCT03346161,Entailment,0.8721888,0.12781121
NCT01629615,Statement: it was typical for the primary clinical trial candidates to suffer from an eating disorder' [SEP] Clinical Trial: NCT01629615,Entailment,0.5997483,0.40025166
NCT01011218,Statement: no fatalities were reported in the adverse events for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01011218,Entailment,0.81708556,0.18291445
NCT01569087,"Statement: persons with stage 4 cancer cannot take part in the secondary clinical trial, but are fit for the primary clinical trial. [SEP] Clinical Trial: NCT01569087",Entailment,0.7984376,0.20156242
NCT00404066,"Statement: patients in the secondary clinical trial encountered adverse events specifically eyelid oedema, upper gastrointestinal haemorrhage and chest pain. no such instances were reported in the primary clinical trial. [SEP] Clinical Trial: NCT00404066",Entailment,0.5650111,0.43498895
NCT00656305,"Statement: no fatalities or hospital stays occurred in the second cohort of the primary clinical trial, and only one instance of atrial fibrillation was observed. [SEP] Clinical Trial: NCT00656305",Entailment,0.62387174,0.37612826
NCT00209092,"Statement: the inclusion of a patient into the primary clinical trial is dependent entirely on the objective criteria for inclusion and exclusion, and is not influenced by the judgment of the health professionals supervising the trial. [SEP] Clinical Trial: NCT00209092",Entailment,0.81589824,0.18410179
NCT00428220,Statement: corneal deposits were less commonly identified amongst the patients in the secondary trial [SEP] Clinical Trial: NCT00428220,Entailment,0.80140996,0.19859001
NCT00076024,Statement: primary clinical trial enforces a strict age limit of 18 to 65 years for all participants [SEP] Clinical Trial: NCT00076024,Entailment,0.6804708,0.31952918
NCT01045421,"Statement: genetic mutations in pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11 are necessary for eligibility in the primary trial, but these conditions do not determine inclusion in the secondary trial [SEP] Clinical Trial: NCT01045421",Entailment,0.5876804,0.4123196
NCT01770353,"Statement: the primary clinical trial and the secondary clinical trial employ different drugs, dosages, and administration schedules, though they both utilize intravenous injections. [SEP] Clinical Trial: NCT01770353",Contradiction,0.15897779,0.84102225
NCT01631552,"Statement: both the secondary trial and primary trial yield similar results, despite varied interventions [SEP] Clinical Trial: NCT01631552",Entailment,0.73791057,0.26208946
NCT00795769,"Statement: Far more patients in the secondary trial were recorded to have experienced Chest Pain, than patients in the primary trial. phf6 gene mutation is a change in the nucleotide sequence of the phf6 gene. [SEP] Clinical Trial: NCT00795769",Entailment,0.58504266,0.41495737
NCT00357734,"Statement: while the intervention in the primary clinical trial comprises one drug, the secondary clinical trial’s intervention mandates not less than three distinct drugs. [SEP] Clinical Trial: NCT00357734",Entailment,0.8667941,0.13320586
NCT01597193,"Statement: cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV. 1p35 is a chromosome band present on 1p [SEP] Clinical Trial: NCT01597193",Entailment,0.5078219,0.49217805
NCT01376349,"Statement: the units of measure for the primary and secondary trials are patients' heart rates and cholesterol levels, respectively. [SEP] Clinical Trial: NCT01376349",Contradiction,0.33302814,0.66697186
NCT01806259,"Statement: in the primary clinical trial, 96 participants from the ketorolac 30 mg group demonstrated recurrence-free survival, as opposed to the 67 from the nacl 0.9% 3ml group [SEP] Clinical Trial: NCT01806259",Contradiction,0.41139165,0.5886084
NCT02104830,"Statement: despite taking reduced doses of empegfilgrastim, cohort 1 patients of the secondary clinical trial had a higher occurrence of neutropenia than those in cohort 2 of the primary clinical trial. [SEP] Clinical Trial: NCT02104830",Entailment,0.63439614,0.36560386
NCT02336737,Statement: Cohort 1 of the primary trial did not report any Aes [SEP] Clinical Trial: NCT02336737,Entailment,0.9250625,0.07493752
NCT01498458,Statement: in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. often feel sad or depressed is a question about whether an individual often feels or felt sad or depressed. [SEP] Clinical Trial: NCT01498458,Contradiction,0.3248338,0.67516613
NCT00999921,"Statement: the secondary clinical trial allows the participation of patients diagnosed with malignant ductal carcinoma in situ and uncontrolled high blood pressure, whereas such patients are excluded from the primary clinical trial. [SEP] Clinical Trial: NCT00999921",Entailment,0.7880139,0.21198606
NCT02336737,Statement: atypical lymphocytes present in bone marrow is a finding indicating that atypical lymphocytes were detected in a bone marrow sample. Cohort 1 of the primary trial did not report any Aes. [SEP] Clinical Trial: NCT02336737,Entailment,0.8320333,0.16796666
NCT00104650,"Statement: in the primary clinical trial, all interventions are delivered via the same method. [SEP] Clinical Trial: NCT00104650",Entailment,0.8865308,0.11346922
NCT01301729,Statement: her2 + patients in the primary trial and patients in cohort 2 of the secondary trial receive varying dosage of trastuzumab at different stages of the trial [SEP] Clinical Trial: NCT01301729,Contradiction,0.42066348,0.5793366
NCT01286168,"Statement: unlike the primary clinical trial, which had no adverse events on record, the secondary one frequently reported anaemia as a side effect. [SEP] Clinical Trial: NCT01286168",Entailment,0.5820808,0.41791928
NCT00956813,Statement: ndc me (milligram) is a recognized billing qualifier that may be used to identify milligrams as the ndc unit of measure. the secondary trial and the primary trial results contain completely different outcome measures . [SEP] Clinical Trial: NCT00956813,Entailment,0.9025639,0.097436056
NCT00404066,"Statement: arm or leg response group answer is an answer belonging to the arm or leg response group query. The only types of Aes observed in patients from the secondary trial were Eyelid oedema, Upper gastrointestinal haemorrhage and Chest pain, no aes wererecorded in the primary trial. [SEP] Clinical Trial: NCT00404066",Entailment,0.7163618,0.28363815
NCT00319748,Statement: both the secondary clinical trial and the primary clinical trial track the percentage of participants showing clinical benefit based on recist criteria. [SEP] Clinical Trial: NCT00319748,Contradiction,0.34578472,0.6542153
NCT02002533,Statement: there are no reported adverse incidents in the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02002533,Entailment,0.8656756,0.13432443
NCT00104650,Statement: The Interventions in the primary trial are administered through different routes. piga gene mutation is a change in the nucleotide sequence of the piga gene. [SEP] Clinical Trial: NCT00104650,Entailment,0.83775437,0.1622456
NCT00021255,"Statement: every cohort in the primary clinical trial is subjected to the same volume of docetaxel, doxorubicin, and cyclophosphamide with the same frequency. the second cohort, conversely, encompasses three more therapy cycles of these exact drugs [SEP] Clinical Trial: NCT00021255",Contradiction,0.36947572,0.6305242
NCT00918281,"Statement: cohort 1 in the primary clinical trial is administered vincristine intravenously, and cohort 1 in the secondary clinical trial is given a rectal suppository of hydroxychloroquine. [SEP] Clinical Trial: NCT00918281",Entailment,0.54513544,0.45486456
NCT00950911,Statement: the dosage of denosumab in intervention 1 of the primary trial is equivalent to the dosage of tamoxifen in intervention 1 of the secondary trial. [SEP] Clinical Trial: NCT00950911,Entailment,0.7570086,0.2429914
NCT00293540,"Statement: patients participating in the primary clinical trial, on average, have a survival rate exceeding two years, with more than fifty patients from each group experiencing life spans over 24 months. [SEP] Clinical Trial: NCT00293540",Contradiction,0.21762197,0.782378
NCT01246973,"Statement: despite the lack of any cardiac or psychiatric aes in the primary clinical trial and secondary clinical trial, a number of other aes were witnessed. [SEP] Clinical Trial: NCT01246973",Contradiction,0.35026383,0.6497361
NCT00656305,"Statement: cohort 2 of the primary clinical trial encountered numerous fatalities and hospital admissions, with multiple incidents of atrial fibrillation. [SEP] Clinical Trial: NCT00656305",Contradiction,0.24382052,0.7561795
NCT00418028,"Statement: the primary trial outlines the duration of response in hours for patients in both the cohorts combined, an total of 312, whereas the secondary trial outlines the profiles of patients that experience disease control [SEP] Clinical Trial: NCT00418028",Contradiction,0.20848589,0.7915141
NCT01383174,Statement: There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial. diaphragm part is any component of the fibromuscular tissue that separates the thoracic from the abdominal cavity. [SEP] Clinical Trial: NCT01383174,Contradiction,0.4340044,0.56599563
NCT00708019,Statement: several of the patients in the primary trial experienced the no pain whatsoever during the 2.5 months of the study. [SEP] Clinical Trial: NCT00708019,Contradiction,0.2467096,0.7532904
NCT03069313,"Statement: the primary trial administers its intervention through injection, and the secondary trial administers it through an intramuscular route. [SEP] Clinical Trial: NCT03069313",Entailment,0.6340111,0.3659889
NCT00999921,Statement: palpable masses sequence number is an identifier that describes the relative position of palpable masses data within a series. Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial. [SEP] Clinical Trial: NCT00999921,Entailment,0.7067821,0.2932179
NCT01252290,Statement: less than 1/20 of patients in the primary trial suffered aes [SEP] Clinical Trial: NCT01252290,Entailment,0.8242909,0.17570913
NCT01306032,Statement: patients in the primary trial and the secondary trial did not experience any thromboembolic events. [SEP] Clinical Trial: NCT01306032,Entailment,0.8962367,0.103763275
NCT00209092,"Statement: the patient's first of kin will make the final enrollment decision for the primary clinical trial, even if the patient meets all exclusion and inclusion requirements. [SEP] Clinical Trial: NCT00209092",Entailment,0.66383404,0.33616596
NCT00076024,Statement: There are no conditions on hepatic function for participants of the primary trial. worry that breast cancer recurrence would mean losing my breast(s) is a question about whether an individual worries that recurrence of their breast cancer would mean losing their breast(s). [SEP] Clinical Trial: NCT00076024,Entailment,0.6792278,0.3207721
NCT01664091,"Statement: There were more cases of Infection, Asymmetry and Deflation in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01664091",Contradiction,0.42457542,0.57542455
NCT00475085,Statement: counselor is a person with training to provide advice or instruction. There are 7 more participants in cohort 2 of the primary trial than in cohort 1. [SEP] Clinical Trial: NCT00475085,Contradiction,0.22028196,0.77971804
NCT02336737,"Statement: cohort 2 of the primary clinical trial did not report any aes, and neither did the candidates in cohort 1 [SEP] Clinical Trial: NCT02336737",Entailment,0.8804405,0.119559556
NCT00321048,"Statement: all participants in the primary clinical trial are subjected to the same duration, intensity and type of radiation therapy. [SEP] Clinical Trial: NCT00321048",Entailment,0.581307,0.418693
NCT01127763,"Statement: in the primary clinical trial, there were patients who did not suffer from 3 or more adverse events. [SEP] Clinical Trial: NCT01127763",Entailment,0.81296283,0.18703717
NCT00143390,Statement: there were no recorded gastro-intestinal adverse events in the primary clinical trial [SEP] Clinical Trial: NCT00143390,Entailment,0.88954425,0.110455684
NCT01048099,Statement: have excessive tearing is a question about whether an individual's eyes have or had excessive tearing. None of the individual adverse event types recorded in the primary trial affected more than one patient. [SEP] Clinical Trial: NCT01048099,Entailment,0.6366622,0.3633378
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID. [SEP] Clinical Trial: NCT00836186",Contradiction,0.3907039,0.60929614
NCT02640053,"Statement: in the primary clinical trial, the lack of paclitaxel infusions resulted in worsened symptoms for the patients compared to those who received them. [SEP] Clinical Trial: NCT02640053",Entailment,0.6829596,0.31704038
NCT00428220,"Statement: ascites was more likely to occur in patients from the secondary clinical trial, and hypersensitivity reactions were more common in the primary clinical trial. [SEP] Clinical Trial: NCT00428220",Entailment,0.62529284,0.37470716
NCT00245050,"Statement: the primary trial had one test group and one placebo group, the secondary trial had 1 test group and 1 control group. [SEP] Clinical Trial: NCT00245050",Entailment,0.8097991,0.1902009
NCT01649271,Statement: all of the patients in the primary trial and the secondary trial developed shingles. [SEP] Clinical Trial: NCT01649271,Contradiction,0.3186523,0.68134767
NCT02104830,"Statement: the primary trial and the secondary trial are studying the same drug, in different doses and with a different outcome measurement. subject identifier is a sequence of characters used to identify, name, or characterize a trial or study subject. [SEP] Clinical Trial: NCT02104830",Contradiction,0.49925327,0.5007467
NCT01383174,Statement: terminator device is a device designed to connect to the end of a bus network. There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial. [SEP] Clinical Trial: NCT01383174,Contradiction,0.31734607,0.68265396
NCT00775645,Statement: In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1% of participants. [SEP] Clinical Trial: NCT00775645,Entailment,0.60372263,0.39627734
NCT00256217,Statement: no patients in either the primary clinical trial or the secondary clinical trial endured fewer than 3 distinct aes. [SEP] Clinical Trial: NCT00256217,Entailment,0.7943662,0.20563379
NCT02041429,"Statement: the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 1500 micrograms per day [SEP] Clinical Trial: NCT02041429",Contradiction,0.2380077,0.76199234
NCT00583700,Statement: women who are at least 18 years old can participate in both the secondary and the primary clinical trial. [SEP] Clinical Trial: NCT00583700,Contradiction,0.3964188,0.6035812
NCT01129622,"Statement: Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial. familial hypocalciuric hypercalcemia is a hereditary condition caused by calcium sensing receptor gene mutations, resulting in calcium-hyposensitivity, and compensatory hypercalcemia and hypocalciuria. [SEP] Clinical Trial: NCT01129622",Contradiction,0.46135008,0.53865
NCT00896454,"Statement: the secondary trial and the primary trial report results from one patient cohort. reviewer is a person with a responsibility for examining something to make sure that it is adequate, accurate, or correct. [SEP] Clinical Trial: NCT00896454",Contradiction,0.39939848,0.6006015
NCT00786838,Statement: The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis. miscellaneous occupation is a listing of occupations that don't fall under another major heading. [SEP] Clinical Trial: NCT00786838,Entailment,0.5646949,0.43530515
NCT01045421,"Statement: the secondary clinical trial, unlike the primary clinical trial, enrolls patients who have a diagnosed mutation in at least one gene among pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11 [SEP] Clinical Trial: NCT01045421",Contradiction,0.4717266,0.52827334
NCT01306032,Statement: primary clinical trial patients experience adverse events identical to the secondary clinical trial.' [SEP] Clinical Trial: NCT01306032,Entailment,0.8942135,0.10578654
NCT02336737,Statement: cohort 1 of the primary clinical trial experienced multiple moderate aes [SEP] Clinical Trial: NCT02336737,Entailment,0.69615144,0.30384856
NCT00825682,Statement: the intervention in the secondary trial last half as long as the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.8193843,0.18061571
NCT03384316,Statement: All Infections and Infestations cases in the primary trial were for patients in cohort 1. [SEP] Clinical Trial: NCT03384316,Entailment,0.79173124,0.20826876
NCT01091974,"Statement: in the primary trial only a single cohort recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 0.1 grams dose of pdr001, and 1 mg/kg dose of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.39725548,0.6027445
NCT02761642,"Statement: cancer patients with epilepsy, thalasemic syndromes, or anemia can participate in the secondary clinical trial. [SEP] Clinical Trial: NCT02761642",Contradiction,0.42635188,0.57364815
NCT00929240,Statement: the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort. [SEP] Clinical Trial: NCT00929240,Entailment,0.9066854,0.09331464
NCT00687102,"Statement: There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial. nervous system neoplasm is a benign or malignant, primary or metastatic neoplasm involving the central or peripheral nervous system. [SEP] Clinical Trial: NCT00687102",Contradiction,0.22092086,0.7790791
NCT00322374,"Statement: There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial  [SEP] Clinical Trial: NCT00322374",Contradiction,0.47175738,0.52824265
NCT01597193,Statement: cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1. moderately dissatisfied is a response indicating a moderate level of dissatisfaction. [SEP] Clinical Trial: NCT01597193,Entailment,0.5711021,0.42889795
NCT00475085,Statement: the primary clinical trial discloses the number of participants included in each specific cohort. [SEP] Clinical Trial: NCT00475085,Entailment,0.7797982,0.22020182
NCT00706030,"Statement: Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2. sulfoxone sodium is a sodium salt form of sulfoxone, a water-soluble sulfonamide antibiotic used in the treatment of leprosy. [SEP] Clinical Trial: NCT00706030",Entailment,0.59514534,0.4048547
NCT00321464,"Statement: Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00321464",Entailment,0.51823163,0.4817684
NCT00659373,"Statement: throughout the duration of the primary clinical trial, cognitive function remained stable in all participants, particularly in the members of the ovarian function suppression group [SEP] Clinical Trial: NCT00659373",Entailment,0.5259591,0.47404093
NCT00146172,Statement: candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial. cardiovascular lesion indicator is an indication as to whether a cardiovascular lesion is present. [SEP] Clinical Trial: NCT00146172,Contradiction,0.4508382,0.5491618
NCT00749931,"Statement: gallbladder infection, ctcae is a disorder characterized by an infectious process involving the gallbladder. the secondary trial and the primary trial share at least one inclusion criteria. [SEP] Clinical Trial: NCT00749931",Contradiction,0.39992663,0.60007334
NCT02441946,"Statement: patients with a breast tumor 2-8 mm in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Entailment,0.5036979,0.49630207
NCT00030823,Statement: There were more participants in the primary trial than in the secondary trial [SEP] Clinical Trial: NCT00030823,Entailment,0.7694814,0.23051855
NCT00365105,"Statement: a 28 year old patient with stage iv lung cancer, absolute neutrophil count less than 500/μl, platelet count of 45000/μl, hemoglobin level less than 80 g/l, and a life expectancy less than 6 months would be rejected from both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Entailment,0.7171118,0.28288814
NCT01383174,Statement: cohort 2 of the primary clinical trial demonstrated superior results compared to cohort 2 of the secondary clinical trial. [SEP] Clinical Trial: NCT01383174,Entailment,0.87287515,0.12712483
NCT01129622,Statement: women with conditions of claustrophobia and osteoporosis are disqualified from participation in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01129622,Entailment,0.86724555,0.13275439
NCT00632489,"Statement: in the primary clinical trial, the group taking lbh589 with capecitabine performed poorer than those taking lbh589 and lapatinib [SEP] Clinical Trial: NCT00632489",Entailment,0.76213765,0.23786233
NCT01649271,"Statement: a single instance of shingles was documented in group 2 of the secondary clinical trial, yet no incidents were reported within the primary clinical trial or group 1 of the secondary trial. [SEP] Clinical Trial: NCT01649271",Entailment,0.7643663,0.23563363
NCT00313170,Statement: only those having colon cancer and showing no response to past hormonal treatments will be considered for the primary clinical trial. [SEP] Clinical Trial: NCT00313170,Entailment,0.6845415,0.31545845
NCT00075764,Statement: entry into the primary clinical trial is open to individuals with definite metastasis or whose cancer has augmented in different locations of the body. [SEP] Clinical Trial: NCT00075764,Contradiction,0.46046078,0.5395392
NCT01831089,Statement: Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial. small plaque parapsoriasis is a variant of parapsoriasis in which the plaques are small. [SEP] Clinical Trial: NCT01831089,Contradiction,0.4598045,0.5401955
NCT02312934,Statement: alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. [SEP] Clinical Trial: NCT02312934,Entailment,0.7053902,0.29460979
NCT01743560,"Statement: whilst the primary clinical trial is not open to children, their eligibility hasn't been explicitly stated for the secondary clinical trial [SEP] Clinical Trial: NCT01743560",Entailment,0.89660406,0.1033959
NCT02891681,Statement: the primary clinical trial and secondary clinical trial are open for severely obese patients to participate. [SEP] Clinical Trial: NCT02891681,Contradiction,0.4146093,0.5853907
NCT00322374,"Statement: monoallelic rad51 gene inactivation is any gain, loss, or exchange of dna that results in monoallelic loss of function mutations in the rad51 gene. There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial . [SEP] Clinical Trial: NCT00322374",Entailment,0.51550025,0.48449975
NCT01008904,Statement: 19p13.12 is a chromosome band present on 19p the primary trial only has a single adverse event recorded for its patient cohort. [SEP] Clinical Trial: NCT01008904,Entailment,0.86151725,0.13848276
NCT00256698,Statement: Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial [SEP] Clinical Trial: NCT00256698,Entailment,0.8083005,0.19169953
NCT02550795,"Statement: group 2 participants in the primary clinical trial are given a 0.5ug/kg regimen of myalgias in a 5ml dosage, though, such regimen does not apply to the secondary clinical trial cohorts. [SEP] Clinical Trial: NCT02550795",Entailment,0.8126393,0.18736069
NCT00698035,"Statement: hormonal methods are being employed in the primary clinical trial, while the secondary clinical trial is experimenting with acupuncture. [SEP] Clinical Trial: NCT00698035",Contradiction,0.3906097,0.60939026
NCT00756496,"Statement: no significant disparities were observed in the outcomes from the groups involved in the primary clinical trial, while in the secondary clinical trial, some differences were noted between the results of the reflexology group and the control group. [SEP] Clinical Trial: NCT00756496",Entailment,0.6599647,0.34003535
NCT00756496,"Statement: distinct variations were noted in the results from the primary trial groups, whereas the reflexology group and the control group had indistinguishable results in the secondary trial. [SEP] Clinical Trial: NCT00756496",Entailment,0.6823944,0.31760558
NCT00698035,"Statement: the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention. problems with thinking or remembering things is a question about whether an individual has or had problems with thinking or remembering things. [SEP] Clinical Trial: NCT00698035",Contradiction,0.49161506,0.50838494
NCT01106898,Statement: 3% of patients in the primary trial did not experience any adverse events [SEP] Clinical Trial: NCT01106898,Entailment,0.8671649,0.13283516
NCT01390818,Statement: canine granular cell tumor is a granular cell tumor occurring in a dog. The all recorded Aes in the primary trial occurred to cohort 1 patients. [SEP] Clinical Trial: NCT01390818,Entailment,0.54786533,0.45213464
NCT00428220,"Statement: the occurrence of ascites was higher in the primary clinical trial, while the cases of pneumocystis jirovecii pneumonia were more prevalent in the secondary clinical trial. [SEP] Clinical Trial: NCT00428220",Contradiction,0.48275176,0.5172483
NCT00569166,"Statement: all cohorts in the primary clinical trial utilize different methods for paced breathing instructions, none of which include a cd. [SEP] Clinical Trial: NCT00569166",Entailment,0.8966914,0.10330861
NCT02404441,"Statement: the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups. thousand is a natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred. [SEP] Clinical Trial: NCT02404441",Contradiction,0.35056555,0.64943445
NCT00405938,"Statement: Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial. pet keeps itself clean is a question about whether an individual's pet keeps itself clean. [SEP] Clinical Trial: NCT00405938",Contradiction,0.46306437,0.5369356
NCT02404441,"Statement: the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups. 2q36.1 is a chromosome band present on 2q [SEP] Clinical Trial: NCT02404441",Entailment,0.6335709,0.36642906
NCT01222390,"Statement: trabecular pattern is a microscopic finding indicating that the neoplastic cells are arranged in trabeculae in a tumor sample. There are no X-rays, ultrasound, CT scans or MRIs included the interventions of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01222390",Contradiction,0.33558947,0.66441053
NCT00956813,Statement: the secondary trial and the primary trial report their results using the same units of measure. superior vesical artery is a blood vessel arising from the internal iliac artery that runs along the bladder with branches supplying the bladder. [SEP] Clinical Trial: NCT00956813,Contradiction,0.3104854,0.6895146
NCT01569087,"Statement: patients in the final stage of cancer, cannot partake in the primary clinical trial, but are eligible for the secondary trial. [SEP] Clinical Trial: NCT01569087",Entailment,0.8047741,0.1952259
NCT00365105,"Statement: A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 110,034/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.3092855,0.6907145
NCT00373256,"Statement: in the primary clinical trial, the subjects of both cohort 1 and cohort 2 are provided with equal doses of 20 mg of sunitinib and 7.5 mg/kg of bevacizumab [SEP] Clinical Trial: NCT00373256",Contradiction,0.40166163,0.59833837
NCT03346161,Statement: there were an equal number of patients suffering adverse events in both cohort 1 and cohort 2 of the primary clinical trial [SEP] Clinical Trial: NCT03346161,Entailment,0.7667025,0.23329753
NCT02807844,Statement: All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks. [SEP] Clinical Trial: NCT02807844,Entailment,0.5047601,0.49523994
NCT01617668,"Statement: Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2. [SEP] Clinical Trial: NCT01617668",Entailment,0.7796217,0.22037831
NCT01301729,Statement: the dosage of trastuzumab given to her2+ patients in both the primary clinical trial and the second cohort of the secondary clinical trial is the same for the entire course of the trial. [SEP] Clinical Trial: NCT01301729,Entailment,0.6369917,0.3630083
NCT02038218,Statement: both the primary clinical trial and the secondary clinical trial's results do not require any units of measurement.' [SEP] Clinical Trial: NCT02038218,Entailment,0.9180641,0.08193591
NCT01250379,"Statement: any adult with old diagnosed, pr-negative, her2-negative breast cancer is eligible for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01250379",Contradiction,0.40169907,0.59830093
NCT02550795,"Statement: group 2 from the primary trial is given 0.5ug/kg of myalgias (5ml), which is the same as what patients in the secondary trial cohorts receive. [SEP] Clinical Trial: NCT02550795",Contradiction,0.3895053,0.61049473
NCT01252290,Statement: there were zero reports of aes among participants in the primary clinical trial. [SEP] Clinical Trial: NCT01252290,Entailment,0.91354793,0.08645211
NCT00828516,Statement: the outcome measure for both the secondary and primary clinical trials does not involve tracking the number of participants with treatment-emergent adverse events. [SEP] Clinical Trial: NCT00828516,Entailment,0.89798725,0.10201279
NCT02640053,Statement: primary clinical trial participants who didn't undergo paclitaxel infusions experienced more severe symptoms compared to those who did. [SEP] Clinical Trial: NCT02640053,Entailment,0.5888409,0.4111591
NCT00538850,"Statement: the the primary trial results report the severity of delayed nausea on a scale of 1 to 7, and the secondary trial measures the change from baseline to 270 days in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850",Contradiction,0.43159217,0.56840783
NCT01129622,Statement: Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial. milliliter per day per microgram is a unit of concentration equal to milliliter per day divided by microgram. [SEP] Clinical Trial: NCT01129622,Entailment,0.51391715,0.48608288
NCT03069313,"Statement: the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally. disposition continuation is an indication or description that the subject will be continuing on to next phase of the trial. [SEP] Clinical Trial: NCT03069313",Entailment,0.5339231,0.46607688
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin twice daily, and the secondary trial administers its patients with Depocyt and HD-MTX. auditory brainstem response wave v, presence is an assessment of the presence of the auditory brainstem response wave v of the auditory evoked potential waveform. [SEP] Clinical Trial: NCT00702949",Contradiction,0.40843898,0.591561
NCT01498458,Statement: the primary clinical trial reported a ten times higher number of hepatotoxicity incidences as compared to hypertension and pancreatectomy cases [SEP] Clinical Trial: NCT01498458,Contradiction,0.40487245,0.5951275
NCT00820872,Statement: Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants [SEP] Clinical Trial: NCT00820872,Contradiction,0.48455226,0.51544774
NCT02239601,Statement: the primary clinical trial and the secondary clinical trial documented identical numbers of adverse events among their patient populations. [SEP] Clinical Trial: NCT02239601,Entailment,0.8363529,0.16364709
NCT00791037,"Statement: the primary trial and the secondary trial evaluate different patient characteristics in their results. poorly differentiated angiosarcoma is an angiosarcoma characterized by the presence of significant cytologic atypia, necrosis and high mitotic activity. [SEP] Clinical Trial: NCT00791037",Entailment,0.5196508,0.4803492
NCT00775645,Statement: several adverse events occurred at an incidence rate greater than 1% in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00775645,Entailment,0.7812591,0.21874087
NCT02306265,"Statement: before participating in the primary clinical trial, candidates are expected to undergo a mammography, in contrast, participation in the secondary clinical trial requires an initial ct scan and blood tests. [SEP] Clinical Trial: NCT02306265",Contradiction,0.3561314,0.6438686
NCT00373256,"Statement: The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab. trichostrongylus colubriformis is a species of parasitic roundworms in the family trichostrongylidae that causes black scour disease in sheep, cattle, and goats. [SEP] Clinical Trial: NCT00373256",Contradiction,0.39745557,0.6025444
NCT01920061,"Statement: the primary trial uses a 360 day cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.9170761,0.08292392
NCT01451632,"Statement: Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention [SEP] Clinical Trial: NCT01451632",Entailment,0.6791577,0.32084233
NCT01967823,Statement: an increased blood bilirubin was recorded in 36.36% of the patients who participated in the primary clinical trial. [SEP] Clinical Trial: NCT01967823,Contradiction,0.2911568,0.70884323
NCT00370552,"Statement: Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period  [SEP] Clinical Trial: NCT00370552",Entailment,0.5979292,0.40207082
NCT00656019,Statement: aq20 - chest trouble make you feel restless is airway questionnaire 20 (aq20) does your chest trouble often make you feel restless? None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes. [SEP] Clinical Trial: NCT00656019,Entailment,0.6184931,0.38150692
NCT01920061,"Statement: while the primary clinical trial follows a treatment regime based on a three-week cycle, there is no set cycle for the intervention in the secondary clinical trial. [SEP] Clinical Trial: NCT01920061",Entailment,0.9273867,0.072613314
NCT01855828,Statement: multiple psychiatric adverse events were noticed in the primary clinical trial impacting more than a quarter of the patients. [SEP] Clinical Trial: NCT01855828,Contradiction,0.4768481,0.52315193
NCT03069313,"Statement: the interventions in the primary clinical trial are administered through inhalation, while the secondary trial employs an intramuscular route. [SEP] Clinical Trial: NCT03069313",Entailment,0.62737,0.37263
NCT00819182,"Statement: the primary clinical trial reported fewer instances of treatment emergent adverse events and serious treatment emergent adverse events in patients within the paced respiration intervention group than those utilizing fast, shallow respirations. [SEP] Clinical Trial: NCT00819182",Entailment,0.55191946,0.44808054
NCT00749931,Statement: unconfirmed progressive disease is a disease process that is increasing in scope or severity but the criteria for progressive disease is not met. All patients eligible for the secondary trial are also eligible for the primary trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.6107455,0.3892545
NCT00867217,"Statement: skin signet ring cell basal cell carcinoma is a rare type of basal cell carcinoma. it is characterized by the presence of mucin containing signet ring cells. Patients with a Vitamin D deficiency are excluded from the primary trial, but may be eligible for the secondary trial. [SEP] Clinical Trial: NCT00867217",Contradiction,0.44726083,0.5527392
NCT01803282,"Statement: all participants in the primary clinical trial, and 1674/1674 participants in the secondary clinical trial experienced an adverse event. [SEP] Clinical Trial: NCT01803282",Entailment,0.7778498,0.22215024
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation, myocardial infarction (mi), stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 60 years if they want to participate in the primary trial, ,   [SEP] Clinical Trial: NCT00405938",Contradiction,0.3995974,0.6004026
NCT00293540,"Statement: raphe nuclei is a group of nuclei that are located in the midline of the brainstem and release serotonin. On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years. [SEP] Clinical Trial: NCT00293540",Contradiction,0.2964789,0.70352113
NCT00759785,Statement: 49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. renal pelvis and ureter urothelial carcinoma is a transitional cell carcinoma that arises from the renal pelvis and ureter. [SEP] Clinical Trial: NCT00759785,Contradiction,0.403119,0.59688103
NCT00878709,Statement: there was no difference in idfs rate between the neratinib group and placebo group in the primary clinical trial [SEP] Clinical Trial: NCT00878709,Entailment,0.89901847,0.100981615
NCT01451632,"Statement: Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2. [SEP] Clinical Trial: NCT01451632",Entailment,0.54390144,0.45609856
NCT01969448,Statement: laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial. [SEP] Clinical Trial: NCT01969448,Contradiction,0.40204594,0.5979541
NCT02403271,Statement: biliary colic and diarrhoea are more frequently observed in the secondary clinical trial as opposed to the primary clinical trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.6854108,0.3145892
NCT00122369,"Statement: the secondary clinical trial necessitates that patients are above a specified age, whereas the primary clinical trial does not stipulate an age criterion for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.9085762,0.091423765
NCT00405938,"Statement: inclusion in the primary clinical trial is ruled out for patients who have had an abdominal fistula, gastrointestinal perforation, myocardial infarction (mi), stroke, transient ischemic attacks, intrabdominal abscess, or significant psychiatric disorders within the past 6 months. [SEP] Clinical Trial: NCT00405938",Entailment,0.5581846,0.44181538
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 0.5 years if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.4108957,0.5891043
NCT00030823,Statement: thirteen individuals participated in the primary clinical trial where they were treated with the enhanced card t cell therapy [SEP] Clinical Trial: NCT00030823,Contradiction,0.29590678,0.7040932
NCT01156987,"Statement: 5% of the participants in group 1 of the primary trial were found to have lesions, and only 30% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.2550037,0.7449963
NCT01770353,"Statement: the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs. organism is a living entity. [SEP] Clinical Trial: NCT01770353",Contradiction,0.19271483,0.80728513
NCT02041429,Statement: the interventions analysed in the primary clinical trial and the secondary clinical trial do not have their maximum tolerated dose (mtd) reported. [SEP] Clinical Trial: NCT02041429,Entailment,0.9205585,0.079441436
NCT02441946,Statement: both the primary clinical trial and secondary clinical trial permit the participation of patients with a 100mm tnbc tumor. [SEP] Clinical Trial: NCT02441946,Contradiction,0.29259586,0.70740414
NCT01313117,"Statement: lymphangiomatosis is a lymphangioma affecting several anatomic sites. Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. [SEP] Clinical Trial: NCT01313117",Contradiction,0.41145423,0.5885458
NCT01964924,"Statement: an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial. burkholderia is a genus of aerobic, gram-negative, rod shaped bacteria assigned to the phylum proteobacteria and the family burkholderiaceae. [SEP] Clinical Trial: NCT01964924",Contradiction,0.35925278,0.6407472
NCT00819182,"Statement: patients in the paced respiration intervention group of the primary clinical trial experienced more hot flashes per day on average than patients in the fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.6092165,0.39078352
NCT01702571,"Statement: fever, ctcae is a disorder characterized by elevation of the body's temperature above the upper limit of normal. All of the Aes recorded for cohort 1 of the primary trial are related to mental health. [SEP] Clinical Trial: NCT01702571",Contradiction,0.41754994,0.5824501
NCT01855828,"Statement: there was one psychiatric adverse event in the primary trial, which affected up to 50% of patients [SEP] Clinical Trial: NCT01855828",Contradiction,0.30086643,0.6991336
NCT00662025,"Statement: in the primary clinical trial, all patients were prescribed sunitinib, which was taken orally on a daily basis for the full length of the investigation. [SEP] Clinical Trial: NCT00662025",Entailment,0.57263607,0.42736387
NCT02286843,Statement: inferior hypophyseal artery is an artery arising from the cavernous portion of the internal carotid artery that supplies the posterior pituitary gland. 13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases. [SEP] Clinical Trial: NCT02286843,Contradiction,0.3669611,0.6330389
NCT00475085,Statement: the number of participants in cohort 1 and cohort 2 of the primary clinical trial are identical [SEP] Clinical Trial: NCT00475085,Entailment,0.7814563,0.21854371
NCT00262834,"Statement: 0.0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 0.3 fraction of patients. [SEP] Clinical Trial: NCT00262834",Entailment,0.6411409,0.35885906
NCT01301729,"Statement: At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial. neonatal culture positive sepsis, ae is an adverse event in a newborn characterized by a systemic inflammatory response to an infection with an identifiable cause. [SEP] Clinical Trial: NCT01301729",Contradiction,0.49552193,0.5044781
NCT01419717,"Statement: the primary trial requires patients to receive 1000 milligrams of denosumab injected subcutaneously every year, the secondary trial also requires injection, adminstering 0.1 to 1.5 mci of radioactive tc99m sulfur colloid. [SEP] Clinical Trial: NCT01419717",Contradiction,0.39200073,0.6079992
NCT01178411,"Statement: eligibility for the primary and secondary clinical trials is not determined by the patient's nationality, ethnicity, weight or gender [SEP] Clinical Trial: NCT01178411",Contradiction,0.43376756,0.56623244
NCT01045421,"Statement: for the primary trial, patients must be diagnosed with a mutation in the one of the following genes; pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11, whereas no such requirement is specified for the secondary trial [SEP] Clinical Trial: NCT01045421",Entailment,0.5545605,0.44543955
NCT00262834,"Statement: within the primary clinical trial, no adverse events were indicated, and for the secondary trial, any adverse outcomes impacted less than 30% of the patients. [SEP] Clinical Trial: NCT00262834",Entailment,0.76653683,0.23346312
NCT01766102,"Statement: Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore Intra-operative Mammography performed better than the Standard Mammography in this regard. In the secondary trial there is no control group against which we can compare. acute physiology and chronic health evaluation ii apch111 original result - >=40 is acute physiology and chronic health evaluation ii apch111 original result - greater than or equal to 40. [SEP] Clinical Trial: NCT01766102",Entailment,0.5605619,0.43943813
NCT01086605,"Statement: there were no instances of hypertension, dehydration and dyspnea in any group of the primary clinical trial [SEP] Clinical Trial: NCT01086605",Entailment,0.55623096,0.44376904
NCT00792077,"Statement: the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1, and the primary trial intervention lasts for a longer period of time. blackout is a suspension of service (especially of radio or tv broadcasting). [SEP] Clinical Trial: NCT00792077",Entailment,0.5296576,0.4703424
NCT01806675,Statement: the primary trial study groups will experience the same 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging techniques. [SEP] Clinical Trial: NCT01806675,Contradiction,0.48889726,0.51110274
NCT01156987,"Statement: none of the participants in group 1 of the primary clinical trial had lesions, in contrast, above 95% of the participants in group 1 of the secondary clinical trial had symptoms of radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.3242312,0.6757688
NCT02273206,"Statement: past seven days voice change is a question about whether or not an individual had any voice changes over the past seven days. The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type. [SEP] Clinical Trial: NCT02273206",Entailment,0.500273,0.49972695
NCT00429299,"Statement: a candidate's her2 status, whether positive or negative, is not a requirement for the primary clinical trial [SEP] Clinical Trial: NCT00429299",Entailment,0.84106606,0.15893394
NCT01629615,Statement: a majority of the primary clinical trial participants experienced some form of eating disorder during the course of the study [SEP] Clinical Trial: NCT01629615,Entailment,0.63203037,0.36796963
NCT00451555,"Statement: Participants must be resistant to AI therapy to participate in the primary trial, but this is not necessary to be included in the secondary trial. play golf, riding cart is a question about whether an individual plays golf, while riding a golf cart. [SEP] Clinical Trial: NCT00451555",Entailment,0.7608117,0.23918827
NCT02178722,Statement: participants in the primary clinical trial are administered epacadostat at a frequency that is double than that of the sunitinib administration to sunitinib-naive patients in the secondary clinical trial. [SEP] Clinical Trial: NCT02178722,Entailment,0.58860654,0.41139346
NCT02807844,"Statement: some patients in the primary clinical trial receive no mcs110 at all, and over 130 mg of pdr001 every other week. [SEP] Clinical Trial: NCT02807844",Contradiction,0.34827355,0.6517264
NCT01967823,Statement: all ae types in the primary trial affected less than 0.1% of patients [SEP] Clinical Trial: NCT01967823,Entailment,0.8915043,0.10849574
NCT00698035,"Statement: the primary clinical trial is examining the efficacy of oral medications, and the secondary clinical trial is focused on intravenous drug administration. [SEP] Clinical Trial: NCT00698035",Entailment,0.5689713,0.43102872
NCT03202472,"Statement: patients who have undergone chemotherapy or radiotherapy within the past two weeks, those with unstable angina, or those who have grade 2 or higher neuropathy are not eligible for the secondary clinical trial. however, these conditions do not inhibit their participation in the primary clinical trial unless they have non-healing surgical wounds. [SEP] Clinical Trial: NCT03202472",Contradiction,0.49745208,0.5025479
NCT00317603,Statement: the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was nausea [SEP] Clinical Trial: NCT00317603,Entailment,0.6670845,0.33291548
NCT01286168,"Statement: the most common adverse event in the secondary trial was anaemia, affecting more than 3/4 patients, there were no recorded aes in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.730183,0.26981696
NCT02431676,Statement: swls questionnaire question is a question associated with the swls questionnaire. Morbidly obese patients are eligible for the primary trial. [SEP] Clinical Trial: NCT02431676,Contradiction,0.46727893,0.53272104
NCT02234479,"Statement: the primary clinical trial focuses on evaluating the efficiency of distinctive medicinal treatment, while the secondary clinical trial is analysing variable amounts of the same drug on its subjects. [SEP] Clinical Trial: NCT02234479",Entailment,0.73323876,0.26676118
NCT02961790,"Statement: any patients exposed to antineoplastic chemotherapy, androgens, estrogens, or progestogens treatment during the two years prior to the study's commencement are not fit for the primary clinical trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.8462137,0.15378632
NCT02222922,"Statement: middle ear disorder is a non-neoplastic or neoplastic disorder that affects the middle ear.  representative examples include infection, cholesteatoma, and carcinoma. All the primary trial participants receive higher doses of ALT-801 than the secondary trial participants. [SEP] Clinical Trial: NCT02222922",Contradiction,0.38099745,0.6190025
NCT00741039,Statement: only participants diagnosed with cancer receive treatment in the primary clinical trial [SEP] Clinical Trial: NCT00741039,Entailment,0.7619898,0.23801027
NCT00262834,"Statement: 0% adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 0.3 of patients. [SEP] Clinical Trial: NCT00262834",Contradiction,0.45885494,0.5411451
NCT00825682,Statement: the intervention in the secondary clinical trial is significantly shorter compared to the primary clinical trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.8984199,0.10158002
NCT02286843,Statement: 5% of the primary trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.44499445,0.55500555
NCT02807844,Statement: All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks. 20q13.2-q13.3 is a chromosome band present on 20q [SEP] Clinical Trial: NCT02807844,Contradiction,0.47332415,0.5266759
NCT00209092,"Statement: the final decision regarding a patient's participation in the primary clinical trial, even if they meet all the inclusion and exclusion criteria, rests solely with the attending clinician. [SEP] Clinical Trial: NCT00209092",Entailment,0.7030494,0.29695058
NCT01803282,Statement: it was observed that 1/1000 patients in the primary trial and 398/1674 in the secondary trial had an acute myocardial infarction. [SEP] Clinical Trial: NCT01803282,Contradiction,0.25586098,0.744139
NCT00321464,"Statement: patients with cytologically confirmed stage 2 ovarian serous carcinoma that is either brca1 positive, brca2 positive or tp53 negative pass the selection process for the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.29508412,0.70491594
NCT02320123,Statement: all cohorts across the primary clinical trial will use the educational dvd as a key component of their intervention. [SEP] Clinical Trial: NCT02320123,Entailment,0.57788175,0.42211828
NCT00146172,Statement: an ecog score of 1 makes a candidate suitable for participation in both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.49887347,0.5011265
NCT00693719,Statement: a diagnosis of leptomeningeal carcinoma would render a patient ineligible for the primary clinical trial [SEP] Clinical Trial: NCT00693719,Entailment,0.8800481,0.119951904
NCT00293384,"Statement: in cohort 2 of the primary clinical trial, acute vomiting was a side effect for over half of the participants post-treatment with aprepitant, dexamethasone, cytoxan, and kytril. [SEP] Clinical Trial: NCT00293384",Entailment,0.50871223,0.49128777
NCT01964924,"Statement: an adult patient diagnosed with ild/dpld within the last 2 weeks, with a life expectancy of 1 hour would be eligible for the primary trial [SEP] Clinical Trial: NCT01964924",Contradiction,0.4506564,0.5493436
NCT01086605,Statement: dehydration was a common side effect observed in both cohorts of the primary clinical trial. [SEP] Clinical Trial: NCT01086605,Entailment,0.7561955,0.24380453
NCT03015649,Statement: the cohorts of both the primary clinical trial and the secondary clinical trial reported over 100 total adverse instances. [SEP] Clinical Trial: NCT03015649,Contradiction,0.42785105,0.572149
NCT02122796,"Statement: the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates, but higher doses of herceptin and doxatel [SEP] Clinical Trial: NCT02122796",Contradiction,0.37234372,0.6276563
NCT00656019,Statement: patients with deficient vitamin d levels in the primary clinical trial displayed a discernible pattern for expression of the 40 evaluated genes. [SEP] Clinical Trial: NCT00656019,Contradiction,0.34419495,0.65580505
NCT01086605,"Statement: there were 50 cases of hypertension, edema and dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Contradiction,0.24564642,0.7543536
NCT00538850,"Statement: the findings from the primary clinical trial indicate shifts in the intensity of pain, contrastingly, the secondary clinical trial examines the fluctuations in the bone mineral density (bmd) of the lumbar spine from its original condition to nine months onward [SEP] Clinical Trial: NCT00538850",Contradiction,0.4741288,0.5258712
NCT00001832,Statement: a weekly cycle of 4-demethyl-4-cholestryloxycarbonylpenclomedine is a shared necessity amongst the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00001832,Entailment,0.62184453,0.37815547
NCT01178411,"Statement: in the primary and secondary clinical trials, nationality, ethnicity, psychiatric condition or gender of a patient do not influence their eligibility [SEP] Clinical Trial: NCT01178411",Contradiction,0.47187114,0.5281288
NCT00588640,Statement: refugee from high tuberculosis prevalent area is an individual that has fled a country for their own safety which has a high occurrence of tuberculosis. the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients. [SEP] Clinical Trial: NCT00588640,Contradiction,0.42657557,0.57342446
NCT01706081,Statement: appendiceal carcinoid pm1 tnm finding v7 is appendiceal carcinoid with distant metastasis. (from ajcc 7th ed.) Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream. [SEP] Clinical Trial: NCT01706081,Contradiction,0.48241943,0.51758057
NCT00828516,Statement: both the primary and secondary clinical trials do not consider mymop score variations as a way of measuring their research results. [SEP] Clinical Trial: NCT00828516,Entailment,0.92251885,0.077481076
NCT00365105,"Statement: a 40 year old patient with medically verified diagnosis of stage iv colon cancer, absolute neutrophil count of 900/μl, platelet count of 60,034/μl, hemoglobin level of 80 g/l, and a life expectancy under 5 months would not be qualified to join the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.37915292,0.62084705
NCT01091974,"Statement: In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same 100 mg dose of PDR001, and 1 mg/kg dose of MCS110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.40778568,0.5922143
NCT00819182,"Statement: the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.52976876,0.4702312
NCT01256567,Statement: recipients of an organ transplant in the past six months who are now ambulatory are able to participate in the primary clinical trial but would not meet the requirements for the secondary clinical trial [SEP] Clinical Trial: NCT01256567,Entailment,0.8050322,0.19496775
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the last 156 weeks would be excluded from the primary trial [SEP] Clinical Trial: NCT01964924,Entailment,0.79709756,0.20290244
NCT00075764,"Statement: patients in whom metastasis cannot be assessed, or whose cancer has not disseminated to other body areas are deemed inappropriate for the primary clinical trial [SEP] Clinical Trial: NCT00075764",Entailment,0.80902636,0.19097365
NCT00775645,"Statement: reactive epithelial hyperplasia of the ciliary body is an increase in cell number and volume of the ciliary epithelium, usually in response to injury. (who 2018) In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants. [SEP] Clinical Trial: NCT00775645",Contradiction,0.4179044,0.58209556
NCT01008904,Statement: the primary trial only has a single adverse event recorded for its patient cohort. planned subject activity group sequence number is an integer specifying the relative sequential or temporal ordering of a visit within a study [SEP] Clinical Trial: NCT01008904,Entailment,0.6466236,0.35337636
NCT02404441,"Statement: in contrast to the secondary clinical trial, which uses the same criteria for all participants, the primary clinical trial has two different sets of inclusion standards for individuals aged 18-50 and those aged 50+. [SEP] Clinical Trial: NCT02404441",Entailment,0.54175997,0.45824006
NCT01806259,Statement: 96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group [SEP] Clinical Trial: NCT01806259,Contradiction,0.43243015,0.5675698
NCT00266110,"Statement: Patients in the primary trial will need to receive one single injection on day 8 of the study. shan language is a kra-dai language that is spoken by the shan people, mostly in the shan state of myanmar. [SEP] Clinical Trial: NCT00266110",Contradiction,0.39361808,0.6063819
NCT02038218,Statement: malignant neoplasm of the upper third of the esophagus is a primary or metastatic malignant neoplasm involving the upper third segment of the esophagus. the secondary trial and the primary trial use different units of measure in their results. [SEP] Clinical Trial: NCT02038218,Entailment,0.80435294,0.19564708
NCT00911898,"Statement: the primary clinical trial's intervention section includes comprehensive descriptions regarding method of administration, dose, and scheduling. [SEP] Clinical Trial: NCT00911898",Contradiction,0.48461416,0.51538587
NCT01037790,Statement: the primary clinical trial has only few spots open for patients diagnosed with metastatic colorectal cancer which carries the kras or braf mutation. [SEP] Clinical Trial: NCT01037790,Entailment,0.50741255,0.49258742
NCT02179515,"Statement: in the primary clinical trial, the entire initial cohort faced a form of adverse event. [SEP] Clinical Trial: NCT02179515",Entailment,0.8836281,0.116371915
NCT02988986,"Statement: after more than 6 weeks of therapy with tak-228 and tamoxifen, there was a 5% reduction in ki67-positive cells in patients participating in the primary clinical trial [SEP] Clinical Trial: NCT02988986",Contradiction,0.49951646,0.5004835
NCT03346161,Statement: there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial  [SEP] Clinical Trial: NCT03346161,Entailment,0.5250966,0.47490343
NCT01967823,"Statement: in the primary clinical trial, there was a rise in blood bilirubin levels in 36.36% of the patients. [SEP] Clinical Trial: NCT01967823",Contradiction,0.28984216,0.7101578
NCT00759785,Statement: 11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. eastern romance language is a group of romance languages centered in romania. [SEP] Clinical Trial: NCT00759785,Contradiction,0.49259168,0.5074083
NCT00372424,"Statement: during the course of the primary clinical trial, 35 patients who were under the combination therapy of sunitinib, docetaxel, and trastuzumab encountered treatment-emergent adverse incidents. [SEP] Clinical Trial: NCT00372424",Entailment,0.5499344,0.45006558
NCT00429182,Statement: fewer than 10% of the primary clinical trial participants noticed a reduction in circulating tumor cells subsequent to multiple months of high-dose chemotherapy preceding purged autologous stem cell products. [SEP] Clinical Trial: NCT00429182,Entailment,0.59291,0.40709
NCT02807844,Statement: all patients in the primary trial receive at least 2ml of mcs110 every 3 weeks. [SEP] Clinical Trial: NCT02807844,Entailment,0.51535815,0.48464185
NCT02891681,Statement: percentage food eaten score 40 is a subjective score of 40% on a scale that ranges from 0%: none to 100%: all of my food. Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.25970712,0.74029285
NCT00320541,Statement: the paclitaxel plus bevacizumab plus gemcitabine group during the primary clinical trial showcased a better orr when juxtaposed with the paclitaxel plus bevacizumab group. [SEP] Clinical Trial: NCT00320541,Entailment,0.6594362,0.34056374
NCT03384316,Statement: gamma-tubulin is a family of globular proteins that plays a role in the nucleation and orientation of microtubules. All Infections and Fever cases in the primary trial were for patients in cohort 1. [SEP] Clinical Trial: NCT03384316,Contradiction,0.44482598,0.555174
NCT00820872,Statement: participants in the primary clinical trial were found to have cholelithiasis at a rate two times higher than those in the secondary clinical trial. [SEP] Clinical Trial: NCT00820872,Contradiction,0.46494505,0.535055
NCT00122369,"Statement: gastric pylorus carcinoma is a carcinoma that arises from the pylorus. 18 years olds are excluded from the secondary trial, but the primary trial does not specify an age range for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.7255803,0.27441967
NCT00828516,Statement: Neither the secondary trial or the primary trial use change in MYMOP score as the outcome measurement for their studies. [SEP] Clinical Trial: NCT00828516,Entailment,0.503538,0.49646196
NCT01908101,Statement: the primary trial patients receive higher doses of radiation therapy than the secondary trial participants [SEP] Clinical Trial: NCT01908101,Entailment,0.783578,0.21642207
NCT00706030,"Statement: Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia [SEP] Clinical Trial: NCT00706030",Contradiction,0.44468117,0.5553189
NCT00795769,"Statement: portable network graphics is an extensible file format for lossless data compression of images. Far more patients in the secondary trial were recorded to have experienced Chest Pain, than patients in the primary trial. [SEP] Clinical Trial: NCT00795769",Contradiction,0.41048443,0.5895155
NCT00432562,Statement: there are zero shared inclusion/exclusion criteria between the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00432562,Entailment,0.91999394,0.08000607
NCT01498458,Statement: in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. cardiovascular lesion indicator is an indication as to whether a cardiovascular lesion is present. [SEP] Clinical Trial: NCT01498458,Contradiction,0.2868595,0.71314055
NCT01011218,Statement: Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events. iv anesthesia was not administered is a response indicating that intravenous anesthesia medications were not administered. [SEP] Clinical Trial: NCT01011218,Entailment,0.6734422,0.3265578
NCT00659373,"Statement: crank arm assembly device is an extension to a shaft designed to impart a rotational energy to the shaft. On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients. [SEP] Clinical Trial: NCT00659373",Contradiction,0.45762014,0.5423798
NCT02234479,"Statement: procedure start relative to reference time point is an indication or description of the start of a procedure in relation to a specific point in time. the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.63339084,0.3666092
NCT00293540,"Statement: on average patients from the primary trial survive less than 24 months, over 40 patients from each cohort survived less than 2 days [SEP] Clinical Trial: NCT00293540",Contradiction,0.37609425,0.6239057
NCT01855828,"Statement: the primary clinical trial witnessed many psychiatric adverse incidents, notably including an eating disorder and schizophrenia [SEP] Clinical Trial: NCT01855828",Entailment,0.5193635,0.48063648
NCT01128543,Statement: 12q24 is a chromosome band present on 12q The majority of patients in the primary trial experienced complete response by week 24. [SEP] Clinical Trial: NCT01128543,Contradiction,0.36181045,0.63818955
NCT01246973,"Statement: during the primary clinical trial and the secondary clinical trial, no cardiac or psychiatric adverse events (aes) were reported, though several other categories of aes were noted. [SEP] Clinical Trial: NCT01246973",Contradiction,0.33743447,0.6625655
NCT02165839,"Statement: gin chinese is a chinese person from the gin ethnic group. Candidates for the primary trial and the secondary trial have to meet a baseline performance status, for the primary trial the baseline is a Karnofsky score >70, and for the secondary trial the baseline is a Karnofsky score >55. [SEP] Clinical Trial: NCT02165839",Contradiction,0.2799723,0.7200277
NCT01591746,Statement: all participants of the secondary clinical trial are administered with enteric-coated tablets [SEP] Clinical Trial: NCT01591746,Entailment,0.70757824,0.2924218
NCT00867217,Statement: 6p25 is a chromosome band present on 6p Patients diagnosed with breact cancer may be eligible for all study groups in the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00867217,Contradiction,0.25987482,0.7401251
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 180 days if they want to participate in the primary trial  [SEP] Clinical Trial: NCT00405938",Contradiction,0.36707804,0.63292193
NCT04080297,Statement: cervical alveolar soft part sarcoma is an alveolar soft part sarcoma arising from the cervix. Any Patients currently taking part in the secondary trial will also be eligible for the primary trial as they have the same inclusion criteria. [SEP] Clinical Trial: NCT04080297,Contradiction,0.42465124,0.57534873
NCT01013740,Statement: In total there are less cases of anemia in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01013740,Entailment,0.74721044,0.25278956
NCT00370552,"Statement: the primary clinical trial welcomes men of potential fertility and women with the potential to conceive, nevertheless, as a requirement they need to undertake a commitment to abstinence for the full course of the study [SEP] Clinical Trial: NCT00370552",Entailment,0.5238096,0.4761904
NCT02599194,Statement: there were fewer suspected serious adverse reactions outlined in the adverse events section of the primary clinical trial compared to the secondary clinical trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.79897624,0.2010238
NCT01419717,"Statement: the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using Lymphoscintigraphy. abnormal involuntary movement scale aims0111 through aims0112 original result - no is abnormal involuntary movement scale aims0111 through aims0112 original result - no. [SEP] Clinical Trial: NCT01419717",Contradiction,0.38786635,0.6121337
NCT00030823,"Statement: in the primary clinical trial, the globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine was used to treat 13 participants [SEP] Clinical Trial: NCT00030823",Contradiction,0.36088428,0.63911575
NCT00569166,"Statement: Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day. [SEP] Clinical Trial: NCT00569166",Contradiction,0.37399182,0.62600815
NCT03384316,Statement: 16p13.13-p13.12 is a chromosome band present on 16p All Infections and Fever cases in the primary trial were for patients in cohort 1. [SEP] Clinical Trial: NCT03384316,Entailment,0.5775169,0.4224831
NCT00321464,"Statement: patients with confirmed stage 1 and 2 breast adenocarcinoma that is er negative, pr negative, or her2/neu positive are able to participate in both the primary clinical trial and the secondary trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.4540336,0.5459663
NCT03403712,"Statement: the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours. [SEP] Clinical Trial: NCT03403712",Entailment,0.5013194,0.4986806
NCT00357734,"Statement: thyroid gland lipoadenoma is a thyroid gland adenoma composed of follicular structures and mature adipocytes. The intervention in the primary trial consists of a single drug, whereas in the secondary trial the intervention requires at least 3 different drugs. [SEP] Clinical Trial: NCT00357734",Contradiction,0.40692148,0.5930785
NCT01975831,Statement: cohort 1 receives more durva in their bi-weekly iv infusions than cohort 2 in the primary clinical trial. [SEP] Clinical Trial: NCT01975831,Entailment,0.7294206,0.27057937
NCT00262834,"Statement: 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients. [SEP] Clinical Trial: NCT00262834",Contradiction,0.43846434,0.56153566
NCT02961790,Statement: individuals that have been treated with androgens in the last month are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT02961790,Contradiction,0.46983397,0.53016603
NCT03015649,Statement: the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts. [SEP] Clinical Trial: NCT03015649,Entailment,0.6640305,0.33596957
NCT01290536,"Statement: The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month. have night sweats is a question about whether an individual has or had night sweats. [SEP] Clinical Trial: NCT01290536",Contradiction,0.39324203,0.606758
NCT00825682,Statement: the intervention in the secondary trial last 25 more days than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Contradiction,0.3352292,0.66477084
NCT00248547,Statement: All Patients receiving the placebo intervention in the primary trial experienced emesis . don't feel like doing anything is a question about whether an individual doesn't feel like doing anything. [SEP] Clinical Trial: NCT00248547,Entailment,0.8171594,0.18284056
NCT01772004,"Statement: African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study. welding occupations is a class of professional or vocational positions of employment that involve work with welding. [SEP] Clinical Trial: NCT01772004",Contradiction,0.397951,0.60204893
NCT02187783,"Statement: More Palpitations, Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.48370725,0.51629275
NCT01468675,"Statement: in the interventions of the primary clinical trial, both cohorts are without any counselling, risk assessment, or cognitive behavioural therapy (cbt). [SEP] Clinical Trial: NCT01468675",Entailment,0.68070763,0.3192924
NCT00321464,"Statement: patients diagnosed with histologically confirmed stage 4 breast adenocarcinoma, that show either er positivity, pr positivity or her2/neu negativity can participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.378954,0.62104607
NCT01252290,Statement: over 20% of participants in the primary clinical trial encountered adverse events [SEP] Clinical Trial: NCT01252290,Entailment,0.80539596,0.194604
NCT00702949,"Statement: body fat measurement is a measurement of the total fat mass within the subject's body. the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with Depocyt and HD-MTX. [SEP] Clinical Trial: NCT00702949",Contradiction,0.42497545,0.57502455
NCT00001832,"Statement: in both the primary and secondary clinical trials, patients are required to participate in a weekly cycle of 4-demethyl-4-cholestryloxycarbonylpenclomedine. [SEP] Clinical Trial: NCT00001832",Contradiction,0.36772454,0.63227546
NCT02320123,Statement: Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention. nasal cartilage is any of the cartilaginous structures that provide structure and support to the nose. [SEP] Clinical Trial: NCT02320123,Contradiction,0.45660934,0.5433907
NCT00372424,"Statement: in the primary clinical trial, except one, all patients who received sunitinib + docetaxel + trastuzumab experienced a treatment-emergent adverse event, and less than fifty percent experienced severe treatment-emergent adverse events. [SEP] Clinical Trial: NCT00372424",Entailment,0.62572664,0.3742733
NCT02403271,Statement: the secondary trial has higher incidents of biliary colic and clostridium difficile colitis compared to the primary trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.6862833,0.3137167
NCT00586326,Statement: agent administration care setting type code is a coded value specifying the medical setting within which the agent administration took place. The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses. [SEP] Clinical Trial: NCT00586326,Entailment,0.85145,0.14854994
NCT01252290,Statement: adverse events were reported by fewer than 5% of the participants in the primary clinical trial [SEP] Clinical Trial: NCT01252290,Entailment,0.90112114,0.09887886
NCT01439282,"Statement: while gender is irrelevant in determining patient eligibility for the primary clinical trial, the secondary clinical trial is open only to female patients. [SEP] Clinical Trial: NCT01439282",Entailment,0.6759778,0.32402217
NCT00956813,Statement: the secondary trial and the primary trial results highlight similar outcome measures [SEP] Clinical Trial: NCT00956813,Entailment,0.8806873,0.119312696
NCT00693719,Statement: A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial [SEP] Clinical Trial: NCT00693719,Entailment,0.87921005,0.12079002
NCT02002533,Statement: there were 4 additional adverse incidents recorded in the primary clinical trial compared to the secondary clinical trial. [SEP] Clinical Trial: NCT02002533,Entailment,0.64040345,0.35959655
NCT01606748,"Statement: several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia. malignant pylorus neoplasm is a primary or metastatic malignant neoplasm that affects the pylorus. [SEP] Clinical Trial: NCT01606748",Contradiction,0.48338485,0.51661515
NCT01383174,Statement:  cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial. [SEP] Clinical Trial: NCT01383174,Entailment,0.92013234,0.079867646
NCT01008150,Statement: more than 65 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 210 days after the surgery [SEP] Clinical Trial: NCT01008150,Contradiction,0.26541573,0.7345842
NCT01535040,Statement: In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time. numerical chromosomal abnormality is an irregularity in the number of chromosomes. [SEP] Clinical Trial: NCT01535040,Contradiction,0.39640406,0.6035959
NCT01011218,"Statement: the secondary clinical trial had several recorded deaths in the adverse events, but the primary trial had no such incident. [SEP] Clinical Trial: NCT01011218",Entailment,0.821046,0.17895399
NCT00256217,"Statement: no patients in the primary clinical trial experienced recorded adverse events, in contrast to the secondary clinical trial where every participant suffered from a minimum of one adverse event. [SEP] Clinical Trial: NCT00256217",Entailment,0.7812678,0.21873216
NCT02734979,Statement: both primary and secondary clinical trials accept participants who have had pulmonary embolisms in the past and currently have breast implants. [SEP] Clinical Trial: NCT02734979,Contradiction,0.3249239,0.6750761
NCT00266110,Statement: participants in the primary clinical trial will be required to take only oral medications. [SEP] Clinical Trial: NCT00266110,Entailment,0.7994133,0.20058663
NCT00245050,"Statement: the primary trial incorporated three test groups and did not use any placebo group, while the secondary trial held only one test group. [SEP] Clinical Trial: NCT00245050",Entailment,0.89121675,0.10878322
NCT01535040,Statement: In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time. [SEP] Clinical Trial: NCT01535040,Entailment,0.57875925,0.42124075
NCT01702571,Statement: all the aes recorded for cohort 1 of the primary clinical trial concern oncological side effects [SEP] Clinical Trial: NCT01702571,Entailment,0.6020946,0.39790538
NCT00586326,Statement: detailed description and treatment cycle are provided in the intervention section of the primary clinical trial. [SEP] Clinical Trial: NCT00586326,Entailment,0.74068874,0.2593113
NCT00496860,Statement: mobilization clinical trial setting is a clinical trial or treatment setting in which the therapy of interest is considered mobilization therapy. cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2. [SEP] Clinical Trial: NCT00496860,Entailment,0.555261,0.44473895
NCT02807844,"Statement: in the primary clinical trial, some patients receive mcs110, but the dosage administered is less than 20mg. [SEP] Clinical Trial: NCT02807844",Entailment,0.62100935,0.37899062
NCT00432562,Statement: there are 10 shared inclusion/exclusion criteria between the secondary trial and the primary trial [SEP] Clinical Trial: NCT00432562,Contradiction,0.49804682,0.50195324
NCT02807844,Statement: all individuals participating in the primary clinical trial are provided with at least 20mg of mcs110 every 3rd week. [SEP] Clinical Trial: NCT02807844,Contradiction,0.4483691,0.5516309
NCT00248547,Statement: sellar teratoma with malignant transformation is a teratoma with malignant transformation that arises from or adjacent to the sellar region. Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant. [SEP] Clinical Trial: NCT00248547,Contradiction,0.3696176,0.63038236
NCT00820872,Statement: Diarrhoea was more common for the primary trial participants than the secondary trial participants [SEP] Clinical Trial: NCT00820872,Entailment,0.7936,0.20639996
NCT00405938,"Statement: patients who have experienced abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess, or major psychiatric disorders in the past 6 months are not considered for the primary clinical trial [SEP] Clinical Trial: NCT00405938",Entailment,0.6114044,0.38859555
NCT01772004,Statement: only caucasian patients are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01772004,Entailment,0.6411419,0.3588581
NCT00075764,"Statement: Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial. left renal artery is an artery arising from the abdominal aorta that supplies the left kidney. [SEP] Clinical Trial: NCT00075764",Entailment,0.61874336,0.3812567
NCT01772004,"Statement: how much bothered by swelling in affected underarm, arm, or hand is a question about how bothered an individual is by swelling in their affected underarm, arm, or hand. African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study. [SEP] Clinical Trial: NCT01772004",Entailment,0.5185336,0.48146644
NCT01649271,"Statement: there were several instances of shingles in both the primary trial and group 1 of the secondary trial, but none in group 2 of the secondary trial. [SEP] Clinical Trial: NCT01649271",Contradiction,0.42649168,0.5735083
NCT00270894,Statement: participants in the primary trial receive 4 different drugs throughout the study duration. nausea during this period is a question about whether an individual had nausea during the specified time period. [SEP] Clinical Trial: NCT00270894,Entailment,0.6352853,0.36471468
NCT02165839,Statement: the performance status for candidates is not influential for admission into the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT02165839,Entailment,0.5299235,0.4700765
NCT00365105,"Statement: A 32 year old patient with histologically verified diagnosis of stage 3 breast cancer, absolute neutrophil count of 1.807 million cells/≈í¬∫l, platelet count of 110,034 thousands cells/≈í¬∫l, hemoglobin level of 90000 mg/l, and a life expectancy exceeding 96 weeks would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.28657275,0.7134273
NCT02234479,"Statement: the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. neither good nor bad is a subjective response indicating that something is neither good nor bad. [SEP] Clinical Trial: NCT02234479",Entailment,0.68426555,0.31573445
NCT00538850,Statement: the the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 3 quarters of a year in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850,Contradiction,0.42512214,0.57487786
NCT01286987,Statement: breast cancer patients in the primary trial are administered 200 mcg/day of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 500 mcg/day talazoparib instead. [SEP] Clinical Trial: NCT01286987,Entailment,0.5886447,0.41135538
NCT00544167,"Statement: patients that have suffered a pulmonary embolism in the last 60 days are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.70374614,0.29625386
NCT00775645,Statement: no adverse outcomes were recorded in more than 1% of participants in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00775645,Entailment,0.8227929,0.17720714
NCT02273206,"Statement: despite the variant cancer types, most patients in the first cohort of the primary clinical trial were screened contemporaneously after the intervention. [SEP] Clinical Trial: NCT02273206",Entailment,0.5033068,0.4966932
NCT01390818,Statement: the primary clinical trial noted a number of adverse effects in patients belonging to cohort 1. [SEP] Clinical Trial: NCT01390818,Entailment,0.82855237,0.17144766
NCT01086605,"Statement: there were 0% cases of hypertension, edema and dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Entailment,0.6259404,0.37405962
NCT00999921,Statement: malfunction only (no ae) report is a report of a device malfunction that does not include an adverse event. Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial. [SEP] Clinical Trial: NCT00999921,Entailment,0.7965506,0.20344947
NCT03202472,"Statement: patients affected by unstable angina or those having undergone either chemotherapy or radiotherapy two weeks prior, or with grade 2 or above neuropathy, are disqualified from inclusion in the secondary clinical trial, but may still participate in the primary clinical trial as long as they meet all relevant inclusion criteria. [SEP] Clinical Trial: NCT03202472",Entailment,0.50309306,0.49690694
NCT01439282,"Statement: Gender is not a determining factor for eligibility in the primary trial or the secondary trial. grade 1 ileal obstruction, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated [SEP] Clinical Trial: NCT01439282",Contradiction,0.38230142,0.6176986
NCT00544167,"Statement: patients that have suffered a pulmonary embolism within the last 300 days are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.7089347,0.29106525
NCT02122796,Statement: the patients in the primary clinical trial are given mm-121 and paclitaxel less frequently on a weekly basis compared to those in cohort 1 of the secondary clinical trial [SEP] Clinical Trial: NCT02122796,Entailment,0.6090574,0.39094257
NCT03069313,Statement: partial or complete response is a partial or complete response to treatment. the primary trial and the secondary trial adminster their interventions orally. [SEP] Clinical Trial: NCT03069313,Contradiction,0.4264281,0.57357186
NCT00146172,Statement: candidates capable of only limited selfcare; confined to bed or chair less than 20% of waking hours are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00146172,Entailment,0.53409207,0.4659079
NCT01376349,"Statement: tumor findings evaluator is a person who determines the significance of a tumor findings assessment. Neither the secondary trial or the primary trial use cm, Number of Participants or a unit of time as their units of measure. [SEP] Clinical Trial: NCT01376349",Contradiction,0.41205385,0.5879461
NCT00030823,Statement: 13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine . confidence is a feeling of trust (in someone or something). [SEP] Clinical Trial: NCT00030823,Contradiction,0.41620687,0.5837931
NCT00753415,"Statement: cohort a and b of the primary trial are given two differing doses of oral ld v935, not necessarily at the same point in time. [SEP] Clinical Trial: NCT00753415",Entailment,0.71605605,0.28394392
NCT00248547,Statement: patients receiving the placebo intervention in the primary clinical trial were less likely to experience emesis compared to patients receiving aprepitant. [SEP] Clinical Trial: NCT00248547,Entailment,0.698408,0.30159202
NCT00496860,Statement: cohort 1 is given a lesser amount of alt-801 as compared to cohort 2 in the primary clinical trial [SEP] Clinical Trial: NCT00496860,Entailment,0.8339394,0.1660606
NCT01013740,"Statement: child-pugh class c10 is a total score of 10 for hepatic function, corresponding to class c in the child-pugh classification. Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome. [SEP] Clinical Trial: NCT01013740",Contradiction,0.17519733,0.8248027
NCT01313117,"Statement: the administration of alpha lipoic acid in the primary clinical trial is at a higher dosage, up to 100 mg thrice daily, compared to a constant dosage of necitumumab given to patients in cohort 1 of the secondary clinical trial. [SEP] Clinical Trial: NCT01313117",Contradiction,0.452463,0.54753697
NCT00021255,"Statement: all participants in the primary clinical trial, irrespective of their cohort, receive a consistent dosage of docetaxel, doxorubicin, and cyclophosphamide at the same frequency. [SEP] Clinical Trial: NCT00021255",Entailment,0.68011665,0.31988332
NCT00749931,Statement: All patients eligible for the secondary trial are also eligible for the primary trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.75420547,0.24579458
NCT01823991,Statement: patients suffering from alzheimer's disease can participate in the primary clinical trial [SEP] Clinical Trial: NCT01823991,Entailment,0.59220654,0.40779346
NCT02286843,Statement: 0.13 of the primary trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.42683768,0.5731623
NCT01964924,Statement: the primary clinical trial would not include an adult diagnosed with diffuse parenchymal lung disease within the prior 3 years [SEP] Clinical Trial: NCT01964924,Entailment,0.86085224,0.1391478
NCT00253708,"Statement: unlike the secondary clinical trial that evaluates various drug dosages in its treatment plan, the primary clinical trial refrains from incorporating drug-based treatments. [SEP] Clinical Trial: NCT00253708",Entailment,0.9155565,0.08444349
NCT01554371,Statement: a patient with frequent smoking habits is eligible for participation in the primary clinical trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.62999916,0.37000084
NCT01246973,Statement: no cardiac or psychiatric adverse events were reported in the course of the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01246973,Contradiction,0.41308835,0.5869117
NCT01783444,"Statement:  Women with Newly diagnosed stage IV breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. adult diffuse mixed cell lymphoma is a b-or t-cell non-hodgkin lymphoma composed of a mixed-sized lymphocytic population occurring in adults. [SEP] Clinical Trial: NCT01783444",Contradiction,0.21012977,0.7898702
NCT00248547,"Statement: compared to patients receiving aprepitant in the primary clinical trial, those who received the placebo intervention had double the likelihood of experiencing emesis. [SEP] Clinical Trial: NCT00248547",Contradiction,0.45314857,0.54685146
NCT00662025,"Statement: mental scale is a range of values that characterizes an individual's mental development. Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study. [SEP] Clinical Trial: NCT00662025",Contradiction,0.44705263,0.55294734
NCT00408681,"Statement: Recurrent malignancies, Graft-versus-host disease, Infection, Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. atevirdine mesylate is a mesylate salt form of atevirdine, a non-nucleoside reverse transcriptase inhibitor. atevirdine is active against azt-resistant virus strains. [SEP] Clinical Trial: NCT00408681",Contradiction,0.45393363,0.54606634
NCT01920061,"Statement: the primary trial uses a 10 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place [SEP] Clinical Trial: NCT01920061",Entailment,0.91647273,0.08352726
NCT01376349,Statement: Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure. [SEP] Clinical Trial: NCT01376349,Contradiction,0.36761695,0.63238305
NCT01194440,"Statement: Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial. [SEP] Clinical Trial: NCT01194440",Contradiction,0.42379352,0.57620645
NCT01781299,"Statement: in the primary clinical trial and the secondary clinical trial, a significant number of unexpected fatalities and hospital stays were observed. [SEP] Clinical Trial: NCT01781299",Contradiction,0.23868613,0.7613139
NCT02312934,Statement: 14q22 is a chromosome band present on 14q alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. [SEP] Clinical Trial: NCT02312934,Entailment,0.661057,0.33894306
NCT01252290,Statement: adverse events were experienced by less than 10 participants in the primary clinical trial [SEP] Clinical Trial: NCT01252290,Entailment,0.8490794,0.15092063
NCT00756496,"Statement: There were no significant differences in the results from the groups in the primary trial, however some differences where found between the Reflexology Group and control group results in the secondary trial. adverse event dictionary is a reference source that provides meanings of words related to adverse events. [SEP] Clinical Trial: NCT00756496",Entailment,0.58755857,0.41244146
NCT00775645,Statement: adverse events affecting more than 1% of participants did not occur in either the primary clinical trial or secondary clinical trial. [SEP] Clinical Trial: NCT00775645,Entailment,0.8909483,0.10905167
NCT00076024,"Statement: the primary clinical trial does not impose restrictions based on life expectancy, pregnancy status, or age for its participants [SEP] Clinical Trial: NCT00076024",Entailment,0.732062,0.26793802
NCT00992602,Statement: the number of bronchopneumonia cases and instances of general physical health deterioration are equal in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00992602,Entailment,0.68602514,0.31397486
NCT01920061,Statement: not a single ae was reported for either cohort in the primary clinical trial [SEP] Clinical Trial: NCT01920061,Entailment,0.9125033,0.08749676
NCT02041429,"Statement: the intervention provided in the secondary clinical trial reports on the mtd, while the intervention provided in the primary clinical trial does not. [SEP] Clinical Trial: NCT02041429",Entailment,0.92420226,0.07579775
NCT00284180,Statement: only patients who demonstrated positive responses to previous herceptin treatments are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT00284180,Entailment,0.609002,0.39099795
NCT02178722,Statement: the secondary trial participants receive pembrolizumab twice as frequently as participants in the primary trial receive sunitinib. [SEP] Clinical Trial: NCT02178722,Entailment,0.5108384,0.48916158
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 0.5 g of fulvestrant in a tablet form to be taken bid. [SEP] Clinical Trial: NCT00836186",Contradiction,0.38423485,0.61576515
NCT00021255,"Statement: the frequency of docetaxel, doxorubicin and cyclophosphamide administration varies between cohorts in the primary clinical trial [SEP] Clinical Trial: NCT00021255",Entailment,0.7413714,0.25862858
NCT00313170,Statement: eligibility for the primary clinical trial requires having colon cancer and a lack of response to prior hormonal treatments. [SEP] Clinical Trial: NCT00313170,Entailment,0.6951619,0.30483812
NCT00319748,Statement: neither the primary clinical trial nor the secondary clinical trial records alterations in ki67 expression in tumors. [SEP] Clinical Trial: NCT00319748,Contradiction,0.3757556,0.62424445
NCT00825682,Statement: the secondary clinical trial's intervention duration extends 15 weeks longer than that of the primary clinical trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.7633712,0.23662873
NCT00373256,"Statement: rifamycin sodium is a sodium salt of rifamycin, an antibiotic produced by streptomyces mediterranei which is used to treat mycobacterium infections. The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel. [SEP] Clinical Trial: NCT00373256",Contradiction,0.35008612,0.6499139
NCT02336737,"Statement: all candidates in cohort 1 of the primary clinical trial experienced at least one adverse event (ae), while none of the cohort 2 candidates did [SEP] Clinical Trial: NCT02336737",Entailment,0.8048501,0.19514993
NCT01127763,Statement: there was not a single adverse event reported during the primary clinical trial. [SEP] Clinical Trial: NCT01127763,Entailment,0.9192926,0.08070738
NCT00467844,Statement: all patients treated with gtx-024 100mg in the primary trial gained lean body mass over a 9 month period [SEP] Clinical Trial: NCT00467844,Contradiction,0.41350114,0.5864988
NCT02961790,"Statement: any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 104 weeks before study entry are excluded from the primary trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.6642516,0.3357483
NCT01803282,"Statement: 15/7 the primary trial participants, and 5/1674 the secondary trial participants suffered an ae. [SEP] Clinical Trial: NCT01803282",Entailment,0.50873214,0.49126792
NCT00143390,Statement: no gastro-intestinal adverse events were observed during the primary clinical trial [SEP] Clinical Trial: NCT00143390,Entailment,0.85734445,0.14265555
NCT01086605,"Statement: there were zero cases of hypertension, edema and dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Entailment,0.60551697,0.394483
NCT00588640,"Statement: the primary clinical trial uses uniform criteria for participant eligibility in every phase, whereas the secondary trial's selection criteria vary per participant. [SEP] Clinical Trial: NCT00588640",Entailment,0.8571755,0.14282446
NCT00118157,"Statement: in the primary clinical trial, participants are administrated 100 mg/m2 of lapatinib orally, twice daily for a period of one month. [SEP] Clinical Trial: NCT00118157",Contradiction,0.3970998,0.60290027
NCT02187783,"Statement: more instances of palpitations, pericardial effusions, and abdominal pains were documented in the primary clinical trial compared to the secondary one. [SEP] Clinical Trial: NCT02187783",Entailment,0.5227366,0.47726342
NCT01989546,Statement: warfarin-based therapy is a mandatory requirement for patients in the primary clinical trial and it disqualifies them from the secondary clinical trial. [SEP] Clinical Trial: NCT01989546,Entailment,0.81479645,0.18520357
NCT00305695,"Statement: in the primary trial, the method of administering the intervention 1 is through oral pills, whereas all intervention drugs in the secondary trial are given via inhalation. [SEP] Clinical Trial: NCT00305695",Entailment,0.6520879,0.34791204
NCT00819182,"Statement: on average, patients in the paced respiration intervention group of the primary clinical trial experienced fewer daily hot flashes than those in the fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.6474246,0.35257536
NCT00963911,Statement: None of the primary trial candidates have to perfom regular exercise as part of the intervention. leporine experimental organism diagnosis is a condition that is relevant to either disease states or models of disease in rabbits. [SEP] Clinical Trial: NCT00963911,Entailment,0.6058824,0.3941176
NCT01806675,"Statement: childhood kidney angiomyolipoma is an angiomyolipoma occurring in childhood. Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2. [SEP] Clinical Trial: NCT01806675",Contradiction,0.4365497,0.5634503
NCT01086605,"Statement: there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Entailment,0.67090744,0.32909256
NCT00583700,Statement: eligibility for both the primary clinical trial and secondary trial requires women to be aged 22 or above [SEP] Clinical Trial: NCT00583700,Contradiction,0.3724394,0.6275606
NCT00496860,Statement: cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2 [SEP] Clinical Trial: NCT00496860,Entailment,0.80403715,0.19596283
NCT01631552,"Statement: while the primary and secondary clinical trials share common intervention methods, their outcome measurements are entirely separate and unrelated. [SEP] Clinical Trial: NCT01631552",Entailment,0.87031007,0.12968998
NCT00583700,Statement: the secondary clinical trial and the primary clinical trial are open to women who are 18 years old and above. [SEP] Clinical Trial: NCT00583700,Contradiction,0.30527323,0.69472677
NCT00513292,"Statement: the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had much better results than arm 1. cardiovascular system findings test is a character or string that represents the long name of the cardiovascular system findings assessment. [SEP] Clinical Trial: NCT00513292",Contradiction,0.32859805,0.6714019
NCT02441946,"Statement: ga-68 psma-r2 positron emission tomography and magnetic resonance imaging is an imaging procedure that combines gallium-68-labelled psma-r2 with an mri scan to overlay activity data onto detailed anatomic images. Patients with a TNBC tumor of 100mm in diameter, are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02441946",Contradiction,0.2662098,0.7337902
NCT04080297,Statement: Any Patients currently taking part in the secondary trial will also be eligible for the primary trial as they have the same inclusion criteria. duodenal extraskeletal osteosarcoma is an extraskeletal osteosarcoma affecting the duodenum. [SEP] Clinical Trial: NCT04080297,Contradiction,0.4286339,0.57136613
NCT00254592,"Statement: in both the primary trial and secondary trial, methotrexate is administered to the patients [SEP] Clinical Trial: NCT00254592",Contradiction,0.44381487,0.5561851
NCT02413008,"Statement: both the primary and secondary clinical trials use the same outcome measure: the proportion of patients with no invasive tumor leftover in the breast post-surgery after finishing chemotherapy, defined as pcr within the breast. [SEP] Clinical Trial: NCT02413008",Contradiction,0.41347158,0.5865284
NCT00322374,Statement: patients must have a karnofsky score of 80 or above to be considered for the primary clinical trial. [SEP] Clinical Trial: NCT00322374,Contradiction,0.44634187,0.5536581
NCT00978250,Statement: patients with unresectable scbc are suitable candidates for the primary clinical trial despite the presence or absence of er or pr factors [SEP] Clinical Trial: NCT00978250,Entailment,0.5283503,0.4716497
NCT00372424,Statement: none of the patients treated with sunitinib + docetaxel + trastuzumab in the primary clinical trial experienced any treatment-emergent adverse events [SEP] Clinical Trial: NCT00372424,Entailment,0.81490755,0.1850924
NCT02807844,"Statement: in the primary clinical trial, all patients get a dose of no less than 20mg of mcs110 every three weeks. [SEP] Clinical Trial: NCT02807844",Entailment,0.5189856,0.48101437
NCT01434342,"Statement: there were fewer cases of mucositis oral, epileptic seizures and thromboembolic events reported in the primary trial compared to the secondary trial [SEP] Clinical Trial: NCT01434342",Entailment,0.53423977,0.4657602
NCT00623831,Statement: 25% of cohort 2 patients in the primary trial suffer Increased pleural effusion. deleterious rpa1 gene mutation is a mutation in the rpa1 gene that is associated with an increased risk of disease. [SEP] Clinical Trial: NCT00623831,Contradiction,0.46342415,0.53657585
NCT02312934,Statement: smokers and alcoholics who consume 6 or more drinks daily are allowed to participate in both the primary and secondary trials. [SEP] Clinical Trial: NCT02312934,Contradiction,0.44947034,0.55052966
NCT01806259,"Statement: in the primary clinical trial, the group given ketorolac 30 mg experienced a recurrence-free survival rate decrease of -6.4% when compared to the group treated with nacl 0.9% 3ml [SEP] Clinical Trial: NCT01806259",Entailment,0.63934267,0.36065736
NCT00587964,Statement: it is rare to find cases of coronary artery stenosis as an ae in the primary clinical trial [SEP] Clinical Trial: NCT00587964,Entailment,0.71091497,0.28908506
NCT00408681,"Statement: Recurrent malignancies, Graft-versus-host disease, Anaemia, Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. did patient receive chemotherapy is a question about whether the patient received chemotherapy. [SEP] Clinical Trial: NCT00408681",Entailment,0.54460543,0.45539457
NCT01806259,Statement: the ketorolac 30mg group in the primary clinical trial showed a -6.4% lower recurrence-free survival rate than the group that was given nacl 0.9% 3ml [SEP] Clinical Trial: NCT01806259,Entailment,0.6151154,0.38488457
NCT01313117,"Statement: in the primary clinical trial, participants are given lower doses of alpha lipoic acid, with a maximum of 20 mg three times daily, while, in the secondary clinical trial, cohort 1 participants are administered fluctuating dosages of necitumumab. [SEP] Clinical Trial: NCT01313117",Contradiction,0.42699653,0.5730035
NCT02178722,Statement: the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib. [SEP] Clinical Trial: NCT02178722,Entailment,0.5101119,0.4898881
NCT00686127,Statement: the primary clinical trial and the secondary clinical trial have an equivalent amount and type of adverse events. [SEP] Clinical Trial: NCT00686127,Entailment,0.8515958,0.14840423
NCT00978250,"Statement: Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both. [SEP] Clinical Trial: NCT00978250",Contradiction,0.40051916,0.59948087
NCT01383174,Statement: cohort 2 of the secondary clinical trial yielded more positive results than cohort 2 of the primary clinical trial. [SEP] Clinical Trial: NCT01383174,Entailment,0.8443066,0.1556934
NCT00656019,Statement: patients with low vitamin d levels in the primary clinical trial showed a discernible pattern for expression of the set of 40 evaluated genes. [SEP] Clinical Trial: NCT00656019,Contradiction,0.3614175,0.63858247
NCT03125941,"Statement: in the primary clinical trial, pre-operative dexamethasone is administered to the first cohort, while the second cohort receives it two hours post-surgery. [SEP] Clinical Trial: NCT03125941",Contradiction,0.45754108,0.54245895
NCT01606748,"Statement: numerous incidences of anaemia and febrile neutropenia were logged in the first group of the primary clinical trial, but no cases of pancytopenia were found. [SEP] Clinical Trial: NCT01606748",Contradiction,0.44937006,0.5506299
NCT00372424,"Statement: All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events. [SEP] Clinical Trial: NCT00372424",Entailment,0.67965686,0.3203431
NCT01783444,"Statement: individuals diagnosed with metastasized breast cancer, confirmed er+ considering hormone therapy, are eligible for primary clinical trial and secondary clinical trial [SEP] Clinical Trial: NCT01783444",Contradiction,0.2430301,0.7569699
NCT00305695,"Statement:  intervention 1 in the primary trial, and all intervention drugs in the secondary trial must be administered intravenously. [SEP] Clinical Trial: NCT00305695",Contradiction,0.41927826,0.58072174
NCT00963911,"Statement: several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention. have mouth discomfort with toothpaste is a question about whether an individual has or had mouth discomfort with toothpaste. [SEP] Clinical Trial: NCT00963911",Contradiction,0.39279675,0.6072033
NCT01869192,"Statement: the findings from the primary clinical trial show that the arm c intervention resulted in the highest overall response rate, and in the secondary clinical trial, the denosumab group showed an improved time to first on-study sre in comparison to the zoledronic acid group. [SEP] Clinical Trial: NCT01869192",Contradiction,0.45281658,0.5471834
NCT01823991,Statement: the primary clinical trial welcomes alzheimer's patients for inclusion [SEP] Clinical Trial: NCT01823991,Entailment,0.6903101,0.30968985
NCT01138046,Statement: japanese nationals are eligible to participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01138046,Contradiction,0.44041196,0.559588
NCT01205503,Statement: the absence of allergies to cephalosporin or trimethoprim/sulfamethoxazole does not restrict a patient's eligibility for either primary trial or secondary trial. [SEP] Clinical Trial: NCT01205503,Entailment,0.72479725,0.27520275
NCT00404066,"Statement: The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain, no aes wererecorded in the primary trial [SEP] Clinical Trial: NCT00404066",Entailment,0.6974209,0.30257913
NCT00054028,Statement: every patient in the secondary clinical trial has been treated with raltitrexed and oxaliplatin. [SEP] Clinical Trial: NCT00054028,Contradiction,0.4097864,0.5902136
NCT00209092,"Statement: margin status cannot be assessed is a result that the margin status cannot be assessed. Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin. [SEP] Clinical Trial: NCT00209092",Entailment,0.66336334,0.33663666
NCT01376349,Statement: Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure. experimental organism benign mixed mullerian tumor is a benign neoplasm arising from pluripotent mesodermal cells of the mullerian ducts. (inhand) [SEP] Clinical Trial: NCT01376349,Contradiction,0.39434272,0.6056573
NCT00843167,"Statement: the secondary trial uses pain as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. [SEP] Clinical Trial: NCT00843167",Contradiction,0.471586,0.528414
NCT00293540,"Statement: On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months. hours missed from work because of health problems is a question about how many hours an individual missed from work because of their health problems. [SEP] Clinical Trial: NCT00293540",Contradiction,0.35653472,0.6434652
NCT02234479,"Statement: the primary trial is testing the effects of different gels on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.8726407,0.12735926
NCT02413008,Statement: the primary clinical trial measures success through the proportion of patients achieving pathological complete response (pcr) in lymph nodes while the secondary clinical trial uses the improvement in the patients' quality of life as the main outcome measure [SEP] Clinical Trial: NCT02413008,Contradiction,0.38423994,0.6157601
NCT02273206,Statement: Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention. [SEP] Clinical Trial: NCT02273206,Contradiction,0.3599895,0.6400105
NCT00702949,"Statement: 150mg of oral pregabalin every two weeks for six weeks is the course of treatment for the patient group in the primary clinical trial, whereas the secondary clinical trial employs depocyt and hd-mtx as the method of administration for its patient group. [SEP] Clinical Trial: NCT00702949",Contradiction,0.44816393,0.5518361
NCT00253708,"Statement: adult extracardiac rhabdomyoma is a benign mesenchymal neoplasm arising from skeletal muscle and occurring in adults. the primary trial does not test any drug based treatments, whereas the secondary trial tests two different drugs. [SEP] Clinical Trial: NCT00253708",Entailment,0.6757306,0.32426944
NCT00708019,Statement: none of the patients in the primary trial experienced the worst pain imaginable for 1/2 an hour. [SEP] Clinical Trial: NCT00708019,Entailment,0.6859728,0.31402722
NCT02187783,"Statement: hypophosphatemia, ctcae is a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood. More Palpitations, Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.39064765,0.60935235
NCT00588640,"Statement: the primary trial's inclusion and exclusion criteria remain constant across phases, and the secondary trial does not differentiate in terms of criteria for healthy participants and those with cancer. [SEP] Clinical Trial: NCT00588640",Entailment,0.90186876,0.09813117
NCT00756717,Statement: There were 0 cases of Febrile neutropenia or Cholelithiasis in the primary trial and the secondary trial. curie extension score is a score assigned to a curie body segment to indicate the quantity of metastases. [SEP] Clinical Trial: NCT00756717,Contradiction,0.38255018,0.6174498
NCT00284180,Statement: endobronchial ultrasound-guided miniforceps biopsy is a technique for obtaining small forceps biopsies under continuous endobronchial ultrasound guidance using a convex probe endobronchial ultrasound bronchoscope. Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial. [SEP] Clinical Trial: NCT00284180,Entailment,0.76897776,0.23102224
NCT00365365,"Statement: the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. tarsus bone is any one of the seven bones forming the instep of the foot. [SEP] Clinical Trial: NCT00365365",Contradiction,0.34099874,0.6590013
NCT00076024,"Statement: malignant oncocyte is a malignant epithelial cell with abundant eosinophilic or clear granular cytoplasm. There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial. [SEP] Clinical Trial: NCT00076024",Contradiction,0.43905362,0.56094635
NCT00749931,Statement: at least one inclusion criteria is common between the secondary clinical trial and the primary clinical trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.83737755,0.16262245
NCT00429182,Statement: microbiology specimen link group identifier is a sequence of characters used to link multiple microbiology specimen records to a single finding. less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products. [SEP] Clinical Trial: NCT00429182,Entailment,0.5805771,0.41942292
NCT01023477,Statement: patients diagnosed with hyperkalemia are ruled out in the primary clinical trial but can possibly qualify for the secondary clinical trial [SEP] Clinical Trial: NCT01023477,Entailment,0.71116203,0.28883794
NCT01023477,Statement: not known if 10q23/pten locus deletion analysis was performed is an indication that it is not known whether 10q23/pten deletion analysis was performed during the study. Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial. [SEP] Clinical Trial: NCT01023477,Entailment,0.74600095,0.25399908
NCT01048099,Statement: no single type of adverse event noted in the primary clinical trial impacted over 25% of the patient population [SEP] Clinical Trial: NCT01048099,Contradiction,0.4461226,0.5538775
NCT00256217,"Statement: There were no patients with recorded Aes in the primary trial, whereas every patient in the secondary trial suffered at least one adverse event. [SEP] Clinical Trial: NCT00256217",Entailment,0.81630933,0.18369064
NCT01967823,Statement: All AE types in the primary trial affected less than 10% of patients. received indicator is an indication as to whether the entity was received. [SEP] Clinical Trial: NCT01967823,Entailment,0.77582395,0.22417606
NCT00143390,Statement: There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial [SEP] Clinical Trial: NCT00143390,Contradiction,0.44907308,0.5509269
NCT02104830,"Statement: patients in both cohort 2 of the primary trial and cohort 1 of the secondary trial reported equal incidence of neutropenia, irrespective of their empegfilgrastim dosage regimen. [SEP] Clinical Trial: NCT02104830",Entailment,0.59604675,0.40395325
NCT01286987,"Statement: in the primary clinical trial, the intervention given to ovarian/ peritoneal cancer patients significantly differs from those with breast cancer. [SEP] Clinical Trial: NCT01286987",Entailment,0.69851387,0.3014861
NCT01468675,"Statement: Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions. [SEP] Clinical Trial: NCT01468675",Entailment,0.69490486,0.3050951
NCT01421472,"Statement: Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial. select one is a directive to choose one of the options provided. [SEP] Clinical Trial: NCT01421472",Contradiction,0.49739397,0.5026061
NCT01037790,"Statement: the primary clinical trial excludes patients diagnosed with tumors that have ccnd1 amplification, cdk4/6 mutation, or ccnd2 amplification. [SEP] Clinical Trial: NCT01037790",Entailment,0.7336591,0.26634097
NCT00686127,"Statement: There are less total adverse events in the primary trial than in the secondary trial, but more cases of Cardiac-ischemia/infarction in the primary trial than in the secondary trial. malignant abdominal neoplasm is a primary or metastatic malignant neoplasm that affects the organs and structures of the abdomen. [SEP] Clinical Trial: NCT00686127",Contradiction,0.45957103,0.540429
NCT00544167,"Statement: Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision. anovulatory cycle is a menstrual cycle in which no ovulation occurs. [SEP] Clinical Trial: NCT00544167",Entailment,0.58516157,0.4148384
NCT01127763,Statement: at least one patient in the primary trial suffered several different adverse events. plate-reader artifact is artifacts resulting from the electronics of the plate reader or from issues associated with the image plate. [SEP] Clinical Trial: NCT01127763,Entailment,0.6467959,0.35320404
NCT00753415,Statement: hpv16 infection is an infection caused by human papillomavirus 16. hpv16 infection is associated with a risk for cervical cancer. Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934. [SEP] Clinical Trial: NCT00753415,Contradiction,0.40990195,0.5900981
NCT00756496,"Statement: viral relapse is a recurrence of the same virus after a finding of aviremia at the end of planned or actual treatment. There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results. [SEP] Clinical Trial: NCT00756496",Contradiction,0.47566622,0.5243338
NCT00254592,"Statement: benign ovarian sex cord-stromal tumor is a sex cord-stromal tumor arising from the ovary, without metastatic potential. the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts. [SEP] Clinical Trial: NCT00254592",Contradiction,0.20299286,0.79700714
NCT01419717,"Statement: the primary trial requires patients to receive 0.120 grams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mci of radioactive tc99m sulfur colloid. [SEP] Clinical Trial: NCT01419717",Contradiction,0.3829833,0.6170167
NCT00319748,"Statement: both the primary and secondary clinical trial abstain from determining the percentage of their study participants who experience clinical benefit, using recist criteria [SEP] Clinical Trial: NCT00319748",Entailment,0.77221763,0.22778231
NCT00256217,"Statement: in the primary clinical trial and the secondary clinical trial, no patients faced fewer than 3 diverse aes. [SEP] Clinical Trial: NCT00256217",Entailment,0.5341846,0.46581542
NCT00544167,"Statement: patients that have suffered a pulmonary embolism within the last 1095 days are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.7002923,0.29970768
NCT00418028,"Statement: the primary clinical trial provides the time to progression in months for a combined total of 156 patients from both cohorts, whereas the secondary clinical trial focuses on the count of patients exhibiting objective response [SEP] Clinical Trial: NCT00418028",Contradiction,0.30466697,0.69533306
NCT01730729,"Statement: the primary clinical trial involves oral administration of the intervention, contrastingly, the secondary clinical trial necessitates the intervention to be given solely via a needle or tube inserted into a vein [SEP] Clinical Trial: NCT01730729",Entailment,0.55048144,0.44951856
NCT00588640,Statement: the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients. [SEP] Clinical Trial: NCT00588640,Entailment,0.5670066,0.4329934
NCT02431676,Statement: Morbidly obese patients are eligible for the primary trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.66523206,0.334768
NCT02122796,Statement: cohort 1 of the secondary trial receives lower weekly mm-121 and paclitaxel doses than those in the primary trial [SEP] Clinical Trial: NCT02122796,Entailment,0.56321114,0.4367888
NCT00756717,Statement: cholelithiasis was a common adverse event recorded in both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00756717,Entailment,0.7318105,0.26818946
NCT01806675,"Statement: primary clinical trial study groups will engage in different imaging procedures, including 18f-fet pet/ct and 18f-fmiso pet/ct. [SEP] Clinical Trial: NCT01806675",Entailment,0.82290006,0.17709988
NCT00317603,Statement: there were no recorded instances of syncope across the patient cohorts of the primary trial and the secondary trial [SEP] Clinical Trial: NCT00317603,Entailment,0.87343824,0.12656179
NCT01498458,Statement: in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. foxo1 gene rearrangement is a molecular abnormality indicating rearrangement of the foxo1 gene. [SEP] Clinical Trial: NCT01498458,Contradiction,0.33594272,0.66405725
NCT00775645,"Statement: in both the primary clinical trial and the secondary clinical trial, there were adverses events which affected less than 1% of the participant group. [SEP] Clinical Trial: NCT00775645",Entailment,0.8744645,0.1255355
NCT03069313,"Statement: the primary clinical trial provides sublingual administration of its intervention, whereas the secondary clinical trial uses oral administration. [SEP] Clinical Trial: NCT03069313",Entailment,0.6894683,0.31053168
NCT02599194,Statement: each adverse event reported in the primary clinical trial was accounted as a suspected serious adverse reaction while there was no such record in the secondary clinical trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.9121597,0.08784037
NCT01171924,"Statement: the primary clinical trial administers the same dosage and frequency of cudc-101 to both cohort 1 and cohort 2, but only cohort 1 gets a weekly pd-0332991 dose. [SEP] Clinical Trial: NCT01171924",Contradiction,0.48932332,0.5106767
NCT02509156,Statement: The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection. neoplastic large cell is a neoplastic cell with abundant amount of cytoplasm and/or large nucleus. [SEP] Clinical Trial: NCT02509156,Contradiction,0.230037,0.76996297
NCT00148668,Statement: Both interventions in the primary trial include the same dose of Paraplatin. globular region is a protein region consisting of a hydrophilic surface and a hydrophobic core. [SEP] Clinical Trial: NCT00148668,Contradiction,0.42773646,0.5722635
NCT00253708,"Statement: the primary trial tests one specific drug, whereas the secondary trial involves stimulated exercises only. [SEP] Clinical Trial: NCT00253708",Entailment,0.65521383,0.34478614
NCT01252290,Statement: more than 10 patients in the primary clinical trial experienced aes. [SEP] Clinical Trial: NCT01252290,Contradiction,0.28645253,0.71354747
NCT00741039,"Statement: within the primary clinical trial, the members of the first cohort receive the pneumococcus vaccine and those in the second cohort are given the influenza vaccine. [SEP] Clinical Trial: NCT00741039",Contradiction,0.4904843,0.5095157
NCT00963911,"Statement: several of the primary trial candidates are administered 1000000 ng of talazoparib daily, as part of the intervention [SEP] Clinical Trial: NCT00963911",Contradiction,0.33118278,0.6688172
NCT03125941,Statement: all cohorts in the primary clinical trial are given dexamethasone before their operation [SEP] Clinical Trial: NCT03125941,Entailment,0.68387336,0.3161266
NCT00693719,Statement: leptomeningeal carcinoma patients are admissible for the primary clinical trial [SEP] Clinical Trial: NCT00693719,Entailment,0.69364244,0.30635753
NCT00467844,Statement: All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period [SEP] Clinical Trial: NCT00467844,Contradiction,0.42155227,0.57844776
NCT01969448,Statement: laser-assisted fluorescence angiography is used for both interventions in the primary trial. [SEP] Clinical Trial: NCT01969448,Entailment,0.60349923,0.39650077
NCT02312934,"Statement: non-drinking patients are eligible for the primary clinical trial, whereas the secondary clinical trial demands a daily alcohol consumption of at least five drinks. [SEP] Clinical Trial: NCT02312934",Entailment,0.5473325,0.45266742
NCT01045421,"Statement: Unlike the primary trial, patients must be diagnosed with a mutation in the one of the following genes; PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ or GNA11 to be included in the secondary trial [SEP] Clinical Trial: NCT01045421",Contradiction,0.3875864,0.6124135
NCT01614210,Statement: Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.36385828,0.6361417
NCT00553358,"Statement: a patient that has a primary tumour with a diameter of 3300 micrometers measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.30307198,0.6969281
NCT01629615,Statement: eating disorders were not common for the primary trial candidates. how much distress problems with sexual interest or activity is a question about an individual's distress from their problems with sexual interest or activity. [SEP] Clinical Trial: NCT01629615,Entailment,0.53495437,0.4650456
NCT01964924,Statement: the primary clinical trial could accept an adult patient who was diagnosed with ild/dpld within the last 3 years and has a life expectancy of half a year [SEP] Clinical Trial: NCT01964924,Contradiction,0.4808931,0.5191069
NCT02286843,Statement: 77% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.38290176,0.6170983
NCT00122369,"Statement: 18 year olds are allowed to participate in the secondary clinical trial, but are not permitted to be a part of the primary clinical trial. [SEP] Clinical Trial: NCT00122369",Entailment,0.8770705,0.12292952
NCT01111825,Statement: Neiter of the primary trial cohorts receive any invasive surgery or Neratinib  [SEP] Clinical Trial: NCT01111825,Entailment,0.63297653,0.3670235
NCT01706081,"Statement: Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream. radium is an element with atomic symbol ra, atomic number of 88, and atomic weight 226.0 [SEP] Clinical Trial: NCT01706081",Contradiction,0.45135623,0.54864377
NCT02320123,Statement: unresectable malignant glomus tumor is a malignant glomus tumor that is not amenable to surgical resection. Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention. [SEP] Clinical Trial: NCT02320123,Entailment,0.69836825,0.30163178
NCT01314963,Statement: the primary clinical trial differentiates between the two interventions by using pihgc for intervention one and standard gp for intervention two [SEP] Clinical Trial: NCT01314963,Contradiction,0.4997055,0.5002945
NCT00254592,"Statement: both the primary clinical trial and the secondary clinical trial provide cyclophosphamide, paclitaxel and pegfilgrastim to their respective patient groups [SEP] Clinical Trial: NCT00254592",Contradiction,0.26512086,0.73487914
NCT01597193,Statement: cohort 2 of the primary clinical trial is given half the dose of enzalutamide compared to cohort 1 [SEP] Clinical Trial: NCT01597193,Entailment,0.6944418,0.30555817
NCT00148668,Statement: the same dosage of paraplatin is applied to both interventions in the primary clinical trial [SEP] Clinical Trial: NCT00148668,Entailment,0.63023204,0.36976793
NCT01881230,Statement: Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin. aortic aneurysm is a sac formation resulting from the localized dilatation of the wall of the aorta. [SEP] Clinical Trial: NCT01881230,Contradiction,0.4449372,0.5550628
NCT00878709,Statement: The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group [SEP] Clinical Trial: NCT00878709,Entailment,0.64522475,0.3547753
NCT00104650,Statement: The Interventions in the primary trial included different medications but are administered through the same routes. [SEP] Clinical Trial: NCT00104650,Entailment,0.85828155,0.14171845
NCT03384316,"Statement: grade 1 acoustic nerve disorder nos, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated All Infections and Fever cases in the primary trial were for patients in cohort 1. [SEP] Clinical Trial: NCT03384316",Entailment,0.6790643,0.32093573
NCT01806675,Statement: publication name is a human readable textual identifier of the publication. Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures. [SEP] Clinical Trial: NCT01806675,Contradiction,0.46692023,0.5330798
NCT02961790,"Statement: any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 2.5 years before study entry are excluded from the primary trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.68253803,0.317462
NCT00321464,"Statement: patients with histologically confirmed early-stage breast adenocarcinoma that is either er negative, pr negative or her2/neu positive are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.46307692,0.53692305
NCT02504424,"Statement: during the primary clinical trial, numerous subjects contracted urinary tract infections [SEP] Clinical Trial: NCT02504424",Contradiction,0.32711175,0.6728882
NCT00583700,"Statement: the secondary clinical trial is open for women aged 18 or 19, but to be considered for the primary clinical trial, they would need to wait 1-2 years [SEP] Clinical Trial: NCT00583700",Entailment,0.6029131,0.39708695
NCT00454532,Statement: over 99.999% of patients in the secondary trial and the primary trial did not suffer any adverse events [SEP] Clinical Trial: NCT00454532,Contradiction,0.47434184,0.5256582
NCT01376349,Statement: the primary clinical trial and the secondary clinical trial both utilize cogstate measured objective cognitive function scores for their units of measurement. [SEP] Clinical Trial: NCT01376349,Contradiction,0.25140506,0.74859494
NCT01194440,Statement: those diagnosed with early stage non-hodgkin lymphoma considering radiation therapy are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01194440,Entailment,0.5537336,0.4462664
NCT02273206,"Statement: regardless of the type of cancer, the majority of patients in the first cohort of the primary clinical trial did not meet the screening timelines post intervention. [SEP] Clinical Trial: NCT02273206",Entailment,0.86899745,0.13100253
NCT00544167,"Statement: Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.73662895,0.26337105
NCT01597193,"Statement: cohort 2 of the primary clinical trial receives enzalutamide through iv, identical to cohort 1's method [SEP] Clinical Trial: NCT01597193",Entailment,0.6495394,0.35046062
NCT00867217,"Statement: patients experiencing a vitamin d insufficiency are not regards fit for the primary clinical trial, but might qualify for the secondary clinical trial. [SEP] Clinical Trial: NCT00867217",Entailment,0.68891114,0.3110888
NCT00950911,Statement: The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial. have painful joints is a question about whether an individual has or had painful joints. [SEP] Clinical Trial: NCT00950911,Entailment,0.5197386,0.48026136
NCT01702571,Statement: All of the Aes recorded for cohort 1 of the primary trial are related to mental health [SEP] Clinical Trial: NCT01702571,Entailment,0.5878234,0.41217658
NCT00030823,Statement: more people participated in the secondary clinical trial than the primary clinical trial. [SEP] Clinical Trial: NCT00030823,Entailment,0.57601666,0.42398337
NCT01908101,Statement: the medicament under test is mutually the same in the primary and secondary clinical trials' [SEP] Clinical Trial: NCT01908101,Entailment,0.81450236,0.18549766
NCT00544167,"Statement: patients with no history of pulmonary embolism over the past decade are ineligible for the primary trial, but the secondary trial admission depends on the investigator's decision [SEP] Clinical Trial: NCT00544167",Entailment,0.8403418,0.1596582
NCT00088413,"Statement: clostridiaceae is a taxonomic family of bacterium in the phylum firmicutes that includes the genera alkaliphilus, clostridium and lutispora, among others. All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.5570802,0.4429198
NCT00632489,Statement: the primary trial does not report any results for the LBH589 and Lapatinib cohort. study requirement object is a dimension table that lists the biospecimen requirements for this study biospecimen requirements include: .  (catissue) [SEP] Clinical Trial: NCT00632489,Entailment,0.8804235,0.11957654
NCT01128543,"Statement: in the primary trial results there were more patients with stable disease after 3 months than after 6 months, but none of the patients had complete response after 3 months or 6 months [SEP] Clinical Trial: NCT01128543",Entailment,0.5501054,0.44989464
NCT00878709,Statement: the placebo group of the primary clinical trial had a lower rate of idfs than the neratinib group [SEP] Clinical Trial: NCT00878709,Entailment,0.6580314,0.34196863
NCT01766102,"Statement: image study is a radiographic technique used to evaluate a specific anatomic location for a specific purpose. Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore the control group performed better than the test group in this regard. In the secondary trial there is no control group against which we can compare. [SEP] Clinical Trial: NCT01766102",Entailment,0.7912224,0.20877759
NCT01091974,"Statement: anti-gm-csf monoclonal antibody is any monoclonal antibody that is directed against granulocyte-macrophage colony-stimulating factor (gm-csf). In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110. [SEP] Clinical Trial: NCT01091974",Entailment,0.5195812,0.48041886
NCT00786838,Statement: the placebo and trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a semi-annual basis. [SEP] Clinical Trial: NCT00786838,Contradiction,0.37513605,0.624864
NCT01252290,Statement: all patients in the primary clinical trial encountered aes. [SEP] Clinical Trial: NCT01252290,Entailment,0.79479975,0.20520025
NCT01920061,"Statement: the primary trial uses a 3 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. 3q21-q25 is a chromosome band present on 3q [SEP] Clinical Trial: NCT01920061",Entailment,0.8759309,0.1240691
NCT00245050,"Statement: the primary trial had one test group and one placebo group, the secondary trial had 1 test group and 1 control group. pragmatic trial is a study designed to test the effectiveness of an intervention in a broad routine clinical practice. [SEP] Clinical Trial: NCT00245050",Entailment,0.7066994,0.29330063
NCT01439282,Statement: primary hypoparathyroidism is abnormally low levels of parathyroid hormone due to a disorder originating within the parathyroid glands. Gender is not a determining factor for eligibility in the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01439282,Contradiction,0.34478408,0.655216
NCT00451555,"Statement: malignant neoplasm by grade is a term that refers to the categorization of malignant neoplasm by histologic grade. Participants must be resistant to AI therapy to participate in the primary trial, but this is not necessary to be included in the secondary trial. [SEP] Clinical Trial: NCT00451555",Entailment,0.7407887,0.2592113
NCT01434342,"Statement: don't really enjoy food is a response indicating that an individual does not really enjoy food. There were more cases of Mucositis Oral, Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01434342",Entailment,0.57537764,0.4246224
NCT00245050,"Statement: the primary trial had three test groups and no placebo group, the secondary trial had two test groups and two control groups. [SEP] Clinical Trial: NCT00245050",Entailment,0.6371177,0.36288232
NCT00322374,"Statement: no specific conditions regarding mental health, bodyweight, age, karnofsky/ecog score or previous treatments are required to qualify for the primary clinical trial. [SEP] Clinical Trial: NCT00322374",Entailment,0.61521745,0.38478252
NCT01781299,"Statement: There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial, the only AEs recorded were 3 cases of Lymphoma. [SEP] Clinical Trial: NCT01781299",Contradiction,0.19286346,0.80713654
NCT02234479,"Statement: the primary clinical trial evaluates the impact of diverse radiation therapies on its participants, while the secondary clinical trial investigates the results of varying doses of identical treatment on its group [SEP] Clinical Trial: NCT02234479",Entailment,0.6183045,0.3816955
NCT01606748,"Statement: specify site if cm1b is a directive to indicate the anatomic sites if metastasis is categorized as cm1b. 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia. [SEP] Clinical Trial: NCT01606748",Contradiction,0.48957634,0.5104236
NCT01806675,Statement: Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures. [SEP] Clinical Trial: NCT01806675,Contradiction,0.45290968,0.5470903
NCT01823991,"Statement: yttrium is an element with atomic symbol y, atomic number 39, and atomic weight 88.91.  Alzheimer's patients are not eligible for the primary trial. [SEP] Clinical Trial: NCT01823991",Entailment,0.79542893,0.20457101
NCT04080297,Statement: simultaneous participation in both the primary and secondary trial is allowed for all patients [SEP] Clinical Trial: NCT04080297,Entailment,0.7888158,0.21118425
NCT00373256,"Statement: in the primary clinical trial, the first cohort is treated with a daily dose of 25 mg sunitinib, differing from the second cohort which gets treated with 90 mg/m^2 paclitaxel. [SEP] Clinical Trial: NCT00373256",Contradiction,0.3853058,0.61469424
NCT00867217,"Statement: for patients with breast cancer, eligibility can extend to all study groups in the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00867217",Contradiction,0.3822303,0.61776966
NCT01376349,"Statement: the secondary trial runs in semesters and uses weeks as a unit of measure, while the primary operates in cycles and uses age of the participant as its unit. [SEP] Clinical Trial: NCT01376349",Contradiction,0.3551253,0.6448747
NCT01806675,"Statement: the primary clinical trial study groups undergo separate pet/ct imaging procedures, only cohort 2 receives an increased dose of 18f-fpprgd2. [SEP] Clinical Trial: NCT01806675",Contradiction,0.4487723,0.5512277
NCT00587964,"Statement: in the primary clinical trial, general symptoms are the most frequently noted adverse event [SEP] Clinical Trial: NCT00587964",Entailment,0.83994913,0.16005085
NCT00708019,Statement: several of the patients in the primary trial experienced the no pain whatsoever during the 3 months of the study. [SEP] Clinical Trial: NCT00708019,Contradiction,0.25983024,0.7401698
NCT00623831,Statement: 25% of the second cohort in the primary clinical trial have experienced a rise in pleural effusion. [SEP] Clinical Trial: NCT00623831,Contradiction,0.43743262,0.5625674
NCT02404441,"Statement: the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups. have raw or sore skin is a question about whether an individual's skin feels or felt raw or sore. [SEP] Clinical Trial: NCT02404441",Entailment,0.6390896,0.36091045
NCT00429182,"Statement: in the primary clinical trial, over 70% of the participants had a decrease in circulating tumor cells despite not receiving any form of chemotherapy [SEP] Clinical Trial: NCT00429182",Entailment,0.5288603,0.47113973
NCT00305695,"Statement: The intervention 1 in the primary trial is administered by IV, and all intervention drugs in the secondary trial can be administered orally. have abdominal discomfort is a question about whether an individual has or had abdominal discomfort. [SEP] Clinical Trial: NCT00305695",Entailment,0.50951815,0.49048188
NCT00956813,Statement: both the primary clinical trial and secondary clinical trial utilize the same system of units when reporting their findings. [SEP] Clinical Trial: NCT00956813,Entailment,0.54785043,0.4521496
NCT01286168,"Statement: The most common adverse event in the secondary trial was Anaemia, there were no recorded AEs in the primary trial. gastric mucinous adenocarcinoma is a variant of gastric adenocarcinoma with more than half of the tumor containing extracellular mucinous pools. [SEP] Clinical Trial: NCT01286168",Entailment,0.6475942,0.35240576
NCT00795769,Statement: the incidence of chest pain among patients was reported to be considerably higher in the secondary clinical trial than in the primary clinical trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.60496175,0.39503822
NCT02273206,"Statement: most patients from the first cohort of the primary clinical trial, irrespective of their cancer type, had completed their screenings following the intervention. [SEP] Clinical Trial: NCT02273206",Entailment,0.51732105,0.48267898
NCT01466972,Statement: cerebellar and brain stem ependymal tumor is a finding indicating the presence of an ependymal tumor in the cerebellum and brain stem. No two patients in the primary trial suffered the same type of adverse event. [SEP] Clinical Trial: NCT01466972,Entailment,0.5918052,0.40819478
NCT01908101,Statement: both primary and secondary clinical trials have the identical medicational substance under investigation' [SEP] Clinical Trial: NCT01908101,Entailment,0.8872894,0.11271062
NCT00416715,"Statement: participants of the secondary clinical trial are administered three subcutaneous injections on a weekly basis, in contrast, participants of the primary clinical trial receive only a single injection at the study's commencement. [SEP] Clinical Trial: NCT00416715",Entailment,0.60579187,0.3942082
NCT02104830,"Statement: deleterious cdh1 gene mutation is a change in the nucleotide sequence of the cdh1 gene that is associated with increased risk of disease. Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim. [SEP] Clinical Trial: NCT02104830",Contradiction,0.49598426,0.50401574
NCT01127763,Statement: multiple diverse negative effects were experienced by at least one patient in the primary clinical trial. [SEP] Clinical Trial: NCT01127763,Entailment,0.7148159,0.2851841
NCT01535040,"Statement: in the primary clinical trial, both the placebo and memantine interventions are given orally on a daily basis. [SEP] Clinical Trial: NCT01535040",Entailment,0.5363378,0.4636622
NCT01128543,"Statement: in the outcome of the primary clinical trial, the number of patients with stable disease was higher in the 12th week than the 24th week, however, no patients showed complete response in either week 12 or 24 [SEP] Clinical Trial: NCT01128543",Contradiction,0.4973442,0.5026558
NCT00820872,Statement: neither the primary trial participants nor the secondary trial participants experienced cholelithiasis [SEP] Clinical Trial: NCT00820872,Entailment,0.5425014,0.45749864
NCT00001832,Statement: porcelain veneer is a restoration consisting of a layer of tooth-colored porcelain material cemented to the surface of a tooth. The interventions in the primary trial and the secondary trial include completely different drug-based treatments. [SEP] Clinical Trial: NCT00001832,Entailment,0.7941531,0.20584695
NCT02165839,"Statement: pharmacogenomics/genetics biomarker supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics biomarker domain. Candidates for the primary trial and the secondary trial have to meet a baseline performance status, each trial is using a different performance status scoring system. [SEP] Clinical Trial: NCT02165839",Entailment,0.63813114,0.36186883
NCT02320123,"Statement: only the first group in the primary clinical trial will be shown the educational dvd as part of the intervention, while the second group will be administered a standard dose of radiotherapy [SEP] Clinical Trial: NCT02320123",Contradiction,0.4556562,0.5443438
NCT02312934,Statement: perineal artery is an artery arising from the internal pudendal artery that supplies the bulbocavernosus and ischiocavernosus muscles of the perineum. Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. [SEP] Clinical Trial: NCT02312934,Contradiction,0.49172485,0.50827515
NCT00708019,Statement: several of the patients in the primary trial experienced the no pain whatsoever during the 70 days of the study. [SEP] Clinical Trial: NCT00708019,Contradiction,0.24589571,0.7541043
NCT00148668,Statement: the primary clinical trial includes the use of trastuzumab in both of its interventions [SEP] Clinical Trial: NCT00148668,Entailment,0.60780495,0.39219505
NCT01975831,Statement: milliliter per square centimeter is a dose calculation unit expressed in milliliter(s) per square centimeter. The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2. [SEP] Clinical Trial: NCT01975831,Entailment,0.5616621,0.43833792
NCT02122796,"Statement: in the primary clinical trial, candidates are given lower weekly doses of mm-121 and paclitaxel in comparison to the first cohort of the secondary clinical trial, but they receive greater volumes of herceptin and docetaxel [SEP] Clinical Trial: NCT02122796",Contradiction,0.35776913,0.64223087
NCT02122796,Statement: participants in the primary trial are given a higher weekly dosage of mm-121 and paclitaxel compared to those in cohort 1 of the secondary trial [SEP] Clinical Trial: NCT02122796,Contradiction,0.40647748,0.5935225
NCT02259114,"Statement: nut midline carcinoma, castrate-resistant prostate cancer, or inflammatory breast cancer patients identified through fluorescence in situ hybridization are eligible for participation in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02259114",Contradiction,0.40361676,0.5963832
NCT01466972,"Statement: in the primary clinical trial, recurring patterns of the same adverse event were observed across multiple patients. [SEP] Clinical Trial: NCT01466972",Entailment,0.6733722,0.32662785
NCT02403271,"Statement: abnormal liver function test is atypical results found on serum liver enzyme testing, which may indicate significant disease and/or disease progression. There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial. [SEP] Clinical Trial: NCT02403271",Contradiction,0.44115934,0.5588407
NCT01702571,Statement: there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial [SEP] Clinical Trial: NCT01702571,Entailment,0.5961006,0.40389943
NCT00825682,Statement: mme positive is an indication that mme expression has been detected in a sample. The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Contradiction,0.3553119,0.64468807
NCT00021255,"Statement: Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency. data analysis whitepaper is an informational document describing a data analysis process. [SEP] Clinical Trial: NCT00021255",Entailment,0.51706326,0.48293674
NCT01803282,"Statement: 0/73 the primary trial participants, and 1674/1674 the secondary trial participants suffered an acute myocardial infarction [SEP] Clinical Trial: NCT01803282",Contradiction,0.40400597,0.595994
NCT00256698,Statement: Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial. fibrous meningioma is a who grade i meningioma characterized by the presence of spindle cells that form bundles in a collagen matrix. [SEP] Clinical Trial: NCT00256698,Entailment,0.63699025,0.36300975
NCT02807844,Statement: All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks. colon mucosa-associated lymphoid tissue lymphoma is an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue that arises from the colon. [SEP] Clinical Trial: NCT02807844,Contradiction,0.45576736,0.5442326
NCT00588640,"Statement: the primary trial has unified criteria for all phases while the secondary trial divides its subjects into healthy and cancer patients, applying a separate set of rules for each. [SEP] Clinical Trial: NCT00588640",Entailment,0.60127854,0.3987215
NCT01171924,"Statement: cohort 1 and 2 of the primary clinical trial receive different dosages of cudc-101, with varying frequencies. [SEP] Clinical Trial: NCT01171924",Entailment,0.6064811,0.39351892
NCT02891681,Statement: Morbidly obese patients can be eligible for the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.21958315,0.78041685
NCT03403712,"Statement: device malfunction code is a coded value specifying the defect or malfunction that occurred during use of the device. the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Median sleep time of its patients in minutes. [SEP] Clinical Trial: NCT03403712",Contradiction,0.47059128,0.5294087
NCT01439282,"Statement: Gender is not a determining factor for eligibility in the primary trial, but only female patients are eligible for the secondary trial. fibroblastic neoplasm is a benign, intermediate, or malignant mesenchymal neoplasm characterized by the presence of neoplastic fibroblasts. [SEP] Clinical Trial: NCT01439282",Contradiction,0.46476358,0.5352364
NCT00838929,Statement: qrs complex is an electrocardiographic finding that represents depolarization of the ventricular myocardium. normally the ventricles are activated simultaneously. Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy. [SEP] Clinical Trial: NCT00838929,Contradiction,0.3414201,0.6585799
NCT00756717,Statement: there were 16 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial [SEP] Clinical Trial: NCT00756717,Contradiction,0.21942794,0.78057206
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation,postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 2 days if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.39024702,0.60975295
NCT02179515,"Statement: in the primary clinical trial, all participants from cohort 1 experienced at least one life-threatening adverse event. [SEP] Clinical Trial: NCT02179515",Entailment,0.74776906,0.25223094
NCT00867217,"Statement: those with an inadequate level of vitamin d will not be included in the primary clinical trial, but they could be suitable for the secondary clinical trial. [SEP] Clinical Trial: NCT00867217",Entailment,0.7289664,0.27103359
NCT01290536,"Statement: while the primary clinical trial employs radioembolization with yttrium-90 glass microspheres and theraspheres as its intervention method, the secondary clinical trial opts for a regimen involving 560 mg of ibrutinib and 10 mg/kg of medi4736, administered twice daily for 30 days. [SEP] Clinical Trial: NCT01290536",Contradiction,0.36578584,0.6342142
NCT01631552,Statement: the secondary trial and the primary trial have completely unrelated outcome measurements. usually have considerable trouble concentrating is a response indicating that an individual usually has or had considerable difficulty concentrating. [SEP] Clinical Trial: NCT01631552,Entailment,0.51354027,0.48645976
NCT01286168,"Statement: the most common adverse event in the secondary trial was anaemia, affecting less than 0.05% of patients, there were no recorded aes in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.8107932,0.18920675
NCT00001832,Statement: the primary clinical trial and the secondary clinical trial each entail entirely distinct pharmacological therapies. [SEP] Clinical Trial: NCT00001832,Entailment,0.89188486,0.108115084
NCT00896454,Statement: distinct units of measure are used to report results in the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00896454,Contradiction,0.3904309,0.6095691
NCT01091974,"Statement: feel hopeless is a question about whether an individual feels or felt hopeless. In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same 100 mg dose of PDR001, and 1 mg/kg dose of MCS110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.48527992,0.5147201
NCT01629615,Statement: having an eating disorder was not a frequent condition among the primary clinical trial candidates [SEP] Clinical Trial: NCT01629615,Entailment,0.8937263,0.10627373
NCT00756717,Statement: neither the primary clinical trial nor the secondary clinical trial registered any adverse events [SEP] Clinical Trial: NCT00756717,Entailment,0.848085,0.15191501
NCT01306032,Statement: acute physiology and chronic health evaluation ii apch101 original result - 32-33.9 is acute physiology and chronic health evaluation ii apch101 original result - 32-33.9. Patients in the primary trial and the secondary trial  suffered Thromboembolic events. [SEP] Clinical Trial: NCT01306032,Contradiction,0.3224379,0.67756206
NCT00632489,Statement: rising from floor functional test question is a question associated with the rising from floor functional test. the primary trial does not report any results for the LBH589 and Lapatinib cohort. [SEP] Clinical Trial: NCT00632489,Entailment,0.9048975,0.09510251
NCT00256217,Statement: neither the primary clinical trial nor the secondary clinical trial had patients experiencing less than 3 separate aes. [SEP] Clinical Trial: NCT00256217,Entailment,0.7229153,0.2770847
NCT00759785,Statement: a higher percentage of participants in the triple negative group of the primary clinical trial showed a decrease in the growth factor signature compared to those in the dalotuzumab 20 mg/kg group. [SEP] Clinical Trial: NCT00759785,Entailment,0.51848656,0.48151338
NCT00662025,"Statement: in the primary clinical trial, sunitinib was administered intravenously instead of orally. [SEP] Clinical Trial: NCT00662025",Entailment,0.6659798,0.33402017
NCT02403271,"Statement: the primary clinical trial has seen a higher prevalence of biliary colic, while instances of diarrhoea are more common in the secondary trial. [SEP] Clinical Trial: NCT02403271",Entailment,0.66440165,0.33559832
NCT02041429,"Statement: the primary clinical trial and the secondary clinical trial both deliver results on the maximum tolerated dose (mtd) of the same treatment, with the mtd of mm-111 for patients in the secondary trial being 30 mg per day [SEP] Clinical Trial: NCT02041429",Contradiction,0.20426972,0.7957303
NCT02550795,"Statement: group 2 of the primary trial does not receive any dosage of dexmedetomidine, while patients in the secondary trial are given 1ug/kg of dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.73768646,0.26231357
NCT01803282,Statement: quarter of the participants in the primary clinical trial and 418/1674 participants in the secondary clinical trial had an adverse event. [SEP] Clinical Trial: NCT01803282,Entailment,0.6338779,0.36612213
NCT01975831,"Statement: in the primary clinical trial, there is more than one difference between interventions 1 and 2, as cohort 1 and 2 have various aspects of their monthly durva injections that differentiate them. [SEP] Clinical Trial: NCT01975831",Contradiction,0.4880767,0.5119233
NCT02286843,Statement: 61% of the primary trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.4077576,0.5922424
NCT00825682,Statement: The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.8524509,0.1475491
NCT00182767,Statement: there were no recorded instances of dose-limiting toxicity from any patients participating in the primary clinical trial. [SEP] Clinical Trial: NCT00182767,Entailment,0.848672,0.15132807
NCT01421472,"Statement: breast cancer patients characterized by estrogen positive, progesterone positive and her2+ tumors are eligible for all cohorts of the primary clinical trial [SEP] Clinical Trial: NCT01421472",Contradiction,0.44847032,0.55152965
NCT00828516,Statement: the primary clinical trial and the secondary clinical trial do not utilize alterations in the mymop score as their method of assessing study outcomes. [SEP] Clinical Trial: NCT00828516,Entailment,0.9206178,0.0793822
NCT00878709,Statement: the number of participants varied significantly between the two cohorts of the primary clinical trial [SEP] Clinical Trial: NCT00878709,Entailment,0.73156655,0.26843345
NCT01498458,"Statement: within the primary clinical trial, occurrences of hepatotoxicity were thrice as common as incidents of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458",Contradiction,0.31976408,0.6802359
NCT00756717,Statement: there were 101 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial [SEP] Clinical Trial: NCT00756717,Contradiction,0.21541555,0.7845845
NCT02222922,Statement: participants in the primary clinical trial are administered drugs at a lower dose compared to those in the secondary clinical trial. [SEP] Clinical Trial: NCT02222922,Entailment,0.8495337,0.15046631
NCT00143390,Statement: one or more gastro-intestinal adverse event and at least two psychiatric events were recorded during the primary clinical trial [SEP] Clinical Trial: NCT00143390,Entailment,0.5166236,0.48337638
NCT00828516,Statement: both primary and secondary clinical trials rely on modifications in mymop score as the assessment of their study findings. [SEP] Clinical Trial: NCT00828516,Entailment,0.5018148,0.49818525
NCT01128543,Statement: the lion's share of patients from the primary clinical trial showed total recovery within the course of 24 weeks. [SEP] Clinical Trial: NCT01128543,Contradiction,0.38712898,0.612871
NCT00978250,"Statement: those with histology-backed metastatic or inoperable scbc are excluded from the primary clinical trial, unless they have either er or pr or both positive. [SEP] Clinical Trial: NCT00978250",Contradiction,0.4038143,0.59618574
NCT01286168,"Statement: The most common adverse event in the secondary trial was Anaemia, affecting more than 5% of patients, there were no recorded AEs in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.81075305,0.18924694
NCT01023477,"Statement: patients with hypokalemia are not included in the primary clinical trial, but patients with hyperkalemia may be suitable for both the primary and secondary clinical trial. [SEP] Clinical Trial: NCT01023477",Entailment,0.63509667,0.3649033
NCT01313117,"Statement: the primary clinical trial administers the same dose of necitumumab to its patients for the entire duration, while the patients of the secondary clinical trial cohort 1 will subject to an escalating dosage of alpha lipoic acid. [SEP] Clinical Trial: NCT01313117",Contradiction,0.47847497,0.521525
NCT00317603,"Statement: The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope, which occurred in 25.00% of the primary trial patients. associated persons exposure domain is a domain utilized for the submission of exposure records related to persons associated with the study subject. [SEP] Clinical Trial: NCT00317603",Contradiction,0.19037351,0.80962646
NCT01770353,"Statement: the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections. consumer safety officer is an official of the food and drug administration who coordinates the review process of sponsor applications. [SEP] Clinical Trial: NCT01770353",Contradiction,0.19231044,0.80768955
NCT01920061,Statement: the number of aes disclosed was identical for the two cohorts in the primary trial [SEP] Clinical Trial: NCT01920061,Entailment,0.87106186,0.12893811
NCT00878709,Statement: the second cohort of the primary clinical trial had fewer participants than the first cohort [SEP] Clinical Trial: NCT00878709,Entailment,0.889087,0.110913
NCT00687102,Statement: There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial. past seven days frequency of pain in the abdomen is a question about the frequency of an individual's abdominal pain during the past seven days. [SEP] Clinical Trial: NCT00687102,Contradiction,0.4375654,0.5624346
NCT01008150,Statement: 9q33 is a chromosome band present on 9q More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study. [SEP] Clinical Trial: NCT01008150,Contradiction,0.4519717,0.5480283
NCT03557801,"Statement: have felt unusual weakness is a question about whether an individual feels or felt unusual weakness. the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.40496388,0.59503615
NCT02273206,Statement: every one of the 61 cervical cancer patients in the initial cohort of the primary clinical trial complied with their screenings before the intervention commenced. [SEP] Clinical Trial: NCT02273206,Entailment,0.5742201,0.42577988
NCT01997333,Statement: the patient with the longest pfs in the primary trial survived 42 weeks without disease progression or death [SEP] Clinical Trial: NCT01997333,Entailment,0.5880121,0.41198793
NCT01997333,Statement: The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death . assign score - risk score is assign cardiovascular disease 10-year risk score (assign score) risk score. [SEP] Clinical Trial: NCT01997333,Entailment,0.55968297,0.440317
NCT02441946,"Statement: leptospiraceae is a taxonomic family of mostile bacterium in the phylum spirochaetes that includes the genera leptospira and turneriella, among others. Patients with a TNBC tumor of 100mm in diameter, are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02441946",Contradiction,0.37190333,0.6280967
NCT00182793,"Statement: in both the primary and secondary clinical trial, at least one infection case was noted [SEP] Clinical Trial: NCT00182793",Entailment,0.7776548,0.2223451
NCT01008904,Statement: only one adverse event has been documented for the patient group in the primary clinical trial. [SEP] Clinical Trial: NCT01008904,Entailment,0.8971687,0.10283127
NCT00404066,"Statement: the only types of adverse events observed in patients from the primary clinical trial were hypertension, angina pectoris and dizziness, no adverse events were recorded in the secondary clinical trial [SEP] Clinical Trial: NCT00404066",Entailment,0.54124755,0.45875245
NCT00538850,Statement: The the primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine [SEP] Clinical Trial: NCT00538850,Contradiction,0.41205838,0.5879416
NCT00416715,"Statement: individuals in the secondary trial receive a single sc injection at the start, unlike those in the primary trial who get a series of injections over four weeks. [SEP] Clinical Trial: NCT00416715",Entailment,0.71074647,0.28925353
NCT00021255,"Statement: cohort a of the primary clinical trial receives a higher dosage of docetaxel, doxorubicin and cyclophosphamide than cohort b [SEP] Clinical Trial: NCT00021255",Contradiction,0.4877844,0.5122156
NCT01286987,Statement: patients with breast cancer and ovarian/peritoneal cancer within the primary clinical trial experience an identical treatment method. [SEP] Clinical Trial: NCT01286987,Entailment,0.8066994,0.19330062
NCT00428220,"Statement: childhood brain anaplastic astrocytoma is an anaplastic astrocytoma that arises from the brain and occurs during childhood. Pericardial effusions were more common for patients in the primary trial, and Corneal deposits were more common in the secondary trial. [SEP] Clinical Trial: NCT00428220",Contradiction,0.38831183,0.61168814
NCT00698035,"Statement: the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention. [SEP] Clinical Trial: NCT00698035",Entailment,0.58895576,0.41104424
NCT00054028,"Statement: abdominal examination is an assessment of the abdomen including the organs within the abdominal cavity. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial. [SEP] Clinical Trial: NCT00054028",Contradiction,0.18918706,0.8108129
NCT01091974,"Statement: a single cohort within the primary clinical trial is provided with armodafinil p.o. daily. on the other hand, each patient in the secondary clinical trial is prescribed an equal dose of 100 mg pdr001 and 1mg/kg of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.42401013,0.57598984
NCT01091974,"Statement: In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same 100 mg dose of PDR001, and 1 mg/kg dose of MCS110. component missing is a device component(s) found to be missing when delivered to the user facility. [SEP] Clinical Trial: NCT01091974",Entailment,0.5549051,0.44509488
NCT02441946,"Statement: patients with a breast tumor 0.8-2 cm in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.475684,0.524316
NCT01222390,"Statement: restriction site is a sequence in dna that can be recognized by a specific restriction enzyme. There are no X-rays, ultrasound, CT scans or MRIs included the interventions of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01222390",Contradiction,0.36722863,0.6327714
NCT00756496,"Statement: There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results. [SEP] Clinical Trial: NCT00756496",Entailment,0.8539548,0.14604525
NCT01252290,"Statement: in the primary clinical trial, aes were reported by more than half of the participants [SEP] Clinical Trial: NCT01252290",Entailment,0.65104306,0.34895697
NCT03346161,Statement: there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial . hard to stay standing when in pain is a question about whether a person had trouble staying standing when they had pain. [SEP] Clinical Trial: NCT03346161,Entailment,0.53557616,0.46442387
NCT01246973,"Statement: There were no cardiac or phsyciatric Aes recorded during the primary trial and the secondary trial, however several other types of Aes were observed. normalization basis is an indication of what method was used to normalize the data. [SEP] Clinical Trial: NCT01246973",Contradiction,0.21236868,0.7876313
NCT01390818,Statement: was kras mutation analysis performed is a question asking if kras mutations were analyzed during the study. Several recorded Aes in the primary trial occurred to cohort 1 patients. [SEP] Clinical Trial: NCT01390818,Entailment,0.5959972,0.4040028
NCT02122796,"Statement: candidates for the primary clinical trial receive smaller weekly quantities of mm-121 and paclitaxel compared to the secondary clinical trial's first group, although their dosage of herceptin and docetaxel is higher [SEP] Clinical Trial: NCT02122796",Contradiction,0.42339262,0.57660735
NCT02259114,"Statement: Patients with NUT midline carcinoma or Castrate-resistant prostate cancer, determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. military occupation is an employment class consisting of all persons employed in the military. [SEP] Clinical Trial: NCT02259114",Contradiction,0.35037282,0.64962715
NCT03403712,"Statement: the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Median sleep time of its patients in minutes. [SEP] Clinical Trial: NCT03403712",Entailment,0.52122074,0.47877926
NCT00146172,Statement: candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.48340136,0.51659864
NCT02509156,Statement: xq27.1 is a chromosome band present on xq. The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection. [SEP] Clinical Trial: NCT02509156,Contradiction,0.27150315,0.72849685
NCT00693719,Statement: A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial. biliary atresia is a congenital disorder characterized by blockage or absence of the intrahepatic or extrahepatic bile ducts. [SEP] Clinical Trial: NCT00693719,Contradiction,0.47643468,0.52356535
NCT00756496,"Statement: There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results. sexual activity is any activity, solitary or between two or more individuals, that induces sexual arousal. [SEP] Clinical Trial: NCT00756496",Entailment,0.5431581,0.45684183
NCT01649271,"Statement: basal cell of the squamous epithelium is a basal cell located in the squamous epithelium. There was one case of shingles recorded in group 2 of the secondary trial, but no cases in group 1 of the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01649271",Contradiction,0.49123034,0.5087697
NCT02002533,Statement: mixture of melanocytic neoplastic components present is a  finding indicating the presence of at least two morphologic components in a melanocytic tumor sample. the primary trial has 4 more adverse events recorded than the secondary trial. [SEP] Clinical Trial: NCT02002533,Entailment,0.5220736,0.47792634
NCT01023477,"Statement: hypokalemic patients are most welcomed to participate in the primary clinical trial, while those with normal potassium levels are preferred in the secondary clinical trial. [SEP] Clinical Trial: NCT01023477",Entailment,0.62508357,0.37491637
NCT00587964,Statement: Coronary artery stenosis are the most common AE recorded in the primary trial. abnormal lymphocyte is a lymphocyte characterized by a structural or functional abnormality. [SEP] Clinical Trial: NCT00587964,Contradiction,0.43051067,0.5694893
NCT00408681,"Statement: conditions including recurrent malignancies, graft-versus-host disease, anaemia, cardiac failure and diffuse alveolar hemorrhage were more often associated with adverse events in the primary clinical trial than in the secondary clinical trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.5309003,0.46909973
NCT01869192,"Statement: assent is agreement with a statement or proposal to do something. The results from the primary trial indicate that the Arm A intervention provided the best overall response rate, additionally, in the secondary trial the Denosumab cohort had a worse Time to First On-Study SRE than the Zoledronic Acid cohort. [SEP] Clinical Trial: NCT01869192",Entailment,0.65239316,0.3476069
NCT00544167,"Statement: patients that have suffered a pulmonary embolism within the last 72 weeks are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.71630037,0.28369957
NCT00322374,"Statement: taq polymerase is a heat stable dna-directed dna polymerase. the enzyme is widely utilized in laboratory polymerase chain reaction applications. There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial . [SEP] Clinical Trial: NCT00322374",Contradiction,0.42890307,0.5710969
NCT00544167,"Statement: 11p12-p11.2 is a chromosome band present on 11p Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision. [SEP] Clinical Trial: NCT00544167",Entailment,0.64851224,0.35148782
NCT01376349,"Statement: Neither the secondary trial or the primary trial use cm, Number of Participants or a unit of time as their units of measure. [SEP] Clinical Trial: NCT01376349",Contradiction,0.32415453,0.67584544
NCT01383174,"Statement: penile pain, ctcae 5.0 is a disorder characterized by a sensation of marked discomfort in the penis.  cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial. [SEP] Clinical Trial: NCT01383174",Entailment,0.64706004,0.35294
NCT01383174,"Statement: paraganglion is a cluster of neural crest cells that are located adjacent to the adrenal gland, nerves, and blood vessels.  cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial. [SEP] Clinical Trial: NCT01383174",Entailment,0.7375319,0.26246813
NCT01498458,Statement: hepatotoxicity cases were ten times more frequent than hypertension and pancreatectomy cases in the primary clinical trial [SEP] Clinical Trial: NCT01498458,Contradiction,0.3994186,0.6005814
NCT01419717,"Statement: the primary trial does not necessitate the administration of any drug, including denosumab; while the secondary trial promotes oral ingestion of tablets, with no required injections. [SEP] Clinical Trial: NCT01419717",Entailment,0.7049907,0.29500932
NCT01743560,"Statement: children are unable to participate in the primary clinical trial, yet it is not explicitly stated that they are ineligible for the secondary clinical trial [SEP] Clinical Trial: NCT01743560",Entailment,0.87821275,0.12178732
NCT00956813,"Statement: the secondary clinical trial uses miles as a unit of measurement, while the primary clinical trial reports in kilometers. [SEP] Clinical Trial: NCT00956813",Entailment,0.54991376,0.45008627
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive intramuscular injections aswell as medication to be taken orally. [SEP] Clinical Trial: NCT00836186",Contradiction,0.43317133,0.5668286
NCT02187783,"Statement: in the primary clinical trial, more incidents of palpitations, pericardial effusions and abdominal pains were observed in the second cohort compared to the first cohort of the secondary clinical trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.43987983,0.56012017
NCT00708019,Statement: None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks. definitely is a subjective answer of very strong agreement. [SEP] Clinical Trial: NCT00708019,Entailment,0.6883802,0.31161982
NCT01783444,"Statement: testicular plasmacytoma is a rare plasmacytoma that arises in the testis. at presentation the involvement is usually unilateral.  Women with Newly diagnosed locally advanced breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01783444",Contradiction,0.21534446,0.7846555
NCT01881230,Statement: carboplatin is administered at dissimilar doses between cohorts in the primary clinical trial [SEP] Clinical Trial: NCT01881230,Entailment,0.84699184,0.15300812
NCT01908101,Statement: the primary trial patients receive lower doses of radiation therapy than the secondary trial participants [SEP] Clinical Trial: NCT01908101,Entailment,0.8320147,0.16798536
NCT03015649,Statement: the primary trial and the secondary trial recorded the same number of adverse events in their cohorts. 1p/19q deletion analysis testing method is a request to enter the specific molecular analysis method used to determine the 1q/19q deletion status. [SEP] Clinical Trial: NCT03015649,Entailment,0.5947191,0.40528095
NCT01629615,Statement: Most the primary trial candidates suffered from some kind of eating disorder during the study duration. central nervous system cyst is a congenital or acquired cyst that is present in the central nervous system. [SEP] Clinical Trial: NCT01629615,Contradiction,0.38716915,0.6128309
NCT00878709,Statement: bladder small cell neuroendocrine carcinoma is a small cell neuroendocrine carcinoma arising from the bladder. The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group. [SEP] Clinical Trial: NCT00878709,Entailment,0.5383274,0.4616726
NCT01597193,"Statement: cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV. additional qualifier is a value specifying a supplemental characterization of the observation or entity. [SEP] Clinical Trial: NCT01597193",Entailment,0.5687599,0.43124014
NCT00686127,"Statement: the primary trial has fewer total adverse events compared to the secondary trial, although the primary trial does record more instances of cardiac-ischemia/infarction. [SEP] Clinical Trial: NCT00686127",Entailment,0.60381293,0.3961871
NCT01351376,Statement: Patients with measurable tumors in both breasts are excluded from the primary trial. ejection fraction decreased is a finding indicating a decrease in the volume of blood ejected during ventricular heart contraction. [SEP] Clinical Trial: NCT01351376,Contradiction,0.48898825,0.5110118
NCT01989546,"Statement: the usage of warfarin-based therapies disqualifies patients from the primary clinical trial, although they could still potentially participate in the secondary clinical trial. [SEP] Clinical Trial: NCT01989546",Entailment,0.60895604,0.39104402
NCT01629615,Statement: most participants of the primary clinical trial encountered some sort of eating disorder in the course of the research period [SEP] Clinical Trial: NCT01629615,Entailment,0.62574446,0.37425557
NCT00365105,"Statement: bassas da india is an atoll in the southern mozambique channel that is part of the french southern and antartic lands. A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 79000/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.34695673,0.65304327
NCT03092934,Statement: patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer. laryngeal small cell neuroendocrine carcinoma is a small cell neuroendocrine carcinoma that arises from the larynx. [SEP] Clinical Trial: NCT03092934,Entailment,0.5495685,0.4504315
NCT00693719,Statement: a patient with a leptomeningeal carcinoma diagnosis would be excluded from the primary clinical trial [SEP] Clinical Trial: NCT00693719,Entailment,0.8450721,0.1549279
NCT01920061,"Statement: the primary clinical trial employs an open-ended treatment process, while the secondary clinical trial operates on a consistent 4-week cycle regimen. [SEP] Clinical Trial: NCT01920061",Entailment,0.5341876,0.46581236
NCT01766102,"Statement: in the primary trial, the control group, arm 1, performed better in terms of operative time than the test group, arm 2. the secondary trial also has a control group against which comparisons are made. [SEP] Clinical Trial: NCT01766102",Entailment,0.6245508,0.37544924
NCT00030823,Statement: 13 individuals received the globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine as part of their treatment in the primary clinical trial [SEP] Clinical Trial: NCT00030823,Contradiction,0.38988227,0.61011773
NCT02988986,Statement: after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression   [SEP] Clinical Trial: NCT02988986,Entailment,0.546047,0.45395303
NCT00775645,"Statement: in the primary clinical trial and the secondary clinical trial, there were no adverse events that occurred in more than 10% of the participants. [SEP] Clinical Trial: NCT00775645",Contradiction,0.39851645,0.6014835
NCT00656019,Statement: None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes [SEP] Clinical Trial: NCT00656019,Entailment,0.5718924,0.42810756
NCT00759785,Statement: a smaller percentage of participants in the er-positive luminal b group of the primary clinical trial showed a decrease in the growth factor signature compared to the triple negative group [SEP] Clinical Trial: NCT00759785,Entailment,0.62965995,0.3703401
NCT00194779,"Statement: participants in the primary clinical trial are subjected to surgeries alongside administration of seven distinct drugs via a subcutaneous route, in direct contrast to participants of the secondary clinical trial who are treated with only two different drugs and several imagistic investigations [SEP] Clinical Trial: NCT00194779",Contradiction,0.29534575,0.7046543
NCT01008150,Statement: over forty-two patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes around 210 days after the surgery [SEP] Clinical Trial: NCT01008150,Contradiction,0.32478318,0.6752168
NCT03092934,"Statement: patients without any evidence of solid tumor, either locally advanced or metastatic, of all genders are welcomed for both phases of the primary clinical trial. [SEP] Clinical Trial: NCT03092934",Entailment,0.54075485,0.45924515
NCT00428220,"Statement: patients in the primary clinical trial saw a higher frequency of ascites, whereas those in the secondary clinical trial had higher incidences of pneumocystis jirovecii pneumonia. [SEP] Clinical Trial: NCT00428220",Entailment,0.50114036,0.49885967
NCT02761642,"Statement: cancer patients diagnosed with thalasemic syndromes, epilepsy, or anemia are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT02761642",Contradiction,0.4306296,0.5693704
NCT01908101,Statement: pre-market approval application is an application to fda for a license to market a new device in the united states. the primary trial patients receive higher doses of radiation therapy than the secondary trial participants. [SEP] Clinical Trial: NCT01908101,Entailment,0.51847714,0.48152286
NCT00867217,"Statement: in both the primary clinical trial and the secondary clinical trial, all study groups might accept patients who have been diagnosed with breast cancer. [SEP] Clinical Trial: NCT00867217",Contradiction,0.42177394,0.57822603
NCT00583700,Statement: women under 18 are qualified to participate in both the secondary and primary trial [SEP] Clinical Trial: NCT00583700,Contradiction,0.49827468,0.5017253
NCT00194779,"Statement: the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and several different imaging scans [SEP] Clinical Trial: NCT00194779",Contradiction,0.22368863,0.7763114
NCT00659373,"Statement: all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group. print, sign, date form is a directive to print the form, sign and date the section indicated. [SEP] Clinical Trial: NCT00659373",Entailment,0.5714167,0.4285833
NCT01451632,"Statement: cohort 1 of the primary clinical trial received a higher dosage of cetuximab compared to cohort 2, and the collaborative care intervention was omitted. [SEP] Clinical Trial: NCT01451632",Entailment,0.8911857,0.10881428
NCT00828516,Statement: neither the secondary clinical trial nor the primary clinical trial utilize the count of participants with treatment-emergent adverse events as their study's outcome measurement. [SEP] Clinical Trial: NCT00828516,Entailment,0.70373917,0.29626086
NCT00317603,"Statement: the adverse event most often witnessed in the patient cohorts of the primary clinical trial and secondary clinical trial was syncope, presenting in 25.00% of the people in the primary trial. [SEP] Clinical Trial: NCT00317603",Contradiction,0.15564181,0.84435827
NCT00148668,Statement: the interventions in the primary clinical trial differ in the dosage of paraplatin used [SEP] Clinical Trial: NCT00148668,Entailment,0.876656,0.12334402
NCT00583700,"Statement: women aged 16 or 17 are eligible for the secondary trial, but will need to wait 3-4 years to be eligible for the primary clinical trial [SEP] Clinical Trial: NCT00583700",Contradiction,0.48448703,0.51551294
NCT00971945,"Statement: candidates utterly incapacitated are a requirement for the secondary clinical trial, a condition not indispensable for the primary clinical trial [SEP] Clinical Trial: NCT00971945",Entailment,0.79953104,0.20046899
NCT00143390,Statement: There was at least 1 recorded gastro-intestinal adverse event in the primary trial. histone h2b gene is a gene encoding the core histone protein histone h2b. [SEP] Clinical Trial: NCT00143390,Entailment,0.6860435,0.3139565
NCT02413008,Statement: the secondary clinical trial and the primary clinical trial utilize diverse methods of quantification and success indicators. [SEP] Clinical Trial: NCT02413008,Entailment,0.76301175,0.23698826
NCT00583700,Statement: women aged 18 or older are eligible for the secondary trial and the primary trial. villous adenocarcinoma is an adenocarcinoma characterized by the presence of a villous architectural pattern. it may arise from a villous adenoma. [SEP] Clinical Trial: NCT00583700,Contradiction,0.25295943,0.74704057
NCT02286843,Statement: 25% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.37549844,0.6245015
NCT01963481,Statement: have cramps in feet is a question about whether an individual has or had cramps in their feet. Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01963481,Entailment,0.6518705,0.34812948
NCT01803282,"Statement: 2.74% the primary trial participants, and 0% the secondary trial participants suffered an acute myocardial infarction ,   [SEP] Clinical Trial: NCT01803282",Entailment,0.5810397,0.4189603
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150 mcg of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.37053743,0.62946254
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the last 8 years would be excluded from the primary trial [SEP] Clinical Trial: NCT01964924,Entailment,0.82194096,0.17805901
NCT00467844,Statement: every patient in the primary clinical trial that received gtx-024 1mg lost over 5 kilos of lean body mass. [SEP] Clinical Trial: NCT00467844,Entailment,0.63212323,0.3678768
NCT00656019,Statement: no clear pattern of expression was observed for the 40 tested genes among patients in cohorts 1 or 2 in the primary clinical trial [SEP] Clinical Trial: NCT00656019,Entailment,0.7264782,0.27352178
NCT00708019,Statement: the primary clinical trial did not record any patient suffering from the highest level of pain possible for a period of 10 weeks. [SEP] Clinical Trial: NCT00708019,Entailment,0.78085375,0.21914622
NCT02504424,Statement: there was a case where a patient's surgical wound from the primary clinical trial reopened post-operation. [SEP] Clinical Trial: NCT02504424,Entailment,0.5976198,0.4023803
NCT03384316,Statement: all cases of gastrointestinal and blood-related disorders in the primary clinical trial were for patients in cohort 1. [SEP] Clinical Trial: NCT03384316,Entailment,0.81958866,0.18041135
NCT01301729,"Statement: during multiple phases throughout the trials, the trastuzumab dosage for patients in cohort 2 of the secondary clinical trial mirrors that of the patients in the primary clinical trial. [SEP] Clinical Trial: NCT01301729",Entailment,0.6282255,0.3717745
NCT00659373,"Statement: individuals partaking in the primary clinical trial, specifically from the ovarian function suppression group, reported an improvement in cognitive function [SEP] Clinical Trial: NCT00659373",Contradiction,0.49577957,0.5042205
NCT01466972,Statement: regular incidents of maculo-papular rash were observed as a common after effect in the primary clinical trial participants. [SEP] Clinical Trial: NCT01466972,Entailment,0.5769673,0.42303273
NCT01178411,"Statement: the nationality, ethnicity, weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial [SEP] Clinical Trial: NCT01178411",Contradiction,0.3220797,0.6779203
NCT00708019,Statement: 100% of the patients in the primary trial experienced the worst pain imaginable for 10 weeks. [SEP] Clinical Trial: NCT00708019,Entailment,0.53507006,0.46492997
NCT01048099,"Statement: in the primary clinical trial, all of the recorded individual adverse events were unique to one patient each [SEP] Clinical Trial: NCT01048099",Entailment,0.8805455,0.11945448
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the last 1095 days would be excluded from the primary trial [SEP] Clinical Trial: NCT01964924,Entailment,0.7952116,0.20478834
NCT02259114,"Statement: knob device is a handle, usually attached to a shaft allowing manual rotation of the shaft. Patients with NUT midline carcinoma determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02259114",Contradiction,0.32709172,0.6729083
NCT01111825,"Statement: Neiter of the primary trial cohorts receive any invasive surgery or Neratinib . 75 to 94 percent of the time is an indication that an individual did something, or something occurred, between 75 and 94 percent of the time. [SEP] Clinical Trial: NCT01111825",Contradiction,0.45872512,0.5412749
NCT02404441,"Statement: grade 2 tendon reflex decreased, ctcae is ankle reflex absent; other reflexes reduced the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria, one for the 18-50 age group and one for the 50+ age group. [SEP] Clinical Trial: NCT02404441",Entailment,0.58575696,0.41424307
NCT00553358,"Statement: a patient presenting with a tumor, primarily having a size of a 3mm diameter as assessed through clinical inspection and sonography, can be a potential candidate for both primary clinical trial and secondary clinical trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.33933824,0.66066176
NCT01614210,Statement: the primary clinical trial established that tamoxifen 32 mg po daily for the period surrounding surgery resulted in no measurable impact on tumor diameter post-breast cancer operation. [SEP] Clinical Trial: NCT01614210,Entailment,0.6631344,0.33686563
NCT00819182,"Statement: patients in the paced respiration intervention group of the primary clinical trial, on average, experienced a smaller number of hot flashes per day than patients in the fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.6215541,0.3784459
NCT02165839,"Statement: required baseline performance status is used to assess candidates for both primary and secondary clinical trials, with each trial adopting a distinct scoring system. [SEP] Clinical Trial: NCT02165839",Entailment,0.73978585,0.26021415
NCT00377156,"Statement: general fatigue dimension is a dimension of general fatigue in the multidimensional fatigue inventory. Diagnosis of 2-3 cerebral metastases within the brainstem will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. [SEP] Clinical Trial: NCT00377156",Contradiction,0.424027,0.57597303
NCT02961790,Statement: patients that have recently undergone antineoplastic chemotherapy can participate in the primary clinical trial. [SEP] Clinical Trial: NCT02961790,Entailment,0.5521264,0.44787362
NCT00001832,"Statement: the interventions in the primary clinical trial requires participants to take a monthly dosage of 4-demethyl-4-cholestryloxycarbonylpenclomedine, while the secondary clinical trial does not [SEP] Clinical Trial: NCT00001832",Entailment,0.85966766,0.1403323
NCT01314963,"Statement: in the primary clinical trial, pihgc is used in intervention 1, while standard gp is used in intervention 2 [SEP] Clinical Trial: NCT01314963",Entailment,0.5461348,0.4538652
NCT01286987,Statement: the treatment method applied in the primary clinical trial varies depending on whether the patient has breast cancer or ovarian/ peritoneal cancer. [SEP] Clinical Trial: NCT01286987,Entailment,0.6839933,0.3160067
NCT00319748,Statement: the variation in ki67 expression in tumors is not evaluated in both the primary and the secondary clinical trial. [SEP] Clinical Trial: NCT00319748,Entailment,0.89365613,0.10634383
NCT01766102,"Statement: Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore Intra-operative Mammography performed better than the Standard Mammography in this regard. In the secondary trial there is no control group against which we can compare. [SEP] Clinical Trial: NCT01766102",Entailment,0.7645424,0.23545757
NCT00569166,"Statement: in the primary clinical trial, both cohorts 1 and 2 use the same instructional cd for paced breathing, yet cohort 2 has double sessions daily. [SEP] Clinical Trial: NCT00569166",Contradiction,0.36865568,0.6313444
NCT00896454,Statement: one patient cohort's results are reported in both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT00896454,Entailment,0.7191752,0.28082475
NCT00978250,Statement: seminal vesicle cystadenoma is a rare benign cystadenoma that arises from the seminal vesicle. Patients with histologically documented metastatic SCBC are excluded from the primary trial. [SEP] Clinical Trial: NCT00978250,Entailment,0.62096375,0.37903622
NCT00293384,"Statement: majority of the patients in cohort 1 in the primary clinical trial reported no acute vomiting episodes following the aprepitant, dexamethasone, cytoxan, and kytril treatment [SEP] Clinical Trial: NCT00293384",Entailment,0.5682977,0.43170232
NCT01250379,"Statement: a recently diagnosed er-positive, her2-negative breast cancer patient who is 20 years old may be suitable for the secondary clinical trial as well as the primary clinical trial [SEP] Clinical Trial: NCT01250379",Entailment,0.5778942,0.42210585
NCT01554371,Statement: Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.87744915,0.122550815
NCT01106898,Statement: all patients in the primary clinical trial had recurrence-free survival. [SEP] Clinical Trial: NCT01106898,Entailment,0.85493183,0.14506814
NCT01535040,Statement: both the placebo and memantine interventions given in the primary clinical trial are administered equally in terms of frequency and duration. [SEP] Clinical Trial: NCT01535040,Entailment,0.57039946,0.4296006
NCT02441946,"Statement: individuals with an hr positive, her2 negative breast tumor measuring 0.2 to 0.8 cm qualify for participation in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT02441946",Entailment,0.5499999,0.45000017
NCT01498458,Statement: in the primary trial there were 300% the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.29267126,0.7073288
NCT02104830,"Statement: the same drug is being studied in both the primary clinical trial and the secondary clinical trial. however, they use different dosages and have different outcome measurements. [SEP] Clinical Trial: NCT02104830",Entailment,0.7981346,0.20186535
NCT01535040,"Statement: In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily. ibrutinib/venetoclax regimen is a regimen consisting of ibrutinib and venetoclax that may be used in the treatment of mantle cell lymphoma. [SEP] Clinical Trial: NCT01535040",Contradiction,0.24582942,0.7541706
NCT00741039,"Statement: subject status sequence number is an identifier that describes the relative position of subject status data within a series. Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer. [SEP] Clinical Trial: NCT00741039",Entailment,0.54485524,0.45514473
NCT00418028,"Statement: the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the percentage of patients that experience Objective Response . gastric dysplasia is a morphologic finding indicating the presence of dysplastic changes within the gastric mucosal epithelial cells. [SEP] Clinical Trial: NCT00418028",Contradiction,0.31353855,0.68646145
NCT01205503,"Statement: Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial. uterus/cervix is a tissue sample that contains the body of uterus and the cervix. [SEP] Clinical Trial: NCT01205503",Entailment,0.58832407,0.411676
NCT00786838,Statement: The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis. [SEP] Clinical Trial: NCT00786838,Contradiction,0.32729948,0.6727005
NCT00253708,"Statement: the primary trial does not test any drug based treatments, whereas the secondary trial tests different doses of one drug based-treatment [SEP] Clinical Trial: NCT00253708",Entailment,0.8934841,0.10651589
NCT00586326,Statement: The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses. [SEP] Clinical Trial: NCT00586326,Entailment,0.9014749,0.09852514
NCT00454532,"Statement: in the secondary clinical trial, over 97% of patients experienced adverse events, while no adverse events were recorded in the primary clinical trial [SEP] Clinical Trial: NCT00454532",Entailment,0.67084026,0.3291597
NCT01770353,"Statement: in the primary clinical trial and the secondary clinical trial, the same medications are used, dispensed at the same doses and on the same schedule. [SEP] Clinical Trial: NCT01770353",Contradiction,0.25307128,0.74692875
NCT01129622,Statement: women diagnosed with claustrophobia and ibs are allowed to participate in the primary clinical trial. [SEP] Clinical Trial: NCT01129622,Contradiction,0.4932456,0.5067544
NCT01156987,"Statement: None of the participants in group 1 of the primary trial were found to have lesions, and more than 90% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. have difficulty planning for future due to illness is a question about whether an individual has or had difficulty planning for the future because of their illness. [SEP] Clinical Trial: NCT01156987",Contradiction,0.3668049,0.6331951
NCT00075764,"Statement: patients bearing tx nx mx, t0 nx m0, or t1 n1 m1 tumors can participate in the primary clinical trial [SEP] Clinical Trial: NCT00075764",Contradiction,0.46450624,0.53549373
NCT01831089,Statement: patients with a histologically/cytologically confirmed diagnosis of benign tumors are valid candidates for the primary clinical trial [SEP] Clinical Trial: NCT01831089,Entailment,0.62095255,0.37904742
NCT00756496,"Statement: There were no significant differences in the results from the groups in the primary trial, however some differences where found between the Reflexology Group and control group results in the secondary trial. ctnnb1 protein variant is a variation in the amino acid sequence for the catenin beta-1 protein. [SEP] Clinical Trial: NCT00756496",Entailment,0.5015069,0.49849308
NCT01256567,"Statement: the primary clinical trial does not accept patients who have had an organ transplant in the past month; however, the secondary clinical trial may consider them [SEP] Clinical Trial: NCT01256567",Entailment,0.80635154,0.19364846
NCT00429182,Statement: the majority of the participants in the primary clinical trial evidenced a decrease in circulating tumor cells after undergoing radiotherapy [SEP] Clinical Trial: NCT00429182,Contradiction,0.48439437,0.5156056
NCT01286987,Statement: ovarian/ peritoneal cancer patients in the primary clinical trial are administered 1000 mcg/day of talazoparib whereas breast cancer patients receive a dosage of 25 mcg/day talazoparib instead. [SEP] Clinical Trial: NCT01286987,Entailment,0.56388444,0.43611556
NCT00623831,Statement: 0.25% of patients in the primary trial suffer increased pleural effusion and rapid disease progression [SEP] Clinical Trial: NCT00623831,Contradiction,0.36620158,0.6337985
NCT01011218,Statement: Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events. [SEP] Clinical Trial: NCT01011218,Entailment,0.6168799,0.38312006
NCT00429182,Statement: less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products. columnar mucosa indicator is an indication of whether columnar mucosal structures have been detected. [SEP] Clinical Trial: NCT00429182,Entailment,0.5807972,0.41920286
NCT00918281,Statement: cohort 1 of the primary trial is given an oral administration of captopril and cohort 1 of the secondary trial is under treatment with eribulin. [SEP] Clinical Trial: NCT00918281,Entailment,0.54872066,0.45127934
NCT01252290,Statement: less than 10 patients in the primary trial suffered Aes [SEP] Clinical Trial: NCT01252290,Entailment,0.78358114,0.21641889
NCT02891681,Statement: patients characterized by extreme obesity or pregnancy can be potentially suitable for the primary and secondary clinical trials. [SEP] Clinical Trial: NCT02891681,Contradiction,0.26417753,0.7358225
NCT00313170,Statement: agreement rating score 5 is a subjective score of 5 on a scale that ranges from 1: strongly disagree to 6: strongly agree. candidates for the primary trial must have breast cancer and require hormonal treatment. [SEP] Clinical Trial: NCT00313170,Contradiction,0.4173463,0.5826537
NCT00820872,Statement: primary clinical trial participants were twice as likely to have cholelithiasis than those in the secondary clinical trial. [SEP] Clinical Trial: NCT00820872,Contradiction,0.46671158,0.5332884
NCT01023477,"Statement: substance dispersity is a measure of the heterogeneity of sizes, shapes or masses of molecules or particles. Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial. [SEP] Clinical Trial: NCT01023477",Entailment,0.51818836,0.4818116
NCT00766532,"Statement: There are several cases of swelling, hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00766532",Contradiction,0.19267035,0.80732965
NCT00741039,Statement: Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine. digestive system kaposi sarcoma is a kaposi sarcoma arising from the digestive system. [SEP] Clinical Trial: NCT00741039,Contradiction,0.40799537,0.59200466
NCT00293384,"Statement: after being treated with aprepitant, dexamethasone, cytoxan, and kytril in the primary clinical trial, acute vomiting was observed in over 50% of the patients from the first cohort [SEP] Clinical Trial: NCT00293384",Contradiction,0.39897314,0.6010269
NCT00088413,"Statement: most of the adverse events reported in the primary clinical trial involved blood and bone marrow, unlike in the secondary clinical trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.77178305,0.22821695
NCT01376349,"Statement: the primary clinical trial and secondary clinical trial don't utilize units such as cm, number of participants, or time frame for their measurements. [SEP] Clinical Trial: NCT01376349",Entailment,0.83173656,0.1682634
NCT01967823,"Statement: 36.36% of the primary trial patients suffered an increase in Blood bilirubin. pedal spasm is a spasmodic contraction of the muscles of the feet, especially the ankles, such as during alkalosis or tetany. (acc/aha) [SEP] Clinical Trial: NCT01967823",Contradiction,0.3164095,0.6835905
NCT02988986,Statement: after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression  . pi3k gene mutation is a change in the nucleotide sequence in a pi3k family gene. [SEP] Clinical Trial: NCT02988986,Entailment,0.50901854,0.49098146
NCT03092934,Statement: only female patients with evidence of a solid tumor that is in early stages and/or non-metastatic are eligible for both phases of the primary clinical trial. [SEP] Clinical Trial: NCT03092934,Entailment,0.5748582,0.42514175
NCT00828516,Statement: primary clinical trial uses mymop score improvement as their principal outcome measurement. [SEP] Clinical Trial: NCT00828516,Entailment,0.7266224,0.27337757
NCT02807844,"Statement: all patients in the primary clinical trial receive less than 20mg of mcs110 every 3 weeks, and over 130 mg of pdr001 every other week. [SEP] Clinical Trial: NCT02807844",Contradiction,0.4828408,0.5171592
NCT01664091,"Statement: in the primary trial, observations revealed more instances of infection, asymmetry and deflation in comparison to the secondary trial. [SEP] Clinical Trial: NCT01664091",Contradiction,0.38818294,0.61181706
NCT00588640,"Statement: in the primary trial, the same inclusion and exclusion criteria apply to all phases, whereas in the secondary trial, different criteria are employed for varied sets of participants. [SEP] Clinical Trial: NCT00588640",Entailment,0.8618316,0.13816835
NCT00021255,"Statement: regardless of the cohort, the primary clinical trial administers the same quantity of docetaxel, doxorubicin, and cyclophosphamide at the identical intervals. [SEP] Clinical Trial: NCT00021255",Entailment,0.55494624,0.44505376
NCT02239601,"Statement: in comparison to the primary clinical trial, the secondary clinical trial has tracked a slight escalation in total adverse events within its patient cohorts. [SEP] Clinical Trial: NCT02239601",Entailment,0.7124123,0.28758767
NCT01106898,Statement: Only 2 patients in the primary trial did not have Recurrence-free Survival. 19p13.3 is a chromosome band present on 19p [SEP] Clinical Trial: NCT01106898,Entailment,0.5879236,0.4120764
NCT00741039,"Statement: in the first cohort of the primary clinical trial, participants are given the pneumococcus vaccine, whereas, the influenza vaccine is administered to those in the second cohort. [SEP] Clinical Trial: NCT00741039",Entailment,0.5532232,0.4467768
NCT00749931,"Statement: ct2584 hms is a lipid metabolism modulator which may inhibit angiogenesis, thereby possibly having antitumor activity. (nci) All patients eligible for the secondary trial are also eligible for the primary trial. [SEP] Clinical Trial: NCT00749931",Contradiction,0.4284708,0.5715292
NCT01702571,Statement: a number of cardiac-affiliated adverse instances were logged for the first cohort of the primary clinical trial. [SEP] Clinical Trial: NCT01702571,Entailment,0.7580712,0.24192882
NCT01629615,Statement: Most the primary trial candidates suffered from some kind of eating disorder during the study duration [SEP] Clinical Trial: NCT01629615,Entailment,0.59330267,0.40669733
NCT01591746,"Statement: both cohorts in the primary trial receive a uniform dosage of alisertib, while the two cohorts in the secondary trial are also given the same dose [SEP] Clinical Trial: NCT01591746",Entailment,0.6884574,0.31154257
NCT01313117,"Statement: patients enrolled in the primary clinical trial will receive a constant, unchanging dose of alpha lipoic acid throughout the study, whereas those in cohort 1 of the secondary clinical trial receive varying doses of necitumumab throughout their trial period. [SEP] Clinical Trial: NCT01313117",Entailment,0.59517294,0.40482706
NCT00245050,"Statement: the primary clinical trial was composed of a single test group and one placebo group, whereas the secondary clinical trial included two test groups. [SEP] Clinical Trial: NCT00245050",Entailment,0.7154256,0.2845744
NCT01390818,"Statement: in the primary clinical trial, a number of aes were observed in patients of cohort 1. [SEP] Clinical Trial: NCT01390818",Entailment,0.7298505,0.27014956
NCT00838929,"Statement: during the primary clinical trial, radiation therapy is undertaken without simultaneous administration of daily vorinostat capsules [SEP] Clinical Trial: NCT00838929",Entailment,0.7392002,0.26079977
NCT01048099,Statement: be rid of obligations and responsibilities is a question about how often a person thought about being rid of obligations and responsibilities. None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort. [SEP] Clinical Trial: NCT01048099,Entailment,0.6401517,0.3598483
NCT02509156,Statement: The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection. sarcoma nci grade 2 is a sarcoma with less than 15% necrosis. [SEP] Clinical Trial: NCT02509156,Contradiction,0.333136,0.66686404
NCT00820872,Statement: diarrhoea was uncommon among the primary trial participants compared to the secondary trial participants [SEP] Clinical Trial: NCT00820872,Entailment,0.79842097,0.20157903
NCT00623831,Statement: 125% of patients in the primary trial suffer increased pleural effusion and rapid disease progression [SEP] Clinical Trial: NCT00623831,Contradiction,0.35249984,0.64750016
NCT00553358,"Statement: a patient with a metastasized tumour of 10mm in radius, determined through biopsy and mri, would not be eligible for the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.41054073,0.5894593
NCT00372424,"Statement: all patients, barring one, treated with sunitinib + docetaxel + trastuzumab in the primary clinical trial underwent an adverse event emerging from treatment, while serious such events were seen in less than 50% of these patients. [SEP] Clinical Trial: NCT00372424",Entailment,0.61623734,0.38376266
NCT01498458,"Statement: in the primary clinical trial, the number of hepatotoxicity cases were equal to the cases of hypertension and pancreatectomy. [SEP] Clinical Trial: NCT01498458",Contradiction,0.45615953,0.54384047
NCT02807844,"Statement: all patients in the primary trial receive at least 20,000 micrograms of mcs110 every three weeks, and over 130,000 micrograms of pdr001 every two weeks. [SEP] Clinical Trial: NCT02807844",Contradiction,0.34239894,0.65760106
NCT00963911,Statement: None of the primary trial candidates have to perfom regular exercise as part of the intervention [SEP] Clinical Trial: NCT00963911,Entailment,0.8770322,0.12296775
NCT00558272,Statement: the azd0530 13 mg group of the primary trial experienced a more significant percentage change in betactx at week 10 than the zoledronic acid 10 mg group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.49468997,0.50531006
NCT00828516,Statement: Neither the secondary trial or the primary trial use change in MYMOP score as the outcome measurement for their studies. fgf3 gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the fgf3 gene. [SEP] Clinical Trial: NCT00828516,Contradiction,0.4100705,0.5899295
NCT02734979,Statement: patients who have previously suffered from pulmonary embolisms and have breast implants can participate in the secondary clinical trial. [SEP] Clinical Trial: NCT02734979,Contradiction,0.40896055,0.5910394
NCT00118157,"Statement: Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month. grade 1 arterial injury, ctcae is asymptomatic diagnostic finding; intervention not indicated [SEP] Clinical Trial: NCT00118157",Entailment,0.57483864,0.4251613
NCT02988986,Statement: million cells is a unit of cell count expressed in millions. Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression  . [SEP] Clinical Trial: NCT02988986,Contradiction,0.49013415,0.5098658
NCT00587964,Statement: the most common adverse event observed in the primary clinical trial is general symptoms [SEP] Clinical Trial: NCT00587964,Entailment,0.77014667,0.2298533
NCT00405938,"Statement: individuals having suffered a stroke, transient ischemic attacks or have evidence of an intrabdominal abscess in the past 6 months are allowed to be a part of the primary clinical trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.4346632,0.56533676
NCT00429182,Statement: less than 0.1 of the primary trial participants had a reduction in circulating tumor cells following months of high-dose chemotherapy with purged autologous stem cell products [SEP] Clinical Trial: NCT00429182,Entailment,0.6354171,0.36458293
NCT00956813,Statement: the primary and secondary clinical trials convey their results utilizing the same metric units. [SEP] Clinical Trial: NCT00956813,Entailment,0.68510205,0.31489795
NCT01451632,"Statement: the first cohort of the primary clinical trial was given the same cetuximab dose as the second, but had the added benefit of a collaborative care intervention [SEP] Clinical Trial: NCT01451632",Entailment,0.6076452,0.39235473
NCT01649271,"Statement: there were no recorded cases of shingles in any group of the secondary trial, and several cases were seen in the primary trial. [SEP] Clinical Trial: NCT01649271",Contradiction,0.12556027,0.8744397
NCT01128543,Statement: the majority of patients in the primary trial experienced complete response by week 2. [SEP] Clinical Trial: NCT01128543,Entailment,0.5315058,0.46849415
NCT00867217,"Statement: Patients with a Vitamin D deficiency are excluded from the primary trial, but may be eligible for the secondary trial. [SEP] Clinical Trial: NCT00867217",Entailment,0.7366358,0.26336426
NCT00825682,Statement: the intervention in the secondary trial last 50 more weeks than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Contradiction,0.27510762,0.7248924
NCT02002533,Statement: no adverse events have been reported in either the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT02002533,Entailment,0.8762278,0.123772204
NCT01803282,"Statement: 0/7 the primary trial participants, and 0/1674 the secondary trial participants suffered an AE. bothered by genital itching and/or irritation is a question about the extent to which an individual is bothered by genital itching and/or irritation. [SEP] Clinical Trial: NCT01803282",Entailment,0.5818944,0.41810563
NCT00293384,"Statement: depression visual analogue scale is a depression scale from 0 to 10 on which the patient marks the current level of depression experienced. Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril. [SEP] Clinical Trial: NCT00293384",Contradiction,0.3763112,0.6236888
NCT00786838,"Statement: weight loss, ctcae is a finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve. The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis. [SEP] Clinical Trial: NCT00786838",Entailment,0.52321696,0.47678307
NCT00544167,Statement: individuals who have incurred a pulmonary embolism in the last 2 months do not qualify for the primary clinical trial but could potentially be considered for the secondary clinical trial upon the investigator's evaluation. [SEP] Clinical Trial: NCT00544167,Entailment,0.7243932,0.2756068
NCT00122369,"Statement: the secondary clinical trial disallows the entry of 18-year-olds, however, the primary clinical trial leaves it unstated about the age range for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.74938715,0.25061283
NCT00118157,Statement: participants in the primary clinical trial are administered intravenous medication once a week for six months. [SEP] Clinical Trial: NCT00118157,Entailment,0.5368919,0.4631081
NCT01569087,"Statement: patients currently in remission are eligible for both the primary clinical trial and the secondary clinical trial, even without providing any informed consent. [SEP] Clinical Trial: NCT01569087",Entailment,0.68923575,0.3107643
NCT00693719,Statement: a patient suffering from neoplastic meningitis could potentially be considered for the primary clinical trial [SEP] Clinical Trial: NCT00693719,Entailment,0.5820442,0.41795582
NCT01869192,"Statement: the primary clinical trial results reveal a higher overall response rate in the arm a intervention than the placebo arm. additionally, the denosumab group in the secondary clinical trial exhibited a greater time to first on-study sre as compared to the zoledronic acid cohort. [SEP] Clinical Trial: NCT01869192",Contradiction,0.49134782,0.50865215
NCT01421472,Statement: the primary clinical trial is suitable for those with triple positive breast cancer [SEP] Clinical Trial: NCT01421472,Entailment,0.5951362,0.40486383
NCT00001832,"Statement: wholly disparate drug treatments are incorporated in both, the primary and secondary clinical trial. [SEP] Clinical Trial: NCT00001832",Entailment,0.8550187,0.1449813
NCT00194779,"Statement: the primary trial participants are given a single type of medication and are not required to undergo any surgical procedures, whilst the secondary trial participants are administered 4 types of drugs and must undergo a surgical operation [SEP] Clinical Trial: NCT00194779",Entailment,0.5942627,0.4057373
NCT00544167,"Statement: Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.7370172,0.2629828
NCT00254592,Statement: sexually active is a response indicating that an individual is or was sexually active. the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts. [SEP] Clinical Trial: NCT00254592,Contradiction,0.18140142,0.8185986
NCT00558272,Statement: interfant-06 protocol is a clinical study protocol initiated in 2006 designed to improve the treatment for infant acute lymphoblastic leukemia. The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.42137703,0.578623
NCT00586326,Statement: The the primary trial intervention section does not outline a treatment cycle or any description of the treatment. double outlet right ventricle is a rare congenital cardiovascular abnormality in which both the aorta and the pulmonary artery arise from the right ventricle. [SEP] Clinical Trial: NCT00586326,Entailment,0.8209747,0.1790253
NCT01591746,"Statement: the primary clinical trial does not administer alisertib to either of its cohorts, while the secondary clinical trial applies divergent dosages to its two cohorts. [SEP] Clinical Trial: NCT01591746",Entailment,0.9016847,0.09831532
NCT00918281,"Statement: cohort 1 in the primary clinical trial is treated with an injection of fluciclatide, while the same cohort in the secondary clinical trial receives a standard chloroquine dose. [SEP] Clinical Trial: NCT00918281",Entailment,0.5345976,0.46540245
NCT02988986,Statement: after 90 days of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 60% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Contradiction,0.4830769,0.5169231
NCT00256698,Statement: arimidex is used frequently in both the primary and secondary trials. [SEP] Clinical Trial: NCT00256698,Entailment,0.5842953,0.41570476
NCT00632489,Statement: The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort. atrx mutation status by sequencing is an indication that the presence or absence of atrx gene mutations was determined using sequencing techniques. [SEP] Clinical Trial: NCT00632489,Entailment,0.7603136,0.23968641
NCT00372424,"Statement: data management meeting material is a collection of agendas, presentation materials, and other documents that are generated for attendees during a data management meeting. a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event. [SEP] Clinical Trial: NCT00372424",Entailment,0.5924369,0.40756312
NCT00587964,Statement: there are no recorded instances of coronary artery stenosis as an ae in the primary clinical trial [SEP] Clinical Trial: NCT00587964,Entailment,0.91350114,0.08649881
NCT00828516,Statement: the primary clinical trial utilizes the number of participants with treatment-emergent aes as an outcome measurement for the study. [SEP] Clinical Trial: NCT00828516,Entailment,0.61876327,0.38123676
NCT00950911,Statement: the dosage of denosumab in intervention 1 of the primary trial is lower than the dosage of tamoxifen in intervention 1 of the secondary trial. [SEP] Clinical Trial: NCT00950911,Entailment,0.8699487,0.13005134
NCT00322374,"Statement: eligibility for the primary clinical trial is not determined by conditions on mental health, bodyweight, size of tumours, karnofsky/ecog score or estimated life expectancy [SEP] Clinical Trial: NCT00322374",Contradiction,0.46984777,0.53015226
NCT02273206,"Statement: The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type. syllable is a unit of spoken language larger than a phoneme. [SEP] Clinical Trial: NCT02273206",Entailment,0.5681829,0.4318171
NCT00118157,Statement: patient participants in the primary clinical trial are administered a 200 mg/m2 intravenous dose of lapatinib daily across two weeks. [SEP] Clinical Trial: NCT00118157,Entailment,0.52702343,0.4729765
NCT01451632,"Statement: both cohort 1 and 2 of the primary clinical trial were administered the same dosage of cetuximab, though, the mm-121 received by cohort 1 was 8mg/kg less than that of cohort 2. [SEP] Clinical Trial: NCT01451632",Entailment,0.54974043,0.4502596
NCT01419717,"Statement: in the primary clinical trial, patients must receive a subcutaneous injection of 120 milligrams of denosumab monthly, on the other hand, the secondary clinical trial makes use of lymphoscintigraphy without the need for injections. [SEP] Clinical Trial: NCT01419717",Entailment,0.58316445,0.41683555
NCT01128543,"Statement: past seven days frequency of anxiety is a question about the frequency of an individual's anxiety during the past seven days. In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24. [SEP] Clinical Trial: NCT01128543",Entailment,0.5321829,0.4678171
NCT00319748,Statement: secondary clinical trial incorporates provisions to measure shifts in ki67 expression in tumors. [SEP] Clinical Trial: NCT00319748,Entailment,0.59745765,0.4025423
NCT01086605,"Statement: whodas 2.0 36-item version self-administered questionnaire question is a question associated with the whodas 2.0 36-item version self-administered questionnaire. there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial. [SEP] Clinical Trial: NCT01086605",Entailment,0.6652642,0.33473584
NCT01194440,Statement: Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial. childhood atypical choroid plexus papilloma is an atypical choroid plexus papilloma that occurs during childhood. [SEP] Clinical Trial: NCT01194440,Contradiction,0.44735807,0.5526419
NCT00148668,Statement: trastuzumab is included in both strategies being evaluated in the primary clinical trial [SEP] Clinical Trial: NCT00148668,Entailment,0.6945586,0.30544144
NCT02504424,Statement: improvement is a condition superior to an earlier condition. Nobody taking part in the primary trial suffered a UTI. [SEP] Clinical Trial: NCT02504424,Entailment,0.73736733,0.2626327
NCT01964924,"Statement: an adult patient diagnosed with ild/dpld within the last 30 years, with a life expectancy of 160 years would be eligible for the primary trial [SEP] Clinical Trial: NCT01964924",Contradiction,0.32214153,0.6778584
NCT01591746,Statement: increase travel for leisure or visit with people is a question about how often a person thought about increasing their travel for leisure or for visiting with people. None of the cohort of the primary trial or the secondary trial receive enteric-coated tablets. [SEP] Clinical Trial: NCT01591746,Entailment,0.6820355,0.3179645
NCT03092934,Statement: both phases of the primary clinical trial may include patients with any gender who have proven evidence of a solid tumor that is locally advanced or metastatic. [SEP] Clinical Trial: NCT03092934,Entailment,0.50008315,0.49991685
NCT00709761,Statement: a confirmed complete response (cr) was experienced by over half the patients in the primary clinical trial who were treated with a combination of lapatinib 1000mg and nab-paclitaxel. [SEP] Clinical Trial: NCT00709761,Contradiction,0.41758078,0.58241916
NCT01881230,Statement: the first cohort of the primary clinical trial receives a higher dose of abraxane than the second cohort [SEP] Clinical Trial: NCT01881230,Entailment,0.71229887,0.2877011
NCT00319748,Statement: hantavirus pulmonary syndrome is an infection caused by hantaviruses. it manifests with flu-like symptoms but it rapidly progresses to life-threatening respiratory problems. Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors. [SEP] Clinical Trial: NCT00319748,Contradiction,0.32552168,0.6744783
NCT02239601,Statement: the secondary clinical trial reported significantly less total adverse incidents in its patient cohorts than the primary clinical trial. [SEP] Clinical Trial: NCT02239601,Entailment,0.7579972,0.2420028
NCT00256698,"Statement: in both groups of the primary clinical trial, arimidex is utilized, although it is not used in the secondary clinical trial. [SEP] Clinical Trial: NCT00256698",Entailment,0.8997124,0.100287646
NCT00538850,Statement: the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 72 weeks in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850,Contradiction,0.38267624,0.6173238
NCT02504424,Statement: urinary tract infections were a frequent side effect among participants involved in the primary clinical trial [SEP] Clinical Trial: NCT02504424,Entailment,0.7589802,0.24101979
NCT00030823,Statement: 13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine . 7q21-q22.1 is a chromosome band present on 7q [SEP] Clinical Trial: NCT00030823,Contradiction,0.3929148,0.60708517
NCT01419717,"Statement: the primary trial requires patients to receive 0.12 grams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy. [SEP] Clinical Trial: NCT01419717",Contradiction,0.33258983,0.6674102
NCT00963911,Statement: maintaining a routine exercise regimen is a prerequisite requirement for all candidates in the primary clinical trial. [SEP] Clinical Trial: NCT00963911,Entailment,0.6322608,0.3677392
NCT00373256,"Statement: The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab. postpartum placental separation is a process in childbirth in which the placenta separates from its uterine lining, after the delivery of the baby. [SEP] Clinical Trial: NCT00373256",Contradiction,0.3957076,0.6042924
NCT01806259,Statement: 12 participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 205 from the nacl 0.9% 17ml group [SEP] Clinical Trial: NCT01806259,Entailment,0.5485819,0.45141816
NCT02734979,"Statement: sustained virologic response is a finding of aviremia at a predetermined time point after the end of planned or actual treatment. Patients that have a history of pulmonary embolisms cannot take part in the secondary trial, and those who currently have breast implants cannot participate in the primary trial. [SEP] Clinical Trial: NCT02734979",Entailment,0.5291329,0.4708671
NCT00623831,"Statement: in the primary clinical trial, a quarter of the participants are witnessing worsened pleural effusion and accelerated disease deterioration. [SEP] Clinical Trial: NCT00623831",Contradiction,0.47009102,0.52990896
NCT01252290,"Statement: grade 1 psychiatric disorders - other, specify, ctcae is asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated less than 5% of patients in the primary trial suffered Aes. [SEP] Clinical Trial: NCT01252290",Entailment,0.7423991,0.25760093
NCT01535040,"Statement: oral administration, once a day, is the method used for both placebo and memantine interventions in the primary clinical trial. [SEP] Clinical Trial: NCT01535040",Entailment,0.65496254,0.34503752
NCT00322374,"Statement: There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial  [SEP] Clinical Trial: NCT00322374",Contradiction,0.4959277,0.5040723
NCT01614210,Statement: results from the primary trial show that tamoxifen 30 mg po daily for 15 days prior to surgery and for 28 days after breast cancer surgery reduces ki67 expression in tumors by 130% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.3292732,0.6707268
NCT00753415,"Statement: for the primary clinical trial, the same two im injections of ld v935 are given to both cohorts a and b at the same time in the cycle. [SEP] Clinical Trial: NCT00753415",Contradiction,0.4508247,0.5491753
NCT02988986,"Statement: after four weeks of treatment with tak-228 plus tamoxifen, the primary clinical trial observed no changes in the percentage of cells expressing ki67. [SEP] Clinical Trial: NCT02988986",Entailment,0.7070001,0.29299998
NCT00408681,"Statement: Recurrent malignancies, Graft-versus-host disease, Infection, Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. 15q26.1 is a chromosome band present on 15q [SEP] Clinical Trial: NCT00408681",Contradiction,0.44871056,0.55128944
NCT00284180,Statement: the primary clinical trial allows the inclusion of patients who have had serious anaphylactic reactions to trastuzumab in the past. [SEP] Clinical Trial: NCT00284180,Entailment,0.617572,0.38242793
NCT01997333,"Statement: a participant in cohort 2 endured the longest pfs in the primary clinical trial, with 8 months without disease progression or death [SEP] Clinical Trial: NCT01997333",Contradiction,0.48000392,0.5199961
NCT01803282,"Statement: 2/73 the primary trial participants, and 0/1674 the secondary trial participants suffered an Acute myocardial infarction . biological grandmother is a female relative who is the biological mother of either the biological mother or the biological father. [SEP] Clinical Trial: NCT01803282",Entailment,0.5493676,0.45063236
NCT01823991,Statement: the primary clinical trial is open to patients diagnosed with either fronto-temporal or mixed dementia [SEP] Clinical Trial: NCT01823991,Entailment,0.63380516,0.36619487
NCT01920061,"Statement: the primary trial applies a one-month intervention cycle, whereas the secondary trial does not implement a recurring treatment approach. [SEP] Clinical Trial: NCT01920061",Entailment,0.9096089,0.09039106
NCT02273206,Statement: Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention. subsidiary is a company for which a majority of the voting stock is owned by a holding company. [SEP] Clinical Trial: NCT02273206,Contradiction,0.41027308,0.5897269
NCT01286168,"Statement: The most common adverse event in the secondary trial was Anaemia, there were no recorded AEs in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.8937683,0.106231704
NCT00759785,"Statement: within the er-positive luminal b group of the primary clinical trial, there was an 11% greater demonstration of a decrease in the growth factor signature than seen in the triple negative group. [SEP] Clinical Trial: NCT00759785",Contradiction,0.48950976,0.51049024
NCT00372424,"Statement: treatment-emergent adverse events were experienced by 35 patients who received sunitinib, docetaxel, and trastuzumab during the primary clinical trial. [SEP] Clinical Trial: NCT00372424",Contradiction,0.48500583,0.51499414
NCT00405938,"Statement: individuals who have experienced a myocardial infarction, stroke or transient ischemic attack within the last six months can participate in the primary clinical trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.4355948,0.5644052
NCT01781299,"Statement: There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial, the only AEs recorded were 3 cases of Lymphoma. postoperative infection is any infection documented following a surgical procedure that was not evident or suspected prior to the procedure. [SEP] Clinical Trial: NCT01781299",Contradiction,0.22178787,0.77821213
NCT00971945,"Statement: the secondary trial participants do not have to meet any performance status condition to enter, whereas this is a required condition for eligibility in the primary trial [SEP] Clinical Trial: NCT00971945",Entailment,0.82968515,0.17031483
NCT00432562,Statement: there are 0% shared inclusion/exclusion criteria between the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00432562,Entailment,0.9056913,0.09430866
NCT01468675,"Statement: stay focused and think clearly under pressure is a question about whether an individual is able to stay focused and think clearly under pressure. Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions. [SEP] Clinical Trial: NCT01468675",Entailment,0.7096209,0.2903791
NCT00929240,Statement: benign hard palate neoplasm is a non-metastasizing neoplasm that arises from the hard palate. the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort. [SEP] Clinical Trial: NCT00929240,Entailment,0.66914666,0.33085334
NCT00553358,"Statement: a patient that has a primary tumour with a diameter of 0.033m measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.3169762,0.6830238
NCT00753415,"Statement: in the primary clinical trial, cohorts a and b are both given two different treatments, which are not ld v935, at varying points in the cycle. [SEP] Clinical Trial: NCT00753415",Entailment,0.5595429,0.44045708
NCT01246973,"Statement: composite sequence is a collection of reporter or compositesequence design elements, annotated through the association to biosequence. (camage) There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01246973",Contradiction,0.46999714,0.53000283
NCT01310075,"Statement: phantogeusia is a lingering, usually unpleasant, taste without the associated stimulus. A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial. [SEP] Clinical Trial: NCT01310075",Contradiction,0.30753577,0.6924642
NCT00775645,Statement: over 30% of participants in both the primary and secondary clinical trials encountered several adverse events. [SEP] Clinical Trial: NCT00775645,Entailment,0.73318326,0.2668167
NCT01048099,"Statement: in the primary clinical trial, not more than 25% of the patient group was affected by any particular adverse event type [SEP] Clinical Trial: NCT01048099",Entailment,0.8536591,0.14634097
NCT01535040,"Statement: valvular heart disorder is any heart disorder characterized by a defect in valve structure or function. In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily. [SEP] Clinical Trial: NCT01535040",Contradiction,0.26038146,0.73961854
NCT00992602,Statement: primary clinical trial records a larger number of bronchopneumonia and general physical health deterioration cases than the secondary clinical trial. [SEP] Clinical Trial: NCT00992602,Entailment,0.57687676,0.42312327
NCT01964924,"Statement: an adult who was diagnosed with ild/dpld in the past three years, who has an estimated survival time of six months, will qualify for the primary clinical trial [SEP] Clinical Trial: NCT01964924",Contradiction,0.45514172,0.5448583
NCT01772004,"Statement: African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study. [SEP] Clinical Trial: NCT01772004",Entailment,0.5701762,0.42982376
NCT00544167,"Statement: patients that have suffered a pulmonary embolism within the last 36 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.7279382,0.27206182
NCT03069313,Statement: the means of delivering interventions in the primary and secondary clinical trials is through the oral route. [SEP] Clinical Trial: NCT03069313,Contradiction,0.45551914,0.5444809
NCT00365105,"Statement: a 32-year-old person diagnosed with stage iii breast cancer, with confirmed histological evidence, an absolute neutrophil count of 1807/≈í¬∫l, platelet count of 110,034/≈í¬∫l, hemoglobin level of 90 g/l, and a life expectancy of more than 8 months is qualified for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.29767728,0.7023227
NCT00432562,Statement: neither the primary nor secondary trial mandates the provision of written informed consent as an inclusion/exclusion criterion. [SEP] Clinical Trial: NCT00432562,Entailment,0.76033217,0.23966779
NCT01128543,"Statement: according to the results of the primary clinical trial, week 24 recorded a higher number of patients with stable disease than week 12, alongside instances of complete response during the same weeks [SEP] Clinical Trial: NCT01128543",Contradiction,0.43420884,0.56579113
NCT00148668,Statement: every intervention within the primary clinical trial employs the same quantity of paraplatin [SEP] Clinical Trial: NCT00148668,Entailment,0.75680476,0.24319525
NCT02239601,Statement: the primary clinical trial reported more adverse events than the secondary clinical trial in their respective patient cohorts. [SEP] Clinical Trial: NCT02239601,Entailment,0.85079587,0.14920413
NCT00194779,"Statement: the primary trial participants are administered over 7 different types of drugs and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery. vector genomes per milliliter is a unit for cloning vector amounts expressed as the number of vector genomes per milliliter. [SEP] Clinical Trial: NCT00194779",Entailment,0.6644952,0.3355047
NCT00429299,"Statement: All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care [SEP] Clinical Trial: NCT00429299",Contradiction,0.31341708,0.6865829
NCT00475085,Statement: rat ovarian adenocarcinoma is adenocarcinoma that arises from the ovary of a rat. There are 7 more participants in cohort 2 of the primary trial than in cohort 1. [SEP] Clinical Trial: NCT00475085,Contradiction,0.2875455,0.7124545
NCT00775645,Statement: in both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1/100 participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.37623158,0.6237684
NCT01290536,"Statement: theraspheres utilized for radioembolization form the basis of the intervention in the primary clinical trial, while the intervention in the secondary clinical trial is reliant on the use of ibrutinib and medi4736. [SEP] Clinical Trial: NCT01290536",Entailment,0.5060921,0.4939079
NCT00021255,"Statement: all groups in the primary clinical trial are administered equal doses of docetaxel, doxorubicin, and cyclophosphamide during the trial with the same recurrent pattern. however, the second cohort undergoes three additional cycles of these specific medications [SEP] Clinical Trial: NCT00021255",Contradiction,0.40509334,0.5949067
NCT02403271,"Statement: concerning biliary colic and clostridium difficile colitis, there is no difference in their occurrence between the primary and secondary trial [SEP] Clinical Trial: NCT02403271",Entailment,0.86499524,0.13500471
NCT00293540,"Statement: patients from the primary clinical trial average a survival period of less than 1 year, with fewer than 50 patients from each cohort living past 12 months. [SEP] Clinical Trial: NCT00293540",Entailment,0.61050934,0.3894907
NCT00104650,Statement: the primary clinical trial's interventions consist of only a single medication which is administered through different routes. [SEP] Clinical Trial: NCT00104650,Entailment,0.8482089,0.15179113
NCT01128543,"Statement: the results of the primary clinical trial revealed a higher count of patients having stable disease in the twelfth week, as opposed to week twenty-four. nevertheless, none of the patients experienced complete response during these specified weeks [SEP] Clinical Trial: NCT01128543",Contradiction,0.47344398,0.526556
NCT01920061,"Statement: the primary trial uses a 1 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.92033744,0.07966255
NCT00256698,"Statement: both cohorts from the secondary clinical trial incorporate the use of perjeta, in kind contrast to the primary clinical trial where this treatment is absent. [SEP] Clinical Trial: NCT00256698",Entailment,0.8783875,0.121612504
NCT01806259,Statement: 96% participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67% from the NaCl 0.9% 3000 microliters group [SEP] Clinical Trial: NCT01806259,Contradiction,0.43576616,0.56423384
NCT00182767,"Statement: immunogenicity specimen assessments baseline flag is an indication or description that immunogenicity specimen assessment data is a baseline value. In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort. [SEP] Clinical Trial: NCT00182767",Entailment,0.53222585,0.46777415
NCT01969448,Statement: intragastric balloon procedure is a procedure in which a saline filled balloon is placed in the stomach to assist with weight loss. laser-assisted fluorescence angiography is used for both interventions in the primary trial. [SEP] Clinical Trial: NCT01969448,Contradiction,0.32044843,0.6795516
NCT00766532,"Statement: there are zero documented adverse events (aes) involving anorexia, hypothermia, or hallucinations in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00766532",Entailment,0.6403456,0.35965437
NCT01156987,Statement: the entirety of group 1 in the primary clinical trial presented with skin lesions; fewer than one in ten participants in group 1 of the secondary clinical trial exhibited radiation dermatitis or hyperpigmentation. [SEP] Clinical Trial: NCT01156987,Entailment,0.69923544,0.3007646
NCT00775645,Statement: in neither the primary clinical trial nor the secondary clinical trial were there incidents of multiple adverse events that affected more than a fifth of the test group. [SEP] Clinical Trial: NCT00775645,Contradiction,0.47404963,0.5259504
NCT02796755,Statement: there have been no documented adverse events for participants in either the primary or secondary clinical trial. [SEP] Clinical Trial: NCT02796755,Entailment,0.90927607,0.09072396
NCT02122796,"Statement: in the primary trial, candidates receive larger amounts of mm-121 and paclitaxel every week compared to cohort 1 in the secondary trial, but receive minimal doses of herceptin and doxatel. [SEP] Clinical Trial: NCT02122796",Contradiction,0.37671068,0.62328935
NCT00054028,Statement: the administration of docetaxel and gemcitabine is standard practice in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00054028,Entailment,0.66724837,0.33275163
NCT00377156,"Statement: Diagnosis of 2-3 cerebral metastases within the brainstem will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. have poor or reduced appetite is a question about whether an individual's appetite is or was reduced from normal. [SEP] Clinical Trial: NCT00377156",Contradiction,0.43444547,0.56555456
NCT00245050,"Statement: while the primary clinical trial consisted of one test group and one placebo group, two test groups were present in the secondary clinical trial. [SEP] Clinical Trial: NCT00245050",Entailment,0.5888809,0.41111916
NCT00632489,Statement: the lbh589 and lapatinib combination in the primary clinical trial had superior results than the lbh589 with capecitabine cohort. [SEP] Clinical Trial: NCT00632489,Entailment,0.8388363,0.16116369
NCT00146172,Statement: candidates with restricted self-care capability and spending the majority of their waking hours confined to a bed or chair can take part in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00146172,Contradiction,0.42881325,0.5711868
NCT00708019,Statement: none of the patients in the primary trial experienced the worst pain imaginable for 70 days. [SEP] Clinical Trial: NCT00708019,Entailment,0.5593665,0.4406335
NCT01766102,"Statement: in the primary clinical trial, arm 1 took less time to operate than arm 2, proving standard mammography to be more efficient than intra-operative mammography. the secondary trial contains a control group for comparison purposes.' [SEP] Clinical Trial: NCT01766102",Entailment,0.50027245,0.49972752
NCT00365105,"Statement: a patient diagnosed with stage ii lymphoma, absolute neutrophil count of 2500/μl, platelet count of 90000/μl, hemoglobin level of 110 g/l, and a life expectancy less than 4 months would be unable to participate in both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Entailment,0.75687873,0.24312124
NCT00317603,Statement: The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope [SEP] Clinical Trial: NCT00317603,Contradiction,0.441787,0.558213
NCT00365365,"Statement: hexadecatetraenoic acid is a polyunsaturated long-chain fatty acid with a 16-carbon backbone and exactly 4 double bonds. the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. [SEP] Clinical Trial: NCT00365365",Contradiction,0.35462788,0.6453721
NCT01383174,"Statement: comparatively, the second cohort of the secondary clinical trial held more patients than the second cohort of the primary clinical trial. [SEP] Clinical Trial: NCT01383174",Entailment,0.6433171,0.3566829
NCT01419717,"Statement: patients in the primary clinical trial are obliged to have subcutaneous injections of 120 milligrams of denosumab monthly, while those in the secondary clinical trial undergo lymphoscintigraphy instead of injections. [SEP] Clinical Trial: NCT01419717",Contradiction,0.40048316,0.5995168
NCT00553358,"Statement: a patient that has a primary tumour with a diameter of 0.66 meters measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.31121212,0.6887879
NCT02599194,Statement: the primary clinical and secondary clinical trials ensured transparency by meticulously recording all adverse events associated with their proceedings. [SEP] Clinical Trial: NCT02599194,Entailment,0.643838,0.35616198
NCT00709761,Statement: over 0.5 patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr). [SEP] Clinical Trial: NCT00709761,Contradiction,0.35218015,0.6478199
NCT02259114,"Statement: patients diagnosed with nut midline carcinoma, castrate-resistant prostate cancer, or inflammatory breast cancer, confirmed by fluorescence in situ hybridization, can participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02259114",Contradiction,0.39289242,0.6071076
NCT01008150,"Statement: less than 21 patients in both cohorts of the primary clinical trial witnessed pathologic complete response in breast and axillary lymph nodes, 3 months following the surgical intervention [SEP] Clinical Trial: NCT01008150",Contradiction,0.497776,0.50222397
NCT00194779,"Statement: the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and several different imaging scans. capsule shape is a cylindrical shape that is rounded at both ends. [SEP] Clinical Trial: NCT00194779",Contradiction,0.27959666,0.7204033
NCT02961790,Statement: someone who underwent androgen-based therapy one and a half years prior to the primary clinical trial retains eligibility for the examination. [SEP] Clinical Trial: NCT02961790,Contradiction,0.49027228,0.5097278
NCT02178722,Statement: amyloid resorption induction is amyloid resorption induction involves initiation of activities involved in the breakdown and assimilation of amyloid deposits. the primary trial particpants receive Epacadostat twice as frequently as Sunitinib-na‚àö√òve participants in the secondary trial receive sunitinib. [SEP] Clinical Trial: NCT02178722,Contradiction,0.41992572,0.5800743
NCT01743560,"Statement: the primary clinical trial does not accept children and adolescents for not fulfilling the height requisites, yet they are not specifically barred from the secondary clinical trial. [SEP] Clinical Trial: NCT01743560",Entailment,0.8103429,0.18965715
NCT00786838,Statement: the placebo and trabectedin intervention in the primary trial are both administered through a 180-minute intravenous infusion on a bi-weekly basis. [SEP] Clinical Trial: NCT00786838,Contradiction,0.31445745,0.6855426
NCT00001832,Statement: laryngeal neuroendocrine carcinoma is a rare neuroendocrine carcinoma that arises from the larynx. The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4-Demethyl-4-cholestryloxycarbonylpenclomedine. [SEP] Clinical Trial: NCT00001832,Contradiction,0.23284745,0.76715255
NCT01246973,"Statement: There were no cardiac or phsyciatric Aes recorded during the primary trial and the secondary trial, however several other types of Aes were observed. combination anti-infective agent is a combination of two or more anti-infective agents in a single product to increase the products effectiveness. [SEP] Clinical Trial: NCT01246973",Contradiction,0.17664598,0.823354
NCT01008904,"Statement: the primary trial only has a single adverse event recorded for its patient cohort. lactococcus is a genus of gram positive, cocci shaped, lactic acid bacterium assigned to the phylum firmicutes and the family streptococcaceae. [SEP] Clinical Trial: NCT01008904",Entailment,0.52177703,0.478223
NCT01037790,"Statement: the primary clinical trial accepts an unlimited number of patients with non-metastatic pancreatic cancer, disregarding presence of kras or braf mutations. [SEP] Clinical Trial: NCT01037790",Entailment,0.627525,0.3724751
NCT02306265,"Statement: candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests. [SEP] Clinical Trial: NCT02306265",Contradiction,0.3643996,0.6356004
NCT01920061,"Statement: the primary trial uses a 1 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. long-handled appliances for reach usually used is a response indicating that an individual usually uses a long-handled appliance for reach. [SEP] Clinical Trial: NCT01920061",Entailment,0.8071719,0.19282807
NCT01591746,Statement: the complete cohort of the primary clinical trial is prescribed enteric-coated tablets [SEP] Clinical Trial: NCT01591746,Entailment,0.69027567,0.3097243
NCT01781299,Statement: There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial. performed histopathology differentiation grade code is a coded value specifying the degree of cellular differentiation in a tissue sample. [SEP] Clinical Trial: NCT01781299,Contradiction,0.34809446,0.65190554
NCT01376349,Statement: cogstate-assessed objective cognitive function scores are the units of measure employed in both the primary clinical trial as well as the secondary clinical trial. [SEP] Clinical Trial: NCT01376349,Entailment,0.5744882,0.42551178
NCT01702571,"Statement: uganda is a country in eastern africa, west of kenya. there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial. [SEP] Clinical Trial: NCT01702571",Contradiction,0.4110612,0.5889388
NCT01702571,"Statement: in the primary clinical trial, cardiac-related adverse events were not reported in cohort 1. [SEP] Clinical Trial: NCT01702571",Entailment,0.89319456,0.106805466
NCT01138046,"Statement: stopcock valve device is a rotating valve designed to regulate the flow of a fluid through a stopcock. Only female patients of a specific nationality can take part in the primary trial, no such condition is required for participation in the secondary trial. [SEP] Clinical Trial: NCT01138046",Entailment,0.6534907,0.34650928
NCT00623831,Statement: no patients in cohort 2 of the primary clinical trial report an increase in pleural effusion. [SEP] Clinical Trial: NCT00623831,Entailment,0.7899913,0.21000867
NCT01205503,"Statement: a patient with a known allergy to doxycycline, not cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib, can participate in both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01205503",Contradiction,0.34777978,0.65222025
NCT01855828,Statement: there were no documented psychiatric adverse events in the primary clinical trial. [SEP] Clinical Trial: NCT01855828,Entailment,0.9049431,0.09505691
NCT01128543,Statement: central nervous system angiolipoma is an angiolipoma that arises from the central nervous system. The majority of patients in the primary trial experienced complete response by week 24. [SEP] Clinical Trial: NCT01128543,Contradiction,0.3407003,0.65929973
NCT01434342,"Statement: the secondary trial documented a higher prevalence of mucositis oral, epileptic seizures and thromboembolic events than the primary trial [SEP] Clinical Trial: NCT01434342",Contradiction,0.4060055,0.5939945
NCT01314963,Statement: The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2. [SEP] Clinical Trial: NCT01314963,Entailment,0.5564385,0.44356146
NCT01649271,"Statement: in total, 7 cases of shingles were detected in the patient cohorts of both the primary and secondary trials. [SEP] Clinical Trial: NCT01649271",Contradiction,0.3647364,0.6352636
NCT00182767,Statement: every patient in each cohort of the primary clinical trial experienced an incidence of dose-limiting toxicity. [SEP] Clinical Trial: NCT00182767,Entailment,0.74150556,0.25849447
NCT01011218,Statement: both the primary and the secondary clinical trials registered just one death in the adverse events. [SEP] Clinical Trial: NCT01011218,Entailment,0.83446527,0.1655347
NCT03015649,Statement: extent of hyperperfusion is a determination of the amount of area that is hyperperfused. the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts. [SEP] Clinical Trial: NCT03015649,Contradiction,0.3924752,0.6075248
NCT01246973,"Statement: cardiac and psychiatric aes were frequently reported in the primary clinical trial and the secondary clinical trial, whereas hardly any other aes were observed. [SEP] Clinical Trial: NCT01246973",Contradiction,0.3856604,0.6143396
NCT03384316,Statement: all infections and fever cases in the primary clinical trial were for patients in cohort 2. [SEP] Clinical Trial: NCT03384316,Entailment,0.782414,0.21758604
NCT00467844,"Statement: in the primary clinical trial, a minimum of one patient who used gtx-024 1mg experienced a gain of over 10 kilos in lean body mass. [SEP] Clinical Trial: NCT00467844",Contradiction,0.46427834,0.53572166
NCT01806259,Statement: the ketorolac 30 mg group of the primary clinical trial experienced a 10% increase in recurrence-free survival compared to the nacl 0.9% 3ml group [SEP] Clinical Trial: NCT01806259,Entailment,0.5124303,0.48756966
NCT01975831,"Statement: in the primary clinical trial, both cohorts receive equal doses of durva in their bi-weekly iv infusions [SEP] Clinical Trial: NCT01975831",Entailment,0.5245463,0.47545367
NCT02807844,Statement: all patients in the primary trial receive at least 1300mg of mcs110 every 3 weeks. [SEP] Clinical Trial: NCT02807844,Contradiction,0.4894748,0.5105252
NCT00182767,Statement: dose-limiting toxicity was experienced by two patients from cohort 2 in the primary clinical trial. [SEP] Clinical Trial: NCT00182767,Entailment,0.6220987,0.37790135
NCT00623831,Statement: 25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression   [SEP] Clinical Trial: NCT00623831,Contradiction,0.33685216,0.66314787
NCT01664091,"Statement: the primary trial recorded lower incident rates of infection, asymmetry and deflation than the secondary trial. [SEP] Clinical Trial: NCT01664091",Entailment,0.5022389,0.49776107
NCT01975831,"Statement: in the primary clinical trial, the only point of difference between interventions 1 and 2 lies in the durva dosage; with cohort 1 getting 0.7mg less in their monthly injections than cohort 2. [SEP] Clinical Trial: NCT01975831",Entailment,0.5273769,0.47262308
NCT02122796,"Statement: the weekly intake of mm-121 and paclitaxel is higher for the primary trial participants than for the cohort 1 in the secondary trial, while the doses of herceptin and doxatel are reduced. [SEP] Clinical Trial: NCT02122796",Entailment,0.5634107,0.4365893
NCT02761642,"Statement: there are no restrictions regarding the participation of cancer patients diagnosed with either fibromyalgia, thalasemic syndromes or anemia in the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02761642",Contradiction,0.40099365,0.59900635
NCT00321048,"Statement: in the primary clinical trial, patients from both cohort 1 and 2 receive equal doses of radiation therapy and also undergo a spect scan. [SEP] Clinical Trial: NCT00321048",Contradiction,0.4358809,0.5641191
NCT00709761,Statement: square millisecond is a unit of time which is equal to one thousandth of a second squared. Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) . [SEP] Clinical Trial: NCT00709761,Contradiction,0.37680435,0.62319565
NCT00262834,"Statement: none of the adverse events occurred during the primary clinical trial. for the secondary clinical trial, all adverse events, expect for skin infections, were seen in less than 30% of the patients. [SEP] Clinical Trial: NCT00262834",Entailment,0.6405488,0.35945123
NCT01964924,"Statement: a minor recently diagnosed with ild/dpld, predicted to live for one year, is permitted to participate in the primary clinical trial [SEP] Clinical Trial: NCT01964924",Entailment,0.5083717,0.4916283
NCT04080297,"Statement: how much did ringing, buzzing, whistling noises make it hard to pay attention to things is a question about how hard it was for an individual to concentrate because of ringing, buzzing, or whistling noises. Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time. [SEP] Clinical Trial: NCT04080297",Entailment,0.70582014,0.29417986
NCT01314963,Statement: neither intervention one nor two in the primary clinical trial employs pihgc or standard gp. [SEP] Clinical Trial: NCT01314963,Contradiction,0.4809402,0.5190598
NCT00956813,Statement: the secondary trial and the primary trial report their results using the same units of measure. median or lower cervical lymph node is a lymph node located in the median or lower region of the neck. (nci) [SEP] Clinical Trial: NCT00956813,Contradiction,0.40866432,0.5913357
NCT00800436,"Statement: previously undergoing gabapentin or herceptin therapy within the previous year excludes a patient from the secondary clinical trial, however it does not affect their inclusion in the primary clinical trial [SEP] Clinical Trial: NCT00800436",Entailment,0.69674414,0.30325586
NCT01421472,"Statement: all cohorts of the primary clinical trial are available to breast cancer patients with estrogen negative, progesterone negative and her2- tumors [SEP] Clinical Trial: NCT01421472",Entailment,0.5330976,0.4669024
NCT02234479,"Statement: teenage pregnancy is a pregnancy in an adolescent between the ages of thirteen and nineteen. the primary trial is testing the effects of different gels on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.6216779,0.3783221
NCT01008150,Statement: More than 97% of patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 12 months of the study [SEP] Clinical Trial: NCT01008150,Contradiction,0.3852513,0.6147487
NCT00467844,Statement: every patient in the primary clinical trial who received 1mg of gtx-024 experienced an increase in lean body mass over four months [SEP] Clinical Trial: NCT00467844,Contradiction,0.4976326,0.50236744
NCT00321048,"Statement: in the primary clinical trial, the patients of cohort 1 and 2 receive varied doses of radiation therapy for the same duration. [SEP] Clinical Trial: NCT00321048",Entailment,0.5752889,0.42471108
NCT00929240,Statement: the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort. [SEP] Clinical Trial: NCT00929240,Entailment,0.62241906,0.37758097
NCT00451555,Statement: neither the primary clinical trial nor the secondary clinical trial require patients to be resistant to ai therapy and mirtazapine for participant eligibility. [SEP] Clinical Trial: NCT00451555,Contradiction,0.42889118,0.5711088
NCT00838929,Statement: patients in the primary clinical trial are not administered any fentanyl sublingual spray during their radiation therapy. [SEP] Clinical Trial: NCT00838929,Entailment,0.834174,0.16582602
NCT00262834,"Statement: 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 0.3 of patients, apart from skin infections [SEP] Clinical Trial: NCT00262834",Contradiction,0.40729305,0.5927069
NCT01086605,"Statement: there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial. do not own smartphone or tablet is a response indicating that an individual does not own a smartphone or tablet. [SEP] Clinical Trial: NCT01086605",Entailment,0.69757855,0.3024215
NCT01803282,"Statement: 100% of the primary trial participants, and 50% of the secondary trial participants suffered an acute myocardial infarction. [SEP] Clinical Trial: NCT01803282",Contradiction,0.3003572,0.6996428
NCT01205503,"Statement: neither the primary clinical trial nor the secondary clinical trial will accept patients with a well-documented allergy to drugs such as cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib. [SEP] Clinical Trial: NCT01205503",Contradiction,0.3026552,0.69734484
NCT00950911,Statement: the dosage of zoledronic acid in intervention 1 of the primary clinical trial is identical to that of denosumab used in intervention 1 of the secondary clinical trial. [SEP] Clinical Trial: NCT00950911,Entailment,0.7257408,0.27425918
NCT01156987,"Statement: every participant in group 1 of the primary trial were diagnosed with lesions, and less than 5% of participants in group 1 of the secondary trial had clean skin without any blemishes. [SEP] Clinical Trial: NCT01156987",Entailment,0.7674576,0.23254234
NCT02187783,"Statement: 2q36.1 is a chromosome band present on 2q More Palpitations, Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.41070217,0.58929783
NCT01351376,Statement: bilateral breast tumor presence is not a reason for exclusion in the primary clinical trial [SEP] Clinical Trial: NCT01351376,Entailment,0.8274987,0.1725013
NCT00825682,Statement: the intervention in the secondary trial last three times longer than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.8830955,0.116904505
NCT00929240,Statement: the bevacizumab cluster of primary clinical trial reported equal instances of disease progression or death as compared to the combined bevacizumab and capecitabine group. [SEP] Clinical Trial: NCT00929240,Entailment,0.6152413,0.38475877
NCT00656019,Statement: patients with high vitamin d levels in the primary clinical trial manifested a noticeable pattern for expression of the group of 40 evaluated genes. [SEP] Clinical Trial: NCT00656019,Contradiction,0.29905707,0.700943
NCT02988986,Statement: over 4 months of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 20% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Entailment,0.5145591,0.48544094
NCT00262834,"Statement: 203 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 10% of patients, apart from skin infections [SEP] Clinical Trial: NCT00262834",Contradiction,0.47907603,0.520924
NCT01314963,"Statement: The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP. choroid plexus meningioma is a meningioma that affects the choroid plexus. [SEP] Clinical Trial: NCT01314963",Contradiction,0.40320256,0.5967974
NCT00971945,"Statement: the secondary clinical trial demands participants to be entirely disabled, a stipulation not requisite for admission into the primary clinical trial [SEP] Clinical Trial: NCT00971945",Entailment,0.77541345,0.22458658
NCT00828516,"Statement: moellerella is a genus of facultatively anaerobic, gram negative, rod shaped bacterium in the phylum proteobacteria and the family enterobacteriaceae. Neither the secondary trial or the primary trial use the Number of Participants With Treatment-emergent Aes as the outcome measurement for their studies. [SEP] Clinical Trial: NCT00828516",Contradiction,0.48598087,0.51401913
NCT00706030,"Statement: three specific adverse events- pancreatitis, cholelithiasis, hepatic pain and febrile neutropenia, occurred amongst patients in the primary clinical trial [SEP] Clinical Trial: NCT00706030",Contradiction,0.48042065,0.5195793
NCT02178722,Statement: spiradenocylindrocarcinoma is a carcinoma that arises in a spiradenocylindroma. the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib. [SEP] Clinical Trial: NCT02178722,Contradiction,0.39238834,0.60761166
NCT00245050,"Statement: avascular necrosis joint laterality is a finding descriptive of the laterality of the avascular necrosis in the joints. the primary trial had one test group and one placebo group, the secondary trial had 1 test group and 1 control group. [SEP] Clinical Trial: NCT00245050",Entailment,0.53405845,0.46594158
NCT01527487,Statement: patients in the first cohort of the primary clinical trial are administered higher doses of eribulin compared to the doses of docetaxel received by the second cohort. [SEP] Clinical Trial: NCT01527487,Entailment,0.6247232,0.37527677
NCT02002533,Statement: the record shows that the primary clinical trial experienced 4 more adverse events than what was observed in the secondary clinical trial. [SEP] Clinical Trial: NCT02002533,Entailment,0.6576461,0.3423539
NCT01252290,Statement: age in days at end of radiation therapy is age of subject (in days) at the end of radiation therapy. less than 5% of patients in the primary trial suffered Aes. [SEP] Clinical Trial: NCT01252290,Entailment,0.6974567,0.30254325
NCT03125941,Statement: the primary clinical trial cohorts do not receive any form of pre-operative medication. [SEP] Clinical Trial: NCT03125941,Entailment,0.92982143,0.07017863
NCT00262834,"Statement: 100 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 150% of patients. [SEP] Clinical Trial: NCT00262834",Contradiction,0.35808134,0.6419186
NCT00963911,"Statement: several of the primary trial candidates are administered 200 mcg of talazoparib daily, as part of the intervention [SEP] Clinical Trial: NCT00963911",Contradiction,0.32544342,0.6745566
NCT00146172,Statement: candidates capable of only limited selfcare; confined to bed or chair more than 80% of waking hours are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.35431483,0.64568514
NCT00819182,"Statement: the primary clinical trial showed that, on average, the paced respiration intervention group experienced fewer hot flashes per day than patients in the fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.6429486,0.35705137
NCT00950911,Statement: the denosumab dosage in intervention 1 of the primary clinical trial is 12 times the tamoxifen dosage used in intervention 1 of the secondary clinical trial. [SEP] Clinical Trial: NCT00950911,Entailment,0.58351135,0.41648862
NCT01313117,"Statement: Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, up to a maximum of 100 mg three times daily, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. high grade liver dysplastic nodule is a hepatic dysplastic nodule characterized by the presence of high grade atypical cellular changes. [SEP] Clinical Trial: NCT01313117",Contradiction,0.3668315,0.6331685
NCT02234479,"Statement: interphalangeal joint 5 is a ginglymoid (hinge) synovial joint between the phalanges of the fifth digit of the hand or foot. the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.588418,0.41158196
NCT00270894,"Statement: participants in the primary trial receive quadruple drug therapies throughout the study duration, with a maximum dose of 1 gram/m^2 [SEP] Clinical Trial: NCT00270894",Contradiction,0.3904043,0.60959566
NCT00370552,"Statement: women with the ability to conceive and sexually productive men qualify for the primary clinical trial, though there are extra prerequisites. [SEP] Clinical Trial: NCT00370552",Entailment,0.5118186,0.48818147
NCT00950911,"Statement: in the initial intervention of the primary clinical trial, zoledronic acid is administered at a concentration 12 times higher than denosumab used in the first intervention of the secondary clinical trial. [SEP] Clinical Trial: NCT00950911",Entailment,0.5021709,0.49782908
NCT01439282,"Statement: the primary clinical trial is open only to female patients, while the secondary clinical trial does not consider gender for eligibility [SEP] Clinical Trial: NCT01439282",Entailment,0.88048863,0.11951137
NCT01975831,"Statement: in the primary clinical trial, the unique difference between interventions 1 and 2 is the lesser quantity (0.7mg/kg) of durva received by the first cohort in their twice weekly iv infusions, compared to the second cohort. [SEP] Clinical Trial: NCT01975831",Entailment,0.51740915,0.48259085
NCT01008150,Statement: More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study. molecular pathology report is a pathology report based upon the underlying protein and genetic defects. [SEP] Clinical Trial: NCT01008150,Contradiction,0.40104216,0.59895784
NCT00569166,"Statement: Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy. a little, but it doesn't worry me is a response indicating that something occurs, but causes little concern. [SEP] Clinical Trial: NCT00569166",Contradiction,0.3377275,0.6622725
NCT00408681,"Statement: Recurrent malignancies, Graft-versus-host disease, Anaemia, Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. am distressed is a question about whether an individual feels distressed. [SEP] Clinical Trial: NCT00408681",Entailment,0.5010469,0.4989531
NCT00321048,"Statement: the radiation therapy for cohort 2 in the primary clinical trial lasts two weeks longer than cohort 1, with identical dosage. [SEP] Clinical Trial: NCT00321048",Entailment,0.55380064,0.44619933
NCT01434342,"Statement: ezh2 inhibitor is any agent that inhibits the histone lysine methyltransferase ezh2. There were more cases of Mucositis Oral, epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01434342",Contradiction,0.4745316,0.5254684
NCT00971945,"Statement: performance status condition fulfillment is a prerequisite for the secondary clinical trial, but not for the primary clinical trial [SEP] Clinical Trial: NCT00971945",Entailment,0.626275,0.373725
NCT01649271,Statement: placental neoplasm is a benign or malignant neoplasm that affects the placenta. representative examples include hemangioma and choriocarcinoma. there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01649271,Contradiction,0.36027083,0.63972914
NCT01301729,"Statement: during various stages of the trials, primary clinical trial participants receive an equivalent dosage of trastuzumab as the cohort 2 patients in the secondary clinical trial. [SEP] Clinical Trial: NCT01301729",Entailment,0.64169973,0.35830027
NCT00553358,"Statement: a patient with a secondary tumour, of 35mm in size detected through mri, would not qualify for either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT00553358",Entailment,0.776227,0.22377306
NCT00408681,"Statement: primary clinical trial exhibited a lower frequency of recurrent malignancies, graft-versus-host disease, anaemia, cardiac failure and diffuse alveolar hemorrhage when compared to the secondary trial. [SEP] Clinical Trial: NCT00408681",Contradiction,0.43532082,0.56467915
NCT01920061,Statement: the primary trial reported an equal number of aes for both groups [SEP] Clinical Trial: NCT01920061,Entailment,0.8289195,0.17108054
NCT00270894,Statement: participants in the primary trial receive 4 different drugs throughout the study duration. almost all of the time is a response indicating that something happens or happened almost all of the time. [SEP] Clinical Trial: NCT00270894,Entailment,0.537016,0.46298406
NCT00313170,Statement: candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments. duodenal band is a pathologic fibrous band that impedes passage of intestinal contents through the duodenum. [SEP] Clinical Trial: NCT00313170,Entailment,0.5370667,0.4629333
NCT00709761,Statement: over 3/4 patients in the primary trial treated with lapatinib 800 mg + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr). [SEP] Clinical Trial: NCT00709761,Contradiction,0.4307832,0.5692168
NCT00365365,"Statement: the primary clinical trial participants are administered her2/neu peptide vaccine mixed with sargramostim (gm-csf) id on day 1, 8 and 15. [SEP] Clinical Trial: NCT00365365",Contradiction,0.29597414,0.70402586
NCT00749931,Statement: every patient that is qualified for the secondary clinical trial will also qualify for the primary clinical trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.6895981,0.31040192
NCT00766532,"Statement: there are no records of swelling, hypothermia, or confusion in the aes of the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00766532",Entailment,0.6273561,0.3726439
NCT00429299,"Statement: renal pelvis papillary urothelial neoplasm is a papillary tumor originating in the renal pelvis. All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care. [SEP] Clinical Trial: NCT00429299",Contradiction,0.32598498,0.67401505
NCT00828516,Statement: both the primary and secondary trials employ the number of participants with treatment-emergent aes as a crucial outcome measurement for the study. [SEP] Clinical Trial: NCT00828516,Contradiction,0.4803267,0.5196733
NCT00544167,"Statement: primary clinical trial excludes patients who have had a recent pulmonary embolism, specifically within the past 2 months. however, their eligibility for the secondary clinical trial is subject to the investigator's discretion. [SEP] Clinical Trial: NCT00544167",Entailment,0.75586003,0.24413998
NCT00266110,"Statement: for the primary clinical trial, patients will receive a single injection on study day 8. [SEP] Clinical Trial: NCT00266110",Entailment,0.54877055,0.45122945
NCT01597193,"Statement: walking question is a question about an individual's walking ability. cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV. [SEP] Clinical Trial: NCT01597193",Contradiction,0.4812428,0.5187572
NCT00467844,Statement: at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass. regret choice made is a question about whether an individual regrets the healthcare choice that they made. [SEP] Clinical Trial: NCT00467844,Entailment,0.61691046,0.38308957
NCT00322374,"Statement: the primary clinical trial imposes no restrictions based on mental health, bodyweight, tumour size, karnofsky/ecog score, or estimated life expectancy for eligibility [SEP] Clinical Trial: NCT00322374",Entailment,0.6248523,0.37514776
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 26 weeks if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.3793194,0.6206806
NCT00429299,Statement: the primary clinical trial mandate is that all participants possess an ihc 3+ confirmed her2 positive tumor and necessitate substantial aid and frequent healthcare support [SEP] Clinical Trial: NCT00429299,Contradiction,0.3503053,0.64969474
NCT01250379,"Statement: egfr nm 005228.3:c.2320 2321ins12 is an insertion of 12 nucleotides, gcaacccccacg, between position 2320 and 2321 of the coding sequence of the egfr gene. a young girl with a Newly diagnosed PR-positive, HER2 positive breast cancer, could be eligible for the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01250379",Contradiction,0.31593937,0.68406063
NCT02404441,"Statement: uniformity characterizes the inclusion/exclusion specifications of all participants in the secondary clinical trial, whereas the primary clinical trial delineates two separate sets of eligibility norms for its differing study cohorts. [SEP] Clinical Trial: NCT02404441",Entailment,0.76183915,0.23816082
NCT00317603,Statement: colon non-hodgkin lymphoma is an extranodal non-hodgkin lymphoma that arises from the colon.  the majority are b-cell non-hodgkin lymphomas. The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope. [SEP] Clinical Trial: NCT00317603,Contradiction,0.35980663,0.64019334
NCT01252290,Statement: more than 95% of patients in the primary trial suffered aes [SEP] Clinical Trial: NCT01252290,Entailment,0.5455439,0.4544561
NCT03125941,Statement: the cohorts of the primary clinical trial are administered dexamethasone pre-operationally [SEP] Clinical Trial: NCT03125941,Entailment,0.67923224,0.32076776
NCT01920061,"Statement: the treatment in the primary trial progresses in a continuous manner without a repeated cycle, however the secondary trial operates on a rigorous 3 weeks cycle [SEP] Clinical Trial: NCT01920061",Entailment,0.5766418,0.42335814
NCT02234479,"Statement: the primary trial is observing the effects of various doses of the same medication on its study participants, while the secondary trial is applying different gels as part of its study. [SEP] Clinical Trial: NCT02234479",Entailment,0.8822903,0.11770968
NCT01419717,Statement: patients need to be given a monthly subcutaneous injection of 120 milligrams of denosumab in the primary clinical trial and the secondary clinical trial requires 0.4 to 1.0 mci of radioactive tc99m sulfur colloid administered via injection. [SEP] Clinical Trial: NCT01419717,Contradiction,0.34533972,0.6546603
NCT00843167,"Statement: the secondary trial uses heart rate as a measure of effectiveness for cardio exercises, whereas the primary trial studies the effect of omega-3 fatty acids on lipid profile in blood. [SEP] Clinical Trial: NCT00843167",Contradiction,0.39360327,0.60639673
NCT01806259,"Statement: during the primary clinical trial, 96 individuals from the ketorolac 30 mg group showed recurrence-free survival, compared to 67 participants from the nacl 0.9% 3ml group [SEP] Clinical Trial: NCT01806259",Contradiction,0.42252126,0.5774787
NCT01301729,Statement: HER2 + Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial. anticonvulsant hypersensitivity syndrome is a form of drug hypersensitivity syndrome caused by anti-convulsants. [SEP] Clinical Trial: NCT01301729,Contradiction,0.44431904,0.555681
NCT00429299,Statement: individuals having confirmed her2 negative tumor through either fish or ihc 3+ are considered for the primary clinical trial [SEP] Clinical Trial: NCT00429299,Entailment,0.56577975,0.43422025
NCT02734979,Statement: Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial. tert promoter mutation analysis is a procedure used to detect and identify mutations in the promoter sequences for the tert gene. [SEP] Clinical Trial: NCT02734979,Entailment,0.53734046,0.46265954
NCT01730729,"Statement: the primary clinical trial intervention is exclusively carried out through intravenous injection, while the secondary trial intervention is administered via oral consumption [SEP] Clinical Trial: NCT01730729",Entailment,0.56926674,0.43073326
NCT00706030,"Statement: Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia. hour per day is a unit of measurement equal to the number of hours within a period of time equal to one day. [SEP] Clinical Trial: NCT00706030",Contradiction,0.40967187,0.59032816
NCT00075764,"Statement: ability to think and solve day-to-day problems is a question about an individual's ability to think and solve day-to-day problems. Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial. [SEP] Clinical Trial: NCT00075764",Contradiction,0.37806424,0.6219357
NCT00702949,"Statement: was 1p/19q deletion analysis performed is a question asking if 1p/19 deletion analysis was performed during the study. the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin twice daily, and the secondary trial administers its patients with Depocyt and HD-MTX. [SEP] Clinical Trial: NCT00702949",Contradiction,0.45692658,0.5430734
NCT01310075,Statement: a woman with no history of any type of cancer treatments is an ideal participant for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT01310075,Entailment,0.62322915,0.37677082
NCT00709761,Statement: Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR). [SEP] Clinical Trial: NCT00709761,Contradiction,0.43278983,0.5672102
NCT00404066,"Statement: historical data type is a data type comprised of information concerning the historical aspects of a particular value. The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain, no aes wererecorded in the primary trial. [SEP] Clinical Trial: NCT00404066",Entailment,0.656433,0.34356707
NCT01138046,"Statement: Only female patients of a specific nationality can take part in the primary trial, no such condition is required for participation in the secondary trial. regimen used to treat malignant peritoneal neoplasm is any regimen that can be used for the treatment of malignant peritoneal  neoplasm. [SEP] Clinical Trial: NCT01138046",Entailment,0.74933183,0.25066814
NCT00405938,"Statement: non-host organism identifiers supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the non-host organism identifiers domain. Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial. [SEP] Clinical Trial: NCT00405938",Contradiction,0.4997439,0.50025606
NCT02891681,Statement: topical solution dosage form is a solution intended for administration to a body surface. Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.18101718,0.8189828
NCT00687102,Statement: both the primary clinical trial and the secondary clinical trial patient cohorts have not reported any cases of intestinal obstructions or pancytopenia. [SEP] Clinical Trial: NCT00687102,Entailment,0.73892367,0.26107636
NCT00451555,"Statement: participants who showed sensitivity to ai therapy are acquitted for the primary clinical trial, and this condition is also not a requirement for the secondary clinical trial. [SEP] Clinical Trial: NCT00451555",Entailment,0.88762075,0.11237925
NCT00999921,"Statement: patients diagnosed with benign fibroadenoma and effectively managed hypertension can participate in the primary clinical trial, but are ineligible for the secondary clinical trial. [SEP] Clinical Trial: NCT00999921",Entailment,0.87666434,0.12333572
NCT00146172,"Statement: window is a time period, or other type of interval, during which something may be achieved, obtained or observed. candidates Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00146172",Contradiction,0.2865954,0.7134046
NCT01989546,Statement: cbt based treatments are integral components of the qualification criteria for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01989546,Contradiction,0.4128912,0.5871088
NCT01855828,"Statement: There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients [SEP] Clinical Trial: NCT01855828",Entailment,0.870888,0.12911202
NCT01246973,Statement: cardiac aes were prominently recorded in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT01246973,Contradiction,0.3500315,0.6499685
NCT00836186,"Statement: in the primary trial, participants undergo oral administration of antiretroviral drugs, while both partitions of the secondary trial receive a course of muscle relaxants alongside physical therapy sessions. [SEP] Clinical Trial: NCT00836186",Contradiction,0.40444842,0.59555155
NCT01706081,Statement: patients in the primary clinical trial experienced more significant improvements in their lymphedema through acupuncture than those on the waitlist. [SEP] Clinical Trial: NCT01706081,Entailment,0.5982171,0.40178287
NCT00513292,"Statement: different endpoints, pfs for the primary trial and os for the secondary trial, are utilised for the two studies. the results of the primary trial indicate that there is a large difference in outcomes between the two cohorts, in contrast to the secondary trial where arm 1 and arm 2 showed comparable results. [SEP] Clinical Trial: NCT00513292",Contradiction,0.4737275,0.52627254
NCT01606748,"Statement: 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia. [SEP] Clinical Trial: NCT01606748",Entailment,0.5746587,0.42534134
NCT00088413,Statement: immigrant from high tuberculosis prevalent area is an individual that has migrated from a country with a high occurrence of tuberculosis. All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial. [SEP] Clinical Trial: NCT00088413,Entailment,0.549329,0.45067102
NCT00843167,"Statement: the outcome measure of the secondary trial is based on functional mobility improvements in physical therapy, while the primary trial investigates the effects of omega-3 fatty acids supplementation on blood triglyceride levels. [SEP] Clinical Trial: NCT00843167",Contradiction,0.48741016,0.5125898
NCT00365105,"Statement: a 60 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 900/≈í¬∫l, platelet count of 220,068/≈í¬∫l, hemoglobin level of 180 g/l, and a life expectancy less than 16 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.34279573,0.6572043
NCT00365105,"Statement: A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 79000/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.32195848,0.6780415
NCT00838929,"Statement: in the primary clinical trial, daily vorinostat capsule intake during radiation therapy is mandatory for every patient. [SEP] Clinical Trial: NCT00838929",Entailment,0.5283595,0.4716405
NCT00800436,"Statement: recql gene mutation is a change in the nucleotide sequence of the recql gene. Prior treatment with gabapentin or herceptin within the last year, will result in exclusion from the secondary trial, but not from the primary trial. [SEP] Clinical Trial: NCT00800436",Entailment,0.59053147,0.40946853
NCT01086605,"Statement: there were 75 cases of hypertension, dehydration and dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Contradiction,0.26829827,0.7317017
NCT00558272,Statement: both the azd0530 175 mg and the zoledronic acid 4 mg groups experienced equivalent percentage change in betactx at week 4 in the primary clinical trial. [SEP] Clinical Trial: NCT00558272,Entailment,0.55752987,0.4424701
NCT03384316,Statement: no infections or fever cases were reported for patients in cohort 1 in the primary clinical trial. [SEP] Clinical Trial: NCT03384316,Entailment,0.8187703,0.18122965
NCT01127763,Statement: none of the patients in the primary clinical trial experienced more than 2 adverse events. [SEP] Clinical Trial: NCT01127763,Entailment,0.850905,0.14909503
NCT00182767,"Statement: robot-assisted laparoscopic surgery is a surgical technique that uses a specially designed robotic system to aid with a laparoscopic surgical procedure. In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2. [SEP] Clinical Trial: NCT00182767",Contradiction,0.46839714,0.53160286
NCT00432562,Statement: the ability to give written informed consent is the sole common eligibility criterium between the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00432562,Entailment,0.67242223,0.32757774
NCT02165839,"Statement: a crucial requirement for both the primary and secondary clinical trials is that candidates must meet a baseline performance status, but the scoring system differs for each trial. [SEP] Clinical Trial: NCT02165839",Entailment,0.77741694,0.22258306
NCT01383174,Statement:  cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial. picogram equivalents per gram is a concentration unit measured as a number of picogram equivalents per gram of substance. [SEP] Clinical Trial: NCT01383174,Entailment,0.76476294,0.2352371
NCT00021255,"Statement: Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs. thyroid gland schwannoma is a rare schwannoma that arises from the thyroid gland. [SEP] Clinical Trial: NCT00021255",Contradiction,0.34053868,0.6594613
NCT00182793,Statement: both the primary clinical trial and the secondary clinical trial reported zero cases of infections among participants during the period of study [SEP] Clinical Trial: NCT00182793,Entailment,0.7281452,0.27185482
NCT01554371,Statement: remarkable or unregulated cardiovascular ailments make patients ineligible for participation in either the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.87186426,0.12813577
NCT00076024,"Statement: participants of the primary clinical trial are not subject to life expectancy, pregnancy, or age conditions [SEP] Clinical Trial: NCT00076024",Entailment,0.72961515,0.27038482
NCT02234479,"Statement: in the primary clinical trial, study groups are subjected to the testing of different gels, on the other hand, the secondary clinical trial is conducting tests on the same treatment but in various doses on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.589737,0.41026303
NCT02961790,Statement: an individual who has undergone a cycle of progestogen therapy six months before the primary clinical trial maintains fitness to participate in the study. [SEP] Clinical Trial: NCT02961790,Entailment,0.54085016,0.45914984
NCT00256217,Statement: both primary and secondary clinical trials involved patients who suffered from four different adverse events. [SEP] Clinical Trial: NCT00256217,Entailment,0.8654974,0.13450257
NCT00122369,"Statement: 18 years olds are excluded from the secondary trial, but the primary trial does not specify an age range for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.836565,0.16343497
NCT00623831,Statement: 75% of patients in the primary trial suffer increased pleural effusion and rapid disease progression [SEP] Clinical Trial: NCT00623831,Contradiction,0.32614633,0.6738537
NCT01969448,"Statement: in the primary clinical trial, both interventions utilize laser-assisted fluorescence angiography and lateral radial incisions. [SEP] Clinical Trial: NCT01969448",Contradiction,0.30464032,0.6953597
NCT00538850,"Statement: the primary clinical trial records general health status via eq-5d questionnaire, while the secondary trial evaluates change in hip circumference from start to the conclusion of the trial [SEP] Clinical Trial: NCT00538850",Contradiction,0.46656978,0.5334302
NCT01730729,"Statement: the primary trial intervention is given orally, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein. armadillo is any of several small, burrowing, chiefly nocturnal mammals with body covered with strong horny plates. [SEP] Clinical Trial: NCT01730729",Contradiction,0.35134175,0.6486582
NCT00404066,"Statement: The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain, no aes wererecorded in the primary trial. english proficiency test is an individual-level measurement of spoken english language proficiency. [SEP] Clinical Trial: NCT00404066",Entailment,0.5857069,0.41429305
NCT01855828,"Statement: There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia [SEP] Clinical Trial: NCT01855828",Entailment,0.5092789,0.49072105
NCT01086605,"Statement: picomole per liter per kilogram per meter squared is a unit of concentration equal to picomoles per liter, divided by kilograms per meter squared. there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial. [SEP] Clinical Trial: NCT01086605",Entailment,0.5747876,0.42521238
NCT02178722,Statement: play doubles tennis is a question about whether an individual played doubles tennis. the primary trial particpants receive Epacadostat twice as frequently as Sunitinib-na‚àö√òve participants in the secondary trial receive sunitinib. [SEP] Clinical Trial: NCT02178722,Contradiction,0.44334143,0.55665857
NCT00451555,Statement: ai therapy responsive participants are allowed to partake in the primary clinical trial and secondary clinical trial. [SEP] Clinical Trial: NCT00451555,Contradiction,0.25541988,0.74458015
NCT01045421,Statement: people with cytologically or histologically confirmed metastatic and/or advanced solid tumor in their breast can participate in phase 1 of the primary clinical trial and are also eligible for every cohort of the secondary clinical trial [SEP] Clinical Trial: NCT01045421,Contradiction,0.44001526,0.55998474
NCT00558272,Statement: the azd0530 1750 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the zoledronic acid 0.004 g group. [SEP] Clinical Trial: NCT00558272,Entailment,0.5183241,0.48167586
NCT02038218,"Statement: the secondary trial and the primary trial use different units of measure in their results. work on car, truck, lawn mower, or other machinery is a question about whether an individual worked on a car, truck, lawn mower, or other machinery. [SEP] Clinical Trial: NCT02038218",Entailment,0.8615748,0.1384252
NCT00786838,"Statement: in the primary clinical trial, both the placebo and trabectedin treatment are delivered via 3-hour iv infusions every two weeks. [SEP] Clinical Trial: NCT00786838",Contradiction,0.49825385,0.5017462
NCT02273206,Statement: neurodevelopmental disorder is a childhood disorder that has a neurological basis and manifests as a developmental disability. Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention. [SEP] Clinical Trial: NCT02273206,Contradiction,0.39215147,0.6078486
NCT00775645,Statement: in both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 0.01 of participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.44542825,0.5545717
NCT03557801,"Statement: the incidence of anemia, pneumonia and stupor was higher in the secondary clinical trial patients compared to the primary clinical trial patients. [SEP] Clinical Trial: NCT03557801",Contradiction,0.4625579,0.5374421
NCT00963911,"Statement: several of the primary trial candidates are administered 1 mg of talazoparib daily, as part of the intervention [SEP] Clinical Trial: NCT00963911",Contradiction,0.34564927,0.6543507
NCT00791037,Statement: the primary trial and the secondary trial assess the same patient characteristics in their results. [SEP] Clinical Trial: NCT00791037,Entailment,0.6806952,0.3193048
NCT00911898,"Statement: the method of administration, dosage, or schedule is not distinguished in the intervention section of the primary clinical trial. [SEP] Clinical Trial: NCT00911898",Entailment,0.9242836,0.07571633
NCT00918281,"Statement: the procedure in the primary clinical trial's first cohort involves an intraosseous injection of fluciclatide, contrastingly, the first cohort in the secondary clinical trial is given an intravenous standard dose of chloroquine. [SEP] Clinical Trial: NCT00918281",Entailment,0.5355704,0.46442965
NCT00820872,Statement: Diarrhoea was more common for the primary trial participants than the secondary trial participants. was csf cytology completed at diagnosis is a question about whether csf cytology was completed at diagnosis. [SEP] Clinical Trial: NCT00820872,Entailment,0.67442626,0.3255737
NCT00871858,Statement: none of the interventions in the primary clinical trial utilize paclitaxel [SEP] Clinical Trial: NCT00871858,Entailment,0.9158211,0.084178954
NCT01250379,"Statement: a 50-year-old women without any type of breast cancer, could be eligible for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01250379",Contradiction,0.260628,0.73937196
NCT02179515,Statement: all participants from the first cohort of the primary clinical trial underwent some adverse event [SEP] Clinical Trial: NCT02179515,Entailment,0.8974988,0.10250121
NCT02179515,Statement: life-threatening adverse events were absent in the first cohort of the primary clinical trial. [SEP] Clinical Trial: NCT02179515,Entailment,0.8788289,0.1211711
NCT01803282,"Statement: 2/73 the primary trial participants, and 0/1674 the secondary trial participants suffered an Acute myocardial infarction  [SEP] Clinical Trial: NCT01803282",Contradiction,0.48992088,0.5100791
NCT00708019,"Statement: throughout the 10 weeks of the primary clinical trial, a number of participants experienced no pain. [SEP] Clinical Trial: NCT00708019",Entailment,0.75386536,0.24613462
NCT01138046,"Statement: male patients of all nationalities are invited to participate in the primary clinical trial, no such condition exists for the secondary clinical trial. [SEP] Clinical Trial: NCT01138046",Entailment,0.90272254,0.097277425
NCT00929240,"Statement: in primary clinical trial, the bevacizumab + capecitabine cohort demonstrated more positive outcomes compared to the bevacizumab cohort. [SEP] Clinical Trial: NCT00929240",Entailment,0.6468726,0.35312742
NCT00687102,Statement: the patient cohorts of the primary clinical trial and the secondary clinical trial have registered 3 total cases of asthenia and 5 total cases of pyrexia. [SEP] Clinical Trial: NCT00687102,Contradiction,0.22112525,0.77887475
NCT02796755,Statement: did the individual have multiple known primary tumors at initial melanoma diagnosis is a question about whether the individual has multiple known primary tumors at the initial melanoma diagnosis. There were more adverse events observed in the secondary trial than in the primary trial. [SEP] Clinical Trial: NCT02796755,Entailment,0.6150541,0.38494593
NCT01631552,"Statement: despite similar intervention strategies, the primary clinical trial and secondary clinical trial exhibit disparate outcome measurement techniques. [SEP] Clinical Trial: NCT01631552",Entailment,0.87886083,0.12113913
NCT01664091,"Statement: the primary clinical trial reported a higher incidence of infection, asymmetry and nausea than the secondary clinical trial. [SEP] Clinical Trial: NCT01664091",Entailment,0.51740134,0.48259866
NCT02550795,"Statement: group 7 of the primary trial recieves 4.5ug/kg of dexmedetomidine (45ml), patients in the secondary trial cohorts do not receive any dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.84642917,0.15357086
NCT00365105,"Statement: A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 79000/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. electron microscopy facility is a shared facility which provides services for electron microscopy. [SEP] Clinical Trial: NCT00365105",Contradiction,0.4281931,0.57180697
NCT01498458,Statement: in the primary trial there were 15% the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.30587035,0.69412965
NCT03384316,Statement: all the instances of infections and fever observed in the primary clinical trial were associated with patients in cohort 1. [SEP] Clinical Trial: NCT03384316,Entailment,0.7589682,0.24103178
NCT01783444,"Statement:  Women with Newly diagnosed stage IV breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial [SEP] Clinical Trial: NCT01783444",Contradiction,0.24800885,0.75199115
NCT00800436,"Statement: Prior treatment with gabapentin or herceptin within the last year, will result in exclusion from the secondary trial, but not from the primary trial. procedure history is a descriptive account of an individual's past medical procedures. [SEP] Clinical Trial: NCT00800436",Entailment,0.6966254,0.3033746
NCT01111825,Statement: the primary clinical trial cohort underwent an invasive cardiac surgery [SEP] Clinical Trial: NCT01111825,Entailment,0.73989314,0.26010683
NCT00451555,"Statement: the primary clinical trial requires participants to display resistance to ai therapy, while the secondary clinical trial has no such requirement [SEP] Clinical Trial: NCT00451555",Entailment,0.90230805,0.09769199
NCT02222922,Statement: the drug dosage for the primary clinical trial participants is lower in comparison to that of the secondary clinical trial participants. [SEP] Clinical Trial: NCT02222922,Entailment,0.8512275,0.1487725
NCT00429299,"Statement: All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care. snare protein is a diverse family of proteins that form various multimeric complexes to regulate the fusion of cellular membranes. [SEP] Clinical Trial: NCT00429299",Contradiction,0.28431892,0.7156811
NCT00956813,Statement: the outcome measures for the primary and secondary trials showcase identical results [SEP] Clinical Trial: NCT00956813,Entailment,0.90961087,0.09038908
NCT01964924,Statement: an individual who has been diagnosed with diffuse parenchymal lung disease as an adult in the past three years would not be eligible for the primary clinical trial [SEP] Clinical Trial: NCT01964924,Entailment,0.85890126,0.1410987
NCT03069313,"Statement: sublingual application is used for the intervention in the primary clinical trial, in contrast to the oral method used in the secondary clinical trial. [SEP] Clinical Trial: NCT03069313",Entailment,0.7465142,0.2534858
NCT00749931,Statement: the secondary trial and the primary trial share at least one inclusion criteria. [SEP] Clinical Trial: NCT00749931,Entailment,0.8945486,0.10545136
NCT00586326,Statement: the primary clinical trial does not provide any guidance regarding the treatment cycle or describe it in the intervention section. [SEP] Clinical Trial: NCT00586326,Entailment,0.9266165,0.07338355
NCT00708019,Statement: instances of pain were frequent among the primary clinical trial patients across the 10 week span. [SEP] Clinical Trial: NCT00708019,Entailment,0.62696755,0.37303248
NCT01222390,"Statement: the interventions of the primary clinical trial and the secondary clinical trial do not include any x-rays, ultrasound, ct scans or mris. [SEP] Clinical Trial: NCT01222390",Entailment,0.6213054,0.37869456
NCT01314963,"Statement: encounter due to exposure to soil pollution is an icd encounter due to exposure to soil pollution. The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP. [SEP] Clinical Trial: NCT01314963",Contradiction,0.4101995,0.58980054
NCT01008150,"Statement: in the primary clinical trial, a pathologic complete response in breast and axillary lymph nodes was observed in more than 42 patients across both groups almost 7 months subsequent to their surgical procedures [SEP] Clinical Trial: NCT01008150",Contradiction,0.3136748,0.68632525
NCT00451555,"Statement: for entry into the primary clinical trial, participants are required to possess a resistance to both ai therapy and mirtazapine, however, this requirement is not present for inclusion in the secondary clinical trial. [SEP] Clinical Trial: NCT00451555",Entailment,0.7881712,0.21182886
NCT00587964,Statement: percentage times minute per hour is a unit of measurement expressed as the percentage times minutes divided by hours. General symptoms are the most common AE recorded in the primary trial. [SEP] Clinical Trial: NCT00587964,Contradiction,0.46796533,0.53203464
NCT00377156,"Statement: amnion nodosum is an amnion with nodular deposits of squamous and cellular debris with varying staging of re-epithelialization. Diagnosis of 2-3 cerebral metastases will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. [SEP] Clinical Trial: NCT00377156",Contradiction,0.3727285,0.62727153
NCT02239601,Statement: patient cohorts in the secondary clinical trial displayed marginally more total negative effects than those in the primary clinical trial. [SEP] Clinical Trial: NCT02239601,Entailment,0.7922456,0.20775437
NCT00262834,"Statement: 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients, apart from Skin infections. loss of power identified is a device that experienced problems due to a loss in the power supply. [SEP] Clinical Trial: NCT00262834",Entailment,0.5190046,0.48099542
NCT01106898,Statement: 0.97 of patients in the primary trial did not experience any adverse events [SEP] Clinical Trial: NCT01106898,Entailment,0.79414535,0.20585471
NCT03015649,Statement: the primary clinical trial and the secondary clinical trial recorded fewer than 50 total adverse events in their cohorts. [SEP] Clinical Trial: NCT03015649,Entailment,0.61858153,0.38141847
NCT00408681,"Statement: in the primary clinical trial, adverse events like recurrent malignancies, graft-versus-host disease, infection, altered mental status and diffuse alveolar hemorrhage were reported more often than in the secondary clinical trial. [SEP] Clinical Trial: NCT00408681",Entailment,0.556894,0.44310603
NCT02640053,Statement: intraosseous route of administration is administration within the marrow of the bone. Patients in the primary trial that didn‚Äö√Ñ√¥t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions. [SEP] Clinical Trial: NCT02640053,Entailment,0.54862046,0.4513795
NCT01106898,Statement: almost all participants in the primary clinical trial reported some form of adverse events' [SEP] Clinical Trial: NCT01106898,Entailment,0.8723489,0.12765108
NCT00372424,"Statement: since first time questionnaire was answered is a question about the status of an individual since the time when they first answered a questionnaire. All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events. [SEP] Clinical Trial: NCT00372424",Entailment,0.5886682,0.41133174
NCT02431676,Statement: anorexic patients are eligible for the primary trial. neither good nor bad is a subjective response indicating that something is neither good nor bad. [SEP] Clinical Trial: NCT02431676,Entailment,0.6358901,0.3641098
NCT00786838,Statement: the primary clinical trial administers both the placebo and trabectedin using a 3-hour intravenous infusion every other week. [SEP] Clinical Trial: NCT00786838,Entailment,0.54735607,0.452644
NCT02002533,Statement: both the primary and secondary clinical trials have documented a number of adverse events. [SEP] Clinical Trial: NCT02002533,Entailment,0.8779015,0.12209848
NCT00950911,"Statement: compared to the tamoxifen dosage in the secondary clinical trial's intervention 1, the dose of denosumab in the primary clinical trial's intervention 1 is multiplied by 12. [SEP] Clinical Trial: NCT00950911",Contradiction,0.3191533,0.68084663
NCT02273206,"Statement: The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type. [SEP] Clinical Trial: NCT02273206",Entailment,0.54354495,0.45645505
NCT01127763,Statement: one or more participants in the primary clinical trial experienced numerous adverse outcomes. [SEP] Clinical Trial: NCT01127763,Entailment,0.79126227,0.20873772
NCT01706081,"Statement: patients in the primary clinical trial, who underwent acupuncture, experienced more favourable modifications in their lymphedema than those treated with testosterone cream. [SEP] Clinical Trial: NCT01706081",Contradiction,0.43924478,0.56075525
NCT00971945,"Statement: stopped in car for few minutes in traffic is a question about an individual's activity of being in a car while stopped for a few minutes in traffic. the secondary trial  candidates must meet some Performance Status condition to participate, whereas this is not required to be accepted into the primary trial. [SEP] Clinical Trial: NCT00971945",Entailment,0.78342104,0.21657892
NCT00370552,"Statement: men of reproductive age and women who can bear children are suitable for the primary clinical trial, although they must align with further stipulations. [SEP] Clinical Trial: NCT00370552",Contradiction,0.4233405,0.5766595
NCT00365105,"Statement: a 28 year old patient with pathologically verified diagnosis of stage i prostate cancer, absolute neutrophil count of 500/μl, platelet count of 50,034/μl, hemoglobin level of 110 g/l, and a life expectancy less than 6 months would be ineligible to participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00365105",Entailment,0.7099072,0.29009283
NCT03092934,Statement: ccnd3 gene mutation is a change in the nucleotide sequence of the ccnd3 gene. patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer. [SEP] Clinical Trial: NCT03092934,Entailment,0.5900019,0.40999806
NCT00513292,"Statement: touchscreen is a control component that operates an electronic device by pressing the display on the screen. the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had much better results than arm 1. [SEP] Clinical Trial: NCT00513292",Contradiction,0.42997015,0.57002985
NCT00513292,"Statement: the primary clinical trial and the secondary clinical trial utilise different outcome measurements, pcr in the primary trial and mrcc in the secondary trial, with distinct results for each cohort. notably, in the primary trial, the difference between the two cohorts is significant, unlike the secondary trial where the performances of arm 1 and 2 are quite similar. [SEP] Clinical Trial: NCT00513292",Contradiction,0.32673636,0.6732636
NCT00553358,Statement: a patient who has had a complete resection of a tumour that was initially 3mm in radius would be unable to participate in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT00553358,Entailment,0.8203641,0.17963584
NCT01498458,Statement: the primary clinical trial recorded hepatotoxicity cases to be triple the combined count of hypertension and pancreatectomy incidents [SEP] Clinical Trial: NCT01498458,Contradiction,0.2839443,0.7160557
NCT01286987,Statement: the same therapeutic approach is applied to breast cancer and ovarian/peritoneal cancer patients participating in the primary clinical trial. [SEP] Clinical Trial: NCT01286987,Entailment,0.59387374,0.40612626
NCT02234479,"Statement: the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.8722857,0.12771423
NCT02761642,"Statement: cancer patients diagnosed with either fibromyalgia, thalasemic syndromes or anemia are allowed to participate in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02761642",Contradiction,0.36565647,0.6343435
NCT00467844,Statement: at least one patient treated with gtx-024 0.001mg in the primary trial gained over 100 kilos of lean body mass. [SEP] Clinical Trial: NCT00467844,Contradiction,0.47212055,0.5278794
NCT01967823,"Statement: in the primary clinical trial, all ae types impacted less than 10% of the patients [SEP] Clinical Trial: NCT01967823",Entailment,0.86039114,0.13960889
NCT00118157,Statement: Patients participating in the primary trial receive oral medication twice a day for a full month. [SEP] Clinical Trial: NCT00118157,Entailment,0.5951792,0.40482083
NCT01702571,Statement: several cardiac-related adverse events have been noted for cohort 1 in the primary clinical trial. [SEP] Clinical Trial: NCT01702571,Entailment,0.79849297,0.20150703
NCT02336737,Statement: there were no adverse events reported by the first group in the primary clinical trial [SEP] Clinical Trial: NCT02336737,Entailment,0.9010927,0.09890735
NCT01920061,"Statement: the primary trial uses a 1 year cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.9207092,0.07929084
NCT00687102,"Statement: in the primary and secondary clinical trials, there were a combined total of 3 cases of asthenia and 5 cases of pyrexia amongst the patient cohorts. [SEP] Clinical Trial: NCT00687102",Contradiction,0.2661467,0.7338533
NCT01766102,"Statement: in the primary clinical trial, the operative time was higher for arm 2 compared to arm 1, suggesting a better performance of the control group over the test group. however, in the secondary clinical trial, no control group exists for relevant comparisons. [SEP] Clinical Trial: NCT01766102",Entailment,0.88361984,0.116380185
NCT00929240,Statement: the primary clinical trial found the bevacizumab cohort's outcomes to be more favorable than those of the bevacizumab + capecitabine cohort. [SEP] Clinical Trial: NCT00929240,Entailment,0.7144779,0.28552204
NCT00662025,"Statement: CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle [SEP] Clinical Trial: NCT00662025",Entailment,0.54937184,0.45062813
NCT02179515,Statement: 100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event. northern sotho language is a niger-congo bantu language spoken primarily in south africa. [SEP] Clinical Trial: NCT02179515,Entailment,0.5746101,0.42538992
NCT01554371,Statement: those suffering from serious or undisciplined heart-related diseases are disqualified from taking part in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT01554371,Entailment,0.8720679,0.12793213
NCT00867217,Statement: patients diagnosed with lung cancer may be eligible for all study groups in the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00867217,Contradiction,0.26140466,0.7385953
NCT03384316,"Statement: picogram per milliliter per milligram per meter squared per day is a unit of concentration equal to picograms per milliliter, divided by milligrams per meter squared per day. All Infections and Infestations cases in the primary trial were for patients in cohort 1. [SEP] Clinical Trial: NCT03384316",Entailment,0.53083706,0.46916297
NCT01855828,"Statement: there was a single psychiatric adverse event in the primary trial, which affected fewer than 1 in 10 patients [SEP] Clinical Trial: NCT01855828",Entailment,0.74046916,0.25953078
NCT01383174,Statement: the results obtained from cohort 2 of the secondary clinical trial were more favorable compared to those from cohort 2 of the primary clinical trial. [SEP] Clinical Trial: NCT01383174,Entailment,0.79513836,0.20486158
NCT01023477,"Statement: patients with perfect potassium balance are the main target for the primary clinical trial, and those with hyperkalemia are usually excluded from the secondary clinical trial. [SEP] Clinical Trial: NCT01023477",Entailment,0.7486315,0.25136852
NCT01178411,Statement: the gender of a patient dictates whether they qualify for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01178411,Contradiction,0.30833802,0.691662
NCT01920061,"Statement: the primary trial uses a 21 day cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.9150387,0.0849613
NCT00708019,Statement: none of the patients in the primary trial experienced the worst pain imaginable for 1680 hours. [SEP] Clinical Trial: NCT00708019,Entailment,0.6849823,0.31501773
NCT02239601,Statement: the secondary clinical trial has reported marginally higher total adverse events in patient groups compared to the primary clinical trial. [SEP] Clinical Trial: NCT02239601,Entailment,0.8026393,0.19736072
NCT00871858,Statement: the primary clinical trial requires the application of paclitaxel in at least one of its interventions [SEP] Clinical Trial: NCT00871858,Entailment,0.7389404,0.26105958
NCT02640053,Statement: Patients in the primary trial that didn‚Äö√Ñ√¥t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy. family cancer history relative primary diagnosis question is a request to report the primary diagnosis for family members who were diagnosed with a neoplastic disease. [SEP] Clinical Trial: NCT02640053,Entailment,0.6062755,0.3937245
NCT01313117,"Statement: subjects participating in the primary clinical trial have a scheduled adjustment of alpha lipoic acid dosage, whereas those in the secondary clinical trial's first cohort have steady unchanged necitumumab quantities. [SEP] Clinical Trial: NCT01313117",Entailment,0.5359255,0.4640745
NCT00632489,Statement: the lbh589 and lapatinib group in the primary clinical trial achieved better outcomes compared to their lbh589 with capecitabine counterparts [SEP] Clinical Trial: NCT00632489,Entailment,0.7730878,0.2269122
NCT03069313,"Statement: the primary trial administers its intervention transdermally, and the secondary trial administers it intranasally. [SEP] Clinical Trial: NCT03069313",Entailment,0.59902054,0.40097952
NCT03403712,"Statement: the number of patients facing treatment-related side effects is the focus of the primary clinical trial, while the secondary clinical trial quantifies the average sleep duration of its patients. [SEP] Clinical Trial: NCT03403712",Contradiction,0.49473408,0.50526595
NCT02734979,"Statement: excellent, very good, or good health is a response indicating that an individual was in excellent, very good, or good health. Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial. [SEP] Clinical Trial: NCT02734979",Contradiction,0.4805909,0.5194091
NCT01129622,Statement: women who have both claustrophobia and ibs are eligible to participate in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT01129622,Contradiction,0.40803915,0.5919609
NCT00245050,"Statement: there were no placebo groups involved in the primary trial, which had two test groups and the secondary trial consisted of three separate test groups. [SEP] Clinical Trial: NCT00245050",Entailment,0.75246847,0.24753152
NCT01881230,Statement: Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin. retinopathy of prematurity stage 2 intraretinal ridge is an ophthalmoscopic finding that references retinopathy of prematurity characterized by the presence of an elevated ridge. [SEP] Clinical Trial: NCT01881230,Contradiction,0.41892913,0.5810709
NCT02413008,"Statement: the secondary trial and the primary trial use the same outcome measurement; the proportion of patients with pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy [SEP] Clinical Trial: NCT02413008",Contradiction,0.33739054,0.66260946
NCT00076024,Statement: There are no conditions on hepatic function for participants of the primary trial [SEP] Clinical Trial: NCT00076024,Entailment,0.9198683,0.08013174
NCT00418028,"Statement: whilst the primary clinical trial presents the time taken for progression recorded in months involving 156 patients from both cohorts, the secondary clinical trial records the number of patients that have undergone objective response [SEP] Clinical Trial: NCT00418028",Contradiction,0.26277584,0.73722416
NCT01129622,Statement: women who have claustrophobia and ibs cannot participate in either the primary clinical trial or the secondary clinical trial [SEP] Clinical Trial: NCT01129622,Entailment,0.68239707,0.31760296
NCT00896454,Statement: there is no uniform unit of measure utilized to report results between the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT00896454,Entailment,0.92601585,0.07398418
NCT00838929,Statement: vorinostat capsule ingestion on a daily basis throughout radiation therapy is a requirement for each patient involved in the primary clinical trial. [SEP] Clinical Trial: NCT00838929,Entailment,0.676498,0.32350203
NCT00878709,Statement: the first cohort of the primary clinical trial had more participants than the second cohort [SEP] Clinical Trial: NCT00878709,Entailment,0.76927686,0.23072311
NCT00992602,"Statement: compared to the secondary clinical trial, the primary clinical trial shows more instances of bronchopneumonia and general health decline. [SEP] Clinical Trial: NCT00992602",Entailment,0.5112294,0.48877054
NCT00838929,Statement: have enough support and advice to make choice is a question about whether an individual has enough support and advice to make a choice. Every patient in the primary trial is receives a dose of 100 to 1600 ¬¨¬µg fentanyl sublingual spray during radiation therapy. [SEP] Clinical Trial: NCT00838929,Contradiction,0.40020698,0.599793
NCT00429299,"Statement: candidates for the primary clinical trial must be her2 negative, based on ihc 0 or 1+ evaluation, and be able to self-care without the need for frequent medical supervision. [SEP] Clinical Trial: NCT00429299",Entailment,0.5205388,0.4794612
NCT00451555,"Statement: ai therapy responsiveness is required for participants to be enrolled in the primary clinical trial, this is also necessary for the inclusion into secondary clinical trial. [SEP] Clinical Trial: NCT00451555",Entailment,0.57471657,0.42528346
NCT01806675,Statement: only one study group in the primary clinical trial will undergo 18f-fdg and 18f-fpprgd2 pet/ct imaging procedures. [SEP] Clinical Trial: NCT01806675,Contradiction,0.44849628,0.5515037
NCT01527487,"Statement: cohort 1 in the primary clinical trial is given larger doses of cyclophosphamide compared to eribulin, whereas cohort 2 is given more substantial quantities of cyclophosphamide when compared to docetaxel. [SEP] Clinical Trial: NCT01527487",Contradiction,0.4869849,0.51301515
NCT01975831,"Statement: during the primary clinical trial, the one difference between interventions 1 and 2 is the lower dose of durva, 0.7mg/kg less, for the first cohort in their bi-weekly iv infusions comparative to the second cohort. [SEP] Clinical Trial: NCT01975831",Entailment,0.50033927,0.4996607
NCT01766102,"Statement: in the realm of the primary clinical trial, the control group evidenced better performance than the test group given the extended operative time of arm 2 over arm 1. still, it's impractical to draw comparisons in the secondary clinical trial due to the absence of a control group. [SEP] Clinical Trial: NCT01766102",Entailment,0.59582454,0.4041755
NCT00418028,"Statement: time to progression in months for a cumulative total of 156 patients from the two groups is reported in the primary clinical trial, contrasting to the secondary clinical trial which presents the volume of patients manifesting objective response [SEP] Clinical Trial: NCT00418028",Contradiction,0.31649786,0.68350214
NCT01770353,"Statement: the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections. vector genomes per milliliter is a unit for cloning vector amounts expressed as the number of vector genomes per milliliter. [SEP] Clinical Trial: NCT01770353",Contradiction,0.18080309,0.8191969
NCT01606748,"Statement: 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia. jingpo chinese is a chinese person from the jingpo ethnic group. [SEP] Clinical Trial: NCT01606748",Contradiction,0.472394,0.52760607
NCT00587964,Statement: the primary clinical trial frequently reports general symptoms as the most common adverse event [SEP] Clinical Trial: NCT00587964,Entailment,0.7956705,0.20432945
NCT00786838,Statement: the primary clinical trial administers trabectedin and the placebo via different methods. [SEP] Clinical Trial: NCT00786838,Entailment,0.91422814,0.08577182
NCT01855828,"Statement: there was a single psychiatric adverse incident in the primary clinical trial, impacting less than 10% of the patients [SEP] Clinical Trial: NCT01855828",Entailment,0.77492255,0.22507739
NCT00248547,Statement: xp22.2 is a chromosome band present on xp All Patients receiving the placebo intervention in the primary trial experienced emesis . [SEP] Clinical Trial: NCT00248547,Entailment,0.5074882,0.49251187
NCT01617668,"Statement: the majority of participants in the first cohort of the primary clinical trial experienced adverse events, while the situation is reversed in the second cohort. [SEP] Clinical Trial: NCT01617668",Entailment,0.81627226,0.18372773
NCT01111825,"Statement: ametropia is an optical condition in the eye where there is an error of refraction of light rays on the retina. cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+. [SEP] Clinical Trial: NCT01111825",Contradiction,0.38911986,0.6108801
NCT00956813,Statement: the secondary clinical trial and the primary clinical trial employ identical units of measurement when reporting outcomes. [SEP] Clinical Trial: NCT00956813,Entailment,0.8765334,0.12346662
NCT00365365,Statement: the primary trial participants do not receive any vaccines [SEP] Clinical Trial: NCT00365365,Entailment,0.9256627,0.07433732
NCT00451555,"Statement: Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial, but this is not necessary to be included in the secondary trial. douche solution dosage form is a solution intended for use as a vaginal irrigant. [SEP] Clinical Trial: NCT00451555",Entailment,0.60482293,0.39517707
NCT01171924,Statement: both cohorts in the primary clinical trial receive cudc-101 at equivalent doses and frequencies. [SEP] Clinical Trial: NCT01171924,Entailment,0.6410506,0.35894945
NCT02286843,Statement: none of the primary clinical trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases [SEP] Clinical Trial: NCT02286843,Entailment,0.63026047,0.36973953
NCT00702949,"Statement: in the primary clinical trial, a regimen of 150 mg of oral pregabalin twice daily is employed on a patient cohort, on the other hand, the treatment method in the secondary clinical trial involves the application of depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.3990992,0.60090077
NCT02404441,"Statement: the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups. [SEP] Clinical Trial: NCT02404441",Entailment,0.80495954,0.19504045
NCT01086605,Statement: several cases of hypertension were detected in both cohorts of the primary clinical trial. [SEP] Clinical Trial: NCT01086605,Contradiction,0.18491274,0.8150873
NCT00709761,Statement: fact-lym version 4 questionnaire question is a question associated with the fact-lym version 4 questionnaire. Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR). [SEP] Clinical Trial: NCT00709761,Entailment,0.5558178,0.44418222
NCT01222390,Statement: mris form a crucial part of the intervention strategies in the primary clinical trial as well as the secondary trial [SEP] Clinical Trial: NCT01222390,Contradiction,0.34552482,0.65447515
NCT02413008,"Statement: primary open angle glaucoma is a form of glaucoma in which there is no visible abnormality in the trabecular meshwork. the secondary trial and the primary trial use the same outcome measurement; the proportion of patients with pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy. [SEP] Clinical Trial: NCT02413008",Contradiction,0.35375324,0.6462468
NCT00454532,"Statement: diffuse midline glioma, h3 k27m-mutant is a diffuse midline glioma characterized by the presence of histone h3 k27m mutation. over 97% of patients in the secondary trial and the primary trial did not suffer any adverse events. [SEP] Clinical Trial: NCT00454532",Contradiction,0.3725155,0.6274845
NCT01013740,Statement: tumour lysis syndrome was not diagnosed in participants of either the primary or the secondary trial [SEP] Clinical Trial: NCT01013740,Entailment,0.89618886,0.10381116
NCT00583700,"Statement: women aged 18 or 19  are eligible for the secondary trial, but will need to wait 365-730 days to be eligible for the primary trial [SEP] Clinical Trial: NCT00583700",Contradiction,0.3924608,0.60753924
NCT00538850,"Statement: cdisc sdtm laboratory test name terminology is a terminology set that includes concepts contained in the cdisc laboratory test codelist. The the primary trial results report the Severity of Delayed Nausea on a scale of 1-7, and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. [SEP] Clinical Trial: NCT00538850",Contradiction,0.44938335,0.5506166
NCT01803282,Statement: none of the primary trial participants and none of the 1674 secondary trial participants experienced an ae. [SEP] Clinical Trial: NCT01803282,Entailment,0.8164446,0.18355545
NCT00709761,Statement: Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) . [SEP] Clinical Trial: NCT00709761,Contradiction,0.42799646,0.57200354
NCT01222390,"Statement: the interventions for the primary and secondary clinical trials do not require the need for x-rays, ultrasound, ct scans or mris. [SEP] Clinical Trial: NCT01222390",Contradiction,0.4485899,0.55141014
NCT00963911,Statement: candidates for the primary clinical trial are given an intervention that does not contain talazoparib [SEP] Clinical Trial: NCT00963911,Entailment,0.9172006,0.08279939
NCT01250379,"Statement: an older male patient with non-metastatic her2-negative, pr-negative breast cancer is eligible for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01250379",Contradiction,0.43091896,0.56908107
NCT02988986,Statement: after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression  . bilen language is an afro-asiatic language spoken by the bilen people in eritrea and eastern sudan. [SEP] Clinical Trial: NCT02988986,Contradiction,0.43403426,0.5659657
NCT00429182,"Statement: in the primary clinical trial, fewer than 50% of participants saw a decrease in circulating tumor cells after treatment with high-dose chemotherapy and cleansed autologous stem cell products. [SEP] Clinical Trial: NCT00429182",Entailment,0.62606615,0.37393388
NCT02038218,Statement: the results of the secondary clinical trial and the primary clinical trial are measured within different units. [SEP] Clinical Trial: NCT02038218,Entailment,0.9035252,0.09647485
NCT01770353,"Statement: both the primary clinical trial and the secondary clinical trial employ a unified protocol for drug, dosage and administration frequency. [SEP] Clinical Trial: NCT01770353",Contradiction,0.30201593,0.6979841
NCT01535040,Statement: the placebo intervention in the primary clinical trial is provided more frequently than the memantine intervention. [SEP] Clinical Trial: NCT01535040,Entailment,0.7940104,0.20598961
NCT03202472,"Statement: patients who have received chemotherapy or radiotherapy in the last 14 days, suffer from unstable angina, or have grade 7 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. [SEP] Clinical Trial: NCT03202472",Contradiction,0.43455818,0.5654418
NCT02259114,"Statement: luer valve device is a valve that incorporates a luer fitting. Patients with NUT midline carcinoma determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02259114",Contradiction,0.3794428,0.6205572
NCT01086605,"Statement: pamabrom is a mixture containing 2-amino-2-methyl-1-propanol and 8-bromotheophylline (a methylxanthine) in a 1:1 ratio, with mild diuretic activity. there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial. [SEP] Clinical Trial: NCT01086605",Entailment,0.58401525,0.41598475
NCT01855828,"Statement: ability to wash your back is a question about an individual's ability to wash their back. There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients. [SEP] Clinical Trial: NCT01855828",Entailment,0.68888503,0.311115
NCT00496860,Statement: cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2 [SEP] Clinical Trial: NCT00496860,Entailment,0.8496896,0.1503104
NCT00708019,Statement: unbearable pain for a duration of 10 weeks was reported by all individuals involved in the primary clinical trial. [SEP] Clinical Trial: NCT00708019,Entailment,0.65728575,0.34271422
NCT00454532,Statement: the majority of individuals in the primary and secondary clinical trials did not have any negative reactions [SEP] Clinical Trial: NCT00454532,Entailment,0.798597,0.20140298
NCT00418028,"Statement: the primary clinical trial recorded time to progression for 156 patients within two cohorts in days. however, the secondary clinical trial indicates the percentage of patients who had an objective response. [SEP] Clinical Trial: NCT00418028",Contradiction,0.36619374,0.6338062
NCT01023477,"Statement: Hypokalemic patients are excluded from the primary trial, but hyperkalemic patients may be eligible for the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01023477",Contradiction,0.32368937,0.6763106
NCT02312934,"Statement: sdha protein variant is a variation in the amino acid sequence for the succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial protein. alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. [SEP] Clinical Trial: NCT02312934",Entailment,0.5466685,0.4533315
NCT02988986,Statement: a 5% decrease in the percentage of cells expressing ki67 was observed in patients from the primary clinical trial following more than 6 weeks of treatment with tak-228 and tamoxifen [SEP] Clinical Trial: NCT02988986,Entailment,0.50205374,0.4979463
NCT00950911,Statement: The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial. [SEP] Clinical Trial: NCT00950911,Entailment,0.525203,0.474797
NCT01997333,Statement: no participant in cohort 1 was able to maintain a progression free survival longer than a month in the primary clinical trial [SEP] Clinical Trial: NCT01997333,Entailment,0.880612,0.119388014
NCT00373256,"Statement: cohort 1 and 2 in the primary clinical trial differ primarily based on the daily treatment received. cohort 1 receives 25 mg sunitinib daily, while 90 mg/m^2 paclitaxel is administered to cohort 2. [SEP] Clinical Trial: NCT00373256",Entailment,0.5129971,0.4870029
NCT01310075,Statement: a woman post-mastectomy may still qualify to participate in the primary or secondary clinical trial. [SEP] Clinical Trial: NCT01310075,Contradiction,0.37485066,0.62514937
NCT00558272,Statement: solid growth pattern is a microscopic finding indicating that the neoplastic cells are arranged in solid sheets in a tumor sample. The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.3873585,0.6126416
NCT00182793,"Statement: during the study period, infections affected more than 15% of patients in both the primary and secondary clinical trials [SEP] Clinical Trial: NCT00182793",Contradiction,0.44998917,0.55001086
NCT00766532,"Statement: the aes of the primary and secondary clinical trials only reflect symptoms of fatigue, nausea, and skin rashes. [SEP] Clinical Trial: NCT00766532",Contradiction,0.4121445,0.5878555
NCT01013740,Statement: In total there are less cases of anemia in the primary trial than in the secondary trial. choroid necrotic melanoma is a choroid melanoma characterized by the presence of tumor cell necrosis. [SEP] Clinical Trial: NCT01013740,Entailment,0.58762383,0.41237617
NCT01421472,"Statement: Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial. hand assisted laparoscopic radical nephrectomy is a radical nephrectomy procedure performed using hand assisted laparoscopy. [SEP] Clinical Trial: NCT01421472",Contradiction,0.41232568,0.5876743
NCT00791037,Statement: the primary clinical trial along with the secondary clinical trial measures the percentage of participants with disease-free survival (dfs). [SEP] Clinical Trial: NCT00791037,Entailment,0.5566384,0.4433616
NCT02115607,Statement: the primary trial recorded 11 more aes than the secondary trial [SEP] Clinical Trial: NCT02115607,Contradiction,0.3307901,0.6692099
NCT02431676,Statement: underweight patients may participate in the primary clinical trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.71103287,0.2889671
NCT00317603,Statement: syncope was the most prevalent adverse event in both the primary and secondary clinical trials patient cohorts [SEP] Clinical Trial: NCT00317603,Entailment,0.74503124,0.2549687
NCT02988986,Statement: over 3 years of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 1% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Entailment,0.6224923,0.37750766
NCT02961790,"Statement: individuals who have received antineoplastic chemotherapy, androgens, estrogens, or progestogens therapy within two years prior to the start of the study are not eligible for the primary clinical trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.82157785,0.17842218
NCT00828516,Statement: have itch is a question about whether an individual has or had itching. Neither the secondary trial or the primary trial use the Number of Participants With Treatment-emergent Aes as the outcome measurement for their studies. [SEP] Clinical Trial: NCT00828516,Contradiction,0.43816608,0.56183386
NCT00950911,Statement: citation description is a bibliographical reference in an acceptable format. The dosage of Zoledronic Acid  in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial. [SEP] Clinical Trial: NCT00950911,Contradiction,0.49660337,0.50339663
NCT00076024,Statement: thyroid gland lipoadenoma is a thyroid gland adenoma composed of follicular structures and mature adipocytes. There are no conditions on hepatic function for participants of the primary trial. [SEP] Clinical Trial: NCT00076024,Entailment,0.5357441,0.46425596
NCT00467844,Statement: All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period. protocol value is a value that is included as part of the study protocol. [SEP] Clinical Trial: NCT00467844,Contradiction,0.40984333,0.5901566
NCT01969448,"Statement: in the primary clinical trial, only catheter-based interventions are performed, without the use of any form of angiography. [SEP] Clinical Trial: NCT01969448",Entailment,0.777007,0.22299302
NCT02509156,"Statement: in the primary clinical trial, the allo-mscs intervention and the placebo intervention are administered in multiple transendocardial injections. [SEP] Clinical Trial: NCT02509156",Contradiction,0.23204963,0.7679504
NCT00266110,Statement: Patients in the primary trial will need to receive several injections [SEP] Clinical Trial: NCT00266110,Contradiction,0.42365503,0.57634497
NCT00558272,Statement: the zoledronic acid 4 mg group experienced a more significant percentage change in betactx at week 4 in the primary clinical trial compared to the azd0530 175 mg group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.49598837,0.50401163
NCT01554371,"Statement: mood is generally good and only occasionally affected by cancer is a response indicating that an individual is in generally good mood, only occasionally affected by their cancer. Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01554371",Entailment,0.6613893,0.3386107
NCT00632489,"Statement: in the primary clinical trial, the lbh589 and lapatinib cohort delivered better outcomes than the lbh589 with capecitabine group. [SEP] Clinical Trial: NCT00632489",Entailment,0.8318919,0.16810812
NCT00305695,"Statement: in the primary clinical trial, intervention 1 and in the secondary clinical trial, all intervention drugs require intravenous administration. [SEP] Clinical Trial: NCT00305695",Contradiction,0.3716205,0.6283795
NCT02179515,Statement: age in days at immunohistochemistry is age of subject (in days) at immunohistochemistry assessment. 100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event. [SEP] Clinical Trial: NCT02179515,Entailment,0.6290071,0.3709929
NCT00791037,Statement: soft tissue disorder is a non-neoplastic or neoplastic disorder that affects the soft tissue. the primary trial and the secondary trial evaluate the Percentage of Participants With Adverse Events of Primary Interest (AEPIs). [SEP] Clinical Trial: NCT00791037,Contradiction,0.49393162,0.50606835
NCT02312934,Statement: smokers are accepted for participation in the primary trial and the secondary trial has no restrictions on alcohol intake. [SEP] Clinical Trial: NCT02312934,Entailment,0.8219567,0.17804332
NCT00820872,Statement: Diarrhoea was more common for the primary trial participants than the secondary trial participants. pttg1 positive is an indication that pttg1 expression has been detected in a sample. [SEP] Clinical Trial: NCT00820872,Entailment,0.53821266,0.46178737
NCT02122796,"Statement: compared to the first cohort of the secondary clinical trial, the patients in the primary clinical trial are administered fewer doses of mm-121 and paclitaxel every week [SEP] Clinical Trial: NCT02122796",Entailment,0.5831737,0.41682634
NCT00553358,"Statement: a patient with a primary tumor, 3mm in size based on both physical examination and ultrasound imaging, is qualified to participate in both primary clinical trial and secondary clinical trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.44950292,0.5504971
NCT00454532,Statement: over 9/10ths of patients in the secondary trial and the primary trial did not suffer any adverse events [SEP] Clinical Trial: NCT00454532,Entailment,0.5727951,0.42720488
NCT00978250,Statement: histopathologically confirmed metastatic scbc patients are eligible to join the primary clinical trial. [SEP] Clinical Trial: NCT00978250,Contradiction,0.49656114,0.5034389
NCT00305695,"Statement: gene variant is a variation in the nucleic acid sequence of a specific gene. The intervention 1 in the primary trial is administered by IV, and all intervention drugs in the secondary trial can be administered orally. [SEP] Clinical Trial: NCT00305695",Entailment,0.50524867,0.4947513
NCT01434342,"Statement: cases of mucositis oral, thromboembolic events, and bladder infection were more prevalent in the primary trial than in the secondary trial [SEP] Clinical Trial: NCT01434342",Entailment,0.52022195,0.47977805
NCT03557801,"Statement: patients in the primary trial reported conditions of anemia, pneumonia, and stupor more frequently than those in the secondary trial. [SEP] Clinical Trial: NCT03557801",Entailment,0.5700649,0.4299351
NCT02038218,"Statement: the secondary trial and the primary trial use different units of measure in their results, for the same outcome measurement. diffusion weighted imaging is a diffusion mri technique in which diffusion-sensitizing gradients are applied to the imaging sequence. [SEP] Clinical Trial: NCT02038218",Entailment,0.65005404,0.34994593
NCT00416715,"Statement: individuals partaking in the secondary clinical trial are administered weekly subcutaneous injections, unlike the participants in the primary clinical trial who refrain from any injections. [SEP] Clinical Trial: NCT00416715",Entailment,0.86348295,0.13651706
NCT00429182,Statement: less than 0.10 of the primary trial participants had a reduction in circulating tumor cells following months of high-dose chemotherapy with purged autologous stem cell products [SEP] Clinical Trial: NCT00429182,Entailment,0.5955391,0.40446088
NCT02273206,Statement: all patients in cohort 1 of the primary clinical trial were behind schedule for their cervical cancer screenings before the intervention. [SEP] Clinical Trial: NCT02273206,Entailment,0.64753455,0.35246548
NCT00467844,Statement: no patient treated with gtx-024 1mg in the primary clinical trial experienced any gain in lean body mass. [SEP] Clinical Trial: NCT00467844,Entailment,0.72490644,0.27509353
NCT01451632,"Statement: Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2. have felt unusually tired during the day is a question about whether an individual has been feeling unusually tired during the day, on the average. [SEP] Clinical Trial: NCT01451632",Entailment,0.5444384,0.45556155
NCT02988986,Statement: a reduction of 10% in the percentage of cells with ki67 expression was noted in the patients of the primary trial following a month treatment with tak-228 plus tamoxifen [SEP] Clinical Trial: NCT02988986,Entailment,0.5046054,0.49539462
NCT01301729,Statement: the administration of trastuzumab in the primary clinical trial does not align with the dosage provided to patients in the cohort 2 of the secondary clinical trial [SEP] Clinical Trial: NCT01301729,Entailment,0.901561,0.098439
NCT03015649,Statement: the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts. cane or crutch needed most of time is a response indicating that a person requires use of one cane or crutch most of the time. [SEP] Clinical Trial: NCT03015649,Entailment,0.50280523,0.49719477
NCT01855828,"Statement: several psychiatric issues, including an eating disorder and schizophrenia, were reported as adverse events in the primary clinical trial [SEP] Clinical Trial: NCT01855828",Entailment,0.6866364,0.31336355
NCT00182793,Statement: infections occurred in over 15% of patients involved in both the primary and secondary clinical trials during the study period [SEP] Clinical Trial: NCT00182793,Contradiction,0.47185215,0.5281478
NCT02403271,Statement: quantitative chemistry is a subdiscipline of chemistry concerned with the study of reaction rates and equilibrium states of chemical reaction There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.5577081,0.44229186
NCT00432562,Statement: all inclusion and exclusion criteria are the same for both the primary and the secondary trial. [SEP] Clinical Trial: NCT00432562,Entailment,0.89565253,0.104347505
NCT01156987,"Statement: 100% of the participants in group 1 of the primary trial were found to have lesions, and only 5% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.3328407,0.6671593
NCT03125941,Statement: neither cohort 1 nor cohort 2 in the primary clinical trial receive dexamethasone; it is an exclusionary criterion. [SEP] Clinical Trial: NCT03125941,Entailment,0.87143314,0.12856688
NCT01194440,"Statement: patients with stage 3 hepatocellular carcinoma that is estrogen and progesterone receptor negative and on chemotherapy, are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01194440",Entailment,0.5101251,0.4898749
NCT00146172,Statement: candidates capable of only limited selfcare; confined to bed or chair about 10% of waking hours are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT00146172,Contradiction,0.3963916,0.6036084
NCT01023477,"Statement: patients suffering from hypokalemia are ineligible for the primary clinical trial. however, those with hyperkalemia can consider participating in both the primary and secondary clinical trial. [SEP] Clinical Trial: NCT01023477",Entailment,0.57050484,0.42949516
NCT01527487,Statement: calla positive lymphoblastic leukemia is acute lymphoblastic leukemia which is positive for the common acute lymphoblastic leukemia antigen. cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel. [SEP] Clinical Trial: NCT01527487,Contradiction,0.45511043,0.54488957
NCT00867217,"Statement: patients with a vitamin d deficiency are eligible for the primary trial, but may not qualify for the secondary trial. [SEP] Clinical Trial: NCT00867217",Entailment,0.8446731,0.15532693
NCT01171924,"Statement: primary amenorrhea is abnormally late or absent menarche in a female with normal secondary sexual characteristics. cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often. [SEP] Clinical Trial: NCT01171924",Contradiction,0.43706438,0.56293565
NCT01649271,"Statement: There was one case of shingles recorded in group 2 of the secondary trial, but no cases in group 1 of the secondary trial and the primary trial. aggravated neurofibromatosis is a condition causing exacerbation of the clinical features of neurofibromatosis. [SEP] Clinical Trial: NCT01649271",Contradiction,0.3704153,0.6295847
NCT00971945,"Statement: adult mixed glioma is a mixed glioma that occurs during adulthood. the secondary trial  candidates must be Completely disabled to participate, whereas this is not required to be accepted into the primary trial. [SEP] Clinical Trial: NCT00971945",Entailment,0.7739401,0.22605993
NCT01048099,Statement: the primary clinical trial recorded adverse events all of which affected not more than one patient individually [SEP] Clinical Trial: NCT01048099,Entailment,0.8939968,0.10600317
NCT00586326,Statement: the intervention mode of the primary clinical trial provides an explicit arrangement of treatment cycles including dosage and delivery of radiation therapy. [SEP] Clinical Trial: NCT00586326,Contradiction,0.39747122,0.60252875
NCT00432562,Statement: There are 0 shared inclusion/exclusion criteria between the secondary trial and the primary trial. how much did pain interfere with enjoyment of life is a question about how much a person's pain interferes or interfered with their enjoyment of life. [SEP] Clinical Trial: NCT00432562,Entailment,0.7369455,0.26305452
NCT00293384,"Statement: in the primary clinical trial's initial cohort, over half of the participants faced acute vomiting as a side effect of being treated with aprepitant, dexamethasone, cytoxan, and kytril [SEP] Clinical Trial: NCT00293384",Contradiction,0.46047577,0.53952426
NCT00293540,"Statement: On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months [SEP] Clinical Trial: NCT00293540",Contradiction,0.1935942,0.8064058
NCT01376349,"Statement: objective cognitive function scores, which are evaluated using cogstate, are used as units of measure in both the secondary clinical trial and the primary clinical trial. [SEP] Clinical Trial: NCT01376349",Entailment,0.5195607,0.48043928
NCT00428220,"Statement: Ascites was more common for patients in the primary trial, and Pneumocystis jirovecii pneumonia was more common in the secondary trial. [SEP] Clinical Trial: NCT00428220",Entailment,0.57868767,0.42131227
NCT02259114,"Statement: people with chronic lymphocytic leukemia or choriocarcinoma, established through cytogenetics, or infiltrating ductal carcinoma are prohibited from participating in the primary and the secondary trial. [SEP] Clinical Trial: NCT02259114",Entailment,0.7373824,0.26261756
NCT01591746,Statement: neither the primary clinical trial nor the secondary clinical trial cohort is given enteric-coated tablets [SEP] Clinical Trial: NCT01591746,Contradiction,0.44529396,0.554706
NCT00429299,Statement: All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+. substudy details is a textual description of the substudy. [SEP] Clinical Trial: NCT00429299,Contradiction,0.37622258,0.62377745
NCT00313170,Statement: eligible subjects for the primary clinical trial should have prostate cancer and need treatment through surgery. [SEP] Clinical Trial: NCT00313170,Contradiction,0.48409346,0.5159065
NCT00429182,"Statement: following high-dose chemotherapy with purged autologous stem cell products, less than half of the individuals involved in the primary clinical trial experienced a reduction in circulating tumor cells. [SEP] Clinical Trial: NCT00429182",Entailment,0.64608455,0.35391542
NCT00496860,"Statement: result classification is a category describing the result as distinguished by anatomical or physiological system, etiology, or purpose. cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2. [SEP] Clinical Trial: NCT00496860",Entailment,0.57557404,0.424426
NCT00313170,Statement: hormone therapy-requiring breast cancer patients are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT00313170,Entailment,0.6616747,0.33832535
NCT01783444,"Statement:  Women with Newly diagnosed stage IV breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. cancer treatment trial is a clinical study designed to evaluate biomedical or behavioral cancer interventions, generating safety data and efficacy information. [SEP] Clinical Trial: NCT01783444",Contradiction,0.21425325,0.78574675
NCT02761642,"Statement: the diagnosis of either fibromyalgia, thalasemic syndromes or anemia does not obstruct the eligibility of cancer patients for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02761642",Contradiction,0.2811896,0.7188104
NCT02306265,"Statement: candidates must undergo a Mammography before being able to participate in the primary trial, this is not required for the secondary trial. [SEP] Clinical Trial: NCT02306265",Entailment,0.8935865,0.1064134
NCT00741039,"Statement: in the primary clinical trial, pneumococcus vaccine is administered to the participants of the first cohort, while the influenza vaccine is given to the second cohort. [SEP] Clinical Trial: NCT00741039",Entailment,0.6855397,0.3144603
NCT00978250,Statement: patients who have a histological documentation of metastatic scbc are not eligible for the primary clinical trial. [SEP] Clinical Trial: NCT00978250,Entailment,0.8531539,0.14684619
NCT01451632,"Statement: Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention. thoracic procedure postoperative complication is any disorder occurring postoperatively as a consequence of a thoracic procedure. [SEP] Clinical Trial: NCT01451632",Contradiction,0.48453397,0.51546603
NCT01617668,Statement: adverse events were not reported in cohort 1 but were reported in cohort 2 in the primary clinical trial. [SEP] Clinical Trial: NCT01617668,Entailment,0.8184356,0.18156445
NCT02259114,"Statement: unmutated immunoglobulin heavy chain variable region gene is a molecular finding indicating that the immunoglobulin heavy chain variable region has an unmutated germline configuration. Patients with NUT midline carcinoma or Castrate-resistant prostate cancer, determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02259114",Contradiction,0.47420985,0.52579015
NCT00792077,"Statement: the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1, and the primary trial intervention lasts for a longer period of time. c3d format is a public domain, binary file format that is used to record synchronized 3d and analog motion capture data. [SEP] Clinical Trial: NCT00792077",Entailment,0.5386678,0.4613322
NCT01963481,Statement: working at a desk or table is a question about an individual's ability to work at a desk or table. Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01963481,Entailment,0.6641399,0.33586007
NCT00825682,Statement: the duration of intervention in the primary clinical trial extends 3 times longer than that of the secondary clinical trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.6551668,0.34483323
NCT01606748,"Statement: the first cohort of the primary clinical trial saw a single case of both anaemia and febrile neutropenia, however, there were no recorded instances of pancytopenia. [SEP] Clinical Trial: NCT01606748",Entailment,0.54750204,0.45249802
NCT00929240,Statement: peritoneal and retroperitoneal disorder is a non-neoplastic or neoplastic disorder that affects the peritoneum and/or retroperitoneum. the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort. [SEP] Clinical Trial: NCT00929240,Contradiction,0.48034617,0.5196538
NCT03202472,"Statement: Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. breast feels heavy is a question about whether an individual feels their breast is or was heavy. [SEP] Clinical Trial: NCT03202472",Contradiction,0.44775653,0.5522435
NCT00553358,"Statement: a patient that has a primary tumour with a radius of 0.003m measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.3089058,0.6910942
NCT01908101,Statement: attachment is a file or document affixed to another file or document. the primary trial and the secondary trial do not test the same drugs. [SEP] Clinical Trial: NCT01908101,Entailment,0.9228253,0.07717471
NCT00293384,"Statement: lung large cell carcinoma is an undifferentiated non-small cell lung carcinoma composed of large polygonal cells without evidence of glandular, squamous, or neuroendocrine differentiation. Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril. [SEP] Clinical Trial: NCT00293384",Contradiction,0.39745092,0.602549
NCT01313117,"Statement: the secondary clinical trial administers higher doses of necitumumab during the duration of the cohort 1 study, while the primary clinical trial provides a fixed dosage of alpha lipoic acid. [SEP] Clinical Trial: NCT01313117",Entailment,0.5564699,0.4435301
NCT00843167,"Statement: the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. ovarian sex cord-stromal tumor associated with peutz-jeghers syndrome is a sex cord-stromal tumor that arises from the ovary in a patient diagnosed with peutz-jeghers syndrome. [SEP] Clinical Trial: NCT00843167",Contradiction,0.4009207,0.5990793
NCT01376349,"Statement: primary anatomic site code is a coded value specifying the anatomic site of the entity. Neither the secondary trial or the primary trial use cm, Number of Participants or a unit of time as their units of measure. [SEP] Clinical Trial: NCT01376349",Contradiction,0.4365958,0.56340414
NCT00245050,"Statement: centimeter of water per milliliter is a unit of measure for pressure change that is expressed in cmh2o per milliliter. the primary trial had one test group and one placebo group, the secondary trial had 2 test groups. [SEP] Clinical Trial: NCT00245050",Contradiction,0.45470962,0.54529035
NCT02115607,Statement: the primary and the secondary trial reported an equal number of intestinal perforation cases [SEP] Clinical Trial: NCT02115607,Entailment,0.5576308,0.4423692
NCT01138046,Statement: the primary clinical trial and the secondary clinical trial are open to any person who is a national of japan. [SEP] Clinical Trial: NCT01138046,Contradiction,0.45470864,0.5452913
NCT02259114,Statement: both the primary clinical trial and the secondary clinical trial accept patients with fluorescence in situ hybridization-identified nut midline carcinoma or inflammatory breast cancer. [SEP] Clinical Trial: NCT02259114,Contradiction,0.409989,0.590011
NCT00558272,Statement: dna adduct is a structure formed when a chemical is attached to dna by a covalent bond. The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.45470992,0.5452901
NCT00475085,"Statement: although the primary clinical trial discloses the overall count of participants included in the study, it does not state the number of participants within each cohort. [SEP] Clinical Trial: NCT00475085",Entailment,0.9164212,0.08357876
NCT01975831,"Statement: intellectual well-being is a question regarding the status of one's mental capacity and ability to think clearly, concentrate, and remember things. The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2. [SEP] Clinical Trial: NCT01975831",Contradiction,0.3674064,0.6325936
NCT00253708,"Statement: the primary trial evaluates three types of drug-based treatments, whereas the secondary trial does not test any medication. [SEP] Clinical Trial: NCT00253708",Entailment,0.92187953,0.078120425
NCT00496860,Statement: cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2. proton is a fundamental particle with a positive charge. [SEP] Clinical Trial: NCT00496860,Entailment,0.5763179,0.4236821
NCT00256217,"Statement: all patients in the primary clinical trial reported experiencing at least one adverse event, while those in the secondary clinical trial completed it without any adverse events. [SEP] Clinical Trial: NCT00256217",Entailment,0.75475484,0.24524511
NCT01537029,"Statement: venezuela, bolivarian republic of is a country in northern south america, bordering the caribbean sea and the north atlantic ocean, between colombia and guyana. Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.40035322,0.59964675
NCT00911898,Statement: the primary clinical trial's intervention section solely demands pharmacological approaches. [SEP] Clinical Trial: NCT00911898,Entailment,0.87711024,0.122889735
NCT01008150,Statement: 0% patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 4 weeks of the study [SEP] Clinical Trial: NCT01008150,Entailment,0.6210712,0.3789288
NCT00702949,"Statement: in the primary trial, a patient cohort is treated with 150 mg of pregabalin injected intravenously every fortnight for over 6 weeks, in contrast, the secondary trial provides its patient cohort with a treatment of marqibo and ifosfamide. [SEP] Clinical Trial: NCT00702949",Contradiction,0.4256852,0.57431483
NCT00687102,Statement: there are no reported cases of asthenia or pyrexia in the patients of the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT00687102,Entailment,0.6427939,0.35720617
NCT02961790,"Statement: about as socially active as before is a response indicating that an individual has been about as socially active as before. Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.61096185,0.38903812
NCT00838929,Statement: every patient in the primary trial is receives a dose of 100 to 1600 microgram fentanyl sublingual spray during radiation therapy [SEP] Clinical Trial: NCT00838929,Contradiction,0.46320835,0.5367917
NCT01045421,Statement: patients with Histologically or cytologically confirmed metastatic and/or advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial [SEP] Clinical Trial: NCT01045421,Contradiction,0.4057584,0.5942416
NCT02178722,"Statement: neisseria gonorrhoeae, penicillinase negative is any bacterial species identified as neisseria gonorrhoeae that does not produce the enzyme penicillinase. the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib. [SEP] Clinical Trial: NCT02178722",Entailment,0.61615676,0.3838433
NCT02286843,Statement: none of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases [SEP] Clinical Trial: NCT02286843,Entailment,0.6399329,0.36006713
NCT01920061,"Statement: the primary trial uses a 1 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. benign pericardial neoplasm is a non-metastasizing neoplasm that arises from the pericardium. [SEP] Clinical Trial: NCT01920061",Entailment,0.86398673,0.1360133
NCT00766532,"Statement: a number of instances of swelling, hypothermia, and confusion have been documented in the adverse events of both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00766532",Entailment,0.6792132,0.3207868
NCT01419717,"Statement: the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid. [SEP] Clinical Trial: NCT01419717",Contradiction,0.3879018,0.6120982
NCT02599194,Statement: Aes were not recorded for the primary trial or the secondary trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.8032536,0.19674635
NCT00076024,Statement: a specific level of hepatic enzyme in the blood is required to participate in the primary clinical trial. [SEP] Clinical Trial: NCT00076024,Entailment,0.67383116,0.3261688
NCT00405938,"Statement: a history of conditions such as abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess, or serious psychiatric illnesses within the preceding six months disqualifies patients from participation in the primary clinical trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.47684324,0.52315676
NCT00373256,"Statement: The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab [SEP] Clinical Trial: NCT00373256",Contradiction,0.40390977,0.59609026
NCT00451555,"Statement: involvement in the primary clinical trial calls for participants to be unresponsive to ai therapy and mirtazapine, but this is not a criterion for the secondary clinical trial. [SEP] Clinical Trial: NCT00451555",Entailment,0.65522647,0.34477347
NCT02404441,"Statement: the secondary clinical trial maintains identical inclusion and exclusion criteria for all its subjects, as opposed to the primary clinical trial, which establishes two distinct sets of eligibility conditions for its diverse study groups. [SEP] Clinical Trial: NCT02404441",Entailment,0.6273117,0.3726883
NCT00538850,"Statement: the the primary trial results report the severity of delayed nausea on a scale of 1-10, and the secondary trial measures the change from baseline to 18 months in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850",Contradiction,0.46936494,0.53063506
NCT01252290,Statement: all 100% of patients in the primary trial suffered aes [SEP] Clinical Trial: NCT01252290,Entailment,0.6269057,0.37309432
NCT00698035,"Statement: the primary clinical trial is applying immuno-oncology techniques, and the secondary clinical trial is using chemotherapy. [SEP] Clinical Trial: NCT00698035",Contradiction,0.3369406,0.6630595
NCT00496860,Statement: gain of chromosome 17q is a cytogenetic abnormality that refers to the duplication of all or part of the long arm of chromosome 17. cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2. [SEP] Clinical Trial: NCT00496860,Entailment,0.646693,0.353307
NCT02179515,Statement: the participants of cohort 1 of the primary clinical trial did not report adverse events [SEP] Clinical Trial: NCT02179515,Entailment,0.9184646,0.08153539
NCT03557801,"Statement: patients in the secondary clinical trial experienced anemia, pneumonia and stupor more frequently than those in the primary clinical trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.44183367,0.5581663
NCT01606748,"Statement: in the primary clinical trial, multiple instances of anaemia and febrile neutropenia were registered in cohort 1, along with numerous cases of pancytopenia. [SEP] Clinical Trial: NCT01606748",Contradiction,0.2666287,0.7333713
NCT03092934,Statement: patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic. non-continuous spinal cord parenchymal is a description that locations of interest are non-continuous and within the spinal parenchyma. [SEP] Clinical Trial: NCT03092934,Contradiction,0.41265562,0.58734435
NCT01963481,Statement: patients with a diagnosis of severe insomnia are not eligible for either the primary or secondary clinical trial [SEP] Clinical Trial: NCT01963481,Entailment,0.8424116,0.1575884
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation,postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 43 hours if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.36539492,0.6346051
NCT00428220,"Statement: japanese is a person having origins in any of the original peoples of japan.. Pericardial effusions were more common for patients in the primary trial, and Corneal deposits were more common in the secondary trial. [SEP] Clinical Trial: NCT00428220",Contradiction,0.459197,0.54080296
NCT01614210,Statement: results from the primary trial show that tamoxifen 100 mg po daily for 50 days prior to surgery and for 60 days after breast cancer surgery reduces the diameter of tumors by 70% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.32112697,0.678873
NCT01629615,Statement: eating disorders were not common for the primary trial candidates [SEP] Clinical Trial: NCT01629615,Entailment,0.900105,0.09989492
NCT02807844,Statement: All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks. other investigational agent is an investigational agent that is not the lead agent being investigated in a clinical trial. [SEP] Clinical Trial: NCT02807844,Entailment,0.86415476,0.13584526
NCT01194440,Statement: patients diagnosed with ductal carcinoma in situ and contemplating ai therapy are suitable for the primary clinical trial. [SEP] Clinical Trial: NCT01194440,Entailment,0.51055455,0.48944545
NCT00182793,Statement: both the primary clinical trial and the secondary clinical trial reported a minimum of one infection case [SEP] Clinical Trial: NCT00182793,Entailment,0.70610744,0.29389253
NCT00686127,"Statement: the primary trial observes less adverse events in total than the secondary trial, yet higher counts of cardiac-ischemia/infarction are reported in the primary trial. [SEP] Clinical Trial: NCT00686127",Contradiction,0.44668978,0.5533102
NCT02179515,Statement: not a single life-threatening adverse event was registered among cohort 1 participants in the primary clinical trial. [SEP] Clinical Trial: NCT02179515,Entailment,0.876422,0.12357805
NCT01127763,Statement: none of the patients in the primary clinical trial experienced any adverse events. [SEP] Clinical Trial: NCT01127763,Entailment,0.8942784,0.105721526
NCT02336737,"Statement: in the first cohort of the primary clinical trial, there were no instances of adverse events, whereas almost every individual in the second cohort encountered at least one [SEP] Clinical Trial: NCT02336737",Entailment,0.73370236,0.26629764
NCT00429182,"Statement: in the primary clinical trial, under a tenth of the participants experienced a decline in circulating tumor cells after months of high-dose chemotherapy accompanied by purged autologous stem cell products. [SEP] Clinical Trial: NCT00429182",Contradiction,0.44463897,0.55536103
NCT00429299,Statement: primary clinical trial enrollment is open to individuals with her2 negative tumors according to ihc 1+ scores and those who have minimal need for medical care or assistance. [SEP] Clinical Trial: NCT00429299,Entailment,0.5318581,0.4681419
NCT02796755,Statement: the primary trial and the secondary trial do not have any recorded adverse events for their participants. [SEP] Clinical Trial: NCT02796755,Entailment,0.92604136,0.073958606
NCT01706081,"Statement: in the primary clinical trial, changes in lymphedema were notably better in acupuncture patients compared to those treated with testosterone cream. [SEP] Clinical Trial: NCT01706081",Entailment,0.5349244,0.4650756
NCT01286168,"Statement: vomiting was the most prevalent adverse event recorded in the primary clinical trial, with an incidence rate above 10%, whereas the secondary clinical trial did not register any adverse events. [SEP] Clinical Trial: NCT01286168",Entailment,0.79373956,0.20626049
NCT00896454,Statement: the secondary trial and the primary trial report results using the same Unit of Measure. spinal leptomeningeal distant disease type is an indication the distant disease type is spinal/leptomeningeal. [SEP] Clinical Trial: NCT00896454,Contradiction,0.38556588,0.61443406
NCT01869192,"Statement: the evidence from the primary clinical trial indicates that the overall response rate was higher in the placebo arm than in arm a intervention. on the other hand, the zoledronic acid group in the secondary clinical trial displayed a superior time to first on-study sre as against the denosumab group. [SEP] Clinical Trial: NCT01869192",Contradiction,0.49947092,0.50052905
NCT02807844,Statement: there are patients in the primary clinical trial who do not receive mcs110 at all. [SEP] Clinical Trial: NCT02807844,Entailment,0.91357994,0.086420044
NCT01806259,"Statement: in the primary clinical trial, the nacl 0.9% 3ml group showed a higher recurrence-free survival rate than the ketorolac 30 mg group [SEP] Clinical Trial: NCT01806259",Entailment,0.6057562,0.3942438
NCT00256217,Statement: every patient in the primary clinical trial experienced at least five distinct adverse events. [SEP] Clinical Trial: NCT00256217,Entailment,0.88668907,0.113310896
NCT02640053,Statement: legacy project is an indication that project information or documentation has been deprecated. Patients in the primary trial that didn‚Äö√Ñ√¥t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions. [SEP] Clinical Trial: NCT02640053,Entailment,0.6482276,0.35177243
NCT00416715,"Statement: while secondary trial participants are required to take oral medication, those enrolled in the primary clinical trial receive daily sc injections. [SEP] Clinical Trial: NCT00416715",Contradiction,0.43546727,0.5645327
NCT01434342,"Statement: the primary trial documented more instances of mucositis oral, thromboembolic events and bladder infection than the secondary trial [SEP] Clinical Trial: NCT01434342",Contradiction,0.39720985,0.6027902
NCT00416715,"Statement: infigratinib regimen is a regimen consisting of infigratinib that can be used for the treatment of hepatobiliary cancers. Candidates for the secondary trial study group receive 3 weekly subcutaneous (SC) injections, whereas the primary trial participants only receive a single injection at the beginning of the study. [SEP] Clinical Trial: NCT00416715",Contradiction,0.48777375,0.5122263
NCT00253708,"Statement: human papillomavirus-negative squamous cell carcinoma is a squamous cell carcinoma not associated with human papilloma virus infection. the primary trial does not test any drug based treatments, whereas the secondary trial tests two different drugs. [SEP] Clinical Trial: NCT00253708",Entailment,0.80852836,0.19147164
NCT01290536,"Statement: in the primary clinical trial, theraspheres are used in radioembolization as the chosen intervention, as opposed to the secondary clinical trial that uses ibrutinib and medi4736 for its intervention. [SEP] Clinical Trial: NCT01290536",Entailment,0.50434995,0.49565005
NCT03202472,"Statement: Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial, unless they have non-healing surgical wounds. diagnosis pathologically confirmed indicator is an indication whether the subject's diagnosis has been confirmed using histopathology. [SEP] Clinical Trial: NCT03202472",Contradiction,0.45419845,0.5458016
NCT01908101,Statement: the primary clinical trial and the secondary clinical trial are investigating the same pharmaceutical agent' [SEP] Clinical Trial: NCT01908101,Entailment,0.8032111,0.19678897
NCT00911898,Statement: infant acute undifferentiated leukemia is an acute undifferentiated leukemia that occurs in infancy. The the primary trial intervention section requires surgical and imaging procedures. [SEP] Clinical Trial: NCT00911898,Contradiction,0.40229937,0.5977006
NCT03202472,"Statement: feeding ability is a question about an individual's ability to self feed. Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. [SEP] Clinical Trial: NCT03202472",Contradiction,0.41645563,0.5835444
NCT02431676,Statement: patients dealing with anorexia are suitable for the primary clinical trial [SEP] Clinical Trial: NCT02431676,Entailment,0.5702761,0.42972395
NCT00319748,Statement: Neither the secondary trial or the primary trial measure the percentage of participants in their studies that experience Clinical Benefit (using (RECIST) criteria). off study reason code is a coded value specifying why the subject is removed from a study. [SEP] Clinical Trial: NCT00319748,Entailment,0.6622949,0.33770502
NCT02761642,"Statement: validation batch is a batch intended for use in verification and demonstration of suitability of the designed process. Any cancer patient diagnosed with either fibromyalgia, thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02761642",Entailment,0.60151106,0.3984889
NCT00319748,Statement: both the primary and secondary clinical trials comprise methods to examine the transformation in  ki67 expression in tumors. [SEP] Clinical Trial: NCT00319748,Contradiction,0.38158876,0.6184113
NCT03092934,"Statement: the primary clinical trial is open to patients of all genders, provided they demonstrate evidence of er negative breast cancer, for each of its phases. [SEP] Clinical Trial: NCT03092934",Entailment,0.65260035,0.34739962
NCT00321048,"Statement: Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer. leptospiraceae is a taxonomic family of mostile bacterium in the phylum spirochaetes that includes the genera leptospira and turneriella, among others. [SEP] Clinical Trial: NCT00321048",Contradiction,0.3252751,0.67472494
NCT01086605,Statement: edema was a common adverse event in the primary trial [SEP] Clinical Trial: NCT01086605,Entailment,0.8159858,0.18401423
NCT01702571,Statement: all the adverse events reported in the first cohort of the primary clinical trial are associated with psychological health issues. [SEP] Clinical Trial: NCT01702571,Entailment,0.62354976,0.37645024
NCT02431676,Statement: only patients with healthy eating habits and nutrition are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.5958012,0.40419883
NCT01013740,Statement: a number of patients involved in both the primary clinical trial and the secondary clinical trial were afflicted with tumour lysis syndrome. [SEP] Clinical Trial: NCT01013740,Contradiction,0.38874808,0.6112519
NCT00513292,"Statement: os is the determinant of outcome measurement in both the primary and secondary trials. the primary trial cohorts show marked difference in their results. in the secondary trial, arm 1 manifests better outcomes than arm 2, as fewer arm 1 patients experienced os. [SEP] Clinical Trial: NCT00513292",Entailment,0.5428206,0.45717946
NCT00357734,"Statement: the primary clinical trial involves the use of a single medication, zd1839, in contrast, the secondary clinical trial necessitates the use of a minimum of three distinct medications, to include zoledronic acid, samarium-153 and pegfilgrastim. [SEP] Clinical Trial: NCT00357734",Contradiction,0.42596188,0.57403815
NCT00999921,Statement: Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial. [SEP] Clinical Trial: NCT00999921,Entailment,0.8105622,0.18943776
NCT00118157,Statement: Patients participating in the primary trial receive oral medication twice a day for a full month. f-actin is a fibrillar actin polymer. [SEP] Clinical Trial: NCT00118157,Contradiction,0.4779999,0.52200013
NCT00971945,"Statement: the secondary trial requires candidates to have a fully functional mobility to participate, with this prime requirement also present in the primary clinical trial [SEP] Clinical Trial: NCT00971945",Entailment,0.5401168,0.45988324
NCT01127763,"Statement: in the primary clinical trial, at least one patient experienced multiple adverse incidents. [SEP] Clinical Trial: NCT01127763",Entailment,0.81145835,0.18854164
NCT01314963,"Statement: the variance in the primary clinical trial's interventions is in the dosage of tc99m sulfur colloid, with intervention 1 utilizing a significantly higher amount than intervention 2. [SEP] Clinical Trial: NCT01314963",Contradiction,0.3953716,0.60462844
NCT02413008,Statement: the secondary trial and the primary trial use different outcome measurements and units of measure. concomitant medication start relative to reference timepoint is an indication or description of the start of concomitant medication usage in relation to a specific point in time. [SEP] Clinical Trial: NCT02413008,Entailment,0.8588494,0.14115058
NCT01256567,Statement: a patient that has undergone a kidney transplant in the past week is eligible for the primary clinical trial but will not qualify for the secondary clinical trial [SEP] Clinical Trial: NCT01256567,Entailment,0.84899586,0.15100414
NCT02988986,Statement: after 720 hours of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 1/10 reduction in the proportion of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Entailment,0.5310392,0.4689608
NCT00759785,Statement: a greater proportion of participants in the triple negative group of the primary clinical trial demonstrated a decrease in the growth factor signature than in the er-positive luminal b group [SEP] Clinical Trial: NCT00759785,Entailment,0.5958833,0.40411672
NCT02761642,"Statement: complaint is a symptom or problem for which a patient seeks medical attention. Any cancer patient diagnosed with either fibromyalgia, thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02761642",Entailment,0.69653463,0.30346537
NCT03092934,"Statement: females with evidence of er positive, her2 negative breast cancer are eligible for the primary trial. [SEP] Clinical Trial: NCT03092934",Entailment,0.6640702,0.3359298
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 1000 mg of fulvestrant in a tablet form to be taken bid. [SEP] Clinical Trial: NCT00836186",Contradiction,0.38587704,0.614123
NCT00320541,"Statement: in the primary clinical trial, the group using paclitaxel plus bevacizumab recorded a higher orr than the group using paclitaxel plus bevacizumab plus gemcitabine. [SEP] Clinical Trial: NCT00320541",Entailment,0.633053,0.366947
NCT00836186,"Statement: the participants of the primary clinical trial receive high-intensity focused ultrasound therapy, while the two cohorts in the secondary clinical trial receive a daily intravenous injection of 500 mg fulvestrant. [SEP] Clinical Trial: NCT00836186",Contradiction,0.4363424,0.5636576
NCT03346161,Statement: adverse events were documented in both cohorts participating in the primary clinical trial [SEP] Clinical Trial: NCT03346161,Entailment,0.88386995,0.11613012
NCT01997333,"Statement: in the primary clinical trial, the patient who survived the longest, 3.5 months, without disease progression or death was from cohort 1 [SEP] Clinical Trial: NCT01997333",Entailment,0.694357,0.30564302
NCT01803282,"Statement: squamous differentiation is a microscopic finding indicating the presence of cells with squamous differentiation in a tumor sample. 0/7 the primary trial participants, and 0/1674 the secondary trial participants suffered an AE. [SEP] Clinical Trial: NCT01803282",Entailment,0.50712854,0.4928715
NCT00656019,"Statement: several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes. human papillomavirus-related mucosal head and neck squamous cell carcinoma is a squamous cell carcinoma associated with human papilloma virus, arising from the mucosal sites of head and neck. [SEP] Clinical Trial: NCT00656019",Contradiction,0.23770592,0.76229405
NCT01803282,"Statement: 20/73 the primary trial participants, and 23/10 the secondary trial participants suffered an acute myocardial infarction [SEP] Clinical Trial: NCT01803282",Contradiction,0.32980573,0.6701942
NCT00756496,"Statement: in the primary clinical trial, all group outcomes showed no considerable variations, but the reflexology group and control group displayed some significant differences in the secondary clinical trial. [SEP] Clinical Trial: NCT00756496",Entailment,0.5473654,0.45263457
NCT00867217,Statement: patients diagnosed with breast cancer may not be eligible for any study groups in the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00867217,Entailment,0.62472814,0.37527186
NCT01920061,"Statement: for its treatment, the primary clinical trial does not conform to a specific cycle arrangement, but rather stands on a comprehensive, ongoing regimen. the secondary clinical trial, in contrast, implements an intensive, monthly cycle intervention. [SEP] Clinical Trial: NCT01920061",Contradiction,0.48476067,0.51523936
NCT00467844,Statement: study procedure deviation is an indication that a protocol deviation involved the trial processes or procedures defined in the study protocol. at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass. [SEP] Clinical Trial: NCT00467844,Contradiction,0.4771811,0.52281886
NCT01194440,"Statement: chryseobacterium is a genus of aerobic, gram negative, rod shaped bacterium in the phylum bacteroidetes and the family flavobacteriaceae. Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial. [SEP] Clinical Trial: NCT01194440",Contradiction,0.36359903,0.636401
NCT01086605,"Statement: there were 150 cases of hypertension, dehydration and dyspnea in either cohort of the primary trial [SEP] Clinical Trial: NCT01086605",Contradiction,0.28108162,0.7189184
NCT00586326,Statement: the intervention segment of the primary clinical trial lacks definition or explanation of a treatment cycle. [SEP] Clinical Trial: NCT00586326,Entailment,0.9231789,0.076821126
NCT01290536,"Statement: The the primary trial intervention consists of Radioembolization using TheraSpheres, on the other hand the secondary trial intervention is based on ibrutinib and MEDI4736. half pint is a non-si unit of volume equal to 8 fluid ounces or 0.2365 liter. [SEP] Clinical Trial: NCT01290536",Contradiction,0.37506655,0.6249335
NCT00656305,"Statement: several mortalities and admissions to the hospital occurred in the second cohort of the primary clinical trial, and atrial fibrillation was also frequently detected. [SEP] Clinical Trial: NCT00656305",Contradiction,0.3858394,0.6141606
NCT01881230,Statement: Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin [SEP] Clinical Trial: NCT01881230,Contradiction,0.48705974,0.5129402
NCT01969448,Statement: laser-assisted fluorescence angiography along with lateral radial incisions are employed for both interventions in the primary clinical trial. [SEP] Clinical Trial: NCT01969448,Contradiction,0.3699868,0.63001317
NCT00320541,Statement: The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group [SEP] Clinical Trial: NCT00320541,Entailment,0.77487767,0.22512235
NCT01806259,Statement: the ketorolac 30000 mcg group of the primary trial had a -6.4% recurrence-free survival compared to the nacl 0.9% 3ml group [SEP] Clinical Trial: NCT01806259,Entailment,0.5645159,0.43548414
NCT01314963,Statement: The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2. sgk1 gene mutation is a change in the nucleotide sequence of the sgk1 gene. [SEP] Clinical Trial: NCT01314963,Entailment,0.5350455,0.46495447
NCT00475085,"Statement: the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort. [SEP] Clinical Trial: NCT00475085",Entailment,0.8986982,0.10130186
NCT00698035,"Statement: the primary clinical trial focuses on chemotherapeutic interventions, and the secondary clinical trial centers on radiation therapy. [SEP] Clinical Trial: NCT00698035",Contradiction,0.43127283,0.56872714
NCT00248547,Statement: All Patients receiving the placebo intervention in the primary trial experienced emesis  [SEP] Clinical Trial: NCT00248547,Entailment,0.6160181,0.3839819
NCT00918281,Statement: cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine by IV. volume alarm device is a device designed to signal that a gas volume level is outside of an established range. [SEP] Clinical Trial: NCT00918281,Entailment,0.5266704,0.4733296
NCT00978250,Statement: Patients with histologically documented metastatic SCBC are excluded from the primary trial. [SEP] Clinical Trial: NCT00978250,Entailment,0.8378793,0.16212064
NCT00075764,"Statement: the primary clinical trial welcomes patients diagnosed with tx nx mx, t0 nx m0, or t1 n1 m1 tumors [SEP] Clinical Trial: NCT00075764",Contradiction,0.48383904,0.51616096
NCT00800436,"Statement: previous use of gabapentin or pregabalin will disqualify a patient from participation in the secondary clinical trial, but not in the primary clinical trial. [SEP] Clinical Trial: NCT00800436",Entailment,0.66113424,0.33886576
NCT01706081,Statement: Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list. [SEP] Clinical Trial: NCT01706081,Entailment,0.6873523,0.31264767
NCT02504424,Statement: Nobody taking part in the primary trial suffered a UTI [SEP] Clinical Trial: NCT02504424,Entailment,0.896256,0.10374392
NCT01156987,Statement: various participants of group 1 in the primary clinical trial had clear evidence of skin lesions; under 10% of participants in group 1 of the secondary clinical trial showed symptoms of radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987,Contradiction,0.3678869,0.6321131
NCT00687102,Statement: mouth partial response gvhd is an nih modified oral mucosa rating scale (omrs) score that has decreased by 2 or more points. There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00687102,Contradiction,0.3807605,0.61923945
NCT02336737,Statement: there were severe adverse events (aes) reported in cohort 1 of the primary clinical trial [SEP] Clinical Trial: NCT02336737,Entailment,0.79718554,0.20281446
NCT01091974,"Statement: only one cohort in the primary trial is given daily armodafinil p.o., while all patients in the secondary trial are administered the same dosage of pdr001, though the quantity of mcs110 varies. [SEP] Clinical Trial: NCT01091974",Contradiction,0.4740384,0.52596164
NCT01086605,Statement: hypertension was reported in both cohorts of the primary clinical trial [SEP] Clinical Trial: NCT01086605,Entailment,0.7529406,0.24705943
NCT00451555,"Statement: femtogram per milliliter per microgram is a unit of concentration equal to femtogram per milliliter, divided by micrograms. Participants must be resistant to AI therapy to participate in the primary trial, but this is not necessary to be included in the secondary trial. [SEP] Clinical Trial: NCT00451555",Entailment,0.6576399,0.3423601
NCT00741039,Statement: Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine. [SEP] Clinical Trial: NCT00741039,Entailment,0.5601889,0.4398111
NCT01631552,Statement: age-days is age of subject in days. the secondary trial and the primary trial have completely unrelated outcome measurements. [SEP] Clinical Trial: NCT01631552,Entailment,0.9064619,0.09353805
NCT00372424,Statement: a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event. [SEP] Clinical Trial: NCT00372424,Entailment,0.6989979,0.30100212
NCT00248547,Statement: patients receiving the placebo intervention in the primary clinical trial had the same likelihood of experiencing emesis as patients receiving aprepitant. [SEP] Clinical Trial: NCT00248547,Entailment,0.58854455,0.41145548
NCT03125941,Statement: pre-operative dexamethasone is only given to one of the cohorts in the primary clinical trial. [SEP] Clinical Trial: NCT03125941,Entailment,0.87515414,0.12484587
NCT00262834,"Statement: 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients, apart from Skin infections. subject status test code is a character or string that represents the short code name of the subject status assessment. [SEP] Clinical Trial: NCT00262834",Contradiction,0.4731825,0.5268175
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 0.15 g of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.37764296,0.622357
NCT03125941,Statement: Both the primary trial cohorts receive pre-operative Dexamethasone [SEP] Clinical Trial: NCT03125941,Entailment,0.6696135,0.33038658
NCT00588640,"Statement: the primary clinical trial has different inclusion and exclusion rules in its two phases, while the secondary clinical trial divides its criteria based on whether patients are healthy or diagnosed with cancer. [SEP] Clinical Trial: NCT00588640",Entailment,0.6868689,0.31313112
NCT01772004,Statement: caucasian patients residing in new york are eligible to participate in the primary clinical trial. [SEP] Clinical Trial: NCT01772004,Entailment,0.51075935,0.4892407
NCT01091974,"Statement: in the primary trial, all cohorts are treated equally and are given the same dosage of simvastatin daily. in the secondary trial, different treatments are prescribed for different patients without a specific dose of pdr001 or mcs110. [SEP] Clinical Trial: NCT01091974",Entailment,0.5319546,0.46804544
NCT00254592,"Statement: adult acute megakaryoblastic leukemia is an acute megakaryoblastic leukemia occurring in adults. the primary trial and the secondary trial both administer cyclophosphamide, Paclitaxel and pegfilgrastim to their patient cohorts. [SEP] Clinical Trial: NCT00254592",Contradiction,0.1786096,0.8213904
NCT00759785,Statement: 3.3% more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group [SEP] Clinical Trial: NCT00759785,Entailment,0.5377877,0.46221235
NCT01554371,Statement: Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial. tsukamurellaceae is a taxonomic family of bacterium in the phylum actinobacteria that includes the genus tsukamurella. [SEP] Clinical Trial: NCT01554371,Entailment,0.73078007,0.26921996
NCT00256217,"Statement: There were no patients with recorded Aes in the primary trial, whereas every patient in the secondary trial suffered at least one adverse event. source-date is a property representing the date each go annotation was added to a concept. [SEP] Clinical Trial: NCT00256217",Entailment,0.7775419,0.2224581
NCT02165839,"Statement: Candidates for the primary trial and the secondary trial have to meet a baseline performance status, for the primary trial the baseline is a Karnofsky score >70, and for the secondary trial the baseline is a Karnofsky score >55. escape from interlabial space or lateral juncture; no extension is a finding of escape from interlabial space or lateral juncture during swallowing, but no extension. [SEP] Clinical Trial: NCT02165839",Contradiction,0.3344268,0.66557324
NCT02988986,Statement: patients in the primary clinical trial reported no observed change in the percentage of cells with ki67 expression following the application of tak-228 plus tamoxifen treatment. [SEP] Clinical Trial: NCT02988986,Entailment,0.6989253,0.30107462
NCT01037790,Statement: there is a limited patient capacity in the primary clinical trial for those who have been diagnosed with metastatic colorectal cancer having the kras or braf mutation. [SEP] Clinical Trial: NCT01037790,Entailment,0.67495525,0.32504472
NCT00404066,"Statement: in the secondary clinical trial, only eyelid oedema and chest pain were the adverse events observed in patients, unlike the primary trial which did not record any. [SEP] Clinical Trial: NCT00404066",Entailment,0.7994252,0.20057489
NCT00569166,"Statement: Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day. liver angiosarcoma is a malignant vascular neoplasm arising from the liver. [SEP] Clinical Trial: NCT00569166",Contradiction,0.3144756,0.6855244
NCT01527487,Statement: cohort 2 patients in the primary clinical trial receive higher doses of docetaxel than cohort 1 patients receive of eribulin. [SEP] Clinical Trial: NCT01527487,Entailment,0.6696638,0.33033618
NCT03202472,"Statement: patients who have received chemotherapy or radiotherapy in the last 336 hours, suffer from unstable angina, or have grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. [SEP] Clinical Trial: NCT03202472",Contradiction,0.40891585,0.5910841
NCT00104650,"Statement: the primary clinical trial does not provide interventions through various methods, it relies on a single method of administration. [SEP] Clinical Trial: NCT00104650",Entailment,0.7809488,0.21905118
NCT01434342,"Statement: There were more cases of Mucositis Oral, epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial [SEP] Clinical Trial: NCT01434342",Contradiction,0.44221726,0.55778277
NCT02038218,Statement: different units of measure are utilized in the results of the secondary clinical trial and the primary clinical trial. [SEP] Clinical Trial: NCT02038218,Entailment,0.82635784,0.17364217
NCT00293540,"Statement: from every cohort in the primary clinical trial, more than 50 individuals lived for more than two years, the average lifespan witnessed in the study participants. [SEP] Clinical Trial: NCT00293540",Contradiction,0.25827995,0.7417201
NCT01770353,"Statement: while the primary clinical trial and the secondary clinical trial both utilize intravenous injections, they do not involve the same drugs, dosages or administer at the same rate. [SEP] Clinical Trial: NCT01770353",Entailment,0.59064305,0.40935695
NCT01037790,Statement: individuals with cdk4/6 mutation can participate in the primary clinical trial. [SEP] Clinical Trial: NCT01037790,Entailment,0.5912571,0.40874285
NCT01013740,"Statement: in comparison, the secondary trial holds fewer anemia cases than the primary trial. [SEP] Clinical Trial: NCT01013740",Entailment,0.7556147,0.24438523
NCT00693719,Statement: patients with benign brain tumor are eligible for the primary clinical trial [SEP] Clinical Trial: NCT00693719,Entailment,0.62810344,0.3718965
NCT01967823,Statement: 50% of the primary trial patients suffered an increase in blood bilirubin. [SEP] Clinical Trial: NCT01967823,Contradiction,0.43663484,0.5633651
NCT00428220,"Statement: in the primary clinical trial, ascites was noted more frequently, while pneumocystis jirovecii pneumonia was observed more often in the secondary clinical trial. [SEP] Clinical Trial: NCT00428220",Entailment,0.5311775,0.46882245
NCT00558272,Statement: the azd0530 150 mg group of the primary trial experienced a lesser reduction in primary tumour diameter than the zoledronic acid 1 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.6701471,0.3298529
NCT00836186,"Statement: whole breast radiation therapy is administered to the participants of the primary clinical trial, whereas both cohorts in the secondary clinical trial receive intramuscular injections and medication that is consumed orally. [SEP] Clinical Trial: NCT00836186",Contradiction,0.4623447,0.5376553
NCT01252290,Statement: less than 0.050 of patients in the primary trial suffered aes [SEP] Clinical Trial: NCT01252290,Entailment,0.8139635,0.18603659
NCT00795769,Statement: there was an equal distribution of adverse events recorded in both the primary and secondary trials. [SEP] Clinical Trial: NCT00795769,Entailment,0.8866324,0.113367654
NCT00759785,Statement: the growth factor signature increased in more participants from the dalotuzumab 20 mg/kg group of the primary clinical trial than in those from the triple negative group. [SEP] Clinical Trial: NCT00759785,Contradiction,0.4701899,0.52981013
NCT00075764,Statement: patients with t2 n2 m2 tumors meet the requirements for participation in the primary clinical trial [SEP] Clinical Trial: NCT00075764,Entailment,0.5954946,0.4045053
NCT00496860,"Statement: in the context of the primary clinical trial, 0.035 mg less of the drug alt-801 is administered to the first cohort compared to the second cohort [SEP] Clinical Trial: NCT00496860",Entailment,0.6182852,0.38171482
NCT01783444,"Statement:  Women with Newly diagnosed stage IV breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. rat insulinoma is an insulin-producing neuroendocrine tumor arising from beta cells of the rat pancreas. [SEP] Clinical Trial: NCT01783444",Contradiction,0.21560334,0.7843967
NCT00270894,"Statement: participants in the primary clinical trial are administered only one type of drug all throughout the study duration, with no prescribed dosage. [SEP] Clinical Trial: NCT00270894",Entailment,0.84979564,0.15020433
NCT02961790,"Statement: Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial. contact dermatitis is an inflammatory skin condition caused by direct contact between the skin and either an irritating substance or an allergen. [SEP] Clinical Trial: NCT02961790",Entailment,0.6154945,0.38450554
NCT01390818,Statement: my disease is out of control is a question about how strongly an individual agrees that they would think that their disease is out of control. The all recorded Aes in the primary trial occurred to cohort 1 patients. [SEP] Clinical Trial: NCT01390818,Entailment,0.6967102,0.30328974
NCT01250379,"Statement: A 20 year old female patient with a Newly diagnosed ER-positive, HER2-negative breast cancer, could be eligible for the secondary trial and the primary trial. this doctor understands what is important to me regarding my health is a question about whether an individual's doctor understands what is important to the individual regarding their health. [SEP] Clinical Trial: NCT01250379",Contradiction,0.38783857,0.6121614
NCT01631552,Statement: the primary clinical trial and the secondary clinical trial both focus on the same outcome measurements. [SEP] Clinical Trial: NCT01631552,Entailment,0.665902,0.33409798
NCT00918281,Statement: cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine. fluorescence in situ hybridization was performed is an indication that fluorescence in situ hybridization was performed during the study. [SEP] Clinical Trial: NCT00918281,Entailment,0.56531996,0.43468004
NCT00182793,Statement: over 15% of patients in the primary trial and the secondary trial suffered from infections during the study period [SEP] Clinical Trial: NCT00182793,Contradiction,0.26970187,0.7302981
NCT00656305,"Statement: multiple deaths and hospitalizations were reported in cohort 2 of the primary clinical trial, along with various cases of atrial fibrillation. [SEP] Clinical Trial: NCT00656305",Contradiction,0.38791054,0.61208946
NCT00950911,Statement: The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial. apoptosis and single cell necrosis is a finding that generally has features of apoptosis and single cell necrosis. [SEP] Clinical Trial: NCT00950911,Contradiction,0.4437946,0.55620545
NCT00405938,"Statement:  patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 2 decades if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.40569475,0.5943053
NCT01730729,"Statement: the primary trial intervention is given orally, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein [SEP] Clinical Trial: NCT01730729",Contradiction,0.4803652,0.5196348
NCT01606748,"Statement: tachypnea is abnormal increase of rate of breathing. several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia. [SEP] Clinical Trial: NCT01606748",Entailment,0.5324507,0.46754935
NCT00963911,Statement: the primary clinical trial mandates regular physical activities as a part of the intervention for all participants. [SEP] Clinical Trial: NCT00963911,Entailment,0.6590499,0.3409501
NCT00088413,Statement: All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial. childhood bladder carcinoma is a rare carcinoma of the bladder that occurs during childhood. [SEP] Clinical Trial: NCT00088413,Entailment,0.7880206,0.21197934
NCT01351376,Statement: individuals with quantifiable tumor growth in both breasts can participate in the primary clinical trial [SEP] Clinical Trial: NCT01351376,Contradiction,0.460499,0.539501
NCT00373256,Statement: cohort 1 of the primary clinical trial is given 90 mg/m^2 paclitaxel daily while cohort 2 receives 25 mg of sunitinib [SEP] Clinical Trial: NCT00373256,Contradiction,0.42051083,0.5794892
NCT00558272,"Statement: in the primary clinical trial, the group taking azd0530 175 mg experienced a greater percentage change in betactx at the fourth week than the group on zoledronic acid 4 mg. [SEP] Clinical Trial: NCT00558272",Entailment,0.5010721,0.4989279
NCT00418028,"Statement: time to progression in days is reported for a pool of 156 patients in the two cohorts for the primary clinical trial, compared to the secondary clinical trial, which conveys the percentage of patients who underwent an objective response. [SEP] Clinical Trial: NCT00418028",Contradiction,0.32857803,0.671422
NCT00709761,Statement: Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR). external iliac artery branch is any artery arising from the external iliac artery. [SEP] Clinical Trial: NCT00709761,Contradiction,0.4334957,0.5665043
NCT01111825,Statement: the primary clinical trial administrates her2+ treatment for both cohort 1 and cohort 2. [SEP] Clinical Trial: NCT01111825,Entailment,0.6691921,0.33080795
NCT01466972,"Statement: the primary participants reported no adverse events, specifically no occurrences of maculo-papular rash. [SEP] Clinical Trial: NCT01466972",Entailment,0.6775053,0.3224947
NCT00659373,"Statement: all individuals in the primary clinical trial experienced a decline in cognitive performance, notably those in the ovarian function suppression group [SEP] Clinical Trial: NCT00659373",Entailment,0.55803776,0.44196227
NCT01781299,Statement: There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial [SEP] Clinical Trial: NCT01781299,Entailment,0.61439276,0.38560718
NCT02807844,"Statement: all patients in the primary trial receive at least 20000µg of mcs110 every 21 days, and over 130000µg of pdr001 every 14 days. [SEP] Clinical Trial: NCT02807844",Contradiction,0.33676022,0.66323984
NCT03202472,"Statement: patients who have undergone chemotherapy or radiotherapy in the recent fortnight, have stable angina, or exhibit grade 1 neuropathy are invited to participate in the secondary trial, but are excluded from the primary trial due to non-healing surgical wounds. [SEP] Clinical Trial: NCT03202472",Contradiction,0.47366676,0.5263332
NCT00702949,"Statement: in the primary clinical trial, a patient group is treated with 150 mg of oral pregabalin, received bi-weekly over a six week period, in contrast to the secondary clinical trial, where treatments involve administration of depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.3531357,0.64686435
NCT01975831,Statement: The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2. seventeen is a natural number greater than 16 and less than 18 and the quantity that it denotes. [SEP] Clinical Trial: NCT01975831,Contradiction,0.41033366,0.5896663
NCT01606748,"Statement: numerous instances of pancytopenia were noted in cohort 1 of the primary clinical trial, but there were no records of anaemia and febrile neutropenia. [SEP] Clinical Trial: NCT01606748",Contradiction,0.4072944,0.59270567
NCT01606748,"Statement: the primary clinical trial registered no instances of anaemia and febrile neutropenia in cohort 1, but there were several cases of pancytopenia. [SEP] Clinical Trial: NCT01606748",Contradiction,0.17958315,0.82041687
NCT00418028,"Statement: the primary trial does not provide a time to progression report and instead focuses on the patient's subjective experience, whereas the secondary trial records the total duration of patient participation across both cohorts. [SEP] Clinical Trial: NCT00418028",Entailment,0.5644654,0.4355346
NCT01383174,Statement: there was no significant difference in the results produced by cohort 2 of the primary and secondary clinical trials. [SEP] Clinical Trial: NCT01383174,Entailment,0.9169947,0.08300525
NCT01989546,"Statement: candidates for the primary clinical trial are not permitted to undergo cbt-based treatments, but they may qualify for the secondary clinical trial. [SEP] Clinical Trial: NCT01989546",Entailment,0.7263244,0.27367565
NCT01964924,Statement: an adult who was diagnosed with diffuse parenchymal lung disease within the last three years would not be considered for the primary clinical trial [SEP] Clinical Trial: NCT01964924,Entailment,0.86399555,0.13600445
NCT00702949,"Statement: the primary trial prescribes a regimen of oral multivitamins for its patients, and the secondary trial manages its patients with depomedroxyprogesterone acetate injection [SEP] Clinical Trial: NCT00702949",Contradiction,0.4460293,0.55397063
NCT03015649,Statement: the primary clinical trial and the secondary clinical trial documented over 100 adverse events within their study groups. [SEP] Clinical Trial: NCT03015649,Entailment,0.62165153,0.37834844
NCT01466972,Statement: several patients in the primary clinical trial experienced identical adverse events. [SEP] Clinical Trial: NCT01466972,Entailment,0.6006043,0.39939567
NCT01434342,"Statement: There were more cases of Mucositis Oral, Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial. tricuspid valve regurgitant volume is a quantitative measurement of the amount of retrograde blood flow across the orifice of the tricuspid valve. [SEP] Clinical Trial: NCT01434342",Contradiction,0.4381986,0.56180143
NCT00076024,"Statement: erbb2 nm 004448.2:c.2324 2325ins12 is an insertion of 12 nucleotides, atacgtgatggc, between position 2324 and 2325 of the coding sequence of the erbb2 gene. There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial. [SEP] Clinical Trial: NCT00076024",Entailment,0.5788906,0.4211094
NCT00001832,Statement: both the primary clinical trial and the secondary clinical trial necessitate that patients partake in a weekly regimen of 4-demethyl-4-cholestryloxycarbonylpenclomedine. [SEP] Clinical Trial: NCT00001832,Contradiction,0.26081976,0.73918027
NCT00118157,"Statement: in the primary clinical trial, 150 mg/m2 of lapatinib is administered orally once daily for two weeks to the patients. [SEP] Clinical Trial: NCT00118157",Contradiction,0.45913625,0.54086375
NCT00432562,Statement: the secondary trial and the primary trial follow identical sets of criteria for participant eligibility. [SEP] Clinical Trial: NCT00432562,Entailment,0.8357798,0.16422027
NCT00963911,"Statement: several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention. discharge indicator is an indication as to whether there is the presence of discharge. [SEP] Clinical Trial: NCT00963911",Contradiction,0.28131765,0.7186823
NCT01421472,"Statement: medulloblastoma, not otherwise specified is a medulloblastoma which has not been further characterized. Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial. [SEP] Clinical Trial: NCT01421472",Entailment,0.7223116,0.2776884
NCT01537029,"Statement: Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer. abnormal vital capacity is a pulmonary function test result indicating an abnormal vital capacity as compared to the predicted value. [SEP] Clinical Trial: NCT01537029",Contradiction,0.40450296,0.595497
NCT00623831,"Statement: within the primary clinical trial, a quarter of cohort 2 patients experience an increased occurrence of pleural effusion. [SEP] Clinical Trial: NCT00623831",Entailment,0.56125253,0.43874753
NCT02599194,Statement: no aes were registered in either the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.91042876,0.08957119
NCT01631552,"Statement: hyoepiglottic ligament is a short elastic band that unites the epiglottis to the upper border of the hyoid bone. the secondary trial and the primary trial have completely unrelated outcome measurements, but the same interventions. [SEP] Clinical Trial: NCT01631552",Contradiction,0.4670432,0.53295684
NCT00182793,Statement: an instance of infection was reported in each of the primary and secondary clinical trial [SEP] Clinical Trial: NCT00182793,Entailment,0.73537964,0.2646203
NCT00963911,"Statement: several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention. marine-based natural product is any substance or product derived from any organism that lives in bodies of fresh or salt water. [SEP] Clinical Trial: NCT00963911",Contradiction,0.3887904,0.6112096
NCT01881230,Statement: both cohorts participating in the primary clinical trial are administered identical dosages of abraxane and carboplatin [SEP] Clinical Trial: NCT01881230,Entailment,0.58270067,0.41729927
NCT03384316,Statement: each patient in cohort 1 of the primary clinical trial that experienced infections and fever were the only ones. [SEP] Clinical Trial: NCT03384316,Contradiction,0.48469338,0.51530665
NCT00021255,"Statement: the primary clinical trial employs unique treatment dosage and frequency for each cohort, excluding any usage of docetaxel, doxorubicin and cyclophosphamide. [SEP] Clinical Trial: NCT00021255",Entailment,0.71638715,0.28361282
NCT00656305,"Statement: cohort 2 of the primary clinical trial reported no deaths or hospitalizations, except for a solitary case of atrial fibrillation. [SEP] Clinical Trial: NCT00656305",Entailment,0.5477403,0.45225972
NCT03384316,Statement: all the instances of infections and infestations in the primary clinical trial pertained to patients in cohort 1. [SEP] Clinical Trial: NCT03384316,Entailment,0.810495,0.18950497
NCT00662025,"Statement: specify another form of birth control that was used is a directive to specify another form of birth control that was used. Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study. [SEP] Clinical Trial: NCT00662025",Entailment,0.5624508,0.43754917
NCT02336737,Statement: the first cohort of the primary clinical trial didn't document any adverse events [SEP] Clinical Trial: NCT02336737,Entailment,0.9208176,0.07918242
NCT00843167,"Statement: in the secondary clinical trial, the efficacy of physical therapy is gauged by measuring pain, unlike the primary clinical trial wherein the effectiveness of sulforaphane supplements is studied based on their impact on isothiocyanate concentration in urine. [SEP] Clinical Trial: NCT00843167",Entailment,0.63972485,0.36027512
NCT01803282,Statement: there were no adverse events reported by participants in either the primary or secondary clinical trials. [SEP] Clinical Trial: NCT01803282,Entailment,0.8956503,0.10434966
NCT01045421,"Statement: patients with a confirmed mutation in any of the following genes; pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11 are required for participation in the secondary clinical trial, not the primary clinical trial [SEP] Clinical Trial: NCT01045421",Contradiction,0.44697914,0.55302083
NCT02306265,"Statement: liter per meter squared is a unit of concentration equal to liter per meter squared. candidates must undergo a Mammography before being able to participate in the primary trial, this is not required for the secondary trial. [SEP] Clinical Trial: NCT02306265",Entailment,0.7232797,0.27672032
NCT00896454,Statement: both the primary clinical trial and the secondary clinical trial present findings from a single patient cohort. [SEP] Clinical Trial: NCT00896454,Entailment,0.8374741,0.1625259
NCT02041429,"Statement: the primary trial and the secondary trial report on the MTD of different interventions, with the MTD of MM-111 for patients in the secondary trial being 15 mg per day [SEP] Clinical Trial: NCT02041429",Contradiction,0.254758,0.745242
NCT02178722,Statement: participants in the primary trial receive epacadostat with the same frequency as sunitinib-na‚àö√òve participants receive sunitinib in the secondary trial. [SEP] Clinical Trial: NCT02178722,Entailment,0.63047653,0.36952347
NCT01964924,"Statement: an adult patient diagnosed with ild/dpld within the last 156 weeks, with a life expectancy of 0.5 years would be eligible for the primary trial [SEP] Clinical Trial: NCT01964924",Contradiction,0.4390598,0.5609402
NCT00871858,Statement: Paclitaxel is not used in either of the primary trial interventions. posterior tongue neoplasm is a benign or malignant neoplasm that affects the base of the tongue. [SEP] Clinical Trial: NCT00871858,Entailment,0.7535491,0.24645089
NCT01855828,"Statement: There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients. coordinating committee is a committee that a sponsor may organize to coordinate the conduct of a multicenter trial. (ich) [SEP] Clinical Trial: NCT01855828",Entailment,0.82626426,0.17373574
NCT01743560,"Statement: children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial. coliform bacteria, lactose fermenting is any rod-shaped, gram-negative, non-spore forming bacteria that is capable of fermenting lactose to produce acid and gas. [SEP] Clinical Trial: NCT01743560",Entailment,0.5482675,0.4517325
NCT02179515,Statement: every individual in the first cohort of the primary clinical trial experienced some form of adverse event. [SEP] Clinical Trial: NCT02179515,Entailment,0.8797162,0.12028378
NCT02796755,Statement: There were more adverse events observed in the secondary trial than in the primary trial. physical activity lifestyle is a description of the subject's lifestyle with respect to physical activity. [SEP] Clinical Trial: NCT02796755,Entailment,0.6967255,0.30327457
NCT02509156,Statement: esophageal hemangioma is a capillary or cavernous hemangioma that arises from the esophagus.  the majority of cases are polypoid intraluminal lesions. The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection. [SEP] Clinical Trial: NCT02509156,Contradiction,0.28976348,0.71023655
NCT01013740,Statement: anemia is more prevalent in the primary trial when opposed to the secondary trial. [SEP] Clinical Trial: NCT01013740,Entailment,0.6911094,0.3088906
NCT00544167,"Statement: patients that have suffered a pulmonary embolism within the last 156 weeks are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.7188617,0.28113827
NCT00693719,Statement: patients with a confirmed diagnosis of leptomeningeal carcinoma can participate in the primary clinical trial [SEP] Clinical Trial: NCT00693719,Entailment,0.5321492,0.4678508
NCT00370552,"Statement: fertile men and women capable of becoming pregnant are fit to partake in the primary clinical trial, under the condition of committing to abstain for the length of the study [SEP] Clinical Trial: NCT00370552",Entailment,0.7693908,0.23060924
NCT00656019,Statement: several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes. 11q22-q23 is a chromosome band present on 11q [SEP] Clinical Trial: NCT00656019,Contradiction,0.23551454,0.7644855
NCT02796755,Statement: the number of adverse events in the secondary clinical trial was greater compared to those in the primary clinical trial. [SEP] Clinical Trial: NCT02796755,Entailment,0.84502506,0.15497491
NCT01617668,Statement: hexadecadienoic acid is a polyunsaturated long-chain fatty acid with a 16-carbon backbone and exactly two double bonds. More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2. [SEP] Clinical Trial: NCT01617668,Entailment,0.5175359,0.48246413
NCT02431676,Statement: patients suffering from severe malnutrition are ineligible for the primary clinical trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.89395726,0.10604271
NCT01468675,Statement: all participants in the primary clinical trial are administered a cocktail of drugs as part of the intervention. [SEP] Clinical Trial: NCT01468675,Entailment,0.7296476,0.2703524
NCT01997333,"Statement: the patient with the shortest pfs in the primary clinical trial came from cohort 1, and experienced disease progression within a week [SEP] Clinical Trial: NCT01997333",Contradiction,0.46857885,0.5314211
NCT00971945,"Statement: the secondary trial  candidates must be Completely disabled to participate, whereas this is not required to be accepted into the primary trial [SEP] Clinical Trial: NCT00971945",Entailment,0.9005225,0.09947756
NCT00838929,"Statement: every patient in the primary trial is receives a dose of 2000 to 5000 ¬¨¬µg fentanyl sublingual spray during radiation therapy,  ,   [SEP] Clinical Trial: NCT00838929",Entailment,0.5276453,0.47235474
NCT00791037,Statement: the primary trial and the secondary trial evaluate different patient characteristics in their results. appendiceal carcinoma pn0 tnm finding v7 is appendiceal carcinoma without regional lymph node metastasis.  (from ajcc 7th ed.) [SEP] Clinical Trial: NCT00791037,Entailment,0.7015106,0.2984894
NCT00313170,Statement: candidates for the primary trial must have breast cancer and require hormonal treatment. [SEP] Clinical Trial: NCT00313170,Entailment,0.52633286,0.47366714
NCT01421472,"Statement: patients who have estrogen negative, progesterone negative and her2- breast cancer, can join the primary clinical trial [SEP] Clinical Trial: NCT01421472",Contradiction,0.41761416,0.58238584
NCT01969448,"Statement: laser-assisted fluorescence angiography is used for both interventions in the primary trial. cisplatin/doxorubicin/paclitaxel regimen is a regimen consisting of cisplatin, doxorubicin and paclitaxel used for the treatment of advanced stage or recurrent endometrial cancer. [SEP] Clinical Trial: NCT01969448",Contradiction,0.3953042,0.6046958
NCT00756717,Statement: both trials saw a considerable number of adverse events throughout their duration [SEP] Clinical Trial: NCT00756717,Entailment,0.6748258,0.3251742
NCT00702949,"Statement: the primary trial treats part of its patient groups with iv infusions of amitriptyline biweekly for a period of 6 weeks, while the secondary trial utilizes carmustine and cyclophosphamide for its administration. [SEP] Clinical Trial: NCT00702949",Contradiction,0.47814843,0.52185154
NCT01649271,"Statement: nasal cream dosage form is a cream intended for administration to the mucosa of the nose. There was one case of shingles recorded in group 2 of the secondary trial, but no cases in group 1 of the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01649271",Contradiction,0.45645937,0.5435406
NCT01702571,Statement: the adverse events reported for cohort 1 of the primary clinical trial pertain to cardiovascular complications [SEP] Clinical Trial: NCT01702571,Entailment,0.6991467,0.30085334
NCT01963481,"Statement: patients with severe insomnia and schizophrenia are eligible for the primary clinical trial, but not the secondary clinical trial [SEP] Clinical Trial: NCT01963481",Contradiction,0.37388667,0.62611336
NCT00122369,"Statement: there is no age restriction for candidates in the secondary clinical trial, but to be eligible for the primary clinical trial, patients need to be less than 30 years old. [SEP] Clinical Trial: NCT00122369",Entailment,0.6445841,0.35541588
NCT00709761,Statement: over 0.5 patients in the primary trial treated with lapatinib 1000 milligrams + nab-paclitaxel experienced a confirmed complete response (cr) . [SEP] Clinical Trial: NCT00709761,Contradiction,0.35047582,0.6495242
NCT02796755,Statement: no adverse events have been reported for participants in both the primary and secondary clinical trial. [SEP] Clinical Trial: NCT02796755,Entailment,0.89186573,0.10813431
NCT01855828,"Statement: in the primary clinical trial, less than 10% of patients experienced one psychiatric adverse event [SEP] Clinical Trial: NCT01855828",Entailment,0.86669326,0.13330673
NCT00659373,"Statement: atypical carcinoid tumor is a carcinoid tumor characterized by a high mitotic rate, often associated with the presence of necrosis and nuclear pleomorphism. On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients. [SEP] Clinical Trial: NCT00659373",Contradiction,0.4530636,0.5469364
NCT01194440,"Statement: patients suffering from stage 4 invasive breast carcinoma, with positive estrogen/progesterone receptors and thinking about ai therapy could be potential candidates for the primary clinical trial. [SEP] Clinical Trial: NCT01194440",Contradiction,0.39772296,0.6022771
NCT02550795,"Statement: while the patients in the second group of the primary clinical trial are administered with 0.5ug/kg of myalgias (5ml), none of the patients in the cohorts of the secondary clinical trial receives any myalgias. [SEP] Clinical Trial: NCT02550795",Entailment,0.68647987,0.3135202
NCT01535040,"Statement: in the primary clinical trial, the placebo intervention is administered intravenously and the memantine intervention is administered orally, twice daily. [SEP] Clinical Trial: NCT01535040",Contradiction,0.4311653,0.5688347
NCT01390818,Statement: every documented adverse event in the primary clinical trial took place among the cohort 1 patients [SEP] Clinical Trial: NCT01390818,Entailment,0.87383324,0.12616669
NCT02796755,Statement: There were more adverse events observed in the secondary trial than in the primary trial. irrecist stable disease is a failure to meet criteria for ircr or irpr in the absence of irpd. [SEP] Clinical Trial: NCT02796755,Entailment,0.599269,0.40073106
NCT01351376,Statement: metastatic neuroendocrine carcinoma is a neuroendocrine carcinoma that has metastasized from its original site of growth to another anatomic site. Patients with measurable bilateral breast cancer are eligible for the primary trial. [SEP] Clinical Trial: NCT01351376,Contradiction,0.4011279,0.59887207
NCT01205503,Statement: Any patients with Documented allergy to cephalosporin or trimethoprim/sulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial. [SEP] Clinical Trial: NCT01205503,Entailment,0.7430619,0.2569381
NCT00553358,"Statement: a patient who has a 33mm primary tumour, as verified by clinical scrutiny and echography, is eligible for the primary clinical trial as well as the secondary clinical trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.3230932,0.67690676
NCT01823991,Statement: the primary clinical trial is available to individuals with fronto-temporal or mixed dementia [SEP] Clinical Trial: NCT01823991,Entailment,0.67734414,0.3226558
NCT00553358,"Statement: a patient that has a primary tumour with a radius of 3000µm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.31366435,0.6863357
NCT01011218,Statement: the adverse event records from the primary and secondary clinical trials show more than 10 deaths. [SEP] Clinical Trial: NCT01011218,Contradiction,0.2860913,0.7139087
NCT02259114,Statement: patients with parathyroid carcinoma evidenced by immunofluorescence microscopy or peripheral blood smear are ineligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02259114,Entailment,0.8575278,0.14247222
NCT01171924,"Statement: cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often. don't know or not sure when smoked a cigarette is a response indicating that an individual doesn't know or is not sure whether they smoked a cigarette. [SEP] Clinical Trial: NCT01171924",Entailment,0.6664732,0.33352682
NCT01881230,Statement: the same amounts of abraxane are provided to both groups in the primary clinical trial [SEP] Clinical Trial: NCT01881230,Entailment,0.7692753,0.2307247
NCT01823991,Statement: those suffering from alzheimer's disease are not applicable for participation in the primary clinical trial [SEP] Clinical Trial: NCT01823991,Entailment,0.90636146,0.09363858
NCT00370552,Statement: the primary clinical trial is solely open to participants who have been sterilized surgically or are not sexually active. [SEP] Clinical Trial: NCT00370552,Entailment,0.67731166,0.32268828
NCT00686127,"Statement: the primary clinical trial records more types of adverse events, yet the total number of adverse events reported is less than in the secondary clinical trial. [SEP] Clinical Trial: NCT00686127",Entailment,0.76742435,0.23257561
NCT01631552,"Statement: the secondary trial and the primary trial have completely unrelated outcome measurements, but the same interventions [SEP] Clinical Trial: NCT01631552",Entailment,0.8126866,0.1873134
NCT00544167,Statement: having a history of pulmonary embolism in the recent 60 days does not disqualify a patient from the primary clinical trial but eliminates the possibility of enrollment in the secondary clinical trial regardless of the investigator's opinion [SEP] Clinical Trial: NCT00544167,Entailment,0.70405155,0.29594845
NCT00800436,"Statement: Prior treatment with gabapentin or herceptin within the last year, will result in exclusion from the secondary trial, but not from the primary trial. [SEP] Clinical Trial: NCT00800436",Entailment,0.7802014,0.21979864
NCT02336737,"Statement: Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae. hard palate squamous cell carcinoma is a squamous cell carcinoma that arises from the hard palate.  it usually presents as a papillary or exophytic mass. [SEP] Clinical Trial: NCT02336737",Contradiction,0.37409472,0.6259053
NCT01770353,"Statement: intravenous injections and mris are used in both the primary clinical trial and the secondary clinical trial, though they differ in the drugs, dosages, and administration frequency applied in their interventions. [SEP] Clinical Trial: NCT01770353",Contradiction,0.38954693,0.61045307
NCT00372424,"Statement: in the primary clinical trial, a total of 35 patients who were administered sunitinib, docetaxel, and trastuzumab suffered treatment-emergent adverse events. [SEP] Clinical Trial: NCT00372424",Entailment,0.6381015,0.36189848
NCT00143390,Statement: missouri is a state in the central midwest united states. its capital is jefferson city. There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial. [SEP] Clinical Trial: NCT00143390,Contradiction,0.44795308,0.5520469
NCT00321048,Statement: patients in cohort 1 of the primary clinical trial receive different radiation therapy doses in comparison to those in cohort 2. [SEP] Clinical Trial: NCT00321048,Entailment,0.8402865,0.1597135
NCT01964924,"Statement: ezh2 gene mutation negative is a genetic finding indicating that ezh2 gene mutations have not been detected in a sample. an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial. [SEP] Clinical Trial: NCT01964924",Entailment,0.5886323,0.41136768
NCT02038218,"Statement: different units of measure are used in the outcomes of the primary clinical trial and the secondary clinical trial, despite being the same form of measurement. [SEP] Clinical Trial: NCT02038218",Entailment,0.71322936,0.28677064
NCT00365105,"Statement: a patient with age equivalent to 11520 weeks with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1.807 x 10^9/l, platelet count of 79 x 10^3/µl, hemoglobin level of 90000 mg/l, and a life expectancy exceeding 32 weeks would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.3186322,0.6813678
NCT00766532,"Statement: germinal center b-lymphocyte is a mature b-lymphocyte that is present in the geminal center of a lymphoid follicle. There are several cases of swelling, hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00766532",Contradiction,0.2195728,0.78042716
NCT00248547,Statement: patients receiving aprepitant in the primary clinical trial were twice as likely to experience emesis as patients receiving the placebo intervention. [SEP] Clinical Trial: NCT00248547,Contradiction,0.3942439,0.60575604
NCT01527487,"Statement: the first patient group in the primary clinical trial is administered with higher doses of cyclophosphamide than eribulin, and the second patient group gets greater doses of cyclophosphamide than docetaxel. [SEP] Clinical Trial: NCT01527487",Entailment,0.61757624,0.38242376
NCT01246973,Statement: There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01246973,Entailment,0.5919801,0.40801984
NCT03069313,Statement: grade 2 follicular lymphoma is a follicular lymphoma which contains 6-15 centroblasts per 40x high-power microscopic field. the primary trial and the secondary trial adminster their interventions orally. [SEP] Clinical Trial: NCT03069313,Contradiction,0.27527896,0.7247211
NCT00588640,Statement: the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants. ms is a courtesy title used before the name of a woman without making a distinction between married and unmarried status. [SEP] Clinical Trial: NCT00588640,Entailment,0.68837404,0.31162593
NCT01498458,"Statement: in the primary clinical trial, the occurrences of hepatotoxicity were tenfold compared to the cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458",Contradiction,0.42663437,0.5733656
NCT02640053,Statement: no differences in symptom severity were noted between patients in the primary clinical trial who received topical cryotherapy and those who did not.' [SEP] Clinical Trial: NCT02640053,Entailment,0.76328844,0.23671158
NCT03125941,"Statement: cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation. splenic rupture is a traumatic break in the fibrous connective tissue capsule surrounding the spleen. [SEP] Clinical Trial: NCT03125941",Contradiction,0.38534382,0.6146562
NCT00317603,"Statement: the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 13.00% of the primary trial patients [SEP] Clinical Trial: NCT00317603",Contradiction,0.21204965,0.7879504
NCT00254592,Statement: the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts [SEP] Clinical Trial: NCT00254592,Contradiction,0.20283651,0.7971635
NCT00254592,Statement: patient cohorts in both the primary and secondary trials receive cyclophosphamide [SEP] Clinical Trial: NCT00254592,Entailment,0.5593969,0.44060305
NCT00270894,"Statement: throughout the period of the primary clinical trial, the study participants are given four distinct drugs. [SEP] Clinical Trial: NCT00270894",Entailment,0.80339926,0.19660081
NCT00775645,Statement: In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.4647417,0.5352583
NCT01048099,Statement: one specific adverse event type impacted multiple participants in the primary clinical trial [SEP] Clinical Trial: NCT01048099,Entailment,0.5589125,0.44108748
NCT00270894,"Statement: participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2. cisplatin/topotecan is a combination of agents containing cisplatin and topotecan. [SEP] Clinical Trial: NCT00270894",Contradiction,0.32825586,0.67174417
NCT00775645,"Statement: in both the primary and secondary clinical trials, more than 30% of participants experienced several adverse events. [SEP] Clinical Trial: NCT00775645",Entailment,0.62728,0.37272
NCT01205503,Statement: Any patients with Documented allergy to cephalosporin or trimethoprim/sulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial. hearing problem causes frustration when talking with family is a question about whether an individual's hearing problem causes them frustration when talking with family members. [SEP] Clinical Trial: NCT01205503,Entailment,0.6081244,0.39187562
NCT01256567,"Statement: a patient that has received an organ transplant within the last month, and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial [SEP] Clinical Trial: NCT01256567",Entailment,0.71968436,0.2803156
NCT01156987,Statement: there were no lesions found on any of the group 1 participants in the primary clinical trial and an overwhelming 95% of group 1 participants in the secondary clinical trial showed signs of radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987,Contradiction,0.24569799,0.754302
NCT00143390,Statement: There was at least 1 recorded gastro-intestinal adverse event in the primary trial. pigmentary change in skin is abnormal skin pigmentation. [SEP] Clinical Trial: NCT00143390,Entailment,0.6264866,0.37351337
NCT01383174,Statement: cohort 2 of the primary clinical trial and the secondary trial had an equal number of patients. [SEP] Clinical Trial: NCT01383174,Entailment,0.56483454,0.43516546
NCT02002533,Statement: the primary trial and the secondary trial have 55 recorded adverse events. [SEP] Clinical Trial: NCT02002533,Entailment,0.74682504,0.2531749
NCT01439282,"Statement: the primary clinical trial accepts patients regardless of gender, whereas the secondary clinical trial only considers females for participation. [SEP] Clinical Trial: NCT01439282",Entailment,0.5768758,0.42312422
NCT01831089,Statement: only those with a histologically/cytologically confirmed diagnosis of colorectal cancer can participate in the primary clinical trial [SEP] Clinical Trial: NCT01831089,Entailment,0.54890037,0.4510996
NCT01664091,"Statement: infection, asymmetry and nausea were observed more frequently in the primary clinical trial compared to the secondary clinical trial. [SEP] Clinical Trial: NCT01664091",Entailment,0.52671844,0.4732816
NCT02599194,Statement: adverse events were carefully documented in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.81054676,0.18945324
NCT02104830,"Statement: the primary trial and the secondary trial are studying the same drug, in different doses and with a different outcome measurement. prostate lymphoma is a rare non-hodgkin or hodgkin lymphoma that arises from the prostate gland. [SEP] Clinical Trial: NCT02104830",Contradiction,0.44615802,0.55384195
NCT00687102,Statement: neither intestinal obstructions nor pancytopenia has been observed within the patient cohorts of the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00687102,Entailment,0.60933363,0.39066634
NCT00322374,"Statement: There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial . ipss-r risk category very high is a total ipss-r score of 6.5 or higher, indicating very high risk. [SEP] Clinical Trial: NCT00322374",Contradiction,0.4181318,0.58186823
NCT01569087,"Statement: stage 4 cancer patients are excluded from the secondary clinical trial, but may participate in the primary clinical trial. [SEP] Clinical Trial: NCT01569087",Entailment,0.7949963,0.20500371
NCT01963481,"Statement: Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial. grade 1 hypophysitis, ctcae is asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated [SEP] Clinical Trial: NCT01963481",Entailment,0.7215282,0.27847186
NCT01023477,"Statement: ophthalmic route of administration is administration of a drug to the external eye. Hypokalemic patients are excluded from the primary trial, but hyperkalemic patients may be eligible for the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01023477",Contradiction,0.33898196,0.661018
NCT00365105,"Statement: A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 110,034/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. first course treatment completion measure of success of outcome not applicable is a response that the first course treatment completion measure of success of outcome is not applicable. [SEP] Clinical Trial: NCT00365105",Entailment,0.7512469,0.24875303
NCT00365365,Statement: the primary clinical trial does not involve administering any vaccines to the participants. [SEP] Clinical Trial: NCT00365365,Entailment,0.9279993,0.07200066
NCT00950911,Statement: The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial. cytolytic process is any cell death process resulting from rupture of cell membranes and loss of cytoplasm. [SEP] Clinical Trial: NCT00950911,Contradiction,0.449702,0.55029804
NCT02187783,"Statement: More Palpitations, Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial. deleterious atm gene mutation is a change in the nucleotide sequence of the atm gene that is associated with increased risk of disease. [SEP] Clinical Trial: NCT02187783",Contradiction,0.4177349,0.5822651
NCT00586326,Statement: the intervention segment of the primary clinical trial fails to delineate either a treatment regimen or the specifics of radiation dosages. [SEP] Clinical Trial: NCT00586326,Entailment,0.8871824,0.11281761
NCT00143390,"Statement: throughout the primary clinical trial, there were no reported cases of gastro-intestinal complications [SEP] Clinical Trial: NCT00143390",Entailment,0.8319312,0.16806886
NCT01171924,Statement: cohort 1 in the primary clinical trial does not receive pd-0332991 as part of their treatment regime. [SEP] Clinical Trial: NCT01171924,Entailment,0.92067075,0.079329245
NCT02320123,"Statement: in the primary clinical trial, the intervention's educational dvd will be made available solely to the members of cohort 1 [SEP] Clinical Trial: NCT02320123",Entailment,0.80286163,0.19713834
NCT02336737,"Statement: Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae. prefer not to answer is a response indicating that an individual prefers or preferred not to answer. [SEP] Clinical Trial: NCT02336737",Entailment,0.59539074,0.4046092
NCT01468675,Statement: counselling is a key component of the interventions in the primary clinical trial. [SEP] Clinical Trial: NCT01468675,Entailment,0.7832588,0.21674117
NCT01920061,Statement: cohort b reported significantly lower adverse events compared to cohort a in the primary clinical trial. [SEP] Clinical Trial: NCT01920061,Entailment,0.7783349,0.22166511
NCT01421472,"Statement: apalutamide regimen is a chemotherapy regimen consisting of apalutamide that may be used in the treatment of prostate cancer. Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial. [SEP] Clinical Trial: NCT01421472",Contradiction,0.41811168,0.5818883
NCT00467844,Statement: all patients treated with gtx-024 500mg in the primary trial gained lean body mass over a 1 month period [SEP] Clinical Trial: NCT00467844,Contradiction,0.4284704,0.5715296
NCT01920061,"Statement: the primary trial uses a 504 hour cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. [SEP] Clinical Trial: NCT01920061",Entailment,0.91603273,0.08396733
NCT00293540,"Statement: On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months. cordonnier grade 3 viral complication, viral encephalitis is any viral encephalitis. [SEP] Clinical Trial: NCT00293540",Contradiction,0.3084713,0.6915287
NCT00918281,Statement: cohort 1 of the primary trial is administered a standard dose of warfarin and cohort 1 of the secondary trial is given an injection of fluvoxamine. [SEP] Clinical Trial: NCT00918281,Entailment,0.5745099,0.42549005
NCT01537029,"Statement: male patients under the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have prostate cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.38611808,0.61388195
NCT01439282,Statement: the eligibility criteria for both the primary and secondary clinical trial does not depend on the gender of the participant [SEP] Clinical Trial: NCT01439282,Entailment,0.8510948,0.14890528
NCT00702949,"Statement: the primary trial provides a patient population with 200 mg of oral cymbalta biweekly for a duration of 6 weeks, and depocyt together with hd-mtx are not used in the secondary trial's patient treatment. [SEP] Clinical Trial: NCT00702949",Entailment,0.8196613,0.18033873
NCT00741039,Statement: participants in cohort 1 of the primary clinical trial are not administered with pneumococcus vaccine. [SEP] Clinical Trial: NCT00741039,Entailment,0.90385944,0.09614058
NCT01527487,Statement: cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel [SEP] Clinical Trial: NCT01527487,Entailment,0.5620697,0.4379303
NCT01617668,Statement: More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2. [SEP] Clinical Trial: NCT01617668,Entailment,0.80912364,0.19087638
NCT01783444,"Statement: received all the services needed is a response indicating that an individual feels or felt that they received all the services they needed.  Women with Newly diagnosed locally advanced breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01783444",Contradiction,0.23709422,0.7629058
NCT00749931,Statement: there is no single common inclusion criteria between the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.92784435,0.07215569
NCT01301729,Statement: At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial [SEP] Clinical Trial: NCT01301729,Entailment,0.6418108,0.3581892
NCT02222922,Statement: all the primary trial participants receive the same doses of alt-801 as the secondary trial participants [SEP] Clinical Trial: NCT02222922,Entailment,0.6218247,0.3781753
NCT00317603,"Statement: The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope, which occurred in 25.00% of the primary trial patients. severe problems performing usual activities is a response indicating that an individual has or had severe problems with performing their usual activities. [SEP] Clinical Trial: NCT00317603",Contradiction,0.20876566,0.7912344
NCT02961790,"Statement: patients that have participated in antineoplastic chemotherapy, androgens, estrogens, or progestogens therapy in the two years preceding study initiation are barred from the primary clinical trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.6517221,0.34827793
NCT00256217,"Statement: There were no patients with recorded Aes in the primary trial, whereas every patient in the secondary trial suffered at least one adverse event. injection site reaction, ctcae is a disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection. [SEP] Clinical Trial: NCT00256217",Entailment,0.6466003,0.35339966
NCT00418028,"Statement: the secondary clinical trial concentrates its studies on time to progression for a total of 300 patients in three distinct cohorts, while the primary clinical trial measures the number of patients with successful treatment response. [SEP] Clinical Trial: NCT00418028",Contradiction,0.2780495,0.7219505
NCT01156987,"Statement: Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. apache ii - arterial ph is acute physiology and chronic health evaluation ii (apache ii) arterial ph (preferred). [SEP] Clinical Trial: NCT01156987",Contradiction,0.3040249,0.69597507
NCT00795769,Statement: chest pain has been more frequently observed in patients participating in the secondary clinical trial than in those in the primary clinical trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.71412885,0.28587118
NCT00843167,"Statement: for the secondary trial, the impact of physical therapy on joint flexibility is quantified, whereas the primary trial examines how zinc supplements affect serum zinc level. [SEP] Clinical Trial: NCT00843167",Contradiction,0.42788354,0.5721165
NCT02891681,Statement: both the primary clinical trial and secondary clinical trial may permit the involvement of morbidly obese patients. [SEP] Clinical Trial: NCT02891681,Contradiction,0.42678803,0.5732119
NCT01629615,Statement: it was unusual for individuals with eating disorders to be candidates in the primary clinical trial [SEP] Clinical Trial: NCT01629615,Entailment,0.65849763,0.3415024
NCT00146172,Statement: candidates who are bedridden for less than 50% of their waking hours are eligible for both primary clinical trial and secondary clinical trial [SEP] Clinical Trial: NCT00146172,Entailment,0.53628236,0.4637176
NCT02122796,Statement: the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates. terrified by thoughts of the future is a response indicating that an individual is or was terrified by thoughts of the future. [SEP] Clinical Trial: NCT02122796,Entailment,0.55820125,0.44179878
NCT00416715,"Statement: participants in the secondary clinical trial are scheduled for three weekly sc injections, on the other hand, a single injection is given to primary clinical trial candidates at the inception of the study. [SEP] Clinical Trial: NCT00416715",Entailment,0.56477165,0.4352283
NCT02550795,Statement: primary trial's group 2 receive 1.5ug/kg dexmedetomidine and patients in grades 2 and 3 of the secondary trial also receive the same amount of dexmedetomidine. [SEP] Clinical Trial: NCT02550795,Contradiction,0.45738676,0.54261327
NCT00305695,"Statement: intervention 1 in the primary clinical trial, along with all intervention drugs in the secondary clinical trial, necessitate intravenous delivery. [SEP] Clinical Trial: NCT00305695",Entailment,0.5122643,0.4877357
NCT00792077,"Statement: the primary clinical trial employs a higher dosage of lenalidomide during the first intervention in comparison to the smaller dosage used for lapatinib in the secondary clinical trial, furthermore, the primary clinical trial's treatment period is extended. [SEP] Clinical Trial: NCT00792077",Entailment,0.58548105,0.41451895
NCT03403712,"Statement: adverse events connected to treatment in patients are being examined in the primary clinical trial, in contrast to the secondary clinical trial which determines the mean hours for which its patients sleep. [SEP] Clinical Trial: NCT03403712",Contradiction,0.49927938,0.50072056
NCT01597193,"Statement: in comparison to the first group that received enzalutamide intravenously in the primary clinical trial, the second group received it orally [SEP] Clinical Trial: NCT01597193",Entailment,0.6545893,0.34541067
NCT01783444,Statement: men with newly diagnosed stage ii prostate cancer not undergoing any surgery are eligible for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01783444,Contradiction,0.3741682,0.6258318
NCT02239601,Statement: the secondary clinical trial noted fewer adverse events in its patient cohort compared to the primary clinical trial. [SEP] Clinical Trial: NCT02239601,Entailment,0.83193,0.16806999
NCT00741039,Statement: participants in cohort 2 of the primary clinical trial are not administered with an influenza vaccine. [SEP] Clinical Trial: NCT00741039,Entailment,0.90874076,0.09125927
NCT01171924,"Statement: both cohort 1 and cohort 2 receive equal amounts of cudc-101 with identical frequency in the primary clinical trial. however, cohort 1 also obtains pd-0332991 every week. [SEP] Clinical Trial: NCT01171924",Contradiction,0.48766732,0.51233274
NCT02002533,"Statement: ,  the primary trial and the secondary trial have zero recorded adverse events. [SEP] Clinical Trial: NCT02002533",Entailment,0.88747376,0.11252628
NCT00999921,"Statement: patients suffering from lobular carcinoma in situ and well-regulated high blood pressure are permitted in the primary clinical trial, but are barred from the secondary clinical trial. [SEP] Clinical Trial: NCT00999921",Entailment,0.78526175,0.21473823
NCT00792077,Statement: higher doses of lenalidomide are utilized in the primary clinical trial compared to the doses of lapatinib used in the secondary clinical trial in the first intervention. [SEP] Clinical Trial: NCT00792077,Entailment,0.67538744,0.32461256
NCT00756496,"Statement: There were no significant differences in the results from the groups in the primary trial, however some differences where found between the Reflexology Group and control group results in the secondary trial. lung carcinoma metastatic in the bone is a carcinoma that arises from the lung and has metastasized to the bone. [SEP] Clinical Trial: NCT00756496",Contradiction,0.4323632,0.5676368
NCT00583700,Statement: women aged 18 or older are eligible for the secondary trial and the primary trial. have poor or reduced appetite is a question about whether an individual's appetite is or was reduced from normal. [SEP] Clinical Trial: NCT00583700,Contradiction,0.33827886,0.6617211
NCT02122796,"Statement: candidates in the primary trial get a higher weekly dose of mm-121 and paclitaxel than those in cohort 1 of the secondary trial, and also a lower weekly dose of herceptin and doxatel. [SEP] Clinical Trial: NCT02122796",Contradiction,0.44384062,0.55615944
NCT01969448,"Statement: laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial. nonpsychotic mental disorder following organic brain damage is any mental disorder that occurs secondary to organic brain damage, and that is not associated with psychosis. [SEP] Clinical Trial: NCT01969448",Contradiction,0.359708,0.64029205
NCT00538850,"Statement: the primary trial provides a report on the severity of delayed nausea on a scale of 1-7, whilst the secondary trial measures the change in bone mineral density (bmd) at the lumbar spine from baseline to 9 months. [SEP] Clinical Trial: NCT00538850",Entailment,0.51272523,0.48727477
NCT00467844,Statement: all patients treated with gtx-024 1mg in the primary clinical trial lost lean body mass over a 4 month period [SEP] Clinical Trial: NCT00467844,Entailment,0.6258146,0.37418535
NCT03092934,Statement: igf1r immunohistochemical expression is an immunohistochemical diagnostic test utilizing an antibody to detect igf1r in tissues. patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic. [SEP] Clinical Trial: NCT03092934,Contradiction,0.43915683,0.5608431
NCT02187783,"Statement: compared to the secondary clinical trial, the primary trial shows a decreased percentage of patients reporting palpitations, pericardial effusions and abdominal pains. [SEP] Clinical Trial: NCT02187783",Contradiction,0.49587828,0.5041217
NCT02234479,"Statement: the study groups in the primary clinical trial are being tested with various types of gels, while the secondary clinical trial evaluates the effects of different doses of one particular treatment on its study group. [SEP] Clinical Trial: NCT02234479",Entailment,0.6288951,0.37110487
NCT01535040,Statement: In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time. found dead is an indication that a subject was found in a deceased state. [SEP] Clinical Trial: NCT01535040,Contradiction,0.46644217,0.53355783
NCT00143390,Statement: There was at least 1 recorded gastro-intestinal adverse event in the primary trial [SEP] Clinical Trial: NCT00143390,Entailment,0.89617497,0.10382505
NCT00270894,"Statement: in the primary clinical trial, participants are given four separate drugs throughout the duration of the research, with the maximum dosage capped at 100 mg/m^2. [SEP] Clinical Trial: NCT00270894",Contradiction,0.35166994,0.6483301
NCT01048099,Statement: each individual adverse event in the primary clinical trial was reported in only one patient [SEP] Clinical Trial: NCT01048099,Entailment,0.88311946,0.11688048
NCT00262834,"Statement: 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients. bergeyella is a genus of aerobic, gram-negative, rod shaped bacterium assigned to the phylum bacteroidetes and the family flavobacteriaceae. [SEP] Clinical Trial: NCT00262834",Contradiction,0.44671726,0.5532828
NCT00270894,Statement: participants in the primary clinical trial are administered single medication for the entire study duration. [SEP] Clinical Trial: NCT00270894,Entailment,0.82039744,0.1796026
NCT00365105,"Statement: both the primary clinical trial and the secondary clinical trial would accept a 32 year old patient diagnosed with stage iii breast cancer who exhibits an absolute neutrophil count of 1807/≈í¬∫l, a platelet count of 79000/≈í¬∫l, a hemoglobin concentration of 90 g/l, and a life expectancy that surpasses 8 months. [SEP] Clinical Trial: NCT00365105",Contradiction,0.27648142,0.7235186
NCT00467844,Statement: one patient or more who were administered with gtx-024 1mg in the primary clinical trial saw an increase of more than 10 kilos in lean body mass. [SEP] Clinical Trial: NCT00467844,Contradiction,0.37445414,0.6255459
NCT02404441,"Statement: the secondary clinical trial implements identical criteria for participant inclusion or exclusion, while the primary clinical trial delineates two separate inclusion standards for age groups 18-50 and 50+ respectively. [SEP] Clinical Trial: NCT02404441",Entailment,0.5020314,0.49796858
NCT02165839,"Statement: Candidates for the primary trial and the secondary trial have to meet a baseline performance status, each trial is using a different performance status scoring system. symptom interference with life score 10 is a subjective score of 10 on a scale that ranges from 0: did not interfere to 10: interfered completely. [SEP] Clinical Trial: NCT02165839",Entailment,0.5512569,0.4487431
NCT01127763,Statement: at least one patient in the primary trial suffered several different adverse events [SEP] Clinical Trial: NCT01127763,Entailment,0.86262524,0.13737476
NCT00693719,"Statement: A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial. lip infection, ctcae is a disorder characterized by an infectious process involving the lips. [SEP] Clinical Trial: NCT00693719",Contradiction,0.37649235,0.6235076
NCT00266110,Statement: only topical treatments will be administered to the patients in the primary clinical trial. [SEP] Clinical Trial: NCT00266110,Entailment,0.76679593,0.23320402
NCT02599194,Statement: Aes were not recorded for the primary trial or the secondary trial. staff not available is a staff member is or was not available. [SEP] Clinical Trial: NCT02599194,Entailment,0.74552643,0.2544736
NCT02222922,Statement: individuals part of the primary clinical trial receive a lower quantity of drug dosage compared to those participating in the secondary clinical trial. [SEP] Clinical Trial: NCT02222922,Entailment,0.83437526,0.16562475
NCT01617668,"Statement: cohort 1 patients in the primary clinical trial enjoyed a primarily favorable prognosis, reflecting the same trend in cohort 2. [SEP] Clinical Trial: NCT01617668",Entailment,0.69056326,0.30943677
NCT01128543,Statement: the majority of patients in the primary trial experienced complete response by month 24. [SEP] Clinical Trial: NCT01128543,Contradiction,0.4557448,0.54425514
NCT02441946,"Statement: seem to get full quickly is a question about whether an individual gets full quickly when they eat. Patients with a breast tumor 0.2-0.8 cm in diameter, with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02441946",Contradiction,0.37917674,0.6208232
NCT00623831,Statement: all the patients in the primary clinical trial see no symptoms of increased pleural effusion or rapid disease progression [SEP] Clinical Trial: NCT00623831,Contradiction,0.43701836,0.5629816
NCT00843167,"Statement: malignant oropharyngeal neoplasm is a primary or metastatic malignant neoplasm that affects the oropharynx. the secondary trial uses pain as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. [SEP] Clinical Trial: NCT00843167",Contradiction,0.43983442,0.5601655
NCT01037790,"Statement: unlimited enrolment is available for the primary clinical trial, targeting patients with early stage colorectal cancer without kras or braf mutations. [SEP] Clinical Trial: NCT01037790",Entailment,0.55000824,0.4499918
NCT00632489,Statement: the primary clinical trial has disclosed findings for the lbh589 and lapatinib group. [SEP] Clinical Trial: NCT00632489,Entailment,0.54141057,0.4585894
NCT01205503,"Statement: Any patients with Documented allergy to cephalosporin or trimethoprim/sulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial. non-neoplastic esophageal disorder is a non-neoplastic disorder that affects the esophagus. representative examples include infections, ulcers, and gastroesophageal reflux disease. [SEP] Clinical Trial: NCT01205503",Entailment,0.629699,0.37030098
NCT00753415,"Statement: Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle. 17q11.2 is a chromosome band present on 17q [SEP] Clinical Trial: NCT00753415",Contradiction,0.32181796,0.67818207
NCT00245050,"Statement: the primary trial consisted of numerous test groups with the absence of a placebo group, while two test groups were absent in the secondary trial which had two control groups. [SEP] Clinical Trial: NCT00245050",Entailment,0.710467,0.289533
NCT02320123,"Statement: all participants in the primary clinical trial, regardless of their cohort, are required to view the educational dvd as part of the intervention [SEP] Clinical Trial: NCT02320123",Entailment,0.59810716,0.4018929
NCT00800436,"Statement: utilization of gabapentin or pregabalin in the past will dismiss the option of partaking in the secondary clinical trial, but the primary clinical trial will not impose this restriction. [SEP] Clinical Trial: NCT00800436",Entailment,0.8470994,0.15290059
NCT00706030,"Statement: adverse events, spanning a variety of types, were evenly distributed among patients across multiple cohorts in the primary clinical trial [SEP] Clinical Trial: NCT00706030",Entailment,0.73695546,0.26304454
NCT01964924,"Statement: an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial [SEP] Clinical Trial: NCT01964924",Contradiction,0.45148286,0.5485171
NCT00054028,"Statement: Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial intervention section does not describe what drugs are to be administered. [SEP] Clinical Trial: NCT00054028",Entailment,0.9172106,0.082789384
NCT02041429,Statement: smoked cigarettes since last visit to this clinic is a question about whether an individual smoked cigarettes since their last visit to this clinic. the primary trial and the secondary trial report on the MTD of different interventions. [SEP] Clinical Trial: NCT02041429,Entailment,0.70647967,0.29352033
NCT01614210,"Statement: nervous system part is any component of the entire nerve apparatus, including the brain, spinal cord, spinal nerves, autonomic ganglia, and plexuses. Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average. [SEP] Clinical Trial: NCT01614210",Contradiction,0.3567438,0.6432562
NCT00992602,"Statement: We cannot compare the adverse events in the primary trial and the secondary trial, as they do not appear to have been recorded for the primary trial. hypothyroidism is abnormally low levels of thyroid hormone. [SEP] Clinical Trial: NCT00992602",Entailment,0.81203175,0.18796828
NCT00370552,"Statement: grade 1 uveitis, ctcae is anterior uveitis with trace cells Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period . [SEP] Clinical Trial: NCT00370552",Contradiction,0.47439617,0.52560383
NCT01614210,Statement: results from the primary trial show that tamoxifen 20000 micrograms po daily for 7 days prior to surgery and for 14 days after breast cancer surgery reduces ki67 expression in tumors by 0.4 on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.42453787,0.5754621
NCT00586326,Statement: the primary clinical trial's intervention section does not provide a clear outline of the treatment cycle or radiation dose details. [SEP] Clinical Trial: NCT00586326,Entailment,0.8896469,0.110353075
NCT00795769,"Statement: Far more patients in the secondary trial were recorded to have experienced Aes, than patients in the primary trial. megacystis - megaureter is a condition characterized by a large capacity, thin-walled bladder and megaureter(s). [SEP] Clinical Trial: NCT00795769",Contradiction,0.38667825,0.6133218
NCT01706081,Statement: Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list. vestibulocochlear nerve disorder is a non-neoplastic or neoplastic disorder affecting the acoustic nerve. [SEP] Clinical Trial: NCT01706081,Entailment,0.5373248,0.4626752
NCT00538850,"Statement: the primary clinical trial measures the stage of chronic kidney disease using glomerular filtration rate (gfr), on the other hand, the secondary trial marks improvement from baseline at 12 months using cardiopulmonary exercise testing (cpet) [SEP] Clinical Trial: NCT00538850",Contradiction,0.42340976,0.5765903
NCT00104650,"Statement: the primary clinical trial saw the use of multiple drugs as interventions, however the route of administration remains the same. [SEP] Clinical Trial: NCT00104650",Entailment,0.5948628,0.4051372
NCT01498458,Statement: in the primary trial there were 300% the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.29267126,0.7073288
NCT01421472,"Statement: medical device time-to-event dataset is a dataset containing data that is used for medical device time-to-event analyses. Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial. [SEP] Clinical Trial: NCT01421472",Contradiction,0.45255807,0.5474419
NCT00800436,"Statement: past treatment with gabapentin or herceptin within the last three months, is necessary for inclusion in the secondary trial, but will result in exclusion from the primary trial [SEP] Clinical Trial: NCT00800436",Entailment,0.71475667,0.28524336
NCT01037790,"Statement: patients with tumors exhibiting ccnd1 amplification, cdk4/6 mutation, or ccnd2 amplification are not eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01037790",Entailment,0.8260153,0.17398475
NCT00021255,"Statement: Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs [SEP] Clinical Trial: NCT00021255",Contradiction,0.3781724,0.6218276
NCT01770353,"Statement: the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections. [SEP] Clinical Trial: NCT01770353",Contradiction,0.18563502,0.814365
NCT00708019,Statement: several of the patients in the primary trial experienced the no pain whatsoever during the 1680 hours of the study. [SEP] Clinical Trial: NCT00708019,Contradiction,0.2778791,0.72212094
NCT00475085,Statement: the primary clinical trial records and reports the number of participants in each subdivision. [SEP] Clinical Trial: NCT00475085,Entailment,0.5546219,0.4453781
NCT00786838,"Statement: in the primary clinical trial, the placebo and trabectedin are delivered identically, but on separate days. [SEP] Clinical Trial: NCT00786838",Entailment,0.69711304,0.30288696
NCT01535040,"Statement: in the primary clinical trial, the frequency and duration of administration are identical for both the placebo and the memantine interventions. [SEP] Clinical Trial: NCT01535040",Entailment,0.79818773,0.20181224
NCT00753415,Statement: cohort a of the primary clinical trial is administered a single infusion of hd v934 [SEP] Clinical Trial: NCT00753415,Contradiction,0.46405557,0.5359444
NCT00786838,"Statement: atrial myxoma is a cardiac myxoma arising from the atrium. The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days. [SEP] Clinical Trial: NCT00786838",Entailment,0.6409035,0.35909653
NCT02550795,"Statement: group 2 of the primary trial recieves 500ng/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. [SEP] Clinical Trial: NCT02550795",Entailment,0.81008154,0.18991844
NCT00825682,Statement: percentage food eaten score 30 is a subjective score of 30% on a scale that ranges from 0%: none to 100%: all of my food. The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Contradiction,0.47251058,0.5274894
NCT00194779,"Statement: participants in the primary clinical trial are required to take more than seven distinct drug types and undergo a surgical procedure, while those in the secondary clinical trial only need to take two different medications and are not required to have surgery [SEP] Clinical Trial: NCT00194779",Entailment,0.75452167,0.24547838
NCT00075764,"Statement: splitting pain is an intense sensation of discomfort or distress that feels like being cut apart. Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial. [SEP] Clinical Trial: NCT00075764",Entailment,0.7065708,0.29342914
NCT03403712,"Statement: the main focus of the primary trial is on the mean sleep duration of its patients, in contrast to the secondary trial that is investigating the number of participants who experience treatment-associated issues. [SEP] Clinical Trial: NCT03403712",Contradiction,0.49494502,0.50505495
NCT00432562,Statement: the primary clinical trial and the secondary clinical trial do not have any common inclusion or exclusion criteria. [SEP] Clinical Trial: NCT00432562,Entailment,0.9283719,0.07162804
NCT00405938,"Statement: light cell is a cell located in the collecting tube of the nephron.. Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial. [SEP] Clinical Trial: NCT00405938",Contradiction,0.35324222,0.6467578
NCT00792077,"Statement: the primary trial and secondary trial both uses the same dose of lenalidomide and lapatinib respectively in intervention 1, with equal periods for the intervention. [SEP] Clinical Trial: NCT00792077",Contradiction,0.42660287,0.57339716
NCT00030823,Statement: the primary clinical trial involved 13 participants who were administered the globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine [SEP] Clinical Trial: NCT00030823,Contradiction,0.3818199,0.6181801
NCT00825682,Statement: the intervention timeline in the secondary clinical trial is exactly identical as in the primary clinical trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.85144246,0.14855751
NCT00583700,"Statement: women aged 18 or 19 are eligible for the secondary trial, but will need to wait 1-2 years to be eligible for the primary trial. infraorder is a taxonomic category of related organisms ranking below a suborder and above a family. [SEP] Clinical Trial: NCT00583700",Contradiction,0.41489372,0.5851063
NCT02312934,"Statement: recovering alcoholics who currently abstain from drinking can participate in the primary clinical trial, but for the secondary clinical trial, regular drinking is a requirement. [SEP] Clinical Trial: NCT02312934",Entailment,0.6092681,0.39073193
NCT02179515,Statement: 100.0% of cohort 1 of the primary trial suffered some kind of adverse event [SEP] Clinical Trial: NCT02179515,Entailment,0.76985806,0.23014197
NCT00867217,Statement: patients with a diagnosis of breast cancer could be suitable for all study groups in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00867217,Contradiction,0.42042652,0.57957345
NCT01286168,"Statement: the most common adverse event in the secondary trial was anaemia, affecting more than 99.9% of patients, there were no recorded aes in the primary trial. [SEP] Clinical Trial: NCT01286168",Entailment,0.69047916,0.3095208
NCT00377156,"Statement: Diagnosis of 2-3 cerebral metastases will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. cgi questionnaire question is a question associated with the cgi questionnaire. [SEP] Clinical Trial: NCT00377156",Contradiction,0.49379793,0.5062021
NCT00496860,"Statement: in the primary clinical trial, cohort 1 receives less than half the dose of alt-801 that cohort 2 does [SEP] Clinical Trial: NCT00496860",Entailment,0.8667177,0.13328227
NCT00076024,Statement: no restrictions are placed on the hepatic function of individuals participating in the primary clinical trial [SEP] Clinical Trial: NCT00076024,Entailment,0.87777567,0.12222437
NCT01256567,Statement: a patient who underwent an organ transplant less than four weeks ago may participate in the primary clinical trial but is excluded from the secondary clinical trial [SEP] Clinical Trial: NCT01256567,Entailment,0.84184444,0.15815553
NCT00766532,"Statement: laryngeal fistula, ctcae is a disorder characterized by an abnormal communication between the larynx and another organ or anatomic site. There are several cases of swelling, hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00766532",Contradiction,0.21322368,0.78677636
NCT00686127,"Statement: the primary trial is found to have fewer total adverse events as compared to the secondary trial, while at the same time reporting lower instances of cardiac-ischemia/infarction than the secondary trial. [SEP] Clinical Trial: NCT00686127",Entailment,0.5432732,0.45672673
NCT01314963,Statement: intervention 2 of the primary clinical trial uses higher doses of radioactive tc99m sulfur colloid than intervention 1. [SEP] Clinical Trial: NCT01314963,Entailment,0.65845937,0.3415406
NCT00122369,"Statement: microscopic findings group identifier is a character or string that represents a microscopic findings group. the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.8663241,0.1336759
NCT01706081,"Statement: both acupuncture and testosterone cream showed similar effectiveness in treating lymphedema in the primary trial, with no apparent advantage of one over the other. [SEP] Clinical Trial: NCT01706081",Entailment,0.7398319,0.26016808
NCT01806259,Statement: 43 participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 20 from the nacl 0.9% 3.86ml group [SEP] Clinical Trial: NCT01806259,Contradiction,0.3821168,0.61788315
NCT00088413,"Statement: The majority of the adverse events recorded in the primary trial were blood and bone marrow related, this is not the case for the secondary trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.87795454,0.12204545
NCT00305695,"Statement: hepatitis b virus surface antigen negative is an indication that the hepatitis b virus surface protein antigen has not been detected in a sample.  intervention 1 in the primary trial, and all intervention drugs in the secondary trial must be administered intravenously. [SEP] Clinical Trial: NCT00305695",Entailment,0.5971045,0.4028955
NCT00538850,"Statement: the the primary trial results report the severity of delayed nausea on a scale of 1-20, and the secondary trial measures the change from baseline to 12 weeks in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850",Contradiction,0.4455283,0.55447173
NCT00929240,Statement: the bevacizumab + capecitabine cohort in the primary clinical trial demonstrated a higher rate of disease progression or death than the bevacizumab only cohort. [SEP] Clinical Trial: NCT00929240,Entailment,0.6653955,0.33460444
NCT02761642,"Statement: representation in either the primary clinical trial or the secondary clinical trial is not open to cancer patients diagnosed with fibromyalgia, thalasemic syndromes, or anemia. [SEP] Clinical Trial: NCT02761642",Entailment,0.61455685,0.38544315
NCT01111825,"Statement: cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+ [SEP] Clinical Trial: NCT01111825",Contradiction,0.47641304,0.5235869
NCT00245050,Statement: both the primary and secondary trials used multiple test groups without any placebo group in either case. [SEP] Clinical Trial: NCT00245050,Entailment,0.8949447,0.10505525
NCT00753415,Statement: Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934. preterm birth complication is a complication related to a premature birth that occurs to a baby born prior to 37 weeks gestation. [SEP] Clinical Trial: NCT00753415,Contradiction,0.3737208,0.62627923
NCT00377156,"Statement: a diagnosis indicating 2-3 cerebral metastases within the brainstem will cause the patient to be ineligible for the secondary clinical trial, yet this diagnosis may still qualify patients for the primary clinical trial. [SEP] Clinical Trial: NCT00377156",Entailment,0.62766725,0.37233278
NCT00838929,Statement: Every patient in the primary trial is receives a dose of 100 to 1600 ¬¨¬µg fentanyl sublingual spray during radiation therapy [SEP] Clinical Trial: NCT00838929,Contradiction,0.45794195,0.5420581
NCT00896454,Statement: the unit of measure reported in the primary clinical trial differs from that used in the secondary clinical trial. [SEP] Clinical Trial: NCT00896454,Entailment,0.91277236,0.08722768
NCT01908101,Statement: the patients in the primary clinical trial receive a greater dosage of radiation treatment than those involved in the secondary clinical trial [SEP] Clinical Trial: NCT01908101,Entailment,0.77626914,0.22373085
NCT00698035,"Statement: the primary clinical trial is focused on the use of external treatments, and the secondary trial is centered around the study of inhalable ones. [SEP] Clinical Trial: NCT00698035",Entailment,0.5426634,0.4573366
NCT02441946,"Statement: patients with a tnbc tumor of 18cm in diameter, are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.32752925,0.67247075
NCT00262834,Statement: several adverse events occurred during the primary clinical trial and skin infections in the secondary clinical trial affected the majority of patients [SEP] Clinical Trial: NCT00262834,Contradiction,0.39601222,0.6039878
NCT03125941,Statement: did you cough up blood is a question about whether an individual coughed up blood. Both the primary trial cohorts receive pre-operative Dexamethasone. [SEP] Clinical Trial: NCT03125941,Entailment,0.5054418,0.4945582
NCT00122369,"Statement: the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation. alpha thalassemia is a genetic hematologic disorder characterized by partial or complete absence of the alpha globin chains of the heme molecule. [SEP] Clinical Trial: NCT00122369",Entailment,0.78689015,0.21310985
NCT01390818,Statement: no adverse events were documented for cohort 1 patients in the primary clinical trial [SEP] Clinical Trial: NCT01390818,Entailment,0.8821553,0.11784473
NCT00950911,"Statement: a dosage of zoledronic acid 12 times greater than the dosage of denosumab is used in the first intervention of the primary clinical trial, as compared to the first intervention in the secondary clinical trial. [SEP] Clinical Trial: NCT00950911",Entailment,0.5940092,0.40599072
NCT01256567,Statement: a patient recuperating from an organ transplant within the last month and still being bedridden would be disqualified from the primary clinical trial but might qualify for the secondary clinical trial [SEP] Clinical Trial: NCT01256567,Entailment,0.73228127,0.2677187
NCT01806675,"Statement: ie rhabdomyosarcoma regimen is a chemotherapy regimen consisting of etoposide and ifosfamide that may be used in the treatment of rhabdomyosarcoma. Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2. [SEP] Clinical Trial: NCT01806675",Contradiction,0.39806575,0.6019343
NCT02222922,"Statement: in the secondary clinical trial, participants are administered lower doses of drugs than the participants in the primary clinical trial [SEP] Clinical Trial: NCT02222922",Entailment,0.8326369,0.16736312
NCT01290536,"Statement: in the secondary clinical trial, the intervention involves proton-beam therapy combined with capecitabine. [SEP] Clinical Trial: NCT01290536",Entailment,0.5396194,0.46038058
NCT01770353,"Statement: although the interventions in the primary clinical trial and the secondary clinical trial both involve intravenous injections, there is a considerable distinction in the drugs, dosages, and frequency of administration used. [SEP] Clinical Trial: NCT01770353",Contradiction,0.274737,0.725263
NCT01989546,"Statement: primary clinical trial does not allow candidates to engage in cbt-based treatments, while the secondary clinical trial might still consider them as potential candidates. [SEP] Clinical Trial: NCT01989546",Entailment,0.78336596,0.21663402
NCT01048099,Statement: not a single kind of adverse event registered in the primary clinical trial influenced more than a quarter of the patient group [SEP] Clinical Trial: NCT01048099,Entailment,0.69265366,0.30734637
NCT02504424,"Statement: Nobody taking part in the primary trial suffered a UTI. mediastinal sarcoma is a rare sarcoma that arises from the mediastinum.  examples include liposarcoma, leiomyosarcoma, and angiosarcoma. [SEP] Clinical Trial: NCT02504424",Entailment,0.55485505,0.44514492
NCT01013740,Statement: patients enrolled in both the primary and secondary trial remained free from tumour lysis syndrome [SEP] Clinical Trial: NCT01013740,Entailment,0.72744155,0.27255842
NCT00293540,"Statement: On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years. [SEP] Clinical Trial: NCT00293540",Contradiction,0.43175983,0.56824017
NCT01008904,Statement: the primary clinical trial has a multitude of adverse events recorded for its patient cohort. [SEP] Clinical Trial: NCT01008904,Entailment,0.88800013,0.111999884
NCT01855828,"Statement: in the primary clinical trial, numerous psychiatric side effects were observed, such as an eating disorder and schizophrenia [SEP] Clinical Trial: NCT01855828",Contradiction,0.4030376,0.5969624
NCT01106898,Statement: 97% of patients in the primary trial did not experience any Adverse Events. bilateral malignant neoplasm is a malignant neoplasm that affects both sides of an organ in a simultaneous or non-simultaneous manner. [SEP] Clinical Trial: NCT01106898,Entailment,0.6153259,0.3846741
NCT01766102,"Statement: Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore the control group performed better than the test group in this regard. In the secondary trial there is no control group against which we can compare. [SEP] Clinical Trial: NCT01766102",Entailment,0.823176,0.17682405
NCT02796755,Statement: there were minimal adverse events observed in the secondary clinical trial as compared to the primary clinical trial.' [SEP] Clinical Trial: NCT02796755,Entailment,0.822162,0.17783809
NCT00262834,Statement: numerous adverse events were noted in the primary clinical trial and over half of the patients in the secondary clinical trial were affected by skin infections [SEP] Clinical Trial: NCT00262834,Contradiction,0.4465127,0.5534873
NCT01908101,Statement: the drugs tested in the primary clinical trial and the secondary clinical trial are not the same [SEP] Clinical Trial: NCT01908101,Entailment,0.92014813,0.079851806
NCT00001832,Statement: the interventions in both the primary trial and secondary trial leverage the same medication for treatment. [SEP] Clinical Trial: NCT00001832,Entailment,0.8044027,0.19559735
NCT02104830,"Statement: cohort 2 of the primary clinical trial experienced significantly fewer incidents of neutropenia compared to cohort 1 of the secondary clinical trial, despite receiving larger doses of empegfilgrastim. [SEP] Clinical Trial: NCT02104830",Entailment,0.5204759,0.47952414
NCT00586326,Statement: The the primary trial intervention section does not outline a treatment cycle or any description of the treatment [SEP] Clinical Trial: NCT00586326,Entailment,0.92879283,0.07120717
NCT01772004,"Statement: the primary clinical trial is open to african-american participants, given that they are residing in texas throughout the study period. [SEP] Clinical Trial: NCT01772004",Entailment,0.52067506,0.479325
NCT00819182,"Statement: the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group. covid-19-associated acute hemorrhagic necrotizing encephalitis is acute hemorrhagic necrotizing encephalitis caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2). [SEP] Clinical Trial: NCT00819182",Contradiction,0.4770252,0.5229748
NCT01614210,"Statement: clinical status ordinal scale is a scale designed to assess a patient's clinical status at enrollment, prior to any on-study therapy. Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average. [SEP] Clinical Trial: NCT01614210",Contradiction,0.40996927,0.5900308
NCT02640053,Statement: patients in the primary clinical trial that received paclitaxel infusions experienced more severe symptoms than those who did not receive paclitaxel infusions. [SEP] Clinical Trial: NCT02640053,Entailment,0.66994506,0.33005494
NCT01252290,Statement: less than 0.05 of patients in the primary trial suffered aes [SEP] Clinical Trial: NCT01252290,Entailment,0.8264221,0.1735779
NCT02550795,"Statement: Group 2 of the primary trial recieves 0.5ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. [SEP] Clinical Trial: NCT02550795",Entailment,0.82191575,0.17808424
NCT02441946,"Statement: vital signs sequence number is an identifier that describes the relative position of vital signs data within a series. Patients with a TNBC tumor of 100mm in diameter, are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02441946",Contradiction,0.37393388,0.62606615
NCT00819182,"Statement: in the primary clinical trial, patients in the fast, shallow respiration group experienced fewer hot flashes per day on average than those in the paced respiration intervention group. [SEP] Clinical Trial: NCT00819182",Entailment,0.6667592,0.33324084
NCT00432562,Statement: there are 0.0 shared inclusion/exclusion criteria between the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00432562,Entailment,0.7958457,0.20415431
NCT02761642,"Statement: Any cancer patient diagnosed with either fibromyalgia, thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial. specify kit exons assessed is a request to enter the kit exons assessed for mutations in this section of the form. [SEP] Clinical Trial: NCT02761642",Entailment,0.60643303,0.39356697
NCT01772004,"Statement: cyp3a4 polymorphism positive is an indication that polymorphism of the cyp3a4 gene has been detected in a sample. African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study. [SEP] Clinical Trial: NCT01772004",Entailment,0.5109219,0.48907813
NCT01997333,"Statement: colorectal adenoma with moderate dysplasia is an adenoma that arises from the colon or rectum.  it is characterized by the presence of moderate epithelial dysplasia. The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death . [SEP] Clinical Trial: NCT01997333",Contradiction,0.40646893,0.5935311
NCT01419717,"Statement: nickel is an element with atomic symbol ni, atomic number 28, and atomic weight 58.69. the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using Lymphoscintigraphy. [SEP] Clinical Trial: NCT01419717",Contradiction,0.35321742,0.6467826
NCT00538850,Statement: the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 18 months in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850,Contradiction,0.39767176,0.6023283
NCT00321048,"Statement: Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan. paraguay is a country in central south america, northeast of argentina. [SEP] Clinical Trial: NCT00321048",Contradiction,0.28015998,0.71984
NCT01011218,Statement: over 10 fatalities were documented as adverse events in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01011218,Entailment,0.7115678,0.2884322
NCT00357734,"Statement: the administration of zd1839 is the sole intervention for the primary clinical trial, whereas the secondary clinical trial commands a multi-drug therapy which includes zoledronic acid, samarium-153, and pegfilgrastim. [SEP] Clinical Trial: NCT00357734",Contradiction,0.47723562,0.5227644
NCT01989546,"Statement: deafness is an inherited or acquired condition characterized by the inability to hear in one or both ears. CBT based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. [SEP] Clinical Trial: NCT01989546",Contradiction,0.46687186,0.53312814
NCT00659373,"Statement: all participants in the primary clinical trial showed a drop in cognitive abilities, especially those in the ovarian function suppression group [SEP] Clinical Trial: NCT00659373",Entailment,0.5383188,0.4616812
NCT00825682,Statement: the intervention in the secondary trial last 300% longer than the intervention detailed in the primary trial. [SEP] Clinical Trial: NCT00825682,Entailment,0.6922101,0.3077899
NCT00569166,"Statement: both cohorts 1 and 2 in the primary clinical trial adhere to the same instruction cd for paced breathing, however, the practice sessions are doubled for cohort 2. [SEP] Clinical Trial: NCT00569166",Contradiction,0.2884737,0.71152633
NCT01351376,Statement: those having assessable bilateral breast cancer are qualified to join the primary clinical trial [SEP] Clinical Trial: NCT01351376,Entailment,0.57387173,0.4261283
NCT02320123,Statement: Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention [SEP] Clinical Trial: NCT02320123,Entailment,0.6031628,0.3968372
NCT01023477,"Statement: patients with a low potassium count are ineligible for the primary clinical trial, yet may qualify for the secondary clinical trial [SEP] Clinical Trial: NCT01023477",Entailment,0.77129734,0.22870272
NCT00373256,Statement: all the participants of cohort 1 and cohort 2 in the primary clinical trial are prescribed a uniform dosage of 5 mg/kg of bevacizumab [SEP] Clinical Trial: NCT00373256,Contradiction,0.31677243,0.6832276
NCT01649271,"Statement: one shingles case was reported in the secondary clinical trial, specifically in group 2. however, both the primary clinical trial and group 1 of the secondary trial recorded no instances of shingles. [SEP] Clinical Trial: NCT01649271",Entailment,0.7382885,0.26171142
NCT00254592,"Statement: 2p16.3 is a chromosome band present on 2p the primary trial and the secondary trial both administer cyclophosphamide, Paclitaxel and pegfilgrastim to their patient cohorts. [SEP] Clinical Trial: NCT00254592",Contradiction,0.17181209,0.82818794
NCT01803282,"Statement: none of the participants, neither in the primary nor in the secondary trial, suffered an acute myocardial infarction. [SEP] Clinical Trial: NCT01803282",Entailment,0.7223489,0.277651
NCT00583700,Statement: women aged 18 or older are eligible for the secondary trial and the primary trial. high inspiratory pressure alarm device is a device designed to signal the occurrence of a high pressure event associated with a mechanical ventilation device. [SEP] Clinical Trial: NCT00583700,Contradiction,0.31001365,0.6899863
NCT00293540,"Statement: on average patients from the primary trial survive over 730 days, however at least one patient from both cohorts died in under 730 days. [SEP] Clinical Trial: NCT00293540",Contradiction,0.44683546,0.5531645
NCT02550795,"Statement: group 2 in the primary trial receive placebo, and patients in the secondary trial cohorts get 0.5ug/kg of myalgias(5ml). [SEP] Clinical Trial: NCT02550795",Contradiction,0.32696113,0.6730389
NCT01023477,"Statement: patients with hyperkalemia, are disqualified from both the primary and the secondary clinical trials, while hypokalemic patients could participate in both trials. [SEP] Clinical Trial: NCT01023477",Entailment,0.6513786,0.3486215
NCT00266110,Statement: Patients in the primary trial will need to receive one single injection on day 8 of the study. [SEP] Clinical Trial: NCT00266110,Entailment,0.560444,0.439556
NCT01129622,Statement: Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01129622,Entailment,0.6488204,0.35117963
NCT00451555,"Statement: Participants must be resistant to AI therapy to participate in the primary trial, but this is not necessary to be included in the secondary trial [SEP] Clinical Trial: NCT00451555",Entailment,0.8673356,0.13266444
NCT01908101,Statement: primary clinical trial patients are administered with larger amounts of radiation therapy compared to the participants of the secondary clinical trial [SEP] Clinical Trial: NCT01908101,Entailment,0.70059955,0.29940045
NCT00454532,Statement: Most patients in the secondary trial and the primary trial did not suffer any adverse events [SEP] Clinical Trial: NCT00454532,Entailment,0.76334924,0.23665082
NCT01781299,Statement: dialpack dosing unit is a dosing unit equal to the amount of active ingredient(s) contained in a reusable circular compact package. There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01781299,Contradiction,0.3660058,0.6339942
NCT02273206,"Statement: many patients in the first cohort of the primary clinical trial did not adhere to their screening schedules following the intervention, independent of their cancer type. [SEP] Clinical Trial: NCT02273206",Entailment,0.7188822,0.2811178
NCT00475085,"Statement: bone marrow collection is any process that harvests bone marrow for clinical or manufacturing purposes. the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort. [SEP] Clinical Trial: NCT00475085",Entailment,0.83822834,0.16177167
NCT00321464,"Statement: Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial. tdi clinical classification question is a question associated with the tdi questionnaire. [SEP] Clinical Trial: NCT00321464",Entailment,0.50441366,0.4955863
NCT02286843,Statement: 5% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.4563228,0.5436772
NCT00254592,"Statement: cyclophosphamide, paclitaxel, and pegfilgrastim are not part of the treatment protocols in either the primary clinical trial or the secondary clinical trial [SEP] Clinical Trial: NCT00254592",Entailment,0.861681,0.13831902
NCT00429182,Statement: under 50% of the primary clinical trial's participants experienced a decrease in circulating tumor cells after receiving high-dose chemotherapy along with purged autologous stem cell products. [SEP] Clinical Trial: NCT00429182,Contradiction,0.44933698,0.55066305
NCT03069313,Statement: oral administration of interventions is utilized by both the primary and the secondary clinical trials. [SEP] Clinical Trial: NCT03069313,Entailment,0.61316466,0.38683528
NCT02002533,Statement: the primary clinical trial recorded multiple adverse events. [SEP] Clinical Trial: NCT02002533,Entailment,0.80183446,0.19816555
NCT01127763,"Statement: 5 patients in the primary trial suffered 3 or more adverse events. intestinal route of administration is administration of a medicinal product to the intestine (duodenum, jejunum, ileum and colon) by means of an appropriate device. [SEP] Clinical Trial: NCT01127763",Entailment,0.5524061,0.4475939
NCT01351376,Statement: participants with quantifiable bilateral breast cancer are suitable for the primary clinical trial [SEP] Clinical Trial: NCT01351376,Entailment,0.6016713,0.3983287
NCT00432562,Statement: having the ability to offer written informed consent is the only mutual inclusion/exclusion condition in both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00432562,Entailment,0.76930285,0.2306972
NCT00146172,"Statement: candidates who are completely independent and physically active, engaged in light work activities for long hours are eligible for both primary clinical trial and secondary clinical trial [SEP] Clinical Trial: NCT00146172",Contradiction,0.3031173,0.69688267
NCT00321048,"Statement: Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan. [SEP] Clinical Trial: NCT00321048",Contradiction,0.3094477,0.6905523
NCT02403271,Statement: unresectable gallbladder carcinoma is a carcinoma that arises from the gallbladder and it is not amenable to surgical resection. There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial. [SEP] Clinical Trial: NCT02403271,Entailment,0.5818152,0.41818482
NCT00054028,Statement: vinblastine and doxorubicin are routinely used in the primary clinical trial and the agent for the secondary clinical trial remains undisclosed. [SEP] Clinical Trial: NCT00054028,Entailment,0.89580935,0.104190595
NCT00104650,Statement: various techniques are used to administer the interventions in the primary clinical trial. [SEP] Clinical Trial: NCT00104650,Entailment,0.7635713,0.23642872
NCT01156987,"Statement: Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. structured title data type is a data type comprised of structured text that comprises a title. [SEP] Clinical Trial: NCT01156987",Contradiction,0.3285307,0.6714693
NCT00305695,"Statement: the primary trial requires that intervention 1 be administered transdermally, and in the secondary trial, all intervention drugs are delivered intramuscularly. [SEP] Clinical Trial: NCT00305695",Entailment,0.6789015,0.32109854
NCT00428220,"Statement: type 2 renal papillary adenoma is a renal papillary adenoma which is characterized by eosinophilic cells. Ascites was more common for patients in the primary trial, and Pneumocystis jirovecii pneumonia was more common in the secondary trial. [SEP] Clinical Trial: NCT00428220",Contradiction,0.39498207,0.6050179
NCT01535040,Statement: get ringing or buzzing in ears is a question about whether an individual gets or has gotten a ringing or buzzing in their ears. In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time. [SEP] Clinical Trial: NCT01535040,Contradiction,0.4144372,0.58556277
NCT01205503,Statement: any patients with a well-documented allergy to cefuroxime or nitrofurantoin can participate in both the primary and secondary trials. [SEP] Clinical Trial: NCT01205503,Entailment,0.5384635,0.4615366
NCT02320123,Statement: Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention. have not received treatment is a response indicating that an individual has not been treated for cancer. [SEP] Clinical Trial: NCT02320123,Entailment,0.71611226,0.28388774
NCT00583700,"Statement: women aged 30 or 35 are eligible for the secondary trial, but will need to wait 5-6 years to be eligible for the primary trial [SEP] Clinical Trial: NCT00583700",Contradiction,0.46097568,0.5390243
NCT02115607,Statement: the primary trial presented fewer cases of intestinal perforation than the secondary trial [SEP] Clinical Trial: NCT02115607,Entailment,0.789529,0.21047093
NCT00956813,Statement: the primary and secondary trials share matching outcome measures in their results [SEP] Clinical Trial: NCT00956813,Entailment,0.8711936,0.12880637
NCT01498458,"Statement: in the primary clinical trial, the number of cases of hepatotoxicity was less than the cases of hypertension and pancreatectomy [SEP] Clinical Trial: NCT01498458",Entailment,0.63108754,0.36891246
NCT02320123,Statement: only the first cohort participating in the primary clinical trial will be exposed to the educational dvd as part of the intervention [SEP] Clinical Trial: NCT02320123,Entailment,0.537236,0.462764
NCT00467844,Statement: acquired cytomegaloviral infection is an infection with the cytomegalovirus that is not present from birth. at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass. [SEP] Clinical Trial: NCT00467844,Contradiction,0.44952735,0.5504727
NCT02441946,"Statement: the primary clinical trial and the secondary clinical trial are open to patients with a lung tumor that is 0.9-3.2 cm in diameter, and have a confirmed kras mutation [SEP] Clinical Trial: NCT02441946",Contradiction,0.25627434,0.74372566
NCT01290536,"Statement: The the primary trial intervention consists of Radioembolization using TheraSpheres, on the other hand the secondary trial intervention is based on ibrutinib and MEDI4736. spinal chordoma is a chordoma that arises from the spine. [SEP] Clinical Trial: NCT01290536",Contradiction,0.37719223,0.6228078
NCT00467844,Statement: no patients treated with gtx-024 1mg in the primary clinical trial gained lean body mass over a 4 month period [SEP] Clinical Trial: NCT00467844,Entailment,0.683047,0.316953
NCT00319748,Statement: the ki67 expression in tumors is not assessed in either the primary or secondary clinical trial. [SEP] Clinical Trial: NCT00319748,Entailment,0.896466,0.10353403
NCT01011218,"Statement: in both the primary clinical trial and the secondary clinical trial, a single death was noted in the adverse events. [SEP] Clinical Trial: NCT01011218",Entailment,0.7403965,0.25960353
NCT00001832,"Statement: the secondary clinical trial requires that patients take a daily dosage of florbetaben (18f), the primary clinical trial, however, demands no medication intake [SEP] Clinical Trial: NCT00001832",Entailment,0.77475893,0.22524104
NCT01975831,"Statement: between interventions 1 and 2 in the primary clinical trial, the only variances exist in the durva dosage; as cohort 1 receives 0.7mg less in their monthly injections than cohort 2. [SEP] Clinical Trial: NCT01975831",Entailment,0.5040375,0.4959625
NCT03092934,"Statement: patients, regardless of their gender, having a solid tumor that is either locally advanced or metastatic may participate in both phases of the primary clinical trial. [SEP] Clinical Trial: NCT03092934",Entailment,0.56119704,0.43880302
NCT00786838,"Statement: The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days. [SEP] Clinical Trial: NCT00786838",Entailment,0.7937023,0.20629764
NCT00454532,Statement: few participants in the primary and secondary clinical trials experienced adverse incidents. [SEP] Clinical Trial: NCT00454532,Entailment,0.76740843,0.23259161
NCT01178411,"Statement: a patient's nationality, ethnicity, mental conditions, or gender are not factors considered when determining eligibility for the primary and secondary clinical trials [SEP] Clinical Trial: NCT01178411",Contradiction,0.4844329,0.5155671
NCT00766532,"Statement: There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial. [SEP] Clinical Trial: NCT00766532",Contradiction,0.37198317,0.6280168
NCT01537029,"Statement: male patients with neuroblastoma over the age of 60 can participate in the primary clinical trial, regardless of race or ethnic origin. however, for the secondary clinical trial, they must have brca1+ ovarian cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.37534127,0.6246587
NCT00911898,"Statement: details regarding the mode of administration, dosage, or cycle are absent in the intervention sector of the primary clinical trial. [SEP] Clinical Trial: NCT00911898",Entailment,0.913112,0.08688805
NCT01048099,Statement: None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort [SEP] Clinical Trial: NCT01048099,Entailment,0.73792785,0.26207218
NCT00756496,"Statement: notable disparities were evident in the assessment of groups in the primary clinical trial, on the contrary, uniform results were recorded between the reflexology group and control group in the secondary clinical trial. [SEP] Clinical Trial: NCT00756496",Contradiction,0.48426154,0.5157385
NCT02640053,"Statement: during the primary clinical trial, patients not receiving topical cryotherapy suffered worse symptoms than the group who underwent the procedure. [SEP] Clinical Trial: NCT02640053",Entailment,0.6526881,0.3473119
NCT01649271,Statement: there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01649271,Contradiction,0.3906998,0.60930026
NCT00270894,Statement: the primary clinical trial prescribes no medication for the duration of the study. [SEP] Clinical Trial: NCT00270894,Entailment,0.92211306,0.077887
NCT01831089,Statement: Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial. specify tumor location is a request to specify the anatomic site of the tumor. [SEP] Clinical Trial: NCT01831089,Entailment,0.5206877,0.47931227
NCT00256698,Statement: Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial [SEP] Clinical Trial: NCT00256698,Entailment,0.8110768,0.1889232
NCT00828516,Statement: is value for gdc property is an association that that connects a concept representing a gdc value to any associated gdc property concept(s). Neither the secondary trial or the primary trial use the Number of Participants With Treatment-emergent Aes as the outcome measurement for their studies. [SEP] Clinical Trial: NCT00828516,Entailment,0.529294,0.470706
NCT01376349,"Statement: neither centimeters, number of individuals, or time duration are used as units of measure in the primary or secondary clinical trial. [SEP] Clinical Trial: NCT01376349",Contradiction,0.4715772,0.52842283
NCT03015649,Statement: both the primary trial and the secondary clinical trial reported no adverse events in their cohorts. [SEP] Clinical Trial: NCT03015649,Entailment,0.9037629,0.09623704
NCT01730729,"Statement: the intervention in the primary trial is given through a needle inserted into a vein, while the secondary trial involves a topical application [SEP] Clinical Trial: NCT01730729",Entailment,0.6236276,0.37637246
NCT00266110,Statement: the primary clinical trial involves patients receiving a number of injections [SEP] Clinical Trial: NCT00266110,Entailment,0.6234117,0.37658828
NCT01171924,"Statement: telecommunication address type is a particular category of telecommunication address regarded as having particular characteristics, qualities, type of usage, and defined similarities. cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly. [SEP] Clinical Trial: NCT01171924",Contradiction,0.40791342,0.59208655
NCT00405938,"Statement: patients can not have a history of abdominal fistula, gastrointestinal perforation,postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 60 years if they want to participate in the primary trial [SEP] Clinical Trial: NCT00405938",Contradiction,0.37676287,0.6232371
NCT01286987,Statement: Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention. adhesion g protein-coupled receptor e1 staining method is an immunohistochemical technique used to detect the presence of adhesion g protein-coupled receptor e1 in a tissue sample. [SEP] Clinical Trial: NCT01286987,Entailment,0.5252787,0.4747213
NCT00708019,Statement: pervasive pain was a common experience reported by patients throughout the full course of the primary clinical trial. [SEP] Clinical Trial: NCT00708019,Entailment,0.642921,0.35707903
NCT00756496,"Statement: substantial variations were seen in the results of the groups participating in the primary clinical trial, while a disparity was observed between the reflexology group and the control group in the secondary clinical trial. [SEP] Clinical Trial: NCT00756496",Entailment,0.6378083,0.36219174
NCT01537029,"Statement: eligibility for the primary clinical trial is determined by being a female cancer patient aged 18 or above, of any race or ethnicity and diagnosed with any type of cancer, while the secondary clinical trial specifically requires patients with brca+ breast cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.44138262,0.55861735
NCT00706030,Statement: four unique adverse events impacted patients in cohort 2 of the primary clinical trial. [SEP] Clinical Trial: NCT00706030,Entailment,0.8161483,0.1838517
NCT00248547,"Statement: All Patients receiving the placebo intervention in the primary trial experienced emesis . dysuria, ctcae is a disorder characterized by painful urination. [SEP] Clinical Trial: NCT00248547",Contradiction,0.4404798,0.55952024
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID. biospecimen condition is a characteristic that refers to the physical and organoleptic state of a biospecimen. [SEP] Clinical Trial: NCT00836186",Contradiction,0.37633508,0.62366486
NCT01614210,Statement: results from the primary trial show that tamoxifen 80 mg po daily for 21 days prior to surgery and for 10 days after breast cancer surgery reduces the diameter of tumors by 90% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.3435352,0.6564648
NCT02187783,"Statement: cohort 2 of the primary clinical trial reported more cases of palpitations, pericardial effusions, and abdominal pains than cohort 1 of the secondary clinical trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.45826653,0.54173344
NCT00756717,Statement: lig4 gene mutation is a change in the nucleotide sequence of the lig4 gene. There were 0 adverse events in the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00756717,Entailment,0.5198944,0.4801056
NCT03202472,"Statement: those patients with a history of chemotherapy or radiotherapy within the preceding 2 weeks or those exhibiting signs of unstable angina or showing grade 2 or better neuropathy, are not eligible for the secondary clinical trial, but could remain eligible for the primary clinical trial if all applicable inclusion criteria are satisfied. [SEP] Clinical Trial: NCT03202472",Contradiction,0.3955036,0.60449636
NCT01351376,Statement: individuals suffering from bilateral non-cancerous breast lesions are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT01351376,Entailment,0.59756285,0.4024371
NCT00253708,"Statement: the primary clinical trial does not conduct any drug-related tests, in contrast, the secondary clinical trial carries out assessments of two varied medications. [SEP] Clinical Trial: NCT00253708",Entailment,0.7875482,0.21245185
NCT03015649,Statement: the primary trial recorded a greater number of adverse events in its cohort compared to the secondary trial. [SEP] Clinical Trial: NCT03015649,Entailment,0.8449375,0.15506253
NCT01617668,"Statement: in the primary clinical trial, cohort 1 experienced a higher incidence of adverse events as compared to those in cohort 2. [SEP] Clinical Trial: NCT01617668",Entailment,0.8238549,0.17614508
NCT00416715,"Statement: candidates for the secondary trial study group receive 6 daily subcutaneous (sc) injections, whereas the primary trial participants only receive 2 injections at the beginning of the study. [SEP] Clinical Trial: NCT00416715",Entailment,0.5496279,0.4503721
NCT00775645,Statement: in both the primary trial and the secondary trial there were several adverse events which occurred in more than 0.3 of participants. [SEP] Clinical Trial: NCT00775645,Contradiction,0.25908655,0.74091345
NCT00451555,"Statement: participants in the primary clinical trial must have responded positively to ai therapy and mirtazapine, and the same response to these treatments is required in the secondary clinical trial [SEP] Clinical Trial: NCT00451555",Contradiction,0.49768382,0.5023162
NCT00454532,Statement: less than 3% of patients in the primary clinical trial and the secondary clinical trial documented adverse events [SEP] Clinical Trial: NCT00454532,Entailment,0.7489163,0.25108364
NCT01091974,"Statement: in the primary clinical trial, all cohorts receive lisdexamfetamine orally, and in the secondary clinical trial, patients receive different doses of pdr001 but the same dose of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.47196797,0.52803206
NCT00104650,Statement: only one type of route is used for administering interventions in the primary clinical trial. [SEP] Clinical Trial: NCT00104650,Entailment,0.84878635,0.15121363
NCT00076024,Statement: all the participants of the primary clinical trial must have demonstrable hepatic disease. [SEP] Clinical Trial: NCT00076024,Entailment,0.63737214,0.36262783
NCT01881230,"Statement: Both cohorts of the primary trial receive the same doses of Abraxane. viral laryngitis is acute inflammation of the larynx caused by viruses, including rhinovirus, influenza virus, parainfluenza virus, and adenovirus. [SEP] Clinical Trial: NCT01881230",Contradiction,0.44891834,0.55108166
NCT01869192,"Statement: the primary clinical trial's results demonstrate a superior overall response rate for the arm a intervention compared to the placebo group. in addition, the secondary clinical trial indicates that the denosumab group had an improved time to first on-study sre compared to the zoledronic acid group. [SEP] Clinical Trial: NCT01869192",Entailment,0.5217144,0.47828558
NCT00836186,"Statement: in the primary clinical trial, whole breast radiation therapy is given to participants, while in the secondary clinical trial, both cohorts receive intramuscular injections and also take prescribed medication orally. [SEP] Clinical Trial: NCT00836186",Contradiction,0.44131052,0.55868953
NCT01286987,Statement: breast cancer patients in the primary clinical trial undergo a different intervention compared to ovarian/ peritoneal cancer patients. [SEP] Clinical Trial: NCT01286987,Entailment,0.83379906,0.16620098
NCT02988986,Statement: over 10 weeks of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 50% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Entailment,0.51433223,0.48566777
NCT00357734,"Statement: The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim. haemophilus parahaemolyticus, penicillinase positive is any bacterial species identified as haemophilus parahaemolyticus that produces the enzyme penicillinase. [SEP] Clinical Trial: NCT00357734",Contradiction,0.4783924,0.52160764
NCT02796755,Statement: assamese language is an eastern indo-aryan language spoken mainly in the indian state of assam. the primary trial and the secondary trial do not have any recorded adverse events for their participants. [SEP] Clinical Trial: NCT02796755,Entailment,0.8213871,0.17861292
NCT01451632,"Statement: while both cohort 1 and cohort 2 of the primary clinical trial were given equal dosage of cetuximab, an additional collaborative care intervention was provided to cohort 1. [SEP] Clinical Trial: NCT01451632",Entailment,0.55692136,0.4430786
NCT00256698,"Statement: perjeta is not used within any cohorts of the secondary trial, but is regularly administered during the primary trial. [SEP] Clinical Trial: NCT00256698",Entailment,0.5559358,0.44406414
NCT00992602,Statement: There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial. direct antiglobulin test is a measurement of the antibody or complement-coated erythrocytes in a blood specimen in vivo. [SEP] Clinical Trial: NCT00992602,Entailment,0.52630806,0.47369194
NCT01008150,"Statement: in the primary clinical trial, both cohorts observed more than a third of their patients achieving pathologic complete response in breast and axillary lymph nodes, approximately seven months into the investigation [SEP] Clinical Trial: NCT01008150",Contradiction,0.3490664,0.65093356
NCT01869192,"Statement: the arm a intervention proved to be the most successful in terms of overall response rate in the primary trial. contrarily, in the secondary trial, the denosumab group showed a lesser performance in time to first on-study sre in comparison to the zoledronic acid group. [SEP] Clinical Trial: NCT01869192",Entailment,0.51789594,0.48210406
NCT02104830,"Statement: while the primary trial explores the impact of a single therapeutic agent, the secondary trial is dedicated to a completely different treatment modality, albeit at similar doses, and is based on similar outcome metrics. [SEP] Clinical Trial: NCT02104830",Entailment,0.70930165,0.29069832
NCT01250379,"Statement: A 20 year old female patient with a Newly diagnosed ER-positive, HER2-negative breast cancer, could be eligible for the secondary trial and the primary trial. how much bothered by discomfort or pain in affected underarm, arm, or hand is a question about how bothered an individual is by discomfort or pain in their affected underarm, arm, or hand. [SEP] Clinical Trial: NCT01250379",Contradiction,0.33552754,0.66447246
NCT00209092,"Statement: although a patient meets all the criteria for the primary clinical trial, final entry is determined by the first of kin. [SEP] Clinical Trial: NCT00209092",Entailment,0.61662775,0.38337225
NCT00825682,Statement: the intervention schedule for both primary clinical trial and secondary clinical trial is of the same duration. [SEP] Clinical Trial: NCT00825682,Entailment,0.83585674,0.16414328
NCT01920061,"Statement: the primary trial uses a 3 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. spastic paraplegia 3a is an autosomal dominant subtype of hereditary spastic paraplegia caused by mutation(s) in the atl1 gene, encoding atlastin-1. [SEP] Clinical Trial: NCT01920061",Entailment,0.85451293,0.14548711
NCT00475085,"Statement: in the primary clinical trial, the participant count in cohort 2 is higher by 7 compared to cohort 1 [SEP] Clinical Trial: NCT00475085",Contradiction,0.2851856,0.7148144
NCT02988986,Statement: over 42 days of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 5% reduction in the percentage of cells with ki67 expression [SEP] Clinical Trial: NCT02988986,Entailment,0.57469153,0.42530844
NCT00075764,"Statement: Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial. application adapter is a software layer that converts data from an application into a form that will allow integration with other applications. [SEP] Clinical Trial: NCT00075764",Contradiction,0.33361083,0.66638917
NCT01498458,"Statement: in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. neonatal sinus tachycardia, ae is an adverse event in a newborn characterized by an abnormally high heart rate for age. [SEP] Clinical Trial: NCT01498458",Contradiction,0.3036601,0.69633985
NCT00583700,"Statement: women aged 25 or 30 are eligible for the secondary trial, but will need to wait 3-4 years to be eligible for the primary trial [SEP] Clinical Trial: NCT00583700",Contradiction,0.44692704,0.5530729
NCT00305695,"Statement: intravenous administration is mandatory for intervention 1 in the primary clinical trial, as well as all intervention drugs employed in the secondary clinical trial. [SEP] Clinical Trial: NCT00305695",Entailment,0.6356207,0.3643793
NCT00143390,"Statement: in the primary clinical trial, there was a minimum of 1 detected gastro-intestinal adverse event and more than one psychiatric event [SEP] Clinical Trial: NCT00143390",Entailment,0.65641034,0.3435897
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 12 weeks, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.40373504,0.59626496
NCT01290536,"Statement: the intervention of the primary clinical trial involves the use of theraspheres for radioembolization, while the secondary clinical trial's intervention incorporates the use of ibrutinib and medi4736. [SEP] Clinical Trial: NCT01290536",Contradiction,0.40417802,0.595822
NCT01205503,"Statement: deriving is an explanation of the historical origins of a word, phrase, or object. Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01205503",Entailment,0.6671945,0.33280554
NCT01194440,Statement: patients who have been diagnosed with ductal carcinoma in situ and are considering getting ai therapy are eligible to participate in the primary clinical trial. [SEP] Clinical Trial: NCT01194440,Contradiction,0.47477412,0.5252259
NCT01806259,Statement: the ketorolac 30 mg group of the primary trial had a -0.4% recurrence-free survival compared to the nacl 0.9% 30ml group [SEP] Clinical Trial: NCT01806259,Entailment,0.59831923,0.40168074
NCT01997333,Statement: the patient with the longest pfs in the primary trial survived 105 days without disease progression or death [SEP] Clinical Trial: NCT01997333,Entailment,0.5734341,0.42656586
NCT01537029,"Statement: female cancer patients with brca- negative status can enroll in the primary clinical trial, with type, age, origin, or ethnicity not being discerning factors. nonetheless, the secondary clinical trial only considers patients with tnbc (triple negative breast cancer). [SEP] Clinical Trial: NCT01537029",Contradiction,0.49457696,0.505423
NCT00999921,"Statement: individuals suffering from malignant ductal carcinoma in situ and with uncontrolled hypertension are not permissible in the primary clinical trial, while the secondary clinical trial considers them eligible. [SEP] Clinical Trial: NCT00999921",Entailment,0.5163144,0.4836856
NCT00709761,Statement: over 89/100 patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr). [SEP] Clinical Trial: NCT00709761,Contradiction,0.33987248,0.6601276
NCT01419717,"Statement: gum dosage form category is a type of solid pharmaceutical dose form consisting of a basis composed of gum(s) or with a gum-like consistency. the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using Lymphoscintigraphy. [SEP] Clinical Trial: NCT01419717",Contradiction,0.34588152,0.6541185
NCT01205503,"Statement: the secondary clinical trial will not accept any patients who have a known allergy to cephalosporin or trimethoprim/sulfamethoxazole, and those with an established allergy to levofloxacin or celecoxib are ineligible for the primary clinical trial. [SEP] Clinical Trial: NCT01205503",Entailment,0.8511292,0.14887089
NCT01766102,"Statement: arm 2 in the primary trial exhibited an increased operative time relative to arm 1, thus marking the advanced effectiveness of intra-operative mammography over standard mammography. in the secondary trial, the lack of a control group makes it impossible to draw comparisons. [SEP] Clinical Trial: NCT01766102",Entailment,0.5821968,0.41780317
NCT02187783,"Statement: there were no recorded cases of palpitations, pericardial effusions and abdominal pains in the primary clinical trial, while multiple instances were noted in the secondary clinical trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.22618668,0.7738133
NCT00950911,Statement: The dosage of Zoledronic Acid  in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial. [SEP] Clinical Trial: NCT00950911,Entailment,0.5007132,0.4992868
NCT01823991,Statement: patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial [SEP] Clinical Trial: NCT01823991,Contradiction,0.409294,0.59070605
NCT00467844,Statement: all patients treated with gtx-024 1000mcg in the primary trial gained lean body mass over a 120 day period [SEP] Clinical Trial: NCT00467844,Contradiction,0.39424044,0.60575956
NCT01535040,Statement: the duration of the memantine intervention in the primary clinical trial is shorter than the placebo intervention. [SEP] Clinical Trial: NCT01535040,Entailment,0.90967953,0.09032052
NCT00416715,"Statement: primary trial candidates receive weekly subcutaneous (sc) infusions, whereas secondary trial participants are not given any injections. [SEP] Clinical Trial: NCT00416715",Entailment,0.89235365,0.1076464
NCT00475085,"Statement: while the primary clinical trial reveals the total number of participants examined in the study, it does not detail the number of participants belonging to each group. [SEP] Clinical Trial: NCT00475085",Entailment,0.9101133,0.089886725
NCT03557801,"Statement: attoliter is a unit of volume equal to one quintillionth of a liter (10e-18 liter) or one cubic micrometer. the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial, but more cases of FEBRILE INFECTIONs were recorded in the primary trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.36805663,0.6319434
NCT00182793,"Statement: in the course of the study period, more than 15% of patients in the primary clinical trial and the secondary clinical trial experienced infections [SEP] Clinical Trial: NCT00182793",Contradiction,0.20705825,0.7929417
NCT00708019,Statement: uterus present is an indication that an individual's uterus is present. None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks. [SEP] Clinical Trial: NCT00708019,Entailment,0.59695506,0.40304494
NCT00878709,Statement: the participant count was the same for both cohorts in the primary clinical trial. [SEP] Clinical Trial: NCT00878709,Entailment,0.8405317,0.15946826
NCT01783444,"Statement: women with recurrent stage i breast cancer, confirmed as er- considering lumpectomy are eligible for the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01783444",Contradiction,0.27186233,0.7281376
NCT01310075,Statement: A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial. [SEP] Clinical Trial: NCT01310075,Contradiction,0.30735883,0.6926412
NCT00253708,"Statement: drug-based treatments are not part of the examination process for the primary clinical trial, however, the secondary clinical trial tests two separate drugs. [SEP] Clinical Trial: NCT00253708",Entailment,0.8678778,0.13212222
NCT01045421,Statement: retroperitoneal undifferentiated pleomorphic sarcoma is a rare undifferentiated pleomorphic sarcoma that arises from the retroperitoneum. patients with Histologically or cytologically confirmed metastatic and/or advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial. [SEP] Clinical Trial: NCT01045421,Contradiction,0.37882602,0.621174
NCT00416715,"Statement: Candidates for the secondary trial study group receive 3 weekly subcutaneous (SC) injections, whereas the primary trial participants only receive a single injection at the beginning of the study. sex genotype code is a coded value specifying the biological sex of the individual, based upon genetic analysis. [SEP] Clinical Trial: NCT00416715",Contradiction,0.4476275,0.55237246
NCT01256567,"Statement: the primary clinical trial would exclude a patient who has had an organ transplant in the past month and is currently bedridden, whereas the secondary clinical trial may admit such a patient [SEP] Clinical Trial: NCT01256567",Entailment,0.65836173,0.3416383
NCT01881230,Statement: mandatory report is a report that is mandated by law and/or regulation. Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin. [SEP] Clinical Trial: NCT01881230,Contradiction,0.48755231,0.51244766
NCT03346161,Statement: there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial . biologic entity administrative gender code is a coded value specifying the physical or societal properties by which male is distinguished from female. [SEP] Clinical Trial: NCT03346161,Contradiction,0.4953921,0.50460786
NCT02239601,Statement: the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial. have to leave in order to smoke is a question about whether an individual needs to leave the house to be able to smoke. [SEP] Clinical Trial: NCT02239601,Entailment,0.60041076,0.3995892
NCT00253708,"Statement: the primary trial involves drug-based treatment, in contrast, the secondary trial focuses on physiotherapy. [SEP] Clinical Trial: NCT00253708",Contradiction,0.4594888,0.5405112
NCT01313117,"Statement: participants in the primary clinical trial maintain a consistent dosage of alpha lipoic acid throughout, never exceeding 50 mg twice daily, in contrast to the secondary clinical trial where cohort 1 patients receive a graduated increase of necitumumab up to a specific limit. [SEP] Clinical Trial: NCT01313117",Contradiction,0.41100332,0.5889967
NCT00662025,"Statement: study protocol version design configuration code is a coded value specifying a trial pattern developed to compare treatment groups in a clinical pre-clinical trial. CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle. [SEP] Clinical Trial: NCT00662025",Entailment,0.51660705,0.48339295
NCT02431676,Statement: patients with a body mass index (bmi) of 20 and above are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT02431676,Contradiction,0.43647635,0.56352365
NCT01629615,Statement: chest wall mass is an abnormal growth in the chest wall. eating disorders were not common for the primary trial candidates. [SEP] Clinical Trial: NCT01629615,Entailment,0.683309,0.31669104
NCT02320123,Statement: participants in cohort 2 of the primary clinical trial will also view the educational dvd instead of receiving a regular dosage of radiotherapy [SEP] Clinical Trial: NCT02320123,Entailment,0.56299865,0.43700138
NCT00878709,"Statement: in the primary clinical trial, the neratinib group demonstrated a lower incidence of idfs than the group given placebo [SEP] Clinical Trial: NCT00878709",Entailment,0.6468688,0.35313112
NCT01664091,"Statement: the primary and secondary trials reported an equal number of infection, asymmetry and nausea cases. [SEP] Clinical Trial: NCT01664091",Contradiction,0.39295456,0.6070455
NCT01128543,"Statement: in the primary trial results there were fewer patients with stable disease in week 15 than week 30, but 8 patients with complete response in week 15 or 30' [SEP] Clinical Trial: NCT01128543",Contradiction,0.2224445,0.7775555
NCT00475085,Statement: the second cohort of the primary clinical trial has 7 participants more than the first cohort [SEP] Clinical Trial: NCT00475085,Contradiction,0.34583372,0.6541662
NCT00373256,"Statement: The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab. malignant pylorus neoplasm is a primary or metastatic malignant neoplasm that affects the pylorus. [SEP] Clinical Trial: NCT00373256",Contradiction,0.44254038,0.55745965
NCT00878709,Statement: Both cohorts of the primary trial contained the same number of participants. double is a twofold increase. [SEP] Clinical Trial: NCT00878709,Contradiction,0.28610036,0.7138997
NCT00454532,"Statement: Most patients in the secondary trial and the primary trial did not suffer any adverse events. sponsor protocol identifier is a unique code, which is assigned by the sponsor, that identifies a specific protocol. [SEP] Clinical Trial: NCT00454532",Entailment,0.6036972,0.3963028
NCT01617668,"Statement: in the primary clinical trial, the number of adverse events was equal in both cohort 1 and cohort 2. [SEP] Clinical Trial: NCT01617668",Entailment,0.8682364,0.13176355
NCT01631552,Statement: the outcome measures for the primary clinical trial and the secondary clinical trial are completely different. [SEP] Clinical Trial: NCT01631552,Entailment,0.92242515,0.07757491
NCT00971945,Statement: patients are not mandated to meet any performance status conditions in either the primary or secondary trial [SEP] Clinical Trial: NCT00971945,Entailment,0.88221276,0.11778723
NCT03125941,"Statement: cohort 1 of the primary clinical trial is administered dexamethasone post-operatively, while cohort 2 receives the drug pre-operatively. [SEP] Clinical Trial: NCT03125941",Entailment,0.6670914,0.3329086
NCT00194779,"Statement: the primary clinical trial participants exclusively receive one type of oral medication and are not required to undergo surgery, while the secondary clinical trial participants are given an array of eight different drugs with a combination of surgical procedures' [SEP] Clinical Trial: NCT00194779",Entailment,0.6029546,0.39704537
NCT00553358,"Statement: A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.344044,0.655956
NCT02002533,Statement: the primary trial has 4 more adverse events recorded than the secondary trial [SEP] Clinical Trial: NCT02002533,Entailment,0.75630224,0.24369776
NCT00775645,Statement: was in situ hybridization performed is a question asking if in situ hybridization assays were performed during the study. In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1% of participants. [SEP] Clinical Trial: NCT00775645,Entailment,0.60330945,0.3966905
NCT01301729,Statement: HER2 + Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial. new hampshire is a state in the northeastern united states. its capital is concord. [SEP] Clinical Trial: NCT01301729,Contradiction,0.43089485,0.56910515
NCT00749931,Statement: a patient may be able to participate in the secondary trial but be ineligible for the primary trial. [SEP] Clinical Trial: NCT00749931,Entailment,0.90149873,0.09850122
NCT00418028,"Statement: the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the number of patients that experience Objective Response . dietary vegetables, red and orange measurement is a determination of the total red and orange vegetables in a nutritional product or meal, or a portion thereof. [SEP] Clinical Trial: NCT00418028",Contradiction,0.3077163,0.6922837
NCT02273206,"Statement: in cohort 1 of the primary clinical trial, most participants fell behind in their screening schedules post-intervention, without being influenced by the type of their cancer. [SEP] Clinical Trial: NCT02273206",Entailment,0.61122495,0.38877502
NCT00662025,Statement: sunitinib was not administered to any patient during the primary clinical trial. [SEP] Clinical Trial: NCT00662025,Entailment,0.9151219,0.084878035
NCT00759785,"Statement: 11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. grade 1 brachial plexopathy, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated [SEP] Clinical Trial: NCT00759785",Entailment,0.62414306,0.37585694
NCT01920061,Statement: the number of aes was higher for one of the cohorts in the primary clinical trial [SEP] Clinical Trial: NCT01920061,Entailment,0.74541557,0.25458443
NCT01286987,Statement: Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead. fact-bl questionnaire is a subscale complement to the fact-g developed specifically for evaluating the quality of life of patents with bladder cancer. [SEP] Clinical Trial: NCT01286987,Contradiction,0.49076018,0.50923985
NCT01086605,"Statement: polycythemia (excluding polycythemia vera) is an increase in the concentration of red blood cells (hemoglobin) that is not caused by polycythemia vera. there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial. [SEP] Clinical Trial: NCT01086605",Entailment,0.59694195,0.40305802
NCT02115607,Statement: the primary trial recorded 11 more instances of intestinal perforation than the secondary trial [SEP] Clinical Trial: NCT02115607,Contradiction,0.4003618,0.59963816
NCT00322374,Statement: enrollment in the primary clinical trial requires a positive mental health assessment [SEP] Clinical Trial: NCT00322374,Entailment,0.76503193,0.2349681
NCT01178411,Statement: only males belonging to a particular ethnic group are eligible to participate in the secondary clinical trial [SEP] Clinical Trial: NCT01178411,Entailment,0.5591535,0.4408465
NCT00266110,Statement: multiple injections are essential for patients participating in the primary clinical trial [SEP] Clinical Trial: NCT00266110,Entailment,0.60269094,0.3973091
NCT01468675,"Statement: Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions. [SEP] Clinical Trial: NCT01468675",Entailment,0.5352397,0.4647603
NCT01920061,Statement: The same perecentage of patients suffered adverse events in both cohorts of the primary trial [SEP] Clinical Trial: NCT01920061,Entailment,0.82117265,0.17882735
NCT02239601,Statement: corresponding author indicator is an indication that the specific author is considered the corresponding author. the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts. [SEP] Clinical Trial: NCT02239601,Entailment,0.58935714,0.41064283
NCT01106898,Statement: the primary clinical trial reported that 97% of its patients did not have any side effects. [SEP] Clinical Trial: NCT01106898,Entailment,0.6595269,0.3404731
NCT00659373,"Statement: on average, cognitive function remained stable in one cohort, while it improved in the other cohort of the primary clinical trial. [SEP] Clinical Trial: NCT00659373",Entailment,0.6041173,0.39588273
NCT00293384,"Statement: more than half of the patients in the first cohort of the primary clinical trial experienced severe nausea following treatment with aprepitant, dexamethasone, cytoxan, and kytril [SEP] Clinical Trial: NCT00293384",Entailment,0.5096089,0.49039108
NCT01617668,Statement: More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2. tuberculous bronchopneumonia is acute and progressive bronchopneumonia caused by mycobacterium tuberculosis bacteria.  it is characterized by widespread pulmonary patchy consolidations. [SEP] Clinical Trial: NCT01617668,Entailment,0.5084895,0.49151048
NCT01086605,Statement: dyspnea was observed in some participants of the primary clinical trial [SEP] Clinical Trial: NCT01086605,Entailment,0.7050979,0.29490203
NCT01908101,"Statement: bronchial stricture, ctcae is a disorder characterized by a narrowing of the bronchial tube. the primary trial and the secondary trial do not test the same drugs. [SEP] Clinical Trial: NCT01908101",Entailment,0.8802548,0.1197452
NCT00256698,"Statement: arimidex is administered in both sections of the primary clinical trial, but it is absent from the secondary clinical trial's procedure. [SEP] Clinical Trial: NCT00256698",Entailment,0.9089212,0.09107887
NCT00709761,Statement: none of the patients in the primary clinical trial who were given lapatinib 1000 mg + nab-paclitaxel reached a confirmed complete response (cr). [SEP] Clinical Trial: NCT00709761,Entailment,0.6575317,0.34246826
NCT00819182,"Statement: patients in the paced respiration intervention group for the primary clinical trial demonstrated fewer treatment emergent adverse events and serious treatment emergent adverse events on average than patients in the fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.54381555,0.45618448
NCT00454532,Statement: the secondary clinical trial was unfortunately halted due to a number of significant adverse events encountered by most participants [SEP] Clinical Trial: NCT00454532,Entailment,0.74335265,0.25664738
NCT00956813,Statement: the secondary trial and the primary trial results contain completely different outcome measures  [SEP] Clinical Trial: NCT00956813,Entailment,0.924481,0.07551905
NCT03015649,Statement: the primary trial recorded fewer adverse events than did the secondary trial within their cohorts. [SEP] Clinical Trial: NCT03015649,Entailment,0.8392235,0.16077645
NCT01434342,"Statement: There were more cases of Mucositis Oral, Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial [SEP] Clinical Trial: NCT01434342",Contradiction,0.48260343,0.5173965
NCT00538850,"Statement: the primary trial evaluates the severity of delayed nausea on a numeric scale from 1 to 7. in contrast, the secondary trial focuses on the changes in bone mineral density (bmd) of the lumbar spine over a period of 9 months from the baseline. [SEP] Clinical Trial: NCT00538850",Contradiction,0.44175163,0.5582484
NCT01664091,"Statement: there were fewer cases of infection, asymmetry and deflation in the primary trial compared to the secondary trial. [SEP] Clinical Trial: NCT01664091",Contradiction,0.49179235,0.5082076
NCT01008150,Statement: patients in neither cohort of the primary clinical trial showed pathologic complete response in breast and axillary lymph nodes throughout the duration of the study [SEP] Clinical Trial: NCT01008150,Entailment,0.637072,0.3629279
NCT00322374,"Statement: to participate in the primary clinical trial, a candidate must have a minimum karnofsky score of 60 [SEP] Clinical Trial: NCT00322374",Contradiction,0.40390363,0.5960964
NCT00313170,Statement: those suffering from breast cancer and necessitating hormone treatment are potential participants in the primary clinical trial. [SEP] Clinical Trial: NCT00313170,Contradiction,0.48907766,0.5109223
NCT01421472,"Statement: patients diagnosed with estrogen-negative, progesterone-negative and her2- breast tumors may participate in the primary clinical trial [SEP] Clinical Trial: NCT01421472",Contradiction,0.4777675,0.5222325
NCT00963911,Statement: the primary clinical trial does not involve the administration of talazoparib in its operation [SEP] Clinical Trial: NCT00963911,Entailment,0.9287513,0.071248755
NCT01631552,"Statement: the outcome measures of the primary and secondary clinical trials are directly related, despite having different interventions [SEP] Clinical Trial: NCT01631552",Entailment,0.86838734,0.1316126
NCT01390818,Statement: agreement likert scale is a 5-point likert scale for agreement that goes from 1: not at all to 5: very much. Several recorded Aes in the primary trial occurred to cohort 1 patients. [SEP] Clinical Trial: NCT01390818,Entailment,0.586864,0.413136
NCT01419717,"Statement: the primary trial requires patients to receive 220 milligrams of denosumab injected subcutaneously every week, the secondary trial also requires injection, adminstering 3.4 to 2.0 mci of radioactive tc99m sulfur colloid. [SEP] Clinical Trial: NCT01419717",Contradiction,0.37922662,0.62077343
NCT00467844,"Statement: at least one patient treated with gtx-024 1mg in the primary trial gained over 10,000 grams of lean body mass. [SEP] Clinical Trial: NCT00467844",Contradiction,0.35596085,0.6440391
NCT00262834,"Statement: in the secondary clinical trial, a single adverse event impacted more than 50% of the subjects involved [SEP] Clinical Trial: NCT00262834",Contradiction,0.4238117,0.5761883
NCT00756717,Statement: distressed by awakening in the early morning is a question about whether an individual is or has been distressed because they are awakening in the early morning. There were 0 adverse events in the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00756717,Contradiction,0.4751105,0.52488947
NCT01468675,"Statement: daxx gene mutation is a change in the nucleotide sequence of the daxx gene. Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions. [SEP] Clinical Trial: NCT01468675",Entailment,0.59939224,0.40060782
NCT00313170,"Statement: candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments. missing information is absence of information e.g. labeling, instruction for use. [SEP] Clinical Trial: NCT00313170",Entailment,0.5305671,0.4694329
NCT03092934,Statement: neoadjuvant therapy clinical trial setting is a clinical trial or treatment setting in which the therapy of interest is considered neo-adjuvant. patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic. [SEP] Clinical Trial: NCT03092934,Contradiction,0.40358436,0.59641564
NCT00365365,"Statement: 8q21.13 is a chromosome band present on 8q the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. [SEP] Clinical Trial: NCT00365365",Contradiction,0.37169525,0.6283048
NCT01967823,Statement: 14.17% of the primary trial patients suffered an increase in blood bilirubin. [SEP] Clinical Trial: NCT01967823,Contradiction,0.41753775,0.5824623
NCT02222922,Statement: all participants in the primary clinical trial are administered higher doses of medication than participants in the secondary clinical trial [SEP] Clinical Trial: NCT02222922,Entailment,0.8422859,0.15771417
NCT03557801,"Statement: anemia, pneumonia, and stupor were more frequent among patients in the secondary trial compared to the primary trial, although the primary trial recorded a greater number of febrile infections. [SEP] Clinical Trial: NCT03557801",Contradiction,0.42707476,0.57292527
NCT00544167,"Statement: patients with recent history (within the last three years) of pulmonary embolism will not be permitted to participate in the primary clinical trial, but might be considered for the secondary clinical trial upon review by the investigator. [SEP] Clinical Trial: NCT00544167",Entailment,0.65114146,0.34885854
NCT03069313,Statement: both the primary and secondary clinical trials administer their treatments orally. [SEP] Clinical Trial: NCT03069313,Entailment,0.68606055,0.3139394
NCT02002533,Statement: the number of adverse events recorded in the primary trial and the secondary trial is identical. [SEP] Clinical Trial: NCT02002533,Entailment,0.8990669,0.10093309
NCT00432562,Statement: sellar germ cell tumor is a germ cell tumor that arises from or adjacent to the sellar region. The only shared inclusion/exclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent. [SEP] Clinical Trial: NCT00432562,Entailment,0.54172504,0.458275
NCT00148668,Statement: the primary clinical trial has interventions where differing doses of paraplatin are administered [SEP] Clinical Trial: NCT00148668,Entailment,0.8072524,0.19274753
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial. gonadotroph cell is an endocrine cell of the adenohypophysis that affects certain cells of the ovary or testis. [SEP] Clinical Trial: NCT01964924,Entailment,0.67909753,0.32090244
NCT01823991,Statement: the primary clinical trial excludes patients with alzheimer's disease [SEP] Clinical Trial: NCT01823991,Entailment,0.9008442,0.09915577
NCT01301729,"Statement: at all times, the dosage of trastuzumab received by patients in the primary clinical trial differs from that administered to patients in cohort 2 of the secondary clinical trial [SEP] Clinical Trial: NCT01301729",Entailment,0.828705,0.17129494
NCT00322374,"Statement: There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial . hyperemia evaluation is an evaluation of hyperemia in a biological specimen or location. [SEP] Clinical Trial: NCT00322374",Contradiction,0.41515192,0.58484805
NCT02413008,Statement: the primary clinical trial and the secondary clinical trial assess patients' progress by the decrease in the size of the tumor following completion of chemotherapy [SEP] Clinical Trial: NCT02413008,Contradiction,0.29329816,0.7067019
NCT00253708,"Statement: cardiovascular system findings derived flag is an indication or description that cardiovascular system data is a derived value. the primary trial does not test any drug based treatments, whereas the secondary trial tests different doses of one drug based-treatment. [SEP] Clinical Trial: NCT00253708",Entailment,0.80943066,0.1905694
NCT01498458,Statement: malignant sweat gland neoplasm is a malignant neoplasm that affects the sweat glands. in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. [SEP] Clinical Trial: NCT01498458,Contradiction,0.30980363,0.6901964
NCT01806675,"Statement: both study groups in the primary clinical trial will undertake identical 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging procedures, but there will be a minor increase in the dosage of 18f-fpprgd2 administered to cohort 1. [SEP] Clinical Trial: NCT01806675",Entailment,0.66755503,0.33244497
NCT01434342,"Statement: there were fewer instances of mucositis oral, bladder infection, and thromboembolic events noted in the primary clinical trial compared to the secondary clinical trial [SEP] Clinical Trial: NCT01434342",Entailment,0.6442159,0.35578418
NCT00365105,"Statement: A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/≈í¬∫L, Platelet count of 110,034/≈í¬∫L, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. fibroblastic neoplasm is a benign, intermediate, or malignant mesenchymal neoplasm characterized by the presence of neoplastic fibroblasts. [SEP] Clinical Trial: NCT00365105",Contradiction,0.33705765,0.6629423
NCT00088413,"Statement: in the primary clinical trial, most of the reported adverse events were related to blood and bone marrow. this observation was not found in the secondary clinical trial. [SEP] Clinical Trial: NCT00088413",Entailment,0.86396617,0.13603382
NCT02259114,"Statement: minor salivary gland is a small salivary gland located within the aerodigestive tract. Patients with NUT midline carcinoma determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02259114",Contradiction,0.3636725,0.6363275
NCT01770353,Statement: both the primary clinical trial and the secondary clinical trial administer drugs orally and rely on ultrasounds instead of mris. [SEP] Clinical Trial: NCT01770353,Contradiction,0.31105906,0.68894094
NCT00963911,Statement: none of the participants in the primary clinical trial are prescribed talazoparib on a daily basis [SEP] Clinical Trial: NCT00963911,Entailment,0.8795241,0.12047587
NCT00820872,"Statement: muscle weakness upper limb, ctcae is a disorder characterized by a reduction in the strength of the upper limb muscles. Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants. [SEP] Clinical Trial: NCT00820872",Contradiction,0.38229752,0.6177025
NCT00929240,Statement: the occurrence of disease progression or death was more prevalent in the bevacizumab cohort in contrast to the bevacizumab + capecitabine cohort in the primary clinical trial. [SEP] Clinical Trial: NCT00929240,Entailment,0.722242,0.27775803
NCT00118157,Statement: patients participating in the primary trial receive 700 mg/week oral lapatinib twice a day for a full 4 weeks. [SEP] Clinical Trial: NCT00118157,Contradiction,0.47105688,0.5289431
NCT01128543,"Statement: In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24. feel angry is a question about whether an individual feels or felt angry. [SEP] Clinical Trial: NCT01128543",Entailment,0.6152805,0.38471952
NCT01664091,"Statement: the primary clinical trial reported a higher incidence of infection, asymmetry, and deflation compared to the secondary clinical trial. [SEP] Clinical Trial: NCT01664091",Entailment,0.50431764,0.4956824
NCT01967823,Statement: 36.36% of the primary trial patients suffered an increase in Blood bilirubin. [SEP] Clinical Trial: NCT01967823,Contradiction,0.36747843,0.6325216
NCT00404066,"Statement: no adverse events were noted in the patients from the secondary clinical trial, however, in the primary clinical trial instances of dyspnoea, hyperkalaemia and renal failure were recorded [SEP] Clinical Trial: NCT00404066",Contradiction,0.405071,0.59492904
NCT02550795,"Statement: group 2 of the primary trial recieves 0.00027ug/kg of myalgias (0.005ml), patients in the secondary trial cohorts do not receive any myalgias. [SEP] Clinical Trial: NCT02550795",Entailment,0.85775244,0.14224751
NCT00365105,"Statement: a 65 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 5000/≈í¬∫l, platelet count of 120000/≈í¬∫l, hemoglobin level of 200 g/l, and a life expectancy exceeding 20 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.3289403,0.67105967
NCT00357734,"Statement: The intervention in the primary trial consists of a single drug, whereas in the secondary trial the intervention requires at least 3 different drugs. egfr nm 005228.3:c.2315 2316insgacacaccc is an insertion of nine nucleotides, gacacaccc, between position 2315 and 2316 of the coding sequence of the egfr gene. [SEP] Clinical Trial: NCT00357734",Entailment,0.63715017,0.36284986
NCT00792077,"Statement: the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1, and the primary trial intervention lasts for a longer period of time. [SEP] Clinical Trial: NCT00792077",Entailment,0.607203,0.39279696
NCT01156987,"Statement: every participant in group 1 of the primary trial were found to have lesions, and merely 1% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.32446095,0.675539
NCT00293540,"Statement: on average patients from the primary trial survive over 4 years, however at least one patient from both cohorts died in under 3 days. [SEP] Clinical Trial: NCT00293540",Contradiction,0.39702398,0.602976
NCT01537029,"Statement: male leukemia patients under the age of 18 can participate in the primary clinical trial, regardless of race or ethnic origin. for the secondary clinical trial, they must have her2/neu- lung cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.3736116,0.6263884
NCT00656019,Statement: None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes. mouth sensitivity at its worst is a question about an individual's mouth sensitivity at its worst. [SEP] Clinical Trial: NCT00656019,Entailment,0.556451,0.44354895
NCT01855828,"Statement: There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia. erbb2 mutation analysis is a procedure used to detect and identify mutations in the erbb2 gene. [SEP] Clinical Trial: NCT01855828",Contradiction,0.4695167,0.5304833
NCT01310075,Statement: a mastectomy may not disqualify a woman from being eligible for both the primary and secondary clinical trial. [SEP] Clinical Trial: NCT01310075,Entailment,0.73423415,0.26576585
NCT02122796,"Statement: mechanical ventilation required is an indication that a patient required mechanical ventilation for respiratory support. the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates, but higher doses of herceptin and doxatel. [SEP] Clinical Trial: NCT02122796",Contradiction,0.38338318,0.6166168
NCT00786838,"Statement: in the primary clinical trial, the placebo is administered orally, while trabectedin is injected directly into the bloodstream. [SEP] Clinical Trial: NCT00786838",Contradiction,0.48379847,0.5162015
NCT03069313,"Statement: in the primary clinical trial, the intervention is administered sublingually, while oral administration is used in the secondary clinical trial. [SEP] Clinical Trial: NCT03069313",Entailment,0.6642441,0.33575588
NCT01629615,Statement: eating disorders were frequently observed among the primary clinical trial candidates' [SEP] Clinical Trial: NCT01629615,Entailment,0.5473331,0.45266688
NCT02320123,Statement: cohort 2 of the primary clinical trial will have access to the educational dvd as part of their intervention program. [SEP] Clinical Trial: NCT02320123,Entailment,0.6359343,0.36406568
NCT00766532,"Statement: no instances of anorexia, hypothermia or hallucinations have been recorded in the adverse events (aes) of either the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT00766532",Entailment,0.55933154,0.44066852
NCT00148668,Statement: only one arm of the primary clinical trial makes use of trastuzumab as part of its intervention [SEP] Clinical Trial: NCT00148668,Entailment,0.791434,0.20856601
NCT01766102,"Statement: rod device is any rod-shaped device. Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore Intra-operative Mammography performed better than the Standard Mammography in this regard. In the secondary trial there is no control group against which we can compare. [SEP] Clinical Trial: NCT01766102",Entailment,0.6648614,0.33513856
NCT00253708,"Statement: the primary clinical trial does not examine any pharmacological treatments, while the secondary clinical trial investigates varying dosages of a singular drug-based method. [SEP] Clinical Trial: NCT00253708",Entailment,0.8318923,0.16810769
NCT01614210,Statement: Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average. as bad as you can imagine is a response indicating a situation is as bad as can be imagined. [SEP] Clinical Trial: NCT01614210,Contradiction,0.3644748,0.63552517
NCT02115607,"Statement: compared to the primary clinical trial, the secondary clinical trial observed an increase of 11 adverse events [SEP] Clinical Trial: NCT02115607",Entailment,0.63097346,0.36902654
NCT00896454,Statement: the secondary trial and the primary trial report results from one patient cohort. [SEP] Clinical Trial: NCT00896454,Entailment,0.6399773,0.3600227
NCT01171924,"Statement: rectal necrosis, ctcae is a disorder characterized by a necrotic process occurring in the rectal wall. cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly. [SEP] Clinical Trial: NCT01171924",Contradiction,0.4021295,0.59787047
NCT00819182,"Statement: patients in the paced respiration intervention group of the primary clinical trial endured more treatment emergent adverse events and serious treatment emergent adverse events on average than those in the fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Entailment,0.5196901,0.48030987
NCT00118157,Statement: patients involved in the primary clinical trial are administered oral drugs twice daily for an entire month. [SEP] Clinical Trial: NCT00118157,Entailment,0.6025065,0.3974935
NCT02286843,"Statement: in the primary clinical trial, 13% of participants who had her2- primary breast cancer and received her2-targeted pet/ct. 89zr-trastuzumab treatment eventually developed imagable her2+ metastases. [SEP] Clinical Trial: NCT02286843",Contradiction,0.39954594,0.6004541
NCT00756496,"Statement: during the primary clinical trial, there were no significant divergences noted in any group's results, but differences emerged between the reflexology group and the control group during the secondary clinical trial. [SEP] Clinical Trial: NCT00756496",Entailment,0.60776055,0.39223948
NCT01390818,Statement: all adverse events recorded in the primary clinical trial were solely associated with members of cohort 2. [SEP] Clinical Trial: NCT01390818,Entailment,0.8794673,0.12053268
NCT02178722,"Statement: primary trial participants never receive epacadostat, while sunitinib-na‚àö√òve participants in the secondary trial always receive sunitinib. [SEP] Clinical Trial: NCT02178722",Entailment,0.6053766,0.39462337
NCT01614210,Statement: the primary clinical trial demonstrates that ki67 expression in tumors increases by 30% on average when tamoxifen 20 mg is administered orally each day for 7 days prior to surgery and 14 days post breast cancer surgery. [SEP] Clinical Trial: NCT01614210,Contradiction,0.31374085,0.68625915
NCT00791037,Statement: the primary clinical trial and the secondary clinical trial assess the participants' overall survival rates. [SEP] Clinical Trial: NCT00791037,Contradiction,0.3901568,0.6098432
NCT00313170,"Statement: candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments. medulloblastoma, not otherwise specified is a medulloblastoma which has not been further characterized. [SEP] Clinical Trial: NCT00313170",Entailment,0.7485119,0.2514881
NCT01466972,Statement: no primary trial participants experienced any form of rash. [SEP] Clinical Trial: NCT01466972,Entailment,0.9109786,0.089021385
NCT00766532,"Statement: both the primary and secondary clinical trials have recorded instances of anorexia, hypothermia and hallucinations in their aes. [SEP] Clinical Trial: NCT00766532",Contradiction,0.3958038,0.6041962
NCT01963481,"Statement: patients with severe insomnia and schizophrenia are not eligible for the primary clinical trial, but are eligible for the secondary clinical trial [SEP] Clinical Trial: NCT01963481",Entailment,0.6666474,0.33335263
NCT01743560,"Statement: the height criterion for the primary clinical trial disqualifies children and adolescents, but the secondary clinical trial does not expressly exclude them. [SEP] Clinical Trial: NCT01743560",Entailment,0.84552073,0.1544793
NCT01128543,"Statement: in the primary trial results there were less patients with stable disease in week 20 than week 34, but 10 patients with complete response in week 20 or 34' [SEP] Clinical Trial: NCT01128543",Contradiction,0.23693086,0.7630691
NCT01376349,"Statement: source type code is a coded value specifying the origination source of the entity. Neither the secondary trial or the primary trial use cm, Number of Participants or a unit of time as their units of measure. [SEP] Clinical Trial: NCT01376349",Contradiction,0.4274582,0.57254183
NCT00871858,"Statement: in the primary clinical trial, paclitaxel is incorporated into both therapeutic interventions [SEP] Clinical Trial: NCT00871858",Entailment,0.6238412,0.37615874
NCT00836186,"Statement: the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID. grade 1 anal mucositis, ctcae is asymptomatic or mild symptoms; intervention not indicated [SEP] Clinical Trial: NCT00836186",Entailment,0.54079694,0.4592031
NCT02222922,Statement: All the primary trial participants receive higher doses of ALT-801 than the secondary trial participants. anpep negative is an indication that anpep expression has not been detected in a sample. [SEP] Clinical Trial: NCT02222922,Entailment,0.73318607,0.26681393
NCT01246973,"Statement: There were no cardiac or phsyciatric Aes recorded during the primary trial and the secondary trial, however several other types of Aes were observed. [SEP] Clinical Trial: NCT01246973",Contradiction,0.18310536,0.81689465
NCT00538850,"Statement: the the primary trial results report the severity of delayed nausea on a scale from 1 to 7, and the secondary trial measures the change from baseline to approximately 3 quarters of a year in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850",Entailment,0.5043479,0.49565205
NCT00405938,"Statement: Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial. grade 1 stomal ulcer, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated [SEP] Clinical Trial: NCT00405938",Entailment,0.53108,0.46892
NCT00544167,"Statement: patients that have suffered a pulmonary embolism within the last 13 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.73824227,0.2617577
NCT01286168,"Statement: The most common adverse event in the secondary trial was Anaemia, affecting more than 5% of patients, there were no recorded AEs in the primary trial. past seven days unexpected decrease in sweating is a question about whether an individual had any unexpected decrease in sweating over the past seven days. [SEP] Clinical Trial: NCT01286168",Entailment,0.5523812,0.4476188
NCT01869192,"Statement: the primary clinical trial results state that the most effective overall response rate was provided by the arm a intervention. in contrast, the secondary clinical trial found that the denosumab group had inferior time to first on-study sre compared to the zoledronic acid group. [SEP] Clinical Trial: NCT01869192",Entailment,0.5772287,0.42277125
NCT00075764,"Statement: Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial [SEP] Clinical Trial: NCT00075764",Contradiction,0.38584712,0.6141529
NCT01205503,"Statement: patients with a confirmed allergy to cephalosporin or trimethoprim/sulfamethoxazole cannot participate in the secondary clinical trial, and those with a documented allergy to levofloxacin or celecoxib will be excluded from the primary clinical trial. [SEP] Clinical Trial: NCT01205503",Entailment,0.79325515,0.20674486
NCT02336737,Statement: Cohort 1 of the primary trial did not report any Aes. how long not feeling like eating lasted is a question about how long not feeling like eating lasted. [SEP] Clinical Trial: NCT02336737,Entailment,0.8296652,0.1703348
NCT00148668,Statement: Both interventions in the primary trial include trastuzumab. paranemin is a type iii intermediate filament protein found in striated muscle cells that provides cytoskeletal integrity and strength. [SEP] Clinical Trial: NCT00148668,Contradiction,0.42294726,0.5770528
NCT01537029,"Statement: interval point in time integer data type is a data type comprised of a set of consecutive values of an ordered point in time integer datatype. Female cancer patients over the age of 18 can participate in the primary trial, regardless of race, ethnic origin or cancer type, however for the secondary trial, they must have BRCA+ breast cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.42150983,0.5784902
NCT02550795,"Statement: group 2 of the primary trial recieves 9ug/kg of dexmedetomidine (90ml), patients in the secondary trial cohorts do not receive any dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.8287442,0.17125584
NCT00766532,"Statement: neither the primary clinical trial, nor the secondary clinical trial have reported any episodes of anorexia, hypothermia, or hallucinations among the adverse events (aes). [SEP] Clinical Trial: NCT00766532",Contradiction,0.49837014,0.5016299
NCT01048099,Statement: the majority of patients in the primary clinical trial experienced a certain type of adverse event. [SEP] Clinical Trial: NCT01048099,Entailment,0.87010866,0.12989138
NCT00317603,"Statement: syncope was the most frequently reported adverse event in both primary clinical trial and secondary clinical trial, affecting 25.00% of the patients in the primary trial. [SEP] Clinical Trial: NCT00317603",Contradiction,0.17936751,0.8206325
NCT00978250,Statement: individuals with histologically proven metastatic scbc are not permitted to participate in the primary clinical trial. [SEP] Clinical Trial: NCT00978250,Entailment,0.85969937,0.1403006
NCT00428220,"Statement: rbm15 gene rearrangement is a molecular abnormality indicating rearrangement of the rbm15 gene. Pericardial effusions were more common for patients in the primary trial, and Corneal deposits were more common in the secondary trial. [SEP] Clinical Trial: NCT00428220",Contradiction,0.46186143,0.53813857
NCT02550795,"Statement: group 2 of the primary trial recieves 0.5kg/ug of myalgias (5000ml), patients in the secondary trial cohorts do not receive any myalgias. [SEP] Clinical Trial: NCT02550795",Entailment,0.8042047,0.19579527
NCT00558272,Statement: the zoledronic acid 4 mg group of the primary clinical trial experienced a greater reduction in primary tumour diameter than the azd0530 175 mg group. [SEP] Clinical Trial: NCT00558272,Entailment,0.56643814,0.43356186
NCT00256217,"Statement: in the primary clinical trial, there were no reported cases of adverse events amongst patients, while every patient had at least one recorded adverse event in the secondary clinical trial. [SEP] Clinical Trial: NCT00256217",Entailment,0.74104154,0.25895852
NCT00245050,"Statement: worse than expected is a subjective response indicating something was worse than expected. the primary trial had one test group and one placebo group, the secondary trial had 1 test group and 1 control group. [SEP] Clinical Trial: NCT00245050",Entailment,0.76290077,0.23709926
NCT01439282,Statement: neither the primary clinical trial nor the secondary clinical trial consider gender as a criteria for eligibility [SEP] Clinical Trial: NCT01439282,Contradiction,0.4384607,0.5615393
NCT00558272,Statement: the primary tumor size reduction was more prominent in the primary clinical trial's azd0530 175 mg participants than those receiving 4mg zoledronic acid. [SEP] Clinical Trial: NCT00558272,Contradiction,0.47342312,0.5265768
NCT00467844,Statement: at least one patient treated with gtx-024 1mg in the primary trial gained over 22 pounds of lean body mass. [SEP] Clinical Trial: NCT00467844,Contradiction,0.37772268,0.6222773
NCT03557801,"Statement: perfusion computed tomography target lesion is a target lesion that has been identified by computed tomography perfusion imaging. the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.43064123,0.56935877
NCT01730729,"Statement: the administrated intervention for the primary clinical trial involves dermal patches, while the treatment for the secondary clinical trial necessitates oral administration [SEP] Clinical Trial: NCT01730729",Entailment,0.56942385,0.43057615
NCT01770353,"Statement: the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs. [SEP] Clinical Trial: NCT01770353",Contradiction,0.17060797,0.829392
NCT02178722,Statement: the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib. connecticut is a state in the northeastern united states. its capital is hartford. [SEP] Clinical Trial: NCT02178722,Contradiction,0.45097202,0.54902804
NCT00194779,"Statement: the primary trial participants are administered over 7 different types of drugs and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery [SEP] Clinical Trial: NCT00194779",Entailment,0.82458216,0.17541784
NCT00377156,"Statement: Diagnosis of 2-3 cerebral metastases will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. have history of opportunistic or frequent infection is a question about whether an individual has a history of opportunistic or frequent infections. [SEP] Clinical Trial: NCT00377156",Contradiction,0.42240015,0.5775999
NCT00088413,"Statement: The majority of the adverse events recorded in the primary trial were blood and bone marrow related, this is not the case for the secondary trial. disseminated adenocarcinoma is adenocarcinoma that is spread throughout the body. [SEP] Clinical Trial: NCT00088413",Entailment,0.690918,0.30908194
NCT00538850,Statement: the the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 36 weeks in bone mineral density (bmd) of the lumbar spine [SEP] Clinical Trial: NCT00538850,Contradiction,0.38622075,0.61377925
NCT02178722,Statement: participants in the primary clinical trial are administered pembrolizumab with a frequency that is double of that given sunitinib in the secondary clinical trial. [SEP] Clinical Trial: NCT02178722,Entailment,0.58956134,0.41043863
NCT02761642,"Statement: Any cancer patient diagnosed with either Epilepsy , thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02761642",Entailment,0.8118412,0.1881588
NCT00418028,"Statement: the primary clinical trial provides a duration in days until disease progression for 156 patients across both cohorts, whereas the secondary clinical trial shows the proportion of patients experiencing objective response. [SEP] Clinical Trial: NCT00418028",Contradiction,0.35217124,0.6478288
NCT00583700,"Statement: women aged 20 or 21 are immediately eligible for the primary clinical trial, but were eligible for the secondary trial 1-2 years prior [SEP] Clinical Trial: NCT00583700",Contradiction,0.4035205,0.59647954
NCT01178411,"Statement: the patient's nationality, ethnicity, weight or gender do not have an impact on their eligibility to participate in either the primary or secondary clinical trial [SEP] Clinical Trial: NCT01178411",Entailment,0.64763254,0.35236743
NCT01975831,Statement: the differences between interventions 1 and 2 of the primary clinical trial do not involve the amount of durva administered monthly to each cohort. [SEP] Clinical Trial: NCT01975831,Entailment,0.8497523,0.15024771
NCT00293384,"Statement: less than 50% of patients in cohort 1 of the primary clinical trial experienced acute vomiting post-treatment with aprepitant, dexamethasone, cytoxan, and kytril [SEP] Clinical Trial: NCT00293384",Entailment,0.6351773,0.36482272
NCT02336737,Statement: Cohort 1 of the primary trial did not report any Aes. sixteen is a natural number greater than 15 and less than 17 and the quantity that it denotes. [SEP] Clinical Trial: NCT02336737,Contradiction,0.43110093,0.5688991
NCT03015649,Statement: the primary trial and the secondary trial recorded the same number of adverse events in their cohorts. [SEP] Clinical Trial: NCT03015649,Entailment,0.8152245,0.18477546
NCT00021255,"Statement: the primary clinical trial ensures a uniform dose of docetaxel, doxorubicin, and cyclophosphamide across both cohorts, and maintains a constant frequency of administration. [SEP] Clinical Trial: NCT00021255",Entailment,0.50614285,0.49385718
NCT00741039,Statement: participants in the primary clinical trial receive tailored interventions based on their cancer diagnosis [SEP] Clinical Trial: NCT00741039,Entailment,0.7347669,0.26523313
NCT03346161,Statement: cohort 2 of the primary clinical trial had a higher number of patients suffering adverse events compared to cohort 1 [SEP] Clinical Trial: NCT03346161,Entailment,0.74427253,0.2557275
NCT02761642,"Statement: cancer patients suffering from either epilepsy, thalasemic syndromes or anemia are disqualified from the primary and secondary clinical trials. [SEP] Clinical Trial: NCT02761642",Entailment,0.7038285,0.29617152
NCT00076024,"Statement: there are no set limitations concerning life expectancy, pregnancy, or age for individuals participating in the primary clinical trial [SEP] Clinical Trial: NCT00076024",Entailment,0.7272934,0.2727067
NCT00076024,Statement: participants of the primary clinical trial must have a life expectancy of more than 6 months [SEP] Clinical Trial: NCT00076024,Entailment,0.651643,0.34835705
NCT01535040,"Statement: in the primary clinical trial, the placebo intervention is delivered via intramuscular injection, once weekly and the memantine is administered topically, twice weekly. [SEP] Clinical Trial: NCT01535040",Contradiction,0.4015527,0.59844726
NCT00792077,"Statement: the primary clinical trial abstains from using lenalidomide, whereas the secondary clinical trial uses high doses of lapatinib in intervention 1. [SEP] Clinical Trial: NCT00792077",Entailment,0.8126647,0.18733528
NCT00322374,"Statement: the eligibility for the primary clinical trial imposes no restrictions on mental health, bodyweight, age, karnofsky/ecog score or prior treatments. [SEP] Clinical Trial: NCT00322374",Entailment,0.53245693,0.46754307
NCT02734979,Statement: individuals with a history of pulmonary embolisms and current breast implants are allowed to participate in the primary clinical trial. [SEP] Clinical Trial: NCT02734979,Contradiction,0.4268153,0.5731847
NCT01256567,Statement: patients actively recovering from recent organ transplantation can be enrolled in the primary clinical trial but not in the secondary clinical trial [SEP] Clinical Trial: NCT01256567,Contradiction,0.43085316,0.5691468
NCT00373256,"Statement: The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel [SEP] Clinical Trial: NCT00373256",Contradiction,0.39190367,0.60809636
NCT01434342,"Statement: the primary clinical trial has observed more instances of mucositis oral, epileptic seizures, and thromboembolic events compared to the secondary clinical trial [SEP] Clinical Trial: NCT01434342",Entailment,0.5089784,0.49102157
NCT01156987,"Statement: 0% of the participants in group 1 of the primary trial were found to have lesions, and over 0.95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Contradiction,0.24827436,0.7517257
NCT01466972,Statement: maculo-papular Rash was a common adverse event for the primary trial participants. eosinophilic infiltrate is an inflammatory infiltrate composed exclusively or predominantly of eosinophils. [SEP] Clinical Trial: NCT01466972,Entailment,0.56249,0.43750995
NCT00632489,Statement: the primary clinical trial has not documented any outcomes for the lbh589 and lapatinib cohort [SEP] Clinical Trial: NCT00632489,Entailment,0.8981077,0.10189234
NCT00245050,"Statement: the primary trial had one test group and one placebo group, the secondary trial had 2 test groups. nucleolar granular material is a collection of preribosomes in the nucleolus. [SEP] Clinical Trial: NCT00245050",Contradiction,0.35124248,0.6487575
NCT00978250,Statement: patients confirmed to have metastatic or unresectable scbc based on histology are not allowed into the primary clinical trial unless they test positive for either er or pr or both. [SEP] Clinical Trial: NCT00978250,Contradiction,0.36941513,0.6305849
NCT00687102,Statement: both the primary and secondary clinical trials reported increased occurrences of intestinal obstructions and case of pancytopenia among the test subjects. [SEP] Clinical Trial: NCT00687102,Contradiction,0.42786184,0.5721382
NCT01498458,Statement: in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy [SEP] Clinical Trial: NCT01498458,Contradiction,0.3301511,0.66984886
NCT00553358,"Statement: anal cancer pmx tnm finding v6 is anal cancer in which distant metastasis cannot be assessed. (from ajcc 6th ed.) A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Entailment,0.6690654,0.33093464
NCT03384316,Statement: cohort 1 was the group where all the cases of infections and infestations were recorded in the primary clinical trial. [SEP] Clinical Trial: NCT03384316,Entailment,0.61774075,0.38225928
NCT00709761,"Statement: over 52% patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) .,  .,   [SEP] Clinical Trial: NCT00709761",Contradiction,0.3133221,0.68667793
NCT02761642,"Statement: cancer patients diagnosed with conditions such as fibromyalgia, thalasemic syndromes or anemia cannot participate in either the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT02761642",Entailment,0.69667494,0.30332506
NCT01045421,Statement: patients with a negative diagnosis for any type of solid tumor are able to participate in phase 1 of the primary clinical trial and for all stages of the secondary clinical trial [SEP] Clinical Trial: NCT01045421,Entailment,0.6611566,0.33884338
NCT02286843,"Statement: among the primary trial participants, 13% with her2- primary breast cancer who underwent her2-targeted pet/ct. 89zr-trastuzumab treatment developed imagable her2+ metastases [SEP] Clinical Trial: NCT02286843",Contradiction,0.40883502,0.59116495
NCT02222922,Statement: higher doses of alt-801 are given to participants in the primary clinical trial than to those in the secondary clinical trial [SEP] Clinical Trial: NCT02222922,Entailment,0.6407011,0.35929888
NCT00971945,"Statement: the secondary trial  candidates must meet some Performance Status condition to participate, whereas this is not required to be accepted into the primary trial. eurotium is a genus of filamentous fungi in the phylum ascomycota that are the sexual states of aspergillus species. [SEP] Clinical Trial: NCT00971945",Entailment,0.83584,0.16416003
NCT02504424,Statement: go ontology object is an object providing entry to a gene object's position in the gene ontology consortium's controlled vocabularies. one patient in the primary trial had an incident where a surgical incision reopened after the surgery. [SEP] Clinical Trial: NCT02504424,Entailment,0.61253995,0.38746002
NCT00867217,"Statement: healthy individuals, not diagnosed with any form of cancer, may be eligible for all study groups in the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00867217",Contradiction,0.27479202,0.7252079
NCT02807844,Statement: all patients in the primary trial receive at least 20000mcg of mcs110 every 21 days. [SEP] Clinical Trial: NCT02807844,Contradiction,0.42339876,0.5766012
NCT02038218,"Statement: the primary clinical trial does not involve any unit of measurement, while the secondary clinical trial does.' [SEP] Clinical Trial: NCT02038218",Entailment,0.8933746,0.1066254
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 8 weeks over 6 weeks, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.40318838,0.5968116
NCT00451555,"Statement: Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial, but this is not necessary to be included in the secondary trial [SEP] Clinical Trial: NCT00451555",Entailment,0.8333476,0.1666524
NCT01730729,"Statement: indwelling urinary catheter is a hollow tube that is inserted and left in the bladder to promote the drainage of urine. the primary trial intervention is given topically, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein. [SEP] Clinical Trial: NCT01730729",Contradiction,0.39116,0.60884
NCT00357734,"Statement: The intervention in the primary trial consists of a single drug, whereas in the secondary trial the intervention requires at least 3 different drugs. [SEP] Clinical Trial: NCT00357734",Entailment,0.8223191,0.1776809
NCT03202472,"Statement: secondary clinical trial stipulates that patients who have been subjected to chemotherapy or radiotherapy within a fortnight, those suffering from unstable angina, or experiencing grade 2 or above neuropathy, are unable to participate. the primary clinical trial, however, remains open to such patients unless they possess non-healing surgical wounds. [SEP] Clinical Trial: NCT03202472",Contradiction,0.49757534,0.50242466
NCT00978250,Statement: Patients with histologically documented metastatic SCBC are excluded from the primary trial. how big a problem is bleeding with urination is a question about an individual's assessment of how big a problem bleeding with urination has been. [SEP] Clinical Trial: NCT00978250,Entailment,0.70996267,0.29003733
NCT00254592,"Statement: patient cohorts in both the primary and secondary clinical trials receive cyclophosphamide, paclitaxel and pegfilgrastim. [SEP] Clinical Trial: NCT00254592",Contradiction,0.3399022,0.6600978
NCT00702949,"Statement: brucella is a genus of aerobic, gram-negative, coccobacilli shaped bacteria assigned to the phylum proteobacteria and the family brucellaceae. the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin twice daily, and the secondary trial administers its patients with Depocyt and HD-MTX. [SEP] Clinical Trial: NCT00702949",Contradiction,0.36679104,0.633209
NCT00871858,"Statement: Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead [SEP] Clinical Trial: NCT00871858",Entailment,0.68358046,0.3164195
NCT00104650,Statement: psa level less than four is a blood concentration of prostate specific antigen less than 4 ng/ml. The Interventions in the primary trial are administered through different routes. [SEP] Clinical Trial: NCT00104650,Entailment,0.7359928,0.2640072
NCT00538850,Statement: The the primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. high calcium level is a higher than average level of calcium in a sample. [SEP] Clinical Trial: NCT00538850,Contradiction,0.3902878,0.6097122
NCT01606748,"Statement: 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia. clinical trial subject questionnaire is a document intended to capture specific subject-related information through a series of questions. [SEP] Clinical Trial: NCT01606748",Entailment,0.5068778,0.49312222
NCT00030823,Statement: 13 participants in the primary clinical trial received the fix-dm1 therapeutic agent as a treatment [SEP] Clinical Trial: NCT00030823,Contradiction,0.4679635,0.53203654
NCT00122369,"Statement: the secondary clinical trial allows participation of patients irrespective of their age, while the primary clinical trial accepts only those between the ages of 18 to 45. [SEP] Clinical Trial: NCT00122369",Entailment,0.5201799,0.47982004
NCT01964924,"Statement: an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial. lead site v10 is a unipolar chest lead at which the electrode is placed over the dorsal spinous process of 7th thoracic vertebra. [SEP] Clinical Trial: NCT01964924",Contradiction,0.38873607,0.61126393
NCT01310075,Statement: a woman who has undergone breast conservation therapy would be excluded from the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01310075,Contradiction,0.46400672,0.5359933
NCT00248547,Statement: the occurrence of emesis was non-existent among patients who received the placebo intervention in the primary clinical trial [SEP] Clinical Trial: NCT00248547,Entailment,0.85697705,0.14302297
NCT03125941,Statement: global partial response gvhd is a clinician overall severity score that has decreased by 2 or more points on a 0-10 scale. Both the primary trial cohorts receive pre-operative Dexamethasone. [SEP] Clinical Trial: NCT03125941,Contradiction,0.48148367,0.5185163
NCT02239601,Statement: the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts. drug used since last visit is an indication that a specified drug was used during the time since the last visit. [SEP] Clinical Trial: NCT02239601,Entailment,0.5177082,0.48229182
NCT02404441,"Statement: the secondary clinical trial uses just one set of criteria for all study participants, whereas the primary clinical trial categorizes participants into different groups, each with their unique inclusion/exclusion criteria. [SEP] Clinical Trial: NCT02404441",Entailment,0.749847,0.250153
NCT02320123,"Statement: while the educational dvd will be an intervention element for the initial cohort in the primary clinical trial, the succeeding cohort will instead undergo standard radiotherapy treatment [SEP] Clinical Trial: NCT02320123",Contradiction,0.4713441,0.5286559
NCT00209092,"Statement: despite satisfying all eligibility conditions for the primary clinical trial, the final call for participation will be taken by the patient's closest family member. [SEP] Clinical Trial: NCT00209092",Entailment,0.6324182,0.36758175
NCT01178411,Statement: only american patients who fall into a specific weight range are eligible for the primary clinical trial [SEP] Clinical Trial: NCT01178411,Entailment,0.6279634,0.37203655
NCT00756496,"Statement: the groups in the primary clinical trial differed significantly in their results, and the reflexology group and control group in the secondary clinical trial generated divergent results. [SEP] Clinical Trial: NCT00756496",Entailment,0.8882775,0.1117226
NCT00370552,"Statement: Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements. [SEP] Clinical Trial: NCT00370552",Entailment,0.5813836,0.4186164
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 150,000 mcg of oral pregabalin every fortnight over 1.5 months, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.38662848,0.61337155
NCT00786838,"Statement: The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days. double is a 64-bit floating point primitive. when wrapped in an immutable object, it is called a double. [SEP] Clinical Trial: NCT00786838",Entailment,0.5234791,0.47652087
NCT00122369,"Statement: neither the primary nor the secondary trial imposes restrictions based on age, but patients must be between 25-55 years old for the primary clinical trial. [SEP] Clinical Trial: NCT00122369",Contradiction,0.23607497,0.763925
NCT03125941,"Statement: cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation. [SEP] Clinical Trial: NCT03125941",Contradiction,0.46706793,0.53293204
NCT00248547,Statement: all the participants of the primary clinical trial subjected to the placebo intervention experienced incidences of vomit [SEP] Clinical Trial: NCT00248547,Entailment,0.69973177,0.30026823
NCT00429299,"Statement: candidates for the primary clinical trial must have a confirmed her2 positive tumor, as ascertained by ihc 3+, and need significant assistance along with regular medical attention [SEP] Clinical Trial: NCT00429299",Contradiction,0.34595993,0.65404004
NCT00583700,"Statement: women aged 60 or 70 are eligible for the secondary trial, but will need to wait 10-20 years to be eligible for the primary trial [SEP] Clinical Trial: NCT00583700",Contradiction,0.42840403,0.571596
NCT00766532,"Statement: box dosing unit is a dosing unit equal to the amount of active ingredient(s) contained in a box. There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial. [SEP] Clinical Trial: NCT00766532",Contradiction,0.37746975,0.6225303
NCT02306265,"Statement: participation in the primary clinical trial is contingent upon a mammography, whereas the secondary clinical trial does not impose such requirement. [SEP] Clinical Trial: NCT02306265",Entailment,0.89263916,0.10736082
NCT01967823,Statement: there was no increase in blood bilirubin levels in any of the patients in the primary clinical trial. [SEP] Clinical Trial: NCT01967823,Entailment,0.8693824,0.13061766
NCT00759785,Statement: the growth factor signature decreased by 49.2% more in the dalotuzumab 20 mg/kg group than in the triple negative group in the primary clinical trial. [SEP] Clinical Trial: NCT00759785,Contradiction,0.46986812,0.53013194
NCT01256567,Statement: patients who have been bedridden following a recent heart transplant are accepted into the primary clinical trial but are disqualified from the secondary clinical trial [SEP] Clinical Trial: NCT01256567,Entailment,0.84144497,0.15855503
NCT00756717,"Statement: There were 0 cases of Febrile neutropenia or Cholelithiasis in the primary trial and the secondary trial. thymic adenocarcinoma, not otherwise specified is a primary thymic adenocarcinoma that does not conform to either low-grade papillary adenocarcinoma or enteric-type adenocarcinoma. [SEP] Clinical Trial: NCT00756717",Contradiction,0.4327901,0.5672099
NCT00194779,"Statement: seven different drugs are administered to participants of the primary clinical trial, who also have to undergo a surgical operation. in comparison, participants in the secondary clinical trial only receive a pair of drugs and do not need surgery [SEP] Clinical Trial: NCT00194779",Entailment,0.6880121,0.31198785
NCT01383174,"Statement: in cohort 2, the primary clinical trial had a significantly higher patient enrollment compared to the secondary clinical trial. [SEP] Clinical Trial: NCT01383174",Entailment,0.62021387,0.37978613
NCT00819182,"Statement: protective face mask is a barrier device that covers the nose and mouth, used in infection control. the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group. [SEP] Clinical Trial: NCT00819182",Contradiction,0.4096713,0.5903287
NCT01127763,Statement: all participants in the primary clinical trial experienced less than 3 adverse events. [SEP] Clinical Trial: NCT01127763,Entailment,0.891144,0.10885609
NCT00686127,Statement: There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial. status code is a coded value specifying the state of the entity or event. [SEP] Clinical Trial: NCT00686127,Entailment,0.573338,0.426662
NCT00786838,Statement: the placebo and trabectedin intervention in the primary trial are both administered on the same day. [SEP] Clinical Trial: NCT00786838,Entailment,0.5808345,0.41916555
NCT00428220,"Statement: Pericardial effusions were more common for patients in the primary trial, and Corneal deposits were more common in the secondary trial. [SEP] Clinical Trial: NCT00428220",Entailment,0.53464943,0.4653506
NCT01664091,"Statement: the number of infection, asymmetry, and deflation cases were found to be greater in the primary trial than those detected in the secondary trial. [SEP] Clinical Trial: NCT01664091",Entailment,0.5045385,0.49546152
NCT00373256,"Statement: radiation anemia is anemia arising due to radiation therapy. The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel. [SEP] Clinical Trial: NCT00373256",Contradiction,0.38286138,0.6171386
NCT00583700,Statement: only men aged 60 and above can participate in the secondary trial and the primary trial [SEP] Clinical Trial: NCT00583700,Contradiction,0.22838551,0.77161443
NCT00365365,Statement: participants of the primary clinical trial are not administered any vaccines. [SEP] Clinical Trial: NCT00365365,Entailment,0.92723644,0.072763555
NCT01803282,"Statement: while 2 in 73 participants of the primary clinical trial had an acute myocardial infarction, none out of the 1674 participants in the secondary clinical trial experienced this. [SEP] Clinical Trial: NCT01803282",Entailment,0.6660596,0.33394033
NCT01908101,Statement: the primary trial patients receive higher doses of radiation therapy than the secondary trial participants. oropharyngeal polyp is a benign exophytic growth that arises from the oropharynx. [SEP] Clinical Trial: NCT01908101,Contradiction,0.43973473,0.5602653
NCT00429299,Statement: behavioral rating scale is a range of values designed to quantify the qualitative responses of an individual to a set of challenges. All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+. [SEP] Clinical Trial: NCT00429299,Contradiction,0.35133198,0.64866805
NCT01591746,Statement: enteric-coated tablets are not received by any of the participants in either the primary or secondary clinical trial [SEP] Clinical Trial: NCT01591746,Entailment,0.90014905,0.099850945
NCT00775645,Statement: have difficulty getting up from chairs is a question about whether an individual has or had difficulty getting up from chairs. In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1% of participants. [SEP] Clinical Trial: NCT00775645,Entailment,0.5644607,0.4355393
NCT02891681,Statement: patients with a body mass index (bmi) in the overweight category can be eligible for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.23946884,0.7605312
NCT01614210,"Statement: Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average. tibia is a bone located between the femur and the tarsus, being part of the lower leg. [SEP] Clinical Trial: NCT01614210",Contradiction,0.38756853,0.6124315
NCT01111825,Statement: Neiter of the primary trial cohorts receive any invasive surgery or Neratinib . icd-10 procedure coding system is an international system of medical classification used for procedural coding. [SEP] Clinical Trial: NCT01111825,Entailment,0.51986253,0.48013744
NCT00786838,Statement: both the placebo and trabectedin used in the primary clinical trial are given as three-hour intravenous infusions biweekly. [SEP] Clinical Trial: NCT00786838,Entailment,0.5020786,0.49792138
NCT04080297,Statement: enrollment in the primary clinical trial is not possible for patients who are at present involved in the secondary clinical trial. [SEP] Clinical Trial: NCT04080297,Entailment,0.89723384,0.10276616
NCT00418028,"Statement: the primary clinical trial does not reveal data about the time to progression among patients, while the secondary clinical trial does not keep track of patients experiencing objective response. [SEP] Clinical Trial: NCT00418028",Entailment,0.87374526,0.12625478
NCT02431676,Statement: only patients with a body mass index within a normal range may enroll in the primary clinical trial. [SEP] Clinical Trial: NCT02431676,Entailment,0.6675276,0.33247238
NCT01421472,"Statement: Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial [SEP] Clinical Trial: NCT01421472",Contradiction,0.47627982,0.5237202
NCT01969448,Statement: intravascular ultrasound and transverse radial incisions form the backbone of the surgical procedures in the primary clinical trial. [SEP] Clinical Trial: NCT01969448,Entailment,0.52183604,0.47816402
NCT00262834,Statement: it was reported that the secondary clinical trial had multiple adverse effects affecting over 90% of the enrolled patients [SEP] Clinical Trial: NCT00262834,Contradiction,0.46469206,0.535308
NCT00256698,"Statement: hour times milligram per milliliter per milligram per kilogram per day is a dose calculation unit expressed in hours times milligrams per milliliter, divided by milligram per kilogram per day. Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial. [SEP] Clinical Trial: NCT00256698",Entailment,0.6965355,0.30346447
NCT02286843,Statement: 13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases [SEP] Clinical Trial: NCT02286843,Contradiction,0.43650883,0.5634911
NCT00370552,Statement: women of child-bearing potential and sexually active men are excluded from the primary clinical trial. [SEP] Clinical Trial: NCT00370552,Entailment,0.856662,0.14333805
NCT00377156,Statement: a diagnosis of a single cerebral metastasis will lead to an automatic exclusion from the primary trial yet it allows eligibility for the secondary trial. [SEP] Clinical Trial: NCT00377156,Entailment,0.5965258,0.40347424
NCT01008904,Statement: no adverse events have been recorded for the patient cohort of the primary clinical trial. [SEP] Clinical Trial: NCT01008904,Entailment,0.9105831,0.08941697
NCT00317603,"Statement: the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 5.00% of the primary trial patients [SEP] Clinical Trial: NCT00317603",Contradiction,0.22106172,0.77893823
NCT00305695,"Statement:  intervention 1 in the primary trial, and all intervention drugs in the secondary trial must be administered intravenously. residual cancer burden is an indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy. [SEP] Clinical Trial: NCT00305695",Contradiction,0.37387297,0.626127
NCT01091974,"Statement: in the primary trial only three cohorts recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 800 mg dose of pdr001, and 10 mg/kg dose of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.3687101,0.6312899
NCT01313117,"Statement: Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. [SEP] Clinical Trial: NCT01313117",Entailment,0.58946425,0.41053578
NCT02122796,"Statement: benign oral cavity soft tissue neoplasm is a non-metastasizing soft tissue neoplasm that arises from the oral cavity. the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates, but higher doses of herceptin and doxatel. [SEP] Clinical Trial: NCT02122796",Contradiction,0.41578054,0.5842195
NCT00836186,"Statement: the main procedure for participants in the primary trial involves insulin injections, and both groups of the secondary trial are offered tryptophan supplements as well as deep sleep therapy. [SEP] Clinical Trial: NCT00836186",Contradiction,0.37241387,0.6275862
NCT01606748,"Statement: in the initial cohort of the primary clinical trial, one instance each of anaemia and febrile neutropenia was documented, while pancytopenia was not observed. [SEP] Clinical Trial: NCT01606748",Entailment,0.56889427,0.43110567
NCT00293384,"Statement: Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril. aortic valve regurgitant volume is a quantitative measurement of the amount of retrograde blood flow across the orifice of the aortic valve. [SEP] Clinical Trial: NCT00293384",Contradiction,0.3748819,0.6251181
NCT01466972,Statement: not a single instance of a maculo-papular rash was reported in the primary clinical trial. [SEP] Clinical Trial: NCT01466972,Entailment,0.8978007,0.10219926
NCT01969448,Statement: the interventions implemented in the primary clinical trial skip the use of laser-assisted fluorescence angiography and adopt different techniques. [SEP] Clinical Trial: NCT01969448,Entailment,0.90999365,0.09000637
NCT00791037,Statement: the primary clinical trial and the secondary clinical trial assess various patient traits in their outcomes. [SEP] Clinical Trial: NCT00791037,Entailment,0.5221809,0.4778191
NCT00104650,Statement: the primary clinical trial implements its interventions via multiple routes. [SEP] Clinical Trial: NCT00104650,Entailment,0.7726293,0.22737072
NCT00432562,Statement: The only shared inclusion/exclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent. glandular odontogenic cyst is a developmental odontogenic cyst with epithelial features that simulate salivary gland or glandular differentiation. (who 2017) [SEP] Clinical Trial: NCT00432562,Entailment,0.528277,0.47172302
NCT01649271,Statement: there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial. vasectomy reversal procedure is a surgical procedure to reattach a previously cut vas deferens. [SEP] Clinical Trial: NCT01649271,Contradiction,0.4023797,0.59762025
NCT00320541,Statement: The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it. internal auditory canal meningioma is a meningioma that affects the internal auditory canal. [SEP] Clinical Trial: NCT00320541,Contradiction,0.34765616,0.6523438
NCT00148668,"Statement: in the primary clinical trial, both treatments involve the use of an identical paraplatin dose [SEP] Clinical Trial: NCT00148668",Entailment,0.5842062,0.41579372
NCT00432562,Statement: there are 5 shared inclusion/exclusion criteria between the secondary trial and the primary trial [SEP] Clinical Trial: NCT00432562,Entailment,0.6585649,0.3414351
NCT00284180,"Statement: Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial. maid regimen is a regimen consisting of doxorubicin, ifosfamide, dacarbazine and mesna used to treat unresectable soft tissue sarcoma. [SEP] Clinical Trial: NCT00284180",Entailment,0.80920905,0.19079094
NCT01129622,Statement: Women suffering from both claustrophobia and osteoporosis or not eligible for either the primary trial or the secondary trial. usual severity difficulty sleeping is a question about the usual severity of an individual's difficulty sleeping. [SEP] Clinical Trial: NCT01129622,Entailment,0.5954993,0.40450075
NCT00706030,"Statement: Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2. lordosis is abnormally increased curvature of the lumbar portion of the spinal column. [SEP] Clinical Trial: NCT00706030",Entailment,0.5250154,0.47498456
NCT01806259,"Statement: squamous papillomatosis is a benign squamous neoplasm characterized by a papillary growth pattern, diffusely involving a specific anatomic site. the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group. [SEP] Clinical Trial: NCT01806259",Contradiction,0.41072991,0.5892701
NCT00867217,Statement: Patients diagnosed with breact cancer may be eligible for all study groups in the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00867217,Contradiction,0.24351873,0.7564813
NCT00270894,Statement: four different medications are administered to the participants during the primary clinical trial. [SEP] Clinical Trial: NCT00270894,Entailment,0.76512134,0.2348787
NCT01256567,"Statement: a patient that has received an organ transplant within the last month, would be excluded from the primary trial but may be eligible for the secondary trial. debug is act to locate and correct errors in a computer program code. [SEP] Clinical Trial: NCT01256567",Entailment,0.69229,0.30771
NCT01256567,"Statement: a patient that has received an organ transplant within the last month, and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial. congo is a country in western africa, bordering the south atlantic ocean, between gabon and the democratic republic of the congo. [SEP] Clinical Trial: NCT01256567",Entailment,0.6151828,0.38481724
NCT02312934,"Statement: patients who consume alcohol are ineligible for the primary clinical trial, yet those who limit their intake to less than five drinks per day may qualify for the secondary clinical trial. [SEP] Clinical Trial: NCT02312934",Entailment,0.68547446,0.31452554
NCT01383174,Statement: cohort 2 of the primary clinical trial had a smaller patient count compared to cohort 2 of the secondary trial. [SEP] Clinical Trial: NCT01383174,Entailment,0.78619176,0.21380822
NCT01649271,"Statement: There was one case of shingles recorded in group 2 of the secondary trial, but no cases in group 1 of the secondary trial and the primary trial. [SEP] Clinical Trial: NCT01649271",Entailment,0.6428722,0.35712776
NCT00766532,"Statement: complete absences of swelling, hypothermia, and confusion were observed in the aes reports from both the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00766532",Entailment,0.63544977,0.36455026
NCT03202472,"Statement: in the secondary trial, it is acceptable for patients to have undergone cancer treatments such as chemotherapy and radiotherapy within the last 14 days, have unstable angina, or grade 2 or above neuropathy. however, these conditions disqualify them from participation in the primary trial if they have non-healing surgical wounds. [SEP] Clinical Trial: NCT03202472",Contradiction,0.49375242,0.50624764
NCT01091974,"Statement: In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110. sinonasal lymphoma is a lymphoma that arises from the sinonasal tract. [SEP] Clinical Trial: NCT01091974",Contradiction,0.4174162,0.5825838
NCT02286843,"Statement: 13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases. male non-neoplastic reproductive system disorder is a non-neoplastic disorder that affects the male reproductive system. representative examples include prostatitis, balanitis, and phimosis. [SEP] Clinical Trial: NCT02286843",Contradiction,0.38854593,0.61145407
NCT01246973,"Statement: a high frequency of cardiac and psychiatric aes were found in the primary clinical trial and secondary clinical trial, while the record showed a low frequency of other aes. [SEP] Clinical Trial: NCT01246973",Contradiction,0.42167953,0.5783205
NCT02165839,"Statement: candidates for the primary clinical trial are acceptable with any performance status, while those for the secondary clinical trial must have a karnofsky score less than 50. [SEP] Clinical Trial: NCT02165839",Entailment,0.6188302,0.3811698
NCT01314963,Statement: intervention 1 of the primary clinical trial uses lower doses of radioactive tc99m sulfur colloid than intervention 2. [SEP] Clinical Trial: NCT01314963,Entailment,0.69467086,0.3053291
NCT02961790,"Statement: any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 730 days before study entry are excluded from the primary trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.6582832,0.34171677
NCT00553358,"Statement: a patient that has a primary tumour with a radius of 0.3cm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.30245712,0.69754285
NCT01527487,"Statement: in the primary clinical trial, both cohorts receive equal doses of cyclophosphamide, eribulin, and docetaxel. [SEP] Clinical Trial: NCT01527487",Entailment,0.6626078,0.33739224
NCT00838929,"Statement: during radiation therapy, all patients participating in the primary clinical trial are given a dosage of fentanyl sublingual spray, ranging from 100 to 1600 ¬¨¬µg [SEP] Clinical Trial: NCT00838929",Contradiction,0.36199906,0.63800097
NCT00971945,"Statement: colon non-hodgkin lymphoma is an extranodal non-hodgkin lymphoma that arises from the colon.  the majority are b-cell non-hodgkin lymphomas. the secondary trial  candidates must be Completely disabled to participate, whereas this is not required to be accepted into the primary trial. [SEP] Clinical Trial: NCT00971945",Entailment,0.661406,0.33859402
NCT00896454,Statement: the primary and secondary clinical trial both use the same unit of measure for reporting their results. [SEP] Clinical Trial: NCT00896454,Contradiction,0.49075407,0.5092459
NCT00104650,Statement: feel worn out is a question about whether an individual feels or felt worn out. The Interventions in the primary trial included different medications but are administered through the same routes. [SEP] Clinical Trial: NCT00104650,Entailment,0.6747053,0.3252947
NCT00795769,Statement: a greater number of patients in the secondary clinical trial were documented as having experienced aes compared to patients in the primary clinical trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.63204783,0.36795214
NCT02599194,Statement: the severity of adverse reactions were somewhat higher in the primary clinical trial as compared to the secondary clinical trial proportion wise. [SEP] Clinical Trial: NCT02599194,Entailment,0.60613585,0.39386415
NCT00836186,"Statement: the primary trial participants receive intra-venous chemotherapy, and all cohorts of the secondary trial are put through a radiotherapy regimen only. [SEP] Clinical Trial: NCT00836186",Entailment,0.54679406,0.45320594
NCT00270894,"Statement: participants in the primary trial receive 1 drug throughout the study duration, with a maximum dose of 1000 kg/m^2 [SEP] Clinical Trial: NCT00270894",Contradiction,0.33766326,0.6623367
NCT02796755,Statement: adverse events observed during the secondary clinical trial exceeded those in the primary clinical trial. [SEP] Clinical Trial: NCT02796755,Entailment,0.8702427,0.12975729
NCT00709761,Statement: no patients in the primary clinical trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) or a confirmed partial response (pr). [SEP] Clinical Trial: NCT00709761,Entailment,0.7778869,0.22211312
NCT01831089,Statement: patients with a clinically speculated diagnosis of an inoperable non-small cell lung cancer or small cell lung cancer are eligible for the primary clinical trial [SEP] Clinical Trial: NCT01831089,Entailment,0.6011454,0.3988546
NCT03125941,"Statement: the administration of dexamethasone in the primary clinical trial is pre-operative for the first cohort, while post-operative (specifically two hours later) for the second cohort. [SEP] Clinical Trial: NCT03125941",Contradiction,0.45508263,0.54491735
NCT01591746,"Statement: the primary clinical trial's cohorts do not receive alisertib; however, each cohort in the secondary clinical trial is given distinctive dosages. [SEP] Clinical Trial: NCT01591746",Entailment,0.7792874,0.22071263
NCT00538850,"Statement: inclusion/exclusion criteria not met supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the inclusion/exclusion criteria not met domain. The the primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. [SEP] Clinical Trial: NCT00538850",Entailment,0.6575392,0.3424608
NCT00999921,"Statement: patients who are healthy and not diagnosed with any form of cancer, are permitted to join the primary clinical trial but are excluded from the secondary clinical trial. [SEP] Clinical Trial: NCT00999921",Entailment,0.83030885,0.16969115
NCT00686127,"Statement: in comparison to the secondary trial, the primary trial has fewer adverse events overall but a higher occurrence of cardiac-ischemia/infarction. [SEP] Clinical Trial: NCT00686127",Entailment,0.54351467,0.4564853
NCT00911898,Statement: cbfa2t3 gene rearrangement is a molecular abnormality indicating rearrangement of the cbfa2t3 gene. The the primary trial intervention section requires surgical and imaging procedures. [SEP] Clinical Trial: NCT00911898,Contradiction,0.47671354,0.5232864
NCT00569166,Statement: the primary clinical trial consists of one cohort that utilize the focused breathing instructional audio guide thrice daily and do not undergo regular chemotherapy sessions. [SEP] Clinical Trial: NCT00569166,Entailment,0.845647,0.15435304
NCT02807844,Statement: some patients participating in the primary clinical trial receive mcs110 more frequently than every 3 weeks. [SEP] Clinical Trial: NCT02807844,Entailment,0.60308474,0.39691526
NCT00054028,"Statement: relational and item-specific encoding task is a clinical test designed to assess episodic memory encoding and retrieval processes in individuals with cognitive impairment. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial. [SEP] Clinical Trial: NCT00054028",Contradiction,0.21648015,0.78351986
NCT00475085,Statement: cohort 2 of the primary clinical trial has 10 participants fewer than cohort 1 [SEP] Clinical Trial: NCT00475085,Entailment,0.8640311,0.13596897
NCT00963911,"Statement: in the primary clinical trial, the intervention includes obligatory fitness routines for all the participants. [SEP] Clinical Trial: NCT00963911",Contradiction,0.49093568,0.5090643
NCT00405938,Statement: patients with a recent history of abdominal fistula or gastrointestinal perforation can participate in the primary clinical trial [SEP] Clinical Trial: NCT00405938,Contradiction,0.48718902,0.51281095
NCT02286843,"Statement: in the primary clinical trial, all patients with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab remained metastases-free [SEP] Clinical Trial: NCT02286843",Contradiction,0.46174902,0.538251
NCT01855828,Statement: no psychiatric disorders like eating disorder or schizophrenia emerged as a consequence of the primary clinical trial. [SEP] Clinical Trial: NCT01855828,Entailment,0.7229599,0.27704018
NCT00587964,Statement: specific symptoms are predominantly reported as adverse events in the primary clinical trial [SEP] Clinical Trial: NCT00587964,Entailment,0.872872,0.127128
NCT00365105,"Statement: a 36 year old patient with clinically confirmed diagnosis of stage ii lung cancer, absolute neutrophil count of 1200/μl, platelet count of 80,034/μl, hemoglobin level of 70 g/l, and a life expectancy not surpassing 4 months would not meet the criteria for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.35815185,0.64184815
NCT02312934,Statement: Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. [SEP] Clinical Trial: NCT02312934,Entailment,0.6721757,0.3278243
NCT00432562,Statement: there is no overlap in the inclusion and exclusion criteria for the primary and secondary clinical trials. [SEP] Clinical Trial: NCT00432562,Entailment,0.92717946,0.07282058
NCT04080297,Statement: not all patients participating in the secondary clinical trial meet the requirements for inclusion in the primary clinical trial due to differing standards [SEP] Clinical Trial: NCT04080297,Entailment,0.8419134,0.15808661
NCT00054028,"Statement: suramin and paclitaxel are given to every participant in the primary clinical trial, unlike the secondary clinical trial which doesn't disclose the drugs to be used in its intervention section. [SEP] Clinical Trial: NCT00054028",Entailment,0.8813602,0.11863985
NCT00194779,"Statement: participants in the primary trial are treated with only 1 drug and no surgery is involved, whereas the participants of the secondary trial are treated with a combination of 5 drugs and surgical intervention is required [SEP] Clinical Trial: NCT00194779",Entailment,0.7931754,0.20682457
NCT01419717,"Statement: the primary trial does not require injections, instead compels patients to adhere to a protocol of guaiacum based treatments; the secondary trial on the other hand requires patients to submit to the administration of a 200 milligrams of selumetinib intravenously every fortnight. [SEP] Clinical Trial: NCT01419717",Contradiction,0.45311916,0.5468808
NCT02234479,"Statement: the primary trial is testing the effects of different gels on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. oral cavity lipoma is a benign adipose tissue neoplasm of the oral cavity. it usually occurs within the lingual and buccal mucosa. [SEP] Clinical Trial: NCT02234479",Entailment,0.6026028,0.3973972
NCT01963481,Statement: Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial [SEP] Clinical Trial: NCT01963481,Entailment,0.81826514,0.18173485
NCT00756496,"Statement: no notable variances were present in the outcomes of the primary clinical trial groups, and both the reflexology group and control group in the secondary clinical trial garnered matching results. [SEP] Clinical Trial: NCT00756496",Entailment,0.5002901,0.4997099
NCT01743560,"Statement: for the primary clinical trial, children and adolescents are not accepted due to not meeting the height requirement. however, the secondary clinical trial does not overtly rule them out. [SEP] Clinical Trial: NCT01743560",Entailment,0.64195615,0.35804382
NCT01286987,Statement: breast cancer patients in the primary trial are administered 50 mcg/day of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 100 mcg/day talazoparib instead. [SEP] Clinical Trial: NCT01286987,Entailment,0.5942819,0.40571806
NCT00702949,"Statement: the primary trial treats one of its patient cohorts with 1000 mg of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx. [SEP] Clinical Trial: NCT00702949",Contradiction,0.36958712,0.6304129
NCT00553358,"Statement: A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. carotid artery disorder is a non-neoplastic or neoplastic disorder affecting the carotid artery. [SEP] Clinical Trial: NCT00553358",Contradiction,0.32771778,0.6722822
NCT00756496,"Statement: There were no significant differences in the results from the groups in the primary trial, however some differences where found between the Reflexology Group and control group results in the secondary trial. [SEP] Clinical Trial: NCT00756496",Entailment,0.5505454,0.44945464
NCT00544167,"Statement: patients that have suffered a pulmonary embolism in the last 1440 hours are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.6890079,0.31099215
NCT00245050,"Statement: one test group and one placebo group constituted the primary clinical trial, in contrast, the secondary clinical trial was composed of two test groups. [SEP] Clinical Trial: NCT00245050",Entailment,0.6250378,0.37496218
NCT02312934,"Statement: if a person smokes, they won't be permitted in the primary clinical trial, however, they may qualify for the secondary clinical trial if their daily alcohol consumption is under 5 drinks. [SEP] Clinical Trial: NCT02312934",Contradiction,0.44524136,0.55475867
NCT02041429,Statement: robotic-assisted imaging is an imaging technique that uses a specially designed robotic system to aid with the imaging of the desired object. the primary trial and the secondary trial report on the MTD of different interventions. [SEP] Clinical Trial: NCT02041429,Contradiction,0.4594747,0.54052526
NCT03346161,Statement: zero adverse events were documented in both cohorts of the primary clinical trial [SEP] Clinical Trial: NCT03346161,Entailment,0.8788383,0.12116177
NCT00377156,"Statement: having multiple cerebral metastases is necessary for admission to the secondary trial, however, for the primary trial, a diagnosis of multiple brain metastases will lead to exclusion. [SEP] Clinical Trial: NCT00377156",Entailment,0.74892235,0.25107762
NCT00838929,Statement: every patient in the primary trial is receives a dose of 500 to 10000 ¬¨¬µg fentanyl sublingual spray during radiation therapy [SEP] Clinical Trial: NCT00838929,Contradiction,0.48813307,0.5118669
NCT00075764,Statement: patients with quantifiable metastasis or with cancer that has spread to other parts of body are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT00075764,Entailment,0.5004104,0.49958965
NCT01569087,"Statement: Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent. [SEP] Clinical Trial: NCT01569087",Contradiction,0.23635109,0.7636489
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial [SEP] Clinical Trial: NCT01964924,Entailment,0.8289014,0.17109863
NCT00001832,Statement: drug-based cures in the primary and the secondary trial are utterly diverse in nature. [SEP] Clinical Trial: NCT00001832,Entailment,0.649523,0.35047695
NCT01920061,Statement: The same perecentage of patients suffered adverse events in both cohorts of the primary trial. skin condition bleeds is a response indicating that an individual's skin condition bleeds. [SEP] Clinical Trial: NCT01920061,Entailment,0.6319979,0.3680021
NCT00632489,Statement: The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort. bio event is an abstract class to capture the concept of an event (either in the laboratory or a computational analysis). (camage) [SEP] Clinical Trial: NCT00632489,Entailment,0.82773143,0.17226855
NCT01222390,"Statement: There are no X-rays, transendocardial injections,  CT scans or MRIs included the interventions of the primary trial and the secondary trial [SEP] Clinical Trial: NCT01222390",Contradiction,0.30397654,0.6960234
NCT02165839,"Statement: for admission into both the primary and secondary clinical trials, it is necessary for applicants to achieve a baseline performance score. this is demarcated by a karnofsky score of more than 70 in the primary trial, and for the secondary clinical trial, a karnofsky score above 55 is necessary. [SEP] Clinical Trial: NCT02165839",Contradiction,0.38945198,0.610548
NCT01967823,Statement: jug dosing unit is a dosing unit equal to the amount of active ingredient(s) in a jug. 36.36% of the primary trial patients suffered an increase in Blood bilirubin. [SEP] Clinical Trial: NCT01967823,Contradiction,0.3716616,0.6283384
NCT00756496,"Statement: significant differences were observed among the groups participating in the primary clinical trial, while all groups including the reflexology group showed similar results in the secondary clinical trial. [SEP] Clinical Trial: NCT00756496",Entailment,0.6683797,0.33162025
NCT01781299,Statement: hospital admissions were reported during the primary clinical trial [SEP] Clinical Trial: NCT01781299,Entailment,0.7462061,0.2537939
NCT00418028,"Statement: the primary trial reports the overall survival in months for all 300 patients included in the study, while the secondary trial reports the percentage of non-responding patients [SEP] Clinical Trial: NCT00418028",Entailment,0.5060219,0.49397802
NCT01823991,Statement: patients diagnosed with alzheimer's disease are eligible for the primary clinical trial [SEP] Clinical Trial: NCT01823991,Entailment,0.6500942,0.34990573
NCT02239601,Statement: the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial. met gene mutation negative is a genetic finding indicating that met gene mutations have not been detected in a sample. [SEP] Clinical Trial: NCT02239601,Entailment,0.7653324,0.23466757
NCT00569166,"Statement: btc gene product is a protein encoded by the btc gene. Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day. [SEP] Clinical Trial: NCT00569166",Contradiction,0.38153425,0.6184657
NCT00544167,"Statement: patients that have suffered a pulmonary embolism in the last 20 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.7176895,0.28231046
NCT01466972,"Statement: No two patients in the primary trial suffered the same type of adverse event. juvenile idiopathic arthritis is a group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints. [SEP] Clinical Trial: NCT01466972",Entailment,0.6162881,0.38371184
NCT01969448,Statement: laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial. t-cell non-hodgkin lymphoma by ann arbor stage is an anatomic stage for t-cell non-hodgkin lymphoma based on the ann arbor classification criteria. [SEP] Clinical Trial: NCT01969448,Contradiction,0.34144804,0.65855193
NCT00553358,"Statement: a patient that has a primary tumour with a radius of 0.3cm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.30245712,0.69754285
NCT01963481,Statement: patients with severe cases of schizophrenia and insomnia are unable to partake in the primary and secondary clinical trials [SEP] Clinical Trial: NCT01963481,Entailment,0.83581394,0.16418608
NCT02550795,"Statement: group 2 of the primary trial receives 0.5mcg/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.89125276,0.108747266
NCT01011218,Statement: synchronous nodules without dominant lesion(s) is a finding of multiple pulmonary nodules in which radiologic imaging shows no evidence of a dominant lesion. Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events. [SEP] Clinical Trial: NCT01011218,Contradiction,0.47060725,0.5293927
NCT00513292,"Statement: the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had much better results than arm 1. [SEP] Clinical Trial: NCT00513292",Contradiction,0.45485967,0.5451404
NCT02431676,Statement: individuals who are significantly overweight are fit for the primary clinical trial [SEP] Clinical Trial: NCT02431676,Entailment,0.6380566,0.36194345
NCT01419717,"Statement: the primary trial requires patients to receive 240 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy. [SEP] Clinical Trial: NCT01419717",Contradiction,0.32425928,0.6757408
NCT02312934,Statement: Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. megakaryopoiesis is a hematopoietic process that refers to the production of megakaryocytes in the bone marrow. [SEP] Clinical Trial: NCT02312934,Entailment,0.5130234,0.48697668
NCT00623831,Statement: 0.25 of patients in the primary trial suffer increased pleural effusion and rapid disease progression [SEP] Clinical Trial: NCT00623831,Contradiction,0.3484763,0.6515237
NCT01178411,"Statement: history of medication is a history of the medication that the patient has taken. the nationality, ethnicity, weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01178411",Contradiction,0.29388544,0.7061146
NCT00709761,Statement: under half of the patients in the primary clinical trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) or a confirmed partial response (pr). [SEP] Clinical Trial: NCT00709761,Contradiction,0.36073485,0.6392651
NCT02259114,Statement: primary clinical trial and secondary clinical trial host patients diagnosed with nut midline carcinoma via fluorescence in situ hybridization and those with inflammatory breast cancer. [SEP] Clinical Trial: NCT02259114,Contradiction,0.33174756,0.6682524
NCT02550795,"Statement: group 2 of the primary trial receives 500ng/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.85034955,0.1496505
NCT00429299,Statement: positive fish or ihc 3+ results confirming a diagnosis of a her2 positive tumor is essential for all primary clinical trial candidates. [SEP] Clinical Trial: NCT00429299,Contradiction,0.45143503,0.548565
NCT00623831,Statement: 25% of cohort 2 patients in the primary trial suffer Increased pleural effusion [SEP] Clinical Trial: NCT00623831,Contradiction,0.44276384,0.55723614
NCT01591746,"Statement: in the primary clinical trial, alisertib isn't included in the treatment of both cohorts, yet the secondary clinical trial uses varying doses for its two cohorts. [SEP] Clinical Trial: NCT01591746",Entailment,0.8141019,0.18589813
NCT00709761,Statement: over 1/2 patients in the primary clinical trial treated with lapatinib 1000 mg + nab-paclitaxel had progression of disease. [SEP] Clinical Trial: NCT00709761,Entailment,0.5960619,0.40393806
NCT01434342,"Statement: There were more cases of Mucositis Oral, epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial. acquired factor x deficiency is an acquired coagulation disorder characterized by the partial or complete absence of factor x activity in the blood. [SEP] Clinical Trial: NCT01434342",Contradiction,0.4372315,0.5627685
NCT01419717,"Statement: the primary clinical trial necessitates a monthly subcutaneous administration of 120 milligrams of denosumab to patients, while the secondary clinical trial involves the injection of 0.4 to 1.0 mci of radioactive tc99m sulfur colloid. [SEP] Clinical Trial: NCT01419717",Contradiction,0.40328214,0.5967179
NCT02038218,"Statement: the secondary trial and the primary trial use different units of measure in their results, for the same outcome measurement. [SEP] Clinical Trial: NCT02038218",Entailment,0.8961425,0.10385753
NCT01606748,"Statement: the primary clinical trial found no traces of anaemia, febrile neutropenia, or pancytopenia in cohort 1. [SEP] Clinical Trial: NCT01606748",Entailment,0.6473365,0.35266358
NCT00293384,"Statement: Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril [SEP] Clinical Trial: NCT00293384",Contradiction,0.37374666,0.6262533
NCT02550795,"Statement: group 2 of the primary trial recieves 0.0000005g/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. [SEP] Clinical Trial: NCT02550795",Entailment,0.8554002,0.14459977
NCT01706081,Statement: Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream. [SEP] Clinical Trial: NCT01706081,Entailment,0.5691715,0.4308285
NCT00256698,Statement: Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial. nova scotia is a canadian province located on canada's southeastern coast. its capital is halifax. [SEP] Clinical Trial: NCT00256698,Entailment,0.6396903,0.36030972
NCT02961790,Statement: those who have received estrogens or progestogens within the month preceding the clinical study can be included in the primary clinical trial. [SEP] Clinical Trial: NCT02961790,Entailment,0.5180612,0.48193878
NCT01967823,Statement: refractory acute myelomonocytic leukemia is acute myelomonocytic leukemia that does not respond to treatment. All AE types in the primary trial affected less than 10% of patients. [SEP] Clinical Trial: NCT01967823,Entailment,0.7702591,0.22974098
NCT00698035,"Statement: the primary trial is using hormonal interventions, and the secondary trial is testing an acupuncture intervention. wwtr1 gene rearrangement is a molecular abnormality indicating rearrangement of the wwtr1 gene. [SEP] Clinical Trial: NCT00698035",Entailment,0.5517139,0.44828612
NCT01451632,"Statement: in the primary clinical trial, both cohorts 1 and 2 were administered identical doses of cetuximab, however, cohort 1 received a supplementary collaborative care intervention. [SEP] Clinical Trial: NCT01451632",Entailment,0.5679983,0.43200168
NCT00753415,Statement: both cohorts a and b in the primary clinical trial are given identical two im injections of ld v935 at similar stages of the cycle. [SEP] Clinical Trial: NCT00753415,Entailment,0.5072476,0.49275237
NCT01963481,Statement: Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial [SEP] Clinical Trial: NCT01963481,Entailment,0.7813133,0.21868666
NCT00317603,Statement: the least frequently reported adverse event across the patient cohorts of the primary trial and the secondary trial was syncope [SEP] Clinical Trial: NCT00317603,Contradiction,0.42370945,0.5762906
NCT01806675,"Statement: all groups in the primary trial study are subjected to the same imaging processes, including 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct). [SEP] Clinical Trial: NCT01806675",Contradiction,0.4956333,0.50436664
NCT01554371,Statement: active smokers are barred from participating in both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.8923905,0.107609555
NCT00950911,Statement: the primary clinical trial's intervention 1 includes a 12-fold higher dosage of zoledronic acid compared to the dosage of denosumab used in the secondary clinical trial's first intervention. [SEP] Clinical Trial: NCT00950911,Entailment,0.5419341,0.45806593
NCT00194779,"Statement: the primary trial participants are administered over 7 different types of drugs and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery. ambamustine is a tripeptidic nitrogen mustard compound and bifunctional alkylating agent with antineoplastic activity. [SEP] Clinical Trial: NCT00194779",Entailment,0.6725538,0.3274462
NCT01008904,Statement: The only AE recorded in the primary trial was Stomatitis. drug accountability assessment test code is a character or string that represents the short code name of the drug accountability assessment. [SEP] Clinical Trial: NCT01008904,Entailment,0.5994472,0.40055275
NCT00370552,"Statement: Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period . skin signet ring cell basal cell carcinoma is a rare type of basal cell carcinoma. it is characterized by the presence of mucin containing signet ring cells. [SEP] Clinical Trial: NCT00370552",Contradiction,0.47185633,0.5281437
NCT01008150,Statement: no notable occurrence of pathologic complete response was observed in breast and axillary lymph nodes among trial participants in either cohort of the primary clinical trial after around 7 months post-surgery [SEP] Clinical Trial: NCT01008150,Entailment,0.5458718,0.4541282
NCT01706081,Statement: acupuncture patients in the primary clinical trial did not see any significant improvements in their lymphedema as compared to those on the waiting list. [SEP] Clinical Trial: NCT01706081,Entailment,0.7305698,0.26943028
NCT02041429,"Statement: in the context of the primary and secondary clinical trials, the maximum tolerated dose of mm-111, for patients involved in the secondary clinical trial, is reallocated at 15 mg on a daily basis [SEP] Clinical Trial: NCT02041429",Contradiction,0.2732942,0.72670585
NCT01008150,Statement: more than 10 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 24 weeks after the surgery [SEP] Clinical Trial: NCT01008150,Contradiction,0.32383096,0.676169
NCT03069313,Statement: the primary trial and the secondary trial adminster their interventions orally. [SEP] Clinical Trial: NCT03069313,Entailment,0.6939798,0.3060202
NCT01008150,"Statement: almost 7 months following the surgical process, more than 42 patients across both batches of the primary clinical trial demonstrated a pathologic complete response in breast and axillary lymph nodes [SEP] Clinical Trial: NCT01008150",Contradiction,0.30863252,0.6913675
NCT01554371,Statement: patients who are currently engaged in smoking are ineligible for both the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.8774792,0.122520804
NCT02961790,"Statement: Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial. supermarket is a large self-serving retail or wholesale market that sells food and household goods. (webs84) [SEP] Clinical Trial: NCT02961790",Entailment,0.60690296,0.39309698
NCT01129622,Statement: women without any health conditions are not eligible for either the primary clinical trial or the secondary clinical trial. [SEP] Clinical Trial: NCT01129622,Entailment,0.79857194,0.20142806
NCT00209092,"Statement: despite fulfilling all the exclusion and inclusion requirements for the primary clinical trial, the ultimate choice of participation is at the discretion of a court appointed guardian or representative. [SEP] Clinical Trial: NCT00209092",Entailment,0.7368901,0.2631099
NCT02734979,"Statement: patients who have had instances of pulmonary embolisms are ruled out from the secondary clinical trial, likewise, patients with breast implants at the moment are also barred from the primary clinical trial. [SEP] Clinical Trial: NCT02734979",Entailment,0.64990085,0.35009918
NCT00075764,"Statement: Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial [SEP] Clinical Trial: NCT00075764",Entailment,0.7748464,0.2251536
NCT03557801,"Statement: the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial. [SEP] Clinical Trial: NCT03557801",Contradiction,0.43793237,0.5620677
NCT00656019,"Statement: in the primary clinical trial, numerous patients with regular vitamin d levels exhibited noticeable trends in the expression of 40 studied genes. [SEP] Clinical Trial: NCT00656019",Contradiction,0.27523446,0.7247656
NCT01250379,"Statement: the primary clinical trial and the secondary clinical trial may be suitable for a 20 year old female recently diagnosed with er-positive, her2-negative breast cancer [SEP] Clinical Trial: NCT01250379",Contradiction,0.48900324,0.51099676
NCT03202472,"Statement: patients experiencing unstable angina, or who have undergone chemotherapy or radiotherapy within the last 2 weeks, or are suffering from grade 2 or higher neuropathy, are ruled out from the secondary clinical trial, although may still be considered for the primary clinical trial if they fulfil the necessary inclusion requirements. [SEP] Clinical Trial: NCT03202472",Contradiction,0.45205846,0.54794157
NCT01831089,Statement: those with a confirmed cytological or histological diagnosis of non-small cell lung cancer or small cell lung cancer are suitable for the primary clinical trial [SEP] Clinical Trial: NCT01831089,Entailment,0.56709665,0.43290332
NCT02239601,"Statement: level is a position on a scale measuring intensity, quality, or amount. the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial. [SEP] Clinical Trial: NCT02239601",Entailment,0.7041308,0.29586917
NCT01156987,"Statement: all of the participants in group 1 of the primary trial were found to have lesions, and less than 5% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. [SEP] Clinical Trial: NCT01156987",Entailment,0.65359056,0.34640944
NCT00293540,"Statement: bone marrow transplant recipient is an individual receiving a bone marrow transplant. On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months. [SEP] Clinical Trial: NCT00293540",Contradiction,0.23172559,0.7682744
NCT00428220,"Statement: compared to the secondary clinical trial, the frequency of pericardial effusions was higher in the primary clinical trial, whereas corneal deposits were more often noted in the latter. [SEP] Clinical Trial: NCT00428220",Contradiction,0.4935485,0.5064515
NCT02734979,"Statement: Patients that have a history of pulmonary embolisms cannot take part in the secondary trial, and those who currently have breast implants cannot participate in the primary trial. ulnar length is a measurement of the length of the ulna. [SEP] Clinical Trial: NCT02734979",Entailment,0.61109227,0.38890773
NCT00538850,Statement: the primary clinical trial results do not concern changes in pain intensity and the secondary trial does not measure the change from baseline to 9 months in bone mineral density (bmd) of the lumbar spine. [SEP] Clinical Trial: NCT00538850,Entailment,0.8434759,0.15652415
NCT00321464,"Statement: Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive or HER2/neu negative are eligible for both the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.47598308,0.5240169
NCT00971945,Statement: both primary and secondary trials demand fulfillment of some performance status conditions for patient participation [SEP] Clinical Trial: NCT00971945,Entailment,0.66788375,0.3321162
NCT01869192,"Statement: The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm, additionally, in the secondary trial the Denosumab cohort had a better Time to First On-Study SRE than the Zoledronic Acid cohort. independent to propel wheelchair is a response indicating that an individual is able to propel their wheelchair independent of help from others. [SEP] Clinical Trial: NCT01869192",Entailment,0.5441214,0.45587865
NCT01969448,"Statement: laser-assisted fluorescence angiography is used for both interventions in the primary trial. gross income is a person's total income before taxes, exclusions, and deductions. [SEP] Clinical Trial: NCT01969448",Contradiction,0.46380326,0.5361967
NCT01967823,Statement: blood bilirubin levels remained unchanged in all the patients in the primary clinical trial. [SEP] Clinical Trial: NCT01967823,Entailment,0.76593393,0.23406607
NCT01011218,Statement: the adverse events of the primary and secondary trials each resulted in multiple deaths. [SEP] Clinical Trial: NCT01011218,Contradiction,0.35776582,0.64223415
NCT02761642,"Statement: minor help to transfer is a response indicating that an individual needs minor verbal or physical help to transfer. Any cancer patient diagnosed with either Epilepsy , thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT02761642",Entailment,0.68956983,0.31043014
NCT02550795,"Statement: Group 2 of the primary trial recieves 0.5ug/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any Dexmedetomidine. [SEP] Clinical Trial: NCT02550795",Entailment,0.8907272,0.10927277
NCT01037790,Statement: map2k2 gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the map2k2 gene. There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation . [SEP] Clinical Trial: NCT01037790,Contradiction,0.47242808,0.5275719
NCT03069313,"Statement: response table is a table of data specifically regarding response. the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally. [SEP] Clinical Trial: NCT03069313",Entailment,0.5912184,0.40878162
NCT00978250,Statement: patients diagnosed with metastatic scbc are allowed to participate in the primary clinical trial. [SEP] Clinical Trial: NCT00978250,Entailment,0.581392,0.418608
NCT00194779,"Statement: the primary clinical trial involves prescribing seven different medications through subcutaneous injection and performing surgical procedures on its participants, on the other hand, the secondary clinical trial restricts its medical intervention to two different drugs and a series of imaging scans [SEP] Clinical Trial: NCT00194779",Entailment,0.5566603,0.4433397
NCT00702949,"Statement: one of the patient groups in the primary clinical trial is treated with 150 mg of oral pregabalin twice a day, contrastingly, the secondary clinical trial applies depocyt and hd-mtx for its patients. [SEP] Clinical Trial: NCT00702949",Contradiction,0.4595561,0.5404439
NCT01313117,"Statement: during the primary clinical trial, patients are administered elevated doses of alpha lipoic acid of up to 100 mg three times daily, in contrast to patients in cohort 1 of the secondary clinical trial who consistently receive the same dosage of necitumumab. [SEP] Clinical Trial: NCT01313117",Contradiction,0.47272617,0.52727383
NCT02306265,"Statement: for the primary clinical trial, prospective candidates are required to have a mammography, but this is not a pre-requisite for the secondary clinical trial. [SEP] Clinical Trial: NCT02306265",Entailment,0.74056286,0.2594371
NCT01806259,Statement: 96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group. mold mix antigen igg antibody measurement is a measurement of the mold mix antigen igg antibody in a biological specimen. [SEP] Clinical Trial: NCT01806259,Contradiction,0.46954855,0.5304515
NCT03384316,Statement: inactive comment is additional description why an entity is no longer active. All Infections and Infestations cases in the primary trial were for patients in cohort 1. [SEP] Clinical Trial: NCT03384316,Entailment,0.714988,0.28501198
NCT01964924,Statement: an adult patient diagnosed with diffuse parenchymal lung disease within the last 36 months would be excluded from the primary trial [SEP] Clinical Trial: NCT01964924,Entailment,0.82015985,0.1798402
NCT00418028,"Statement: the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the number of patients that experience Objective Response  [SEP] Clinical Trial: NCT00418028",Contradiction,0.30986392,0.6901361
NCT01803282,"Statement: ,  0.0274 of the primary trial participants, and 0/1674 the secondary trial participants suffered an acute myocardial infarction [SEP] Clinical Trial: NCT01803282",Entailment,0.60581064,0.39418936
NCT01702571,Statement: the documented adverse events for cohort 1 of the primary clinical trial are connected to respiratory issues [SEP] Clinical Trial: NCT01702571,Entailment,0.61908,0.38091996
NCT01617668,"Statement: Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2. ring chromosome 12 is an aberration of chromosome 12 where the arms have fused to form a ring. [SEP] Clinical Trial: NCT01617668",Entailment,0.6466513,0.35334867
NCT02891681,"Statement: normal weighted, non-pregnant individuals can participate in the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02891681",Contradiction,0.243376,0.7566239
NCT01048099,Statement: more than 75% of the patients in the primary clinical trial suffered a specific adverse event type. [SEP] Clinical Trial: NCT01048099,Entailment,0.75848246,0.24151751
NCT01597193,Statement: the primary clinical trial administers a dosage of enzalutamide to cohort 2 that is double the corresponding dosage for cohort 1 [SEP] Clinical Trial: NCT01597193,Entailment,0.55780065,0.44219938
NCT01855828,"Statement: there was one psychiatric adverse event in the primary trial, which affected less than 0.1 of patients [SEP] Clinical Trial: NCT01855828",Entailment,0.8104504,0.18954962
NCT04080297,"Statement: both the primary clinical trial and secondary clinical trial have distinct criteria for participation, preventing overlap of participants between the two studies. [SEP] Clinical Trial: NCT04080297",Entailment,0.7524711,0.24752885
NCT00321048,"Statement: in the primary clinical trial, patients in both cohort 1 and 2 are subjected to the same radiation therapy doses, but the procedure for cohort one extends for an extra two weeks. [SEP] Clinical Trial: NCT00321048",Contradiction,0.3935988,0.60640126
NCT01869192,"Statement: the results from the primary clinical trial suggest that the arm b intervention yielded the most promising overall response rate. moreover, in the secondary clinical trial, the denosumab cohort demonstrated a better time to first on-study sre than the zoledronic acid cohort. [SEP] Clinical Trial: NCT01869192",Contradiction,0.43737882,0.5626211
NCT01967823,"Statement: in the primary clinical trial, 50% of participants experienced adverse events (aes) of various types [SEP] Clinical Trial: NCT01967823",Entailment,0.6443872,0.35561284
NCT01989546,"Statement: candidates undergoing treatments based on warfarin are not permitted for the primary clinical trial, but their participation in the secondary clinical trial might still be possible. [SEP] Clinical Trial: NCT01989546",Entailment,0.6800966,0.31990334
NCT01554371,Statement: Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial. [SEP] Clinical Trial: NCT01554371,Entailment,0.8826388,0.11736124
NCT00429182,Statement: less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products [SEP] Clinical Trial: NCT00429182,Entailment,0.7353193,0.2646807
NCT02187783,"Statement: pharmacodynamics assay development laboratory is a laboratory that specializes in developing biomarkers for use during drug development. More Palpitations, Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.40919533,0.59080464
NCT01306032,Statement: none of the adverse events seen in secondary clinical trial are faced by patients in the primary clinical trial. [SEP] Clinical Trial: NCT01306032,Entailment,0.89679456,0.10320543
NCT00795769,"Statement: Far more patients in the secondary trial were recorded to have experienced Aes, than patients in the primary trial. pseudomonas oryzihabitans is a species of gram-negative, rod-shaped, motile bacterium in the phylum proteobacteria. [SEP] Clinical Trial: NCT00795769",Contradiction,0.44947293,0.5505271
NCT01975831,Statement: The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2. loss of chromosome 5 is a cytogenic abnormality that refers to loss of all or part of chromosome 5. [SEP] Clinical Trial: NCT01975831,Contradiction,0.48157907,0.518421
NCT01920061,Statement: the treatment intervention in the primary clinical trial adheres to a three-week cycle whereas the secondary clinical trial does not implement cyclic treatment. [SEP] Clinical Trial: NCT01920061,Entailment,0.9188915,0.08110857
NCT01286168,"Statement: The most common adverse event in the secondary trial was Anaemia, affecting more than 5% of patients, there were no recorded AEs in the primary trial. somewhat difficult is a subjective response indicating that an individual finds something to be somewhat difficult. [SEP] Clinical Trial: NCT01286168",Entailment,0.5972045,0.40279546
NCT00182793,Statement: cdisc adas-cog - delayed word recall: word 8 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) delayed word recall task for word 8. There was at least 1 case of infection in both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00182793,Entailment,0.5972778,0.40272218
NCT02320123,"Statement: gray commissure is a small area of gray matter surrounding the central canal in the spinal cord. Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy. [SEP] Clinical Trial: NCT02320123",Contradiction,0.3717121,0.62828785
NCT01766102,"Statement: the operative time was notably longer in arm 2 than in arm 1 during the primary clinical trial, an indication that the control group outperformed the test group. the secondary clinical trial, on the other hand, lacks a control group for suitable comparisons. [SEP] Clinical Trial: NCT01766102",Entailment,0.8275809,0.17241904
NCT01963481,Statement: patients who are diagnosed with severe schizophrenia and chronic insomnia are not allowed to participate in both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01963481,Entailment,0.8625811,0.13741896
NCT01783444,"Statement:  Women with Newly diagnosed locally advanced breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. bartholin gland adenocarcinoma is an adenocarcinoma that arises from the bartholin gland. subtypes include papillary and mucinous adenocarcinoma. [SEP] Clinical Trial: NCT01783444",Contradiction,0.22324215,0.77675784
NCT00756717,Statement: no adverse events were reported in both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT00756717,Entailment,0.8700572,0.12994276
NCT00266110,Statement: Patients in the primary trial will need to receive several injections. gas cylinder is a container designed specifically to hold gases. [SEP] Clinical Trial: NCT00266110,Contradiction,0.37874678,0.6212532
NCT00143390,Statement: the primary clinical trial reported at least one gastro-intestinal side effect and two psychiatric events [SEP] Clinical Trial: NCT00143390,Contradiction,0.33741707,0.662583
NCT02122796,"Statement: periodontitis is an acute or chronic inflammatory process that affects the tissues that surround and support the teeth. the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates, but higher doses of herceptin and doxatel. [SEP] Clinical Trial: NCT02122796",Contradiction,0.31474143,0.68525857
NCT01964924,"Statement: an adult patient diagnosed with ild/dpld within the last 9 months, with a life expectancy of 16 days would be eligible for the primary trial [SEP] Clinical Trial: NCT01964924",Contradiction,0.43063223,0.56936777
NCT01967823,Statement: all ae types witnessed in the primary clinical trial affected less than a tenth of the patients [SEP] Clinical Trial: NCT01967823,Entailment,0.8245791,0.17542095
NCT02403271,Statement: biliary colic and clostridium difficile colitis are less prevalent in the secondary trial compared to the primary trial [SEP] Clinical Trial: NCT02403271,Entailment,0.7710394,0.2289606
NCT01803282,"Statement: ikzf1 gene rearrangement is a molecular abnormality indicating rearrangement of the ikzf1 gene. 2/73 the primary trial participants, and 0/1674 the secondary trial participants suffered an Acute myocardial infarction . [SEP] Clinical Trial: NCT01803282",Contradiction,0.46257502,0.537425
NCT02273206,"Statement: in the primary clinical trial's first cohort, most patients had undergone their screenings post-intervention, no matter the type of cancer they had [SEP] Clinical Trial: NCT02273206",Entailment,0.56263644,0.4373635
NCT01664091,"Statement: neither the primary nor the secondary trial reported any cases of infection, asymmetry or nausea. [SEP] Clinical Trial: NCT01664091",Contradiction,0.35629433,0.64370567
NCT03015649,"Statement: in the primary and secondary clinical trials, the number of adverse events reported by participating cohorts exceeded 100. [SEP] Clinical Trial: NCT03015649",Contradiction,0.35366237,0.6463376
NCT00836186,Statement: the primary clinical trial involves radioembolization treatment for patients and the detainees from all cohorts of the secondary clinical trial are prescribed 500mg of fulvestrant via intramuscular injection twice a day. [SEP] Clinical Trial: NCT00836186,Contradiction,0.43667048,0.56332946
NCT01766102,"Statement: to some extent is an indication that something has been accomplished to some degree or has resulted in some amount of satisfaction. Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore the control group performed better than the test group in this regard. In the secondary trial there is no control group against which we can compare. [SEP] Clinical Trial: NCT01766102",Entailment,0.70904416,0.29095578
NCT00871858,"Statement: fulvestrant is only used in the cohort 1 intervention of the primary clinical trial, whereas cohort 2 is administered paclitaxel instead [SEP] Clinical Trial: NCT00871858",Entailment,0.68349767,0.31650236
NCT01537029,"Statement: Female cancer patients over the age of 18 can participate in the primary trial, regardless of race, ethnic origin or cancer type, however for the secondary trial, they must have BRCA+ breast cancer. [SEP] Clinical Trial: NCT01537029",Contradiction,0.31573045,0.68426955
NCT01649271,"Statement: multiple shingles cases were observed in both groups of the secondary trial, but none in the primary trial. [SEP] Clinical Trial: NCT01649271",Entailment,0.65274405,0.347256
NCT00284180,Statement: individuals who have a severe anaphylactic history to trastuzumab are excluded from the primary clinical trial. [SEP] Clinical Trial: NCT00284180,Entailment,0.85987407,0.14012596
NCT02599194,Statement: adcs-adl severe dementia questionnaire question is a question associated with the adcs-adl severe dementia questionnaire.  Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT02599194,Entailment,0.72061086,0.27938914
NCT00992602,Statement: there are no cases of bronchopneumonia and general physical health deterioration reported in either the primary or secondary clinical trials. [SEP] Clinical Trial: NCT00992602,Entailment,0.68459594,0.31540406
NCT01434342,"Statement: the secondary clinical trial noted a higher prevalence of mucositis oral, bladder infection, and thromboembolic incidents than what the primary clinical trial recorded [SEP] Clinical Trial: NCT01434342",Contradiction,0.49542052,0.5045795
NCT00766532,"Statement: There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial. kit protein variant is a variation in the amino acid sequence for the mast/stem cell growth factor receptor kit protein. [SEP] Clinical Trial: NCT00766532",Contradiction,0.3557145,0.6442855
NCT02961790,"Statement: Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial. [SEP] Clinical Trial: NCT02961790",Entailment,0.6890776,0.31092244
NCT00878709,Statement: granuloma assessment is an evaluation of the presence or degree of granuloma in a sample. The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group. [SEP] Clinical Trial: NCT00878709,Entailment,0.57007545,0.42992458
NCT01128543,"Statement: in the primary clinical trial, there were less patients with stable disease in week 12 compared to week 24, and there were reports of complete response in both weeks [SEP] Clinical Trial: NCT01128543",Entailment,0.5249014,0.4750986
NCT00662025,"Statement: carboplatin, not capecitabine, was administered orally twice a week, to all participants in the second cohort of the primary clinical trial over a 21-day cycle [SEP] Clinical Trial: NCT00662025",Entailment,0.5073931,0.49260682
NCT00253708,"Statement: the primary trial does not test any drug based treatments, whereas the secondary trial tests different doses of one drug based-treatment. 12q11-q13 is a chromosome band present on 12q [SEP] Clinical Trial: NCT00253708",Entailment,0.80862945,0.19137055
NCT00320541,Statement: the paclitaxel plus bevacizumab group had a higher orr compared to the paclitaxel plus bevacizumab plus gemcitabine group during the primary clinical trial [SEP] Clinical Trial: NCT00320541,Entailment,0.6531889,0.3468111
NCT02807844,"Statement: All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week. [SEP] Clinical Trial: NCT02807844",Contradiction,0.38053304,0.6194669
NCT02312934,"Statement: the primary clinical trial does not accept patients who regularly consume alcohol, yet those who typically have fewer than five drinks daily could be acceptable for the secondary clinical trial. [SEP] Clinical Trial: NCT02312934",Entailment,0.6540194,0.34598058
NCT00693719,Statement: a patient with a diagnosis of neoplastic meningitis might qualify for the primary clinical trial [SEP] Clinical Trial: NCT00693719,Entailment,0.6245274,0.37547258
NCT01045421,"Statement: Unlike the primary trial, patients must be diagnosed with a mutation in the one of the following genes; PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ or GNA11 to be included in the secondary trial. pdgfrb protein variant is a variation in the amino acid sequence of the platelet-derived growth factor receptor beta protein. [SEP] Clinical Trial: NCT01045421",Contradiction,0.39873925,0.6012607
NCT00544167,"Statement: patients that have suffered a pulmonary embolism in the last 6 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision [SEP] Clinical Trial: NCT00544167",Entailment,0.73234373,0.26765627
NCT01881230,Statement: ability to get up from kneeling is a question about an individual's ability to get up from kneeling. Both cohorts of the primary trial receive the same doses of Abraxane. [SEP] Clinical Trial: NCT01881230,Contradiction,0.47963798,0.5203621
NCT02509156,"Statement: the identical dose of allo-mscs and placebo interventions are delivered in the primary clinical trial, using a single transendocardial injection. [SEP] Clinical Trial: NCT02509156",Contradiction,0.48181584,0.5181842
NCT01806259,"Statement: compared to the group that received nacl 0.9% 3ml in the primary clinical trial, the group that was administered ketorolac 30 mg had a -6.4% lower recurrence-free survival rate [SEP] Clinical Trial: NCT01806259",Entailment,0.65227056,0.34772947
NCT02796755,Statement: the primary trial and the secondary trial do not have any recorded adverse events for their participants. clavicle fracture is a traumatic or pathologic injury to the clavicle in which the continuity of the clavicle is broken. [SEP] Clinical Trial: NCT02796755,Entailment,0.81581146,0.18418856
NCT00795769,"Statement: Far more patients in the secondary trial were recorded to have experienced Aes, than patients in the primary trial. megacolon is an abnormal dilation of the colon not due to obstruction. [SEP] Clinical Trial: NCT00795769",Contradiction,0.47902697,0.520973
NCT00270894,"Statement: participants in the primary trial receive 14 different drugs throughout the study duration, with a maximum dose of 200 mg/m^2 [SEP] Clinical Trial: NCT00270894",Contradiction,0.2866293,0.71337074
NCT02104830,"Statement: hemolytic uremic syndrome, ctcae is a disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia. the primary trial and the secondary trial are studying the same drug, in different doses and with a different outcome measurement. [SEP] Clinical Trial: NCT02104830",Contradiction,0.49993128,0.5000687
NCT00262834,"Statement: 10 adverse events were observed in the primary trial, and 90% of the adverse events in the secondary trial affected more than 95% of patients. [SEP] Clinical Trial: NCT00262834",Contradiction,0.34589857,0.65410143
NCT01527487,Statement: cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel [SEP] Clinical Trial: NCT01527487,Entailment,0.6281101,0.37188992
NCT01091974,"Statement: in the primary trial only two cohorts recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 200 mg dose of pdr001, and 4 mg/kg dose of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.37347165,0.6265283
NCT01664091,"Statement: the infection, asymmetry and deflation cases were less prevalent in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01664091",Entailment,0.70755875,0.29244122
NCT00182793,Statement: the outcomes of both the primary and secondary clinical trials were not marred by any instances of infection [SEP] Clinical Trial: NCT00182793,Entailment,0.8778247,0.12217525
NCT00558272,Statement: the azd0530 0.175 g group of the primary trial experienced a more significant percentage change in betactx at week 28 days than the zoledronic acid 4 mg group. [SEP] Clinical Trial: NCT00558272,Contradiction,0.4769407,0.5230593
NCT01048099,Statement: None of the individual adverse event types recorded in the primary trial affected more than one patient. reconstructive plastic surgery is a surgical procedure to reconstruct a damaged or deformed part of the body to improve function or aesthetics. [SEP] Clinical Trial: NCT01048099,Entailment,0.64603716,0.35396287
NCT02306265,"Statement: millimole per liter per microgram per kilogram per day is a unit of concentration equal to millimoles per liter, divided by micrograms per kilogram per day. candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests. [SEP] Clinical Trial: NCT02306265",Contradiction,0.39561233,0.60438764
NCT01908101,Statement: higher doses of radiation therapy are given to the patients of the primary clinical trial as compared to the secondary clinical trial participants [SEP] Clinical Trial: NCT01908101,Entailment,0.6675362,0.3324638
NCT02179515,Statement: 100.0% of cohort 1 of the primary trial suffered some kind of adverse event. self-evident change is an information error that can be quickly and accurately fixed based on existing data on the form. [SEP] Clinical Trial: NCT02179515,Entailment,0.57557726,0.42442274
NCT02734979,Statement: Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial. [SEP] Clinical Trial: NCT02734979,Entailment,0.5790125,0.42098746
NCT02550795,"Statement: in the primary clinical trial, group 2 patients receive a dosage of 0.5ug/kg of dexmedetomidine (5ml), whereas the secondary clinical trial does not administer dexmedetomidine to its cohorts. [SEP] Clinical Trial: NCT02550795",Entailment,0.8631503,0.13684969
NCT01869192,"Statement: in the primary clinical trial, the outcomes from the placebo arm suggest superior overall response rate than the arm a intervention. however, in the secondary clinical trial, the zoledronic acid cohort recorded a shorter time to first on-study sre compared to the denosumab cohort. [SEP] Clinical Trial: NCT01869192",Entailment,0.54428625,0.4557138
NCT01246973,Statement: the primary clinical trial and secondary clinical trial saw no instances of cardiac or psychiatric adverse events. [SEP] Clinical Trial: NCT01246973,Entailment,0.6995608,0.30043918
NCT02286843,Statement: her2+ metastases developed in 13% of the participants with pr+ primary breast cancer treated using her2-targeted pet/ct. 89zr-trastuzumab in the primary clinical trial [SEP] Clinical Trial: NCT02286843,Contradiction,0.41558126,0.5844188
NCT00182793,Statement: over 0.15 of patients in the primary trial and the secondary trial suffered from infections during the study period [SEP] Clinical Trial: NCT00182793,Contradiction,0.2154646,0.7845354
NCT02640053,Statement: the symptoms experienced by patients who didn't receive topical cryotherapy in the primary clinical trial were more intense than those who did receive the treatment. [SEP] Clinical Trial: NCT02640053,Entailment,0.67300934,0.32699063
NCT00918281,"Statement: helcococcus is a genus of gram positive, cocci shaped bacterium assigned to the phylum firmicutes and the family clostridiales xi. cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine by IV. [SEP] Clinical Trial: NCT00918281",Contradiction,0.3891462,0.6108538
NCT01127763,Statement: global complete response in blood is a score of b0 by repeat bone marrow biopsy with no residual disease. 5 patients in the primary trial suffered 3 or more adverse events. [SEP] Clinical Trial: NCT01127763,Entailment,0.5331309,0.4668691
NCT00262834,"Statement: deleterious fancd2 gene mutation is a change in the nucleotide sequence of the fancd2 gene that is associated with increased risk of disease. 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients. [SEP] Clinical Trial: NCT00262834",Contradiction,0.49779356,0.50220644
NCT00759785,"Statement: in the primary clinical trial, there was an 11% higher rate of participants showing a reduction in the growth factor signature in the er-positive luminal b group as compared to the triple negative group. [SEP] Clinical Trial: NCT00759785",Contradiction,0.49951681,0.50048316
NCT00753415,Statement: the same three electroporation injections of ld v934 are given to cohort a and b in the primary clinical trial [SEP] Clinical Trial: NCT00753415,Contradiction,0.43759808,0.5624019
NCT01048099,"Statement: in the primary clinical trial, a single type of adverse event was noticed in more than one patient [SEP] Clinical Trial: NCT01048099",Entailment,0.84315145,0.1568486
NCT01439282,"Statement: in both the primary and secondary clinical trials, eligibility is not determined by the gender of the individual [SEP] Clinical Trial: NCT01439282",Entailment,0.8427268,0.15727316
NCT00825682,Statement: The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial. arterial access site is anatomical location where an artery was accessed for a diagnostic or therapeutic procedure. [SEP] Clinical Trial: NCT00825682,Contradiction,0.38608083,0.61391914
NCT01997333,Statement: the patient with the longest pfs in the primary trial survived 14 days without disease progression or death [SEP] Clinical Trial: NCT01997333,Entailment,0.61305875,0.3869412
NCT02187783,"Statement: the secondary clinical trial showed a higher incidence rate of palpitations, pericardial effusions and abdominal pains than the primary clinical trial. [SEP] Clinical Trial: NCT02187783",Contradiction,0.45140043,0.54859954
NCT01091974,"Statement: in the primary clinical trial, armodafinil p.o. is delivered daily to a specific cohort, while in the secondary clinical trial, all participants receive a uniform dose of 100 mg pdr001 and 1mg/kg of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.42043188,0.57956815
NCT01617668,Statement: the frequency of adverse events was higher in the first cohort of the primary clinical trial than in the second cohort. [SEP] Clinical Trial: NCT01617668,Entailment,0.87036073,0.1296393
NCT01111825,"Statement: in the primary clinical trial, cohort 1 is given pr negative, er negative, and her-, while cohort 2 is administered her2+ [SEP] Clinical Trial: NCT01111825",Contradiction,0.46990323,0.5300968
NCT00321048,"Statement: equal amounts of radiation therapy are provided to patients of cohort 1 and 2 in the primary clinical trial, and a spect scan is performed on each of them. [SEP] Clinical Trial: NCT00321048",Contradiction,0.4896102,0.51038975
NCT02115607,Statement: there were 11 additional instances of intestinal perforation reported in the secondary clinical trial compared to the primary clinical trial [SEP] Clinical Trial: NCT02115607,Contradiction,0.44277522,0.5572248
NCT00122369,"Statement: abnormal involuntary movement scale aims0108 through aims0109 original result - moderate is abnormal involuntary movement scale aims0108 through aims0109 original result - moderate. the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation. [SEP] Clinical Trial: NCT00122369",Entailment,0.81213456,0.18786539
NCT00659373,"Statement: on average, there was no change in cognitive function for patients in either cohort of the primary clinical trial. [SEP] Clinical Trial: NCT00659373",Entailment,0.88210124,0.117898785
NCT02431676,Statement: the primary clinical trial is open to patients suffering from anorexia. [SEP] Clinical Trial: NCT02431676,Entailment,0.77912384,0.22087623
NCT02891681,Statement: patients with healthy weight according to body mass index (bmi) standards can be eligible for the primary clinical trial and the secondary clinical trial. [SEP] Clinical Trial: NCT02891681,Contradiction,0.23308362,0.7669164
NCT02041429,Statement: the primary trial and the secondary trial report on the MTD of different interventions [SEP] Clinical Trial: NCT02041429,Entailment,0.8489793,0.15102077
NCT00182793,Statement: There was at least 1 case of infection in both the primary trial and the secondary trial. malignant bronchial neoplasm is a malignant neoplasm that affects the bronchial tree. [SEP] Clinical Trial: NCT00182793,Entailment,0.63694674,0.36305323
NCT01128543,Statement: the majority of patients in the primary trial experienced complete response by the 24th week. [SEP] Clinical Trial: NCT01128543,Contradiction,0.47539088,0.52460915
NCT00586326,Statement: The the primary trial intervention section does not outline a treatment cycle or any description of the treatment. senior is a suffix used to distinguish a father from his son when they have the same given name. [SEP] Clinical Trial: NCT00586326,Entailment,0.72543985,0.2745601
NCT00432562,Statement: The only shared inclusion/exclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent. malignant cervical soft tissue neoplasm is a rare malignant mesenchymal neoplasm that arises from the cervix. [SEP] Clinical Trial: NCT00432562,Entailment,0.5215118,0.4784882
NCT01806259,Statement: the ketorolac 30 milligram group of the primary trial had a -0.064 recurrence-free survival compared to the nacl 0.9% 3mL group [SEP] Clinical Trial: NCT01806259,Entailment,0.58287966,0.4171203
NCT01967823,Statement: every single patient in the primary clinical trial experienced a decrease in blood bilirubin levels. [SEP] Clinical Trial: NCT01967823,Entailment,0.7233632,0.2766368
NCT02178722,Statement: participants in the primary trial receive sunitinib twice as frequently as participants in the secondary trial receive pembrolizumab. [SEP] Clinical Trial: NCT02178722,Entailment,0.51227486,0.48772514
NCT00775645,Statement: in both the primary trial and the secondary trial there were 0 adverse events which occurred in less than 2% of participants. [SEP] Clinical Trial: NCT00775645,Entailment,0.83913916,0.16086084
NCT01855828,"Statement: There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia. food consumption is a measurement of a subject's nutritional intake. [SEP] Clinical Trial: NCT01855828",Contradiction,0.41729456,0.58270544
NCT01706081,Statement: Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list. 6p21.33 is a chromosome band present on 6p [SEP] Clinical Trial: NCT01706081,Entailment,0.5375932,0.4624068
NCT00118157,Statement: recipients in the primary clinical trial receive injectable medication thrice per day for two weeks. [SEP] Clinical Trial: NCT00118157,Entailment,0.55187404,0.448126
NCT00756717,"Statement: There were 0 cases of Febrile neutropenia or Cholelithiasis in the primary trial and the secondary trial. monoclonal antibody b1 is a monoclonal antibody that targets cd20, a b-cell-specific cell surface protein expressed on mature b lymphocytes. (nci) [SEP] Clinical Trial: NCT00756717",Contradiction,0.44341162,0.5565884
NCT01194440,"Statement: patients with a diagnosis of stage 4 invasive breast carcinoma, positive for estrogen and/or progesterone receptors, and weighing the option of ai therapy, are suitable for the primary clinical trial. [SEP] Clinical Trial: NCT01194440",Contradiction,0.41142687,0.58857316
NCT00256217,"Statement: trichomonas infection is an infection that is caused by trichomonas. There were no patients with recorded Aes in the primary trial, whereas every patient in the secondary trial suffered at least one adverse event. [SEP] Clinical Trial: NCT00256217",Entailment,0.6091668,0.3908332
NCT01301729,Statement: At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial. negative biospecimen is a grouping category for samples that tested negative. [SEP] Clinical Trial: NCT01301729,Entailment,0.6047811,0.39521894
NCT01730729,"Statement: the primary clinical trial uses a topical administration of it's intervention, contrasting the secondary clinical trial’s exclusive use of an intravenous route [SEP] Clinical Trial: NCT01730729",Entailment,0.7716441,0.22835584
NCT01706081,Statement: satisfaction with overall sexual life is a question about how satisfied an individual is or has been with their overall sexual life. Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream. [SEP] Clinical Trial: NCT01706081,Contradiction,0.47644892,0.5235511
NCT00709761,Statement: the majority of patients in the primary clinical trial treated with lapatinib 1000 mg + nab-paclitaxel did not achieve a confirmed complete response (cr). [SEP] Clinical Trial: NCT00709761,Entailment,0.7226605,0.27733955
NCT00558272,"Statement: during the fourth week of the primary clinical trial, a more significant percentage change in betactx was observed in the azd0530 175 mg group than in those taking zoledronic acid 4 mg. [SEP] Clinical Trial: NCT00558272",Contradiction,0.47407392,0.5259261
NCT00182793,Statement: over 15% of patients in the primary trial and the secondary trial suffered from infections during the study period. cell surface receptor is a receptor protein that is localized to the plasma membrane and may have exposure to the extracellular milieu. [SEP] Clinical Trial: NCT00182793,Contradiction,0.24286264,0.75713736
NCT00320541,Statement: the paclitaxel plus bevacizumab plus gemcitabine group had a worse orr than the paclitaxel plus bevacizumab group in the primary clinical trial [SEP] Clinical Trial: NCT00320541,Entailment,0.8088875,0.19111249
NCT01554371,Statement: both the primary clinical trial and the secondary clinical trial do not entertain the participation of patients who are currently smoking. [SEP] Clinical Trial: NCT01554371,Entailment,0.8992002,0.10079981
NCT01772004,Statement: African-american patients can participate in the primary trial. borderline resectable mass is a tumor mass finding that refers to a continuum between resectable and locally advanced unresectable disease. [SEP] Clinical Trial: NCT01772004,Entailment,0.5750152,0.42498478
NCT00182793,Statement: there were no recorded incidents of infections among patients in both the primary clinical trial and the secondary clinical trial during the study period [SEP] Clinical Trial: NCT00182793,Entailment,0.8599926,0.14000733
NCT01881230,Statement: abraxane and carboplatin dosages differentiate between the cohorts of the primary clinical trial [SEP] Clinical Trial: NCT01881230,Entailment,0.77139264,0.2286074
NCT00929240,Statement: 3q21-q24 is a chromosome band present on 3q the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort. [SEP] Clinical Trial: NCT00929240,Entailment,0.65026313,0.34973684
NCT02041429,Statement: the primary trial and the secondary trial report on the MTD of different interventions. smoked cigarettes after diagnosis and before treatment start is a question about whether an individual smoked cigarettes after diagnosis and before treatment started. [SEP] Clinical Trial: NCT02041429,Contradiction,0.48158133,0.51841867
NCT00256217,"Statement: every patient in the primary clinical trial experienced multiple adverse events, while patients in the secondary clinical trial were unscathed by any. [SEP] Clinical Trial: NCT00256217",Entailment,0.8461157,0.15388422
NCT03384316,Statement: all infections and infestations cases in the primary clinical trial were evenly distributed among all cohorts. [SEP] Clinical Trial: NCT03384316,Entailment,0.659369,0.340631
NCT00800436,"Statement: exposure to gabapentin or herceptin within the last 12 months disqualifies patients from the secondary clinical trial, yet it won't prevent them from being part of the primary clinical trial [SEP] Clinical Trial: NCT00800436",Entailment,0.63861305,0.36138695
NCT00693719,Statement: a patient diagnosed with a non-neoplastic disorder is eligible for the primary clinical trial [SEP] Clinical Trial: NCT00693719,Entailment,0.7764571,0.2235429
NCT00194779,"Statement: the primary clinical trial entails a medical plan where participants are given multiple drug types via subcutaneous injection and surgery. however, the secondary clinical trial approach involves only two basic drugs and employs several imaging scans for follow-ups [SEP] Clinical Trial: NCT00194779",Contradiction,0.23278067,0.76721936
NCT00365365,"Statement: in the primary clinical trial, participants are provided her2/neu peptide vaccine in combination with sargramostim (gm-csf) id on days 1, 8, and 15. [SEP] Clinical Trial: NCT00365365",Contradiction,0.37156218,0.6284378
NCT00357734,"Statement: the intervention in the primary trial involves a drug cocktail, including paclitaxel, bevacizumab, and gemcitabine. the secondary trial includes only doxorubicin as its intervention. [SEP] Clinical Trial: NCT00357734",Contradiction,0.4592674,0.5407326
NCT00918281,"Statement: in the primary clinical trial, cohort 1 is given a subcutaneous injection of docetaxel and in the secondary clinical trial, cohort 1 receives a high dose of methotrexate orally. [SEP] Clinical Trial: NCT00918281",Contradiction,0.4776831,0.52231693
NCT02441946,"Statement: patients with a tnbc tumor of 50cm in diameter, are eligible for both the primary trial and the secondary trial [SEP] Clinical Trial: NCT02441946",Contradiction,0.32599434,0.6740057
NCT02599194,Statement: both the primary clinical trial and the secondary clinical trial did not make a record of any adverse events. [SEP] Clinical Trial: NCT02599194,Entailment,0.92185503,0.07814495
NCT01351376,Statement: Patients with measurable tumors in both breasts are excluded from the primary trial. mixed endometrial stromal and smooth muscle neoplasm is a rare primary neoplasm of the uterine corpus characterized by the presence of endometrial stromal and smooth muscle components. [SEP] Clinical Trial: NCT01351376,Entailment,0.65221786,0.3477821
NCT01855828,"Statement: activity tracking is a method to track an individual's physical activity using an activity monitor or other tracking device. There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia. [SEP] Clinical Trial: NCT01855828",Contradiction,0.49517164,0.50482833
NCT03403712,Statement: the primary trial is assessing the length of patients' slumber while the secondary trial is evaluating the frequency of the patients' post treatment complications. [SEP] Clinical Trial: NCT03403712,Entailment,0.5425646,0.4574355
NCT00293384,"Statement: less than half of the patients in cohort 2 of the primary clinical trial experienced acute vomiting following treatment with aprepitant, dexamethasone, cytoxan and kytril [SEP] Clinical Trial: NCT00293384",Entailment,0.540598,0.459402
NCT01967823,Statement: 4.9% of the primary trial patients suffered an increase in blood bilirubin. [SEP] Clinical Trial: NCT01967823,Entailment,0.55443585,0.44556418
NCT00708019,Statement: None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks. [SEP] Clinical Trial: NCT00708019,Entailment,0.7070065,0.29299352
NCT01997333,"Statement: in the primary clinical trial, the individual with maximum pfs managed to live 3.5 months without disease advancement or death. [SEP] Clinical Trial: NCT01997333",Contradiction,0.48230878,0.51769125
NCT01023477,Statement: patients with normal potassium levels are disqualified from the primary clinical trial while they have potential eligibility for the secondary clinical trial [SEP] Clinical Trial: NCT01023477,Entailment,0.731889,0.268111
NCT01439282,"Statement: Gender is not a determining factor for eligibility in the primary trial, but only female patients are eligible for the secondary trial. keyword code is a coded value specifying the words or phrases that best describe an entity and/or its context and content. [SEP] Clinical Trial: NCT01439282",Entailment,0.51045763,0.48954237
NCT01649271,"Statement: in the patient groups of the primary and secondary clinical trials, a total of three shingles cases were identified. [SEP] Clinical Trial: NCT01649271",Contradiction,0.3000772,0.6999228
NCT01730729,"Statement: unlike the secondary clinical trial that specifically administers treatment intravenously, the intervention in the primary clinical trial is given topically [SEP] Clinical Trial: NCT01730729",Entailment,0.7926554,0.2073446
NCT00759785,"Statement: in the primary clinical trial, there was a 49.2% higher reduction in the growth factor signature in the dalotuzumab 20 mg/kg group than in the triple negative group. [SEP] Clinical Trial: NCT00759785",Contradiction,0.43806756,0.5619324
NCT01614210,Statement: defined notification delivery mechanism code is a coded value specifying how the notification message is to be delivered. Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.448912,0.551088
NCT00795769,Statement: a larger percentage of participants in the primary trial were reported to have experienced chest pain than in the secondary trial. [SEP] Clinical Trial: NCT00795769,Entailment,0.6563368,0.34366325
NCT00838929,Statement: aids-related non-hodgkin lymphoma is a non-hodgkin lymphoma that develops in a patient with aids. Every patient in the primary trial is receives a dose of 100 to 1600 ¬¨¬µg fentanyl sublingual spray during radiation therapy. [SEP] Clinical Trial: NCT00838929,Contradiction,0.38063276,0.61936724
NCT00632489,Statement: the lbh589 with capecitabine cohort of the primary clinical trial outperformed the lbh589 and lapatinib cohort. [SEP] Clinical Trial: NCT00632489,Entailment,0.59082925,0.40917078
NCT00558272,"Statement: the azd0530 175,000 microgram group of the primary trial experienced a more significant percentage change in betactx at week 4 than the zoledronic acid 0.004 g group. [SEP] Clinical Trial: NCT00558272",Contradiction,0.49503386,0.5049661
NCT01290536,"Statement: The the primary trial intervention consists of Radioembolization using TheraSpheres, on the other hand the secondary trial intervention is based on ibrutinib and MEDI4736. [SEP] Clinical Trial: NCT01290536",Contradiction,0.38571823,0.61428183
NCT01963481,Statement: insomnia patients irrespective of the severity of their condition are invited to take part in both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01963481,Contradiction,0.44008058,0.5599194
NCT01468675,"Statement: in the primary clinical trial, interventions do not include any drug usage, radiotherapy or cognitive behavioral therapy (cbt) for either cohort. [SEP] Clinical Trial: NCT01468675",Entailment,0.7498556,0.25014442
NCT00321464,"Statement: patients with clinically diagnosed stage 4 lung adenocarcinoma that is either egfr positive, alk positive or ros1 negative are signed up for both the secondary trial and the primary trial. [SEP] Clinical Trial: NCT00321464",Contradiction,0.39484194,0.6051581
NCT02115607,Statement: gain of chromosome 2p is a cytogenetic abnormality that refers to the duplication of all or part of the short arm of chromosome 2. the secondary trial recorded 11 more Aes than the primary trial. [SEP] Clinical Trial: NCT02115607,Contradiction,0.24553517,0.75446486
NCT01011218,Statement: Across both the primary trial and the secondary trial only one death was recorded in the adverse events. [SEP] Clinical Trial: NCT01011218,Entailment,0.801028,0.198972
NCT00284180,Statement: individuals who have had severe anaphylactic responses to herceptin or have shown no response to herceptin treatment are suitable candidates for the primary clinical trial. [SEP] Clinical Trial: NCT00284180,Entailment,0.6911252,0.30887485
NCT02413008,"Statement: the identical outcome measure for the secondary and primary clinical trials is the proportion of patients with pcr within the breast; in other words, no evidence of invasive tumor remaining in the breast after the completion of chemotherapy and surgery. [SEP] Clinical Trial: NCT02413008",Entailment,0.54299444,0.45700556
NCT01781299,"Statement: in the primary clinical trial as well as secondary clinical trial, there were neither unexpected deaths nor hospital stays, just three known cases of lymphoma. [SEP] Clinical Trial: NCT01781299",Contradiction,0.21451177,0.7854883
NCT00284180,"Statement: patients who have previously experienced serious anaphylactic reactions to herceptin, or those who experienced no improvement with herceptin treatment may participate in the primary clinical trial. [SEP] Clinical Trial: NCT00284180",Entailment,0.58645606,0.41354388
NCT01048099,Statement: None of the individual adverse event types recorded in the primary trial affected more than one patient [SEP] Clinical Trial: NCT01048099,Entailment,0.8587591,0.14124092
NCT01569087,"Statement: Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent. surface immunoglobulin-positive cells present is a microscopic finding indicating that immunoglobulins are bound to or expressed on the surface of cells in a sample. [SEP] Clinical Trial: NCT01569087",Contradiction,0.24020623,0.75979376
NCT00451555,"Statement: the primary clinical trial necessitates participants to display resistance towards ai therapy and mirtazapine, a condition not enforced in the secondary clinical trial. [SEP] Clinical Trial: NCT00451555",Entailment,0.8551605,0.14483953
NCT02431676,Statement: anorexic patients can be considered for the primary clinical trial [SEP] Clinical Trial: NCT02431676,Entailment,0.5950008,0.40499917
NCT00693719,Statement: A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial. patent delivery system vial is a vial that has a patented delivery system. [SEP] Clinical Trial: NCT00693719,Entailment,0.6148115,0.38518855
NCT00429182,Statement: feelings about ability to deal with treatment and recovery is a question about an individual's feelings regarding their ability to deal with treatment and recovery. less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products. [SEP] Clinical Trial: NCT00429182,Entailment,0.50685,0.49315
NCT00365105,"Statement: a 42 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1600/≈í¬∫l, platelet count of 132,040/≈í¬∫l, hemoglobin level of 110 g/l, and a life expectancy exceeding 16 months would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00365105",Contradiction,0.3087113,0.69128877
NCT01614210,Statement: results from the primary trial show that tamoxifen 45 mg po daily for 15 days prior to surgery and for 30 days after breast cancer surgery reduces the diameter of tumors by 20% on average. [SEP] Clinical Trial: NCT01614210,Contradiction,0.3547,0.6453
NCT01011218,"Statement: across the primary clinical trial and the secondary clinical trial, it was recorded that there were no deaths in the adverse events. [SEP] Clinical Trial: NCT01011218",Contradiction,0.45787263,0.5421274
NCT02179515,Statement: none of the participants of cohort 1 of the primary clinical trial experienced any adverse events [SEP] Clinical Trial: NCT02179515,Entailment,0.8891758,0.110824205
NCT02222922,"Statement: food preparation and serving, related occupations is a class of professional or vocational positions of employment that involve food preparation or serving. All the primary trial participants receive lower doses of drugs than the secondary trial participants. [SEP] Clinical Trial: NCT02222922",Contradiction,0.48693985,0.51306015
NCT01963481,Statement: distress over family problem with family health issues is a question about an individual's distress related to their family problems dealing with family health issues. Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT01963481,Entailment,0.68297243,0.3170276
NCT00553358,"Statement: a patient that has a primary tumour with a diameter of 100mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. [SEP] Clinical Trial: NCT00553358",Contradiction,0.33675957,0.66324043
NCT01091974,"Statement: in the primary trial only 1 group recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 100,000 μg dose of pdr001, and 1 mg/kg dose of mcs110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.42631486,0.57368517
NCT00702949,"Statement: diffuse midline glioma, egfr-mutant is a diffuse midline glioma, h3 k27-altered, characterized by the presence of egfr gene mutation. the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with Depocyt and HD-MTX. [SEP] Clinical Trial: NCT00702949",Contradiction,0.37127247,0.6287275
NCT01091974,"Statement: everyone in the primary clinical trial gets the same dosage of armodafinil orally daily, and in the secondary clinical trial, all participants get varied dosages of chs828 and mvc110. [SEP] Clinical Trial: NCT01091974",Contradiction,0.42377642,0.5762236
NCT01855828,"Statement: a single psychiatric adverse event was reported in the primary clinical trial, affecting fewer than 10% of the patients [SEP] Clinical Trial: NCT01855828",Entailment,0.79537374,0.20462622
NCT01537029,"Statement: Female cancer patients over the age of 18 can participate in the primary trial, regardless of race, ethnic origin or cancer type, however for the secondary trial, they must have BRCA+ breast cancer. human fetal tissue is any tissue from a human fetus. [SEP] Clinical Trial: NCT01537029",Contradiction,0.3433164,0.6566836
NCT01964924,"Statement: for the primary clinical trial, adults who have been diagnosed with ild/dpld within the previous 3 years and have a projected life span of 6 months are considered eligible [SEP] Clinical Trial: NCT01964924",Contradiction,0.4685787,0.53142136
NCT00741039,"Statement: all participants of the primary clinical trial undergo the same treatment, irrespective of their cancer status. [SEP] Clinical Trial: NCT00741039",Entailment,0.7417215,0.25827852
NCT02115607,Statement: the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial. percentage relief from pain treatment or medication score answer is an answer for a percentage relief from pain treatment or medication score query. [SEP] Clinical Trial: NCT02115607,Contradiction,0.3531001,0.64689994
NCT00293540,"Statement: on average, patients from the primary clinical trial do not survive beyond 2 years and there were no cases where any patient from either cohort died in under 2 years. [SEP] Clinical Trial: NCT00293540",Entailment,0.5901028,0.4098972
NCT00322374,Statement: inclusion in the primary clinical trial is restricted to those who have not received chemotherapy or radiotherapy in the past 6 months and have a proven clean mental health record. [SEP] Clinical Trial: NCT00322374,Entailment,0.6232295,0.3767705
NCT00248547,Statement: emesis was not a reported symptom for patients receiving the placebo intervention in the primary clinical trial [SEP] Clinical Trial: NCT00248547,Entailment,0.8884929,0.11150711
NCT00054028,"Statement: Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial intervention section does not describe what drugs are to be administered. kbtbd4 gene mutation is a change in the nucleotide sequence of the kbtbd4 gene. [SEP] Clinical Trial: NCT00054028",Entailment,0.8468933,0.15310669
NCT01246973,Statement: a number of psychiatric aes were noted in the secondary clinical trial. [SEP] Clinical Trial: NCT01246973,Entailment,0.6743181,0.32568192
NCT01664091,"Statement: tpm3 gene product is a protein encoded by the tpm3 gene. There were more cases of Infection, Asymmetry and Deflation in the primary trial than in the secondary trial. [SEP] Clinical Trial: NCT01664091",Contradiction,0.31541458,0.68458545
NCT00759785,Statement: monophasic synovial sarcoma is a synovial sarcoma characterized by the presence of an epithelial or a spindle cell component only. 49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. [SEP] Clinical Trial: NCT00759785,Contradiction,0.39970577,0.60029423
NCT03092934,Statement: individuals with er negative prostate cancer are eligible for the primary clinical trial. [SEP] Clinical Trial: NCT03092934,Entailment,0.7326405,0.26735947
NCT01127763,"Statement: treadmill is a piece of exercise equipment used to walk or run on, for the purposes of cardiovascular training or testing. 5 patients in the primary trial suffered 3 or more adverse events. [SEP] Clinical Trial: NCT01127763",Contradiction,0.48681492,0.5131851
NCT01855828,"Statement: locally advanced breast carcinoma is a breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes. There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients. [SEP] Clinical Trial: NCT01855828",Entailment,0.66923374,0.3307663
NCT01569087,"Statement: patients who have completed their treatment and are now cancer-free, can participate in the primary clinical trial and the secondary clinical trial, regardless of their consent status. [SEP] Clinical Trial: NCT01569087",Contradiction,0.27570403,0.72429603
NCT02988986,Statement: patients in the primary trial noted a 10% decrease in the percentage of cells with ki67 expression after a month of undergoing tak-228 plus tamoxifen treatment [SEP] Clinical Trial: NCT02988986,Entailment,0.52781624,0.47218376
NCT01045421,"Statement: diffuse laminar endocervical hyperplasia is a benign band-like proliferation of tightly-packed, small to medium sized endocervical glands below the surface of the endocervical canal. Unlike the primary trial, patients must be diagnosed with a mutation in the one of the following genes; PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ or GNA11 to be included in the secondary trial. [SEP] Clinical Trial: NCT01045421",Contradiction,0.3251793,0.6748207
NCT01451632,"Statement: Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention. folliculitis, ctcae is a disorder characterized by inflammation or infection of the hair follicles. [SEP] Clinical Trial: NCT01451632",Contradiction,0.39040315,0.6095968
NCT01783444,"Statement: women recently identified with locally advanced er-positive breast cancer who are contemplating mastectomy, qualify for both the primary clinical trial and the secondary clinical trial [SEP] Clinical Trial: NCT01783444",Contradiction,0.40008965,0.5999104
NCT02222922,Statement: paternal half sibling is a relative with whom you share a biological father but you have different mothers. All the primary trial participants receive lower doses of drugs than the secondary trial participants. [SEP] Clinical Trial: NCT02222922,Entailment,0.65323627,0.3467637
